0001558370-25-003482.txt : 20250321 0001558370-25-003482.hdr.sgml : 20250321 20250321171559 ACCESSION NUMBER: 0001558370-25-003482 CONFORMED SUBMISSION TYPE: 10-K PUBLIC DOCUMENT COUNT: 84 CONFORMED PERIOD OF REPORT: 20241231 FILED AS OF DATE: 20250321 DATE AS OF CHANGE: 20250321 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Annovis Bio, Inc. CENTRAL INDEX KEY: 0001477845 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 262540421 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39202 FILM NUMBER: 25761547 BUSINESS ADDRESS: STREET 1: 101 LINDENWOOD DRIVE, SUITE 225 CITY: MALVERN STATE: PA ZIP: 19355 BUSINESS PHONE: 484-875-3192 MAIL ADDRESS: STREET 1: 101 LINDENWOOD DRIVE, SUITE 225 CITY: MALVERN STATE: PA ZIP: 19355 FORMER COMPANY: FORMER CONFORMED NAME: QR Pharma, Inc. DATE OF NAME CHANGE: 20091202 10-K 1 anvs-20241231x10k.htm 10-K ANNOVIS BIO, INC._December 31, 2024
00014778452024FYfalsetrue000010519933141415210http://fasb.org/us-gaap/2024#MonteCarloModelMemberhttp://fasb.org/us-gaap/2024#BlackScholesMertonModelMember0.0001P5Y0001477845anvs:WarrantsClassifiedAsLiabilitiesMember2024-06-300001477845us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputSharePriceMember2024-12-310001477845us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2024-12-310001477845us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2024-12-310001477845us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember2024-12-310001477845us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExercisePriceMember2024-12-310001477845us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputSharePriceMember2023-12-310001477845us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputRiskFreeInterestRateMember2023-12-310001477845us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputPriceVolatilityMember2023-12-310001477845us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExpectedTermMember2023-12-310001477845us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputExercisePriceMember2023-12-310001477845us-gaap:FairValueInputsLevel3Memberus-gaap:MeasurementInputConversionPriceMember2023-12-310001477845us-gaap:FairValueInputsLevel3Memberanvs:MeasurementInputSuccessRateMember2023-12-310001477845us-gaap:ResearchMember2024-12-310001477845anvs:CommonStockPurchaseAgreementMember2024-01-012024-12-310001477845us-gaap:RetainedEarningsMember2024-12-310001477845us-gaap:AdditionalPaidInCapitalMember2024-12-310001477845us-gaap:RetainedEarningsMember2023-12-310001477845us-gaap:AdditionalPaidInCapitalMember2023-12-310001477845us-gaap:RetainedEarningsMember2022-12-310001477845us-gaap:AdditionalPaidInCapitalMember2022-12-310001477845us-gaap:CommonStockMember2024-12-310001477845us-gaap:CommonStockMember2023-12-310001477845us-gaap:CommonStockMember2022-12-310001477845srt:DirectorMemberanvs:ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember2024-01-012024-12-310001477845srt:DirectorMember2024-01-012024-12-310001477845anvs:ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember2024-01-012024-12-310001477845anvs:PerformanceBasedVestingConditionsMember2024-01-012024-12-310001477845anvs:ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember2023-01-012023-12-310001477845us-gaap:EmployeeStockOptionMemberanvs:EquityIncentivePlan2018Member2024-12-310001477845anvs:EquityIncentivePlan2019Member2024-12-310001477845anvs:EquityIncentivePlan2019Member2024-06-120001477845anvs:EquityIncentivePlan2019Member2021-06-010001477845srt:WeightedAverageMemberus-gaap:EmployeeStockOptionMember2024-01-012024-12-310001477845srt:WeightedAverageMemberus-gaap:EmployeeStockOptionMember2023-01-012023-12-310001477845us-gaap:EmployeeStockOptionMember2024-01-012024-12-310001477845us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001477845us-gaap:EmployeeStockOptionMemberanvs:EquityIncentivePlan2019Member2024-01-012024-12-310001477845anvs:ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember2024-01-012024-12-310001477845anvs:ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember2023-01-012023-12-310001477845us-gaap:ResearchAndDevelopmentExpenseMember2024-01-012024-12-310001477845us-gaap:GeneralAndAdministrativeExpenseMember2024-01-012024-12-310001477845us-gaap:ResearchAndDevelopmentExpenseMember2023-01-012023-12-310001477845us-gaap:GeneralAndAdministrativeExpenseMember2023-01-012023-12-310001477845anvs:November2023PrivatePlacementMember2023-11-270001477845anvs:April2023PrivatePlacementMember2023-04-070001477845anvs:March2023AtMarketEquityOfferingMember2023-04-040001477845us-gaap:SubsequentEventMemberanvs:December2024AtMarketEquityOfferingMember2025-01-012025-02-010001477845anvs:CommonStockPurchaseAgreementCommitmentSharesMember2024-01-012024-12-310001477845anvs:November2023EquityOfferingAndWarrantIssuanceMember2023-10-312023-10-310001477845us-gaap:DomesticCountryMemberanvs:GeneratedIn2017AndPriorMember2024-12-310001477845us-gaap:StateAndLocalJurisdictionMember2024-12-310001477845us-gaap:DomesticCountryMember2024-12-310001477845us-gaap:RetainedEarningsMember2024-01-012024-12-310001477845us-gaap:RetainedEarningsMember2023-01-012023-12-310001477845us-gaap:WarrantMember2024-01-012024-12-310001477845anvs:ServiceBasedOptionsMember2024-12-310001477845anvs:ServiceBasedOptionsMember2024-01-012024-12-310001477845anvs:CommonStockPurchaseAgreementMember2024-12-310001477845anvs:CommonStockPurchaseAgreementMember2024-09-300001477845anvs:CommonStockPurchaseAgreementMember2024-06-300001477845us-gaap:FairValueInputsLevel3Member2024-12-310001477845us-gaap:FairValueInputsLevel3Member2023-12-310001477845anvs:WarrantsClassifiedAsEquityMember2023-12-310001477845anvs:WarrantsClassifiedAsEquityMember2024-12-310001477845anvs:November2023EquityOfferingAndWarrantIssuanceMember2023-10-3100014778452022-12-310001477845us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-12-310001477845us-gaap:FairValueInputsLevel1Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001477845us-gaap:WarrantMember2024-01-012024-12-310001477845us-gaap:EmployeeStockOptionMember2024-01-012024-12-310001477845us-gaap:WarrantMember2023-01-012023-12-310001477845us-gaap:EmployeeStockOptionMember2023-01-012023-12-310001477845anvs:MarkWhiteMember2024-12-310001477845anvs:MariaMaccecchiniMember2024-12-310001477845anvs:ClaudineBruckMember2024-12-310001477845anvs:MarkWhiteMember2024-10-012024-12-310001477845anvs:MariaMaccecchiniMember2024-10-012024-12-310001477845anvs:ClaudineBruckMember2024-10-012024-12-3100014778452024-10-012024-12-3100014778452024-06-3000014778452025-03-180001477845us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-12-310001477845us-gaap:CarryingReportedAmountFairValueDisclosureMember2024-12-310001477845anvs:WarrantsClassifiedAsLiabilitiesMember2024-12-310001477845us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-12-310001477845us-gaap:CarryingReportedAmountFairValueDisclosureMember2023-12-310001477845anvs:WarrantsClassifiedAsLiabilitiesMember2023-12-310001477845anvs:WarrantsClassifiedAsLiabilitiesMember2023-10-312023-10-310001477845us-gaap:AdditionalPaidInCapitalMember2023-01-012023-12-310001477845us-gaap:CommonStockMember2023-01-012023-12-310001477845us-gaap:SubsequentEventMember2025-02-032025-02-030001477845us-gaap:ForeignCountryMember2024-01-012024-12-310001477845us-gaap:DomesticCountryMember2024-01-012024-12-310001477845anvs:WarrantsClassifiedAsEquityMember2020-01-310001477845us-gaap:SubsequentEventMemberanvs:SecondaryOfferingMember2025-02-030001477845us-gaap:PrivatePlacementMember2024-03-152024-03-210001477845anvs:CommonStockPurchaseAgreementMember2024-04-252024-04-250001477845srt:ChiefExecutiveOfficerMember2024-12-310001477845us-gaap:SubsequentEventMemberanvs:SecondaryOfferingMember2025-02-032025-02-030001477845anvs:December2024AtMarketEquityOfferingMember2024-01-012024-12-310001477845anvs:November2023PrivatePlacementMember2023-11-272023-11-270001477845anvs:April2023PrivatePlacementMember2023-04-072023-04-070001477845anvs:March2023AtMarketEquityOfferingMember2023-03-312023-04-040001477845anvs:SingleReportableSegmentMember2024-01-012024-12-310001477845anvs:SingleReportableSegmentMember2023-01-012023-12-310001477845anvs:CommonStockPurchaseAgreementMember2024-10-012024-12-310001477845anvs:CommonStockPurchaseAgreementMember2024-07-012024-09-300001477845anvs:CommonStockPurchaseAgreementMember2024-04-262024-06-300001477845us-gaap:CommonStockMember2024-01-012024-12-310001477845us-gaap:AdditionalPaidInCapitalMember2024-01-012024-12-310001477845anvs:WarrantsClassifiedAsLiabilitiesMember2024-01-012024-12-310001477845anvs:WarrantsClassifiedAsLiabilitiesMember2023-11-012023-12-310001477845anvs:CommonStockPurchaseAgreementCommitmentSharesMember2024-12-310001477845srt:MinimumMemberanvs:CommonStockPurchaseAgreementFixedPurchaseMember2024-04-250001477845anvs:CommonStockPurchaseAgreementCommitmentSharesMember2024-04-250001477845anvs:CommonStockPurchaseAgreementMember2024-04-250001477845anvs:CommonStockPurchaseAgreementFixedPurchaseMember2024-04-252024-04-250001477845anvs:CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember2024-04-252024-04-250001477845anvs:CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember2024-04-252024-04-250001477845anvs:WarrantsClassifiedAsEquityMember2024-01-012024-12-310001477845anvs:WarrantsClassifiedAsEquityMember2023-01-012023-12-3100014778452024-01-012024-12-3100014778452023-01-012023-12-310001477845anvs:WarrantsClassifiedAsLiabilitiesMember2023-10-310001477845anvs:December2024AtMarketEquityOfferingMember2024-12-110001477845anvs:March2023AtMarketEquityOfferingMember2023-03-3100014778452024-12-3100014778452023-12-31iso4217:USDxbrli:sharesiso4217:USDxbrli:sharesxbrli:pureanvs:leaseanvs:Voteanvs:Danvs:segment

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 10-K

ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

 

For the fiscal year ended December 31, 2024

OR

 

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Commission file number 001-39202

ANNOVIS BIO, INC.

(Exact name of registrant as specified in its charter)

Delaware
(State or other jurisdiction of
incorporation or organization)

26-2540421
(I.R.S. Employer
Identification No.)

101 Lindenwood Drive, Suite 225

Malvern, PA 19355

(Address of principal executive offices including zip code)

(484875-3192

(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act:

Title of Each Class

     

Trading Symbol

     

Name of Each Exchange on Which Registered

Common Stock, par value $0.0001 per share

 

ANVS

 

New York Stock Exchange

Securities registered pursuant to Section 12(g) of the Act: None.

Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes   No 

Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Exchange Act. Yes   No 

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes   No 

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes  No 

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Large accelerated filer 

Accelerated filer 

Non-accelerated filer 

Smaller reporting company 

Emerging growth company

 

 

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant has filed a report on and attestation to its management’s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.

If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. 

Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant’s executive officers during the relevant recovery period pursuant to Section 240.10D-1(b). 

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes   No 

As of June 30, 2024, the last business day of the registrant’s most recently completed second fiscal quarter, the aggregate market value of the registrant’s common stock held by non-affiliates of the registrant was $51,312,050 based on the closing sale price as reported on the NYSE.

The number of shares of the issuer’s common stock outstanding as of March 18, 2025, was 19,486,231.

Documents Incorporated by Reference

Certain portions, as expressly described in this report, of the registrant’s proxy statement for the 2025 Annual Meeting of the Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K.

TABLE OF CONTENTS

Page

Cautionary Note Regarding Forward-Looking Statements.

2

Summary of Risk Factors.

3

Part I.

5

Item 1.

Business.

5

Item1A.

Risk Factors.

28

Item1B.

Unresolved Staff Comments.

77

Item1C.

Cybersecurity.

77

Item 2.

Properties.

78

Item 3.

Legal Proceedings.

78

Item 4.

Mine Safety Disclosures.

78

Part II.

79

Item 5.

Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

79

Item 7.

Management’s Discussion and Analysis of Financial Condition and Results of Operations.

79

Item 7A.

Quantitative and Qualitative Disclosures About Market Risk.

89

Item 8.

Financial Statements and Supplementary Data.

89

Item 9.

Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

89

Item 9A.

Controls and Procedures.

89

Item 9B.

Other Information.

90

Item 9C.

Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

90

Part III.

91

Item 10.

Directors, Executive Officers and Corporate Governance.

91

Item 11.

Executive Compensation.

91

Item 12.

Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

91

Item 13.

Certain Relationships and Related Transactions and Director Independence.

91

Item 14.

Principal Accountant Fees and Services.

91

Part IV.

92

Item 15.

Exhibits and Financial Statement Schedules.

92

Item 16.

Form 10-K Summary.

93

Index to Financial Statements.

F-1

Signatures.

98

1

Cautionary Note Regarding Forward-Looking Statements.

This Annual Report on Form 10-K contains express or implied forward-looking statements, within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that involve substantial risks and uncertainties. In some cases, you can identify forward-looking statements by the words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “might,” “objective,” “ongoing,” “plan,” “predict,” “project,” “potential,” “should,” “will,” or “would,” and / or the negative of these terms, or other comparable terminology intended to identify statements about the future. These statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report on Form 10-K, we caution you that these statements are based on a combination of facts and factors currently known by us and our expectations of the future, about which we cannot be certain.

The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements about:

our cash and cash equivalents balance, runway and needs, as well as financing plans;
the timing of regulatory submissions;
our ability to obtain and maintain regulatory approval of our existing product candidates and any other product candidates we may develop, and the labeling under any approval we may obtain;
our business strategies;
risks relating to the timing and costs of clinical trials and the timing and costs of other organizational expenses;
risks related to market acceptance of products;
risks associated with our reliance on third-party organizations;
our competitive position;
assumptions regarding the size of the available market, product pricing and timing of commercialization of our product candidates;
our intellectual property position and our ability to maintain and protect our intellectual property rights;
our results of operations, financial condition, liquidity, prospects, and growth strategies;
the industry in which we operate; and
the trends that may affect the industry or us.

You should refer to Part I, Item 1A “Risk Factors” of this Annual Report on Form 10-K for a discussion of important factors that may cause our actual results to differ materially from those expressed or implied by our forward-looking statements. As a result of the risks, uncertainties and assumptions described under “Risk Factors” and elsewhere, we cannot assure you that the forward-looking statements in this Annual Report on Form 10-K will prove to be accurate. Furthermore, if our forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all.

2

You should not rely upon forward-looking statements as predictions of future events. Although we believe that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee that the future results, levels of activity, performance, or events and circumstances reflected in the forward-looking statements will be achieved or occur. We undertake no obligation to update publicly any forward-looking statements for any reason after the date of this report to conform these statements to new information, actual results or changes in our expectations, except as required by law.

Summary of Risk Factors.

The following is a summary of the principal risks described below in Part I, Item 1A “Risk Factors” in this Annual Report on Form 10-K. We believe that the risks described in the “Risk Factors” section are material to investors, but other factors not presently known to us or that we currently believe are immaterial may also adversely affect us. The following summary should not be considered an exhaustive summary of the material risks facing us, and it should be read in conjunction with the “Risk Factors” section and the other information contained in this Annual Report on Form 10-K.

As a result of our history of operating losses and accumulated deficit, there is substantial doubt on our ability to continue as a going concern and therefore, an increased risk associated with an investment in our company.
Our auditor’s opinion on our audited financial statements for the year ended December 31, 2024 includes an explanatory paragraph relating to our ability to continue as a going concern.
We have incurred significant net losses since inception and anticipate that we will continue to incur net losses for the foreseeable future and may never achieve or maintain profitability.
We will require substantial additional capital to fund our operations, and if we fail to obtain necessary funding, we may not be able to complete the development and commercialization of our product candidates.
We have limited operating history and no history of commercializing pharmaceutical products.
Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.
We are heavily dependent on the success of buntanetap, our most advanced product candidate, which is still under clinical development, and if this drug does not receive regulatory approval or is not successfully commercialized, our business will be materially harmed.
We have concentrated our research and development efforts on the treatment of Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”), diseases that have historically seen limited success in drug development. Further, buntanetap is based on a novel approach to treating AD and PD, which makes it difficult to predict the time and cost of development and subsequently, obtaining regulatory approval.
If we are not successful in discovering, developing, and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives may be impaired.
Clinical trials, including the enrollment and retention of patients, are expensive, time-consuming, difficult to design and implement, and involve an uncertain outcome(s).
The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for buntanetap or any other product candidates, our business will be substantially harmed.
Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials. Interim “top-line” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are further subject to audit and verification procedures that could result in material changes in the final data. Furthermore, undue reliance on interim analyses may be detrimental to our long-term clinical development plans, which could harm our business, operating results, prospects or financial condition.

3

Our product candidates may cause serious adverse events or undesirable side effects, which may delay or prevent marketing approval, or, if approved, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.
The market opportunities for buntanetap or any other product candidates, if approved, may be smaller than we anticipate, which could adversely affect our business, financial condition and results of operations.
Even if we obtain regulatory approval for buntanetap or any of our product candidates, we will still face extensive and ongoing regulatory requirements and obligations.
We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.
The successful commercialization of buntanetap and any other product candidates we develop will depend in part on market acceptance; the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies; and our sales, marketing and distribution capabilities.
A variety of risks associated with operating internationally could materially adversely affect our business.
We currently rely on third parties for the production of clinical supply of buntanetap and for the conduct, supervision and monitoring of our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner or do not comply with regulatory standards and requirements, it may harm our business.
Changes in methods of product candidate manufacturing or formulation may result in additional costs or delays.
Enacted and future healthcare and other legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved, and increase the liabilities to which we may become subject, as well as affect the prices we may set or the manner in which we conduct and plan to conduct our business.
If we are unable to obtain, maintain and enforce patent or other intellectual property protection for buntanetap or any future product candidates or technology, or if the scope of the patent protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products similar or identical to ours, our ability to successfully commercialize buntanetap or any future product candidates may be adversely affected and we may not be able to compete effectively in our markets.
We may be subject to claims challenging the inventorship of our patents and other intellectual property. We may additionally become subject to third parties’ claims alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to protect or enforce our patents, which could be costly, time consuming, delay or prevent the development and commercialization of our product candidates or put our patents and other proprietary rights at risk.
The cash and cash equivalents that we use to meet our working capital and operating expense needs are held in deposit accounts at two financial institutions. If one or both financial institutions fail, our deposit accounts could be adversely affected due to the loss of or delay in obtaining access to all or a portion of our uninsured funds.
The market price of our common stock has been volatile and fluctuated substantially in the past, and may continue to experience volatility and substantial fluctuations in the future, which could result in substantial losses for purchasers of our common stock.
We have been subject to securities class action litigation in the past and could be subject to such litigation in the future.

4

PART I

Item 1. Business.

Our Company

We are a late-stage clinical drug platform company addressing neurodegeneration, such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). We are developing our lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. In several studies, buntanetap was observed to inhibit the synthesis of neurotoxic proteins — APP/Aβ (“APP”), tau/phospho- tau (“tau”) and α-Synuclein (“αSYN”) — that are some of the main causes of neurodegeneration. High levels of neurotoxic proteins lead to reduced axonal transport, which is responsible for the communication between and within nerve cells. When that communication is compromised, the immune system is activated and attacks the nerve cells, eventually killing them. We have observed in our clinical studies in early AD and early PD patients and pre-clinical studies in mice and rats that buntanetap lowered neurotoxic protein levels leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved affected function.

In 2021, we completed two Phase 1/2 clinical studies: one in 14 early AD patients, and one in 54 early PD patients (together, the “AD/PD Trial”). In the AD/PD Trials, early AD patients were defined as those with a Mini Mental State Examination (“MMSE”) score between 19 and 28 and early PD patients as those patients at Hoehn & Yahr stages 1, 2 or 3. MMSE is a brief screening instrument used to assess cognitive function, with total scores ranging from 0 to 30 and a lower score indicating greater disease severity, while the Hoehn & Yahr scale is a medical assessment used to measure staging of the functional disability associated with PD where a higher stage indicates greater disease severity. In collaboration with the Alzheimer’s Disease Cooperative Study (“ADCS”), we also conducted a trial in 16 early AD patients (the “ADCS Trial”). In the ADCS Trial, early AD patients were defined as those patients with a MMSE score between 19 and 28. At the completion of the ADCS Trial, the data showed that buntanetap acts as a translational inhibitor in humans just like in animals, and we further observed that there was statistical improvement in cognition in early AD patients, just like in the AD/PD Trials.

All three clinical trials above were double-blind, placebo-controlled. We designed the studies by applying our understanding of the underlying neurodegenerative disease states and measured both target and pathway validation in the spinal fluid of patients to determine whether patients underlying disease condition improved following treatment. In addition to meeting their primary endpoints of safety and tolerability and secondary endpoint of pharmacokinetics (“PK”) of buntanetap, our AD/PD Trials also met exploratory endpoints of measures of biomarkers and improvements in cognition in AD patients, as well as function in PD patients. We believe that the AD/PD Trial represents the first double-blind, placebo-controlled study that showed improvements in AD patients, as measured by Alzheimer’s Disease Assessment Scale-Cognitive Subscale (“ADAS-Cog”) and in PD patients, as measured by Unified Parkinson’s Disease Rating Scale (“MDS-UPDRS” or “UPDRS”). ADAD-Cog is an assessment scale that measures cognitive functions and non-cognitive functions such as mood and behavior. More specifically, ADAS-Cog 11 is the cognitive assessment scale used to measure areas commonly seen to decline in AD patients. It consists of 11 specific tasks such as word recall, comprehension, object-naming, etc., in order to produce a scale measurement. UPDRS Part II and III are composed of a 42-item rating scale designed to assess Parkinson’s disease-related disability and impairment and also evaluate the activities of daily living and motor function.

Following completion of the AD/PD Trial, we submitted our data to the U.S. Food and Drug Administration (“FDA”) and requested direction to further pursue the development of buntanetap in early PD patients. With the FDA’s guidance, we initiated a Phase 3 study in early PD patients in August 2022 (our “Phase 3 PD Study”). In the Phase 3 PD Study, early PD patients were defined as those at Hoehn & Yahr stages 1, 2 or 3 and OFF times of less than two hours per day. OFF time refers to periods when PD motor and/or non-motor symptoms occur between medication doses. We also submitted a proposed protocol for the treatment of moderate AD to the FDA, and after receiving permission to proceed, we initiated a Phase 2/3 study in mild to moderate AD patients in February 2023 (our “Phase 2/3 AD Study”). In the Phase 2/3 AD Study, mild to moderate AD patients were defined as those with a MMSE score between 14 and 24. Our Phase 3 PD Study and Phase 2/3 AD Study each had built in interim analyses.

Our Phase 3 PD Study incorporated an interim analysis at two months, the results of which were disclosed on March 31, 2023. The pre-planned interim analysis was conducted by our data analytics provider based on 132 patients from all cohorts collectively, for which baseline and two-month data was available. Based on the results of the interim analysis, we proceeded with the Phase 3 PD Study as planned in accordance with the previously established protocol. The study was completed on December 4, 2023, and we released the topline PD Study efficacy data on July 2, 2024. The study data showed that in two subgroups, buntanetap

5

improved UPDRS 2, 3, 2+3 and total. It also showed that in the entire intent to treat (“ITT”) population, buntanetap stopped the loss of cognition and that in the 12% of patients that already had cognitive issues, buntanetap improved cognition in a dose-dependent, statistically significant way. We expect to discuss the Phase 3 PD data with the FDA in a Type C meeting during 2025. During that meeting, we plan to propose continued development of buntanetap with an additional, pivotal Phase 3 trial.

With respect to the Phase 2/3 AD Study, we disclosed the results of the interim analysis on October 23, 2023, and similar to our PD study, based on the outcome of the interim analysis, we proceeded with the study as planned. The Phase 2/3 AD study was completed on February 13, 2024, and on April 29, 2024, we announced topline efficacy data. The data showed that in early AD patients, buntanetap improved ADAS-Cog11 in a dose-dependent fashion and was statistically significant from placebo and from baseline.

On October 10, 2024, the Company met with the FDA in an end-of-phase 2 meeting to discuss its Phase 2/3 AD data and to agree on a regulatory path forward. Annovis and the FDA have aligned on a development path for buntanetap towards the filing of New Drug Applications (NDAs), one for short-term and one for long-term efficacy. The Phase 3 AD program will investigate buntanetap in patients with early AD and will consist of one study that first incorporates a 6-month period aimed at confirming buntanetap’s symptomatic effects, while continuing blinded for an additional 12 months to show potential disease-modifying efficacy at 18 months. The completion of the first 6-month period, if well-designed and well-executed, may be sufficient to support an NDA filing, potentially within one year of the 6-month treatment period initiation.

During the end-of-phase 2 meeting for AD, the FDA raised no concerns with the Company’s data on buntanetap’s safety, including impact on liver enzymes, drug interactions, dose selection, pharmacokinetics and population pharmacokinetics. Further, the FDA confirmed that future development can proceed using the new crystal form of buntanetap.

We believe that we are the only company developing a drug for AD and PD that is designed to inhibit more than one neurotoxic protein and has a mechanism of action designed to restore nerve cell axonal and synaptic activity. By improving brain function, our goal is to treat memory loss and dementia associated with AD, as well as body and brain function issues associated with PD. Based on pre-clinical and clinical data collected to date, we believe that buntanetap has the potential to be the first drug to interfere with the underlying mechanism of neurodegeneration, potentially enabling buntanetap to be the only drug to improve cognition in AD and motor function in PD. The industry has historically encountered challenges in specifically targeting one neurotoxic protein, be it APP, tau or αSYN, indicating that doing so does not change the underlying course of neurodegeneration. Our ultimate goal is to develop a disease modifying drug (“DMD”) for patients with neurodegeneration by leveraging our clinical and pre-clinical data, which shows inhibition of the most relevant neurotoxic proteins. Studies have found that AD and PD are the most common neurodegenerative diseases in the U.S., and accordingly these diseases present two unmet needs of the aging population and two potentially large U.S. markets, if a DMD is developed and approved.

Our leadership team has substantial experience and extensive industry knowledge and has been successful with respect to meeting clinical timelines, enrollment progression and data readouts.

Company Leadership

Maria L. Maccecchini, our Founder, President and CEO, founded Annovis in May 2008 to develop improved therapeutics for neurodegeneration. She was previously the Founder and CEO of Symphony Pharmaceuticals/Annovis, a biotech company that was sold to Transgenomic in 2001. She was previously the General Manager of Bachem Bioscience, the U.S. subsidiary of Bachem AG, Switzerland. Dr. Maccecchini completed one postdoc at Caltech and another at the Roche Institute of Immunology. Her PhD in biochemistry is from the Biocenter of Basel with a two-year visiting fellowship at The Rockefeller University.

Cheng Fang, Senior Vice President, Research and Development, has broad scientific knowledge and over a decade of experience working in the field of neurodegenerative diseases. She previously worked at Clarivate Analytics and the Cornell Institute for Medical Research. As a Research Assistant Professor at Boston University, she designed projects that addressed prion diseases and AD. Dr. Fang has a PhD in biology and neuroscience from Pennsylvania State University. She also holds a B.S. in biopharmaceutics from Nanjing University.

Eve Damiano, Senior Vice President, Regulatory, has spent over 35 years in the biotechnology sector, focusing on the definition and execution of regulatory strategies. Ms. Damiano has held various senior management positions throughout her career,

6

with experience garnered at companies including Centocor, MedImmune, OraSure Technologies and Vicuron Pharmaceuticals. Ms. Damiano holds a track record in the definition and execution of regulatory strategies. She holds an M.S. from the Drexel University College of Medicine.

Melissa Gaines, Senior Vice President, Clinical Operations, is an accomplished clinical research professional with over 20 years of experience garnered from positions held in academia, contract research organizations and pharmaceutical companies. She was previously Senior Director, Clinical Operations, for Worldwide Clinical Trials, and has over a decade of experience at INC Research. She has demonstrated proven success in leading cross-functional teams as well as driving operational success. Ms. Gaines holds a B.A. in Psychology from Millersville University of Pennsylvania.

Mike Christie, our Vice President, Process Chemistry, has spent over 40 years working in the pharmaceutical industry, with a focus on process chemistry R&D, pilot plant production and good manufacturing practice (“cGMP”) operations. He has held senior management positions in both large (SmithKline, Rhodia, Teva) and mid-size (Cephalon) companies, as well as being the founder of a company providing contract process R&D services (later acquired by ChiRex). Dr. Christie is co-author or co-inventor on several publications and patents. He earned his BS in chemistry from the University of Michigan and his doctorate from MIT.

Andrew Walsh, our Vice President, Finance, has over 13 years of diverse finance experience at both public and private companies. Prior to joining Annovis, Mr. Walsh served as Senior Director, Finance and Treasury at Ocugen, a Nasdaq-listed biotech developing gene and cell therapies. There he provided oversight over all areas of finance, including SEC Reporting, FP&A, as well as Treasury. He also previously served as Director, Treasury and Tax at Potters Industries, a private equity sponsored materials manufacturer. Mr. Walsh began his career at KPMG as a member of its tax practice. He holds a B.S. in Accounting from Drexel University, summa cum laude.

Mechanism of Action

Our lead product candidate, buntanetap, is designed as an oral translational inhibitor of neurotoxic aggregating proteins such as APP, tau and αSYN. To understand how buntanetap can potentially inhibit translation, we undertook two complementary approaches: a macro approach to examine all proteins in the cell whose translation is affected by buntanetap, and a micro approach to study the mechanism of action using molecular biology, to understand and validate the binding and function.

First, the non-biased proteomics approach was applied to explore what proteins in the total protein universe were specifically downregulated by buntanetap. We have observed that, in addition to the proteins already known to be reduced by buntanetap, other neurotoxic aggregating proteins - huntingtin protein (“HTT”) and TDP43 - were downregulated as well.

A detailed analysis of the reduction of these protein levels was conducted in five different laboratories using multiple methodologies. The results observed in the analysis revealed that the mRNAs of these proteins have a special region, an atypical stem loop, that is preserved and responsible for their translation. When this region is bound to an RNA binding protein, the mRNA is not translated. When this region is free, the mRNA is translated. In neurodegenerative conditions, the mRNA coding for these neurotoxic proteins is over-translated, produces high levels of these proteins and causes them to become toxic. Buntanetap was observed to specifically increase the affinity between this special region and the RNA binding protein, preventing the mRNA from being released and translated.

The process outlined above leads to lower translation, lower levels of neurotoxic proteins, and less toxicity in the brain. By preventing the overexpression of these neurotoxic proteins, buntanetap is designed to reverse the downstream toxic cascade that leads to neurodegeneration and reinstates homeostasis.

7

The following illustration visually depicts the mechanism of action of buntanetap:

Graphic

MOA; Chen XQ et al. Pharmaceutics 09-2021 Iron and Neurodegeneration; Wong f. et al. Frontiers Aging Neuroscience; 03-2022

The special region in the mRNA is a 5’UTR iron responsive element (“IRE”) present in all mRNAs of neurotoxic aggregating proteins. The RNA binding protein is the Iron Regulatory Protein -1 (“IRP1”) that specifically binds the IREs of neurotoxic aggregating proteins.

The Toxic Cascade Leading to Nerve Cell Death and Loss of Function

The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. Buntanetap and ANVS405, our product candidates designed to treat acute neurodegeneration, including traumatic brain injury (“TBI”), have a mechanism of action we believe to be unique. The mechanism of action is designed to inhibit the over-translation of and ultimately reduce the levels of APP, tau and αSYN, which play a central role in the pathogenesis of both AD and PD. This leads us to believe that buntanetap has the potential to be a promising drug for the treatment of both AD and PD. Our approach is innovative in that we do not have a single

8

therapeutic target for a single disease; instead, we are developing a technology platform that has the potential to target the mRNAs of multiple neurotoxic proteins, which are potentially impactful for multiple diseases.

Graphic

In our AD/PD Trials in human AD and PD patients, we observed that buntanetap reduced levels of neurotoxic proteins, improved axonal transport and synaptic function, reduced inflammation, improved the health of nerve cells and improved cognition and function in mild to moderate AD and PD patients. Further, we have also observed that buntanetap reduced the levels of multiple neurotoxic proteins in animals, reversed the entire toxic cascade and recovered the affected function, be it in the brain, the body, or the eyes.

Pipeline

Our pipeline consists of: buntanetap for chronic neurodegeneration - including AD, PD and Lewy Body Dementia - as well as within certain combination therapies summarized below; ANVS405 for acute neurodegeneration; and ANVS301 for advanced AD.

Graphic

9

Buntanetap

Our lead product candidate, buntanetap, is an orally administered drug being developed for chronic indications such as AD and PD. Buntanetap has been observed to improve axonal transport in these diseases in preclinical studies by inhibiting the overproduction of neurotoxic proteins that kill nerve cells. In Phase 2/3 early AD patients, we have seen a statistically significant improvement in ADAS-Cog. In Phase 3 PD patients, we have seen statistically significant improvement in cognition for an ITT population, as well as in UPDRS scores for a per protocol population. The drug has further demonstrated improvements of cognition, including memory and learning, in AD mice, as well as movement, including colonic motility and grip strength, in PD mice. Buntanetap was tested in three Phase 1 clinical studies that showed it to be well tolerated. This safety data is applicable to the clinical development of buntanetap for AD, PD, and potentially other chronic neurodegenerative diseases.

Below is a summary depiction of our previously completed clinical studies of buntanetap. To date, over 1,000 human patients have been treated in the clinic and the drug has consistently shown to be well tolerated with minimal side effects:

Graphic

We believe that buntanetap has the potential to be the only drug to improve both cognition in AD patients, and motor function in PD patients.

ANVS405

ANVS405 is an intravenous drug being developed for acute indications and focused on protecting the brain after Traumatic Brain Injury (“TBI”) and/or stroke. ANVS405 is the same compound as buntanetap, given in cases of acute head and brain trauma. In prior animal studies, ANVS405 was given to rats intravenously after TBI to determine whether ANVS405 would reach the brain in less than 15 minutes, as opposed to 1.5 hours if given orally. TBI rats that were treated with ANVS405 after the injury exhibited enhanced memory and learning and lower microglia activation, a measure of inflammation. The program has previously been funded by a grant from the U.S. Army and has since been completed. We therefore plan to seek additional grant funding to further the development of ANVS405 for acute indications of brain and nerve trauma. If and when we receive such sufficient funding, we plan to conduct a follow-on study to evaluate the effect of ANVS405 administered to TBI rats at various intervals post-injury to determine how long after a TBI a patient can effectively be treated. Our plan is to seek further funding to conduct the toxicology and pharmacokinetics (“PK”) studies in animals, file the initial new drug application (“IND”), conduct the safety and PK studies in humans and later, continue with Phase 2 and Phase 3 efficacy studies.

ANVS301

ANVS301 is an orally administered drug being developed to increase cognitive capability in later stages of AD and dementia. ANVS301 was observed to improve memory and learning in rats of an advanced age by lowering the number of errors from six to three and shortening run times from approximately 75 to approximately 28 seconds. ANVS301 previously finished a single ascending dose Phase 1 clinical trial that was conducted and financed by the National Institutes of Health (“NIH”).

10

Clinical Trials of Buntanetap

Future Development Plan for Alzheimer’s Disease

The future development of buntanetap for AD includes the recently initiated pivotal Phase 3 study for early AD patients. This study was designed to include both a 6-month treatment window to demonstrate symptomatic efficacy, combined with a 12-month extension that will allow the study to achieve an 18-month treatment window that demonstrates disease modifying effects. We also expect future development to include an open-label extension for AD.

In February of 2025, we initiated the Phase 3 AD study of buntanetap in 750 early AD patients, which will be separated into two cohorts of 375 patients (the “Phase 3 AD Trial”). The trial is expected to be conducted at up to 100 sites in the U.S. The Phase 3 AD Trial is a double-blind, placebo-controlled efficacy study which treats early AD patients. The inclusion criteria for early AD is an MMSE score of 21 to 28 and diagnosis according to NIA and NIA-AAA criteria. Patients participating in the trial are age 55-85, have a study partner, are of non-child-bearing age or agree to effective contraception, and have no evidence of suicidal ideation. Additionally, for Phase 3 AD we are incorporating a new biomarker-based inclusion criteria, for a positive reading of pTau217 levels in plasma. pTau217, a phosphorylated form of the tau protein, has been recognized by the FDA as an acceptable early detection biomarker for AD.

Patients participating in the trial can remain on any drugs they regularly take, whether for AD or for other conditions, as long as they are stable on such medication. Patients with uncontrolled diabetes, cardiovascular issues or seizures, patients with clinically significant abnormal laboratory values, patients with cancer within the last year and patients suffering from alcohol or substance abuse are excluded from participating.

Patients are to be randomly assigned to receive either 30 mg of buntanetap or placebo, once per day. Patients will visit the clinic for the first-time dosing in clinic, followed by an at home dosing period of 24/72 weeks. As described above, the study plan calls for opening the blind to a select group of individuals who will analyze the data after the 24-week treatment window, in order to evaluate 6-month efficacy of buntanetap. Study participants will remain blinded and will continue participation for an additional 48 weeks so that buntanetap’s disease modifying efficacy can be evaluated over a total of 18 months.

Below is a visual depiction of the development path and study design for the active Phase 3 AD program:

Graphic

We expect the 6-month symptomatic component of the combined AD trial to read-out in the second half of 2026. The 18-month disease modifying component is expected to read out in the second half of 2027.

Future Development Plan for Parkinson’s Disease

As mentioned above, we also intend to propose a pivotal Phase 3 trial for Parkinson’s patients to the FDA during 2025. Buntanetap has been shown to prevent worsening of cognition in the entirety of our previous Phase 3 ITT population. In the same study, the drug also showed statistically significant improvement in MDS-UPDRS Part II, III, IV, total and MMSE in a per protocol subgroup population. Our plan is to continuing refining a proposed pivotal Phase 3 program design during 2025 and when it is finalized, we will propose a meeting with the FDA to solidify the path forward for clinical development of buntanetap in PD.

11

Similar to the AD program, we also expect to ask the FDA for clearance to add an open-label extension to allow all patients that participate in our pivotal Phase 3 PD program to continue on the medication.

Initiation of the pivotal Phase 3 PD program and open-label extension is also currently contingent on additional fundraising.

Phase 3 PD Trial

In August 2022, we initiated a Phase 3 clinical trial of buntanetap in 450 early PD patients, which were separated into three cohorts of 150 patients (the “Phase 3 PD Trial”). The Phase 3 PD Trial was conducted at 53 sites in the U.S. and 49 sites in the EU. The Phase 3 PD Trial was a double-blind placebo-controlled efficacy study which treated early PD. The inclusion criteria for early PD was Hoehn & Yahr 1, 2 and 3 with less than 2 hours of OFF time, as well as a MMSE score of 22 to 30. Patients participating in the trial were age 40-85, were of non-child-bearing age or agree to effective contraception and had no evidence of suicidal ideation. Patients participating in the trial were permitted to remain on any drugs they regularly took, whether for PD or for other conditions, as long as were stable on such medication. Patients with uncontrolled diabetes, cardiovascular issues or seizures, patients with clinically significant abnormal laboratory values, patients with cancer within the last year and patients suffering from alcohol or substance abuse were excluded from the trial. Patients were randomly assigned to receive either 10 or 20 mg of buntanetap or placebo, once per day. Patients visit the clinic for the first-time dosing in clinic, followed by an at home dosing period of 6 months. The study plan incorporated an interim analysis at two months, the results of which were disclosed by the Company on March 31, 2023. Based on the results of the interim analysis, we proceeded with the Phase 3 PD Study as planned in accordance with the previously established protocol.

The Phase 3 PD Trial’s primary endpoints were evaluated using the following measures: MDS-UPDRS Part II and III. Specifically, The FDA requested two co-primary endpoints to have an objective primary endpoint (MDS-UPDRS Part III, motor function) and a subjective primary endpoint (MDS-UPDRS Part II, activities of daily living). Together, these co-primary endpoints were intended to provide a more complete picture of the study and treatment results. The secondary endpoints were evaluated using the following measures: the MDS-UPDRS total score, which includes the Part II and III measures we well as mentation, behavior, and mood symptoms, and complications of dopaminergic therapy; the participant global impression of change (“PGIC”), a participant-reported outcome which asks how their condition has changed compared to their condition at the beginning of treatment; and the Change on Clinical Global Impression of Severity (“CGIS”), which measures the severity of movement impairment as assessed by a site rater.

The study was completed on December 4, 2023, and we released the topline PD Study efficacy data on July 2, 2024. The data showed that in two subgroups, buntanetap improved UPDRS 2, 3, 2+3 and total score. It also showed that in the entire ITT population, buntanetap stopped the loss of cognition and that in the 12% of patients that already had cognitive issues, buntanetap improved cognition in a dose-dependent, statistically significant way. We expect to discuss the PD data with the FDA at an end-of-study meeting during 2025. During that meeting, we plan to propose continued development of buntanetap with a pivotal Phase 3 trial.

Phase 2/3 AD Trial

In February 2023, we initiated a Phase 2/3 clinical trial of buntanetap in 320 mild to moderate AD patients, which were separated into four cohorts of 80 patients (the “Phase 2/3 AD Trial”). The Phase 2/3 AD Trial was conducted at 64 sites in the U.S. The Phase 2/3 AD Trial was a double-blind, placebo-controlled efficacy study which treated mild to moderate AD. The inclusion criteria for mild to moderate AD was a MMSE score of 14 to 24. Patients participating in the trial were age 55-85, had a study partner, were of non-child-bearing age or agreed to effective contraception, and had no evidence of suicidal ideation. Patients participating in the trial were permitted to remain on any drugs they regularly took, whether for AD or for other conditions, as long as they were stable on such medication. Patients with uncontrolled diabetes, cardiovascular issues or seizures, patients with clinically significant abnormal laboratory values, patients with cancer within the last year and patients suffering from alcohol or substance abuse were excluded from participating.

Patients were randomly assigned to receive either 7.5, 15 or 30 mg of buntanetap or placebo, once per day. Patients visited the clinic for the first-time dosing in clinic, followed by an at home dosing period of 12 weeks. The study plan incorporated an interim analysis at six-weeks, the results of which were disclosed on October 23,2023. Similar to above for the PD study, based on the outcome of the interim analysis, we proceeded with the remaining AD study as planned after the interim analysis.

12

The co-primary endpoints of the Phase 2/3 AD Trial were evaluated using the following measures: ADAS-Cog 11 and ADCS-Clinical Global Impression of Change (“ADCS-CGIC”), which focuses on clinicians’ observations of change in the patient’s cognitive, functional, and behavioral performance since the beginning of a trial. The FDA requested the inclusion of two co-primary endpoints to have an objective primary endpoint (ADAS-Cog, cognition) and a subjective primary endpoint (ADCS-CGIC, activities of daily living). Together, these co-primary endpoints were intended to provide a more complete picture of the study and treatment results. The secondary endpoints were evaluated using the following measures: the ADCS-Instrumental Activities of Daily Living Scale (“ADCS-ADL”), which measures 6 basic activities of daily living items, including basic self-care tasks such as feeding, mobility and bathing, and 17 instrumental activities of daily living items, which include a broad range of activities based on cultural norms and gender roles; MMSE; and the digital symbol substitution test (“DSST”), which asks individuals to record associations between different symbols and numbers within time limits to assess cognition.

The Phase 2/3 AD study was completed on February 13, 2024, and on April 29, 2024, we announced topline efficacy data. The data showed that in a subgroup of early AD patients, buntanetap improved ADAS-Cog11 in a dose-dependent fashion and was statistically significant from placebo and from baseline.

On October 10, 2024, the Company met with the FDA in an end-of-phase 2 meeting to discuss its Phase 2/3 AD data and to agree on a regulatory path forward. Annovis and the FDA have now aligned on a development path for buntanetap towards the filing of New Drug Applications (NDAs), one for short-term and one for long-term efficacy. The Phase 3 program will investigate buntanetap in patients with early AD and will consist of one study that first incorporates a 6-month study period aimed at confirming buntanetap’s symptomatic effects and later moving into an 18-month study period designed to demonstrate potential disease-modifying effects. While the overall study will last for the entire 18 months, the completion of the first 6-month treatment period, if well-designed and well-executed, may be sufficient to support an NDA filing, potentially within one year of the study’s initiation.

During the end-of-phase 2 meeting, the FDA raised no concerns with the Company’s data on buntanetap’s safety, including liver enzymes, drug interactions, dose selection, pharmacokinetics, population pharmacokinetics, and confirmed that development can proceed using the new crystal form of buntanetap.

.Phase 1/2 AD/PD Trials

In 2021, we completed a Phase 1/2 clinical trial of buntanetap in 14 early AD and 54 early PD patients (the “AD/PD Trials”) which were conducted at 12 clinical sites in the U.S. The AD/PD Trials were double-blind, placebo-controlled studies which treated mild to moderate AD and early PD patients for 25 +/- 2 days. The inclusion criteria for the AD portion of the AD/PD Trials were MMSE 18-28 and age 45 and older. For the PD portion of the AD/PD Trials, inclusion criteria were MMSE 18-30, age 45 and older and Hoehn & Yahr 1, 2 or 3. Patients participating in the trial were of non-child-bearing age or agreed to effective contraception and had no evidence of suicidal ideation. Patients participating in the trial could remain on any drugs they regularly took, whether for PD, for AD or for other conditions, as long as they were stable on such medication. Patients with uncontrolled diabetes, cardiovascular issues or seizures, patients with clinically significant abnormal laboratory values, patients who had cancer within the prior year and patients who suffered from alcohol or substance abuse were excluded from the trial.

The AD/PD Trials were designed to assess the safety, tolerability, and PK of buntanetap. The studies met their primary endpoints of safety and tolerability, as measured by the percentage of patients with treatment-emergent adverse events in the buntanetap treatment arms as compared to the placebo groups, and secondary endpoint of pharmacokinetics of buntanetap, as measured by the concentration of buntanetap in plasma. The studies also met exploratory endpoints of measures of biomarkers related to neurotoxic protein cascade, and improvements in cognition in AD patients and function in PD patients. We believe the AD/PD Trials were the first double-blind, placebo-controlled studies that showed improvements in AD patients as measured by ADAS-Cog, and in PD patients as measured by UPDRS.

The studies were conducted in two parts. The first part of the AD/PD Trials was in 14 early AD patients and 14 early PD patients. Patients were randomly assigned to receive either 80 mg of buntanetap or placebo, once per day. The second part of the AD/PD Trials was a dose response analysis performed in 40 early PD patients in which patients were randomly assigned to receive 5 mg, 10 mg, 20 mg, or 40 mg of buntanetap, once per day. In both parts of the AD/PD Trials, patients visited the clinic for the first-time dosing in clinic, followed by an at home dosing period of 25 +/- 2 days. We measured levels of neurotoxic proteins, neurotransmitters, neurotrophic factors, inflammation, and nerve cell death in all patients, as well as cognitive and functional improvements.

13

Safety results showed that buntanetap was well-tolerated in all dose groups. No serious adverse events were reported. The adverse events seen included problems related to CNS sampling: headaches, back and leg pain. PK parameters for buntanetap in plasma of AD and PD patients were similar to those seen in Phase 1 in our single ascending dose (“SAD”) and multiple ascending dose (“MAD”) studies in healthy volunteers, and in a proof-of-concept study in mild-cognitive impaired (“MCI”) patients.

We observed that buntanetap administration for 25 days lowered secreted APP α and β as well as total-tau and phosphorylated-tau levels in AD patients, and alpha-synuclein levels in PD patients. APP and its downstream products and tau are the neurotoxic proteins involved in AD, while αSYN is the primary neurotoxic culprit of PD.

CSF was extracted before starting the study at baseline and at time 0 to 6 hours at the end of the study in both placebo and buntanetap treated patients. The values from time 0 to 6 hours were pooled to lower variability and the placebo values were deducted from the treated values. In all but one case, Ab42, we saw that the levels in buntanetap treated patients were lower than in placebo patients. With respect to Ab42, we observed that levels were slightly higher, which is consistent with our hypothesis that Ab42 levels are lower in advanced AD and higher in early AD. We believe that higher Ab42 levels we observed suggest that the course of AD was reversed and the patients improved. Again, CSF was extracted at baseline and for 6 hours after the study and the values of the placebo patients were subtracted from the buntanetap treated patients. We observed that inflammatory markers were generally reduced in both patient populations.

We observed that buntanetap reduced neurofilament light (“NFL”) levels in both AD and PD patients, suggesting a potential improvement in axonal integrity. We also observed that buntanetap reduced neurogranin (“NG”) levels in both AD and PD, potentially suggesting more intact synaptic functions. The same CSF as above was used to measure neurofilament light and neurogranin before and after treatment and to compare buntanetap patients to placebo. In both patient populations, neurofilament light and neurogranin are lower in treated than in placebo patients.

These results suggest that buntanetap has the potential to reduce neurotoxic proteins, rescue axonal transport, reduce inflammation, and protect synaptic functions.

We performed ADAS-Cogs and WAIS coding tests to evaluate buntanetap’s effects on AD patients’ cognition. ADAS-Cog11 was performed at the beginning of the study at baseline and at the end at 25 days in the buntanetap-treated and the placebo groups. Although the study was not powered for efficacy, ADAS-Cog11 improved by 4.4 points, a statistically significant improvement of 28.57%. An improvement in ADAS-Cog11, which is reflected by a lower ADAS-Cog11 result, indicates increased cognitive performance. At 25 days, the treated group’s improvement from baseline was 3.3 points, or 20.71%, better than the placebo group’s improvement from baseline.

The WAIS coding test measures speed in movement and thinking. Treated AD patients showed a 6.6 point, or 16.17%, statistically significant improvement from baseline. Furthermore, the treated group’s improvement from baseline was 3.1 points, or 8.8%, better than the placebo group’s improvement from baseline.

In Parkinson’s disease, we pooled the original 14 PD patients with the additional 40 PD patients and looked at the MDS-UPDRS and WAIS coding tests to evaluate buntanetap’s effects on PD patients’ mobility and functionality. The 54 PD patients received doses of either 5mg, 10mg, 20mg, 40mg or 80mg buntanetap treatment or placebo, once per day. We observed a statistically significant improvement in UPDRS Part II, III and IV individually. Specifically, Part III of the MDS-UPDRS measures the motor functions and has long been used as a standard to assess drugs’ effects on patients’ mobility.

We combined the two best doses, 10 and 20 mgs, and all doses, and saw an improvement of 3.6 (16.4%) for 10 and 20 mg, and of 2.4 (13.3%) for all doses combined compared to baseline. In the WAIS coding test, PD patients showed a statistically significant improvement both from baseline (17.1% for 10+20mg; 13.3% for all doses combined) and from placebo (27.1% for 10+20mg; 23.3% for all doses combined).

Axonal Transport in Human Nerve Cells

When the information highway of a nerve cell slows down, the nerve cell is unable to properly communicate with other nerve cells, internal organs and the periphery and it gets sick and dies.

14

The transfer of information in a nerve cell is called axonal transport. Axonal transport is responsible for:

Neurotransmitters GABA (anxiety), ACh (cognition), dopamine (movement), serotonin (mood)
Neurotrophic factors NGF, BDNF, and
All communication within and between nerve cells

When transport and synaptic transmission are impaired, the cell releases lower levels of neurotransmitters, leading to impaired nerve cell health. The diseased cell is then attacked by the immune system, which is activated when it detects a diseased cell, and it eventually kills the cell. Impairment in axonal transport, therefore, leads to inflammation and eventually to nerve cell death. This is visually illustrated below.

Graphic

TBI Study in Rats

TBI causes severe cognitive and neurological impairment, which can incapacitate the patient, reduce quality of life, and increase the risk of morbidity and mortality. TBI is known to increase the risk for neurodegenerative disorders such as AD and PD. Several studies have analyzed changes in the brain after TBI and identified up-regulation of neurotoxic proteins, such as APP, tau, and αSYN.

In our study, rats were subjected to either fluid percussion injury (“FPI”) or sham operation to one side of the brain. Three different ANVS405 doses or saline were given intraperitoneally to rats subjected to FPI for four weeks, with the first dose administered one-hour post-injury. At the termination of the treatment, all of the rats were first tested for their performance in a water

15

maze, and then they were sacrificed for brain staining of living cells and determination of microglia activation. 10 mg/kg ANVS405 was shown to improve memory and learning as measured by water maze performance. Furthermore, sections of the brain were stained with tyrosine hydroxylase (“TH”), wherein TH stains only live cells. The amounts of TH immunoreactivity in the whole striatum of the brain slices were measured. The rats treated with all three doses of ANVS405 showed higher TH staining in the ipsilateral area of the brain than the vehicle treated animals. Thus, ANVS405 demonstrated the ability to protect the striatum following FPI in rats.

Because FPI can induce microglial activation, we next checked whether ANVS405 would reverse this pathology. In our study, we found that ANVS405 increased the number of resting microglia and reduced the number of activated microglia.

Stroke Mice Model

Buntanetap was also tested in a stroke model, in which mice were challenged with MCAo-induced stroke (middle carotid artery occlusion induced stoke) and after four weeks, the number of surviving neurons was quantified. After four weeks the locomotor function, behavior, and cognition of these mice were also evaluated.

Buntanetap, in combination with pifithrin-α (“PFT-α”) given to mice after the induced stroke improved mice locomotor activity and cognitive function. While both treatments yielded improvements in locomotor and cognitive function, the combined buntanetap/PFT-α treatment proved able to enhance stroke-induced endogenous neurogenesis and improve the functional recovery in stroke animals. The combined treatment also significantly improved cognitive function more than the single treatment with PFT-α.

Potential Markets for our Lead Drug Candidate

With there being a very large potential market for neurodegenerative diseases, most pharma companies have a program studying some aspect of nerve and brain degeneration. Some newer approaches target tau, whose expression is more closely associated with cognitive decline. Similarly, for PD, several companies are trying to inhibit αSYN. So far, we believe that generally, neither drugs attacking tau nor αSYN have shown positive results. Hence there is a substantial need for a new and different disease-modifying strategy. There is more than one neurotoxic protein in the brain of AD and of PD patients, and the same neurotoxic proteins are involved in the pathogenesis of AD and PD.

Graphic

A significant portion of AD patients’ brains display mixed PD pathology and vice versa. Therefore, just attacking one of these proteins may result in no or lower efficacy than attacking them all. To prove that this approach is possible, we are studying the effects of buntanetap on the levels of several neurotoxic proteins and other surrogate markers, in parallel, in both AD and PD patients.

16

Alzheimer’s Disease Market

AD is a neurodegenerative disorder with cognitive, functional, and behavioral alterations. AD is age-related, and its incidence is increasing with the aging of the population. It is estimated that currently 55 million victims of AD or some form of dementia exist in the world and by 2050, the number will grow to nearly 140 million people worldwide. In the United States, it is estimated that there are nearly seven million patients with AD currently and that by 2060, the number of people aged 65 and older with AD is projected to reach nearly 14 million people. Nearly eightfold as many people have preclinical AD as have symptomatic AD and are at risk for progressing to full manifestation of the disease. Disease modifying treatments (“DMTs“) that will prevent or delay the onset or slow the progression of AD are urgently needed. Similarly, medications to effectively improve cognition or ameliorate neuropsychiatric symptoms of patients in the symptomatic phases of AD are needed to improve memory and behavior.

The incidence rate of AD increases significantly with age. Individuals between ages 64 to 75 have an incidence rate of 0.4%, which increases to 3.2% for people between ages 75 and 84 and finally to 7.6% for people aged 85 and above. These incidence rates are cumulative as an individual ages, which means that an individual reaching 90 years of age will have a 38% chance of suffering from AD while an individual reaching the age of 95 will have a 76% chance of suffering from AD. AD is becoming increasingly common as the global population ages and as the health systems in developing countries improve. There is a significant need to identify drugs that prevent, delay the onset, slow the progression, or improve the symptoms of AD.

Parkinson’s Disease Market

PD is also a progressive neurodegenerative disorder with both movement and non-movement symptoms, functional, behavioral and cognitive alterations. PD, like AD, is age-related and is becoming markedly more common with the aging of the world’s population. PD affects about 1% of the population over the age of 60, while in individuals over the age of 85, this prevalence reaches 5%, highlighting the impact that advancing age has on the risk of developing this condition.

PD affects more than 10 million people worldwide, of which nearly one million are in the U.S. While a 2014 study estimated that the incidence in the U.S. will rise to 1.2 million by 2030, a later 2022 study found that there are nearly 90,000 new cases of PD diagnosed each year in the U.S., potentially supporting an even greater future incidence rate. By 2050, the number of worldwide PD patients is expected to grow to up to 30 million.

The National Parkinson’s Foundation estimates that the economic burden of PD is at least $25 billion a year in the United States.

To date, there are no available treatments capable of curing PD, with current therapies seeking only to ameliorate dopamine-related motor symptoms of the disease. There is a clear and unmet medical need for new DMTs that can slow or prevent PD progression.

Mixed Pathologies Market

In addition to the unmet need of AD and PD patients, approximately 50% of patients exhibit mixed pathologies, with some pathologies resembling AD and some resembling PD.

Dementia is increasingly being recognized in cases of PD; such cases are termed PD dementia (“PDD”). The spread of fibrillar αSYN pathology from the brainstem to limbic and neocortical structures seems to be the strongest neuropathological correlate of emerging dementia in PD. Up to 50% of patients with PDD develop sufficient numbers of Aβ plaques and tau-containing neurofibrillary tangles for a secondary diagnosis of Alzheimer’s disease, and these pathologies may act synergistically with αSYN pathology to confer a worse prognosis.

Another study looked at the incidence of mixed pathologies diagnosed community-dwelling older persons. Those with dementia most often have multiple brain pathologies, which greatly increases the odds of dementia. Specifically, in people with dementia, over 50% had multiple diagnoses (AD, PD/Lewy body dementia, PDD or infarcts). After accounting for age, persons with multiple diagnoses were almost three times more likely to exhibit dementia compared to those with one pathologic diagnosis.

17

We believe that a therapy that only addresses Aβ, tau or αSYN is less likely to help people with mixed pathologies. Since buntanetap is designed to inhibit more than one neurotoxic protein, we believe that it may have the potential to slow or eventually stop AD, PD and mixed pathology diseases.

Therapeutic Approaches and Competition

Alzheimer’s Disease Approaches

Drug development for AD has historically proven to be very difficult. Drugs which have been approved for the treatment of AD include cholinesterase inhibitors (tacrine, donepezil, rivastigmine, galantamine),an N-methyl-D-aspartate receptor antagonist (memantine) and more recently, monoclonal antibody treatments (donanemab, lecanemab). Many failures in AD drug development have occurred, with both small molecules and immunotherapies failing to show a dramatic drug/placebo difference or having unacceptable toxicity.

Most clinical trials conducted have addressed amyloid targets. Since Aβ accumulates for years before the symptoms of AD are visible, some pharmaceutical companies are testing their drugs earlier, including in cognitively normal people or those who have genetic profiles that place them at high(er) risk for developing AD.

An increasing number of agents are also directed at tau-related targets. Neurofibrillary tangles are one of two major pathological hallmarks of AD. Correlation studies conducted by Braak and Braak demonstrate that neurofibrillary tangle burden more closely correlates with cognitive decline than amyloid plaque load. Several phase 3 studies conducted with tau approaches have failed. There are still several anti-tau approaches in the clinic.

In summary, at present there are few disease-modifying agents currently on the market and existing treatments show limited efficacy. Previous large efforts to develop a DMD for AD has targeted Aβ42, but many Aβ42 approaches to date have failed and again, have shown limited efficacy when treating AD. Further, most companies testing tau have shown negative results as well. As a result, many organizations have pulled out of AD research and are waiting to see if a new or alternative approach may have a better outcome. Since the AD brain contains several neurotoxic proteins—amyloid precursor protein and its toxic fragments Aβ42 and IC99, as well as tau and αSYN, we believe an Aβ42-only approach is not sufficient in order to develop a DMD drug. We believe that a DMD drug needs to target more than just one toxic protein to be efficacious and we are developing buntanetap with this approach in mind. A concerning observation derived from a review of the existing industry AD pipeline is the lack of agents targeting the moderate to advanced stages of AD. With over 15 million people affected by AD dementia worldwide, there is an urgent need to develop more effective symptomatic treatments for moderate to advanced stage disease. The paucity of agents directed at this population represents a significant weakness of the AD drug development pipeline.

Parkinson’s Disease Approaches

Levodopa (“L-DOPA”) was introduced for use in treating PD more than 40 years ago and remains the mainstay of therapy for improving the symptoms of the disease. Unlike dopamine, which cannot cross the blood—brain barrier, L-DOPA is effectively absorbed into the brain, where it metabolizes into dopamine. It is typically administered five times a day and works well in controlling symptoms for one to five years. Unfortunately, the effects of L-DOPA in any patient diminish with time. There are several other drugs available to treat PD, which also seek to modulate dopamine levels. Combination drug therapy is common in PD. For instance, the use of other drug classes such as the catechol-O-methyltransferase (“COMT”) inhibitors and the monoamine oxidase (“MAO”) inhibitors allow patients to reduce L-DOPA dosing levels.

The current global market for PD drugs is estimated at $5 to $6 billion worldwide, despite high-volume generics. The most important current therapy for PD, L-DOPA, is prescribed as a generic. While volume growth in the category is expected to remain healthy, dollar growth will likely remain relatively flat as some of the category’s larger brands contend with generic inroads. The size of the current market reflects the absence of innovative branded therapies more than it does the medical need.

So far, we believe that only buntanetap and Exenatide are in the later stages of clinical development for disease-modification and no products have yet shown efficacy in PD patients long term. Although several drugs have shown potential neuroprotective ability in preclinical studies, demonstrating these effects in clinical studies remains a challenge. Beyond drug therapies, a few cell and gene therapy approaches are also being explored. Progress across these newer technology platforms has been slow.

18

Intellectual Property Overview

We strive to protect and enhance the proprietary technologies, inventions and improvements that we believe are important to our business, including seeking, maintaining and defending patent rights, whether developed internally or licensed from third parties. Our policy is to seek to protect our proprietary position by, among other methods, pursuing and obtaining patent protection in the United States and in jurisdictions outside of the United States related to our proprietary technology, inventions, improvements, platforms and our product candidates that are important to the development and implementation of our business.

Annovis has filed fourteen (14) families of patents and patent applications to prolong the patent life of buntanetap. The pending patent applications invented and filed by Annovis include claims directed to:

a method of treating neurodegenerative diseases such as AD and PD;
a method of treating and/or preventing acute brain and nerve injuries;
a method of prevention and treatment of disease states due to metal dis-homeostasis such as AD or PD as well as other acute or chronic neurodegenerative diseases;
a method of treating viral and bacterial infections of the brain, including COVID-19;
a method of inhibiting cancer metastasis;
combinations of buntanetap with some drugs and uses of these combinations to treat neurodegenerative diseases;
a method of treating neuropsychiatric indications;
a new composition of matter of Posiphen, Form B or ANVS402; and
new methods for making buntanetap and Posiphen Form B.

Solid forms of chemical compounds can exist in different crystalline structures. One crystalline structure of Posiphen is buntanetap. Annovis, through its research efforts, invented a new crystalline form of Posiphen, known as Form B (“ANVS402”). Form B, or ANVS402, has demonstrated certain improvements over buntanetap and was filed as a new composition of matter patent application.

As of February 9, 2024, our patent portfolio comprised 39 total issued patents plus 18 pending patent applications in various jurisdictions.

The patents, granted and if granted based on the pending applications, have expiration dates between 2031 and 2045. The first patent application family we filed, which would be expected to expire in 2031, before any patent term adjustments or extensions, covers the use of buntanetap in the treatment of AD, PD and other neurodegenerative disorders such as Huntington’s disease, prion diseases, amyotrophic lateral sclerosis, tauopathies, frontotemporal dementia, Lewy bodies disease, and chronic traumatic encephalopathy, based on our preclinical research. In August 2019, the U.S. Patent and Trademark Office (“USPTO”) granted the first of our Annovis patents from this family covering treatment of PD and Lewy body diseases. Subsequently, the USPTO also granted patents covering treatment frontotemporal dementia and Prion’s disease, tauopathies, chronic traumatic encephalopathy, prion diseases, amyotrophic lateral sclerosis, Alzheimer’s and Huntington’s disease.

The second patent application family covers ANVS405’s use in acute brain and nerve trauma and would be expected to expire in 2036, before any patent term adjustments or extensions. In December 2020, the EPO approved the whole patent and it has since been approved in most countries filed claiming a method of treating acute nerve and brain injuries by administering ANVS405 before and after the injury. The US patent office instead has asked us to separate the application into four divisional applications covering stroke, traumatic brain injury, nerve injury and spinal cord injury.

19

The third patent application family relates to the use of the mechanism of action of buntanetap and ANVS405 to prevent and treat neurodegenerative diseases and would be expected to expire in 2038, before any patent term adjustments or extensions. The first divisional of this application was approved in December 2022, it covers the prevention of neurodegenerative diseases.

The fourth patent application family relates to a method of inhibiting, preventing, or treating neurological injuries due to viral, bacterial, fungal, protozoan, or parasitic infections in humans and in animals via administration of buntanetap or related compounds. In May 2020, we filed a patent application with the USPTO concerning a method of inhibiting, preventing, or treating neurological injuries due to viral, bacterial, fungal, protozoan, or parasitic infections in humans and in animals via administration of buntanetap or related compounds, which would be expected to expire in 2041, before any patent term adjustments or extensions.

The fifth patent family application is directed to a method of maintaining heavy metal homeostasis avoiding the effect of toxic levels of a heavy metal in cells in a healthy human or restoring heavy metal homeostasis in a sick human patient. The USPTO granted the first patent in this family on March 7, 2023, which is expected to expire in 2039, before any patent term adjustments or extensions.

The sixth patent application family relates to treating brain metastasis via administration of buntanetap or related compounds. In September 2023, we filed a U.S. nonprovisional patent application directed to treatment of brain metastasis via administration of buntanetap or related compounds with the USPTO, which, if allowed, would be expected to expire in 2043, before any patent term adjustments or extensions.

The seventh patent application family relates to treatment of mental illness via administration of buntanetap or related compounds. In January 2024, we filed an International (PCT) application and a U.S. nonprovisional patent application directed to treatment of mental illness via administration of buntanetap or related compounds with the USPTO, which, if allowed, would be expected to expire in 2044, before any patent term adjustments or extensions.

The eighth patent application family relates to treatment of neurodegenerative diseases and other diseases via co-administration of buntanetap or related compounds and an antidiabetic agent. In September 2024, we filed an International (PCT) application and a U.S. nonprovisional patent application directed to treatment of neurodegenerative diseases and other diseases via administration of this combination.

The ninth patent application family relates to treatment of neurodegenerative diseases and other diseases via co-administration of buntanetap or related compounds and a phosphodiesterase inhibitor. In September 2024, we filed an International (PCT) application and a U.S. nonprovisional patent application directed to treatment of neurodegenerative diseases and other diseases via administration of this combination.

The tenth patent application family relates to treatment of neurodegenerative diseases and other diseases via co-administration of buntanetap or related compounds and an antihypertensive agent. In September 2024, we filed an International (PCT) application and a U.S. nonprovisional patent application directed to treatment of neurodegenerative diseases and other diseases via administration of this combination.

The eleventh patent application family relates to treatment of neurodegenerative diseases and other diseases via co-administration of buntanetap with two additional therapeutic agents. In August 2024, we filed a provisional U.S. Patent application directed to treatment of neurodegenerative diseases and other diseases via administration of this combination.

The twelfth patent application family relates to treatment of neurodegenerative diseases and other diseases via co-administration of buntanetap or related compounds and an additional therapeutic agent. In February 2025, we filed a provisional U.S. Patent application directed to treatment of neurodegenerative diseases and other diseases via administration of this combination.

The thirteenth patent application family relates to the new Form B of Posiphen (ANVS402); it demonstrates that it can be used instead of buntanetap, including in the foregoing uses of buntanetap of the Company’s patent portfolio. Posiphen Form B may be the compound of choice in current uses of buntanetap, because it may have advantageous properties such as better stability and higher purity. In 2023, the Company filed with the USPTO two provisional patent applications as to Posiphen Form B. In 2024, the Company filed an International (PCT) as to Posiphen Form B and uses thereof. The “International Search Report and Written Opinion” issued by the USPTO in the prosecution of the PCT application was favorable, indicating that the searched claims directed to Posiphen Form

20

B are novel and inventive. The Company expects to further file patent applications in the U.S. and outside the U.S. as National and Regional Phase patent applications of the PCT application. As to this family of patent applications involving Posiphen Form B and uses thereof, patents would be expected to expire in 2044, before any patent term adjustments or extensions. The Company also expects to seek New Chemical Entity status for Posiphen Form B before the US Food and Drug Administration (FDA), and to seek additional regulatory exclusivity based thereon.

The fourteenth patent application family relates to new, improved and commercially advantageous methods for preparing buntanetap and Posiphen Form B. The Company sees this patent application family as providing further protection as to methods that use buntanetap or Posiphen form B, and for Posiphen form B. More in particular, in 2024 the Company filed with the USPTO a provisional patent application directed to these new methods of for preparing buntanetap and Posiphen Form B. The Company expects in 2025 to further file at least an International (PCT) application, claiming priority from that provisional patent application, and directed to the new, improved and commercially advantageous methods for preparing buntanetap and Posiphen Form B, and thereafter patent applications in the U.S. and outside the U.S. as National and Regional Phase patent applications of the PCT application. As to this family of patent applications, patents would be expected to expire in 2045, before any patent term adjustments or extensions.

It is possible that we will fail to identify further patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own may fail to result in issued patents with claims that provide further coverage of buntanetap or any other product candidate in the United States or in other foreign countries.

Furthermore, we rely upon trade secrets and know-how and continuing technological innovation to develop and maintain our competitive position. We seek to protect our proprietary information, in part, using confidentiality agreements with our collaborators, employees and consultants and invention assignment agreements with our employees. We also have confidentiality agreements or invention assignment agreements with our collaborators and selected consultants.

Sales and Marketing

If buntanetap is approved for AD or PD, we plan to enter into sales and marketing agreements with one or several pharmaceutical companies to sell to neurologists, geriatric specialists and to primary care physicians. We also may explore the use of a variety of types of collaboration, co-promotion, distribution and other marketing arrangements with one or more third parties to commercialize our product candidates.

Manufacturing

Buntanetap is a small molecule that is manufactured using a patented process. We do not own, operate, and currently have no plans to establish, any manufacturing facilities. We therefore rely, and expect to continue to rely, solely on third-party contractors for manufacturing clinical supplies for our current and future potential product candidates, and plan to do so for commercial supplies also if any of our product candidates received marketing approval. We also rely on these third parties for encapsulating, packaging and stabilizing clinical trial materials. Presently we are working with a U.S. supplier for the manufacture of cGMP active pharmaceutical ingredient (API) to meet our buntanetap clinical study supply demands. We have also engaged a backup API manufacturing contractor, with primary operations in China. We also have an agreement with a local U.S. supplier for the encapsulating, packaging, and stability of the clinical trial material. These arrangements will allow us to enter large and long-term advanced clinical studies. We have only limited supply agreements in place with respect to buntanetap and our product candidates, and these arrangements do not currently extend to commercial supply. We do not have long-term committed arrangements with respect to buntanetap, any of our other product candidates, or other materials.

Government Regulation

The FDA and comparable regulatory authorities in state and local jurisdictions and in other countries impose substantial and burdensome requirements upon companies involved in the clinical development, manufacturing, marketing and distribution of drugs, such as those we are developing. These agencies and other federal, state and local entities regulate, among other things, the research and development, testing, manufacturing, quality control, safety, effectiveness, labeling, storage, record-keeping, approval, advertising and promotion, distribution, post-approval monitoring and reporting, sampling and export and import of our product candidates.

21

U.S. Government Regulation of Drug Products

In the United States, the FDA regulates drugs under the Federal Food, Drug, and Cosmetic Act (“FDCA”) and its implementing regulations. Failure to comply with the applicable U.S. requirements at any time during the product development process, approval process or after approval, may subject an applicant to a variety of administrative or judicial sanctions, such as the FDA’s refusal to approve pending NDAs, withdrawal of an approval, imposition of a clinical hold, issuance of warning letters, product recalls, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement or civil or criminal penalties.

The process required by the FDA before a drug may be marketed in the United States generally involves the following:

Completion of preclinical laboratory tests, animal studies and formulation studies in compliance with the FDA’s good laboratory practice regulations.
Submission to the FDA of an Investigational New Drug application (“IND”), which must become effective before human clinical trials may begin.
Approval by an independent institutional review board (“IRB”), at each clinical site before each trial may be initiated.
Performance of adequate and well-controlled human clinical trials in accordance with good clinical practice (“GCP”), requirements to establish the safety and efficacy of the proposed drug product for each indication.
Submission to the FDA of an NDA.
Satisfactory completion of an FDA advisory committee review, if applicable.
Satisfactory completion of an FDA inspection of the manufacturing facility or facilities at which the product is produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the drug’s identity, strength, quality and purity.
Satisfactory completion of FDA audits of clinical trial sites to assure compliance with GCPs and the integrity of the clinical data.
Payment of user fees and securing FDA approval of the NDA.
Compliance with any post-approval requirements, including the potential requirement to implement a Risk Evaluation and Mitigation Strategy (“REMS”) and the potential requirement to conduct post-approval studies.

Preclinical Studies

Preclinical studies include laboratory evaluation of product chemistry, toxicity and formulation, as well as animal studies to assess potential safety and efficacy. An IND sponsor must submit the results of the preclinical tests, together with manufacturing information, analytical data and any available clinical data or literature, among other things, to the FDA as part of an IND. Some preclinical testing may continue even after the IND is submitted. An IND automatically becomes effective 30 days after receipt by the FDA, unless before that time the FDA raises concerns or questions related to one or more proposed clinical trials and places the clinical trial on a clinical hold. In such a case, the IND sponsor and the FDA must resolve any outstanding concerns before the clinical trial can begin. As a result, submission of an IND may not result in the FDA allowing clinical trials to initiate.

Clinical Trials

Clinical trials involve the administration of the investigational new drug to human subjects under the supervision of qualified investigators in accordance with GCP requirements, which include the requirement that all research subjects provide their informed consent in writing for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other

22

things, the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. A protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, an IRB at each institution participating in the clinical trial must review and approve the plan for any clinical trial before it initiates at that institution. Information about certain clinical trials must be submitted within specific timeframes for public dissemination on www.clinicaltrials.gov.

Human clinical trials are typically conducted in three sequential phases, which may overlap or be combined:

Phase 1: The drug is initially introduced into healthy human subjects or patients with the target disease or condition and tested for safety, dosage tolerance, absorption, metabolism, distribution, excretion and, if possible, to gain an early indication of its effectiveness.
Phase 2: The drug is administered to a limited patient population to identify possible adverse effects and safety risks, to preliminarily evaluate the efficacy of the product for specific targeted diseases and to determine dosage tolerance and optimal dosage.
Phase 3: The drug is administered to an expanded patient population, generally at geographically dispersed clinical trial sites, in well-controlled clinical trials to generate enough data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk-benefit profile of the product, and to provide adequate information for the labeling of the product.

Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur.

Special FDA Expedited Review and Approval Programs

The FDA has various programs, including fast track designation, accelerated approval, priority review, and breakthrough therapy designation, which are intended to expedite or simplify the process for the development and FDA review of drugs that are intended for the treatment of serious or life-threatening diseases or conditions and demonstrate the potential to address unmet medical needs. The purpose of these programs is to provide important new drugs to patients earlier than under standard FDA review procedures.

To be eligible for a fast-track designation, the FDA must determine, based on the request of a sponsor, that a product is intended to treat a serious or life-threatening disease or condition and demonstrates the potential to address an unmet medical need. The FDA will determine that a product will fill an unmet medical need if it will provide a therapy where none exists or provide a therapy that may be potentially superior to existing therapy based on efficacy or safety factors. The FDA may review sections of the NDA for a fast-track product on a rolling basis before the complete application is submitted, if the sponsor provides a schedule for the submission of the sections of the NDA, the FDA agrees to accept sections of the NDA and determines that the schedule is acceptable, and the sponsor pays any required user fees upon submission of the first section of the NDA.

The FDA may give a priority review designation to drugs that offer major advances in treatment or provide a treatment where no adequate therapy exists. A priority review means that the goal for the FDA to review an application is six months, rather than the standard review of ten months under current PDUFA guidelines. Under the current PDUFA agreement, these six- and ten-month review periods are measured from the “filing” date rather than the receipt date for NDAs for new molecular entities, which typically adds approximately two months to the timeline for review and decision from the date of submission. Most products that are eligible for fast-track designation are also likely to be considered appropriate to receive a priority review.

In addition, products tested for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may be eligible for accelerated approval and may be approved on the basis of adequate and well-controlled clinical trials establishing that the drug product has an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit, or on a clinical endpoint that can be measured earlier than irreversible morbidity or mortality (“IMM”) that is reasonably likely to predict an effect on IMM or other clinical benefit, taking into account the severity, rarity or prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require a

23

sponsor of a drug receiving accelerated approval to perform post-marketing studies to verify and describe the predicted effect on IMM or other clinical endpoint, and the drug may be subject to accelerated withdrawal procedures.

Moreover, under the provisions of the Food and Drug Administration Safety and Innovation Act passed in July 2012, a sponsor can request designation of a product candidate as a “breakthrough therapy.” A breakthrough therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening disease or condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. Drugs designated as breakthrough therapies are also eligible for accelerated approval. The FDA must take certain actions, such as holding timely meetings and providing advice, intended to expedite the development and review of an application for approval of a breakthrough therapy. Annovis would like to petition the FDA to classify buntanetap as a breakthrough therapy in the future.

Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or decide that the time period for FDA review or approval will not be shortened. We may explore some of these opportunities for our product candidates as appropriate.

Orphan Drug Designation and Exclusivity

Under the Orphan Drug Act, the FDA may designate a drug product as an “orphan drug” if it is intended to treat a rare disease or condition (generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a drug product available in the United States for treatment of the disease or condition will be recovered from sales of the product). A company must request orphan product designation before submitting an NDA. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan product designation does not convey any advantage in or shorten the duration of the regulatory review and approval process.

If a product with orphan status receives the first FDA approval for a disease or condition, the product generally will be receiving orphan product exclusivity. Orphan product exclusivity means that the FDA may not approve any other applications for the same product for the same indication for seven years, except in certain limited circumstances. If a drug or drug product designated as an orphan product ultimately receives marketing approval for an indication broader than what was designated in its orphan product application, it may not be entitled to exclusivity. Orphan exclusivity will not bar approval of another product under certain circumstances, including if a subsequent product with the same active ingredient for the same indication is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care, or if the company with orphan drug exclusivity is not able to meet market demand. Further, the FDA may approve more than one product for the same orphan indication or disease if the products contain different active ingredients. Moreover, competitors may receive approval of different products for the indication for which the orphan product has exclusivity or obtain approval for the same product but for a different indication for which the orphan product has exclusivity.

Marketing Approval and Post-Approval Requirements

Assuming successful completion of the required clinical testing, the results of the preclinical and clinical studies, together with detailed information relating to the product’s chemistry, manufacture, controls and proposed labeling, among other things, are submitted to the FDA as part of an NDA requesting approval to market the product for one or more indications. In most cases, the submission of an NDA is subject to a substantial application user fee. Under the Prescription Drug User Fee Act (“PDUFA”) guidelines that are currently in effect, the FDA has a goal of ten months from the date of “filing” of a standard NDA, for a new molecular entity to review and act on the submission. This review typically takes twelve months from the date the NDA is submitted to FDA because the FDA has approximately two months to make a “filing” decision.

The FDA also may require submission of a REMS plan to ensure that the benefits of the drug outweigh its risks. The REMS plan could include medication guides, physician communication plans, assessment plans, and/or elements to assure safe use, such as restricted distribution methods, patient registries, or other risk minimization tools.

The FDA conducts a preliminary review of all NDAs within the first 60 days after submission, before accepting them for filing, to determine whether they are sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA reviews an NDA to determine, among other things, whether the drug is safe and

24

effective and whether the facility in which it is manufactured, processed, packaged or held meets standards designed to assure the product’s continued safety, quality and purity.

Before approving an NDA, the FDA typically will inspect the facility or facilities where the product is manufactured. Additionally, before approving an NDA, the FDA may inspect one or more clinical trial sites to assure compliance with GCP requirements.

The FDA may refer an application for a novel drug to an advisory committee. While the FDA is not bound by the recommendations of an advisory committee, it considers such recommendations carefully when making decisions.

After evaluating the NDA and all related information, including the advisory committee recommendation, if any, and inspection reports regarding the manufacturing facilities and clinical trial sites, the FDA may issue an approval letter, or, in some cases, a complete response letter. A complete response letter generally contains a statement of specific conditions that must be met in order to secure final approval of the NDA and may require additional clinical or preclinical testing for the FDA to reconsider the application. If and when those conditions have been met to the FDA’s satisfaction, the FDA will typically issue an approval letter. An approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications.

Even if the FDA approves a product, it may limit the approved indications for use of the product, require that contraindications, warnings or precautions be included in the product labeling, require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess a drug’s safety after approval, require testing and surveillance programs to monitor the product after commercialization, or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS.

Once an approval of a drug or medical device is granted, the FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in mandatory revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things:

Restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls.
Fines, warning letters or holds on post-approval clinical trials.
Refusal of the FDA to approve pending NDAs or supplements to approved NDAs, or suspension or revocation of product approvals.
Product seizure or detention, or refusal to permit the import or export of products.
Injunctions or the imposition of civil or criminal penalties.

The FDA strictly regulates marketing, labeling, advertising and promotion of products that are placed on the market. Drugs or devices may be promoted only for the approved indications and in accordance with the provisions of the approved label. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses, and a company that is found to have improperly promoted off-label uses may be subject to significant liability.

U.S. Coverage and Reimbursement

Significant uncertainty exists as to the coverage and reimbursement status of our lead product candidate, buntanetap, or any other candidate for which we may seek regulatory approval. Sales in the U.S. will depend in part on the availability of adequate financial coverage and reimbursement from third-party payors, which include government health programs such as Medicare,

25

Medicaid, TRICARE and the Veterans Administration, as well as managed care organizations and private health insurers. Prices at which we or our customers seek reimbursement for our product candidates can be subject to challenge, reduction or denial by payors.

The process for determining whether a payor will provide coverage for a product is typically separate from the process for setting the reimbursement rate that the payor will pay for the product. Third-party payors may limit coverage to specific products on an approved list or formulary, which might not include all the FDA-approved products for a particular indication. Also, third-party payors may refuse to include a branded drug on their formularies or otherwise restrict patient access to a branded drug when a less costly generic equivalent or another alternative is available. Medicare Part D, Medicare’s outpatient prescription drug benefit, contains protections to ensure coverage and reimbursement for oral oncology products, and all Part D prescription drug plans are required to cover substantially all oral anti-cancer agents. However, a payor’s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be available. Private payors often rely on the lead of the governmental payors in rendering coverage and reimbursement determinations. Sales of buntanetap or any other product candidates will therefore depend substantially on the extent to which the costs of our products will be paid by third-party payors. Achieving favorable coverage and reimbursement from the Centers for Medicare and Medicaid Services (“CMS”) and/or the Medicare Administrative Contractors is typically a significant gating issue for successful introduction of a new product.

Third-party payors are increasingly challenging the price and examining the medical necessity and cost-effectiveness of medical products and services, in addition to their safety and efficacy. In order to obtain coverage and reimbursement for any product that might be approved for marketing, we may need to conduct studies in order to demonstrate the medical necessity and cost-effectiveness of any products, which would be in addition to the costs expended to obtain regulatory approvals. Third-party payors may not consider our product candidates to be medically necessary or cost-effective compared to other available therapies, or the rebate percentages required to secure favorable coverage may not yield an adequate margin over cost or may not enable us to maintain price levels sufficient to realize an appropriate return on our investment in drug development.

U.S. Healthcare Fraud and Abuse Laws and Compliance Requirements

We are subject to various federal and state laws targeting fraud and abuse in the healthcare industry. These laws may impact, among other things, our proposed sales and marketing programs. In addition, we may be subject to patient privacy regulation by both the federal government and the states in which we conduct our business. The laws that may affect our operations include:

the federal Anti-Kickback Statute, which prohibits, among other things, persons from soliciting, receiving, offering or paying remuneration, directly or indirectly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, order or recommendation of, an item or service reimbursable under a federal healthcare program, such as the Medicare and Medicaid programs. The term “remuneration” has been broadly interpreted to include anything of value;
federal false claims and civil monetary penalties laws, including the federal civil False Claims Act, which prohibits anyone from, among other things, knowingly presenting, or causing to be presented, for payment to federal programs (including Medicare and Medicaid) claims for items or services that are false or fraudulent;
provisions of the U.S. federal Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which created new federal criminal statutes that prohibit, among other things, knowingly and willfully executing a scheme to defraud any healthcare benefit program or making false statements in connection with the delivery of or payment for healthcare benefits, items or services. In addition, HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act and its implementing regulations, impose certain requirements relating to the privacy, security and transmission of individually identifiable health information; and
the federal Physician Payment Sunshine Act requirements, under the Patient Protection and Affordable Care Act, which require manufacturers of certain drugs and biologics to track and report to CMS payments and other transfers of value they make to U.S. physicians and teaching hospitals as well as physician ownership and investment interests in the manufacturer.

26

Regulation Outside of the United States

To the extent that any of our product candidates, once approved, are sold in a foreign country, we may be subject to similar foreign laws and regulations, which may include, for instance, applicable post-marketing requirements, including safety surveillance, anti-fraud and abuse laws and implementation of corporate compliance programs and reporting of payments or other transfers of value to healthcare professionals.

To market our future products in the European Economic Area (“EEA”), which is comprised of the 27 Member States of the EU plus Norway, Iceland and Liechtenstein, and many other foreign jurisdictions, we must obtain separate regulatory approvals. More concretely, in the EEA, medicinal products can only be commercialized after obtaining a Marketing Authorization (“MA”). There are two types of MAs:

The Community MA, which is issued by the European Commission through the Centralized Procedure, based on the opinion of the Committee for Medicinal Products for Human Use of the European Medicines Agency (“EMA”) and which is valid throughout the entire territory of the EEA. The Centralized Procedure is mandatory for certain types of products, such as biotechnology medicinal products, orphan medicinal products and medicinal products indicated for the treatment of AIDS, cancer, neurodegenerative disorders, diabetes, auto-immune and viral diseases. The Centralized Procedure is optional for products containing a new active substance not yet authorized in the EEA, or for products that constitute a significant therapeutic, scientific or technical innovation or which are in the interest of public health in the EU; and
National MAs, which are issued by the competent authorities of the Member States of the EEA and only cover their respective territory, are available for products not falling within the mandatory scope of the Centralized Procedure. Where a product has already been authorized for marketing in a Member State of the EEA, this National MA can be recognized in another Member State through the Mutual Recognition Procedure. If the product has not received a National MA in any Member State at the time of application, it can be approved simultaneously in various Member States through the Decentralized Procedure.

Under the above-described procedures, before granting the MA, the EMA or the competent authorities of the Member States of the EEA assess the risk-benefit balance of the product based on scientific criteria concerning its quality, safety and efficacy.

Data and Marketing Exclusivity

In the EEA, new products authorized for marketing, or reference products, qualify for eight years of data exclusivity and an additional two years of market exclusivity upon marketing authorization. The data exclusivity period prevents generic or biosimilar applicants from relying on the pre-clinical and clinical trial data contained in the dossier of the reference product when applying for a generic or biosimilar marketing authorization in the EU during a period of eight years from the date on which the reference product was first authorized in the EU. The market exclusivity period prevents a successful generic or biosimilar applicant from commercializing its product in the EU until 10 years have elapsed from the initial authorization of the reference product in the EU. The 10-year market exclusivity period can be extended to a maximum of eleven years if, during the first eight years of those 10 years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies.

Orphan Drug Designation

In the EEA, a medicinal product can be designated as an orphan drug if its sponsor can establish that the product is intended for the diagnosis, prevention or treatment of a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the EU when the application is made, or that the product is intended for the diagnosis, prevention or treatment of a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify the necessary investment in development. For either of these conditions, the applicant must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the drug will be of significant benefit to those affected by that condition.

27

In the EEA, an application for designation as an orphan product can be made any time prior to the filing of an application for approval to market the product. Marketing authorization for an orphan drug leads to a ten-year period of market exclusivity. During this market exclusivity period, the EMA or the member state competent authorities, cannot accept another application for a marketing authorization, or grant a marketing authorization, for a similar medicinal product for the same indication. The period of market exclusivity is extended by two years for medicines that have also complied with an agreed PIP.

This period may, however, be reduced to six years if, at the end of the fifth year, it is established that the product no longer meets the criteria for orphan drug designation, for example because the product is sufficiently profitable not to justify market exclusivity. Market exclusivity can be revoked only in very selected cases, such as consent from the marketing authorization holder, inability to supply sufficient quantities of the product, demonstration of “clinical superiority” by a similar medicinal product, or, after a review by the Committee for Orphan Medicinal Products, requested by a member state in the fifth year of the marketing exclusivity period (if the designation criteria are believed to no longer apply). Medicinal products designated as orphan drugs are eligible for incentives made available by the EU and its Member States to support research into, and the development and availability of, orphan drugs.

Human Capital

As of February 28, 2025, we had eight full-time employees. We also utilize the services of seven key part-time employees or consultants. We contract with consultants and third parties for the conduct of certain clinical development, accounting and administrative activities. We anticipate hiring of additional employees as we continue to advance our clinical trial programs. None of our employees are represented by labor unions or covered by collective bargaining agreements.

Our human capital resource objectives include, as applicable, identifying, recruiting, retaining, training, incentivizing, and integrating our existing and new employees, advisors and consultants. We offer competitive compensation packages that are competitive within our industry. We incentivize high performance through an annual bonus program based on organizational performance, for which all employees are eligible. We also offer equity incentive plans, the purpose of which are to attract, retain and reward personnel through the granting of stock-based compensation awards. These awards are granted in order to align employee and consultant performance incentives with objectives that will increase stockholder value.

Corporate Information

We were incorporated in Delaware in 2008. Our principal executive offices are located at 101 Lindenwood Drive, Suite 225, Malvern, PA 19355 and our telephone number is (484) 875 3192.

Available Information

We file annual, quarterly, and current reports, proxy statements, and other documents with the SEC under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). The SEC maintains an internet website, www.sec.gov, that contains reports, proxy, and information statements, and other information regarding issuers, including us, that file electronically with the SEC. Copies of each of our filings with the SEC on Form 10-K, Form 10-Q, and Form 8-K and amendments to those reports, can be viewed and downloaded free of charge at our website, www.annovisbio.com, as soon as reasonably practicable after the reports and amendments are electronically filed with or furnished to the SEC. Our website and the information contained on, or that can be accessed through, our website shall not be deemed to be incorporated by reference in, and is not considered part of this Annual Report on Form 10-K.

Item 1A. Risk Factors

Risks Related to Our Financial Position and Need for Additional Capital

Our recurring operating losses, negative cash flows from operations, and accumulated deficit raise substantial doubt about our ability to continue as a going concern, if we are unable to obtain additional financings.

Management has concluded that substantial doubt exists about the Company’s ability to continue as a going concern for the next twelve months from the date of the financial statements included in this Annual Report on Form 10-K. As of December 31, 2024, we had cash and cash equivalents of $10.6 million and current liabilities of $3.9 million. We believe that we have sufficient resources

28

available to support our development activities and business operations and satisfy our obligations into the fourth quarter of 2025. We do not have sufficient cash and cash equivalents as of the date of this Annual Report on Form 10-K to support our operations for at least the 12 months following the date that the financial statements are issued.

We will require substantial additional financing to fund our ongoing clinical trials and future operations, and to continue to execute our corporate strategy. To alleviate the conditions that raise substantial doubt about our ability to continue as a going concern, we plan to explore various dilutive and non-dilutive opportunities, including equity and debt financings, strategic partnerships, business development and other transactions. The future success of the Company is dependent upon our ability to obtain additional funding. There can be no assurance, however, that we will be successful in obtaining sufficient amounts of funding, on terms acceptable to us, or at all. Failure to obtain sufficient capital on acceptable terms when needed would have a material adverse effect on our business, results of operations, and financial condition. Accordingly, we have concluded that substantial doubt exists with respect to our ability to continue as a going concern within one year after the date that these financial statements are issued.

The report of our independent registered accounting firm on our audited financial statements for the fiscal year ended December 31, 2024 contains an explanatory paragraph relating to our ability to continue as a going concern.

The auditor’s opinion on our audited financial statements for the year ended December 31, 2024 includes an explanatory paragraph stating that we have incurred recurring losses from operations that raise substantial doubt about our ability to continue as a going concern for the next twelve months from the date of the financial statements included in this Annual Report on Form 10-K. While we believe that we will be able to raise the capital we need to continue our operations, there are no assurances that we will be successful in these efforts or will be able to resolve our liquidity issues or eliminate our operating losses. If we are unable to obtain sufficient funding, we would need to significantly reduce our operating plans and curtail some or all of our development efforts. Accordingly, our business, prospects, financial condition, and results of operations will be materially and adversely affected, and we may be unable to continue as a going concern. If we seek additional financing to fund our business activities in the future and there remains substantial doubt about our ability to continue as a going concern, investors or other financing sources may be unwilling to provide additional funding on commercially reasonable terms or at all.

We have incurred significant net losses since inception and anticipate that we will continue to incur net losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability.

Biopharmaceutical product development is a highly speculative undertaking and involves a substantial degree of risk. We are a clinical stage biopharmaceutical company with a limited operating history and have incurred losses since our formation. We incurred net losses of $24.6 million and $56.2 million for the years ended December 31, 2024 and 2023, respectively. In addition, the Company’s operating loss was $26.7 million and $45.0 million for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, we had an accumulated deficit of $134.8 million. We have not commercialized any products and have never generated revenue from the commercialization of any product. To date, we have devoted most of our financial resources to research and development, including our preclinical and clinical work, and to intellectual property.

We expect to incur significant additional operating losses for the next several years, at least, as we advance buntanetap and any other product candidates through clinical development, complete clinical trials, seek regulatory approval and commercialize the drug or any other product candidates, if approved. The costs of advancing product candidates into each clinical phase tend to increase substantially over the duration of the clinical development process. Therefore, the total costs to advance any of our product candidates to marketing approval in even a single jurisdiction will be substantial. Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses or when, or if, we will be able to begin generating revenue from the commercialization of any products or achieve or maintain profitability. Our expenses will also increase substantially if and as we:

continue to progress our development in AD and PD with additional pivotal Phase 3 studies, or conduct clinical trials for any other product candidates;
scale-up cGMP drug supply manufacturing and complete necessary work to support an NDA for buntanetap in AD or in PD;

29

are required by the FDA to complete additional toxicological/pharmacological studies to support an NDA for buntanetap in AD or in PD;
establish a sales, marketing and distribution infrastructure to commercialize our drug, if approved, and for any other product candidates for which we may obtain marketing approval;
maintain, expand and protect our intellectual property portfolio;
hire additional clinical, scientific and commercial personnel;
add operational, financial and management information systems and personnel, including personnel to support our product development and future commercialization efforts, as well as to support our requirements as a public reporting company; and
acquire or in-license or invent other product candidates or technologies.

Furthermore, our ability to successfully develop, commercialize and license any product candidates and generate product revenue is subject to substantial additional risks and uncertainties, as described under “—Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval” and “—Risks Related to Commercialization.” This will require us to be successful in a range of challenging activities, including completing clinical trials of buntanetap and any other product candidates, acquiring additional product candidates, obtaining regulatory approval for buntanetap and any other product candidates, and manufacturing, marketing, and selling any products for which we may obtain regulatory approval. As a result, we expect to continue to incur net losses and negative cash flows for the foreseeable future. These net losses and negative cash flows have had, and will continue to have, an adverse effect on our stockholders’ equity and working capital. The amount of our future net losses will depend, in part, on the rate of future growth of our expenses and our ability to generate revenues. If we are unable to develop and commercialize one or more product candidates, either alone or through collaborations, or if revenues from any product that receives marketing approval are insufficient, we will not achieve profitability. Even if we do achieve profitability, we may not be able to sustain profitability or meet outside expectations for our profitability. If we are unable to achieve or sustain profitability or to meet outside expectations for our profitability, the value of our company will be materially and adversely affected. Furthermore, this could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product candidates, achieve our strategic objectives or even continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.

We will require substantial additional capital to fund our operations, and if we fail to obtain necessary financing, we may not be able to complete the development and commercialization of buntanetap.

The development of biopharmaceutical product candidates is capital-intensive. Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to advance the clinical development of buntanetap. If we obtain receive regulatory approval for buntanetap or any other product candidates, we also expect to incur significant commercialization expenses related to product manufacturing, marketing, sales, and distribution. We will require additional capital for the further development and potential commercialization of buntanetap and may also need to raise additional funds sooner to pursue a more accelerated development of buntanetap. Because the outcome of any clinical trial or preclinical study is highly uncertain, we cannot reliably estimate the actual amount of financing necessary to successfully complete the development and commercialization of buntanetap or any other product candidates. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts.

Based on our current operating plan, we believe that our current cash and cash equivalents will enable us to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2025. We have based this estimate on assumptions that may prove to be wrong, and we could deploy our available capital resources sooner than we currently expect. Our operating plans and other demands on our cash resources may change as a result of many factors currently unknown to us, and we may need to seek additional funds sooner than planned. Our current cash and cash equivalents will not be sufficient to complete development of buntanetap or any other product candidates, and we will require substantial capital in order to advance buntanetap or any other product candidates through clinical trials, regulatory approval and commercialization. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. Our ability to raise additional funds may be adversely impacted by

30

potential worsening global economic conditions and the disruptions to, and volatility in, the credit and financial markets in the United States and worldwide resulting from factors that include but are not limited to, inflation, progression of geopolitical events (including in the relation to the conflict between Russia and Ukraine and the conflict between Hamas and Israel), diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates, and uncertainty about economic stability. If the equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research and development programs or any future commercialization efforts, or even cease operations. We expect to finance our cash needs through public or private equity or debt financings or other capital sources, including potential collaborations, licenses and other similar arrangements. In addition, we may seek additional capital due to favorable market conditions or strategic considerations even if we believe we have sufficient funds for our current or future operating plans. Attempting to secure additional financing may divert our management from our day-to-day activities, which may adversely affect our ability to develop buntanetap or any other product candidates.

Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:

the initiation, progress, timing, costs and results of preclinical studies and clinical trials, including patient enrollment in such trials, for buntanetap or any other future product candidates;
the clinical development plans we establish for buntanetap and any other future product candidates, including any modifications to clinical development plans based on feedback that we may receive from regulatory authorities;
the number and characteristics of product candidates that we discover or in-license and develop;
the outcome, timing and cost of regulatory meetings and reviews by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than those that we currently expect;
the requirements of regulatory authorities in any additional jurisdictions in which we may seek approval for buntanetap and any future product candidates and our anticipated timing for seeking approval in such jurisdictions;
the costs of filing, prosecuting, defending and enforcing any patent claims and maintaining and enforcing other intellectual property and proprietary rights;
the effects of competing technological and market developments;
the costs associated with hiring additional personnel and consultants as our business grows, including additional executive officers and clinical development, regulatory, CMC, quality and commercial personnel;
the costs and timing of the implementation of commercial-scale manufacturing activities, if any product candidate is approved, including as a result of inflation, any supply chain issues or component shortages;
the costs and timing of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval;
our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products;
the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and
the costs associated with any products or technologies that we may in-license or acquire;

Conducting clinical trials and preclinical studies and potentially identifying future product candidates is a time consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to

31

obtain regulatory approval and commercialize buntanetap or any future product candidates. If approved, buntanetap and any future product candidates may not achieve commerciab success. Our commercial revenue, if any, will initially be derived from sales of buntanetap, which we do not expect to be commercially available for many years, if at all. Accordingly, we will need to continue to rely on additional financing to achieve our business objectives. Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to expand our operations or otherwise capitalize on our business opportunities due to a lack of capital, our ability to become profitable will be compromised.

Raising additional capital may cause dilution to our stockholders, restrict our operations, or require us to relinquish rights to our technologies or product candidates.

Until such time, if ever, that we can generate substantial revenue, we may finance our cash needs through a combination of equity offerings, debt financings, marketing and distribution arrangements and other collaborations, strategic alliances and licensing arrangements or other sources. We do not currently have any committed external source of funds. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe that we have sufficient funds for our current or future operating plans.

To the extent that we raise additional capital through the sale of equity or convertible debt securities, the ownership interest of our stockholders will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends. Such restrictions could adversely impact our ability to conduct our operations and execute our business plan. If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our technologies, intellectual property, future revenue streams or product candidates or grant licenses on terms that may not be favorable to us and/or that may reduce the value of our common stock. If we are unable to raise additional funds through equity or debt financings when needed, we would be required to delay, limit, reduce or terminate product candidate development or future commercialization efforts, or grant rights to develop and market product candidates that we might otherwise prefer to develop and market ourselves, or on less favorable terms than we would otherwise choose.

We have limited operating history and no history of commercializing pharmaceutical products.

We were established and began operations in 2008. Our operations to date have been primarily focused on conducting preclinical and clinical studies. We have not yet demonstrated the ability to successfully complete a large-scale, pivotal clinical trial, obtain marketing approval, manufacture a commercial scale product, arrange for a third party to do so on our behalf, or conduct sales and marketing activities necessary for successful product commercialization. Consequently, any predictions made about our future success or viability may not be as accurate as they could be if we had a history of successfully developing and commercializing biopharmaceutical products. In addition, as a business with a limited operating history, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors.

As we continue to build our business, we expect our financial condition and operating results may fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, reliance should not be placed upon the results of any particular quarterly or annual period as indications of future operating performance.

Our ability to use our tax net operating losses is uncertain.

We have incurred significant net operating losses since our inception. As of December 31, 2024, we had U.S. federal net operating loss carryforwards of approximately $54.1 million. Our ability to utilize these net operating losses to offset future tax liabilities depends on the successful development of our product candidates and future financial performance.

Additionally, our net operating losses may be subject to Section 382 of the Internal Revenue Code of 1986, as amended (“Section 382”). Generally, if an ownership change occurs within three years of the closing date of an entity’s most recent change in control transaction, any existing net operating losses and certain built-in losses would be subject to an additional limitation, pursuant to Section 382. Change in control as defined by Section 382 occurs when there is an ownership change among stockholders owning directly or indirectly 5% or more of our common stock, as well as an aggregate ownership change with respect to such stockholders of

32

more than 50% of our common stock. We have not yet conducted a comprehensive study to assess whether a change of ownership as defined by Section 382 has occurred since our inception. If it is determined that we are unable to use our net operating losses to reduce future tax liabilities, our financial condition, results of operations, and cash flows may be adversely affected.

Inflation could adversely affect our business and results of operations.

While inflation in the United States has been relatively low in recent years, during 2023 and 2024, the economy in the United States encountered a material level of inflation. The residual impacts of COVID-19, geopolitical developments such as the Russia-Ukraine and Israel-Hamas conflict and global supply chain disruptions continue to increase uncertainty in the outlook of near-term and long-term economic activity, including whether inflation will continue and how long, and at what rate. Increases in inflation raise our costs for commodities, labor, materials and services and other costs required to grow and operate our business, and failure to secure these on reasonable terms may adversely impact our financial condition. Additionally, increases in inflation, geopolitical developments and global supply chain disruptions, have caused, and may in the future cause, global economic uncertainty and uncertainty about the interest rate environment, which may make it more difficult, costly or dilutive for us to secure additional financing. A failure to adequately respond to these risks could have a material adverse impact on our financial condition, results of operations or cash flows.

Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price.

The global credit and financial markets have recently experienced extreme volatility and disruptions, including severely diminished liquidity and credit availability, declines in consumer confidence, declines in economic growth, increases in unemployment rates and uncertainty about economic stability. The financial markets and the global economy may also be adversely affected by the current or anticipated impact of military conflict, including the conflict between Russia and Ukraine, Isreal and Hamas, terrorism or other geopolitical events. Sanctions imposed by the United States and other countries in response to such conflicts, including the one in Ukraine, may also adversely impact the financial markets and the global economy, and any economic countermeasures by the affected countries or others could exacerbate market and economic instability. There can be no assurance that further deterioration in credit and financial markets and confidence in economic conditions will not occur. Our general business strategy may be adversely affected by any such economic downturn, volatile business environment or continued unpredictable and unstable market conditions. If the current equity and credit markets deteriorate, it may make any necessary debt or equity financing more difficult, more costly and more dilutive. Failure to secure any necessary financing in a timely manner and on favorable terms could have a material adverse effect on our growth strategy, financial performance and stock price and could require us to delay, limit, reduce, or terminate our product development or future commercialization efforts or grant rights to develop and market our product candidates even if we would otherwise prefer to develop and market such product candidates ourselves, or on less favorable terms than we would otherwise choose. In addition, if one or more of our current service providers, manufacturers and other partners may not survive an economic downturn, which could directly affect our ability to attain our clinical development goals on schedule and on budget.

Risks Related to Development, Clinical Testing, Manufacturing and Regulatory Approval

We are heavily dependent on the success of buntanetap, our most advanced product candidate, which is still under clinical development, and if this drug does not receive regulatory approval or is not successfully commercialized, our business will be materially harmed.

We do not have any products that have gained regulatory approval. Currently, our lead clinical stage product candidate is buntanetap. As a result, our business is entirely dependent on our ability to successfully complete clinical development of, obtain regulatory approval for, and, if approved, successfully commercialize buntanetap in a timely manner. This may make an investment in our company riskier than similar companies that have multiple product candidates in active development and may be able to better sustain the delay or failure of a lead product candidate. We cannot commercialize buntanetap in the United States without first obtaining regulatory approval from the FDA; similarly, we cannot commercialize buntanetap outside of the United States without obtaining regulatory approval from comparable foreign regulatory authorities. Before obtaining regulatory approvals for the commercial sale of buntanetap for a target indication, we must demonstrate with substantial evidence gathered in preclinical studies and clinical trials, generally including two adequate and well-controlled clinical trials, and, with respect to approval in the United States, to the satisfaction of the FDA, that buntanetap is safe and effective for use for that target indication and that the manufacturing

33

facilities, processes and controls are adequate. If the FDA is not satisfied with the quantity and nature of the data we collect, we may be forced to undertake additional preclinical studies or clinical trials to obtain regulatory approval, which will lead to delays in our clinical development plans and cause us to incur additional costs, both of which may have a material adverse effect on our business. Even if buntanetap were to successfully obtain approval from the FDA and comparable foreign regulatory authorities, any approval might contain significant limitations related to use restrictions for specified age groups, warnings, precautions or contraindications, or may be subject to burdensome post-approval study or risk management requirements. If we are unable to obtain regulatory approval for buntanetap in one or more jurisdictions, or any approval contains significant limitations, we may not be able to obtain sufficient funding or generate sufficient revenue to continue the development of any other product candidate that we may in-license, develop or acquire in the future. Furthermore, even if we obtain regulatory approval for buntanetap, we will still need to develop a commercial organization, establish commercially viable pricing and obtain approval for adequate reimbursement from third-party and government payors. If we are unable to successfully commercialize buntanetap, we may not be able to earn sufficient revenue to continue our business.

If we are not successful in discovering, developing and commercializing additional product candidates, our ability to expand our business and achieve our strategic objectives would be impaired.

Research programs to identify product candidates require substantial technical, financial and human resources, whether or not any product candidates are ultimately identified. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for many reasons, including the following:

competitors may develop alternatives that render any product candidates we develop obsolete;
any product candidates we develop may nevertheless be covered by third parties’ patents or other exclusive rights;
a product candidate may be shown to have harmful side effects or other characteristics that indicate it is unlikely to be effective or otherwise does not meet applicable regulatory criteria;
a product candidate may not be capable of being produced in commercial quantities at an acceptable cost, or at all; and
a product candidate may not be accepted as safe and effective by physicians, patients, the medical community or third-party payors.

We have limited financial and personnel resources and, as a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater market potential. Our resource allocation decisions may cause it to fail to capitalize on viable commercial drugs or profitable market opportunities. If we do not accurately evaluate the commercial potential or target market for a particular product, we may relinquish valuable rights to that product through collaboration, licensing or other royalty arrangements in circumstances under which it would have been more advantageous for us to retain sole development and commercialization rights to such product. If we are unsuccessful in identifying and developing additional product candidates or are unable to do so, our business, results of operations, cash flows, financial condition and/or prospects may be materially and adversely affected.

Business disruptions could harm our ability to complete or could materially delay our clinical trials, as well as cause disruptions to the FDA and other governmental authorities.

Our operations and the operations of our suppliers, contract research organizations (“CROs”), hospitals, clinical trial sites, regulators, consultants and other third parties with whom we conduct business could be subject to earthquakes, power shortages, telecommunications or infrastructure failures, cybersecurity incidents, physical security breaches, water shortages, floods, hurricanes, typhoons, blizzards and other extreme weather conditions, fires, and other natural or manmade disasters or business interruptions, for which we are predominantly self-insured. We rely on third-party manufacturers or suppliers to produce buntanetap and its components and on CROs and clinical sites to conduct our clinical trials, and do not have a redundant source of supply for all components of our product candidate. Our ability to obtain clinical or, if approved, commercial, supplies of buntanetap or any future product candidates could be disrupted if the operations of these suppliers were affected by a man-made or natural disaster or other business interruption, and our ability to commence, conduct or complete our clinical trials in a timely manner could be similarly adversely affected by any of

34

the foregoing. The occurrence of any of these business disruptions could seriously harm our operations and financial condition and increase our costs and expenses.

Clinical trials are expensive, time-consuming and difficult to design and implement, and involve an uncertain outcome.

Clinical development is expensive and can take many years to complete, and its outcome is inherently uncertain. Failure can occur at any time during the clinical trial process. Because the results of preclinical studies and early clinical trials are not necessarily predictive of future results, buntanetap and our other product candidates may not have favorable results in later preclinical and clinical studies or receive regulatory approval. The historical failure rate for product candidates in our industry is high, particularly in the earlier stages of development. Furthermore, product candidates in later stages of clinical trials may fail to show the desired safety and efficacy characteristics despite having progressed through preclinical studies and initial clinical trials. We may experience delays in initiating and completing any clinical trials that we intend to conduct, and we do not know whether planned clinical trials will begin on time, need to be redesigned, enroll patients on time or be completed on schedule, or at all. Clinical trials can be delayed for a variety of reasons, including delays related to:

the FDA or comparable foreign regulatory authorities disagreeing as to the design or implementation of our clinical studies;
obtaining regulatory approval to commence a trial;
reaching an agreement on acceptable terms with prospective CROs, and clinical trial sites, the terms of which can be subject to extensive negotiation and may vary significantly among different CROs and trial sites;
obtaining Institutional Review Board (“IRB”) approval at each site, or Independent Ethics Committee (“IEC”) approval at sites outside the United States;
recruiting suitable patients to participate in a trial in a timely manner and in sufficient numbers;
patients failing to complete a trial or return for post-treatment follow-up;
imposition of a clinical hold by regulatory authorities, including as a result of unforeseen safety issues or side effects or failure of trial sites to adhere to regulatory requirements or follow trial protocols;
clinical sites deviating from trial protocol or dropping out of a trial;
addressing patient safety concerns that arise during the course of a trial;
adding a sufficient number of clinical trial sites; or
manufacturing sufficient quantities of product candidate for use in clinical trials.

We could also encounter delays if a clinical trial is suspended or terminated by us, the IRBs or IECs of the institutions in which such trials are being conducted, the Data Safety Monitoring Board (“DSMB”) for such trial or the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a drug, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Furthermore, we rely on CROs and clinical trial sites to ensure the proper and timely conduct of our clinical trials and, while we have agreements governing their committed activities, we have limited influence over their actual performance, as described in “—Risks Related to Our Dependence on Third Parties.”

35

The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for buntanetap or any other product candidates, our business will be substantially harmed.

The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate’s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate and it is possible that we will never obtain regulatory approval for buntanetap or any other product candidate. We are not permitted to market any of our product candidates in the United States until we receive regulatory approval of an NDA from the FDA. Approval from the FDA and comparable foreign authorities may be delayed or denied for a variety of reasons, including:

we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe and effective for its proposed indication;
serious and unexpected drug-related side effects experienced by participants in our clinical trials or by individuals using drugs similar to our product candidates, or other products containing the active ingredient in our product candidates;
negative or ambiguous results from our clinical trials or results that may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;
we may be unable to demonstrate that a product candidate’s clinical and other benefits outweigh its safety risks;
the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from preclinical studies or clinical trials;
the data collected from clinical trials of our product candidates may not be acceptable or sufficient to support the submission of an NDA or other submission or to obtain regulatory approval in the United States or elsewhere, and we may be required to conduct additional clinical trials;
the FDA or comparable foreign authorities may disagree regarding the formulation, labeling and/or the specifications of our product candidates;
the FDA or comparable foreign regulatory authorities may fail to approve or find deficiencies with the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and
the approval policies or regulations of the FDA or comparable foreign regulatory authorities may significantly change in a manner rendering our clinical data insufficient for approval.

Prior to obtaining approval to commercialize a product candidate in the United States or abroad, we must demonstrate with substantial evidence from well-controlled clinical trials, and to the satisfaction of the FDA or foreign regulatory agencies, that such product candidates are safe and effective for their intended uses. Results from preclinical studies and clinical trials can be interpreted in different ways. Even if we believe the preclinical or clinical data for our product candidates are promising, such data may not be sufficient to support approval by the FDA and other regulatory authorities. For diseases like AD and PD, the FDA has stated that one single Phase 3 trial is adequate for approval if it demonstrates robust and unquestionable efficacy. However, the circumstances under which a single adequate and controlled study can be used as the sole basis of demonstrating efficacy of a drug are exceptional.

The FDA or any foreign regulatory bodies can delay, limit or deny approval of our product candidates or require us to conduct additional preclinical or clinical testing or abandon a program for many reasons, including:

the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;

36

the FDA or comparable foreign regulatory authorities may disagree with our safety interpretation of our drug;
the FDA or comparable foreign regulatory authorities may disagree with our efficacy interpretation of our drug;
the FDA or comparable foreign regulatory authorities may regard our CMC package as inadequate.

Of the large number of drugs in development, only a small percentage successfully complete the regulatory approval processes and are commercialized. This lengthy approval process, as well as the unpredictability of future clinical trial results, may result in our failing to obtain regulatory approval to market buntanetap or another product candidate, which would significantly harm our business, results of operations and future commercial prospects.

In addition, the FDA or the applicable foreign regulatory agency also may approve a product candidate for a more limited indication or patient population than we originally requested, and the FDA or applicable foreign regulatory agency may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.

We have concentrated our research and development efforts on the treatment of AD and PD, diseases that have seen limited success in drug development. Further, buntanetap is based on a new approach to treating AD and PD, which makes it difficult to predict the time and cost of development and subsequent obtaining of regulatory approval.

Efforts by biopharmaceutical and pharmaceutical companies in treating AD and PD have seen limited success in drug development, and there are few FDA-approved disease modifying therapeutic options available for patients with AD and PD. As a result, the design and conduct of clinical trials of buntanetap or any future product candidate may take longer, be more costly or be less effective as a result of the novelty of development in these diseases. We cannot be certain that our approach will lead to the development of approvable or marketable products. In some cases, we may use endpoints or methodologies that regulatory authorities may not consider to be clinically meaningful and that we may not continue to use in clinical trials or that we may determine after the initiation of the trial to no longer be an appropriate endpoint or methodology. Any such regulatory authority may require evaluation of additional or different clinical endpoints in our clinical trials or ultimately determine that these clinical endpoints do not support marketing approval. In addition, if we are required to use additional or different clinical endpoints by regulatory authorities, buntanetap may not achieve or meet such clinical endpoints in our clinical trials. Even if a regulatory authority finds our clinical trial success criteria to be sufficiently validated and clinically meaningful, we may not achieve the pre-specified endpoint to a degree of statistical significance in any pivotal or other clinical trials we may conduct for our product candidate. Further, even if we do achieve the prespecified criteria, our trials may produce results that are unpredictable or inconsistent with the results of other efficacy endpoints in the trial. Regulatory authorities also could give overriding weight to other efficacy endpoints over a primary endpoint even if we achieve statistically significant results on that primary endpoint if we do not do so on our secondary efficacy endpoints. Regulatory authorities also weigh the benefits of a product against its risks and may view the efficacy results in the context of safety as not being supportive of approval.

The majority of drugs approved by the FDA to treat AD and PD to date address only the diseases’ symptoms. Only a small number of new treatments have been approved for AD since 2003. From 2004 to 2025, phase 2 and 3 clinical trials for unique compounds with various mechanisms of action intended to combat AD had a development success rate of just 8%. AD drug candidates have the highest failure rate of nearly 100%, compared to 50% to 80% for all other drug candidates. As a result, the FDA has a limited set of products to rely on in evaluating buntanetap. This could result in a longer than expected regulatory review process, increased expected development costs or the delay or prevention of commercialization of buntanetap for the treatment of AD and PD. We cannot be sure that buntanetap, or any other product candidate we develop, will ultimately prove to be safe and effective, scalable or profitable. Moreover, public perception of drug safety issues, including adoption of new therapeutics or novel approaches to treatment, may adversely influence the willingness of subjects to participate in clinical trials, or if approved, of physicians to prescribe novel treatments.

Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.

As product candidates progress through clinical trials to marketing approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize safety, efficacy, yield and manufacturing batch size, minimize costs and achieve consistent quality and results. For example,

37

the manufacturing process being used to produce clinical material for our planned clinical trials is different than that used in prior trials of buntanetap. There can be no assurance that such changes will achieve these intended objectives. These changes and any future changes we may make to buntanetap or any future product candidates may also cause such candidates to perform differently and affect the results of future clinical trials conducted with the altered materials. Such changes or related unfavorable clinical trial results could delay initiation or completion of additional clinical trials, require the conduct of bridging studies or clinical trials or the repetition of one or more studies or clinical trials, increase development costs, delay or prevent potential marketing approval and jeopardize our ability to commercialize buntanetap or any future product candidates, if approved, and generate revenue.

We may develop buntanetap and future product candidates for use in combination with other therapies, which could expose us to additional regulatory risks.

We may develop buntanetap and future product candidates for use in combination with one or more other approved therapies for AD or PD. Even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risk that the FDA or comparable foreign regulatory authorities could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. This could result in our own products being removed from the market or being less successful commercially.

Further, we will not be able to market and sell any product candidate we develop in combination with an unapproved AD or PD therapy for a combination indication if that unapproved therapy does not ultimately obtain marketing approval either alone or in combination with our product. In addition, unapproved AD and PD therapies face the same risks described with respect to our product candidates currently in development and clinical trials, including the potential for serious adverse effects, delay in their clinical trials and lack of FDA approval.

Enrollment and retention of patients in clinical trials is an expensive and time-consuming process and could be made more difficult or rendered impossible by multiple factors outside our control.

The timely completion of clinical trials in accordance with their protocols depends, among other things, on our ability to enroll a sufficient number of patients who remain in the study until its conclusion. We may encounter delays in enrolling, or be unable to enroll, a sufficient number of patients to complete any of our clinical trials, and even once enrolled, we may be unable to retain a sufficient number of patients to complete any of our trials.

Patient enrollment and retention in clinical trials depends on many factors, including:

the patient eligibility and exclusion criteria as defined in the protocol;
the size of the patient population required for analysis of the trial’s primary endpoints;
the nature and design of the trial protocol;
the existing body of safety and efficacy data with respect to the product candidate;
the proximity of patients to clinical sites;
our ability to recruit clinical trial investigators with the appropriate competencies and experience;
clinicians’ and patients’ perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new drugs that may be approved for the indications we are investigating;
competing clinical trials being conducted by other companies or institutions;
our ability to obtain and maintain patient consents; and

38

the risk that patients enrolled in clinical trials will drop out of the trials before completion.

Potential patients for any planned clinical trials may not be adequately diagnosed or identified with the diseases which we are targeting, which could adversely impact the outcomes of our trials and could have safety concerns for the potential patients. Additionally, other pharmaceutical companies targeting these same diseases are recruiting clinical trial patients from these patient populations, which may make it more difficult to fully enroll our clinical trials. We may not be able to initiate or continue clinical trials if we are unable to locate a sufficient number of eligible patients to participate in the clinical trials required by the FDA or comparable foreign regulatory authorities. In addition, the process of finding and recruiting patients may prove costly. The timing of our clinical trials depends, in part, on the speed at which we can recruit patients to participate in our trials, as well as completion of required follow-up periods. If patients are unwilling or unable to participate in our trials for any reason, including the existence of concurrent clinical trials for similar target populations, the availability of approved or authorized therapies, or the fact that enrolling in our trials may prevent patients from taking a different product, or we otherwise have difficulty enrolling a sufficient number of patients, the timeline for recruiting patients, conducting trials and obtaining regulatory approval of our product candidates may be delayed. Our inability to enroll a specified number of patients for any of our future clinical trials would result in significant delays or may require us to abandon one or more clinical trials altogether.

Results of preclinical studies, early clinical trials or analyses may not be indicative of results obtained in later trials.

The results of preclinical studies, early clinical trials or analyses of our product candidates may not be predictive of the results of later-stage clinical trials. Product candidates in later stages of clinical trials may fail to show the desired safety and efficacy traits despite having progressed through preclinical studies and initial clinical trials. Furthermore, results of early clinical trials may differ from results of later clinical trials due to changes in patient population size. The clinical trials that we have completed to date included a limited patient population, and we may observe differences in the safety and efficacy of buntanetap and our other product candidates as the patient population increases in size. Accordingly, the data that we have observed to date may not be reflective of ongoing and future clinical trial data. A number of companies in the biopharmaceutical industry have suffered significant setbacks in advanced clinical trials due to lack of efficacy or adverse safety profiles, notwithstanding promising results in earlier trials. In addition, conclusions based on promising data from analyses of clinical results may be shown to be incorrect when implemented in prospective clinical trials. Even if our clinical trials for buntanetap are completed as planned, we cannot be certain that their results will support the safety and efficacy sufficient to obtain regulatory approval.

Further, others, including regulatory agencies may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular development program, the approvability or commercialization of the particular product candidate or product and our company in general. In addition, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and others may not agree with what we determine is the material or otherwise appropriate information to include in our disclosure. Any information we determine not to disclose may ultimately be deemed meaningful by others with respect to future decisions, conclusions, views, activities or otherwise regarding a particular product candidate or our business. If the interim, topline or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, product candidates may be harmed, which could significantly harm our business prospects.

Interim “top-line” and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are further subject to audit and verification procedures that could result in material changes in the final data. Furthermore, undue reliance on interim analyses may be detrimental to our long-term clinical development plans, which could harm our business, operating results, prospects or financial condition.

From time to time, we may publish interim “top-line” or preliminary data from our clinical studies, which is based on a preliminary analysis of then-available data, and the results and related findings and conclusions are subject to change following a more comprehensive review of the data related to the particular study. We also make assumptions, estimations, calculations and conclusions as part of our analyses of data, and we may not have received or had the opportunity to evaluate all data fully and carefully. Preliminary or “top-line” data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our

39

business prospects. Further, disclosure of interim data by us or by our competitors could result in volatility in the price of our common stock.

In addition, others, including regulatory authorities, may not accept or agree with our assumptions, estimates, calculations, conclusions or analyses or may interpret or weigh the importance of data differently, which could impact the value of the particular program, the approvability or commercialization of the particular product candidate or product and our company in general. Moreover, the information we choose to publicly disclose regarding a particular study or clinical trial is based on what is typically extensive information, and you or others may not agree with what we determine is material or otherwise appropriate information to include in our disclosure, and any information we determine not to disclose may ultimately be deemed significant with respect to future decisions, conclusions, views, activities or otherwise regarding a particular drug, product candidate or our business. If the interim “topline” or preliminary data that we report differ from actual results, or if others, including regulatory authorities, disagree with the conclusions reached, our ability to obtain approval for, and commercialize, buntanetap and any future product candidates may be harmed, which could harm our business, operating results, prospects or financial condition.

Our product candidates may cause serious adverse events or undesirable side effects, which may delay or prevent marketing approval, or, if approved, require them to be taken off the market, require them to include safety warnings or otherwise limit their sales.

As is the case with biopharmaceuticals generally, it is likely that there may be adverse side effects associated with buntanetap or any future product candidates’ use. Serious adverse events or undesirable side effects caused by buntanetap or any other product candidates could cause us or regulatory authorities to interrupt, delay or halt clinical trials and could result in a more restrictive label or the delay or denial of regulatory approval by the FDA or other comparable foreign authorities. Results of any clinical trial we conduct could reveal a high and unacceptable severity and prevalence of side effects or unexpected characteristics. Patients treated with buntanetap to date, at high doses have experienced adverse events that include nausea, vomiting and dizziness.

If unacceptable side effects arise in the development of our product candidates, we, the FDA or the IRBs at the institutions in which our studies are conducted, or the DSMB, if constituted for our clinical trials, could recommend a suspension or termination of our clinical trials, or the FDA or comparable foreign regulatory authorities could order us to cease further development of or deny approval of a product candidate for any or all targeted indications. In addition, drug-related side effects could affect patient recruitment or the ability of enrolled patients to complete a trial or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may harm our business, financial condition and future commercial prospects significantly.

Moreover, if buntanetap or any future product candidates are associated with undesirable side effects in clinical trials or demonstrate characteristics that are unexpected, we may elect to abandon their development or limit their development to more narrow uses or subpopulations in which the undesirable side effects or other characteristics are less prevalent, less severe or more acceptable from a risk-benefit perspective, which may limit the commercial expectations for the product candidate if approved. We may also be required to modify our development and clinical trial plans based on findings in our ongoing clinical trials. Many product candidates that initially showed promise in early-stage testing have later been found to cause side effects that prevented further development of the product candidates.

It is possible that as we test buntanetap or any future product candidates in larger, longer and more extensive clinical trials, including with different dosing regimens, or as the use of these product candidates becomes more widespread following any regulatory approval, more illnesses, injuries, discomforts and other adverse events than were observed in earlier trials, as well as new conditions that did not occur or went undetected in previous trials, may be discovered. If such side effects become known later in development or upon approval, if any, such findings may harm our business, financial condition and prospects significantly.

Additionally, if one or more of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:

regulatory authorities may withdraw approvals of such product;

40

regulatory authorities may require additional warnings on the label, such as a “black box” warning or contraindication;
additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;
we may be required to implement a REMS or create a medication guide outlining the risks of such side effects for distribution to patients;
we could be sued and held liable for harm caused to patients;
the product may become less competitive; and
our reputation may suffer.

Any of these events could prevent us from achieving or maintaining market acceptance of a product candidate, if approved, and could significantly harm our business, results of operations and future commercial prospects.

The market opportunities for buntanetap or any other product candidates, if approved, may be smaller than we anticipate, which could adversely affect our business, financial condition and results of operations.

We expect to initially seek approval for buntanetap for AD and PD in the U.S. The precise incidence and prevalence for the conditions we aim to address with buntanetap or any future product candidates are unknown. Our projections of both the number of people who have these diseases, as well as the subset of people with these diseases who have the potential to benefit from treatment with our product candidates, are based on a number of internal and third-party estimates. These estimates have been derived from a variety of sources, including relevant scientific literature, patient foundations and market research, and may prove to be incorrect. Further, new trials may change the estimated incidence or prevalence of these indications. While we believe our assumptions and the data underlying our estimates are reasonable, we have not independently verified the accuracy of the third-party data on which we have based our assumptions and estimates, and these assumptions and estimates may not be correct and the conditions supporting our assumptions or estimates may change at any time, including as a result of factors outside our control, thereby reducing the predictive accuracy of these underlying factors. The total addressable market across all of the potential indications for buntanetap and any future product candidates will ultimately depend upon, among other things, the diagnosis criteria included in the final label for each such product candidate which receives marketing approval for these indications, the availability of alternative treatments and the safety, convenience, cost and efficacy of such product candidates relative to such alternative treatments, acceptance by the medical community and patient access, drug pricing and reimbursement. The number of patients in the United States and other major markets and elsewhere may turn out to be lower than expected, patients may not be otherwise amenable to treatment with our product candidates or new patients may become increasingly difficult to identify or gain access to, all of which would adversely affect our business, financial condition and results of operations. Even if we obtain significant market share for any product candidate, if approved, if the potential target populations are small, we may never achieve profitability without obtaining marketing approval for additional indications.

We have never obtained marketing approval for a product candidate and we may be unable to obtain, or may be delayed in obtaining, marketing approval for any of our product candidates. Further, even if marketing approval is obtained, we have no experience as a company in commercializing products.

We have never obtained marketing approval for a product candidate. It is possible that the FDA may refuse to accept for substantive review any NDAs that we submit for our product candidates or may conclude after review of our data that our application is insufficient to obtain marketing approval of our product candidates. If the FDA does not accept or approve our NDAs for our product candidates, it may require that we conduct additional clinical, preclinical or manufacturing validation studies and submit that data before it will reconsider our applications. Depending on the extent of these or any other FDA-required studies, approval of any NDA that we submit may be delayed or may require us to expend more resources than we have available. It is also possible that additional studies, if performed and completed, may not be considered sufficient by the FDA to approve our NDAs.

41

Any delay in obtaining, or an inability to obtain, marketing approvals would prevent us from commercializing our product candidates, generating revenues and achieving and sustaining profitability. If any of these outcomes occur, we may be forced to abandon our development efforts for our product candidates, which could significantly harm our business.

Furthermore, we have no internal sales, marketing or distribution capabilities, nor have we commercialized a product. If buntanetap or any future product candidates ultimately receives marketing approval, we must build a marketing and sales organization with technical expertise and supporting distribution capabilities to commercialize each such product in major markets, which will be expensive and time consuming, or collaborate with third parties that have direct sales forces and established distribution systems, either to augment our own sales force and distribution systems or in lieu of our own sales force and distribution systems. We have no prior experience as a company with the marketing, sale or distribution of biopharmaceutical products and there are significant risks involved in the building and managing of a sales organization, including our ability to hire, retain and incentivize qualified individuals, generate sufficient sales leads, provide adequate training to sales and marketing personnel and effectively manage a geographically dispersed sales and marketing team. Any failure or delay in the development of our internal sales, marketing and distribution capabilities would adversely impact the commercialization of these products. We may not be able to enter into collaborations or hire consultants or external service providers to assist us in sales, marketing and distribution functions on acceptable financial terms, or at all. In addition, our product revenue and our profitability, if any, may be lower if we rely on third parties for these functions than if we were to market, sell and distribute any products that we develop ourselves. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we are not successful in commercializing our products, either on our own or through arrangements with one or more third parties, we may not be able to generate any future product revenue and we would incur significant additional losses.

Even if we obtain FDA approval for buntanetap or any other product candidates in the United States, we may never obtain approval for or commercialize buntanetap or any other product candidates in any other jurisdiction, which would limit our ability to realize their full market potential.

Our future growth may depend, in part, on our ability to develop and commercialize buntanetap and any future product candidates in foreign markets. We are not permitted to market or promote any product candidate before we receive regulatory approval from applicable regulatory authorities in foreign markets, and we may never receive such regulatory approvals for buntanetap or any future product candidates. In order to market any products in any particular jurisdiction, we must establish and comply with numerous and varying regulatory requirements on a country-by-country basis regarding safety and efficacy. Approval by the FDA in the United States does not ensure approval by regulatory authorities in other countries or jurisdictions. However, the failure to obtain approval in one jurisdiction may negatively impact our ability to obtain approval elsewhere. In addition, clinical trials conducted in one country may not be accepted by regulatory authorities in other countries, and regulatory approval in one country does not guarantee regulatory approval in any other country.

Approval processes vary among countries and can involve additional product testing and validation and additional administrative review periods. Seeking foreign regulatory approval could result in difficulties and increased costs for us and require additional preclinical studies or clinical trials which could be costly and time consuming. Regulatory requirements can vary widely from country to country and could delay or prevent the introduction of our products in those countries. We do not have any product candidates approved for sale in any jurisdiction, including in international markets, and we do not have experience in obtaining regulatory approval in international markets. If we fail to comply with regulatory requirements in international markets or to obtain and maintain required approvals, or if regulatory approvals in international markets are delayed, our target market will be reduced and our ability to realize the full market potential of any product we develop will be unrealized.

If we obtain regulatory approval of product candidates and ultimately commercialize our products in foreign markets, we would be subject to additional risks and uncertainties, including:

different regulatory requirements for approval of drugs in foreign countries;
reduced protection for intellectual property rights;
the existence of additional third-party patent rights of potential relevance to our business;
unexpected changes in tariffs, trade barriers and regulatory requirements;

42

economic weakness, including inflation, or political instability in particular foreign economies and markets;
compliance with export control and import laws and regulations;
compliance with tax, employment, immigration and labor laws for employees living or traveling abroad;
foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country;
foreign reimbursement, pricing and insurance regimes;
workforce uncertainty in countries where labor unrest is common;
differing regulatory requirements with respect to manufacturing of products;
production shortages resulting from any events affecting raw material supply or manufacturing capabilities abroad; and
business interruptions resulting from geopolitical actions, including war and terrorism, or natural disasters including earthquakes, typhoons, floods and fires.

Even if we obtain regulatory approval for buntanetap or any product candidates, we will still face extensive and ongoing regulatory requirements and obligations and any product candidates, if approved, may face future development and regulatory difficulties.

Any product candidate for which we obtain marketing approval, along with the manufacturing processes, post-approval clinical data, labeling, packaging, distribution, adverse event reporting, storage, recordkeeping, export, import, advertising and promotional activities for such product, among other things, will be subject to extensive and ongoing requirements of and review by the FDA and other regulatory authorities. These requirements include submissions of safety and other post-marketing information and reports, establishment registration and drug listing requirements, continued compliance with cGMP requirements relating to manufacturing, quality control, quality assurance and corresponding maintenance of records and documents, requirements regarding the distribution of samples to physicians and recordkeeping and GCP requirements for any clinical trials that we conduct post-approval.

Even if marketing approval of a product candidate is granted, the approval may be subject to limitations on the indicated uses for which the product candidate may be marketed or to the conditions of approval, including a requirement to implement a REMS. If any of our product candidates receive marketing approval, the accompanying label may limit the approved indicated use of the product candidate, which could limit sales of the product candidate. The FDA may also impose requirements for costly post-marketing studies or clinical trials and surveillance to monitor the safety or efficacy of a product. The FDA closely regulates the post-approval marketing and promotion of drugs to ensure drugs are marketed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers’ communications regarding off-label use, and if we market our products for uses beyond their approved indications, we may be subject to enforcement action for off-label marketing. Violations of the FDCA relating to the promotion of prescription drugs may lead to FDA enforcement actions and investigations alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws.

In addition, later discovery of previously unknown adverse events or other problems with our products, manufacturers or manufacturing processes or failure to comply with regulatory requirements, may yield various results, including:

restrictions on manufacturing such products;
restrictions on the labeling or marketing of products;
restrictions on product distribution or use;

43

requirements to conduct post-marketing studies or clinical trials;
warning letters or untitled letters;
withdrawal of the products from the market;
refusal to approve pending applications or supplements to approved applications that we submit;
recall of products;
fines, restitution or disgorgement of profits or revenues;
suspension or withdrawal of marketing approvals;
refusal to permit the import or export of our products;
product seizure; or
injunctions or the imposition of civil or criminal penalties.

Further, the FDA’s policies may change, and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, which would adversely affect our business, prospects and ability to achieve or sustain profitability.

We also cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative or executive action, either in the United States or abroad. For example, certain policies of the current presidential administration may impact our business and industry. Namely, the current presidential administration has taken several executive actions, including the issuance of a number of Executive Orders, that could impose significant burdens on, or otherwise materially delay, the FDA’s ability to engage in routine regulatory and oversight activities such as implementing statutes through rulemaking, issuance of guidance, and review and approval of marketing applications. It is difficult to predict how these executive actions will be implemented, and the extent to which they will impact the FDA’s ability to exercise its regulatory authority. If these executive actions impose constraints on FDA’s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted.

The FDA and other regulatory agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses.

The FDA and other regulatory agencies strictly regulate the promotional claims that may be made about prescription products, such as buntanetap or any future product candidates, if approved. In particular, a product may not be promoted for uses that are not approved by the FDA or such other regulatory agencies as reflected in the product’s approved labeling. If we receive marketing approval for buntanetap or any future product candidate, physicians may nevertheless prescribe it to their patients in a manner that is inconsistent with the approved label. If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The government has also required companies to enter into consent decrees or imposed permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of buntanetap or any future product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.

44

We may seek a Breakthrough Therapy designation for buntanetap from the FDA in PD and AD. However, we might not receive such designation, and even if we do, such designation may not lead to a faster development or regulatory review or approval process.

We may seek a Breakthrough Therapy designation for buntanetap or one or more of our other product candidates. A Breakthrough Therapy is defined as a drug that is intended, alone or in combination with one or more other drugs, to treat a serious condition, and preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For drugs that have been designated as breakthrough therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens. Drugs designated as breakthrough therapies by the FDA may also be eligible for priority review if supported by clinical data at the time the NDA is submitted to the FDA.

Designation as a Breakthrough Therapy is within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for designation as a Breakthrough Therapy, the FDA may disagree and instead determine not to make such designation. Even if we receive Breakthrough Therapy designation, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to drugs considered for approval under conventional FDA procedures and does not assure ultimate approval by the FDA. In addition, even if one or more of our product candidates qualify as breakthrough therapies, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.

Potential product liability lawsuits against us could cause us to incur substantial liabilities and limit, delay or cease commercialization of any products that we may develop.

The use of buntanetap or any other product candidates we may develop in clinical trials and the sale of any products for which we obtain marketing approval exposes us to the risk of product liability claims. This risk will be even greater if we commercialize our product candidates, especially if our products are prescribed for off-label uses (even if we do not promote such uses). For example, we may be sued if our product candidates allegedly cause injury or are found to be otherwise unsuitable during product testing, manufacturing, marketing or sale. Any such product liability claims may include allegations of defects in manufacturing, defects in design, a failure to warn of dangers inherent in the product candidate, negligence, strict liability and a breach of warranties. Product liability claims might be brought against us by patients, healthcare providers, pharmaceutical companies or others selling or otherwise coming into contact with our products. Claims could also be asserted under state consumer protection acts. On occasion, large judgments have been awarded in class action lawsuits based on drugs that had unanticipated adverse effects. If we cannot successfully defend against product liability claims, we could incur substantial liability and costs or be required to limit, delay or cease the commercialization of our products. Even a successful defense would require significant financial and management resources. In addition, regardless of merit or eventual outcome, product liability claims may result in:

impairment of our business reputation and significant negative media attention;
withdrawal of participants from our clinical trials;
significant costs to defend the litigation;
distraction of management’s attention and our resources from our primary business;
substantial monetary awards to patients or other claimants;
inability to commercialize buntanetap or any other product candidate;
product recalls, withdrawals or labeling, marketing or promotional restrictions;
decreased market demand for any product;

45

significant negative financial impact; and
a decline in our stock price.

The product liability insurance coverage we carry or acquire in the future may not be sufficient to reimburse us for any expenses or losses we may suffer. In connection with all our clinical studies, we carry insurance for product liability claims in the United States and in Europe. Insurance coverage is increasingly expensive. Our inability to obtain and retain sufficient product liability insurance at an acceptable cost to protect against potential product liability claims could prevent or inhibit the commercialization of buntanetap or any future product candidates. Although we maintain such insurance, a successful product liability claim, or series of claims, brought against us could cause our share price to decline and, if judgments exceed our insurance coverage, could adversely affect the results of our operations and business, including preventing or limiting the commercialization of any product candidates we develop. Our insurance policies also have various exclusions, and we may be subject to a product liability claim for which we have no coverage.

Our insurance policies are expensive and only protect us from some business risks, which will leave us exposed to significant uninsured liabilities.

We do not carry insurance for all categories of risk that our business may encounter. Some of the policies we currently maintain include general liability, cyber security liability, employment benefits liability, workers’ compensation, products liability, and directors’ and officers’ insurance. We do not know, however, if we will be able to maintain insurance with adequate levels of coverage. No assurance can be given that an insurance carrier will not seek to cancel or deny coverage after a claim has occurred. Any significant uninsured liability may require us to pay substantial amounts, which would adversely affect our financial position and results of operations.

Risks Related to Commercialization

We face significant competition from other biotechnology and pharmaceutical companies and our operating results will suffer if we fail to compete effectively.

The biopharmaceutical and pharmaceutical industries are highly competitive and subject to significant and rapid technological change. Our success is highly dependent on our ability to acquire, develop, and obtain marketing approval for new products on a cost-effective basis and to market them successfully. If buntanetap is approved, we will face intense competition from a variety of businesses, including large, fully integrated pharmaceutical companies, specialty pharmaceutical companies and biopharmaceutical companies in the United States and other jurisdictions. These organizations may have significantly greater resources than we do and may conduct similar research, seek patent protection and establish collaborative arrangements for research, development, manufacturing and marketing of products that may compete with us.

Our competitors may, among other things:

have significantly greater name recognition, financial, manufacturing, marketing, drug development, technical, and human resources than we do, and future mergers and acquisitions in the biotechnology and pharmaceutical industries may result in even more resources being concentrated in our competitors;
develop and commercialize products that are safer, more effective, less expensive, more convenient, or easier to administer, or have fewer or less severe side effects;
obtain quicker regulatory approval;
implement more effective approaches to sales and marketing; or
form more advantageous strategic alliances.

46

Smaller and other early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These third parties compete with us in recruiting and retaining qualified scientific and management personnel; establishing clinical trial sites and patient registration; and in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are more effective, have fewer or less severe side effects, or are more convenient or are less expensive than buntanetap. Our competitors may also obtain FDA or other regulatory approval for their product candidates more rapidly than we may obtain approval for buntanetap, which could result in our competitors establishing or strengthening their market position before we are able to enter the market. Competing products could present superior treatment alternatives, including by being more effective, safer, more convenient, less expensive or marketed and sold more effectively than any products we may develop. Competing products may render buntanetap or any future product candidates we develop obsolete or noncompetitive before we recover the expense of developing and commercializing our product candidates. If we are unable to compete effectively, our opportunity to generate revenue from the sale of our products we may develop, if approved, could be adversely affected.

The successful commercialization of buntanetap and any other product candidates we develop will depend in part on the extent to which governmental authorities and health insurers establish adequate coverage, reimbursement levels, and pricing policies. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.

The availability and adequacy of coverage and reimbursement by governmental healthcare programs such as Medicare and Medicaid, private health insurers and other third-party payors are essential for most patients to be able to afford prescription medications such as buntanetap, if approved. Our ability to achieve acceptable levels of coverage and reimbursement for products by governmental authorities, private health insurers and other organizations will have an effect on our ability to successfully commercialize our drug and any other product candidates we develop. Accordingly, we will need to successfully implement a coverage and reimbursement strategy for any approved product candidate. Assuming we obtain coverage for our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States or elsewhere will be available for our product candidates or any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.

For products administered under the supervision of a physician, obtaining coverage and adequate reimbursement may be particularly difficult because of the higher prices often associated with such drugs. Additionally, separate reimbursement for the product itself or the treatment or procedure in which the product is used may not be available, which may impact physician utilization. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available, or at an acceptable level, for any product that we may develop, and any reimbursement that may become available may be decreased or eliminated in the future.

Third-party payors increasingly are challenging prices charged for pharmaceutical products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar, or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and offer to reimburse patients only for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing drugs may limit the amount we will be able to charge for our product candidates. These payors may deny or revoke the reimbursement status of a given product or establish prices for new or existing marketed products at levels that are too low to enable us to realize an appropriate return on our investment in our product candidates. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our product candidates.

There is significant uncertainty related to the insurance coverage and reimbursement of newly approved products. In the United States, third-party payors, including private and governmental payors, such as the Medicare and Medicaid programs, play an important role in determining the extent to which new drugs and biologics will be covered. The Medicare and Medicaid programs increasingly are used as models in the United States for how private payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. It is difficult to predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.

47

No uniform policy for coverage and reimbursement for products exists among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that will require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement change frequently, in some cases at short notice, and we believe that changes in these rules and regulations are likely.

We may also be subject to extensive governmental price controls and other market regulations outside of the United States, and we believe the increasing emphasis on cost-containment initiatives in other countries have and will continue to put pressure on the pricing and usage of medical products. In many countries, the prices of medical products are subject to varying price control mechanisms as part of national health systems. Other countries allow companies to fix their own prices for medical products but monitor and control company profits.

Additional foreign price controls or other changes in pricing regulation could restrict the amount that we are able to charge for our product candidates. Accordingly, in markets outside the United States, the reimbursement for our product candidates may be reduced compared with the United States and may be insufficient to generate commercially reasonable revenue and profits.

Moreover, increasing efforts by governmental and third-party payors in the United States to cap or reduce healthcare costs may cause such organizations to limit both coverage and the level of reimbursement for newly approved products and, as a result, they may not cover or provide adequate payment for our product candidates. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.

Even if buntanetap or any product candidate we develop receives marketing approval, it may fail to achieve market acceptance by physicians, patients, third-party payors or others in the medical community necessary for commercial success, which would adversely affect our business.

Buntanetap and any future product candidates may not be commercially successful. If buntanetap or any other product candidate we develop receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. If it does not achieve an adequate level of acceptance, we may not generate significant product revenues or become profitable. The degree of market acceptance of our product candidates, if approved, will depend on a number of factors, including but not limited to:

the efficacy and potential advantages compared to alternative treatments;
the indications for which our product candidates are approved;
the limitation of our targeted patient population and other limitations or warnings contained in any FDA-approved labeling;
effectiveness of sales and marketing efforts;
the cost of treatment in relation to alternative treatments, including any similar generic treatments;
our ability to offer our products for sale at competitive prices;
the convenience and ease of administration compared to alternative treatments;
the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;
the strength of marketing and distribution support;

48

the availability of third-party coverage and adequate reimbursement;
the willingness of patients to pay all, or a portion of, out-of-pocket costs associated with our products in the absence of sufficient third-party coverage and adequate reimbursement;
the prevalence and severity of any side effects;
any restrictions on the use of our product together with other medications;
potential product liability claims;
the timing of market introduction of our products as well as availability, safety and efficacy of competitive drugs; and
unfavorable publicity relating to the product.

Because we expect sales of our product candidates, if approved, to generate substantially all of our revenues for the foreseeable future, the failure of our product candidates to find market acceptance would harm our business and could require us to seek additional financing. Our efforts to educate the medical community and third-party payors regarding the benefits of our products may require significant resources and may never be successful.

If we are unable to establish sales, marketing and distribution capabilities, we may not be successful in commercializing buntanetap, if approved.

We do not have any infrastructure for the sales, marketing or distribution of buntanetap, and the cost of establishing and maintaining such an organization may exceed the cost-effectiveness of doing so. In order to market and successfully commercialize our drug or any product candidate we develop, if approved, we must build our sales, distribution, marketing, managerial and other non-technical capabilities or collaborate with third parties to perform these services.

We do not anticipate having the resources in the foreseeable future to allocate to the sales and marketing of our product candidates, if approved, in certain markets overseas. Therefore, our future success will depend, in part, on our ability to enter into and maintain collaborative relationships for such capabilities, the collaborator’s strategic interest in a product and such collaborator’s ability to successfully market and sell the product. We intend to pursue collaborative arrangements regarding the sale and marketing of buntanetap, if approved, for certain markets overseas; however, there can be no assurance that we will be able to establish or maintain such collaborative arrangements, or if able to do so, that they will have effective sales forces. To the extent that we depend on third parties for marketing and distribution, any revenues we receive will depend upon the efforts of such third parties, and there can be no assurance that such efforts will be successful.

If we are unable to build our own sales force or negotiate a collaborative relationship for the commercialization of buntanetap, we may be forced to delay the potential commercialization of the drug or reduce the scope of our sales or marketing activities. If we need to increase our expenditures to fund commercialization activities for buntanetap we will need to obtain additional capital, which may not be available to us on acceptable terms, or at all. We may also have to enter into collaborative arrangements for buntanetap at an earlier stage than otherwise would be ideal and we may be required to relinquish rights to it or otherwise agree to terms unfavorable to us. Any of these occurrences may have an adverse effect on our business, operating results and prospects.

If we are unable to establish adequate sales, marketing and distribution capabilities, we will not be successful in commercializing our product candidates and may never become profitable. We will be competing with many companies that currently have extensive and well-funded marketing and sales operations. Without an internal team or the support of a third party to perform marketing and sales functions, we may be unable to compete successfully against these more established companies.

49

A variety of risks associated with operating internationally could materially adversely affect our business.

We currently have no international operations, but our business strategy includes potentially expanding internationally if any of our product candidates receive regulatory approval. Doing business internationally involves a number of risks, including but not limited to:

the burden of complying with multiple, conflicting and changing laws and regulations, such as privacy regulations, tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;
failure by us to obtain and maintain regulatory approvals for the use of our products in various jurisdictions;
additional potentially relevant third-party patent rights;
complexities and difficulties in obtaining protection and enforcing our intellectual property;
difficulties in staffing and managing foreign operations;
complexities associated with managing multiple payor reimbursement regimes, government payors or patient self-pay systems;
limits in our ability to penetrate international markets;
financial risks, such as longer payment cycles, difficulty collecting accounts receivable, the impact of local and regional financial crises on demand and payment for our products and exposure to foreign currency exchange rate fluctuations;
natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions;
certain expenses including, among others, expenses for travel, translation and insurance; and
regulatory and compliance risks that relate to maintaining accurate information and control over sales and activities that may fall within the purview of the U.S. Foreign Corrupt Practices Act, its books and records provisions, or its anti-bribery provisions.

Any of these factors could significantly harm any future international expansion and operations and, consequently, our results of operations.

Risks Related to Our Dependence on Third Parties

Our employees and independent contractors, including principal investigators, CROs, consultants, vendors, and any third parties we may engage in connection with development and commercialization, may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, which could have a material adverse effect on our business.

Our employees and independent contractors, including principal investigators, consultants, vendors and any third parties we may engage in connection with development and commercialization of our product candidates, could engage in misconduct, including intentional, reckless or negligent conduct or unauthorized activities that violate: the laws and regulations of the FDA or other similar regulatory requirements of other authorities, including those laws that require the reporting of true, complete and accurate information to such authorities; manufacturing standards; data privacy, security, fraud and abuse and other healthcare laws and regulations; or laws that require the reporting of true, complete and accurate financial information and data. Specifically, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations may restrict or prohibit a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Activities

50

subject to these laws could also involve the improper use or misrepresentation of information obtained in the course of clinical trials, creation of fraudulent data in preclinical studies or clinical trials or illegal misappropriation of drug product, which could result in regulatory sanctions and cause serious harm to our reputation. It is not always possible to identify and deter misconduct by employees and other third parties, and the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with such laws or regulations. Additionally, we are subject to the risk that a person or government could allege such fraud or other misconduct, even if none occurred. If any such actions are instituted against us and we are not successful in defending ourselves or asserting our rights, those actions could have a significant impact on our business and results of operations, including the imposition of significant civil, criminal and administrative penalties, damages, monetary fines, disgorgements, possible exclusion from participation in Medicare, Medicaid, other U.S. federal healthcare programs or healthcare programs in other jurisdictions, individual imprisonment, other sanctions, contractual damages, reputational harm, diminished profits and future earnings, and curtailment of our operations.

We currently rely on third-party contract manufacturing organizations (“CMOs”) for the production of clinical supply of buntanetap and intend to rely on CMOs for the production of commercial supply of buntanetap, if approved. Our dependence on CMOs may impair the development and commercialization of the drug, which would adversely impact our business and financial position.

We have limited personnel with experience in manufacturing, and we do not own facilities for manufacturing. Instead, we rely on and expect to continue to rely on CMOs for the supply of cGMP grade clinical trial materials and commercial quantities of buntanetap and any product candidates we develop, if approved. Reliance on CMOs may expose us to more risk than if we were to manufacture our product candidates ourselves. We intend to have manufactured a sufficient clinical supply of buntanetap drug substance to enable us to complete our clinical trials, and we have also engaged two CMOs to provide clinical and commercial supply of the drug product.

The facilities used to manufacture our product candidates must be inspected by the FDA and comparable foreign authorities. While we provide oversight of manufacturing activities, we do not and will not control the execution of manufacturing activities by, and are or will be essentially dependent on, our CMOs for compliance with cGMP requirements for the manufacture of our product candidates. As a result, we are subject to the risk that our product candidates may have manufacturing defects that we have limited ability to prevent. If a CMO cannot successfully manufacture material that conforms to our specifications and the regulatory requirements, we will not be able to secure or maintain regulatory approval for the use of our product candidates in clinical trials, or for commercial distribution of our product candidates, if approved. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or comparable foreign regulatory authority finds deficiencies with or does not approve these facilities for the manufacture of our product candidates or if it withdraws any such approval or finds deficiencies in the future, we may need to find alternative manufacturing facilities, which would delay our development program and significantly impact our ability to develop, obtain regulatory approval for or commercialize our product candidates, if approved. In addition, any failure to achieve and maintain compliance with these laws, regulations and standards could subject us to the risk that we may have to suspend the manufacture of our product candidates or that obtained approvals could be revoked. Furthermore, CMOs may breach existing agreements they have with us because of factors beyond our control. They may also terminate or refuse to renew their agreement at a time that is costly or otherwise inconvenient for us. If we were unable to find an adequate CMO or another acceptable solution in time, our clinical trials could be delayed, or our commercial activities could be harmed.

We rely on and will continue to rely on CMOs to purchase from third-party suppliers the raw materials necessary to produce our product candidates. We do not and will not have control over the process or timing of the acquisition of these raw materials by our CMOs. Supplies of raw material could be interrupted from time to time and we cannot be certain that alternative supplies could be obtained within a reasonable timeframe, at an acceptable cost, or at all. In addition, a disruption in the supply of raw materials could delay the commercial launch of our product candidates, if approved, or result in a shortage in supply, which would impair our ability to generate revenues from the sale of our product candidates. Growth in the costs and expenses of raw materials may also impair our ability to cost effectively manufacture our product candidates. There are a limited number of suppliers for the raw materials that we may use to manufacture our product candidates and we may need to assess alternative suppliers to prevent a possible disruption of the manufacture of our product candidates.

51

Finding new CMOs or third-party suppliers involves additional cost and requires our management’s time and focus. In addition, there is typically a transition period when a new CMO commences work. Although we generally have not, and do not intend to, begin a clinical trial unless we believe we have on hand, or will be able to obtain, a sufficient supply of our product candidates to complete the clinical trial, any significant delay in the supply of our product candidates or the raw materials needed to produce our product candidates, could considerably delay conducting our clinical trials and potential regulatory approval of our product candidates.

As part of their manufacture of our product candidates, our CMOs and third-party suppliers are expected to comply with and respect the proprietary rights of others. If a CMO or third-party supplier fails to acquire the proper licenses or otherwise infringes the proprietary rights of others in the course of providing services to us, we may have to find alternative CMOs or third-party suppliers or defend against claims of infringement, either of which would significantly impact our ability to develop, obtain regulatory approval for or commercialize our product candidates, if approved.

We currently rely and in the future intend to rely on third parties to conduct, supervise and monitor our clinical trials. If those third parties do not successfully carry out their contractual duties, or if they perform in an unsatisfactory manner, it may harm our business.

We rely, and will continue to rely, on CROs, CRO-contracted vendors and clinical trial sites to ensure the proper and timely conduct of our clinical trials. Our reliance on CROs for clinical development activities limits our control over these activities, yet we remain responsible for ensuring that each of our trials is conducted in accordance with the applicable protocol and legal, regulatory and scientific standards.

We and our CROs will be required to comply with the Good Laboratory Practice (“GLP”) requirements for our preclinical studies and GCP requirements for our clinical trials, which are regulations and guidelines enforced by the FDA and are also required by comparable foreign regulatory authorities. Regulatory authorities enforce GCP requirements through periodic inspections of trial sponsors, principal investigators and clinical trial sites. If we or our CROs fail to comply with GCP requirements, the clinical data generated in our clinical trials may be deemed unreliable and the FDA or comparable foreign regulatory authorities may require us to perform additional clinical trials before approving our marketing applications. There can be no assurance that upon inspection by a given regulatory authority, such regulatory authority will determine that any of our clinical trials comply with GCP requirements. In addition, our clinical trials must be conducted with product produced under cGMP requirements. Accordingly, if our CROs fail to comply with these requirements, we may be required to repeat clinical trials, which would delay the regulatory approval process.

Our CROs are not our employees, and we do not control whether or not they devote sufficient time and resources to our clinical trials. Our CROs may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials, or other drug development activities, which could harm our competitive position. We face the risk of potential unauthorized disclosure or misappropriation of our intellectual property by CROs, which may reduce our trade secret protection and allow our potential competitors to access and exploit our proprietary technology. If our CROs do not successfully carry out their contractual duties or obligations, fail to meet expected deadlines, or if the quality or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or regulatory requirements or for any other reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain regulatory approval for, or successfully commercialize any product candidate that we develop. As a result, our financial results and the commercial prospects for any product candidate that we develop would be harmed, our costs could increase, and our ability to generate revenue could be delayed.

If our relationship with any CROs terminate, we may not be able to enter into arrangements with alternative CROs or do so on commercially reasonable terms. Switching or adding additional CROs involves substantial cost and requires management’s time and focus. In addition, there is a natural transition period when a new CRO commences work. As a result, delays occur, which can materially impact our ability to meet our desired clinical development timelines. Though we intend to carefully manage our relationships with our CROs, there can be no assurance that we will not encounter challenges or delays in the future or that these delays or challenges will not have an adverse impact on our business, financial condition and prospects. Additionally, working with collaborators presents risks, including but not limited to:

the number and type of our collaborations could adversely affect our attractiveness to future collaborators or acquirers; and
the loss of, or a disruption in our relationship with, any one or more collaborators could harm our business.

52

If any collaborations do not result in the successful development and commercialization of products or if one of our collaborators terminates its agreement with us, we may not receive any future research and development funding or milestone or royalty payments under such collaborations. If we do not receive the funding we expect under these agreements, our continued development of our product candidates could be delayed, and we may need additional resources to develop additional product candidates. All of the risks relating to product development, regulatory approval and commercialization described in this Annual Report on Form 10-K also apply to the activities of any collaborators and there can be no assurance that our collaborations will produce positive results or successful products on a timely basis or at all.

In addition, subject to its contractual obligations to us, if one of our collaborators is involved in a business combination or otherwise changes its business priorities, the collaborator might deemphasize or terminate the development or commercialization of our product candidates. If a collaborator terminates its agreement with us, we may find it more difficult to attract new collaborators and the perception of our business and our stock price could be adversely affected.

We may in the future collaborate with additional pharmaceutical and biotechnology companies for development and potential commercialization of therapeutic products. We face significant competition in seeking appropriate collaborators. Our ability to reach a definitive agreement for a collaboration will depend, among other things, upon our assessment of the collaborator’s resources and expertise, the terms and conditions of the proposed collaboration and the proposed collaborator’s evaluation of a number of factors. If we are unable to reach agreements with suitable collaborators on a timely basis, on acceptable terms, or at all, we may have to curtail the development of a product candidate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund and undertake development or commercialization activities on our own, we may need to obtain additional expertise and additional capital, which may not be available to us on acceptable terms or at all. If we fail to enter into collaborations and do not have sufficient funds or expertise to undertake the necessary development and commercialization activities, we may not be able to further develop our product candidates or bring them to market or continue to develop our programs, and our business may be materially and adversely affected.

Risks Related to Healthcare Laws and Other Legal Compliance Matters

Enacted and future healthcare legislation may increase the difficulty and cost for us to obtain marketing approval of and commercialize our product candidates, if approved, and may affect the prices we may set.

In the United States and other jurisdictions, there have been, and we expect there will continue to be, a number of legislative and regulatory changes and proposed changes to the healthcare system that could affect our future results of operations. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, in March 2010, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act (collectively the “ACA”) was enacted, which substantially changed the way healthcare is financed by both governmental and private insurers.

Since its enactment, there have been judicial and Congressional challenges to certain aspects of the ACA, and we expect there may be additional challenges and amendments to the ACA in the future. It is uncertain the extent to which any such changes may impact our business or financial condition.

Other legislative changes have been proposed and adopted in the United States since the ACA was enacted. For example, the Budget Control Act of 2011, resulted in aggregate reductions of Medicare payments to providers of 2% per fiscal year. These reductions went into effect in April 2013 and, due to subsequent legislative amendments to the statute, will remain in effect through 2027 unless additional action is taken by Congress. In January 2013, the American Taxpayer Relief Act of 2012 was signed into law, which, among other things, further reduced Medicare payments to several types of providers, including hospitals, imaging centers and cancer treatment centers, and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. Additionally, the orphan drug tax credit was reduced as part of a broader tax reform. These new laws or any other similar laws introduced in the future may result in additional reductions in Medicare and other health care funding, which could negatively affect our customers and accordingly, our financial operations.

In addition, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, there have been Congressional inquiries and proposed federal and state legislation designed to bring

53

more transparency to drug pricing, reduce the cost of prescription drugs under Medicare, review the relationship between pricing and manufacturer patient programs and reform government program reimbursement methodologies for drugs. Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that the U.S. federal government will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.

Individual states in the United States have also become increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates or put pressure on our product pricing.

In markets outside of the United States, reimbursement and healthcare payment systems vary significantly by country, and many countries have instituted price ceilings on specific products and therapies. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative action in the United States or any other jurisdiction. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.

Our business operations and current and future relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers will be subject to applicable healthcare regulatory laws, which could expose us to penalties.

Our business operations and current and future arrangements with investigators, healthcare professionals, consultants, third-party payors, patient organizations, and customers, may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations. These laws may constrain the business or financial arrangements and relationships through which we conduct our operations, including how we research, market, sell and distribute our product candidates, if approved. Such laws include:

the U.S. federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from knowingly and willfully soliciting, offering, receiving, or providing any remuneration (including any kickback, bribe, or certain rebate), directly or indirectly, overtly or covertly, in cash or in kind, to induce or reward, or in return for, either the referral of an individual for, or the purchase, lease, order, or recommendation of, any good, facility, item, or service, for which payment may be made, in whole or in part, under U.S. federal and state healthcare programs such as Medicare and Medicaid. A person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. The U.S. federal Anti-Kickback Statute has been interpreted to apply to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers and formulary managers on the other hand;
the U.S. federal false claims and civil monetary penalties laws, including the civil False Claims Act (“FCA”) which, among other things, impose criminal and civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities for knowingly presenting, or causing to be presented, to the U.S. federal government, claims for payment or approval that are false or fraudulent, knowingly making, using or causing to be made or used, a false record or statement material to a false or fraudulent claim, or from knowingly making a false statement to avoid, decrease or conceal an obligation to pay money to the U.S. federal government. In addition, the government may assert that a claim including items and services resulting from a violation of the U.S. federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. A claim includes “any request or demand” for money or property presented to the federal government. In addition, manufacturers can be held liable under the FCA even when they do not submit claims directly to government payors if they are deemed to “cause” the submission of false or fraudulent claims;

54

Health Insurance Portability and Accountability Act of 1996 (“HIPAA”), which imposes criminal and civil liability for, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program or obtain, by means of false or fraudulent pretenses, representations, or promises, any of the money or property owned by, or under the custody or control of, any healthcare benefit program, regardless of the payor (e.g., public or private) and knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false statement, in connection with the delivery of, or payment for, healthcare benefits, items or services. Similar to the U.S. federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation;
HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act of 2009 (“HITECH”) and their respective implementing regulations, which impose, among other things, specified requirements relating to the privacy, security and transmission of individually identifiable health information without appropriate authorization by covered entities subject to the rule, such as health plans, healthcare clearinghouses and healthcare providers as well as their business associates that perform certain services involving the use or disclosure of individually identifiable health information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates and gave state attorneys general new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys’ fees and costs associated with pursuing federal civil actions;
the Federal Food, Drug and Cosmetic Act (“FDCA”), which prohibits, among other things, the adulteration or misbranding of drugs, biologics and medical devices;
the U.S. federal legislation commonly referred to as the Physician Payments Sunshine Act, enacted as part of the ACA, and its implementing regulations, which requires certain manufacturers of drugs, devices, biologics, and medical supplies that are reimbursable under Medicare, Medicaid, or the Children’s Health Insurance Program to report annually to the government information related to certain payments and other transfers of value to physicians and teaching hospitals, as well as ownership and investment interests held by the physicians described above and their immediate family members; and
analogous U.S. state laws and regulations, including: state anti-kickback and false claims laws, which may apply to our business practices, including but not limited to, research, distribution, sales, and marketing arrangements and claims involving healthcare items or services reimbursed by any third-party payor, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry’s voluntary compliance guidelines and the relevant compliance guidance promulgated by the U.S. federal government, or otherwise restrict payments that may be made to healthcare providers and other potential referral sources; state laws and regulations that require drug manufacturers to file reports relating to pricing and marketing information, which requires tracking gifts and other remuneration and items of value provided to healthcare professionals and entities; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.

Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our business activities, including our consulting agreements and other relationships with physicians and other healthcare providers, some of whom receive stock or stock options as compensation for their services, could be subject to challenge under one or more of such laws. Ensuring that our current and future internal operations and business arrangements with third parties comply with applicable healthcare laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices do not comply with current or future statutes, regulations, agency guidance or case law involving applicable fraud and abuse or other healthcare laws and regulations.

If our operations are found to be in violation of any of the laws described above or any other governmental laws and regulations that may apply to us, we may be subject to the imposition of civil, criminal and administrative penalties, damages, disgorgement, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, individual imprisonment, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements or oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws, and curtailment or restructuring of our operations, any of which could adversely affect our ability to

55

operate our business and our results of operations. If any of the physicians or other providers or entities with whom we expect to do business are found to not be in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded healthcare programs and imprisonment, which could affect our ability to operate our business. Further, defending against any such actions can be costly, time-consuming and may require significant personnel resources. Therefore, even if we are successful in defending against any such actions that may be brought against us, our business may be impaired.

Any clinical trial programs we conduct or research collaborations we enter into in the EEA may subject us to the General Data Protection Regulation.

If we conduct clinical trial programs or enter into research collaborations in the EEA, we may be subject to the General Data Protection regulation (“GDPR”). The GDPR applies extraterritorially and implements stringent operational requirements for processors and controllers of personal data, including, for example, high standards for obtaining consent from individuals to process their personal data, robust disclosures to individuals, a comprehensive individual data rights regime, data export restrictions governing transfers of data from the European Union (“EU”) to other jurisdictions, short timelines for data breach notifications, limitations on retention of information, increased requirements pertaining to health data, other special categories of personal data and coded data and additional obligations if we contract third-party processors in connection with the processing of personal data. The GDPR provides that EU member states may establish their own laws and regulations limiting the processing of personal data, including genetic, biometric or health data, which could limit our ability to use and share personal data or could cause our costs to increase. If our or our partners’ or service providers’ privacy or data security measures fail to comply with the GDPR requirements, we may be subject to litigation, regulatory investigations, enforcement notices requiring us to change the way we use personal data and/or fines of up to €20 million or up to 4% of the total worldwide annual turnover of the preceding financial year, whichever is higher, as well as compensation claims by affected individuals, negative publicity, reputational harm and a potential loss of business and goodwill.

We are subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We could face criminal liability and other serious consequences for violations, which could harm our business.

We are subject to export control and import laws and regulations, including the U.S. Export Administration Regulations, U.S. Customs regulations, and various economic and trade sanctions regulations administered by the U.S. Treasury Department’s Office of Foreign Assets Controls and anti-corruption and anti-money laundering laws and regulations, including the U.S. Foreign Corrupt Practices Act of 1977, as amended, the U.S. domestic bribery statute contained in 18 U.S.C. § 201, the U.S. Travel Act, the USA PATRIOT Act and other state and national anti-bribery and anti-money laundering laws in the countries in which we conduct activities. Anti-corruption laws are interpreted broadly and prohibit companies and their employees, agents, CROs, contractors and other collaborators and partners from authorizing, promising, offering, providing, soliciting or receiving, directly or indirectly, improper payments or anything else of value to recipients in the public or private sector. We may engage third parties for clinical trials outside of the United States, to sell our products abroad if and when we enter a commercialization phase, and/or to obtain necessary permits, licenses, patent registrations and other regulatory approvals. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We can be held liable for the corrupt or other illegal activities of our employees, agents, CROs, contractors and other collaborators and partners, even if we do not explicitly authorize or have actual knowledge of such activities, and any training or compliance programs or other initiatives we undertake to prevent such activities may not be effective. Any violations of the laws and regulations described above may result in substantial civil and criminal fines and penalties, imprisonment, the loss of export or import privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.

Furthermore, U.S. export control laws and economic sanctions prohibit the provision of certain products and services to countries, governments, and persons targeted by U.S. sanctions. U.S. sanctions that have been or may be imposed as a result of military conflicts in other countries may impact our ability to continue activities at future clinical trial sites within regions covered by such sanctions. If we fail to comply with export and import regulations and such economic sanctions, penalties could be imposed, including fines and/or denial of certain export privileges. These export and import controls and economic sanctions could also adversely affect our supply chain.

56

We are subject to environmental, health and safety laws and regulations, and we may become exposed to liability and substantial expenses in connection with environmental compliance or remediation activities.

We and any contract manufacturers and suppliers we engage are subject to numerous environmental, health and safety laws and regulations. These laws and regulations govern, among other things, the controlled use, handling, release and disposal of and the maintenance of a registry for, hazardous materials and biological materials, such as chemical solvents, human cells, carcinogenic compounds, mutagenic compounds and compounds that have a toxic effect on reproduction, laboratory procedures and exposure to blood-borne pathogens. While the materials we use require operations involving the use of hazardous and flammable materials, including chemicals and biological materials, we do not produce any materials ourselves and contract with third parties for the manufacture and the disposal of these materials and wastes.

As with other companies engaged in activities similar to ours, we face a risk of environmental liability inherent in our current and historical activities, including liability relating to releases of or exposure to hazardous or biological materials. Environmental, health and safety laws and regulations are becoming more stringent. We may be required to incur substantial expenses in connection with future environmental compliance or remediation activities, in which case, the production efforts of our third-party manufacturers or our development efforts may be interrupted or delayed.

Recent U.S. tax legislation may materially adversely affect our financial condition, results of operations and cash flows.

On March 27, 2020, the Coronavirus Aid, Relief, and Economic Security Act (“CARES Act”) was enacted in response to the COVID-19 pandemic. The CARES Act, among other things, permits NOL carryovers and carrybacks to offset 100% of taxable income for taxable years beginning before 2021. Previously, NOLs generated after December 31, 2017 were limited to 80% of taxable income in future years. In addition, the CARES Act allows NOLs incurred in 2018, 2019 and 2020 to be carried back to each of the five preceding taxable years to generate a refund of previously paid income taxes. The NOL carryback provision of the CARES Act had no impact on us due to our tax losses generated during all prior years.

U.S. tax legislation enacted in 2017 has significantly changed the U.S. federal income taxation of U.S. corporations, including by reducing the U.S. corporate income tax rate, limiting interest deductions, and revising the rules governing NOLs. The legislation could be subject to potential amendments and technical corrections, as well as interpretations and implementing regulations by the U.S. Treasury and Internal Revenue Service, any of which could lessen or increase certain adverse impacts of the legislation. In addition, it is remains unclear how these U.S. federal income tax changes will affect state and local taxation, which often uses federal taxable income as a starting point for computing state and local tax liabilities.

Risks Related to Our Intellectual Property

If we are unable to obtain, maintain and enforce patent or other intellectual property protection for buntanetap, Posiphen Form B or any future product candidates or technology or if the scope of the patent protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products similar or identical to ours, our ability to successfully commercialize buntanetap, Posiphen Form B, or any future product candidates may be adversely affected and we may not be able to compete effectively in our markets.

We rely upon a combination of patents, trade secret protection and confidentiality agreements to protect the intellectual property related to our drug development programs and product candidates. These legal measures afford only limited protection, and competitors or others may gain access to or use our intellectual property and proprietary information. Our success depends in large part on our ability to obtain, maintain and defend patent protection in the United States and other countries with respect to buntanetap, Posiphen Form B, and any future product candidates. Because we have not conducted a formal freedom to operate analysis for patents related to buntanetap since 2008, we may not be aware of patents issued since then that a third-party might assert are infringed by buntanetap, Posiphen Form B, or any future product candidates, which could materially impair our ability to commercialize buntanetap, Posiphen Form B, or any future product candidates. We generally seek to protect our proprietary position, in part, by filing patent applications in the United States and abroad relating to buntanetap, Posiphen Form B, and any future product candidates, manufacturing processes, and methods of use. If we are unable to obtain, maintain or enforce patent protection, our business, financial condition, results of operations and prospects could be materially harmed.

57

Changes in either the patent laws or their interpretation in the United States and other jurisdictions may diminish our ability to protect our intellectual property, obtain, maintain and enforce our intellectual property rights and, more generally, could affect the value of our intellectual property or narrow the scope of our protection. We cannot predict whether the patent applications we currently or may in the future pursue will issue as patents in any particular jurisdiction, will provide sufficient protection against competitors or other third parties, or if these patents are challenged by our competitors, will be found to be invalid, unenforceable, or not infringed. Our pending and future patent applications may not result in patents being issued which protect our technology or product candidates, in whole or in part, or which effectively prevent others from commercializing competitive technologies and product candidates. It is also possible that we will fail to identify patentable aspects of our research and development output in time to obtain patent protection before public disclosures are made. Although we enter into non-disclosure and confidentiality agreements with parties who have access to confidential or patentable aspects of our research and development output, such as our employees, third-party collaborators, CROs, contract manufacturers, consultants, advisors and other third parties, any of these parties may breach the agreements and disclose such output before a patent application is filed, thereby jeopardizing our ability to seek patent protection. Consequently, we may not be able to prevent any third party from using any of our technology that is in the public domain to compete with buntanetap, Posiphen Form B, and any future product candidates or technologies. In addition, our ability to obtain and maintain valid and enforceable patents depends on whether the differences between our inventions and the prior art allow our inventions to be patentable in light of the prior art. Furthermore, publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot be certain that we or our licensors were the first to invent or file on the inventions claimed in any of our licensed patents or pending patent applications, or that we or our licensors were the first to make the inventions claimed in those owned or licensed patents or pending patent applications, or that we or our licensors were the first to file for patent protection of such inventions. If a third party can establish that we or our licensors were not the first to make or the first to file for patent protection of such inventions, our owned or licensed patents and patent applications may not issue as patents and even if issued, may be challenged and invalidated or rendered unenforceable. Furthermore, even if a patent is granted, our competitors or other third parties may be able to circumvent the patent by developing similar or alternative technologies or products in a non-infringing manner which could materially adversely affect our business, financial condition, results of operations and prospects.

If we are unable to obtain additional patent protection to prolong the patent life of our product candidates, we may not be able to continue development of our product candidates.

We seek to protect and prolong our proprietary position by filing patent applications in the United States and abroad related to our development programs and product candidates. If the patent applications we own with respect to our development programs and product candidates fail to issue, if their breadth or strength of protection is threatened, or if they fail to provide meaningful exclusivity for buntanetap, Posiphen Form B, or any future product candidate, it could dissuade companies from collaborating with us to develop product candidates, and threaten our ability to commercialize future product candidates. Any such outcome could have a materially adverse effect on our business and our company could cease to exist.

Annovis has filed fourteen families of patent applications to prolong the patent life of buntanetap, Posiphen Form B. Unless these applications are approved by the U.S. and international patent offices, the patent life of using buntanetap, and Posiphen Form B is limited. The first patent application family we filed, which would be expected to expire in 2031, before any patent term adjustments or extensions, covers the use of buntanetap in the treatment of AD, PD and other neurodegenerative disorders such as Huntington’s disease, prion diseases, amyotrophic lateral sclerosis, tauopathies, frontotemporal dementia, Lewy bodies disease, and chronic traumatic encephalopathy, based on our preclinical research. In August 2019, the U.S. Patent and Trademark Office (“USPTO”) granted the first of our Annovis patents from this family covering treatment of PD and Lewy body diseases. Subsequently, the USPTO also granted patents covering treatment frontotemporal dementia and Prion’s disease, tauopathies, chronic traumatic encephalopathy, prion diseases, amyotrophic lateral sclerosis, Alzheimer’s and Huntington’s disease. The second patent application family covers ANVS405’s use in acute brain and nerve trauma and would be expected to expire in 2036, before any patent term adjustments or extensions. In December 2020, the EPO approved the whole patent and it has since been approved in most countries filed claiming a method of treating acute nerve and brain injuries by administering ANVS405 before and after the injury. The US patent office instead has asked us to separate the application into four divisional applications covering stroke, traumatic brain injury, nerve injury and spinal cord injury. The third patent application family relates to the use of the mechanism of action of buntanetap and ANVS405 to prevent and treat neurodegenerative diseases and would be expected to expire in 2038, before any patent term adjustments or extensions. The first divisional of this application was approved in December 2022, it covers the prevention of neurodegenerative diseases. The fourth patent application family relates to a method of inhibiting, preventing, or treating neurological injuries due to viral, bacterial, fungal, protozoan, or parasitic infections in humans and in animals via administration of buntanetap or related

58

compounds. In May 2020, we filed a patent application with the USPTO concerning a method of inhibiting, preventing, or treating neurological injuries due to viral, bacterial, fungal, protozoan, or parasitic infections in humans and in animals via administration of buntanetap or related compounds, which would be expected to expire in 2041, before any patent term adjustments or extensions. The fifth patent family application is directed to a method of maintaining heavy metal homeostasis avoiding the effect of toxic levels of a heavy metal in cells in a healthy human or restoring heavy metal homeostasis in a sick human patient. The USPTO granted the first patent in this family on March 7, 2023, which is expected to expire in 2039, before any patent term adjustments or extensions. The sixth patent application family relates to treating brain metastasis via administration of buntanetap or related compounds. In September 2023, we filed a U.S. nonprovisional patent application directed to treatment of brain metastasis via administration of buntanetap or related compounds with the USPTO, which, if allowed, would be expected to expire in 2043, before any patent term adjustments or extensions. The seventh patent application family relates to treatment of mental illness via administration of buntanetap or related compounds. In January 2024, we filed an International (PCT) application and a U.S. nonprovisional patent application directed to treatment of mental illness via administration of buntanetap or related compounds with the USPTO, which, if allowed, would be expected to expire in 2044, before any patent term adjustments or extensions. The eighth patent application family relates to treatment of neurodegenerative diseases and other diseases via co-administration of buntanetap or related compounds and an antidiabetic agent. In September 2024, we filed an International (PCT) application and a U.S. nonprovisional patent application directed to treatment of neurodegenerative diseases and other diseases via administration of this combination. The ninth patent application family relates to treatment of neurodegenerative diseases and other diseases via co-administration of buntanetap or related compounds and a phosphodiesterase inhibitor. In September 2024, we filed an International (PCT) application and a U.S. nonprovisional patent application directed to treatment of neurodegenerative diseases and other diseases via administration of this combination. The tenth patent application family relates to treatment of neurodegenerative diseases and other diseases via co-administration of buntanetap or related compounds and an antihypertensive agent. In September 2024, we filed an International (PCT) application and a U.S. nonprovisional patent application directed to treatment of neurodegenerative diseases and other diseases via administration of this combination. The eleventh patent application family relates to treatment of neurodegenerative diseases and other diseases via co-administration of buntanetap with two additional therapeutic agents. In August 2024, we filed a provisional U.S. Patent application directed to treatment of neurodegenerative diseases and other diseases via administration of this combination. The twelfth patent application family relates to treatment of neurodegenerative diseases and other diseases via co-administration of buntanetap or related compounds and an additional therapeutic agent. In February 2025, we filed a provisional U.S. Patent application directed to treatment of neurodegenerative diseases and other diseases via administration of this combination. The thirteenth patent application family relates to the new Form B of Posiphen (ANVS402); it demonstrates that it can be used instead of buntanetap, including in the foregoing uses of buntanetap of the Company’s patent portfolio. Posiphen Form B may be the compound of choice in current uses of buntanetap, because it may have advantageous properties such as better stability and higher purity. In 2023, the Company filed with the USPTO two provisional patent applications as to Posiphen Form B. In 2024, the Company filed an International (PCT) as to Posiphen Form B and uses thereof. The International Search Report and ‘Written Opinion” issued by the USPTO in the prosecution of the PCT application was favorable, indicating that the search claims directed to Posiphen Form B are novel and inventive. The Company expects to further file patent applications in the U.S. and outside the U.S. as National and Regional Phase patent applications of the PCT application. As to this family of patent applications involving Posiphen Form B and uses thereof, patents would be expected to expire in 2044, before any patent term adjustments or extensions. The Company also expects to seek New Chemical Entity status for Posiphen Form B before the US Food and Drug Administration (FDA), and to seek additional regulatory exclusivity based thereon. The fourteenth patent application family relates to new, improved and commercially advantageous methods for preparing buntanetap and Posiphen Form B. The Company sees this patent application family as providing further protection as to methods that use buntanetap or Posiphen Form B, and for Posiphen form B. More in particular, in 2024 the Company filed with the USPTO a provisional patent application directed to new methods of preparing buntanetap and Posiphen Form B. The Company expects in 2025 to further file at least an International (PCT) application, claiming priority from that provisional patent application, and directed to the new, improved and commercially advantageous methods for preparing buntanetap and Posiphen Form B, and thereafter patent applications in the U.S. and outside the U.S. as National and Regional Phase patent applications of the PCT application. As to this family of patent applications, patents would be expected to expire in 2045, before any patent term adjustments or extensions. It is possible that we will fail to identify further patentable aspects of our research and development output before it is too late to obtain patent protection. The patent applications that we own may fail to result in issued patents with claims that provide further coverage of buntanetap, Posiphen Form B, or any other product candidate in the United States or in other foreign countries.

59

Our patents may be challenged in courts, in patent offices or before other administrative bodies which could result in the invalidation, narrowing or unenforceability of our patents and our patent portfolio, along with the unpredictable nature of patent prosecution, may not provide us with sufficient rights to similarly challenge other parties or exclude others from commercializing products similar or identical to ours.

Even if patents do successfully issue and even if such patents further cover buntanetap, Posiphen Form B, or any future product candidate, third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, invalidated, or held unenforceable. Our patent rights may be subject to such priority, validity, inventorship, scope and enforceability disputes. Legal proceedings relating to intellectual property claims, with or without merit, are unpredictable and generally expensive and time-consuming and likely to divert significant resources from our core business, including distracting our management and scientific personnel from their normal responsibilities and generally harm our business. Any successful opposition to these patents or any other patents owned by or licensed to us could deprive us of rights necessary for the successful commercialization of any product candidates that we may develop. If we encounter delays in regulatory approvals, the period during which we could market a product candidate under patent protection could be reduced.

The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. However, in certain instances, the laws of the United States are more restrictive than those of foreign countries. For example, a recent series of U.S. Supreme Court cases has narrowed the types of subject matter considered eligible for patenting. Accordingly, certain diagnostic methods are considered ineligible for patenting because they are directed to a “law of nature.” Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned and licensed patents may be challenged in the courts or patent offices in the United States and abroad. Such challenges may result in patent claims being narrowed, invalidated, held unenforceable, in whole or in part, or reduced in term. Such a result could limit our ability to stop others from using or commercializing similar or identical technology and products.

We may be subject to claims challenging the inventorship of our patents and other intellectual property.

We or our licensors may be subject to claims that former employees, consultants, collaborators or other third parties have an interest in our patent rights, any potential trade secrets, or other intellectual property as an inventor, co-inventor or owner of any potential trade secrets. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our product candidates and other proprietary technologies we may develop. Litigation may be necessary to defend against these and other claims challenging inventorship or our patent rights, any potential trade secrets or other intellectual property. If we or our licensors fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, intellectual property that is important to our product candidates and other proprietary technologies we may develop. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to our management and other employees. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations and prospects.

We may become subject to third parties’ claims alleging infringement of their patents and proprietary rights, or we may need to become involved in lawsuits to protect or enforce our patents, which could be costly, time consuming, delay or prevent the development and commercialization of our product candidates or put our patents and other proprietary rights at risk.

Our commercial success depends, in part, upon our ability to develop, manufacture, market and sell our product candidates without alleged or actual infringement, misappropriation or other violation of the patents and proprietary rights of third parties. Litigation relating to infringement or misappropriation of patent and other intellectual property rights in the pharmaceutical and biotechnology industries is common, including patent infringement lawsuits, interferences, oppositions and reexamination proceedings before the USPTO and corresponding foreign patent offices. The various markets in which we plan to operate are subject to frequent and extensive litigation regarding patents and other intellectual property rights. In addition, many companies in intellectual property-dependent industries, including the biotechnology and pharmaceutical industries, have employed intellectual property litigation as a means to gain an advantage over their competitors. Numerous U.S., EU and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing product candidates. Some claimants may have

60

substantially greater resources than we do and may be able to sustain the costs of complex intellectual property litigation to a greater degree and for longer periods of time than we could. In addition, patent holding companies that focus solely on extracting royalties and settlements by enforcing patent rights may target us. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may be subject to claims of infringement of the intellectual property rights of third parties.

We may be subject to third-party claims including infringement, interference or derivation proceedings, post-grant review and inter partes review before the USPTO or similar adversarial proceedings or litigation in other jurisdictions. Even if we believe third party infringement claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, and the holders of any such patents may be able to block our ability to commercialize the applicable product candidate unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Proceedings challenging our patents or those that we license may also result in our patent claims being invalidated or narrowed in scope. Similarly, if our patents or patent applications are challenged during interference or derivation proceedings, a court may hold that a third-party is entitled to certain patent ownership rights instead of us. Further, if any third-party patents were held by a court of competent jurisdiction to cover aspects of our compositions, formulations, methods of manufacture, or methods of treatment, prevention or use, the holders of any such patents may be able to block our ability to develop and commercialize the applicable product candidate unless we obtained a license or until such patent expires or is finally determined to be invalid or unenforceable. In addition, defending such claims would cause us to incur substantial expenses and, if successful, could cause us to pay substantial damages, if we are found to be infringing a third party’s patent rights. If we are found to have infringed such rights willfully, the damages may be enhanced and may include attorneys’ fees. Further, if a patent infringement suit is brought against us or our third-party service providers, our development, manufacturing or sales activities relating to the product or product candidate that is the subject of the suit may be delayed or terminated. Modifying our product candidates to design around third-party intellectual property rights may result in significant cost or delay to us and could prove to be technically infeasible. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business. In addition, if the breadth or strength of protection provided the patents and patent applications we own or in-license is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates.

If we were to initiate legal proceedings against a third party to enforce a patent covering one of our product candidates, the defendant could counterclaim that our patent is invalid or unenforceable. In patent litigation in the United States and in Europe, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, for example, lack of eligibility, lack of novelty, obviousness or non-enablement. Third parties might allege unenforceability of our patents because someone connected with prosecution of the patent withheld relevant information, or made a misleading statement, during prosecution. The outcome of proceedings involving assertions of invalidity and unenforceability during patent litigation is unpredictable. With respect to the validity of patents, for example, we cannot be certain that there is no invalidating prior art of which we and the patent examiner were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we would lose at least part, and perhaps all, of the patent protection on our product candidates. Furthermore, our patents and other intellectual property rights also will not protect our technology if competitors design around our protected technology without infringing on our patents or other intellectual property rights.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions or other interim proceedings or developments. If securities analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected.

Finally, even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors view these announcements in a negative light, the price of our common stock could be adversely affected. Such litigation or proceedings could substantially increase our operating losses and reduce our resources available for development activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of

61

their substantially greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have an adverse effect on our ability to compete in the marketplace.

We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope, or expiration of a third-party patent, which might adversely affect our ability to develop, manufacture and market our product candidates.

We cannot guarantee that any of our or our licensors’ patent searches or analyses, including but not limited to the identification of relevant patents, the scope of patent claims or the expiration of relevant patents, are complete or thorough, nor can we be certain that we have identified each and every third-party patent and pending application in the United States, Europe and elsewhere that is relevant to or necessary for the commercialization of our product candidates in any jurisdiction. For example, in the United States, applications filed before November 29, 2000 and certain applications filed after that date that will not be filed outside the United States remain confidential until patents issue. Patent applications in the United States, EU and elsewhere are published approximately 18 months after the earliest filing for which priority is claimed, with such earliest filing date being commonly referred to as the priority date. Therefore, patent applications covering our future product candidates, or their manufacture or use may currently be unpublished. Additionally, pending patent applications that have been published can, subject to certain limitations, be later amended in a manner that could cover our product candidates or the use of our product candidates. The scope of a patent claim is determined by an interpretation of the law, the written disclosure in a patent and the patent’s prosecution history. Our interpretation of the relevance or the scope of a patent or a pending application may be incorrect, which may negatively impact our ability to market our product candidates. We may incorrectly determine that our product candidates are not covered by a third-party patent or may incorrectly predict whether a third party’s pending application will issue with claims of relevant scope. Our determination of the expiration date of any patent in the United States, the EU or elsewhere that we consider relevant may be incorrect, which may negatively impact our ability to develop and market our product candidates. Our failure to identify and correctly interpret relevant patents may negatively impact our ability to develop and market our product candidates.

From time to time we may identify patents or applications in the same general area as our products and product candidates. We may determine these third-party patents are irrelevant to our business based on various factors including our interpretation of the scope of the patent claims and our interpretation of when the patent expires. If the patents are asserted against us, however, a court may disagree with our determinations. Further, while we may determine that the scope of claims that will issue from a patent application does not present a risk, it is difficult to accurately predict the scope of claims that will issue from a patent application, our determination may be incorrect, and the issuing patent may be asserted against us. We cannot guarantee that we will be able to successfully settle or otherwise resolve such infringement claims. If we fail in any such dispute, in addition to being forced to pay monetary damages, we may be temporarily or permanently prohibited from commercializing our product candidates. We might, if possible, also be forced to redesign our product candidates so that we no longer infringe on the third-party intellectual property rights. Any of these events, even if we were ultimately to prevail, could require us to divert substantial financial and management resources that we would otherwise be able to devote to our business.

Changes in patent laws or patent jurisprudence could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.

As is the case with other biopharmaceutical and pharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biopharmaceutical and pharmaceutical industries involve both technological complexity and legal complexity. Therefore, obtaining and enforcing biopharmaceutical and pharmaceutical patents is costly, time-consuming and inherently uncertain. In addition, the America Invents Act (“AIA”) which was passed in September 2011, resulted in significant changes to the U.S. patent system.

An important change introduced by the AIA is that, as of March 16, 2013, the United States transitioned to a “first-to-file” system for deciding which party should be granted a patent when two or more patent applications are filed by different parties claiming the same invention. A third party that files a patent application in the USPTO after that date but before us could therefore be awarded a patent covering an invention of ours even if we made the invention before it was made by the third party. This will require us to be cognizant going forward of the time from invention to filing of a patent application, but circumstances could prevent us from promptly filing patent applications on our inventions.

Among some of the other changes introduced by the AIA are changes that limit where a patentee may file a patent infringement suit and provide opportunities for third parties to challenge any issued patent with the USPTO. This applies to all of our

62

U.S. patents, even those issued before March 16, 2013. Because of a possibly different evidentiary standard in USPTO proceedings compared to the evidentiary standard in U.S. federal courts necessary to invalidate a patent claim, a third party could potentially provide evidence in a USPTO proceeding sufficient for the USPTO to hold a claim invalid even though the same evidence would be insufficient to invalidate the claim if first presented in a district court action.

Accordingly, a third party may attempt to use the USPTO procedures to invalidate our patent claims that would not have been invalidated if first challenged by the third party as a defendant in a district court action. It is not clear what, if any, impact the AIA will have on the operation of our business. However, the AIA and its implementation could increase the uncertainties and costs surrounding the prosecution of our or our licensors’ patent applications and the enforcement or defense of our or our licensors’ issued patents.

Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years either narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. Similarly, the complexity and uncertainty of European patent laws has also increased in recent years. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution. Changes in patent law and regulations in other countries or jurisdictions or changes in the governmental bodies that enforce them or changes in how the relevant governmental authority enforces patent laws or regulations may weaken our ability to obtain new patents or to enforce patents that we have licensed or that we may obtain in the future. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business.

Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.

Periodic maintenance and annuity fees on any issued patent are due to be paid to the USPTO and European and other patent agencies over the lifetime of a patent. In addition, the USPTO and European and other patent agencies require compliance with a number of procedural, documentary, fee payment and other similar provisions during the patent application process. While an inadvertent failure to make payment of such fees or to comply with such provisions can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which such noncompliance will result in the abandonment or lapse of the patent or patent application, and the partial or complete loss of patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents within prescribed time limits. If we or our licensors fail to maintain the patents and patent applications covering our product candidates or if we or our licensors otherwise allow our patents or patent applications to be abandoned or lapse, our competitors might be able to enter the market, which would hurt our competitive position and could impair our ability to successfully commercialize our product candidates in any indication for which they are approved.

We enjoy only limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive. Competitors may use our and our licensors’ technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection, but enforcement is not as strong as that in the United States or the EU. These products may compete with our product candidates, and our and our licensors’ patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

In addition, we may decide to abandon national and regional patent applications before grant. The grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications might in some jurisdictions be refused by the relevant patent offices, while granted by others. Furthermore, the requirements for patentability differ in certain jurisdictions and countries. For example, unlike other countries, China has a heightened requirement for patentability, and

63

specifically requires a detailed description of medical uses of a claimed drug. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors’ patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings. Generic drug manufacturers may develop, seek approval for and launch generic versions of our products. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology. The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or rules and regulations in the United States and the EU, and many companies have encountered significant difficulties in protecting and defending such rights in such jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property protection, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. Prosecution of patent applications in other jurisdictions is often a longer process and patents may grant at a later date, and with a shorter term, than in the United States.

Proceedings to enforce our patent rights in other jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing, and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. We may not be able to prevent third parties from practicing our or our licensors’ inventions in all countries outside the United States, or from selling or importing products made using our intellectual property in and into the United States or other jurisdictions. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished, and we may face additional competition from others in those jurisdictions.

If we do not obtain patent term extension in the United States under the Hatch-Waxman Act and under similar legislation in foreign countries, thereby potentially extending the term of marketing exclusivity for our product candidates, our business may be materially harmed.

Patents have a limited lifespan. In the United States, if all maintenance fees are timely paid, the natural expiration of a patent is generally 20 years from its earliest U.S. non-provisional filing date. Various extensions may be available, but the life of a patent, and the protection it affords, is limited. Even if patents covering our product candidates are obtained, once the patent life has expired for a product, we may be open to competition from competitive medications, including generic medications. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. If we do not have sufficient patent life to protect our products, our business, financial condition, results of operations, and prospects will be adversely affected.

Depending upon the timing, duration and conditions of FDA marketing approval of our product candidates, we may be able to extend the term of a patent covering each product candidate under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Amendments and similar legislation in the EU. The Hatch-Waxman Amendments permit a patent term extension of up to five years for a patent covering an approved product as compensation for effective patent term lost during product development and the FDA regulatory review process. The total patent term including the extension cannot exceed 14 years following regulatory approval. However, we may not receive an extension if we fail to apply within applicable deadlines, fail to apply prior to expiration of relevant patents or otherwise fail to satisfy applicable requirements. Moreover, the length of the extension could be less than we request. If we are unable to obtain patent term extension or the term of any such extension is less than we request, the period during which we can enforce our patent rights for that product will be shortened and our competitors may

64

obtain approval to market competing products sooner. As a result, our revenue from applicable products could be reduced, possibly materially.

Further, under certain circumstances, patent terms covering our products or product candidates may be extended for time spent during the pendency of the patent application in the USPTO, referred to as Patent Term Adjustment (“PTA”). The laws and regulations underlying how the USPTO calculates the PTA is subject to change and any such PTA granted by the USPTO could be challenged by a third-party. If we do not prevail under such a challenge, the PTA may be reduced or eliminated, resulting in a shorter patent term, which may negatively impact our ability to exclude competitors. Because PTA added to the term of patents covering pharmaceutical products has particular value, our business may be adversely affected if the PTA is successfully challenged by a third party and our ability to exclude competitors is reduced or eliminated.

Intellectual property rights do not address all potential threats to our competitive advantage.

The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations, and may not adequately protect our business, or permit us to maintain our competitive advantage. The following examples are illustrative:

others may be able to make products that are similar to buntanetap, Posiphen Form B, or our future product candidates but that are not covered by the claims of the patents that we own or license from others;
others may independently develop similar or alternative technologies or otherwise circumvent any of our technologies without infringing our intellectual property rights;
we or any of our collaborators might not have been the first to conceive and reduce to practice or file on the inventions covered by the patents or patent applications that we own, license or will own or license;
it is possible that our pending patent applications will not lead to issued patents;
issued patents that we own may not provide us with any competitive advantage, or may be held invalid or unenforceable, as a result of legal challenges by our competitors;
our competitors might conduct research and development activities in countries where we do not have patent rights, or in countries where research and development safe harbor laws exist, and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;
ownership of our patents or patent applications may be challenged by third parties; and
the patents of third parties or pending or future applications of third parties, if issued, may have an adverse effect on our business.

Our reliance on third parties requires us to share our trade secrets, which increases the possibility that our trade secrets will be misappropriated or disclosed, and confidentiality agreements with employees and third parties may not adequately prevent disclosure of trade secrets and protect other proprietary information.

In addition to seeking patent protection for our product candidates and proprietary technologies, we may also rely on trade secret protection and confidentiality agreements to protect our unpatented know-how, technology, and other proprietary information and to maintain our competitive position. We consider proprietary trade secrets or confidential know-how and unpatented know-how to be important to our business. We may rely on trade secrets or confidential know-how to protect our technology, especially where patent protection is believed by us to be of limited value. Because we expect to rely on third parties to manufacture buntanetap, Posiphen Form B, and any future product candidates, and we expect to collaborate with third parties on the development of buntanetap, Posiphen Form B, and any future product candidates, we must, at times, share trade secrets with them. We also conduct joint research and development programs that may require us to share trade secrets under the terms of our research and development partnerships or similar agreements. However, trade secrets or confidential know-how can be difficult to maintain as confidential.

65

To protect this type of information against disclosure or appropriation by competitors, our policy is to require our employees, consultants, contractors and advisors to enter into confidentiality agreements and, if applicable, material transfer agreements, consulting agreements or other similar agreements with us prior to beginning research or disclosing proprietary information. These agreements typically limit the rights of the third parties to use or disclose our confidential information, including our trade secrets. However, current or former employees, consultants, contractors and advisers may unintentionally or willfully disclose our confidential information to competitors, and confidentiality agreements may not provide an adequate remedy in the event of unauthorized disclosure of confidential information. Furthermore, we cannot guarantee that we have entered into applicable agreements with each party that may have or have had access to any potential trade secrets or proprietary technology and processes. The need to share trade secrets and other confidential information increases the risk that such trade secrets become known by our competitors, are inadvertently incorporated into the technology of others, or are disclosed or used in violation of these agreements. Given that our proprietary position is based, in part, on our know-how and trade secrets, a competitor’s discovery of our trade secrets or other unauthorized use or disclosure would impair our competitive position and may have an adverse effect on our business and results of operations. Enforcing a claim that a third party obtained illegally and is using trade secrets or confidential know-how is expensive, time-consuming and unpredictable. The enforceability of confidentiality agreements may vary from jurisdiction to jurisdiction.

In addition, these agreements typically restrict the ability of our advisors, employees, third-party contractors and consultants to publish data potentially relating to our trade secrets, although our agreements may contain certain limited publication rights. Despite our efforts to protect our trade secrets, our competitors may discover our trade secrets, either through breach of our agreements with third parties, independent development or publication of information by any of our third-party collaborators. If any of our potential trade secrets were to be lawfully obtained or independently developed by a competitor or other third party, we would have no right to prevent them, or those to whom they communicate it, from using that technology or information to compete with us. A competitor’s discovery of our trade secrets would impair our competitive position and have an adverse impact on our business.

We have not yet registered our trademarks in the United States or other jurisdictions. Failure to secure such registrations could adversely affect our business.

We have not yet registered our trademarks in the United States or other jurisdictions. If we do not successfully register our trademarks, we may encounter difficulty in enforcing, or be unable to enforce, our trademark rights against third parties, which could adversely affect our business and our ability to effectively compete in the marketplace. We have also not yet registered trademarks for any of our product candidates in any jurisdiction. When we file registration applications for trademarks relating to our product candidates, those applications may be rejected, and registered trademarks may not be obtained, maintained or enforced. During trademark registration proceedings in the United States and foreign jurisdictions, we may receive rejections. We are given an opportunity to respond to those rejections, but we may not be able to overcome such rejections. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties may oppose pending trademark registration applications or seek to cancel registered trademarks. Opposition or cancellation proceedings may be filed against our trademarks, and our trademark registrations may not survive such proceedings.

In addition, any proprietary name we may propose to use with buntanetap, Posiphen Form B, or any future product candidate in the United States must be approved by the FDA, regardless of whether we have registered, or applied to register, the proposed proprietary name as a trademark. The FDA typically conducts a review of proposed product names, including an evaluation of potential for confusion with other product names. If the FDA or an equivalent administrative body in a foreign jurisdiction objects to any of our proposed proprietary product names, we may be required to expend significant additional resources in an effort to identify a suitable substitute name that would qualify under applicable trademark laws, not infringe, misappropriate or otherwise violate the existing rights of third parties and be acceptable to the FDA.

If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.

Our unregistered trademarks or trade names may be challenged, infringed, circumvented or declared generic or determined to be infringing on, misappropriating or violating other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential collaborators or customers in our markets of interest. During trademark registration proceedings, we may receive rejections of our applications by the USPTO or in other foreign jurisdictions. Although we are given an opportunity to respond to such rejections, we may be unable to overcome them. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market

66

confusion. In addition, in the USPTO and in comparable agencies in many foreign jurisdictions, third parties are given an opportunity to oppose pending trademark applications and to seek to cancel registered trademarks. There could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our unregistered trademarks or trade names. Furthermore, in many countries, owning and maintaining a trademark registration may not provide an adequate defense against a subsequent infringement claim asserted by the owner of a senior trademark. Over the long term, if we are unable to successfully register our trademarks and trade names and establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade names, domain names or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.

In response to an inability to enforce our patent rights, or in the event of successful litigation against us by third parties, or in the normal course of future business operations, we may need to license certain intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.

As a result of patent infringement claims, or in order to avoid potential infringement claims, we may choose to seek, or be required to seek, a license from the third party, which may require us to pay license fees or royalties or both. Furthermore, if we or our licensors are unsuccessful in any proceedings sought to enforce our patent rights, such patents and patent applications may be narrowed, invalidated or held unenforceable, we may be required to obtain licenses from third parties. Although at this time, we are unaware of any intellectual property that interferes with ours or is complementary and needed to commercialize buntanetap, or Posiphen Form B, a third party may also hold intellectual property, including patent rights that are important or necessary to the future development or commercialization of buntanetap, Posiphen Form B, or our future product candidates. It may be necessary for us to use the patented or proprietary technology of third parties to commercialize buntanetap, Posiphen Form B, or our product candidates, in which case we would be required to obtain a license from these third parties. If any of these situations were to occur, such a license may not be available on commercially reasonable terms, or at all, which could materially harm our business. Even if a license can be obtained on acceptable terms, the rights may be nonexclusive, which could give our competitors access to the same intellectual property rights. If we are unable to enter into a license on acceptable terms, we could be prevented from commercializing one or more of our product candidates, forced to modify such product candidates, or to cease some aspect of our business operations, which could harm our business significantly.

We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties or claims asserting ownership of what we regard as our own intellectual property.

We employ individuals who were previously employed at other biotechnology or pharmaceutical companies. Although we seek to protect our ownership of intellectual property rights by ensuring that our agreements with our employees, contractors, collaborators and other third parties with whom we do business include provisions requiring such parties to assign rights in inventions to us and not use the proprietary information or know-how of others in their work for us, we may be subject to claims that we or our employees, consultants or independent contractors have inadvertently or otherwise used or disclosed confidential information of our employees’ former employers or other third parties. In addition, while it is our policy to require our employees and contractors who may be involved in the conception or development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who, in fact, conceives or develops intellectual property that we regard as our own. The assignment of intellectual property rights may not be self-executing, or the assignment agreements may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against any of the foregoing claims. There is no guarantee of success in defending these claims, and if we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership or right to use. Even if we are successful, litigation could result in substantial cost and be a distraction to our management and other employees.

Our proprietary information may be lost, or we may suffer security breaches.

In the ordinary course of our business, we collect and store sensitive data, including intellectual property, clinical trial data, proprietary business information, personal data and personally identifiable information of our clinical trial subjects and employees, in our data centers and on our networks. The secure processing, maintenance and transmission of this information is critical to our

67

operations. Despite our security measures, our information technology and infrastructure may be vulnerable to attacks by hackers or breached due to employee error, malfeasance or other disruptions. Certain federal, state and foreign government requirements include obligations of companies to notify individuals of security breaches involving particular categories of personally identifiable information, which could result from breaches experienced by us or by our vendors, contractors, or organizations with which we have formed strategic relationships. Although, to our knowledge, we have not experienced any such material security breach to date, any such breach could compromise our networks and the information stored there could be accessed, publicly disclosed, lost or stolen. Any such access, disclosure or other loss of information could result in legal claims or proceedings, liability under laws that protect the privacy of personal information, significant regulatory penalties, disruption of our operations, delays in our regulatory approval efforts, damage to our reputation, costs to recover or reproduce the data and cause a loss of confidence in us and our ability to conduct clinical trials, which could adversely affect our reputation and delay our clinical development of our product candidates.

If any security breach or other incident, whether actual or perceived, were to occur, it could impact our reputation and/or operations, cause us to incur significant costs and liabilities, including legal expenses, harm customer confidence, hurt our expansion into new markets, cause us to incur remediation costs, or cause us to lose existing customers. For example, the loss of clinical trial data from clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. We also rely on third parties to manufacture buntanetap, or Posiphen Form B, and similar events relating to their computer systems could also have a material adverse effect on our business. To the extent that any actual or perceived disruption or security breach affects our systems (or those of our third-party collaborators, service providers, contractors or consultants) or were to result in a loss of or accidental, unlawful or unauthorized access to, use of, release of, or other processing of personally identifiable information, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, the further development and commercialization of buntanetap, Posiphen Form B, or any future product candidates could be delayed, and we could be subject to significant fines, penalties or liabilities. In addition, a security failure could result in violations of applicable privacy and other laws. If this information is inappropriately accessed and used by a third party or a team member for illegal purposes, such as identity theft, we may be responsible to the affected individuals for any losses they may have incurred as a result of misappropriation. In such an instance, we may also be subject to regulatory action, investigation or liable to a governmental authority for fines or penalties associated with a lapse in the integrity and security of our team members’ or patients’ information. We may be required to expend significant capital and other resources to protect against and remedy any potential or existing security breaches and their consequences. In addition, our remediation efforts may not be successful, and we may not have adequate insurance to cover these losses.

Security breaches could also significantly damage our brand and our reputation with existing and prospective clients and third parties with whom we do business. Any publicized security problems affecting our businesses and/or those of such third parties may negatively impact the market perception of our products and discourage third parties from doing business with us.

Risks Related to Our Employees, Managing Our Growth and Our Operations

Our future success depends on our ability to retain our key personnel and to attract, retain and motivate qualified personnel.

We are highly dependent on the development, regulatory, commercialization and business development expertise of Maria L. Maccecchini, PhD, as well as the other principal members of our management, scientific and clinical teams. Although we have employment agreements, offer letters or consulting agreements with our executive officers, these agreements do not prevent them from terminating their services at any time.

If we lose one or more of our executive officers or key employees, our ability to implement our business strategy successfully could be seriously harmed. Furthermore, replacing executive officers and key employees may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop product candidates, gain regulatory approval, and commercialize new products. Competition to hire from this limited pool is intense, and we may be unable to hire, train, retain or motivate these additional key personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies for similar personnel. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our consultants and advisors may be engaged by entities other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us.

68

Other pharmaceutical companies with which we compete for qualified personnel have greater financial and other resources, different risk profiles, and a longer history in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we have to offer. If we are not able to attract, integrate, retain and motivate necessary personnel to accomplish our business objectives, we may experience constraints that will significantly impede the achievement of our development objectives, our ability to raise additional capital and our ability to implement our business strategy.

We expect to expand our development, regulatory, and sales and marketing capabilities, and as a result, we may encounter difficulties in managing our growth, which could disrupt our operations.

We expect to experience significant growth in the number of our employees and the scope of our operations. To manage our anticipated future growth, we must continue to implement and improve our managerial, operational and financial systems, expand our facilities or acquire new facilities and continue to recruit and train additional qualified personnel. Due to our limited financial resources and the limited experience of our management team in managing a company with such anticipated growth, we may not be able to effectively manage the expansion of our operations or recruit and train additional qualified personnel. The expansion of our operations may lead to significant costs and may divert our management and business development resources. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.

We may engage in acquisitions that could disrupt our business, cause dilution to our stockholders or reduce our financial resources.

In the future, we may enter into transactions to acquire other businesses, products or technologies. If we do identify suitable candidates, we may not be able to make such acquisitions on favorable terms, or at all. Any acquisitions we make may not strengthen our competitive position, and these transactions may be viewed negatively by customers or investors. We may decide to incur debt in connection with an acquisition or issue our common stock or other equity securities to the stockholders of the acquired company, which would reduce the percentage ownership of our existing stockholders. We could incur losses resulting from undiscovered liabilities of the acquired business that are not covered by the indemnification we may obtain from the seller. In addition, we may not be able to successfully integrate the acquired personnel, technologies and operations into our existing business in an effective, timely and nondisruptive manner. Acquisitions may also divert management attention from day-to-day responsibilities, increase our expenses and reduce our cash available for operations and other uses. We cannot predict the number, timing or size of future acquisitions or the effect that any such transactions might have on our operating results. Furthermore, we may experience losses related to investments in other companies, including as a result of failure to realize expected benefits or the materialization of unexpected liabilities or risks, which could have a material negative effect on our results of operations and financial condition. Accordingly, although there can be no assurance that we will undertake or successfully complete any additional transactions of the nature described above, any additional transactions that we do complete could have a material adverse effect on our business, results of operations, financial condition and prospects.

We may seek to enter into collaborations, license agreements and other similar arrangements in the future, and may not be successful in doing so.

We may seek to enter into collaborations, joint ventures, licensing arrangements or other similar arrangements with third parties for the development or commercialization of buntanetap and any future product candidates, due to capital costs required to develop or commercialize the product candidate or manufacturing constraints. These relationships or those like them may require us to incur non-recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our stockholders or disrupt our management and business. In addition, we face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Moreover, we may not be successful in our efforts to establish or maintain a strategic partnership or other alternative arrangements for any future product candidates and programs because our research and development pipeline may be insufficient, our product candidates and programs may be deemed to be at too early a stage of development for collaborative effort and third parties may not view our product candidates and programs as having the requisite potential to demonstrate safety and efficacy. Even if we are successful in our efforts to establish such collaborations, the terms that we agree upon may not be favorable to us. For example, we may need to relinquish valuable rights to our future revenue streams, research programs, intellectual property or product candidates, or grant licenses on terms that may not be favorable to us, as part of any such arrangement, and such arrangements may restrict us from entering into additional agreements with other potential collaborators. If we license products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate

69

them with our existing operations and company culture. In addition, if we enter into such collaborations, we will have limited control over the amount and timing of resources that our collaborators will dedicate to the development or commercialization of our product candidates. Our ability to generate revenue from these arrangements will depend on any future collaborators’ abilities to successfully perform the functions assigned to them in these arrangements. We cannot be certain that, following a strategic transaction or license, we will achieve the revenues or specific net income that justifies such transaction. Furthermore, we may not be able to maintain such collaborations if, for example, the development or approval of a product candidate is delayed, the safety of a product candidate is questioned or the sales of an approved product candidate are unsatisfactory. Any delays in entering into new strategic partnership agreements related to our drug candidates could also delay the development and commercialization of our product candidates and reduce their competitiveness even if they reach the market.

Collaborations involving buntanetap or any future product candidates would pose significant risks to us, including the following:

collaborators have significant discretion in determining the efforts and resources that they will apply to these collaborations;
collaborators may not perform their obligations as expected or at all;
we could grant exclusive rights to our collaborators that would prevent us from collaborating with others;
collaborators may not pursue development and commercialization of any product candidates that achieve regulatory approval or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborators’ strategic focus or available funding, or external factors, such as an acquisition, that divert resources or create competing priorities;
collaborators may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials or require a new formulation of a product candidate for clinical testing;
collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours;
product candidates discovered in collaboration with us may be viewed by our collaborators as competitive with their own product candidates or drugs, which may cause collaborators to cease to devote resources to the commercialization of our product candidates;
a collaborator with marketing and distribution rights to any product candidate that achieves regulatory approval may not commit sufficient resources to the marketing and distribution of such products;
a collaborator’s sales and marketing activities or other operations may not be in compliance with applicable laws, resulting in civil or criminal proceedings;
disagreements with collaborators, including disagreements over proprietary rights, contract interpretation or the preferred course of development, might cause delays in or termination of the research, development or commercialization of product candidates, might lead to additional responsibilities for us with respect to product candidates, or might result in litigation or arbitration, any of which would be time-consuming and expensive;
collaborators may not properly enforce, maintain or defend our or their intellectual property rights or may use our or their proprietary information in such a way as to invite litigation that could jeopardize or invalidate such intellectual property or proprietary information or expose us to potential litigation;

70

collaborators may infringe, misappropriate or otherwise violate the intellectual property rights of third parties, which may expose us to litigation and potential liability;
collaborators may not provide us with timely and accurate information regarding development, regulatory or commercialization status or results, which could adversely impact our ability to manage our own development efforts, accurately forecast financial results or provide timely information to our stockholders regarding our out-licensed product candidates;
we may be required to invest resources and attention into such collaboration, which could distract from other business objectives;
disputes may arise between the collaborators and us regarding ownership of or other rights in the intellectual property generated in the course of the collaborations;
collaboration agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all;
if a collaborator of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program could be delayed, diminished or terminated; and
collaborations may be terminated, including for the convenience of the collaborator, prior to or upon the expiration of the agreed upon terms and, if terminated, we may find it more difficult to enter into future collaborations or be required to raise additional capital to pursue further development or commercialization of the applicable product candidates.

Any termination of collaborations we enter into in the future, or any delay in entering into collaborations related to buntanetap or any future product candidates, could delay the development and commercialization of our product candidates and reduce their competitiveness if they reach the market, which could have a material adverse effect on our business, financial condition, results of operations and future commercial prospects.

Our business and operations would suffer in the event of failures involving our information technology systems, or those of any of our service providers.

We are increasingly dependent upon information technology systems, infrastructure and data to operate our business. Our computer systems, as well as those of our CROs and other contractors and consultants, are vulnerable to damage from computer viruses, unauthorized access, natural disasters (including hurricanes), team member misconduct, human error, terrorism, war and telecommunication and electrical failures. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our development programs. For example, the loss of preclinical or clinical trial data from completed, ongoing or planned trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of or damage to our data or applications, or inappropriate disclosure of personal, confidential or proprietary information, we could incur liability and the further development of buntanetap or any other product candidate could be delayed. It is not possible to prevent all threats or to our information technology systems and information and those of our third-party service providers, over which we exert less control, and any controls we implement to do so may prove to be ineffective.

Disruption, failure or cybersecurity breaches affecting or targeting computers and infrastructure used by us or our business partners may adversely impact our business and operations.

We use computers and telecommunication systems to analyze and store financial and operating data and to communicate within our company, with outside business partners, and across international borders. These systems can be subject to technical system flaws; power loss; cyber attacks, including viruses, malware, phishing, ransomware, terrorism, and surveillance, unauthorized access, malicious software, intentional or inadvertent data privacy breaches by employees or others with authorized access, hacktivism, ransomware, physical or electronic break-ins, fires or natural disasters, supply chain attacks, and other cybersecurity issues. We have no assurance that our systems are appropriately redundant to withstand these events. Accordingly, such events could cause adverse

71

effects and material disruptions to our operations or systems or those of our business partners; compromise the security, integrity, availability, and confidentiality of customer information, employee information, strategic projects, product formulas and other trade secrets, other business or personal sensitive data, including third party confidential information in our possession. Release of third party confidential information could materially harm our reputation, affect our relationships with such parties and expose us to liability. Although we have introduced many security measures, including firewalls and information technology security policies and training, these measures may not offer the appropriate level of security. A security breach or other compromise of our information security safeguards could expose our confidential information, including third party confidential information in our possession (such as customer information) to theft and misuse, which could in turn adversely affect our relationships with such third parties and have an adverse effect on our business, financial condition, results of operations and cash runway.

The cash and cash equivalents that we use to meet our working capital and operating expense needs are held in deposit accounts at two financial institutions. If one or both financial institutions fail, our deposit accounts could be adversely affected due to the loss of or delay in obtaining access to all or a portion of our uninsured funds.

The cash and cash equivalents that we use to meet our working capital and operating expense needs are held in deposit accounts at two financial institutions. The balance held in these accounts regularly exceeds the Federal Deposit Insurance Corporation (“FDIC”), standard deposit insurance limit or similar government guarantee schemes. If one or both of the financial institutions in which we hold such funds fails or is subject to significant adverse conditions in the financial or credit markets, we could be subject to a risk of loss of all or a portion of such uninsured funds or be subject to a delay in accessing all or a portion of such uninsured funds. Any such loss or lack of access to these funds could adversely impact our short-term liquidity and ability to meet our operating expense obligations.

For example, on March 10, 2023, Silicon Valley Bank (“SVB”) and Signature Bank, were closed by state regulators and the FDIC was appointed as the receiver for each bank. The FDIC created successor bridge banks and all deposits of SVB and Signature Bank were transferred to the bridge banks under a systemic risk exception approved by the U.S. Department of the Treasury, the Federal Reserve and the FDIC. If one or both of the financial institutions in which we hold our funds for working capital and operating expense needs were to fail, we cannot provide any assurances that such governmental agencies would take action to protect our uninsured deposits in a similar manner.

Risks Related to Our Common Stock

The market price of our common stock has been volatile and fluctuated substantially in the past and may continue to experience volatility and substantial fluctuations in the future, which could result in substantial losses for purchasers of our common stock.

The market price of our common stock is highly volatile. For example, from July 1, 2024 to February 28, 2025, the closing price of our common stock on the New York Stock Exchange ranged from as low as $1.74 to as high as $15.46 and daily trading volume ranged from 67,300 shares to 40,734,200 shares. The market price of our common stock may be subject to wide fluctuations in response to a variety of factors, including the following:

results of our clinical trials, and the results of trials of our competitors or those of other companies in our market sector;
our ability to enroll subjects in our future clinical trials;
delays or unanticipated developments in the completion of our planned clinical trials;
any delay in submitting an NDA and any adverse development or perceived adverse development with respect to the FDA’s review of that NDA;
our ability to obtain and maintain regulatory approval of buntanetap or any future product candidates or additional indications thereof, or limitations to specific label indications or patient populations for its use, or changes or delays in the regulatory review process;
failure to successfully develop and commercialize buntanetap or any future product candidates;

72

the degree and rate of physician and market adoption of any of our current and future product candidates;
inability to obtain additional funding or obtaining funding on unattractive terms;
regulatory or legal developments in the United States and other countries applicable to buntanetap or any other product candidates;
adverse regulatory decisions;
changes in the structure of healthcare payment systems;
manufacturing, supply or distribution delays or shortages, including our inability to obtain adequate product supply for buntanetap or any other product candidates, or the inability to do so at acceptable prices;
the success or failure of our efforts to identify, develop, acquire or license additional product candidates;
introduction of new products, services or technologies by our competitors;
failure to meet or exceed financial projections we provide to the public;
failure to meet or exceed the estimates and projections of the investment community;
changes in the market valuations of companies similar to ours;
market conditions in the pharmaceutical and biotechnology sectors, and the issuance of new or changed securities analysts’ reports or recommendations;
announcements of significant acquisitions, strategic collaborations, joint ventures or capital commitments by us or our competitors;
any changes to our relationship with any manufacturers, suppliers, collaborators or other strategic partners;
significant lawsuits, including patent or shareholder litigation, and disputes or other developments relating to our proprietary rights, including patents, litigation matters and our ability to obtain patent protection for our technologies;
additions or departures of key scientific or management personnel;
sales of our common stock by us or our stockholders in the future;
changes in our capital structure, such as future issuances of securities and the incurrence of additional debt;
changes in accounting standards, policies, guidelines, interpretations or principles;
trading volume of our common stock;
actual or anticipated fluctuations in our financial condition and results of operations;
publication of news releases by other companies in our industry, and especially direct competitors, including about adverse developments related to safety, effectiveness, accuracy and usability of their products, reputational concerns, reimbursement coverage, regulatory compliance, and product recalls;

73

announcement or progression of geopolitical events (including in relation to the conflict between Russia and Ukraine or Isreal and Hamas); and
the other factors described in this “Risk Factors” section.

In addition, the stock markets have experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations have often been unrelated or disproportionate to the operating performance of those companies. Broad market and industry factors, as well as general economic, political, regulatory and market conditions, may negatively affect the market price of our common stock, regardless of our actual operating performance. The market price of our common stock may decline, and our stockholders may lose some or all of their investment.

Our failure to meet the New York Stock Exchange’s continued listing requirements could result in a delisting of our common stock.

If we fail to satisfy the continued listing requirements of the New York Stock Exchange, such as the corporate governance requirements, market capitalization or the minimum closing bid price requirement, the New York Stock Exchange may take steps to delist our common stock. Such a delisting would likely have a negative effect on the price of our common stock and would impair our stockholders’ ability to sell or purchase our common stock when they wish to do so. In the event of a delisting, we can provide no assurance that any action taken by us to restore compliance with listing requirements would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, or prevent future non-compliance with the listing requirements of the New York Stock Exchange.

We have been subject to securities class action litigation in the past and could be subject to such litigation in the future.

In the past, securities class action litigation has often been brought against companies following a decline in the market price of their securities. This risk is especially relevant for us because biotechnology companies have experienced significant share price volatility in recent years. During the year ended December 31, 2021, two securities class action complaints were filed against us and our executive officers following disclosure of interim results from the AD/PD Trials. Both complaints were voluntarily dismissed without prejudice by the plaintiffs. If we again face such litigation in the future, it could result in substantial costs, a diversion of management’s attention and resources, and damage to our reputation, which could have a material adverse effect on our business, financial condition and results of operations and prospects.

Our directors, executive officers and certain stockholders own a significant percentage of our common stock and, if they choose to act together, will be able to exert significant control over matters subject to stockholder approval.

Our directors, executive officers, and stockholders affiliated with our directors and executive officers own 14.3% of the current voting power of our outstanding common stock. Therefore, acting together, they have the ability to substantially influence all matters submitted to our board of directors or stockholders for approval. For example, these holders may be able to control the appointment of our management, elections and removal of directors, amendments of our organizational documents, or approval of any merger, sale of assets, or other major corporate transaction. The interests of these holders may not always coincide with our corporate interests or the interests of other stockholders, and they may act in a manner with which our stockholders may not agree or that may not be in the best interests of our other stockholders. This concentration of ownership may have the effect of delaying, deferring or preventing a change in control, impeding a merger, consolidation, takeover or other business combination involving us, or discouraging a potential acquiror from making a tender offer or otherwise attempting to obtain control of our business, even if such a transaction would benefit other stockholders. So long as they continue to own a significant amount of our equity, these holders will be able to strongly influence or effectively control our decisions.

If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our common stock, our stock price and trading volume could decline.

The trading market for our common stock depends, in part, on the research and reports that securities or industry analysts may publish about us, our business, our market or our competitors. We do not have any control over these analysts. If our financial performance fails to meet analyst estimates or one or more of the analysts who cover us downgrade our common stock or change their opinion of our common stock, our share price would likely decline. If one or more of these analysts cease coverage of us or fail to

74

regularly publish reports on us, we could lose visibility in the financial markets, which could cause our share price or trading volume to decline.

Because we do not anticipate paying any cash dividends on our common stock in the foreseeable future, capital appreciation, if any, will be the sole source of gain for our stockholders.

We have never declared or paid any cash dividends on our common stock. We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. In addition, any future debt agreements may preclude us from paying dividends. As a result, capital appreciation, if any, of our common stock would be our stockholders’ sole source of gain on an investment in our common stock for the foreseeable future. There is no guarantee that shares of our common stock will appreciate in value or even maintain the price at which stockholders have purchased their shares. See “Dividend Policy” for additional information.

We incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to compliance initiatives and corporate governance practices.

As a public company, and particularly after we no longer qualify as an emerging growth company, we will incur significant legal, accounting and other expenses. The Sarbanes-Oxley Act of 2002 (“SOX”), the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of the New York Stock Exchange, and other applicable securities rules and regulations impose various requirements on U.S. reporting public companies, including the establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, these rules and regulations increase our legal and financial compliance costs and make some activities more time-consuming and costly. For example, these rules and regulations may make it more expensive for us to obtain director and officer liability insurance, which in turn could make it more difficult for us to attract and retain qualified senior management personnel or members for our board of directors. In addition, these rules and regulations are often subject to varying interpretations, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. Pursuant to Section 404 of SOX, we are required to furnish a report by our senior management on our internal control over financial reporting. While we remain an emerging growth company, we will not be required to include an attestation report on internal control over financial reporting issued by our independent registered public accounting firm.

To comply with Section 404, we are required to engage in a process to document and evaluate our internal control over financial reporting, which is both costly and challenging. In this regard, we need to continue to dedicate internal resources, engage outside consultants and adopt a detailed work plan to assess and document the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and maintain a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude, within the prescribed timeframe or at all, that our internal control over financial reporting is effective as required by Section 404. We have had a material weakness in our internal control over financial reporting in the past, and cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting once that firm begins its Section 404 reviews, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by the NYSE, SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.

We are an “emerging growth company,” and the reduced reporting requirements applicable to emerging growth companies may make our common stock less attractive to investors.

We are an “emerging growth company,” as defined in the Jumpstart Our Business Startups Act (“JOBS Act”). For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are

75

applicable to other public companies that are not emerging growth companies, including exemption from compliance with the auditor attestation requirements of Section 404, reduced disclosure obligations regarding executive compensation and exemptions from the requirements of holding a nonbinding advisory vote on executive compensation and shareholder approval of any golden parachute payments not previously approved. We will remain an emerging growth company until the earlier of (1) the last day of the fiscal year (a) following the fifth anniversary of the closing of our initial public offering (“IPO”) on January 31, 2020, (b) in which we have total annual gross revenue of at least $1.235 billion or (c) in which we are deemed to be a large accelerated filer, which means the market value of our common stock held by non-affiliates exceeds $700 million as of the end of our prior second fiscal quarter, and (2) the date on which we have issued more than $1.0 billion in non-convertible debt during the prior three-year period.

In addition, under the JOBS Act, emerging growth companies can delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

We cannot predict if investors will find our common stock less attractive because we may rely on these exemptions. If some investors find our common stock less attractive as a result, there may be a less active trading market for our common stock and our share price may be more volatile.

Provisions in our restated certificate of incorporation and amended and restated bylaws and under Delaware law could make an acquisition of our company, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.

Provisions in our restated certificate of incorporation and our amended and restated bylaws that became effective upon the closing of our IPO may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which our stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions include those establishing advance notice bylaw provisions for proposals from stockholders for presentation at annual meetings and forum selection bylaw provisions.

Because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the General Corporation Law of the State of Delaware, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner.

Furthermore, our restated certificate of incorporation that became effective upon the closing of our IPO specifies that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware will be the sole and exclusive forum for most legal actions involving actions brought against us by stockholders. We believe this provision benefits us by providing increased consistency in the application of Delaware law by chancellors particularly experienced in resolving corporate disputes, efficient administration of cases on a more expedited schedule relative to other forums and protection against the burdens of multi-forum litigation. However, the provision may have the effect of discouraging lawsuits against our directors and officers. The enforceability of similar choice of forum provisions in other companies’ certificates of incorporation has been challenged in legal proceedings, and it is possible that, in connection with any applicable action brought against us, a court could find the choice of forum provisions contained in our restated certificate of incorporation to be inapplicable or unenforceable in such action.

Our bylaws designate the Court of Chancery of the State of Delaware as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.

Our bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders with respect to our company and our directors. This choice of forum provision may limit a stockholder’s ability to bring a claim in a

76

judicial forum that the stockholder believes is favorable for disputes with us or our directors, which may discourage meritorious claims from being asserted against us and our directors. Alternatively, if a court were to find this provision of our charter inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs associated with resolving such matters in other jurisdictions, which could adversely affect our business, financial condition or results of operations. We adopted this provision because we believe it makes it less likely that we will be forced to incur the expense of defending duplicative actions in multiple forums and less likely that plaintiffs’ attorneys will be able to employ such litigation to coerce us into otherwise unjustified settlements, and we believe the risk of a court declining to enforce this provision is remote, as the General Assembly of Delaware has specifically amended the Delaware General Corporation Law to authorize the adoption of such provisions.

Item 1B. Unresolved Staff Comments.

None.

Item 1C. Cybersecurity.

Risk Management and Strategy

The Company has adopted processes designed to identify, assess and manage material risks from cybersecurity threats, which are integrated into the Company’s overall risk management systems and processes. Those processes include response to and an assessment of internal and external threats to the security, confidentiality, integrity and availability of our data and information systems, along with other material risks to our operations. The Company references the National Institute of Standards and Technology Cybersecurity Framework to help identify, assess, and manage cybersecurity risks and has adopted and tested a formal cybersecurity incident response plan. As part of our risk management process, the Company engages a third-party provider to conduct periodic maturity assessments. The Company stores data in cloud environments, with security appropriate to the data involved and has adopted controls around, among other things, access and acceptable use, backup and recovery and vendor risk assessment.

Our cybersecurity program is managed by the Annovis Incident Management Committee (the “AIMC”). The AIMC serves as the core team responsible for managing the enterprise-wide cybersecurity policy, maintenance and compliance across all platforms. The AIMC is responsible for the detection and initial assessment of potential cybersecurity threats and incidents. The AIMC classifies detected cyber incidents to allow prioritization, response and escalation. Incidents (if any) are documented for internal reporting processes and regularly shared with senior management.

Our third-party IT service provider is a key part of our cybersecurity program. We partner with a cybersecurity company and leverage their technology and expertise to better protect the Company. From time to time, we engage this vendor to monitor our environment, which includes an outsourced security operations center. We may also from time to time engage partners for periodic penetration testing and vulnerability assessments. We intend to continue to work to formalize our cybersecurity program, including developing processes for third-party service provider cyber-risk oversight and management.

In the event of a potential cybersecurity incident, the AIMC will conduct an assessment to determine the nature and scope of the incident and manages the incident in accordance with our incident response plan until the incident is contained and resolved. The AIMC will document findings and make them available to the Disclosure Committee, which includes cross functional senior management representation from, legal, finance, investor relations and business segments. The Disclosure Committee, in conjunction with third-party experts, including outside legal counsel, is responsible for assessing the materiality of any cybersecurity incident and coordinating external communications and disclosures, including with the Securities and Exchange Commission.

As of December 31, 2024, we are not aware of any cybersecurity threats that have materially affected or are reasonably likely to materially affect the Company's business strategy, results of operations, or financial condition, although we may be materially affected in the future by such risks or future material incidents. See “Risk Factors—Risks Related to Our Business Operations—Disruption, failure or cyber security breaches affecting or targeting computers and infrastructure used by us or our business partners may adversely impact our business and operations” for additional information regarding cybersecurity risks.

77

Governance

Roles and Responsibilities

Cybersecurity is an important part of our risk management processes and an area of focus for the Annovis management and Board of Directors. We continue to invest in cybersecurity and enhance our internal controls and processes, which are designed to help protect our systems and the information they contain.

Our Board is actively involved in the assessment, oversight and management of the material risks that could affect the Company. The Board has delegated to the Audit Committee the responsibility to oversee the integrity of the Company’s information technology and cybersecurity risks and to assess the risks and incidents relating to cybersecurity threats. While our Board and Audit Committee oversee cybersecurity risk, management, through the AIMC, is responsible for the implementation and management of cybersecurity risk management systems and processes and for the communication of incidents to senior management and the Audit Committee.

The AIMC meets with the Audit Committee on a quarterly basis and meets with the BOD at least annually. Additionally, the Audit Committee regularly meets with members of the Company’s internal audit function to discuss risk management activities, compliance, best practices, and other related matters.

Item 2. Properties.

Our offices are in Malvern, Pennsylvania, where we have leased and have access to approximately 1,500 square feet of office space pursuant to a short-term lease agreement. We believe that our facilities are adequate to meet our current needs.

Item 3. Legal Proceedings.

From time to time, we may become subject to litigation and claims arising in the ordinary course of business. We are not currently a party to any material legal proceedings, and we are not aware of any pending or threatened legal proceedings against us that we believe could have a material adverse effect on our business, operating results or financial condition.

Item 4. Mine Safety Disclosures.

Not applicable.

78

PART II

Item 5. Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities.

Market Information

Our common stock is listed on the New York Stock Exchange under the symbol “ANVS”. Our common stock began trading on the New York Stock Exchange on November 18, 2021. From January 29, 2020, the date of our initial public offering, to November 17, 2021, our common stock traded on the NYSE American. Prior to January 29, 2020, there was no public market for our stock.

Holders of Record

As of March 18, 2025, there were approximately 23 holders of record of shares of our common stock. This number does not reflect the beneficial holders of our common stock who hold shares in street name through brokerage accounts or other nominees.

Dividend Policy

We have never declared or paid any cash dividends on our common stock. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business. We do not intend to pay cash dividends on our common stock for the foreseeable future.

Securities Authorized for Issuance Under Equity Compensation Plans

The information called for by this item regarding equity compensation plans is incorporated by reference to Part III, Item 12 of this Annual Report on Form 10-K.

Issuer Purchases of Equity Securities

None.

Recent Sales of Unregistered Securities

None.

Item 7. Management’s Discussion and Analysis of Financial Condition and Results of Operations.

You should read the following discussion and analysis of our financial condition and results of operations together with our financial statements and the related notes appearing at the end of this Annual Report on Form 10-K. Some of the information contained in this discussion and analysis or set forth elsewhere in this Annual Report on Form 10-K, including information with respect to our plans and strategy for our business and related financing, includes forward-looking statements that involve risks and uncertainties. You should read “Cautionary Note Regarding Forward-Looking Statements” and Item 1A. Risk Factors of this Annual Report on Form 10-K for a discussion of important factors that could cause actual results to differ materially from the results described in or implied by the forward-looking statements contained in the following discussion and analysis.

79

Overview

Company Overview

We are a late-stage clinical drug platform company addressing neurodegeneration, such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). We are developing our lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. In several studies, buntanetap was observed to inhibit the synthesis of neurotoxic proteins — APP/Aβ (“APP”), tau/phospho- tau (“tau”) and α-Synuclein (“αSYN”) — that are some of the main causes of neurodegeneration. High levels of neurotoxic proteins lead to reduced axonal transport, which is responsible for the communication between and within nerve cells. When that communication is compromised, the immune system is activated and attacks the nerve cells, eventually killing them. We have observed in our clinical studies in early AD and early PD patients and pre-clinical studies in mice and rats that buntanetap lowered neurotoxic protein levels leading to improved axonal transport, reduced inflammation, lower nerve cell death and improved affected function.

We designed the studies by applying our understanding of the underlying neurodegenerative disease states, and measured both target and pathway validation in the spinal fluid of patients to determine whether patients underlying disease condition improved following treatment. In addition to meeting their primary endpoints of safety and tolerability and secondary endpoint of pharmacokinetics (“PK”) of buntanetap, our AD/PD Trials also met exploratory endpoints of measures of biomarkers and improvements in cognition in AD patients, as well as function in PD patients. We believe that the AD/PD Trials represent the first double-blind, placebo-controlled study that showed improvements in AD patients, as measured by ADAS-Cog, and in PD patients, as measured by UPDRS. Following completion of the AD/PD Trials, we submitted our data to the U.S. Food and Drug Administration (“FDA”) and requested direction to further pursue the development of buntanetap in early PD patients. With the FDA’s guidance, we initiated a Phase 3 study in early PD patients in August 2022 (our “Phase 3 PD Study”). In the Phase 3 PD Study, early PD patients were defined as those at Hoehn & Yahr stages 1, 2 or 3 and OFF times of less than two hours per day. OFF time refers to periods when PD motor and/or non-motor symptoms occur between medication doses. We also submitted a proposed protocol for the treatment of moderate AD to the FDA, and after receiving permission to proceed, we initiated a Phase 2/3 study in mild to moderate AD patients in February 2023 (our “Phase 2/3 AD Study”). In the Phase 2/3 AD Study, mild to moderate AD patients were defined as those with a MMSE score between 14 and 24. Our Phase 3 PD Study and Phase 2/3 AD Study each had built in interim analyses.

Our Phase 3 PD Study incorporated an interim analysis at two months, the results of which were disclosed on March 31, 2023. The pre-planned interim analysis was conducted by our data analytics provider based on 132 patients from all cohorts collectively, for which baseline and two-month data was available. Based on the results of the interim analysis, we proceeded with the Phase 3 PD Study as planned in accordance with the previously established protocol. The study was completed on December 4, 2023, and we released the topline PD Study efficacy data on July 2, 2024. The study data showed that in two subgroups, buntanetap improved UPDRS 2, 3, 2+3 and total. It also showed that in the entire intent to treat (“ITT”) population, buntanetap stopped the loss of cognition and that in the 12% of patients that already had cognitive issues, buntanetap improved cognition in a dose-dependent, statistically significant way. We expect to discuss the Phase 3 PD data with the FDA at an end-of-study meeting during 2025. During that meeting, we plan to propose continued development of buntanetap with an additional, pivotal Phase 3 trial.

With respect to the Phase 2/3 AD Study, we disclosed the results of the interim analysis on October 23, 2023, and similar to our PD study, based on the outcome of the interim analysis, we proceeded with the study as planned. The Phase 2/3 AD study was completed on February 13, 2024, and on April 29, 2024, we announced topline efficacy data. The data showed that in early AD patients, buntanetap improved ADAS-Cog11 in a dose-dependent fashion and was statistically significant from placebo and from baseline.

On October 10, 2024, the Company met with the FDA in an end-of-phase 2 meeting to discuss its Phase 2/3 AD data and to agree on a regulatory path forward. Annovis and the FDA have aligned on a development path for buntanetap towards the filing of New Drug Applications (“NDAs”), one for short-term and one for long-term efficacy. The Phase 3 AD program will investigate buntanetap in patients with early AD and will consist of one study that first incorporates a 6-month study period aimed at confirming buntanetap’s symptomatic effects, then later transitioning into an 18-month study period, designed to demonstrate potential disease-modifying effects. While the overall study will span the combined 18-month treatment period, the completion of the first 6-month period, if well-designed and well-executed, may be sufficient to support an NDA filing, potentially within one year of the 6-month treatment period initiation.

80

During the end-of-phase 2 meeting for AD, the FDA raised no concerns with the Company’s data on buntanetap’s safety, including impact on liver enzymes, drug interactions, dose selection, pharmacokinetics and population pharmacokinetics. Further, the FDA confirmed that future development can proceed using the new crystal form of buntanetap.

We believe that we are the only company developing a drug for AD and PD that is designed to inhibit more than one neurotoxic protein and has a mechanism of action designed to restore nerve cell axonal and synaptic activity. By improving brain function, our goal is to treat memory loss and dementia associated with AD, as well as body and brain function issues associated with PD. Based on pre-clinical and clinical data collected to date, we believe that buntanetap has the potential to be the first drug to interfere with the underlying mechanism of neurodegeneration, potentially enabling buntanetap to be the only drug to improve cognition in AD and motor function in PD. The industry has historically encountered challenges in specifically targeting one neurotoxic protein, be it APP, tau or αSYN, indicating that doing so does not change the underlying course of neurodegeneration. Our ultimate goal is to develop a disease modifying drug (“DMD”) for patients with neurodegeneration by leveraging our clinical and pre-clinical data, which shows inhibition of the most relevant neurotoxic proteins. Studies have found that AD and PD are the most common neurodegenerative diseases in the U.S., and accordingly these diseases present two unmet needs of the aging population and two potentially large U.S. markets, if a DMD is developed and approved.

We believe that we are the only company developing a drug for AD and PD that is designed to inhibit more than one neurotoxic protein and has a mechanism of action designed to restore nerve cell axonal and synaptic activity. By improving brain function, our goal is to treat memory loss and dementia associated with AD, as well as body and brain function issues associated with PD. Based on pre-clinical and clinical data collected to date, we believe that buntanetap has the potential to be the first drug to interfere with the underlying mechanism of neurodegeneration, potentially enabling buntanetap to be the only drug to improve cognition in AD and motor function in PD. The industry has historically encountered challenges in specifically targeting one neurotoxic protein, be it APP, tau or αSYN, indicating that doing so does not change the underlying course of neurodegeneration. Our ultimate goal is to develop a disease modifying drug (“DMD”) for patients with neurodegeneration by leveraging our clinical and pre-clinical data, which shows inhibition of the most relevant neurotoxic proteins. Studies have found that AD and PD are the most common neurodegenerative diseases in the U.S., and accordingly, these diseases present two unmet needs of the aging population and two potentially large U.S. markets, if a DMD is developed and approved.

We have never been profitable and have incurred net losses since inception. Our accumulated deficit at December 31, 2024 was $134.8 million. We expect to incur losses for the foreseeable future, and we expect these losses to increase as we continue our development of, and seek regulatory approvals for, our product candidates. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when we will be able to achieve or maintain profitability, if at all.

Financial Operations Overview

The following discussion sets forth certain components of our statements of operations as well as factors that impact those items.

Segment Information

As of December 31, 2024, we viewed our operations and managed our business as one operating segment consistent with how our chief operating decision-maker, our Chief Executive Officer, makes decisions regarding resource allocation and assessing performance. As of December 31, 2024, substantially all of our assets were located in the United States. Our headquarters are located in Malvern, Pennsylvania.

Research and Development Expenses

Our research and development (“R&D”) expenses consist of expenses incurred in development and clinical studies relating to our product candidates, including:

expenses associated with clinical development;

81

personnel-related expenses, such as salaries, benefits, travel and other related expenses, including stock-based compensation; and
payments to third-party contract research organizations (“CROs”), contract manufacturing organizations (“CMOs”), contractor laboratories and other independent contractors.

Research and development costs are either expensed as incurred or recorded separately as a prepaid asset, whereby expense is recognized when the service is performed. Clinical development expenses for our product candidates are a significant component of our current research and development expenses. Product candidates in later stage clinical development generally have higher research and development expenses than those in earlier stages of development, primarily due to increased size (e.g., patient population) and duration of the clinical trials. We track and record information regarding external research and development expenses for each study or trial that we conduct. We often use third-party CROs, contractor laboratories and independent contractors to help us complete clinical studies. We recognize the expenses associated with third parties performing these services for us in our clinical studies based on the percentage of each study (or study activity) completed at the end of each reporting period.

Our research and development expenses in 2024 were primarily related to the wind-down and analysis of our Phase 3 study in early PD patients and our Phase 2/3 study in AD patients, as well as preparatory work for our pivotal Phase 3 AD study program in early AD patients. Our research and development expenses in 2023 were primarily related to the execution of our Phase 3 study in early PD patients and our Phase 2/3 study in AD patients. We expect that our research and development expenses in 2025 and for the next several years will continue to remain elevated as a result of costs associated with completing our Phase 3 trial for AD, our planned Phase 3 trial for PD and other subsequent planned activities leading up to a potential NDA filing(s) with the FDA. These expenditures are subject to numerous uncertainties regarding timing and cost to achieve completion. Completion of our clinical development and clinical trials may take several years or more and the length of time generally varies according to the type, complexity, novelty and intended use of our product candidates. The cost of clinical trials may vary significantly over the life of a project as a result of differences arising during clinical development.

Due to the ongoing and uncertain nature of our research and development, we are unable to accurately determine the duration or completion costs of our development of buntanetap. As a result of the difficulties of forecasting research and development costs of buntanetap as well as the other uncertainties discussed above, we are unable to determine when and to what extent we will generate revenues from the commercialization and sale of approved product candidates.

General and Administrative Expenses

General and administrative (“G&A”) expenses consist primarily of salaries, benefits and other related costs, including public company costs as well as stock-based compensation, for personnel serving in our executive, finance, accounting, and administrative functions. Our general and administrative expenses also include professional fees for legal services, including patent-related expenses, consulting, tax and accounting services, insurance, rent and general corporate expenses. We expect that our general and administrative expenses will increase as a result of the continued clinical development and potential commercialization of our product candidates.

Income Taxes

As of December 31, 2024, the Company had U.S. federal net operating loss (“NOL”) carryforwards of $54.1 million, which may be available to offset future income tax liabilities. Federal NOL carryforwards generated in 2017 and prior of $2.8 million will expire beginning 2032. The remaining federal NOL carryforwards generated beginning in 2018, do not expire. NOL carryforwards generated beginning in 2018 are permitted to offset 80% of taxable income in future years. As of December 31, 2024, the Company also had U.S. state NOL carryforwards of $56.6 million, which may be available to offset future income tax liabilities and will expire beginning in 2028.

NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service (the “IRS”) and may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant shareholders over a three-year period in excess of 50% as defined under Sections 382 and 383 in the Internal Revenue Code. This could substantially limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of the annual limitation is determined based on our value immediately prior to the ownership change. Subsequent ownership

82

changes may further affect the limitation in future years. We have not yet conducted a comprehensive study to assess whether a change of ownership as defined by Section 382 has occurred since our inception.

Results of Operations

Years ended December 31, 2024 and 2023

Operating expenses and other income (expense) were comprised of the following:

Year Ended

December 31, 

    

2024

    

2023

Change

(in thousands)

Operating expenses:

Research and development

$

19,995

$

38,791

$

(18,796)

General and administrative

6,699

6,244

455

Total operating expenses

26,694

45,035

(18,341)

Other income (expense):

Interest income

332

668

(336)

Other financing costs

(1,853)

-

(1,853)

Change in fair value of warrants

3,626

(11,837)

15,463

Other income (expense), net

2,105

(11,169)

13,274

Net loss

$

24,589

$

56,204

$

(31,615)

Research and Development Expenses

Research and development expenses decreased by $18.8 million for the year ended December 31, 2024 compared to the year ended December 31, 2023. The decrease was primarily the result of our Phase 3 PD and Phase 2/3 AD studies being active during the majority of 2023, whereas 2024 study activity was minimal because the aforementioned trials had been completed. This decrease related to timing of study costs was primarily offset by increases in statistics, bioanalytical and CMC costs during the year ended December 31, 2024. Year-over-year increases for these items took place as we analyzed data from our completed Phase 3 PD and Phase 2/3 AD studies and performed preparatory work for our pivotal Phase 3 AD study.

General and Administrative Expenses

General and administrative expenses increased by $0.5 million for the year ended December 31, 2024, compared to the year ended December 31, 2023. The increase was primarily a result of warrant exercise commissions expensed during the current year.

Interest Income

Interest income decreased by $0.3 million for the year ended December 31, 2024 compared to the year ended December 31, 2023. The decrease was primarily the result of lower cash and cash equivalent balances on hand year-over-year.

Other Financing Costs

Financing costs were $1.9 million for the year ended December 31, 2024. We did not incur any financing costs for the year ended December 31, 2023. The change was attributable to issuance costs as well as changes in derivative fair value associated with our ELOC financing with an ELOC Purchaser, described further below.

Change in Fair Value of Warrants

Change in fair value of warrants was a gain of $3.6 million for the year ended December 31, 2024 compared to a loss of $11.8 million the year ended December 31, 2023. This change was attributable to the fair value remeasurement with respect to our liability-classified Canaccord Warrants during 2024. The current year loss recorded in the statements of operations was primarily

83

driven by warrant exercises made at higher stock prices during the third quarter of 2024, triggering remeasurement. The remaining change in fair value was primarily driven by the change in our stock price during 2024. For the year ended December 31, 2023, the change in fair value was primarily attributable to issuance of the liability-classified Canaccord Warrants and the increase in our stock price during the fourth quarter.

Liquidity and Capital Resources

Since our inception in 2008, we have devoted most of our cash resources to research and development and general and administrative activities. We have financed our operations primarily with the proceeds from the sale of common stock and warrants. To date, we have not generated any revenues from the sale of products, and we do not anticipate generating any revenues from the sales of products for the foreseeable future. We have incurred losses and generated negative cash flows from operations since inception. As of December 31, 2024, our principal source of liquidity was our cash and cash equivalents, which totaled $10.6 million.

Equity Financings

March 2024 Registered Direct Offerings

On March 15, 2024 and March 21, 2024, we entered into two separate securities purchase agreements with the same institutional investor. When aggregating the results of both purchase agreements, we issued 0.4 million shares for net proceeds of $3.9 million registered direct offerings.

April 2024 ELOC Purchase Agreement

On April 25, 2024, we entered into an ELOC Purchase Agreement with an ELOC Purchaser, whereby we could offer and sell, from time to time at our sole discretion, and whereby the ELOC Purchaser committed to purchase, up to 2.0 million shares of shares of our common stock. The term of the agreement was until the expiration of our active S-3 Registration Statement, unless earlier terminated or exhausted.

Upon execution of the ELOC Purchase Agreement, we agreed to issue 33,937 shares of common stock as commitment shares to the ELOC Purchaser. In addition to the commitment shares referenced above, as of the year ended December 31, 2024 we have sold 2.0 million shares of our common stock under the purchase agreement and received net proceeds of $14.6 million. There are no shares remaining to sell under this agreement after December 31, 2024.

January and July 2024 Warrant Exercises

During July of 2024, 0.8 million of our Canaccord warrants were exercised at $9.00 per share in a series of transactions. The exercises resulted in gross proceeds of $7.5 million. There were also 0.1 million warrants exercised in January of 2024, for gross proceeds of $0.5 million. Total warrant commissions payable to Canaccord for these exercises totaled $0.5 million, which was expensed in the Statements of Operations for the year ended December 31, 2024.

December 2024 ATM

On December 11, 2024, we entered into an Equity Distribution Agreement (“Distribution Agreement”) with Oppenheimer & Co. Inc. (“OpCo”), relating to the sale of shares of our common stock. In accordance with the terms of the Distribution Agreement, we may offer and sell shares of our common stock having an aggregate offering price of up to $50.0 million from time to time through or to OpCo, acting as our agent or principal.

During the year ended December 31, 2024, we have sold 26,788 shares of common stock pursuant to the Distribution Agreement for gross proceeds of $0.2 million before commissions.

February 2025 ThinkEquity Offering

On February 3, 2025, we entered into an Underwriting Agreement with ThinkEquity LLC, acting as representative of the underwriters with respect to an underwritten public offering of 5.3 million units of the Company. Each unit sold consisted of one share

84

of common stock and one warrant to purchase one share of common stock (the “ThinkEquity Warrants”), at a per unit price of $4.00 (the “Offering”). Aggregate gross proceeds from the Offering were $21.0 million before deducting underwriting discounts and other estimated offering expenses. The Warrants have an exercise price of $5.00 per share, are immediately exercisable and expire five years from the date of issuance. The shares of Common Stock and Warrants were issued separately. We have agreed to suspend sales of our Common Stock under the OpCo ATM Facility for a period of six months after the closing of the Offering.

Future Capital Requirements

We do not have sufficient capital on hand to fund our operations for the next 12 months and will need to raise additional capital to meet our obligations as they become due. We believe that our current cash and cash equivalents will be sufficient to fund our operating expenses and capital expenditure requirements into the fourth quarter of 2025. We will need to raise substantial additional capital to complete the development and commercialization of our product candidates through public or private equity offerings, debt financings, collaboration and licensing arrangements or other financing alternatives. However, there can be no assurance that we will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to us. If we are unable to raise sufficient additional capital or defer sufficient operating expenses, we may be compelled to reduce the scope of our operations. Accordingly, we have concluded that substantial doubt exists with respect to our ability to continue as a going concern within one year after the date that these financial statements are issued.

We expect to incur significant operating losses for the foreseeable future. We also expect these losses to further increase, as we ramp up our clinical development programs and begin activities for commercial launch readiness. We may also encounter unforeseen expenses, difficulties, complications, delays and other currently unknown factors that could adversely affect our business.

Our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:

the initiation, progress, timing, costs and results of preclinical studies and clinical trials, including patient enrollment in such trials, for buntanetap or any other future product candidates;
the clinical development plans we establish for buntanetap and any other future product candidates, including any modifications to clinical development plans based on feedback that we may receive from regulatory authorities;
the number and characteristics of product candidates that we discover or in-license and develop;
the outcome, timing and cost of regulatory meetings and reviews by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than those that we currently expect;
the requirements of regulatory authorities in any additional jurisdictions in which we may seek approval for buntanetap and any future product candidates and our anticipated timing for seeking approval in such jurisdictions;
the costs of filing, prosecuting, defending and enforcing any patent claims and maintaining and enforcing other intellectual property and proprietary rights;
the effects of competing technological and market developments;
the costs associated with hiring additional personnel and consultants as our business grows, including additional executive officers and clinical development, regulatory, CMC, quality and commercial personnel;
the costs and timing of the implementation of commercial-scale manufacturing activities, if any product candidate is approved, including as a result of inflation, any supply chain issues or component shortages;
the costs and timing of establishing sales, marketing and distribution capabilities for any product candidates for which we may receive regulatory approval;

85

our ability to achieve sufficient market acceptance, coverage and adequate reimbursement from third-party payors and adequate market share and revenue for any approved products;
the terms and timing of establishing and maintaining collaborations, licenses and other similar arrangements; and
the costs associated with any products or technologies that we may in-license or acquire.

A change in the outcome of any of these or other variables with respect to the development of any of our product candidates could significantly change the costs and timing associated with the development of that product candidate. Furthermore, our operating plans may change in the future, and we will continue to require additional capital to meet operational needs and capital requirements associated with such operating plans. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments or engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders.

Adequate funding may not be available to us on acceptable terms or at all. Our potential inability to raise capital when needed could have a negative impact on our financial condition and our ability to pursue our business strategies. If we are unable to raise additional funds as required, we may need to delay, reduce, or terminate some or all development programs and clinical trials. We may also be required to sell or license our rights to product candidates in certain territories or indications that we would otherwise prefer to develop and commercialize ourselves. If we are required to enter into collaborations and other arrangements to address our liquidity needs, we may have to give up certain rights that limit our ability to develop and commercialize our product candidates or may have other terms that are not favorable to us or our stockholders, which could materially and adversely affect our business and financial prospects. See the section of this Annual Report on Form 10-K titled “Risk Factors” for additional risks associated with our substantial capital requirements.

Cash Flows

The following table summarizes our cash flows from operating, investing and financing activities the years ended December 31, 2024 and 2023.

Year Ended

December 31, 

    

2024

    

2023

(in thousands)

Total net cash (used in) provided by:

 

  

 

  

Operating activities

$

(21,895)

$

(39,967)

Financing activities

 

26,692

 

17,344

Net increase (decrease) in cash and cash equivalents

$

4,797

$

(22,623)

Operating Activities

For the year ended December 31, 2024, cash used in operations was $21.9 million compared to $40.0 million for the year ended December 31, 2023. The decrease in cash used in operations was primarily the result of our Phase 3 PD and Phase 2/3 AD studies being active during the majority of 2023, whereas 2024 study activity was minimal because the aforementioned trials had been substantially completed in 2023. The reduction in clinical activity during 2024 significantly reduced our operating cash burn year-over-year.

We expect cash used in operating activities to once again increase in 2025 as compared to 2024, due to an expected increase in our operating losses associated with continued development of our product candidates (i.e., pivotal Phase 3 AD Program) as well as planned increases in our personnel count.

86

Financing Activities

Cash provided by financing activities was $26.7 million during the year ended December 31, 2024, which was primarily attributable to proceeds from issuance of common stock and warrants for capital raises, including our ELOC and ATM facilities, as well as proceeds from exercises of our Canaccord Warrants.

Cash provided by financing activities was $17.3 million during the year ended December 31, 2023, which was primarily attributable to proceeds from issuance of common stock and warrants for capital raises, including proceeds from our equity financing with Canaccord as well as proceeds from exercises of our Canaccord Warrants.

Off-Balance Sheet Arrangements

We did not have any off-balance sheet arrangements during the periods presented, and we do not currently have any off-balance sheet arrangements as defined in the rules and regulations of the SEC.

Critical Accounting Policies and Use of Estimates

We have based our management’s discussion and analysis of financial condition and results of operations on our financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of these financial statements requires us to make estimates that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements as well as the reported revenues and expenses during the reporting periods. On an ongoing basis, we evaluate our estimates and judgments, including those related to clinical development expenses, fair value of warrants and stock-based compensation. The clinical development cost to advance any of our product candidates to marketing approval is substantial and involves numerous risks and uncertainties associated with pharmaceutical product development. As a result, we are unable to accurately predict the timing or amount of increased expenses and, as a result, clinical development expense could be materially different as the costs are incurred. In determining warrant fair value, we maximize the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. We measure and record stock compensation expense using the applicable accounting guidance for share-based payments using the Black-Scholes option pricing model to value option awards which requires the use of subjective assumptions, including the expected life of the option and expected share price volatility. These assumptions used in calculating the fair value of stock-based awards represent our best estimates and involve inherent uncertainties and the application of judgment. As a result, if factors change and we used different assumptions, stock-based compensation expense could be materially different for stock-based awards.

While our significant accounting policies are more fully discussed in Note 2 to our audited financial statements appearing at the end of this Annual Report on Form 10-K, we believe that the following accounting policies are critical to the process of making significant judgments and estimates in the preparation of our financial statements.

Research and Development Expenses and Clinical Trial Accruals

As part of the process of preparing the financial statements included elsewhere in this Annual Report on Form 10-K, we are required to estimate and record expenses, for which a large portion are research and development expenses. Research and development expenses include, among other categories - development, clinical trials, and regulatory compliance costs incurred with research organizations, contract manufacturers, and other third-party vendors. We rely on third-parties to conduct our clinical studies and to provide many of these services, including data and project management, statistical analysis and electronic compilation. At the end of each reporting period, the estimation process involves identifying services that have been performed on our behalf by third-parties, estimating and accruing expenses in our financial statements based on the evaluation of the progress to completion of specific tasks and the facts and circumstances known to us at the time of the estimate, and assessing the accuracy of these estimates going forward to determine if adjustments are required. We periodically collaborate with our third-party vendors to assist in determining our estimates. Payments for these activities performed by our third-party vendors are based on the terms of the individual arrangements with our third-party vendors, which may differ from the pattern of costs incurred, and are reflected in the financial statements as prepaid or accrued research and development expense, as applicable. We believe our estimates and assumptions are reasonable under the current conditions; however, actual results may differ from these estimates. Any changes to estimates will be recorded in the

87

period in which a circumstance causing a change in estimate becomes known and the impact of any change in estimate could be material.

Stock-Based Compensation

We account for our stock-based compensation awards in accordance with the Financial Accounting Standards Board (“FASB”) Accounting Standards Codification (“ASC”) Topic 718, Compensation—Stock Compensation (“ASC 718”). We have issued stock-based compensation awards that are stock options, in accordance with ASC 718. ASC 718 requires all stock-based payments, including grants of stock options, to be recognized in the statements of operations based on their grant date fair values. We use the Black-Scholes option-pricing model to determine the fair value of options granted. We recognize forfeitures as they occur. Expense related to stock-based compensation awards are recorded to research and development expense or general and administrative expense based on the underlying function of the individual that was granted the stock-based compensation award. Estimating the fair value of stock options requires the input of subjective assumptions, including the expected term of the stock option, stock price volatility, the risk-free interest rate, and expected dividends. The assumptions used in our Black-Scholes option-pricing model represent our best estimates and involve a number of variables, uncertainties, assumptions, and the application of our judgment, as they are inherently subjective.

The assumptions used in our Black-Scholes option-pricing model for stock options are as follows:

Expected Term. As we do not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the expected term of employee options is determined using the “simplified” method, as prescribed in SEC’s Staff Accounting Bulletin No. 107, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the option.

Expected Volatility. The expected volatility is based on our historical volatilities and that of similar entities within our industry for periods commensurate with the assumed expected term.

Risk-Free Interest Rate. The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.

Expected Dividends. The expected dividend yield is 0% because we have not historically paid, and do not expect for the foreseeable future to pay, a dividend on our common stock.

Stock-based compensation expense was $3.8 million and $4.6 million for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, we had $2.4 million of unrecognized stock-based compensation expense, related to service-based options, which will be recognized over a remaining weighted-average period of 1.0 years.

Valuation of Common Stock Warrant Liabilities

The fair value of Common Stock Warrant Liabilities is determined using a Black-Scholes option-pricing model. Determining the appropriate fair value model and calculating the fair value of Common Stock Warrants requires considerable judgment. Any change in the estimates used may cause the value to be higher or lower than that reported. The Common Stock Warrants are not traded in an active market and the fair value is determined using valuation techniques. The estimates may be significantly different from those recorded in the financial statements because of the use of judgment and the inherent uncertainty in estimating the fair value of these instruments that are not quoted in an active market. All changes in the fair value are recorded in the statements of operations each reporting period.

Recently Adopted Accounting Pronouncements

Effective January 1, 2024, the Company retrospectively adopted Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) on an annual basis, which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items. ASU 2023-07 also requires public entities with a single reportable segment to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in FASB ASC Topic 280, Segment Reporting. This guidance is effective for

88

fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. See Note 11 for additional disclosures made as a result of adopting ASU 2023-07.

Recent Accounting Pronouncements

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which improves income tax disclosures by requiring: (1) consistent categories and greater disaggregation of information in the rate reconciliation, and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The ASU indicates that all entities will apply the guidance prospectively with an option for retroactive application to each period presented in the financial statements. The Company has not determined the impact ASU 2023-09 may have on the Company’s financial statement disclosures but is not expecting material impacts.

In November 2024, the FASB issued ASU 2024-03, Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires public entities, at annual and interim reporting periods, to disclose in a tabular format additional information about specific expense categories in the notes to the financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is still evaluating the impacts of this ASU on its future financial statements and disclosures.

JOBS Act

Section 107 of the JOBS Act also provides that an “emerging growth company” can take advantage of the extended transition period provided in Section 7(a)(2)(B) of the Securities Act for complying with new or revised accounting standards. In other words, an “emerging growth company” can delay the adoption of new or revised accounting standards until those standards would otherwise apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, we will be subject to the same new or revised accounting standards as other public companies that are not emerging growth companies.

Item 7A. Quantitative and Qualitative Disclosures About Market Risk.

This item is not required for smaller reporting companies.

Item 8. Financial Statements and Supplementary Data.

Our financial statements, accompanying notes and Report of Independent Registered Public Accounting Firm are included in this Annual Report on Form 10-K beginning on page F-1, which are incorporated in this Item 8 by reference.

Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.

None.

Item 9A. Controls and Procedures.

Evaluation of Disclosure Controls and Procedures

Our management, with the participation of our Chief Executive Officer, has evaluated the effectiveness of our disclosure controls and procedures (as such term is defined in Rules 13a-15I and 15d-15(e) under the Exchange Act) as of the end of the period covered by this Annual Report on Form 10-K. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost benefit relationship of possible controls and procedures. Based on such evaluation, our Chief Executive Officer has concluded that, as of the end of the period covered by this report, our disclosure controls and procedures were effective to ensure that the information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed in

89

the reports we file or submit under the Exchange Act is accumulated and communicated to our management, including our Chief Executive Officer, as our interim principal financial and accounting officer, to allow timely decisions regarding required disclosures.

Management’s Report on Internal Control Over Financial Reporting

Management is responsible for establishing and maintaining adequate internal control over financial reporting as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act. Our internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Management utilized the criteria established in the Internal Control – Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission (“COSO”) to assess the effectiveness of our internal control over financial reporting as of December 31, 2024. Based on the assessment, management has concluded that, as of December 31, 2024, our internal control over financial reporting was effective.

As an emerging growth company, management’s assessment of internal control over financial reporting was not subject to attestation by our independent registered public accounting firm.

Changes in Internal Control Over Financial Reporting

There have been no changes in our internal control over financial reporting during our most recent fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

Item 9B. Other Information.

During the three months ended December 31, 2024, the following directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated a “Rule 10b5-1 trading arrangement” or “non-Rule 10b5-1 trading arrangement,” as each term is defined in Item 408(c) of Regulation S-K:

Name and Title

Action

Date

Plan

Aggregate Number of securities to be sold

Plan Expiration Date

Maria MaccecchiniCEO & Director

Adoption

17-Dec-24

Rule 10b5-1

270,000

16-Sep-26

Claudine Bruck, Director

Adoption

17-Dec-24

Rule 10b5-1

21,426

31-Dec-25

Mark WhiteDirector

Adoption

17-Dec-24

Rule 10b5-1

51,426

30-Sep-26

Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.

Not Applicable.

90

PART III

Item 10. Directors, Executive Officers and Corporate Governance.

We incorporate the information required by this Item 10 by reference to the definitive proxy statement for our 2025 annual meeting of shareholders, to be filed with the SEC.

Item 11. Executive Compensation.

We incorporate the information required by this Item 11 by reference to the definitive proxy statement for our 2025 annual meeting of shareholders, to be filed with the SEC.

Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters.

We incorporate the information required by this Item 12 by reference to the definitive proxy statement for our 2025 annual meeting of shareholders, to be filed with the SEC.

Equity Compensation Plan Information

    

Number of

    

    

securities to be issued

Number of securities remaining

upon exercise of

Weighted-average

available for future issuance under

outstanding options,

exercise price of outstanding

equity compensation plans (excluding

Plan category

warrants and rights

options, warrants and rights

securities reflected in column (a))

(a)

(b)

(c)

Equity compensation plans approved by security holders

 

2,336,020

$

11.39

 

354,299

Equity compensation plans not approved by security holders

 

310,733

$

8.99

 

Total

 

2,646,753

$

11.11

 

354,299

Item 13. Certain Relationships and Related Transactions and Director Independence.

We incorporate the information required by this Item 13 by reference to the definitive proxy statement for our 2025 annual meeting of shareholders, to be filed with the SEC.

Item 14. Principal Accountant Fees and Services.

We incorporate the information required by this Item 14 by reference to the definitive proxy statement for our 2025 annual meeting of shareholders, to be filed with the SEC.

91

PART IV

Item 15. Exhibits and Financial Statement Schedules.

(a)Documents filed as part of this report:
1.Financial Statements. The financial statements as set forth under Item 8 of this Annual Report on Form 10-K are incorporated herein.
2.Financial Statement Schedules. All financial statement schedules have been omitted because they are not applicable, not required, or the information is shown in the financial statements or related notes.
3.Exhibits. See (b) below.
(b)Exhibits:

Exhibit
Number

    

Description of Exhibit

3.1

Amended and Restated Certificate of Incorporation of the Registrant. (Incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed February 6, 2020.)

3.2

Amended and Restated Bylaws of the Registrant. (Incorporated by reference to Exhibit 3.2 to the Current Report on Form 8-K filed February 6, 2020.)

3.3

Certificate of Amendment to the Amended and Restated Certificate of Incorporation of the Registrant. (Incorporated by reference to Exhibit 3.1 to the Current Report on Form 8-K filed June 16, 2023.)

4.1

Specimen Certificate evidencing shares of the Registrant’s common stock. (Incorporated by reference to Exhibit 4.1 to Amendment No. 3 to the Registration Statement on Form S-1 filed September 20, 2019.)

4.2

Form of Warrant Agreement (Incorporated by reference to Exhibit 10.1 to the Current Report on Form 8-K filed on November 1, 2023.)

4.3

Form of Warrant (Incorporated by reference to Exhibit 4.1 to the Current Report on Form 8-K filed on February 5, 2025)

4.4

Warrant Agency Agreement (Incorporated by reference to Exhibit 4.2 to the Current Report on Form 8-K filed on February 5, 2025)

4.5

Description of Registrant’s Securities.

10.1+

Second Amended and Restated Employment Agreement dated as of March 24, 2020 between the Registrant and Maria Maccecchini. (Incorporated by reference to Exhibit 10.1 to Form 10-K filed March 25, 2020.)

10.2+

Annovis Bio, Inc. 2018 Equity Incentive Plan. (Incorporated by reference to Exhibit 4.3 to the Registration Statement on Form S-8 filed February 14, 2020.)

10.3+

Amendment to Annovis Bio, Inc. 2019 Equity Incentive Plan (Incorporated by reference to form DEF 14A filed April 29, 2024.)

10.4

Registration Rights Agreement dated as of December 19, 2014 among the Registrant and the signatories thereto. (Incorporated by reference to Exhibit 10.5 to Amendment No. 1 to Form S-1 filed August 8, 2019.)

92

Exhibit
Number

    

Description of Exhibit

10.5+

Form of Non-Qualified Stock Option Award Agreement for the Annovis Bio, Inc. 2019 Equity Incentive Plan. (Incorporated by reference to Exhibit 10.6 to the Annual Report on Form 10-K filed on March 31, 2023).

10.6

Distribution Agreement, dated December 11, 2024, by and between Annovis Bio, Inc. and Oppenheimer & Co. Inc. (Incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K filed on December 12, 2024)

10.7

Underwriting Agreement, dated February 3, 2025, by and between Annovis Bio., Inc. and ThinkEquity LLC (Incorporated by reference to Exhibit 1.1 to the Current Report on Form 8-K filed on February 5, 2025)

19.1

Insider Trading Policy

23.1

Consent of Ernst & Young LLP

31.1

Certification Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1

Certification Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

97.1

Clawback Policy (Incorporated by reference to Exhibit 97.1 to the Annual Report on Form 10-K filed March 29, 2024)

101.INS

XBRL Instance Document – the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

101.SCH

XBRL Taxonomy Extension Schema Document

101.CAL

XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF

XBRL Taxonomy Extension Definition Linkbase Document

101.LAB

XBRL Taxonomy Extension Labels Linkbase Document

101.PRE

XBRL Taxonomy Extension Presentation Linkbase Document

104

Cover Page Interactive Data File – the cover page interactive data file does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document.

+

Indicates management contract or compensatory plan.

(c)Financial Statement Schedules:

None.

Item 16. Form 10-K Summary.

Not Applicable.

93

Report of Independent Registered Public Accounting Firm

To the Shareholders and the Board of Directors of Annovis Bio, Inc.

Opinion on the Financial Statements

We have audited the accompanying balance sheets of Annovis Bio, Inc. (the Company) as of December 31, 2024 and 2023, the related statements of operations, changes in stockholders’ equity (deficit) and cash flows for each of the two years in the period ended December 31, 2024, and the related notes (collectively referred to as the “financial statements”). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December 31, 2024 and 2023, and the results of its operations and its cash flows for each of the two years in the period ended December 31, 2024, in conformity with U.S. generally accepted accounting principles.

The Company's Ability to Continue as a Going Concern

The accompanying financial statements have been prepared assuming that the Company will continue as a going concern. As discussed in Note 1 to the financial statements, the Company has suffered recurring losses from operations and has stated that substantial doubt exists about the Company’s ability to continue as a going concern. Management's evaluation of the events and conditions and management’s plans regarding these matters are also described in Note 1. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Basis for Opinion

These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company’s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.

We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over financial reporting. Accordingly, we express no such opinion.

Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.

/s/ Ernst & Young LLP

We have served as the Company’s auditor since 2023.

Philadelphia, Pennsylvania

March 21, 2025

F-2

ANNOVIS BIO, INC.

Balance Sheets

As of December 31, 

    

2024

    

2023

Assets

  

 

  

Current assets:

  

 

  

Cash and cash equivalents

$

10,551,916

$

5,754,720

Prepaid expenses and other current assets

 

3,373,717

 

4,453,544

Total assets

$

13,925,633

$

10,208,264

Liabilities and stockholders’ equity (deficit)

 

  

 

  

Current liabilities:

 

  

 

  

Accounts payable

$

2,305,974

$

1,292,837

Accrued expenses

 

1,575,013

 

2,986,273

Total current liabilities

 

3,880,987

 

4,279,110

Non-current liabilities:

Warrant liability

737,000

13,680,000

Total liabilities

 

4,617,987

 

17,959,110

Commitments and contingencies (Note 6)

 

  

 

  

Stockholders’ equity (deficit) :

 

  

 

  

Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding

Common stock - $0.0001 par value, 70,000,000 shares authorized and 14,141,521 and 10,519,933 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively

 

1,414

 

1,052

Additional paid-in capital

 

144,155,694

 

102,507,189

Accumulated deficit

 

(134,849,462)

 

(110,259,087)

Total stockholders’ equity (deficit)

 

9,307,646

 

(7,750,846)

Total liabilities and stockholders’ equity (deficit)

$

13,925,633

$

10,208,264

See accompanying notes to financial statements.

F-3

ANNOVIS BIO, INC.

Statements of Operations

Year Ended December 31, 

    

2024

    

2023

Operating expenses:

  

 

  

Research and development

$

19,995,447

$

38,790,603

General and administrative

 

6,699,481

 

6,244,408

Total operating expenses

 

26,694,928

 

45,035,011

Operating loss

 

(26,694,928)

 

(45,035,011)

Other income (expense):

 

  

 

  

Interest income

 

331,849

 

667,898

Other financing costs (Note 7)

(1,853,189)

Change in fair value of warrants (Note 7)

3,625,893

(11,837,200)

Total other income (expense), net

 

2,104,553

 

(11,169,302)

Net loss

$

(24,590,375)

$

(56,204,313)

Net loss per share (Note 9)

Basic

$

(2.02)

$

(6.23)

Diluted

$

(2.31)

$

(6.23)

Weighted-average number of common shares used in computing net loss per share

Basic

12,182,475

9,023,138

Diluted

 

12,235,444

 

9,023,138

See accompanying notes to financial statements.

F-4

ANNOVIS BIO, INC.

Statements of Changes in Stockholders’ Equity (Deficit)

Stockholders’ Equity (Deficit)

Additional

Total

Common Stock

Paid-In

Accumulated

Stockholders’ Equity

    

Shares

    

Amount

    

Capital

    

Deficit

    

(Deficit)

Balance, December 31, 2022

 

8,163,923

$

816

$

82,377,488

$

(54,054,774)

$

28,323,530

Exercise of stock options

59,897

6

8,379

8,385

Stock-based compensation expense

4,628,406

4,628,406

Exercise of common stock warrants, inclusive of warrant reduction

 

50,000

 

5

 

1,056,196

 

 

1,056,201

Issuance of common stock, net of issuance costs and warrant liability

2,246,113

225

14,436,720

14,436,945

Net loss

 

 

 

 

(56,204,313)

 

(56,204,313)

Balance, December 31, 2023

 

10,519,933

$

1,052

$

102,507,189

$

(110,259,087)

$

(7,750,846)

Cashless exercise of stock options

220,339

22

(22)

Stock-based compensation expense

 

 

 

3,836,770

 

 

3,836,770

Exercise of common stock warrants, inclusive of warrant reduction

891,667

89

17,342,022

17,342,111

Issuance of common stock pursuant to Equity Distribution Agreement, net of issuance costs

26,788

3

156,766

156,769

Issuance of common stock pursuant to ELOC, net of issuance costs

2,051,428

205

16,438,012

16,438,217

Issuance of common stock pursuant to registered direct offering, net of issuance costs

431,366

43

3,874,957

3,875,000

Net loss

(24,590,375)

(24,590,375)

Balance, December 31, 2024

14,141,521

$

1,414

$

144,155,694

$

(134,849,462)

$

9,307,646

See accompanying notes to financial statements.

F-5

ANNOVIS BIO, INC.

Statements of Cash Flows

Year Ended December 31, 

    

2024

    

2023

Cash flows from operating activities:

  

 

  

Net loss

$

(24,590,375)

$

(56,204,313)

Adjustments to reconcile net loss to net cash used in operating activities:

 

 

Stock-based compensation expense

 

3,836,770

 

4,628,406

Change in fair value of warrants

(3,625,893)

11,837,200

Non-cash other financing costs, including change in fair value of derivative

 

1,803,189

 

Changes in operating assets and liabilities:

Prepaid expenses and other current assets

 

1,079,827

 

3,190,832

Accounts payable

 

1,013,138

 

(2,668,417)

Accrued expenses

 

(1,411,260)

 

(751,012)

Net cash used in operating activities

 

(21,894,604)

 

(39,967,304)

Cash flows from financing activities:

 

  

 

  

Proceeds from issuance of common stock, net

18,666,797

16,885,946

Proceeds from exercise of warrants

8,025,003

450,000

Proceeds from exercise of stock options

 

 

8,385

Net cash provided by financing activities

 

26,691,800

 

17,344,331

Net increase (decrease) in cash and cash equivalents

 

4,797,196

 

(22,622,973)

Cash and cash equivalents, beginning of year

 

5,754,720

 

28,377,693

Cash and cash equivalents, end of year

$

10,551,916

$

5,754,720

Supplemental disclosure of cash flow information:

Other adjustment to value of warrants related to exercises

$

9,317,108

$

606,201

Cash paid for financing costs

$

50,000

$

See accompanying notes to financial statements.

F-6

Annovis Bio, Inc.

Notes to Financial Statements

December 31, 2024 and 2023

(1) Nature of Business and Management’s Plans

Annovis Bio, Inc. (the “Company” or “Annovis”) was incorporated on April 29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company’s lead product candidate, buntanetap, is a small molecule administered orally that is designed to attack neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby impeding the toxic cascade.

Going Concern

Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has not generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company’s future operations are dependent on the success of the Company’s efforts to raise additional capital.

The Company has a history of incurring net losses and anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company’s primary source of capital has been the issuance of common stock and warrants to purchase common stock.

Since the Company’s inception, the Company has incurred losses and negative cash flows from operations. At December 31, 2024, the Company had cash and cash equivalents of $10.6 million and an accumulated deficit of $134.8 million. The Company’s net loss was $24.6 million and $56.2 million for the years ended December 31, 2024 and 2023, respectively. In addition, the Company’s operating loss was $26.7 million and $45.0 million for the years ended December 31, 2024 and 2023, respectively. The Company follows the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 205-40, Presentation of Financial Statements-Going Concern, or ASC 205-40, which requires management to assess the Company’s ability to continue as a going concern for one year after the date the financial statements are issued. The Company expects that its existing balance of cash and cash equivalents as of December 31, 2024, combined with cash raised in the first quarter of 2025 in connection with its December 2024 ATM with OpCo and February 2025 stock offering with ThinkEquity, is not sufficient to fund operations for the period through one year after the date of this filing and therefore management has concluded that substantial doubt exists about the Company’s ability to continue as a going concern. Management’s plans to mitigate this risk include raising additional capital through equity financings, debt or other potential alternatives. Management’s plans may also include the deferral of certain operating expenses unless and until additional capital is received. However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company, or that the Company will be successful in deferring certain operating expenses. As such, management concluded that such plans do not alleviate the substantial doubt. If the Company is unable to raise sufficient additional capital or defer sufficient operating expenses, the Company may be compelled to reduce the scope of its operations.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

F-7

(2) Summary of Significant Accounting Policies

(a) Basis of Presentation

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).

(b) Use of Estimates

In preparing the financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the accounting for research and development contracts, including clinical trial accruals, common stock warrant liabilities, derivative liabilities and the accounting and fair value measurement of equity awards.

(c) Segment Information

As of December 31, 2024, the Company viewed its operations and managed its business as one operating segment consistent with how the Company's chief operating decision-maker, the Company's Chief Executive Officer, makes decisions regarding resource allocation and assesses performance. As of December 31, 2024, substantially all of the Company's assets were located in the United States. Refer to Note 11 for additional information

(d) Basic and Diluted Net Income per Share

Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options and warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion or exercise of securities that would have an anti-dilutive effect.

(e) Cash and Cash Equivalents

The Company considers all highly-liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents may include bank demand deposits and money market funds that invest primarily in certificates of deposit, commercial paper, and U.S. government agency securities and treasuries. The Company records interest income received on cash and cash equivalents to other income (expense), net in the statements of operations. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse effect on the Company’s financial condition, results of operations, and cash flows.

(f) Issuance Costs Associated with Equity Issuances

Issuance costs incurred in connection with the Company’s equity issuances, which primarily consist of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. Issuance costs related to the Equity Line of Credit (“ELOC”) Purchase Agreement are expensed as incurred as prescribed by ASC 815.

(g) Derivative Liability

The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separate accounting from the underlying agreement under ASC 815 – Derivatives and Hedging. An embedded derivative

F-8

that requires separation is accounted for as a separate liability or asset from the host agreement. The separated embedded derivative is accounted for at fair market value, with changes in fair value recognized in the statements of operations within the other financing costs line item. The Company determined that certain features under the ELOC Purchase Agreement (See Note 7 — Stockholders’ Equity (Deficit)) collectively qualified as an embedded derivative. The derivative was accounted for separately from the underlying ELOC Purchase Agreement and is accounted for at fair value. As of December 31, 2024, the liability balance was zero because the ELOC facility had been exhausted and all shares from the equity line had been sold.

(h) Common Stock Warrants

On October 31, 2023, the Company completed an underwritten offering whereby the Company sold (i) 1,250,000 shares of common stock and (ii) warrants to purchase an aggregate of 1,250,000 shares of common stock at an exercise price of $9.00 per share (“Canaccord Warrants”). The warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company’s control or not deemed to be indexed to the Company’s stock. The warrant liabilities are recorded at fair value regardless of the timing of the redemption feature, the redemption price, or the likelihood of redemption. These warrants are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of change in fair value of warrant liability in the statements of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise, expiration, or other settlement of the warrants. The warrants are classified as Level 3 liabilities.

(i) Research and Development

Research and development costs are either expensed as incurred, or recorded separately as a prepaid asset where expense is recognized when the service is performed. These costs are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on the Company’s contracts with its vendors and are realized in the ordinary course of business.

(j) Patent Costs

All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.

(k) Stock-Based Compensation

The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, Compensation—Stock Compensation (“ASC 718”). The Company has issued stock-based compensation awards, including stock options. ASC 718 requires all stock-based payments, including grants of stock options, to be recognized in the financial statements based on their grant date fair values. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. The Company recognizes forfeitures as they occur.

Expense related to stock-based compensation awards granted with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock options have a contractual term of 10 years. Expense for stock-based compensation awards with performance-based vesting conditions is only recognized when the performance-based vesting condition is deemed probable to occur. Expense related to stock-based compensation awards are recorded in research and development expense or general and administrative expense based on the underlying function of the individual that was granted the stock-based compensation award.

Estimating the fair value of stock options requires the input of subjective assumptions, including the expected term of the stock option, stock price volatility, the risk-free interest rate, and expected dividends. The assumptions used in the Company’s Black-Scholes option-pricing model represent Management’s best estimates and involve a number of variables, uncertainties, assumptions,

F-9

and the application of Management’s judgment, as they are inherently subjective. If any assumptions change, the Company’s stock-based compensation expense could be materially different in the future.

The assumptions used in the Company’s Black-Scholes option-pricing model for stock options are as follows:

Expected Term. As Annovis does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the expected term of employee stock options subject to service-based vesting conditions is determined using the “simplified” method, as prescribed in SEC’s Staff Accounting Bulletin No. 107, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock option.

Expected Volatility. The expected volatility is based on historical volatilities of Annovis and similar entities within the Company’s industry for periods commensurate with the assumed expected term.

Risk-Free Interest Rate. The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.

Expected Dividends. The expected dividend yield is 0% because Annovis has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.

(l) Income Taxes

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2024 and 2023, the Company had a full valuation allowance against its deferred tax assets.

The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions as of December 31, 2024 or 2023.

(m) Recently Adopted Accounting Pronouncements

Effective January 1, 2024, the Company retrospectively adopted Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) on an annual basis, which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items. ASU 2023-07 also requires public entities with a single reportable segment to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in FASB ASC Topic 280, Segment Reporting. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. See Note 11 for additional disclosures made as a result of adopting ASU 2023-07.

(n) Recent Accounting Pronouncements

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which improves income tax disclosures by requiring: (1) consistent categories and greater disaggregation of information in the rate reconciliation, and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The ASU indicates that all entities will apply the guidance prospectively with an option for retroactive application to each period presented in the financial statements. The Company has not determined the impact ASU 2023-09 may have on the Company’s financial statement disclosures, but it does not anticipate material impacts.

F-10

In November 2024, the FASB issued ASU 2024-03, Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires public entities, at annual and interim reporting periods, to disclose in a tabular format additional information about specific expense categories in the notes to the financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is still evaluating the impacts of this ASU on its future financial statements and disclosures.

(3) Fair Value Measurements

The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.

The following tables provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of December 31, 2024 and 2023:

    

    

Fair Value Measurement at

December 31, 2024

Carrying Value

Level 1

    

Level 2

    

Level 3

Assets:

Cash equivalents

$

491,006

$

491,006

$

$

Total assets measured and recorded at fair value

$

491,006

$

491,006

$

$

Liabilities:

Warrant liability

$

737,000

$

$

$

737,000

Total liabilities measured and recorded at fair value

$

737,000

$

$

$

737,000

    

    

Fair Value Measurement at

December 31, 2023

Carrying Value

Level 1

    

Level 2

    

Level 3

Assets:

Cash equivalents

$

5,136,677

$

5,136,677

$

$

Total assets measured and recorded at fair value

$

5,136,677

$

5,136,677

$

$

Liabilities:

Warrant liability

$

13,680,000

$

$

$

13,680,000

Total liabilities measured and recorded at fair value

$

13,680,000

$

$

$

13,680,000

The Company did not transfer any financial instruments into or out of Level 3 classification, during the year ended December 31, 2024 or 2023.

F-11

(a)Canaccord Warrants

The common stock warrants issued in connection with the Company’s equity financing in November 2023 (“Canaccord Warrants”) were classified as liabilities at the time of issuance due to certain cash settlement adjustment features that are outside of the Company’s control or not deemed to be indexed to the Company’s stock. The Canaccord Warrant liability is remeasured each reporting period with the change in fair value recorded to other income (expense), net in the statements of operations until the warrants are exercised, expired, reclassified, or otherwise settled. From their date of issuance until the period ended June 30, 2024, the fair value of the Canaccord Warrants was estimated using a Monte Carlo simulation model, given the performance conditions outlined further below. However, during the quarter ended September 30, 2024, the Company determined that certain performance conditions could not be met and that going forward, their use as inputs for determining fair value was no longer appropriate. As such, after the period ended June 30, 2024, the fair value of the Canaccord Warrants is estimated using a Black-Scholes option-pricing model.

The estimated fair value of the Canaccord Warrants is determined using Level 3 inputs. Inherent in both a Monte Carlo simulation model and a Black-Scholes option-pricing model are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and other inputs. The Company estimates the volatility of its warrants based on an implied asset volatility calculated and believed to be reasonable for the Company over the holding period remaining. The risk-free interest rate is based on the market yield of U.S. Treasuries over a term commensurate with the remaining term to expiration. Any changes in these assumptions can change the associated valuation significantly.

The following tables provide quantitative information regarding Level 3 fair value measurements inputs as of their respective measurement dates. The table for the year ending December 31, 2024 presents inputs used under a Black-Scholes option-pricing model. The table for the year ending December 31, 2023 presents inputs used under a Monte Carlo simulation model:

    

December 31, 2024

    

December 31, 2023

 

Exercise price

$

9.00

$

9.00

Closing stock price

$

5.03

$

18.70

Number of warrants outstanding

 

308,333

 

1,200,000

Phase III data probability of success

 

%  

 

60

%

Volatility

 

80

%  

 

55

%

Term (time to expiration in years)

 

3.84

 

4.84

Redemption hurdle price

$

$

14.25

Risk-free rate

 

4.3

%  

 

3.9

%

The Canaccord Warrants were exercisable immediately at an exercise price of $9.00 per unit, and redeemable at the Company’s option, in whole or in part, at a redemption price equal to $0.001 per Warrant upon 30 days’ prior written notice, at any time after:

the Company’s public announcement of Positive Topline Data (as defined in the Warrant Agreement) from its Phase 3 in patients with Parkinson’s Disease; and
the date on which (a) the closing price of the Company’s common stock on the principal exchange or trading facility on which it is then traded has equaled or exceeded $14.25 and (b) the average daily trading value (“ADTV”) of the Company’s common stock is equal to or exceeds $2,000,000, for two consecutive Trading Days.

During the year ended December 31, 2024, the Company released topline data from its Phase 3 study in patients with Parkinson’s Disease. It was determined that based on the data, both criteria required for redemption of the Canaccord Warrants were not met. As such, the probability of success and redemption hurdle price inputs were no longer used in the Black-Scholes option-pricing model outlined above for the year ending December 31, 2024.

The Warrants were exercisable immediately and will expire on November 2, 2028, five years from the date of issuance. See Note 7 – Stockholders’ Equity (Deficit) for additional background.

F-12

(4) Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:

As of December 31, 

    

2024

    

2023

Prepaid clinical expenses

$

2,998,811

$

4,391,219

Prepaid other

346,313

23,455

Prepaid insurance

21,098

18,074

Security deposits

 

7,495

 

20,796

Total prepaid expenses and other current assets

$

3,373,717

$

4,453,544

(5) Accrued Expenses

Accrued expenses consisted of the following:

As of December 31, 

    

2024

    

2023

Accrued clinical expenses

$

948,695

$

2,645,589

Payroll and related benefits

364,717

96,848

Accrued professional fees and other

 

261,601

 

243,836

Total accrued expenses

$

1,575,013

$

2,986,273

(6) Commitments and Contingencies

(a) Research & Development

The Company has entered contracts with CROs and CMOs related the Company’s clinical trials. The contracts require upfront payments, milestone payments, and pass-through cost reimbursements, to be made. While the contracts are generally cancellable with (written) notice, the Company is obligated to make payments for services rendered through the termination date of the project with any applicable CRO/CMO.

(b) Leases

The Company maintains one short-term lease associated with occupying its corporate headquarters. Total rental expense was $0.1 million and $0.1 million for the years ended December 31, 2024 and 2023, respectively.

(c) Employment Agreements

The Company has an agreement with its Chief Executive Officer that provides for severance payments upon termination of the agreement by the Company for any reason other than for cause, death or disability or by the employee for good reason. The maximum aggregate severance payments under the agreement was estimated to be $1.1 million at December 31, 2024.

(d) Litigation

The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows.

For both the years ended December 31, 2024 and December 31, 2023 the Company did not have any pending legal actions deemed to be material.

F-13

(7) Stockholders’ Equity (Deficit)

(a) Overview

The Company’s Amended and Restated Certificate of Incorporation was adopted on January 31, 2020, in conjunction with the closing of the Company’s initial public offering (the “IPO”) and amended on June 15, 2023 to increase the authorized number of shares. Currently, there are two classes of stock authorized which are designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is 72,000,000, each with a par value of $0.0001 per share. Of these shares, 70,000,000 is designated as common stock and 2,000,000 is preferred stock.

(b) Common Stock

Dividends

Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board of Directors.

Liquidation

Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.

Voting

The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.

(c) Preferred Stock

Preferred stock may be issued from time to time by the Board in one or more series. There was no preferred stock issued or outstanding as of December 31, 2024 or December 31, 2023.

(d) IPO Warrants

In conjunction with the closing of the Company’s Initial Public Offering (“IPO”), the Company granted its underwriters 0.1 million warrants to purchase shares of Company common stock (“IPO Warrants”) at an exercise price of $7.50 per share, which was 125% of the IPO price. The IPO Warrants have a five-year term and were exercisable as of January 29, 2021 and have been classified by the Company as a component of stockholders’ equity. At both December 31, 2024 and December 31, 2023, 2,400 of the IPO Warrants were outstanding. No IPO Warrants were exercised during the years ended December 31, 2024 or 2023.

(e) March 2023 ATM

On March 31, 2023, the Company, entered into an At the Market (“ATM”) Equity Offering Sales Agreement (the “Sales Agreement” or “March 2023 ATM”) with BofA Securities, Inc. (“BofA”) and ThinkEquity LLC (“ThinkEquity” and, together with BofA, the “Sales Agents”), as sales agents, pursuant to which the Company could offer and sell, from time to time through the Sales Agents, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $50.0 million.

On April 4, 2023, the Company delivered written notice to BofA and ThinkEquity to terminate the Sales Agreement, effective April 9, 2023. The Company was not subject to any termination penalties related to the termination of the Sales Agreement.

F-14

Prior to termination of the Sales Agreement, the Company sold 0.7 million shares of Common Stock pursuant to the Sales Agreement at a price of $10.88 per share, for gross proceeds of $7.6 million before commissions. As a result of the termination of the Sales Agreement, the Company will not offer or sell any additional shares of Common Stock under the Sales Agreement.

(f) April 2023 Private Placement

On April 7, 2023, the Company sold 0.1 million shares of its common stock in a private placement to individual members of its Board of Directors and management at a price of $12.61 per share, for aggregate proceeds of $1.1 million.

(g) November 2023 Equity Offering and Warrant Issuance

On October 31, 2023, the Company entered into an underwritten offering with a Canaccord Genuity LLC whereby the Company sold (i) 1,250,000 shares of common stock and (ii) warrants (“Canaccord Warrants”) to purchase an aggregate of 1,250,000 shares of common stock at an exercise price of $9.00 per share. The offering closed on November, 2, 2023. The warrants were exercisable immediately on the date of issuance and will expire five years after the date of issuance. The Company received $6.8 million in net cash proceeds after deducting underwriter discount and fees, as well as other third-party costs. The Canaccord Warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company’s control or not deemed to be indexed to the Company’s stock.

The following is a roll forward of the Common Stock Warrant Liability during the years ended December 31, 2023 and 2024, respectively:

Issuance of Canaccord Warrants

$

2,449,001

Exercise of 50,000 warrants

(606,201)

Change in fair value of warrant liabilities

11,837,200

Warrant liability at December 31, 2023

13,680,000

Change in fair value of warrant liabilities

 

(3,625,893)

Exercise of 891,667 warrants

 

(9,317,107)

Warrant liability at December 31, 2024

$

737,000

(h) Warrant Summary

As of December 31, 2024, the Company had the following common stock warrants outstanding:

    

    

Outstanding 

    

    

    

Outstanding 

    

Exercise 

    

December 31,

Exercised or

December 31,

price per

Expiration

Classification

2023

Granted

Expired

2024

share

date

IPO warrants

 

Equity

 

2,400

 

 

 

2,400

$

7.50

January 29, 2026

Canaccord warrants

 

Liability

 

1,200,000

 

 

(891,667)

 

308,333

$

9.00

November 2, 2028

(i) November 2023 Private Placement

On November 27, 2023, the Company sold 0.2 million shares of its common stock in a private placement to individual members of its Board of Directors and management at a price of $6.10 per share, for aggregate proceeds of $1.3 million.

(j) March 2024 Registered Direct Offerings

On March 15, 2024 and March 21, 2024, the Company entered into two separate securities purchase agreements with the same institutional investor. When aggregating the results of both purchase agreements, the Company issued 0.4 million shares for net proceeds of $3.9 million in registered direct offerings.

F-15

(k) April 2024 ELOC Purchase Agreement

On April 25, 2024, the Company entered into an ELOC Purchase Agreement with an ELOC Purchaser, whereby we could offer and sell, from time to time at our sole discretion, and whereby the ELOC Purchaser committed to purchase, up to 2.0 million shares of shares of the Company’s common stock. The term of the agreement was until the expiration of the Company’s active S-3 Registration Statement, unless earlier terminated or exhausted. Due to certain pricing and settlement provisions, the ELOC Purchase Agreement qualified as a standby equity purchase agreement and included an embedded put option and embedded forward option. The Company therefore accounted for the ELOC Purchase Agreement as a derivative measured at fair value, with changes in the fair value recognized in the statements of operations within other financing costs. The Company initially recognized a derivative liability of $1.7 million related to the purchased put option at inception of the ELOC Purchase Agreement. The Company then expensed the difference between the discounted purchase price of the settled forward and the fair value of shares on the date of settlement as a noncash financing issuance cost. The Company recognized $1.3 million of noncash financing costs during the year ended December 31, 2024 related to the discounted purchase price of the settled forward and the underlying fair value of the shares issued.

Upon execution of the ELOC Purchase Agreement, the Company agreed to issue to the ELOC Purchaser 33,937 shares of Common Stock as commitment shares (the “Commitment Shares”). The fair value of the Commitment Shares was $0.5 million, which was expensed within other financing costs in the statements of operations during the year ended December 31, 2024. The Company also incurred issuance costs of $0.1 million, consisting of legal costs incurred in connection with the ELOC Purchase Agreement, which were expensed within other financing costs in the statements of operations during the year ended December 31, 2024. The ELOC Purchaser agreed that during the term of the Purchase Agreement, neither it nor any of its affiliates would engage in any short sales or hedging transactions involving the Company’s common stock.

Under the ELOC Purchase Agreement, on any business day (the “Purchase Date”), if the Company’s stock price is greater than or equal to $5.00 per share, the Company could direct the ELOC Purchaser to purchase common stock. The ELOC Purchaser’s committed obligation under any single Fixed Purchase could not exceed the lower of 25,000 shares of Common Stock or $250,000 (“Fixed Purchases”).

In addition, the Company could also direct the ELOC Purchaser, on any trading day in which the Company submitted a Fixed Purchase notice for the maximum amount allowed for such Fixed Purchase, to purchase an additional amount of the Company’s common stock (a “VWAP Purchase”). The ELOC Purchaser’s committed obligation under any single VWAP Purchase could not exceed a number of shares of Common Stock equal to the lesser of (i) 300% of the number of Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Fixed Purchase Notice and (ii) 30% of the trading volume in the Company’s Common Stock on the NYSE during the applicable VWAP Purchase Period on the applicable VWAP Purchase Date (“VWAP Purchase Maximum Amount”).

The Company could also direct the ELOC Purchaser, on any trading day for which a VWAP Purchase had been completed and all of the shares had been placed, to purchase an additional amount of the Company’s common stock (an “Additional VWAP Purchase”). The ELOC Purchaser’s committed obligation under any single Additional VWAP Purchase was the lesser of (i) 300% of the number of Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Fixed Purchase Notice and (ii) a number of Shares equal to (A) the Additional VWAP Purchase Share Percentage multiplied by (B) the trading volume of shares of Common Stock traded during the applicable Additional VWAP Purchase Period on the applicable Additional VWAP Purchase Date for such Additional VWAP Purchase (“Additional VWAP Purchase Maximum Amount”). The applicable pricing structure for each purchase type is outlined below:

The purchase price per share for Fixed Purchases (“Fixed Purchase Price”) equals 95% of the lesser of:

the daily volume weighted average price (“VWAP”) of the Company’s Common Stock on the NYSE for the five (5) Trading Days immediately preceding the applicable Fixed Purchase Date for such Fixed Purchase; and
the Closing Sale Price of a share of Common Stock on the applicable Fixed Purchase Date.

The purchase price per share for VWAP Purchases (“VWAP Purchase Price”) equals 95% of the lesser of:

the VWAP during the applicable VWAP Purchase Period during the applicable VWAP Purchase Date.
the Closing Sale Price of the Common Stock on the applicable VWAP Purchase Date.

F-16

The purchase price per share for Additional VWAP Purchases (“Additional VWAP Purchase Price”) equals 95% of the lesser of:

the VWAP for the applicable Additional VWAP Purchase Period during the applicable Additional VWAP Purchase Date; and
the Closing Sale Price of the Common Stock on such applicable Additional VWAP Purchase Date.

In addition to the commitment shares referenced above, a total of 2.0 million shares of the Company’s common stock were issued under the ELOC Purchase Agreement during the year ended December 31, 2024, for net proceeds of $14.6 million. The facility was fully exhausted during 2024 and no further shares are available to issue as of December 31, 2024.

The following is a roll-forward of the ELOC derivative liability from date of execution to December 31, 2024:

Fair value at April 25, 2024

    

1,697,500

Settlements and changes in fair value of ELOC derivative liability

 

(1,192,500)

Fair value at June 30, 2024

 

505,000

Settlements and changes in fair value of ELOC derivative liability

 

(62,500)

Fair value at September 30, 2024

 

442,500

Settlements and changes in fair value of ELOC derivative liability

 

(442,500)

Fair value at December 31, 2024

 

(l) December 2024 ATM

On December 11, 2024, the Company entered into an Equity Distribution Agreement (“Distribution Agreement”) with Oppenheimer & Co. Inc., (“OpCo”) relating to the sale of shares of the Company’s common stock. In accordance with the terms of the Distribution Agreement, The Company may offer and sell shares of its common stock having an aggregate offering price of up to $50.0 million from time to time through or to OpCo, acting as agent or principal.

During the year-ended December 31, 2024, the Company sold 26,788 million shares of common stock pursuant to the Distribution Agreement for gross proceeds of $0.2 million before commissions.

(8) Stock-Based Compensation

Effective upon the closing of the Company’s IPO on January 31, 2020, the Company’s 2019 Equity Incentive Plan (the “2019 Plan”) became effective, succeeding the Company’s previous equity incentive plan. No new options may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 12, 2024, the 2019 Plan was amended to increase the number of shares authorized from 2,000,000 to 3,000,000. As of December 31, 2024, the 2019 Plan contained 354,299 shares available for future grants.

The 2019 Plan provides for grants to employees, members of the Board, consultants and advisors to the Company, in the form of stock options, stock awards and other equity-based awards. The amount and terms of grants are determined by the Board, except when they are below previously approved thresholds allowing the Company’s CEO to grant awards on a discretionary basis. The Company’s stock options generally carry a maximum term of 10 years after date of grant and are exercisable in cash, or as otherwise determined by the Board.

F-17

Stock-based compensation expense in the statements of operations, including the fair value of stock awards to consultants and advisors for services rendered, for the years ended December 31, 2024 and 2023 was as follows:

Year Ended

December 31, 

    

2024

    

2023

General and administrative

$

2,510,444

$

2,414,867

Research and development

 

1,326,326

2,213,539

$

3,836,770

$

4,628,406

The following table summarizes the Company’s stock option activity:

    

    

    

Weighted

Average

Remaining

Aggregate

Weighted

Contractual

Intrinsic

Number of

Average

Term

Value

Shares

Exercise Price

(Years)

    

(In Thousands)

Outstanding at December 31, 2023

 

1,954,774

$

13.41

6.1

$

17,863

Granted

870,494

6.01

Exercised

(300,000)

3.13

570

Forfeited

(189,248)

20.61

Outstanding at December 31, 2024

 

2,336,020

$

11.39

7.3

$

1,298

Exercisable at December 31, 2024

1,824,122

$

12.80

6.8

$

1,298

The weighted average grant date fair value of stock options granted during the years ended December 31, 2024 and 2023 was $5.16 and $7.39, respectively. During the year ended December 31, 2024 the Company received no cash proceeds from the exercises of stock options. For the year ended December 31, 2023, the Company received $8,385 cash proceeds from the exercises of stock options. As of December 31, 2024, there was unrecognized stock-based compensation expense related to unvested stock option awards, related to service-based options of $2.4 million, which will be recognized over a remaining weighted-average period of 1.0 years.

During the years ended December 31, 2024 and 2023, the Company issued 870,494 and 367,329 options, respectively. Under the grant agreements for the 2024 stock option grants, 382,282 of the options vested immediately and 468,212 of the options vest in substantially equal quarterly installments over two years from the date of grant. There are also 20,000 stock option grants that vest as consulting services are performed and awards are earned. Under the grant agreements for the 2023 stock option grants, 94,624 of the options vested immediately, and 272,705 of the options vest in substantially equal quarterly installments over two years from the date of grant. All of the options have a 10-year term prior to expiration.

The assumptions utilized in the fair value calculations for stock options granted during the years ended December 31, 2024 and 2023, respectively, were as follows:

    

Year Ended

 

Year Ended

 

December 31, 2024

 

December 31, 2023

 

Weighted average risk-free interest rate

 

4.18

%  

4.17

%

Weighted average expected option term (years)

 

5.3

5.5

Weighted average expected volatility

 

123

%  

120

%

Expected dividend yield

 

Related Party Transaction

During the year ended December 31, 2024, the Company issued 20,000 non-qualified stock options to a member of its Board of Directors in consideration for the member’s agreement to serve as a consultant to the Company. The options were issued in one tranche, at a grant price of $5.27 per share. 8,069 of the awards became vested during the year ended December 31, 2024.

F-18

(9) Net Loss Per Share

The Company has reported a net loss for the years ended December 31, 2024 and 2023, and the basic and diluted net loss per share attributable to common stockholders are the same for both years because all warrants and stock options have been excluded from the computation of diluted weighted-average shares outstanding because such securities would have an antidilutive impact.

The following table sets forth the computation of basic and diluted net loss per common share for the years ended December 31, 2024 and 2023:

Year Ended

December 31, 

    

2024

    

2023

Net loss per share – Basic:

  

 

  

Numerator

Net loss

$

(24,590,375)

$

(56,204,313)

Denominator

 

 

Weighted-average common shares outstanding, basic

12,182,475

9,023,138

Basic net loss per common share

$

(2.02)

$

(6.23)

Net loss per share – Diluted:

Numerator

Net loss

$

(24,590,375)

$

(56,204,313)

Less: gain from change in fair value applicable to dilutive liability-classified warrants

(3,625,893)

Numerator for diluted net loss per share

$

(28,216,268)

$

(56,204,313)

Denominator

Denominator for basic net loss per share

12,182,475

9,023,138

Plus: incremental shares underlying “in the money” liability-classified warrants outstanding

52,969

Denominator for diluted net loss per share

12,235,444

9,023,138

Diluted net loss per common share

$

(2.31)

$

(6.23)

Potentially dilutive securities, whose effect would have been antidilutive, were excluded from the computation of diluted earnings per share for each of the years ended December 31, 2024 and 2023. Total antidilutive securities that were excluded from the computation of diluted weighted-average shares outstanding were as follows:

December 31, 

    

2024

    

2023

Stock options

2,336,020

1,954,774

Warrants

2,400

1,202,400

F-19

(10) Income Taxes

The federal and state provision (benefit) for income taxes was $0 for the years ended December 31, 2024 and 2023.

A reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements for the years ended December 31, 2024 and 2023 is as follows:

Year Ended

 

December 31, 

 

    

2024

    

2023

 

Federal income tax benefit at statutory rate

 

21.0

%  

21.0

%

State and local tax, net of federal benefit

 

4.0

%  

3.1

%

State and local tax, change in rates

0.0

%

(3.5)

%

Permanent differences

 

(1.9)

%  

(0.4)

%

Research and development credit

4.3

%  

4.5

%

Stock-based compensation

0.0

%  

0.4

%

Change in fair value of warrants

1.5

%

(4.4)

%

Change in valuation allowance

 

(28.9)

%  

(20.7)

%

Effective income tax rate

 

0.0

%  

0.0

%

Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company’s deferred tax assets are comprised of the following:

As of December 31, 

    

2024

    

2023

Net operating loss carryforwards

$

13,634,896

$

9,607,158

Stock compensation

4,390,635

4,245,472

Capitalized R&D

 

1,137,406

 

1,334,494

Section 174

12,802,738

10,793,442

R&D credit carryforwards

 

5,198,123

 

4,132,475

Other

76,757

14,553

Total deferred tax assets

 

37,240,555

 

30,127,594

Less valuation allowance

 

(37,240,555)

 

(30,127,594)

Net deferred taxes

$

$

As of December 31, 2024, the Company had U.S. federal net operating loss (“NOL”) carryforwards of $54.1 million which may be available to offset future income tax liabilities. Federal NOL carryforwards generated in 2017 and prior of $2.8 million will expire beginning in 2032. The remaining federal NOL carryforwards generated in 2018 and later do not expire. As of December 31, 2024, the Company also had U.S. state NOL carryforwards of $56.6 million which may be available to offset future income tax liabilities and will expire beginning in 2028.

The Company has recorded a full valuation allowance against its net deferred tax assets as of December 31, 2024 and 2023 because the Company has determined that is it more likely than not that these assets will not be fully realized due to historic net operating losses incurred. The Company recorded a net change in valuation allowance of $7.1 million and $11.7 million in the years ended December 31, 2024 and 2023, respectively.

As of December 31, 2024, the Company had federal research and development tax credit carryforwards of $5.2 million available to reduce future tax liabilities, which expire beginning in 2028.

Under the provisions of the Internal Revenue Code, the NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of

F-20

the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code, or could result in a change in control in the future.

The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The Company’s tax years from 2021 to the present remain open for review. All open years may be examined to the extent that tax credits or NOL carryforwards are used in future periods. To the extent the Company utilizes any tax attributes from a tax period that may otherwise be closed due to statute expiration, the tax authorities may adjust the tax attributes upon their examination of the future period in which the attribute was utilized. The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2024, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company’s statements of operations.

Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (R&E) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&E activities in the US must be amortized over a 5-year period if incurred, and R&E expenses incurred outside the US must be amortized over a 15-year period. R&E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2024, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&E capitalization and amortization to require it to pay cash taxes now or in the near future.

(11) Segment Information

The Company is a clinical-stage biopharmaceutical company and has not generated any revenue since commencing significant operations in 2008. The Company’s operations are organized and reported as a single reportable segment, which includes all activities related to the discovery, development, and commercialization of our lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. This presentation is consistent with how the Company’s chief operating decision maker (“CODM”), its Chief Executive Officer, assesses the performance of the Company and makes operating decisions. The accounting policies of the segment are the same as those described in the summary of significant accounting policies (see Note 2). The CODM assesses performance and decides how to allocate resources based on net loss as reported on the statements of operations. The CODM uses net loss to monitor actual operating results, assess cash runway, and benchmark against the Company’s competitors. The measure of segment assets is reported on the balance sheets as total assets. The Company’s assets are held in the United States.

When evaluating the Company’s financial performance, the CODM regularly reviews the following expense categories that comprise net loss. The table below sets forth the Company’s segment information as reviewed by the CODM:

Year Ended December 31, 

2024

    

2023

Program expenses related to clinical-stage product candidates

$

(16,723,518)

$

(35,104,702)

Program expenses related to preclinical and discovery programs

(568,214)

(583,154)

Personnel-related expenses (including stock-based compensation)

(6,525,586)

(6,444,920)

General and administrative professional and consultant fees

(1,687,276)

(2,152,485)

Other segment items¹

(1,190,333)

(749,750)

Interest income

331,849

667,898

Other non-cash income (expense) items²

1,772,704

(11,837,199)

Net Loss

$

(24,590,374)

$

(56,204,313)

F-21

¹ Other segment items included in net loss include insurance expense, information technology expenses, warrant commissions and other miscellaneous expenses.

² Other non-cash income (expense) items includes financing costs from our ELOC and change in fair value of our liability classified warrants.

(12) Subsequent Events

Subsequent to December 31, 2024, the Company sold 0.1 million shares of its common stock under its ATM with OpCo, which the Company entered into in December 2024. The Company received net proceeds of $0.5 million after deducting commissions and fees.

On February 3, 2025, the Company entered into an Underwriting Agreement with ThinkEquity LLC, acting as representative of the underwriters with respect to an underwritten public offering of 5.3 million units of the Company. Each unit sold consisted of one share of common stock and one warrant to purchase one share of common stock (the “ThinkEquity Warrants”), at a per unit price of $4.00 (the “Offering”). Aggregate gross proceeds from the Offering were $21.0 million before deducting underwriting discounts and other estimated offering expenses. The Warrants have an exercise price of $5.00 per share, are immediately exercisable and expire five years from the date of issuance. The shares of Common Stock and Warrants were issued separately. The Company has agreed to suspend sales of its Common Stock under the OpCo ATM Facility for a period of six months after the closing of the Offering.

F-22

SIGNATURES

In accordance with the requirements Section 13 or 15(d) of the Securities Exchange Act of 1934, the registrant duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

ANNOVIS BIO, INC.

 

 

By: 

/s/ MARIA MACCECCHINI

 

 

Name: 

Maria Maccecchini

 

 

Title:

President and Chief Executive Officer

Date:

March 21, 2025

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.

Signature

    

Title

    

Date

 

 

 

/s/ MARIA MACCECCHINI

President and Chief Executive Officer

March 21, 2025

Maria Maccecchini

(principal executive officer; interim principal financial and accounting officer)

 

 

 

 

/s/ MICHAEL HOFFMAN

Chairman of the Board and Director

March 21, 2025

Michael Hoffman

 

 

 

 

 

/s/ CLAUDINE BRUCK

Director

March 21, 2025

Claudine Bruck

 

 

 

 

 

/s/ REID MCCARTHY

Director

March 21, 2025

Reid McCarthy

 

 

 

 

 

/s/ MARK WHITE

Director

March 21, 2025

Mark White

 

 

98

EX-4.5 2 anvs-20241231xex4d5.htm EX-4.5

Exhibit 4.5

DESCRIPTION OF REGISTRANT’S SECURITIES REGISTERED PURSUANT TO SECTION 12 OF THE SECURITIES EXCHANGE ACT OF 1934

The following description of our capital stock is intended as a summary only and therefore is not a complete description of our capital stock. This description is based upon, and is qualified by reference to, our amended and restated certificate of incorporation (the “Amended Certificate”), our amended and restated bylaws (the “Amended Bylaws”) and applicable provisions of Delaware corporate law. You should read our Amended Certificate and Amended Bylaws, which are filed as exhibits to our Annual Report on Form 10-K, to which this exhibit is also appended.

Our authorized capital stock consists of 70,000,000 shares of common stock, par value $0.0001 per share, and 2,000,000 shares of preferred stock, par value $0.0001 per share.

Our common stock is the only class of securities registered under Section 12 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

Common Stock

Voting

The holders of our common stock are entitled to one vote for each share of common stock held on all matters submitted to a vote of stockholders. There is no cumulative voting. An election of directors by our stockholders shall be determined by a plurality of the votes cast by stockholders entitled to vote in the election. Subject to the supermajority votes for some matters, other matters shall be decided by the affirmative vote of our stockholders having a majority in voting power of the votes cast by the stockholders present or represented and voting on such matter.

Dividends

Subject to the rights of holders of all classes of our stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive proportionately any dividends when and as declared by our board of directors.

Liquidation

In the event of our liquidation, dissolution or winding up, the holders of common stock are entitled to receive on a pro rata basis our net assets available for distribution to stockholders after the payment of all debts and other liabilities, subject to the rights of holders of all classes of our stock outstanding having rights that are senior to or equivalent to holders of common stock.

Other

Holders of common stock have no preemptive, subscription, redemption or conversion rights.

All of our outstanding shares of common stock are fully paid and nonassessable, and any shares of common stock to be issued upon an offering pursuant to this prospectus and the related prospectus supplement will be fully paid and nonassessable upon issuance.

Preferred Stock

Under the terms of our amended and restated certificate of incorporation, our board of directors is authorized to direct us to issue shares of preferred stock in one or more series without stockholder approval. Our board of directors has the discretion to determine the rights, preferences, privileges and restrictions, including voting rights, dividend rights, conversion rights, redemption privileges and liquidation preferences, of each series of preferred stock.

We will fix the designations, powers, preferences and rights of the preferred stock of each series, as well as the qualifications, limitations or restrictions thereon, in the certificate of designation relating to that series. The applicable prospectus supplement will contain the terms of and other information relating to the preferred stock which will include, as applicable:

the title and stated value;

1


the number of shares we are offering;
the liquidation preference per share;
the purchase price; the dividend rate, period and payment date and method of calculation for dividends;
whether dividends will be cumulative or non-cumulative and, if cumulative, the date from which dividends will accumulate;
the procedures for any auction and remarketing, if any;
the provisions for a sinking fund, if any;
the provisions for redemption or repurchase, if applicable, and any restrictions on our ability to exercise those redemption and repurchase rights;
any listing of the preferred stock on any securities exchange or market;
whether the preferred stock will be convertible into our common stock, and, if applicable, the conversion price, or how it will be calculated, and the conversion period;
voting rights, if any, of the preferred stock;
preemptive rights, if any;
restrictions on transfer, sale or other assignment, if any;
whether interests in the preferred stock will be represented by depositary shares;
a discussion of any material United States federal income tax considerations applicable to the preferred stock;
the relative ranking and preferences of the preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs;
any limitations on the issuance of any class or series of preferred stock ranking senior to or on a parity with the series of preferred stock as to dividend rights and rights if we liquidate, dissolve or wind up our affairs; and
any other specific terms, preferences, rights or limitations of, or restrictions on, the preferred stock.

Our board of directors may authorize the issuance of preferred stock with voting, conversion or other rights that could adversely affect the voting power or other rights of the holders of our common stock. Preferred stock could be issued quickly with terms designed to delay or prevent a change in control of our company or make removal of management more difficult. Additionally, the issuance of preferred stock may have the effect of decreasing the market price of our common stock.

Anti-Takeover Effects of Delaware Law and Our Certificate of Incorporation and Bylaws

Some provisions of Delaware law, our amended and restated certificate of incorporation and our amended and restated bylaws could make the following transactions more difficult: an acquisition of us by means of a tender offer; an acquisition of us by means of a proxy contest or otherwise; or the removal of our incumbent officers and directors. It is possible that these provisions could make it more difficult to accomplish or could deter transactions that stockholders may otherwise consider to be in their best interest or in our best interests, including transactions which provide for payment of a premium over the market price for our shares.

These provisions, summarized below, are intended to discourage coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of directors. We believe that the benefits of the increased protection of our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us outweigh the disadvantages of discouraging these proposals because negotiation of these proposals could result in an improvement of their terms.

Authorized but Unissued Shares

2


Our authorized but unissued shares of common stock and preferred stock are available for future issuance without stockholder approval. These additional shares may be utilized for a variety of corporate purposes, including future public offerings to raise additional capital and corporate acquisitions. The existence of authorized but unissued shares of common stock and preferred stock could render more difficult or discourage an attempt to obtain control of a majority of our common stock by means of a proxy contest, tender offer, merger or otherwise.

Stockholder Meetings

Any action to be taken by our stockholders must be effected at a duly called annual or special meeting of stockholders and not be taken by written consent.

Requirements for Advance Notification of Stockholder Nominations and Proposals

Stockholders seeking to present proposals before a meeting of stockholders or to nominate candidates for election as directors at a meeting of stockholders must provide advance notice in writing, and also specify requirements as to the form and content of a stockholder’s notice.

Delaware Anti-Takeover Statute

We are subject to Section 203 of the General Corporation Law of the State of Delaware, which prohibits persons deemed to be “interested stockholders” from engaging in a “business combination” with a publicly held Delaware corporation for three years following the date these persons become interested stockholders unless the business combination is, or the transaction in which the person became an interested stockholder was, approved in a prescribed manner or another prescribed exception applies. Generally, an “interested stockholder” is a person who, together with affiliates and associates, owns, or within three years prior to the determination of interested stockholder status did own, 15% or more of a corporation’s voting stock. Generally, a “business combination” includes a merger, asset or stock sale, or other transaction resulting in a financial benefit to the interested stockholder. The existence of this provision may have an anti-takeover effect with respect to transactions not approved in advance by the board of directors.

Choice of Forum

The Court of Chancery of the State of Delaware is the exclusive forum in which we and our directors may be sued by our stockholders, to the fullest extent permitted by law, for:

any derivative action or proceeding brought on our behalf;
any action asserting a breach of fiduciary duty;
any action asserting a claim against us arising pursuant to the Delaware General Corporation Law, our amended and restated certificate of incorporation, or our amended and restated bylaws; or
or any action asserting a claim against us that is governed by the internal affairs doctrine.

Our amended and restated bylaws will not apply to suits brought to enforce a duty or liability created by the Securities Act or the Exchange Act, or any other claim for which federal courts have exclusive jurisdiction.

These choice of forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or any of our directors, officers, or other employees, which may discourage lawsuits with respect to such claims. Alternatively, if a court were to find either choice of forum provision contained in our amended and restated bylaws to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could harm our business, results of operations, and financial condition.

Advance Notice Requirements

Our bylaws establish an advance notice procedure for stockholder proposals to be brought before an annual meeting of our stockholders, including proposed nominations of persons for election to the board of directors. Stockholders at an annual meeting will only be able to consider proposals or nominations specified in the notice of meeting or brought before the meeting by or at the direction of the board ofdirectors or by a stockholder who was a stockholder of record on the record date for the meeting, who is entitled to vote at the meeting and who has given our Secretary timely written notice, in proper form, of the stockholder’s intention to

3


bring that business before the meeting. Although our bylaws do not give the board of directors the power to approve or disapprove stockholder nominations of candidates or proposals regarding other business to be conducted at a special or annual meeting, our bylaws may have the effect of precluding the conduct of certain business at a meeting if the proper procedures are not followed or may discourage or deter a potential acquirer from conducting a solicitation of proxies to elect its own slate of directors or otherwise attempting to obtain control of us.

Warrants to Purchase Common Stock

On October 31, 2023, the Company completed an underwritten offering whereby the Company sold (i) 1,250,000 shares of common stock and (ii) warrants to purchase an aggregate of 1,250,000 shares of common stock (“Canaccord Warrants”). The Canaccord Warrants were exercisable immediately at an exercise price of $9.00 per unit, and redeemable at the Company’s option, in whole or in part, at a redemption price equal to $0.001 per Warrant upon 30 days’ prior written notice, at any time after:

the Company’s public announcement of Positive Topline Data (as defined in the Warrant Agreement) from its Phase 3 in patients with Parkinson’s Disease; and
the date on which (a) the closing price of the Company’s common stock on the principal exchange or trading facility on which it is then traded has equaled or exceeded $14.25 and (b) the average daily trading value (“ADTV”) of the Company’s common stock is equal to or exceeds $2,000,000, for two consecutive Trading Days.

During the year ended December 31, 2024, the Company released topline data from its Phase 3 study in patients with Parkinson’s Disease. It was determined that based on the data, both criteria required for redemption of the Canaccord Warrants were not met.

On February 3, 2025, the Company entered into an Underwriting Agreement with ThinkEquity LLC, acting as representative of the underwriters with respect to an underwritten public offering of 5.3 million units of the Company. Each unit sold consisted of one share of common stock and one warrant to purchase one share of common stock (the “ThinkEquity Warrants”), at a per unit price of $4.00 (the “Offering”). Aggregate gross proceeds from the Offering were $21.0 million before deducting underwriting discounts and other estimated offering expenses. The Warrants have an exercise price of $5.00 per share, are immediately exercisable and expire five years from the date of issuance. The shares of Common Stock and Warrants were issued separately.

Transfer Agent and Registrar

The transfer agent and registrar for our common stock is Equiniti Trust Company, LLC.

National Securities Exchange Listing

Our common stock is listed on the New York Stock Exchange under the symbol “ANVS.”

4


EX-19.1 3 anvs-20241231xex19d1.htm EX-19.1

Exhibit 19.1

ANNOVIS BIO, INC.

INSIDER TRADING POLICY

(Adopted July 31, 2019)

This Insider Trading Policy is designed to help persons understand the federal securities laws relating to insider trading and describes certain prohibited transactions in securities of Annovis Bio, Inc. (the “Company”) and, in certain cases, the securities of other companies. It also provides general guidelines with respect to maintaining the confidentiality of information that has not yet been publicly disclosed.

This policy is intended to promote compliance with federal securities laws. However, each person is ultimately responsible for ensuring that he or she does not violate state or federal securities laws or this policy. Violation of the securities laws can result in significant civil and criminal penalties (including fines and jail) and other liabilities. In addition, persons who violate this Insider Trading Policy will be subject to appropriate disciplinary action by the Company, up to and including dismissal.

This Policy contains four Sections:

Section I. General.

This section contains the general Insider Trading Policy of the Company, applicable to every director, officer, employee and associate (including consultants) of the Company (each a “Covered Person”).

Section II. Additional Trading Restrictions for Insiders.

Directors, officers and other personnel whom the Company designates as regularly having access to or generate material, non-public information (the “Insiders”) are subject to additional restrictions on the purchase and sale of the Company’s securities, which are set forth in Section II.

Section III. Certification.

Please read this Insider Trading Policy carefully and sign and return the attached certification.

Please contact the Chief Financial Officer with any questions about this Insider Trading Policy, who will coordinate with the Company’s attorneys with respect to questions that arise in connection with this policy. Please keep a copy of this policy for future reference.


SECTION I

GENERAL

INSIDER TRADING

The insider trading laws prohibit persons from buying or selling securities while in possession or aware of material, non-public information (as defined below) or passing on such information (“tipping”) to others who buy or sell securities. These laws apply to trading in the Company’s securities while in possession or aware of material, undisclosed information and also to trading in the securities of other companies about which the person has acquired information in the course of his or her employment or association with the Company.

This policy applies to all types of securities transactions, including purchases and sales of stocks, bonds, debentures, options, puts, calls, and other securities.

RESTRICTIONS

Insider Trading Restrictions

If any Covered Person is in possession or aware of material, non-public information relating to the Company or any of its subsidiaries, or information that might affect the market value of securities of any other company that is obtained in the course of employment by, service as a director of, or other association with, the Company or any of its subsidiaries, neither that Covered Person, any related person (e.g., spouse, parent, child or sibling) nor any person living in his or her household may buy or sell the Company’s securities or the securities of such other company (including options or other derivative securities related to such securities), or engage in any other actions that would take advantage of, or pass on to others, that information. This prohibition continues whenever and for as long as the Covered Person knows material, non-public information.

Additional Prohibited Transactions

The Company considers it improper and inappropriate for any Company personnel to engage in short-term or speculative transactions involving the Company’s securities. It is also the Company’s policy that Covered Persons may not engage in any of the following activities with respect to the Company’s securities at any time: (i) “short” sales (sales of securities which are not owned by the seller at the time of the sale), (ii) sales “against the box” (sales of securities which are owned at the time of sale but are not delivered promptly), and (iii) buying or selling puts or calls or other derivative instruments based on the Company’s securities. In addition, it is generally illegal for any director or executive officer of the Company to engage in short sales or sales against the box.

Transactions By Family Members

The same restrictions that apply to a Covered Person also apply to his or her family members or to other persons living in his or her household. Each Covered Person is expected to be responsible for his or her related family and household member’s compliance with the terms of this policy.

DEFINITIONS

“Material” information is any information for which there is a substantial likelihood that a reasonable investor would consider it important in making a decision to buy, sell or hold the securities of a company. In other words, any information, which reasonably could be expected to affect the price of the stock to which it

2


relates is “material” information. This can be positive or negative information. It is important to remember that materiality will always be judged with the benefit of hindsight. When in doubt, a Covered Person should assume that the information is material, and treat it accordingly.

While it is impossible to provide a complete list, some examples of information that could be “material” are:

·

financial results, reports or projections;

·

early indications of clinical trial results;

·

known but unannounced clinical trial results;

·

known but unannounced analyses of clinical trial results;

·

news of a pending or proposed merger, acquisition, divestiture or tender offer;

·

securities offerings, changes in dividend policy or declarations of stock splits;

·

changes in dividend policy;

·

calls, redemptions or purchases of a company’s own securities;

·

significant changes in the Company’s operations;

·

changes in top management;

·

initiation or settlement of significant litigation or governmental investigation or other governmental action;

·

significant developments related to intellectual property;

·

industry information;

·

substantial changes in accounting methods; and

·

changes in debt ratings or problems relating to debt service or liquidity.

“Non-public” information is any information which has not been disclosed generally to the marketplace or the investing public. Information becomes public when it has been released through appropriate channels, such as a press release or governmental filing, and enough time has passed after such a release for the investing public to receive and evaluate the information. The appropriate interval following public disclosure will depend on the nature and complexity of the information. As a general rule it would be appropriate to refrain from trading for at least three business days after the initial release of the information. At that point, and not before, the information is considered “public.” All information that a Covered Person learns about the Company (or any other company in connection with his or her employment or service as a director) is potentially “insider” information until publicly disclosed.

“Tipping” is the passing along of material, non-public information to others. Penalties for tipping can apply whether or not the Covered Person derives benefit from another’s actions. Recommending or hinting that

3


others buy or sell securities when the Covered Person possesses or is aware of material non-public information, even without telling them why, can still be unlawful.

SAFEGUARDING CONFIDENTIAL INFORMATION

Treat all sensitive, non-public information about the Company (or any other company) as confidential and proprietary to that company. Do not disclose such information to others (such as family members, relatives, business or social acquaintances) who do not have a legitimate need for such information in connection with the Company’s business. Treat all such information carefully and avoid inadvertent or indirect disclosure of it. Even within the Company, confidential information should be distributed to or discussed with others only on a need-to-know basis, and those people should be told that the information is confidential. Be careful that conversations are not overheard on elevators, airplanes or other public places; do not leave confidential documents on conference tables, desks or otherwise unguarded; and take whatever steps are reasonably necessary to keep confidential information from being disclosed. This prohibition applies also to inquiries about the Company that may be made by the financial press, investment analysts or others in the financial community. Such inquiries should be referred to the Chief Financial Officer or another authorized representative of the Company.

STOCK OPTIONS, WARRANTS, ETC.

The exercise of stock options in accordance with their terms, standing alone, is not considered “insider trading” under the Company’s policy, but please note that “exercise and sell” or “cashless exercise” transactions (i.e., the concurrent sale of stock acquired upon the exercise of an option to cover the option price, withholding for taxes and/or broker’s commission) or any similar transaction involving a sale of the Company’s securities into the market or otherwise involving a third party and the Company would be covered by this policy.

Please note that, in all instances, this policy applies to sales of stock acquired upon the exercise of stock options.

4


SECTION II

ADDITIONAL TRADING RESTRICTIONS FOR INSIDERS

The general Insider Trading Policy in Section I applies to all Covered Persons. Insiders are subject to certain additional restrictions on transactions in the Company’s securities to reduce the risk of securities law violations or the appearance of impropriety with respect to such transactions. This Section II outlines those procedures.

PRE-CLEARANCE OF TRADES

Insiders must pre-clear with the Chief Financial Officer at least one day in advance of each proposed purchase, sale or other transfer of Company securities, other than purchases or sales pursuant to a plan known as a “Rule 10b5-1 Plan,” as to which an Insider should consult a financial advisor or attorney if the Insider is interested (see the section below regarding Rule 10b5-1 Plans). Insiders requiring pre-clearance will be notified by the Company. The purpose of this additional pre-clearance requirement is to allow an Insider to confirm that the status of corporate disclosure does not preclude lawful transactions involving the Company’s securities. Unless such confirmation is received, the transaction should not be undertaken.  After receiving clearance to engage in a transaction, the Insider should either complete it (including settlement) within one week or submit a new request. Any advice will relate solely to the restraints imposed by this policy and will not constitute advice regarding the investment aspects of any transaction.

Even if pre-clearance is received, the Insider and any family member sharing the household with the Insider may not trade in the Company’s securities if the Insider is in possession of material, non-public information. The procedures set forth herein are in addition to the general provisions included in Section I and are not a substitute for those provisions. These restrictions are also in addition to the legal requirements that may otherwise apply to an Insiders’ transactions under Section 16 of the Securities Exchange Act of 1934 (the “Exchange Act”) and Rule 144 under the Securities Act of 1933.

EXCEPTIONS

10b5-1 Plans

SEC Rule 10b5-1 under the Exchange Act provides a defense from insider trading liability if trades occur pursuant to a pre-arranged “trading plan” that meets specified conditions (a “trading plan”). A trading plan must be a binding contract, an instruction or a written plan that specifies the amount, price and date on which securities are to be purchased or sold, and it must be established at a time when the Insider does not possess material non-public information. If such a plan exists, the Insider can claim a defense to insider trading liability if the transactions under the trading plan occur at a time when the Insider has subsequently learned material non-public information. Arrangements under the rule may specify amount, price and date through a formula or may specify trading parameters that another person has discretion to administer, but the Insider must not exercise any subsequent discretion affecting the transactions, and if the Insider’s broker or any other person exercises discretion in implementing the trades, the Insider must not influence the broker’s or other person’s actions and the broker or other person must not possess any material non-public information at the time of the trades. Trading plans can be established for a single trade or a series of trades.

It is important to document promptly the details of a trading plan. Please note that, in addition to the requirements of a trading plan described above, there are a number of additional procedural conditions that must be satisfied before a person can rely on a trading plan.

5


SECTION III

CERTIFICATION

The undersigned hereby certifies that he/she has read and understands, and agrees to comply with, the Company’s Insider Trading Policy.

Date: ______________________

Signature:

_____________________________________________

Name: ____________________________________________

6


EX-23.1 4 anvs-20241231xex23d1.htm EX-23.1

Exhibit 23.1

Consent of Independent Registered Public Accounting Firm

We consent to the incorporation by reference in the following Registration Statements:

(1)

Registration Statement (Form S-3 No. 333-276814) of Annovis Bio, Inc.,

(2)

Registration Statement (Form S-8 No. 333-236457) of Annovis Bio, Inc. pertaining to the 2018 and 2019 Equity Incentive Plans, and

(3)   Registration Statement (Form S-8 No. 333-280417) of Annovis Bio, Inc. pertaining to the Amended and Restated 2019 Equity Incentive Plan;

of our report dated March 21, 2025, with respect to the financial statements of Annovis Bio, Inc., included in this Annual Report (Form 10-K) of Annovis Bio, Inc. for the year ended December 31, 2024.

/s/ Ernst & Young LLP

Philadelphia, Pennsylvania

March 21, 2025


EX-31.1 5 anvs-20241231xex31d1.htm EX-31.1

Exhibit 31.1

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER AND

INTERIM PRINCIPAL FINANCIAL OFFICER

PURSUANT TO

EXCHANGE ACT RULES 13a-14(a) AND 15d-14(a),

AS ADOPTED PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Maria Maccecchini, certify that:

1.

I have reviewed this Annual Report on Form 10-K of Annovis Bio, Inc.;

2.

Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.

Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4.

I am responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a)

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under my supervision, to ensure that material information relating to the registrant is made known to me, particularly during the period in which this report is being prepared;

(b)

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under my supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report my conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)

Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting; and

5.

I have disclosed, based on my most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

(a)

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

(b)

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

Date: March 21, 2025

    

/s/ Maria Maccecchini

Maria Maccecchini

President and Chief Executive Officer


EX-32.1 6 anvs-20241231xex32d1.htm EX-32.1

Exhibit 32.1

CERTIFICATION PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of Annovis Bio, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2024 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Maria Maccecchini, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

1.

The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

2.

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operation of the Company.

Date: March 21, 2025

    

/s/ Maria Maccecchini

 

Maria Maccecchini

President and Chief Executive Officer


GRAPHIC 7 anvs-20241231x10k003.jpg GRAPHIC begin 644 anvs-20241231x10k003.jpg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anvs-20241231x10k004.jpg GRAPHIC begin 644 anvs-20241231x10k004.jpg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anvs-20241231x10k005.jpg GRAPHIC begin 644 anvs-20241231x10k005.jpg M_]C_X 02D9)1@ ! @ 0 ! #_VP!# ," @," @,# P,$ P,$!0@%!00$ M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_ MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04 M%!04%!04%!04%!04%!04%!04%!04%!3_P 1" (2 WP# 2( A$! Q$!_\0 M'P 04! 0$! 0$ $" P0%!@<("0H+_\0 M1 @$# P($ P4% M! 0 %] 0(# 01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D* M%A<8&1HE)B7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7& MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$ P$! 0$! M 0$! 0 $" P0%!@<("0H+_\0 M1$ @$"! 0#! <%! 0 0)W $" M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$ MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4 MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,! (1 Q$ /P#]4Z*** "B MBB@ HHJ&XO+>T&9YXX1ZR.%_G0-)MV1-14-O>V]VNZ">*9?6-PP_2IJ ::=F M%%%% @HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0G I:\P_:.\9:AX. M^%U[_8T;RZYJLL>E6$$I[S:6NROU?DM MWY'C_P"T;^UO<:%J4OA+X?E;K6 =EUJ4:>:(3W2)>06]6/3MSR/#8/@1\;OB M>QU&[L=2E\SYO-U6]$).?178']*^NO@#^S?HWPCTB&\O((M0\4SH&N;V0;O+ M8\E(\] #W[U[/7-[)U-9OY'ZO'C# \,Q^I\/8:,W'1U9J[F^K2332[*^W0_- MB]^!WQK^%;?VC;V&IP+'SY^E7@GQ[D(Q('U%>X_LW?M<7FN:O#X/\>[8M28^ M5::FR^69'_YYS+T#>C#&>A&>3];5X3^T1^S1I7Q0TF?5M'@CTSQ9;*98;B ; M?M!'(1\=3GHW44>R=/6#^1JN,,!Q1'ZCQ#AXP M4?LS>.;WQQ\*[%]5+G6--D?3[SS?O&2,XR??&*]7KHB^97/R3,,%4R[%U<)5 M^*#:?9VZKR>Z"BBBJ. **** "BBB@ HHHH **** "BBB@ HHHH **;)(L2%W M8(HZLQP!0CK(H9&#*>05.0: '445GZOX@TO0%MSJ>HVFG"XD$,)NIEB\R0]$ M7<1D^PYHW T**Y_P_P#$'PSXLUO6]'T77M.U35=$E6'4[*TN5DELW;.%E4'* MD[6Z^A]*Z"FTUN 444PRH-V74;1EN>GUI /HKGO!?Q"\,_$;3[F^\+:]I_B" MSMKAK6:?3KA9DCE7[R,5)PPR.*Z&FTT[, HHHI %%%% !1110 445QS?$:)? MBTG@;["_G-I!U;[;Y@VX$OE[-N.O?.::3>P'8T457.HV@;:;F'=G&/,&S@O]1M+&:\D\JVCN)EC:=_[J GYC["L_PY\0 M/#7B_5=:TS0]>T_5M1T686^I6MG<+))9R'.$E4'*D[6X/H?2G9VN!T%%%<_X M6^(/AGQOT_69]+N#:WT=C<+*UM*.J. ?E;V-%GN!T%%%%( HK/TK MQ!I>NM=#3=1M-0-K*8+@6LRR>3(.J/M)VM['FM"C8 HJM=WBVLMJC DSR^4. MO!VLWI_LU9H ***B^UP?O/WT?[O[_P P^7Z^E $M%,:>-8O,,BB/&=Y88_.H MY+VWBV[[B)-PR-S@9% $]%1Q3QSKNBD61?5&!%24 %%%5TNU>_EM<'='$DI/ M/1BP_P#930!8HHJ*:ZAML>;-'%GIO8#/YT 2T57DU"UBM9;I[F%;:)2\DQ@ IFE:O8Z[817VFWEOJ%E*"8[BUE62-\'!PRD@\B@"W1110 4444 % M%0F\@6;RC/&)$#!BP">>B%AN_*I: "BH+V[%E;F5@6 95P M,]V [?6IZ "BBB@ HHJN^H6L;E'N85<'!5I "* +%%9^J^(=+T)+=]2U*TT] M+B00PM=3K&)'/15W$9)[ 5H4 %%%% !112$@ DG '>@!:*K#4K0D 74!)["0 M?XU9H **** "BBB@ HHHH **** "BBB@ J*YF%M;RRD;A&A;'K@9J6JNI_\ M(-N_^N+_ /H)H ^.O"7_ 4 \9_$.QO]3\(_L[^*/$FC6=[-8M?V6J0%6DB; M#@*5SGIQ[UZ;\,/CYX#_ &B_"]AX]GG/ABT\(ZE-%J-GXA=+8V%[L\H+(S$* M,>8<'/4BOC3]C;PIKNL_"OQ%-I_[2/\ PJNV/B/4E_L3R+%MIWC,NZ9@XW?D M,<5SVC3A/V'_ -I[P5826WB<^'-;CFE\6:>S2#6=\\,8I-7- M:56=&7/3=G9KY--/\&?JMK7C+0/#6BIK&KZYINE:0^W9J%[=QPV[;N5Q(Q"G M/;GFHM2\=^&M&U&XL-0\0Z58WUM;_;)[6YO8HY8H,X\UE9@53/&X\>]?G1^W MW\:/ WB;_@GWX-TK2?%.EZEJE['I?E6-K=))./+A'F;D!RNTC!R!S72_%[X. M^%OC9_P5'M-#\8Z?_:^B0^"H+MM/>1EBF=99MN\*06 SG%,R/NO_ (6/X6?P MA=^*8/$6E77AVU1Y)=4M[Z)[90O7,H;8.PY/4UQGP(_:=^'_ .T5H@O_ EK M$37'F3(=*NYH5OE6)]C2&%79@A.,-T((]:^4/AS\&/"?@C]L'XY?"?1-'6+X M>:QX.M=1G\-%W>U,YP,JI.1SD]?XB.G%8O\ P3ZTSX4^!_VI7H MO?['M[^%KB-O+42?N@VX*['4?&_AS2-1FT^_U_2[*_AMS=RVMQ>QQRQP M#K*RE@0@_O$8]Z_$KXCPZ>_P7T?XA^&O!_PV\!I)?VUWI4NC:_++XB@?SUX* M;\EAU;(^4^/G_!1+P)I/C>R_MC29_!$>H7-B79([B15# . M%()7H%)*QT5Z]3$S]I4=W9+[DDOP1^AGASQ5HOC#3AJ&@ZQ8:W8,2HNM M.N4N(B1U&Y"1G\:KS^.O#=KXCC\/S>(=*BU^10R:4][&MTP(R"(BVXC'M7P7 MX3\'C]GS]K_XU>$_A/9/H]C/\/VUFRT.W=G@_M$)((BB,3SN5>/(?$LUMX@M[WS6)E<,X*N&/&!@\=3FF< MY^L?Q+_:P^''PE^)OAOP)XCUN&TUK6]^U_M$"PV0558&Z9I 80P8%21SSBO1 M-6\>>&=!T2#6=3\1:3IVD7 #0ZA=WT45O(",@K(S!3D>AK\W?CG\*/#:_&S] ME:]^*]AH5_J.OV#VOBK6)I@UKJ(_C9X"^ M'WA[X?\ @77[JW\-&YT_6O%NKM;:7'9AR%AAVN$D/!())[XZ< 'Z#IXIT63P M^^O+J]@VAI"UPVIBY0VRQ 9,AESM"@ DG.*S8/B;X.NK_3K*'Q9HO?V KGQ-JVH:3_PL&/1IYFU"34B-3AU% M WDQ)'OSC<$ 7!!S[@ _6ZBO(/V0]:\2^(OV8_AKJ7B]YY?$5SHL$EU+=9\ MZ3CY'?/.YDVL2>+M<2WV8O]+LDDMY=R*WRL7! M.-VT\=0::3>P'J%%>*_\-)7?_1*?'O\ X+HO_CM'_#25W_T2GQ[_ ."Z+_X[ M5\D@/:J*\5_X:2N_^B4^/?\ P71?_':/^&DKO_HE/CW_ ,%T7_QVCDD![517 MBO\ PTE=_P#1*?'O_@NB_P#CM'_#25W_ -$I\>_^"Z+_ ..T# M]D/XH21NT;KI1(93@C]XG>OF+PW\9?BKHFD?LQ?#KX>ZIIEA)XM\,R-<7.K6 MWGK$T89O-Z@G"J?E[G%>_P#Q;^(T'QD^&^O^"]9^%_Q&M]+UFW^S7$MI80K* MJ[@?E)D(!X':O/="\,^'= \3_"_7+?X;_%%KKX>Z?+IVEH]E 4EC=64F4;N3 MACTQ7;2E&-/EDKN[?X:?B,YT_MI?$3X*6GQT\/\ CUM-\6>(_ 4-M-8ZC86Q MMHKDW 0H'3)P )%)^A%>;_M.VWQHFT+X&:O\2_$?A_7-+U?Q38WD-II5F89+ M&=D9ECWY(E38S?-QRH]:]NO_ QX0UKQU\2/$VK?";XD:JWCVTBLM6L+FQA^ MSA(T1%,8#@J1Y:G.3SS7FEO^S7X-CN/#CW/ACXYZG!XQ1# MD0Q1LY")PO3!PH%;PG2BU)*S]/+IVU"Y=T;]H>3X):]^U_XNM/#NDMJ&AZW8 M6ULUO;^4]S)*\Z*T[Y^8 X)QCN>IKW+X677[06E3Z3XF\<^+_!VH^"K_ $B7 M4K_9:M;2:7^ZWQE6R1(HR-S' !]17$Z=X4\'V]U\5GOOA+\2-8M?B1/'<:Q M9WME"8T9/,V^5M<%<&0G.2<@5R_@OX,^#O"NJBZO_ _QJ\66L.FW6D6>G:]< M>?;6=I<1F.:*-/-&%9&(QTZ'&0,9R=.2>GX7Z+STU Y[0?VV?B)X>^)'PZ>[ M\9:3\0/"_BG6X=(N$L/#5WI\$/FRK'O@NI5"3;2V< ]JVOV>+/XHWG[<7QCL MKOQW!=:;I5S#)J=G-9LT5U \0,<<*E\0D!E!(!S@^M5K'X$^&;0^$(9?#/QN MOM,\)ZG#J>C:9=B![:U:.02! N>5) SGG'0BNXU+P]HEQ\<9/BEIG@7XO^'M M@Z9XK\6?$.ZT*SFCM3%:0?)&QFD7)+-\W SCTQBO9+C]H3XO\ MP2^+E_\ #/X@ZKHOBJZU3PQ=:YH^MZ79&W-O+$DIV21$G*YB89SZ'UK%TSX. M> ++X2:A\/KGX5?%&_TNYUF37H;V6VA2[L[M@HWPR(XVX"^GV92I2)FD^7@XS@\<="P'2OT=T/54UW1=/U*)#''>6\=PJMU =0P!_.OBB]\#^&+[]G&S^"[_#GXIC MPQ;2QRI(K]-O^&DKO_HE/CW_ M ,%T7_QVO+/@;=:1\ I_&$N@?#/XF7+>)]5;5[S[;8P-LE;J$PXPOUS730FZ M,97W=MF!X?I7QM_:!^&7PB_9P\.17*6_BSQEJM]IK#Q- 7E-N'A%J9B?F!59 M"3W(Q7<_%_\ ::^*7@[XIZ/\'[7Q):VNOV&D+J.M^*+7PSZI8ZHVG0WF@>%[O_B8 M1;=RW @=59%(]>]1>-_VCOB'\6/C5X:^&OPJFM_!+W_AV/Q)=ZEXHTYFN88Y M"P2(VY8%7&WD$\9KIOA#X]3X.^#T\/V'P_\ BOK<8F>XDO==1;RYDD0V(W3AYI$)FR?G."<=,$ MD]2:[?2_A;X-T;3/ EG;?#?XM,/".M2:_;S7,<6<.Z"X))#0LK@I@GCKZ<@ MFIC.E;WH^MO7_(-#TK0I/C]\-[;6=6^('CCP7J'AJ/19;MM0-F]K_9]T%R@* M@G?&#U;@GL*\.^''[8WQ#T_XT_#C2-4\66'C[POXSG>V$]OX:NM*C@88VO!+ M,H6=>>JD].>HJ[X;^#'A#2VU,ZWX)^-GC/[9I;Z,@\0W/V@6MHW_ "SC'FC M&!C.<8%-\/\ P@T#1-=\"ZG<>&?C9K/_ A,B'0[345MY(+2)5"B%4!'RX"C M/7"@9P*2]EKS*_R2Z =S_P $ZO\ D*_M!?\ 8_W7_HM*^RJ^2O@QJ^F? ZX\ M83:'\,OB5<-XHU>36;S[98PL$F=0"$PXPO X.:]+_P"&DKO_ *)3X]_\%T7_ M ,=KDK)SFY(1ZIK>/MFBYV_\?O&?^N,O2M:O!-6_:.NWN=*)^%OCN/;=9 ;3 MH_G_ '4G _>]>_X5H_\ #25W_P!$I\>_^"Z+_P".UCR2 ]JK\J4O[G^S_P#@ MH ?M$O[JYLO+^<_)^]O^GI7W9_PTE=_]$I\>_P#@NB_^.U\^CX=^%1!\88O^ M%<_%3'Q0DBDU@_8[?,)1IF'D_-\O,[=<]!77AW[._-UM^#3&CYHU3X^>+_AU M^Q_XA^$?Q*>X9M=\/V^I>#=?!8K=0^?"[VQ?^\@SCZ8/49]$\<>"-,^*_P"T M!^R;X1\1?:+G0]6\'L+N"*=HS)LM)I%^8'/WD4_A7L_Q%\*>#OBC\$=%^&6O M?"/XCW&E:+%$FGZ@MC"+RV9!@.K[\9*Y!&,$'ITQSWC[X7Z#XYU+P-J4?A+X MS>'=5\':8-*TR_T2."WG6,*5+%PV=Q4D$C'!-=BK0W2L]?Q5DQW(]1\'K^QY M^UM\+/#OP]U[5)/#7C-IK?4O#%]>-_L:^_:^'_A)X,\+?"K MQQ-XUE^''Q:\:>,WC,*:[XJ"WUS"A[(6D^7CCCH.!BO=O^&DKO\ Z)3X]_\ M!=%_\=KAK_O&K:M+5]Q'M59<&/\ A)[W[N?L<'U^_-7E/_#25W_T2GQ[_P"" MZ+_X[6?%^T?=C7[I_P#A5OCLDVL(\O\ LZ/(^>7G_6]#_0US!_&^J?#3XF0:KX1E::QBMK&!8I"W7S 7)/X$5TX= M^RJ@2> K*Z%M_PCCV)-S+;O'3X@ZI(I4E29.N#7C=_X)\,ZA M^SC8?!>3X<_%-?#-DZO'P_L_2(-2'ARW\,W>JW*EHE=EN9H5*P@DX!/3(S5+Q M%^UM\7O&?PH^$GB?PUIK>'M'\16LLNO^)+31)M72PEC+ +Y$7S!6*]>V[VIV MN?"_PWJ/B76-9TSP9\9O##ZY916&LVVBK##%J,:)L!D^8D$CJ5(ZGUJ(?"_2 M+'P3X4\-Z)H/QU\,1^&[>2UM;S0[A+262-WWL)-C@-R?2I3I))6_!=O\_411 M\6_MN>+]%\ > =&T'QAHOBOQ1XGU&XMY?$^G:)<216D,>./L2@RF7GE,5Z[^ MR7\>/B)XT\?^)/!WC>RO-8L+.V6\TWQ;_P ([=Z1#<@G#0M'.BX=<]CSBO+V M^"GPY_X5U9^%H_A-\58;JSU!M6@\1Q!5U1+QL;IA.),[C@=NO/6O1/@KK8^" MR:N\7A/XS>++W5)$>XO/$SB]D^484+NEPO!QP/2IJ>R<&H+7Y=QLXK]K/X:Z M)X4_;"_9_P#%VFI<0ZUXC\4K%J,AN&*2K%'&$ 3.!@5]VU\F?%#6]-^*_C/P M#XEU;X9?$J&^\&:@VI6"6UC"J22$ 8D!]>3_\-)7?_1*?'O\ X+HO_CM4 M;+]I"[&HW[?\*L\>,24RHTZ/*\=_WM8\D@/>*_*GX\W/PK?_ (*#?$:#XPWF MHP^&AI-H;5;'[0S"X^SPXXB!(XW=>*^[/^&DKO\ Z)3X]_\ !=%_\=KRO0KC M2- ^/WB#XN6_PT^)K>(M;LH[&XMWL8#;*B*B@JN_(.(QW[FNK#R=)R;ZKI\A MH^,?%C>+&_8_\>'_ (G4GP]'CG31X*/B0.+AH=TN_&_YO+_U6.V=V*^LO"/Q ME^,/P@^/WPJ\#_$/6="\1^'_ !U82>0--LC;OILD<)8#<6.\9"@GC@GTKJ?C MSKVG?M"^"(O"_B'X9?$JTL([Z&_$EA8PI)OB)*C+.1CGGBL_QJ^C>._B-\/O M&6H?#+XF+J7@I)$L(8K& 12ATV-Y@+Y/'H173*K&I&TH]_R5OQW"YXI\6?VX MOB'\-+S4O%ND>.]#\;^'-.UHVD^C:;X;NTMO(WD;?[0*^49 H&1GJ>,UZ!^T M%^T7\7O!WQC\2:#=<\+:IX57PE\;+'PC>WC7Z^'[?R!9P3ELEE4DD]QAB<9]:ZKXH?#O2O MBMXDUK4M1T'X[V&GZT4_M'0M/NQ%I]R%55"F'S" ,*.!1>C=:?@O+_@@4_BA M^V-X[USXPS^ _ _B*TTNRT?1+6_N=?M/#EUK0U*:6*.0&..W5C'$1(N&/^ K MZ2_9*^+GBGXT?"1M3\9Z!>>'?$=E?3:;?&GPM\&>(]3T75="^'/Q>^'^LZ5IL6D1:EX39;*>6UC4(D-= M?\5Z5:?'_0]=UR5I;Z\TV>&&27+;MI=6W%0>@)["OJ'P_P#'V\T'0M.TP_#3 MXC:@;.VCM_M=[91R3S[%"[Y&\WYF.,D]R317?/&,4[V_K[@N>S^(U5^1FK7/P6E_:P^/:?&6]UB,1ZJO]DII?VEGW;%W!?*! /3&[%? MH3_PTE=_]$I\>_\ @NB_^.UY=\-;[2OA=\2?'7C72_AG\2YM4\87"7%]'M-:\-3:] M9ZM961M$L6C\WM7XWZKI?QYMO#4&O?#+XEVR:#JT.L6WV* MQA7=-$&KNQMXU9L!H+R10DI'/W3VZ8KI_B7^TQ\8?#GQ8\3VNO^(['X2^&]/U!; M;2WUKPQAZ5D_P##/_A5M.\.Z7+X8^-]QH?AS4$U#2-) MF\A[:S923M5">0)_C'XV\,^!=9@T#2O" M@CACE3PQ>:R=3G:,/RUNC")#D $]0<@&OJ;]G/XB:S\=O@5IFL>,/#EYX8UN M]BFL]2TR[MY+9U=249E5P&"L/F'UKYI\>?#'PIXL\5R>(]$\!_&3X?:K<6D5 MC=R^$9!8B[@C4(B2!9>0% 'T KV'P]\48O#7P[M?!EM\,OB;-I=M8?V,DJ?45^I]I<175K#/ P>&1%=&'=2,@ M_E7Y[V7P(\*&^TI=9\+_ !V\4:!I5PMS9>'-;O/M&GPNOW<1F3H.P]SZU]11 M?M'7,,:1Q_"?QXD: *JKIL0 Z ?O:,1+VBBD[M?UW&SVRBO%?\ AI*[_P"B M4^/?_!=%_P#':/\ AI*[_P"B4^/?_!=%_P#':X^20CVJBO%?^&DKO_HE/CW_ M ,%T7_QVC_AI*[_Z)3X]_P#!=%_\=HY) >U45POPY^*$WQ!N;Z&7PAXA\,BV M17$FMVRQ++DD83:[9(QS]17=5#5M& 4444@"BBB@ ILB+*C(XW*P((/<4ZB@ M#P6Z_80^ -Y!?"N,-D<'.'%AOV#S MJMKC<0=PP0$V^(@\>'0[4^,!9BP_M?!\[[."2(^N,9)[=ZZ MJB@#F;7X:^&++Q]?>-H-&MH_%=[:)8W&JJ#YLL"G*QGG&!CTKG=%_9P^&'AS MQ[>>-=,\#Z/8^*+L2"?4H;<+(_F B3(Z98$@G'.3FO2** /"E_9+^ H\1:MI MZ_#/P['J.HVPN;D+:A6>,R4.<;>!VKS']H;Q9N:=;W]A<1W=G<()(IHFRK*1D$5"E=M=CV\9EL\/A,/C M8ZTZJ>O:46TXOST3]&C#A^&?A>W\?W'C>/1;9/%EQ:+8RZJ ?.>!22(SSC ) M/:N,U[]DOX-^)_%S>)]4^&WAV]UUY/.DNY+)!-#U32M 7[/I]O);C_ $-1_ C#! Z9&<'O76_$?X@:7\,_"-_K MVJSI%!;QDHA.&E?^%%'P( M%3?6QZ:P%3ZC+'RTAS**\W9MV]$E?U1QWQ!_9A\+0?!KXH>'/AWX9TGPWK7B MWP_<:5OMD\F*1S \<(8#@ %^P[FN0^!'["WPY\)_#?P3'XV^'_AK5O&^CV20 MW6H?95E$DBDX8\8U5XI*C:W[I!D;'7^\<\L/3Z]C,_[4WA!.MMJG_?A/\ XNG]6K?R ML+,]CHKQ9_VL/!R=;75O^_"?_%U"_P"UWX*3K:ZO_P" Z?\ Q=/ZK6_E869[ M?17A3_MB^!TZVFL?^ \?_P DZV>M_^ T?_P (O_ .+_X[ M4#_\%(_A:G73_$?_ (!Q?_':?]GXK_GVQ\K/JVBODQ_^"EWPJ3KI_B7_ , X MO_CM0M_P4X^$Z==.\3?^ 4/_ ,>I_P!G8O\ Y]L.5GUS17R _P#P5"^$B==- M\3_^ 4/_ ,>J%_\ @J;\(4ZZ;XI_\ 8?_CU/^S<9_P ^F'*S[%HKXV/_ 54 M^$ _YAGBG_P!A_\ CU)_P]5^#_\ T#/%7_@##_\ 'J?]F8S_ )],.5GV56=8 M'_B:ZER>L?7I]VOD7_AZM\'_ /H&>*O_ !A_P#CU5;?_@J9\((+R[F.G>*B MLQ4@?88.,#'_ #VI?V;C/^?;#E9]JT5\9?\ #UGX/#_F&>*O_ &'_P"/4'_@ MJU\'A_S#/%7_ ( P_P#QZC^S<7_S[8P?!S_ *!GBO\ \ (?_CU']G8O_GVPY6?:-%?%I_X*Q?!L?\PS MQ7_X 0__ !ZD_P"'L?P;_P"@9XK_ / "'_X]2_L_%_\ /MBLS[3HKXK_ .'L MOP;_ .@7XL_\ (?_ (]0?^"LWP:'_,+\6?\ @!#_ /'J/[/Q7_/MA9GV%X@. M-+8@D?O8NG_71:TJ^']4_P""KGPI?4,5_P ^V%F?:U%?%!_X*U_!D?\ ,+\6?^ $/_QZ MD/\ P5L^#(_YA?BS_P (?\ X_1]0Q7_ #[869]L45\3_P##VWX,?] OQ;_X M 0__ !^FG_@K?\&!_P POQ;_ . $'_Q^CZABO^?;"S/MJBOB7_A[C\%_^@7X MM_\ "#_ ./TG_#W+X+_ /0+\6_^ $'_ ,?I?4<3_(PLS[;HKXC_ .'N?P6_ MZ!?BW_P @_\ C])_P]U^"P_YA?B[_P (/\ X_1]1Q/\C"S/MVBOB$_\%=O@ MJ/\ F%^+O_!?!_\ 'Z3_ (>\?!7_ *!?B[_P7P?_ !^E]2Q/\C"S/M^BOA__ M (>]?!7_ *!7B[_P7P?_ !^MGPG_ ,%6O@7XFU>.QNKG7/#J2<"[U6P A!]" MT;N1]2,>])X/$)7Y&%F?8]%<[X.^(GACXA:='?>&M?T_7+20;EEL;A91C\#7 M15R--.S$%%%%( HHHH **** "BBB@ HHHH **** "BBB@ HHHH YKXC> =,^ M)O@[4?#NK1[K2[3 =?O1N.5=?<'!KX=T;XE?$']D+Q9<^&-3A_M/0Q(7B@GR M(YH^TD+_ ,.>X]>U?H/7/^-/ .@?$+2FT[Q!ID&I6QY42K\R'U5NH/TK&I3< MO>B[,^[X S*C[;"U-91ZI_S1[/YJ_='A6@_MZ^ +^V0ZI8ZOI-SC M+J(%GCSZ!E;)_%16=XL_;\\)V5LZ^'M&U+5;K'RO=JMO%G\RQ_(5=UK]@OP3 M?W+2V.HZEIR,<^4'5P/89%:_A#]B7X?>&[J.XO4NM4_]HC&K)_R:V]+Z?\ I1X]\.O"OC?]KGQG!XF\7RO:>#-/E#1P*I6& M5@?]7$O?I\SGZ=>GV_!!';0QPQ($BC4*JJ, < 4RQL;?3+.&TM(([:VA4)' M#$H5$4= .@J>MH0Y%YGY]Q!GTLZJP5.FJ5"FK0A':*_5OJPHHHK0^5"BBB@ M#)\6^)[#P5X7U;7]4G6VT[3+62[N)7. J(I8G\A7S_\ "W]K+4OB5\$?B+XG MNO#:^%_%GA?3[G4$T6\DWDP_9FN+25@"#MD0+G'?(SQ7:_M0_"SQ'\;/ -CX M)T6]BTS2M5U*!=?OC+MFCT]"7D6%=I#.S*BX.!M+5Y)KO[(7C/P]XJUG5/#? MC&X\30^)?"FH>&M93Q!)'"5!MF6Q>/RH@#LD8J<]%,,%26*!T.2"M'M([?3=3U>>%&U)(PK7#JL)#["/DST/. :[Q?V=O%5 MW#^TA)=II0N/B+%#_9:K,S*C+IZP,)24^4"0'&,\8/7B@#TCQY^U!\,/AIKE MOI'B'Q5#:7\T"7)2"UGND@A?[DL[PQNL"-V:4J".*?B/?^ M)O&FFKX1\.6.DW3PVVFW+2V"W?FA)))51EF64I\OEYVA3NQD9^<\YQ0!Z3_ ,-V M?! _:47QG*]S P#6::+J#73*5+"1(!!YDD6 3YJ*4_VJZ+Q'^U7\*_"V@:#K M-YXLCGL==@-UIW]FV=S?2W$(ZR"*"-Y @Z%F4 '@X-9TWP:U3_AJR3XBQ1V* M:"W@QM "AL3_ &@W2R#Y=N-FP8SGVQ7S-?\ [!OQ!T_0/!VH:5J$$GB#2[&Y MTV\TZU\07>EPM&]T\T;I<0+N. ^"A7'Y4 ?5>L_M5?"S0KGPM;W'BM)Y?%%O M]JT86%EUC4=6 MU.#2K#2-.O;N6ZL;:Y:%;CR(XGE53MSN90"K*>,U0^#?[+.H_"SQS\-=1B2R M72_#_AZ_LKQ1=23R+>7,ZS.8RXW,A;?R2#S5O]J[X)^-/B;K&@ZIX)L-)_M6 MPMYK>/5IM7N=-O;0N0*/B!XGT?P9KUC9^'=*\ W?B2 M?6=6T:]26PNHIP@,MLZ)*T8C8/@(2V01FO0_B!\#?%OCS]FO1O!FH^([;4O& M^FK87;:M=PY@N[RVD27]XH_@=DP?KFO'_%G[.7QI^*_B[Q[XE\4VOA'2[K6_ MAQ?>$+*UTJ\E94N990T;2.T>2IP26QQD#!QF@#VV']K#X<:))H&BZUXK%YXB MO;&SGE.FZ/>RP@SHI1W*1,+<.6R%E*D C-;%S^U#\+[/Q]_PADOBN%=>%T+% ME%K.;9+D](&NA'Y"R]O++AL\8S7SKXH_97^+?]O:%/X-N=%\(7T>GZ9:7?B; M3]6NDFS;QQJ_FVFTQ7'".H)V\,/2L<_L"^*+;XFWL,EZ-8\"ZAX@?7))9?$5 M[;-"'F$QC^Q)^Z=@V*O%=QX=TKQ,;R_@:='G73KL61,() ME"W9B$#;=K9VR'H?0U\PZW^QI\8?$'Q:37-6\2P:UIUEXICUFVN;G7+I5>T$ MVY819;?)C:-. PSN*YXSFM6Q_8_^)FH^*-7TK[=IG@7P'J,=]%?6NA:M2C=0?6@#Z2^'?[2_PU^*WB)]"\+^)TU#5!&\T4,EI<6PN M8U.&DMWEC59U!(RT18#(YIFM?%#4U_:(\/?#W3(+9K%M%N-:U:YE!,B*)!%" MB8/!+;B<@\#BOG_]FS]C3Q5\-_B=X?UGQ?*E]9>%K>:/2[U?$=[>-)(\?E;A M;2_NX04+94$]O2NB^,D'B;P]^T]?2>%#9IXF\7>!+C3M!FU&4Q6ZWT$NX@L M22J2>9@#G9CU( .K^%G[6$?Q(^.WB/P/_8ALM"MY+B#1->,N5U66U*K=JH[; M'; /< D5SOA[]HSXQ>.KGXB:AX2^'WAC6M \'^)M2\/M:RZU/!J5[]DE*EHT M\AHMS+@@%QSD>EV>GZN\:63EV_TQ M-Z1[P) \AR<\D?6KG@/X9?M#_"K5?B9IOAG2_!!TCQ5XOU;Q!:ZS?:E.UQ:Q MWW6G-*A6\M=2L MY%%S;S8)7 5\(=;O", M$&[9(T8C^'S)FFPOHOM7VC0 5XG-_P G@1?]BN7'2LZXZUHW'2LZXZTX@9TU9MQUK2FK-N.M;(:,Z?M6=LV? MJ:W0&=-WK-N.]:4W>LVX[UO$HSI^E9MSWK2GZ5FW/>MX@9\_0UFW'>M*?H:S M;CO6L0,ZXK-N.M:5Q6;<=:WB-&=/TK-N>AK2GZ5FW/0UNAF=-WK.N*T9N]9U MQ6T1F=<]ZS;CO6E<]ZS;CO6Z SY^AK-N*TI^AK-N*VB!FS=ZSI^IK1F[UG3] M36Z*,^X[UFW'0UI7'>LVXZ&MT!3/2FTX]*;5#&GK2-TI3UI&Z5 #&Z4T]*E-IQZ4VH8AIZTUNM./6FM MUJ&-#6Z5&>M2-TJ,]:EB&GK33TIQZTT]*D!IZ4P]*>>E,/2H :>E,IYZ4RH8 M#::W6G4UNM2 QJ93VIE0 P]:1NE*>M(W2I$;7A/QQXA\":@E]X=UJ^T6[4[A M+93M$<^^#S^-?77P>_X*N?%?P"L%IXHCL_'&G)A2UXODW./^NB]3]0:^*:;7 M-5H4ZVDXW)/VW^#/_!4;X-?% PV>M7UQX"UB3"^1K2_Z,S?[-PN5Q_O[*^L= M$\0:9XEL([W2=1M=3LY!N2XM)EE1A[%217\RFTNRJH+,Q "@9)/H*^LOV7/V M<_VH;N_MM4^'D&N>"K&1@_V_49FL[5QQR8G_ -8,8_@->%B,NI07-&?+ZDM' M[DT5YW\$?#WQ$\.^$DM_B1XFT_Q/K>%_?Z?9_9U3CD'D[C[\?2O1*^?DK.U[ MD!1114@%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 % M>)S?\G@1?]BG_ AS?^E8K2'7T ];N.E9UQUK9D>$ M?>'Z56DGL!]Y1^1H3 YZ:LVXZUU4ESI(^\B_]\FJTE[H(^\B_P#?!K12\AHX MV?M6=C3_O@U6DU7PD/O1)_W[:M5-]F!Y[/UK-GKTN36?!0^ M]"G_ 'Z:JTFN> A]Z"/_ +]-6JJ/^5C/+)ZS;CK7KDGB#X=#[T$7_?EZK2>) M/AD/O6\7_?AZU55_RL#QR>LV?J:]MD\3_"M?O6T/_?AZJR>+/A&/O6L/_@.] M:JM+^1_<.YX7-WK-N.]>^R>+_@V!\UI!_P" TE5I/&?P3'WK.#_P&DK55Y?\ M^W]P[GSU/TK-N>]?0>I^-/@H9K'RK. (L^9O]&E&4V/^?)6G2>.O@&/O6-O_ M . DM:K$2_Y]R^X+GS5/T-9MQWKZ>D\??L^#[UC;?^ DM5Y/B%^SH/O6%M_X M!RUJL3+_ )]2^X+GRQ<5FW'6OJ^3XC?LV#[VGVW_ (!2U7?XD_LRC[VG6O\ MX!35JL5/_GU+[AW\CY'GZ5FW/0U]@R?$W]ET?>TVU_\ &:JLGQ1_95'WM-M M/_ ":M5BY_\ /F7W!?R/C>;O6=<5]HR?%3]DT?>TRS_\ )ZR_P#A:O[)JZK. MTFF6AMC#&$'V"?[^Y]W'T*UJL9/_ )\S^X=_(^,;GO6;<=Z^XI/BY^Q\/O:5 M9_\ @NGJM)\8/V-A][2;+_P73UJL;4_Y\3^X+^1\+3]#6;<5]Y/\8_V+L_-I M%C_X+;BHF^+_ .Q4W71K$_\ <-N*T6.J+_EQ/[AW\CX F[UG3]37Z&-\6OV) MFZZ)8'_N&W%1M\5/V(CUT+3S_P!PVXK19C-?\N)_<'-Y'YSW'>LVXZ&OTF;X MG_L/-UT#3S_W#+BHV^)7[#)Z^'M./_<,N*T69R7_ "XG]P^;R/S1/2FU^EO_ M LC]A?_ *%S3O\ P67'^--_X61^PM_T+FG?^"RX_P :?]J/_GQ/[@YO(_-( M]:1NE?I:?B3^PI_T+FF_^"RX_P :JP?$;]AE;NY,GA[33$Q7RQ_9MSQQSWJ/ M[4?_ #XG]PF?\ @KN:3_A9W[!?_0MZ M9_X*[G_&I>9/_GS/[A7\C\QCUIK=:_3D_$[]@G_H6],_\%=S2'XG?L$?]"WI MG_@KN:EYD_\ GS+[@YO(_,5NE1GK7Z::E\3/V#GM"MOXF?^"NY_QJ?[2?\ SYE]PM-/2OT__ .%H?L"_ M]"WIG_@KN:]F^%OP8_9#^,]BMSX/\,>$]7)'S6Z,RS)]8RP8?E64\T4%>5*2 M7H+F/Q8/2F'I7[U_\,+_ $_Z)?H?_?M_P#XJC_AA;X"?]$NT/\ [X?_ .*K MG_MJC_*_P_S#G1^"1Z4ROWO_ .&%O@'_ -$NT+_OA_\ XJC_ (85^ ?_ $2[ M0O\ OA__ (JI_MFC_*_P_P PYT?@=36ZU^^7_#"?P"_Z);H7_?#_ /Q5'_#" M7P!/_-+="_[X?_XJE_;-'^5_A_F',C\"FIE?OO\ \,(_ '_HENA?]\/_ /%4 M?\,(_ '_ *);H7_?#_\ Q53_ &Q1_E?X?YBYS\!3UI&Z5^_7_#!_P /_ #2S M0O\ OA__ (JM7PS^QO\ !+P?JL6I:3\,_#]M>Q'*2O:^;M/J Y(!]\5+S>E; M2+_ .8_$GX3?LI?%3XUO&WA?P?J%Q8N1C4+F,P6V/4.^ ?PS7VQ\'?\ @CI- M+Y%[\2?%HA7AFTS1%RWT:5N!^ K]/X((K:)8H8TBC485$4 >P%25YM7,ZU3 M2'NHGF/&?A!^Q_\ "3X'^3-X8\'6":G$!C5+U/M-WGU$CY*_\!Q7LU%%>5*< MIN\G=DA1114 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 M%%%% !1110!YY\>?B\GP.^'-SXJ;1KCQ \=U:V<6GVTR0O+)/,D* ._RCYG' M6N1\(_M.K-XYN_!_C_P??_#/78M*DUN+^U+ZVN;6>SC8+)(L\+LH*$\@XP.: MD_;$^&?B'XN?!*Z\-^%X9I=6FU339E:WGCADBCCNXI))%:0A'_ CXSUWPUXKU/QK\5;S0Y=)TK5?&DZ7$<$3,&>%5"!%WX(W% M3R1G@4 >PZ/\??AOK^@ZOK>G>-]#O=)TB/S=0O(;U&CM4_O2'/RCW->?P5H6E:3=6>KZAHKP1/;%[9$"!=P+!F7!* \#J,YH ]IN? MCOINI^-?"%IX;UWPKJ?AW5#J"7MU)JF+D-;(K,+9 ")=NX[^1M&/6M?PS^T- M\,O&>N6VC:%X[T'5M5N5+P6EI?1O)*!UV@'G%?-^@?!SXI7^N?!R/6/ UIH\ M?@:RU_1;NZTZ]M?LES');)%:W,,8DWJLQ'*LH96#%@ 0:71/V8?$VC?L]_!3 M1K;P?:6_C#P[XIL]3U58Y[9)(80\QN',P?#Y5QD*S$YX!Q0!]-:'\,=&U#6;02-/8V]XCRQA/OE@#QM[^E)X7^.7P]\;7-_;Z#XST75Y[ M"-I;J.SO4D:%%^\S 'H,')KXU\/_ +,?Q?U*\\5>$M-\/M\./!>IZ5JUG+/J MFM6FJQF6XC80FR,2"XC7S#E_,(RIP.>*ZWPC\$?B3XFU[PC+JWPUT?X=6_@K M0;W2OM.GZK;W#Z[)):^2@C$8&R'(W_O2&SCCK0!]'Z%^T/\ #GQE&/&F M@^(-5:U:[@L;/4(V>9 NX$8/0\<]JYGP%^U-X9OOAGX0\1?$&^TGX=:UXBM3 M=Q:+J&I(SB,R,L;*Q"E@RA6!P,;L=J\C\*_LS^)/#G@/]EVUM?"5K8ZSX0N( M9/$I@EME>W4VCI-N:YU8Z3'I MD>OV^N6<%K$JR.PBNK.XC.^)2P(,66.2,<"@#ZJ\1^,]"\'^'I=>US5[/2=& MB4.]_=S+'"H/0[CQSFOGK5_VR[75]3^)EIX-F\+7UEX4TS2[^UU_4]9\K3[A MKN8QNDKJA\O;M(')W,5'&:W_ -H_X6^,?'GPS\"R:7IVF^)/$7A;6;+7+O0I MY1;VNK>3%(DD"LPVKDR;UW#;E%SCJ/G#Q?\ L\?%SXB6'[0>IGX5V?@^Z\9Z M3H4&DZ-::O92F26WN]\PD=75%<+\Q)PIZ L: /M1OC=X$MO%5KX4N_%VBP^* MIV2-=)%XIF,C#(4+U)/;C)JQIGQE\"ZSXOF\*V/B[1[OQ'$65]+AO$:=2OWA MM!SD=Q7RI??!+XKZ;^T/'J7@[P'-5DU.W\30^(K,6$I#NZ M$6HA^T[FW .K,!RWSGB@#[?\/_'/X>^*_$<^@:/XST74M:@#F2QM[U&E4+][ MY<]N]-\/?'?X=^+-3O\ 3]&\:Z)J5[81O-=0VUZCM"B'#LV#P >IKX6\-?LQ M?'K4/BMX/UGQ7X=GO(='U:Z-_+_;M@NG3PR13*'M8(D66*(Y12&)?YL[#R1H MZ)^RO\9]=T/Q-X*L=$;X=>#)=%N;"&/6M9L]39Y25,"6DMNGFQQ94[_.Y((X M)% 'W/X&^+/@SXF-=KX4\3Z7XA:T(%PNGW2RF+/3< >*\T^)O[4*?#SQ;X^T MZ+0#JVG>"/"K>)-6N8[GRY-YW&*W12I!+*C'<6XXX->4_LA?L[^./!GQ3N?% MGC72M>T6;3](.D6S:GXALK^.[5G4L$BMH5VQC8"ID8,,XV\DBG\4/!FL^)?B M9^U%X+TNR-YX@\7>![=]%@>5(OM9,,L)16V]VRQ>=Y;&%R8V* D!AV/2N=\-?MM:MK'@" MS^(5]\'O$5C\.;@NS>(+;4+.[,,2R-&TKVZ.)0@96R=O &<5J?##]D9/#L/A MG7O%7BKQ-XR\0Z)INS3K'7;Z.2WTR=X/+<1*@"DC)4,2>.AKR/X8>%?V@M)_ M9OM?@E_PI^#06>UNM.F\6ZKXDLIK6**::1VD%O [R,0LG"^HY(H ^FOA[\<8 M?&_Q9\7>"GLX;?\ LS3[#6M*OX;CS%U.PNE8>:!M&TI)&RD&;N=C]ZXENFFB!_VO+A)]MP]:^L* "O$Y MO^3P(_\ L36_]*Q7ME>)S?\ )X$?_8FM_P"E8K2'7T ];N>]9-SWK6N>]9-S MWIQ S+GJ:R;GJ:UKGJ:R;GJ:Z(C1E77>LNY[UJ77>LNY[UT1&9-SWK+N*U+G MO67<5O$9DW'6LJYZUJW'6LJYZUT1 R[GO65<]36K<]ZRKGJ:Z(C,NYZ&LFYZ MFM:YZ&LFYZFNF(S*N>M9=ST-:ESUK+N>AK>(S)N.]9=UWK4N.]9=UWKHB!E7 M'6LJYK5N.M95S71$HRKKI63<5K772LFXKHB!F7/>LJXZUJW/>LJXZUT1&C)N M.M9=UTK4N.M9=UTKHB,RYOO5">M33?>J$]:U8QAZTUJ<>M-:H :U1GK4C5&> MM0(93#TI],/2I8="-J8W6GM3&ZUFR1K4T]*M2-TJ,]:S8#* M:>M.IIZU+ 8>],/2GGO3#TJ&!&W2FGI3FZ4T]*S8#&Z5&>M2-TJ,]:A@,/6K M>DZUJ'A_4(K[3+VXT^\C.4GMI3&ZGV(-5#UIK=:AZB/K[X*?\%0?B]\*6M[3 M6KBW\>:(F%:VU?*W"K_L3KSG_>#"OOKX*?\ !3WX/?%9K>RU>]F\"ZU)@?9M M9P(&;T6N6&G[ANN[MS#I@'^T9/E8>R@G MVK]HOA%9>/K'P?;1?$?4=&U/Q& /-FT2!XH?_'CR?< #VKYK$X98=V4D_P R M&K';4445PB"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "J,FAZ=+J\6JOI]J^J0Q-!'?-"IG2,G)0/C<%) ) . M.*O44 %%%% %*QT33M,N[Z[L["UM+J^D$MW/!"J/<.%"AI& RQ"@#)SP *NT M44 %>)S?\G@1_P#8FM_Z5BO;*\4EQ_PV#%GI_P (>77>LNY[UZ=(?"G\;6__?357D;P7_$UM_WTU;*I;HQGD=SWK+N*]GD/@+^- MK3\6>J\A^'7\3V?XL]:JM_=8'A5QUK*N>M?0,A^&/\3V/_?IKZ9D;X/_QR:=^+R?XU6D;X+?Q2:9^+R_XU MJL3;[#^X=SY;N>AK)N>IKZRD/P.YW2Z5_P!_)?\ &JLC? 7^.72?^_DW^-;+ M%V_Y=R^X=SY"N>M9=ST-?7VI-\!?.L?*FT@)Y_[[]Y-]S8_O_>VTYV_9S_BE MT;_O[-_C6RQO_3N7W!<^*;CO67==Z^X9#^S5_'-HGXRS_P"-5Y&_9A_CFT+\ M99_\:U6._P"G4ON"Y\(W'6LJYK[ZD;]EG^.;0?\ O]]95QUK]*Y&_8V_BN/#?_ '_N?\:S1_PQLVJ3 M[[CPT;7R8]G[^Y^_N?=_%Z;:V69V_P"7,_N'S>1^:%QUK+NNE?J0T'[%+=9? M#)_[;W7^-1-8_L2-U?PP?^WBZ_\ BJU6;)?\N9_<'-Y'Y43?>J$]:_5DZ5^P M^>2?"_\ X$77_P 53/[)_8=]?"W_ ($77_Q55_;"_P"?,_N#F\C\ICUIK5^K M1TG]ASU\+?\ @1=__%4ATG]AOU\+?^!%W_\ %5/]KK_GS/[@Y_(_*1JC/6OU M>.D?L->OA;_P(N__ (JD_LG]ACU\+?\ @1=__%5/]KQ_Y\S^X.;R/R?IAZ5^ ML/\ 9/["_KX6_P# B[_^*I/[(_86]?"O_@1=_P#Q5+^UH_\ /F?W!S>1^3;4 MQNM?K,=(_85]?"O_ ($7?_Q55H-(_8:^UW/F'PIY7R^7_I%WZ<_Q5']K1_Y] M3^X7-Y'Y0-33TK]:/[)_82/?PK_X$7?_ ,52'2?V$?7PI_X$7?\ \54O-5_S MZG]P%_"GAS7K,C)DL+^:7;_ +P$ MN5/L<5T7_# _P _Z)IIO_?\ N/\ XY7/+.:*=G!_A_F',C\%VZ4T]*_>G_A@ M7X ?]$TTW_O_ ''_ ,F?]_[C_P".5']LT?Y7^'^8M:WA7P=KOCO6HM(\.:/?:[JYXK]V_P#A@']GW_HF6F?]_P"X_P#CE>L_#[X6>$/A1I']E^#_ YI MWAVQ/+1V$"QESZNW5C[L2:RGF\+>Y%W\Q^-KRV\$ M:8V&:W8B>\8>FT?*OXD_2OO3X+_\$[O@Y\'&M[L:"OB?6(L$7VM@3@-ZK&?E M'Y&OIRBO&K8ZO6T;LO(B[([>WBM84A@C2&) %6.-0JJ!T Z5)117 (**** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@#Q_]K#XB:[\+/@IJ?B+PY=)9:K!>6,*3/$L MH"R744;C:P(Y5B.E;OQP^-FB_ GPC;ZWK$4MU)>7L6G6-E R*]SZT3XG_%^X\9QQ7%OJ&CSP>&[*P;3;R%B5EPFY9E()5HW&TJ M3T/( +/A/]MSPWXB\1Z;H-WH]SINJ3:O#I%VHN[>XBM'GC9K>0R1.RNDC(4& MTDAB 14EC^V[X1U2T^(4EIIM]+/X5U./2[> E%;5W>=K='MB3RIE1UR?[IJC M8?L3V_\ PI[Q5X0U3Q:MWKFM20SP^(M/T&TTUM/EA<20/%#;A>5=03E\GG!& M:L6G[$GAK2=?^%NJV^JW7D^!K%;::R$((UAT)=)9CN^\)6>3G/S.>>] &OH_ M[76C:KX$AUAM!U"V\0MXG;PC-X8D>,W<-^LI5D)!VD"/$N0?NFN,_;?^-7BW MX6>(_A5I?AWQA<^";+Q!,+;D$GYF()4C@Y/2L_P"$ MWPINOB+^UQXA^+-UX1\1>#/#EI:QF+2O$,2P?;-:V&"2]CB5F&U;=40.?O$Y M'0Y]7^/_ , ]<^+OB7P)XC\,^.W\!:]X2FNY;:\728M1$GVB)8V!25@HPJGD M@]>V* /#/@E^VAJVF^&?&TGC/4YO'ATS6;'1]!EM=$_LK5=5N+H8CB:R)PF6 MX5^ 0#Z5Z;J7[:6D>$['Q';^+O"6M^'/%6D?9!'X=?RYY[]KE_+MQ;LC%7+/ ME>HQ@YK)'[#2:^OB'6?&7Q%UCQ%\0M4N+"[M_%=I90:>VG363E[5X8(P4^5F M.[=G<#CCK5BZ_8CA\7:7XBN_'?Q!UGQ5XXU4VC0^*(;6"Q?36M9/,MFMX(P4 M7:_)SG=D].P!QWB?]K'Q;X4^,\UQK_@SQ#H.CZ-X6EU*^\/O-!()E,\8^THR M,5;RU+;AG( -?1FC?&73/$?Q0C\&Z5;2WSKH<6NW.HQ,I@MXIG*P(W.2SA78 M8[*37B>H? G7_AGKFI?$KQSXH\3_ !NOY=&ET"XT32=!MHI'MY7ZPPQNJC S MNZELYXQBMS]A7X&:O\'/A1-=^*!=+XJUZ=9IH;YP\]E90H(+&T9@2,QP(F0. MC.PYQD@&(9OC1\4_CA\5M,\*?%JV\&Z+X4O[.UM-*G\,6U^DOF6<4QW2LRN M68^IYX/:JVA_MQ/HGAS3=(\5:'#>?$=M3OM)GT_3+J*VM)#:$"6X$L[JL:$, MN%9B";#Q5<07%]I<'ANUNW#16Z096 M>5BRDJF<@#!/0XK(\6?L"^%=5\)^&;/0]=N])\3:#+=3Q>(=2LX-4:\>Y.;@ MW4$R^7+N8!A]W:0,=P0"['^VYI6LV?@Q?#?A#5_$>K^);V]TU-,M)H ]KQTCP]J:Z1XBO93!MTNX,HCP0' MS( 64DH",,*[/P9^RM:^$-5^'&HCQ#]JN_"4E]/,T>EP6JZA) _BKX:_P"$EDB7QYK?]M27/V($V1\R)_+"[_G_ -3C M.5^]TXH Q/%7[=_@_P -^+M>TV/3KB_T7P]?C3-7UE+NWC6WN,@2*L+N)9!& M6 8JI (/7%/\2_MI1Z)JGCP6/P]U_6M!\%3QIK&MVDD(@CB>%)?,16<,^%?) M4#( ![BLW7OV"]'NOB9J/B?0_$PT33=:OQJFLZ1/H-E?_:;DX,CPSSHSP"0C M+*-PRQ(Q7>7/[,]O/X8^,>BKKSQ1?$2=YBZV@_XEX:TBMMH&_P#>8\K=_#UQ MCC- '(^"OVG/%/CK]H'QAX,A\)[O!5AHUEJ=KK5M*B7$,=Q#+()9-TAW!]BA M%5 RG.ZL?PC^U$/ GP-\$:K;Z/XA\86M]ILMX=0U[6+&*]94=@5'O'=UID4FB6FAZ]ICZ;#-%JT5M$T<+!V.Z C>2=I M.>E>?ZG_ ,$]+2[TSP;:VWCVYM'T/2FT:Z>71;6[6[MVD9RT23AQ;R_,1YB[ MN@XH ^F_AQX\TSXH^ ]!\6Z*TC:5K-G'>V_FKM<(XR P[$=#71UQ?P8^&T?P M>^%7A?P5#?MJD6AV,=DMX\7E&8*/O%V5XG/\ \G@1_P#8G-_Z5BM(=?0#U>ZZ&L:ZZULW70UC776JB!CW74UD M774_6M>ZZFLBZZGZUTQ*1D77]:QKKO6S=?UK&NN]=,0,BZZFL>Y[UL774UCW M/>NF(T8]UU-9%YU-:]UU-9%YU-=,1HQ[K[M8UST-;-U]VL:YZ&NF(S(NNAK' MNN];%UT-8]UWKIB,Q[KJ:Q[OH:V+KJ:Q[OH:Z8C,>[Z&LFY[UK7?0UDW/>NF M(S&N^I^M9%W6O=]3]:R+NNE 8USWK)NN]:USWK)NN]=,1HQKKJ:S6[UI774U MFMWKH10P]*8>E//2F'I4L!C=*C/6I&Z5&>M0Q##TJ-NE2'I4;=*AAT(V[TP] M*>W>F'I4,D;49Z5)49Z5DP(SUIE//6F5(##TIC=*>>E,;I6; C;K3#UI[=:8 M>M9L!A[U&W6I#WJ-NM9L2-7POXSU_P #:K'J7AW6K_0]0C.5N=/N'A\"^TR#!_X$I/O7Q8>M,/6N:K0I MUE:I&XFC]L_A'_P5&^#GQ&,%MK%Y<^"]1DP#'JR?N<^TJY'YXKZN\/\ B?1_ M%FGQWVBZI::K9R ,L]G,LJ$?4&OYFVZFO3O@=J7Q>L_$$"_"R7Q)_:+, D>B M>:P)R.H7C\Z\2ME=.UZI'*?T,>(?^06W7_6Q= #_RT7UK2KY,_9IN_P!I M^?P]$/C'9^'5THM%MD9RFK?ZQ<;EA!B/XX/K7UG7SM2'LYV5 MXI(,_MA1?]B/77]:QKKO7NK>$-'?K M8QG\3_C43>!M"?KIL1_%O\:U6(BN@7/GBZZFL>Y[U]--\/?#K]=+B/XM_C43 M?#/PP_72(3_P)O\ &MEBX+HQW/E*ZZFLB\ZFOK]OA5X3?KHL!_X$W^-1-\(/ M!S_>T*W/_ G_ ,:U6-@NC"Y\6W7W:QKGH:^YF^"W@E^OA^W/_ G_ /BJB;X& M>!'Z^'+8_P# W_\ BJV684UT8^8^![KH:Q[KO7Z%M\ _A^_7PS:G_@]9-UWK]H6_8V^##=? .GG_MI-_\ %U$W[%OP M3?K\/M./_;6;_P"+K99]AU]E_A_F/G1^)5UU-9K=Z_<)OV(_@<_7X=Z:?^VL MW_Q=9T?[$GP0;6[F!OASIGD+;Q.H\R?[Q:0'^/T5>]:KB'#_ ,DOP_S#G1^) M9Z4P]*_<3_AAKX%?]$YTW_O[/_\ '*3_ (89^!/_ $3C3/\ O[/_ /'*7^L. M'_DE^'^8>4/Y7^'^81O\--+\N,IL_>W'<<_QTO[ M;H?RO\/\PYT?A4>E,;I7[R?\,%? '_HFFE_]_9__ (Y2?\,$_ '_ *)GI?\ MW]G_ /CE2\ZH?RO\/\PYT?@PW6F'K7[T_P##!'P _P"B9Z7_ -_I_P#XY2?\ M,#?L_P#_ $3+2_\ O]/_ /'*AYS1_E?X?YASH_!0]ZC;K7[W_P## O[/_P#T M3+2_^_L__P R@:61C[*H)KZQ^#G_ 2T^,?Q+\F\U^VM? 6D/@[]7??= M,O\ LP)DC_@96OV$\ _";P;\+=.6Q\)>&=,T"W P196ZHS?[S?>;\2:ZRN&M MFTY:4HV]1.1\6?"'_@E/\)/ #P7?B3[7XWU&/!/V]O+ML_\ 7)>H^I-?7/A; MP5H'@C3TL?#^C6.C6B#:(K*!8QC\!S6U17C5*U2L[SE<@S?$/_(+;@'][%U( M'_+1?4BM*L[Q "VF, ,GS8N.?^>B^E:-8@%%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110!F^(_$6G^$]$N]7U6Y6TL+5-\LK G Z #DDG ' M)) KG_#_ ,19- ,_-AB5R.F13/BYX9U'Q1X4 MABTJ*.YOK+4+344M9GV)<>1,DAC+=!N"\$\9Q7*_$/\ X3#XG^ ->T*S\,W> M@/<01[GN[R)3=()HVFM08V)42PB6/?QC?6L8IK49Z'I?CGPWK=O?SZ=X@TJ_ M@T_=]LEM;V.1;;:,MYA5B$P BR-NPI/H<5XQX\^&.N?$*TNTTOPC'X5T^XTV/P]+9EXHY)K2>XB6XR(S@)' M!YNT9R2< 5W4OPGT^+XJ)K\/A?3!8Z5H)LM/"01KF1GR448^4!5 _P"!?6JY M(+J!O^+?BWH'@W4_#=O?WMK%9:T)I%U*6ZCCMH(8XMYE9V(&TDHHP>KBMF\\ M6VD8T.2REMM0M]5FV131W<84Q>4\AE3)_> !!PN>#GH#7A7AKX::]X)U/X>3 M7O@Q?$UGX<\+FQ7RYX?,MK^>16F,:.0H0+$%!!X# #(SA+3X2^,;&[:_CTN" M!;71]=N;'389U\N&^U"XB,<*G@#RH8I!N )G;%5[.'<#WC2/''ASQ!J4^G: M7K^EZEJ$""26TL[V.66-#T9D5B0/VTABGMH[^) MI(G +%64-E3A6.#V4GM7D'B/X#ZA8Z!X1T+P;#;:'/HWAS5+6+6(0J-%>2VB MP0DX^8Y=WE)]8P>N*70?A_>W_BWX?R1?#Z'POIWA>SN<3RRPLPG:$1JB["2R MG=V/X6 M91_$!D9R*Z2U\8Z!?:]<:';ZWIL^MVZ[YM-BNXVN8AZM&#N ^HKQ'PW\,_$U M]X#^'VA2Z0=!N=&EDN+ZYEEC?-VL#A)AM)W RRL>>>.E5K7X>>(SX0\*:-IG M@R+0=3\-,+Z35'FB+7-S'&V1&RDLQGD)WL^,AF)R33<(=&![EI_CSPSJVL?V M38^(M)O=5\OS?L-O?123[/[VP-NQ[XQ5'Q!\5/"7A7Q7I/AK5O$.G:?KFJY^ MR65S=1QR28( PI(.6) 4?Q'@9KS_ $3X,?\ "+Z+\)](TS2+6 :-J'VW5+V) M45XR+6;<<]6:29T!/<%LUNZ]H&K/\FZ#\.(ETFUL]2M=:DUS6;F()YB2O%<$C=U;,DR*<9R%Q7*_#WX*^)]$_LE= M5N/$MQJ.A33ZDKL=)6SO+S:_/F);"Y99"Y)WR9Z;B<5;A!W:8'T#+\0/"\$% M[/)XDTB.&R0/=2/?1!8%+%07.[Y065ADXY4CM4MKXV\.WVGM?VVOZ7<6*A"U MS%>1M& _W"6#8^;MZ]J\7T[X-7'@7P_\,TM_#<6N6^BPO+JVFQ-'OGOWB&;I MMY"R,)#(>3QNR.@KD?$7@[4K&(6=QX(MA=^,?'0U27P_'+&5>RM+97W,?N;F M-LI(/&Z7'?-"IP>S ^B;CXA:/<^$[_7M"U'3O$-O; JIL]0A,4DN<"+S=VQ6 M+$#D]2*OQ^+]#DU[^PO[9T\:[Y?FG2Q=QFY"_P![R\[L>^,5XI>?#/Q#XI\4 MW.KC04T'2]5U/15N-+:2/*06$LMR;B0(2I9Y/)CVC)VHN?08WA3X*^)+'58Q MJ\_B:ZDL-7FUM6@.D1VMU*LC21J)?LWVG#@B)LR [2P+8IE>,_#^ MNZG>:;IFNZ;J.HV9VW-I:7D0-NR8UE@ +QX[R9;/)8UW7B75?%UGJAZ!I^I6(L9)4GNM1 M,#M= _)$5$;80CJ^>/0UG**4K)B.IHKA+G7OB$BWWD>$](E,=I;26P;667S9 MV/[^-OW/RJ@^ZW.[T6II]:\=I/.(O#&E21+J4,,;-JS O9$#S9R/*X=3D"/^ M+'WA4\K [6O%9/\ D\*+_L3F_P#2L5V]GK/CF2^L4N?#.EPVCWMQ'![IIK!-3+0I*MW M^Y02^4"0_&6VC;GH:TA%Z^@'TO17 W&O_$9;*1X?".C270TF"=(FUIE4WY(\ MVW+>1Q&HSB7&6Q]T5/>:WX^CN-46V\+:3-#%/:)9.^KLIGB8#[2[CR3L,9R% M7G?ZK4BN,&L^.?M,2GPSI8@.K-;N_\ :K973]A(N,>5S(6P/*Z8.=W: MF6.M^/)9+(7?A?2K='6Z-RR:NSF(K_Q[A1Y0W>9QNZ;/]JERL#MJ*X$Z_P#$ M7^S#)_PB&C_;O[,\_P C^VFV?;<_ZC=Y/W,<^9C_ (#5B^UOQ[$]X+7PMI4Z MHMJ;5GH,[NU1VFN>/Y)M+%SX5TB&.6>[6]9-89C!$H_P!& M=!Y(WF0_>'&SU:CE8'<45P-OK_Q&>T1IO".C1W!TF:=HUUIF4:@"?*M\^1S& MPQF7&5S]TTMYK_Q%CL[Q[;PCH\UREE;26\3ZTRK)5]59&EMF4&>5E\H[61LA4R=P& M-HZT\;\9SY,O3/? MZV8M_"NCR!-1MEMR^L.OFQM#)Y['$7RE.=H^;=C^'MK) MK?CXZD(V\+:2+'^U'@,XU=B_V$#Y9]OD_P"L)ZQYP/[QI\K [>BO/[#Q!\2) M8-.:[\'Z+!+(EV;Q(];9Q"R_\>P0^0-XD_B/&S_:IJ^(/B4;<,?!VB";^QS< M%/[<; U'>0+;/D?ZK;@^;UR2-G&:.1_TP/0J*X*^U[XBQ6^IM:^$M&GFBBM& MLDDUID$\C$?:5<^2=@C&2IYWXZ+4\NM>/%U!HX_"^DO9_P!JQ0"8ZNP%'*P.VHKA+77?B&]Q;+<>$]'BA:[N8YG3668I;J#Y$@ M'DC+.RLWG\&Z)%=/8SRW$2:XS+%=!R(HE;R/F1EVDO@; M22,'&:.5_P!,#T.LJ +_ ,)1>G";OL<&2,;L;YNO?'7]?>N3G\0?$I8[HQ># MM%D=+&"6!6UQ@)+IB/.B)\CY409(?G=@?*,U4?7?B"GB75!!X5T>7:]E%"&U MAUWVK&7SIC^Z(#J> F/F[L.@.5_TP/3**XFTUOQ[)J-G'<>%M)BLGU"6*XF3 M5V9X[0#]W,J^2-SL>#'D8_O&J]CK_P 19;6T:Z\(Z-!.]KWW>3_ M *L#)$N,G^Z*EOM=^(,4VJBT\*:1/'%):"Q:36&0W"/G[27'DG88^-HYW^JT M%=(-O\ VQ]G,G]L-N&G;0?M./)_UN[(\K..,[Z;I^N_ M$*6:Q%YX4T>WBD:[%TT>LLYB"@_9BH\D;O,.T-TV9/WL49H1K;%1>AL+!N\C[A7DR8XZ;34]YKOQ"C6Z^S>$](F9+ M>V>$/K++YDS8^T(?W)VJG.UN=WHM'*P.ZHKBGUKQV+NZ1?"^E-;KJ4<,,AU9 M@TED5!>_P#]>N7M==^(,EO$T_A32(IC MIL\SHNL,P6]5L0P ^3RC#DR?P]-IK,_M_P"(D9UN2T\):-/?)86DT$$FM.BO M=L/WT+-Y1VH@SMD ^;^Z*.5@>FT5Q>H:UX[BU"_2S\,Z5<6<=[;1VLTFK,C3 M6S#]_*R^4=CH<[4R=WJM);ZUX\>Y19O#&E1P'5I8&D75F8C3PN8[C'D\R,W! MBZ#KN-'*P.UHKAK/7/B!(-,^T^%=)A,L-VU[LUAF\B13_HRI^Y&\2#[QXV>C M4PZ]\0_L,SCPEI'VM=*$\<7]LMM:^W(\<^;CVVT8K8^T$_N3MV<[>N_'\-3'6?&_]HM&/#6F?8AJ?DB;^ MU6WFRVY\_;Y7W]W'EY]]U'*P.QHKAK+7/B!+'8&Z\*:3 \CW8N@FL,XA52?L MQ7]R-WF<;AQLS_%4*Z_\1S;QL?"&C"8Z2\[I_;3874 V%M\^1S&5P?-Z@\;: M?*P._HK@KW7OB+':ZFUKX2T::>*WM'LHY-:9%GF9E%RCGR3L6-2Q5N=Y &%S M5BXUKQVE[,D/A?2I+8:G##'*VK,K-9%?FZ[A1RL#HO$04Z4V MX(1YL/W\8_UB^M:=>=ZMK7CIX8DF\,Z5#:MJKQ22KJS,R6BR#R)@HC&7?C,> M0%S]YNE36FO_ !%DL;![CPCH\-U)97$MU$FM,RPW*G]S$K>2-RN,%GP-OH:7 M*P.^HK@9]?\ B*L5R8O".C22+IL,T*MK3 />EL2P$^3PBCD2<[NFT5)>:[\0 MHS>?9O"FD3!+JV2W+ZPR^; P_?R-^Y.UD/W5YW>JT&Y:=$U MMG$1_JPN#YN,D\;>]37FO?$6-]4%MX2T:98A9_82^M,IN-X7[5O_6V_>WX'W6Q M1RL#N:*\[@\0_$QK"!YO!NAQW;:=+-+"NNL52\#8CA#>1RC+R9,#!XVGK3[K MQ!\24@G:#P?HLLRV-M)$CZVRA[IL>?$3Y!PB<[7_ (L#Y5S1R/\ I@>@T5PD MVN_$);J]6+PIH[VZ7\,5O(VLL&EM2/WLS#R?E=3P$R=W]X4L&N_$%[FR6;PI MI$<+WT\5RZZRS&*U5?W,JCR?F=CP4XV^IHY6!W5%<#9Z]\19(;%M)6#^UWMRXU=B?[." I*R?\ )X47_8G-_P"E8KVJO%9/^3PHO^Q. M;_TK%:0Z^@'M5%%%9@%%%% !1110 4444 %%%% !1110 4444 96M_\ 'WHW M3_C\[_\ 7&3V_P *U:RM:_X^]&_Z_/3_ *8R5JT %%%% !1110 4444 %9<' M_(S7G3_CS@^OWY?;^M:E9D'_ ",UY_UZ0=O]N6@#3HHHH **** "BBB@ HHH MH **** "LVP_Y"NI=.L?_H/TK2K.L/\ D*ZE]8^W^S0!HT444 %%%% !1110 M 4444 %%%% &;XA_Y!;=/];%U_ZZ+[&M*LWQ#_R"V_ZZQ=L_\M%K2H **** M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#&\4^,_#_@:PBOO$>NZ M;X?LI91!'1VT;R%68(&<@%B%8XZX4GM3O#/C#0?&MBU[X>UO3M>LU?RV MN-,NX[F,-_=+(2,^U?,?_!1:SCU#P;\)+>:3PY%')\0;-6?Q="LNE ?8+_\ MX^$8@%/8U\Y^%-9O/A+K7[0LOA&_\(R>)#X"76+34/A9 D6CV1MRX :%0RB< M[B^3G(#<<4 ?I_17QVO[2S>+/B/X%TGPMXZMM7AE\ 7VJ:I!ITT4P%VL,9C> M0J#M<$M\O'N*X[X=^,?BAI'A']G3Q+JWQ/U?7G^)*QV6J6<]M;)';B:T:5)8 M"L>1(F%Y;<&.3CM0!]ZT5^;O[/\ X_M?@[^Q?K=VWQ"UK^V4UZYL9=*LI[+[ M3I,CZI.BG;(F(?-SN9YQZAHGBG0M/TO M7)I;.]N8H;N6,2H\D"^3*!\P! Z$CJ* /T@HKX7^*OQ<^*7[/%_\8-!TWQ-? M^/[C3/"%MXATN?5;6)KBSD>Z$$YQ$BAD5"TN".-G)QFO,M9^(GC[XH?!WXMZ M,WB^^UGPXG@JZU.::35--O+Q9TC8[ +53M@D7<&5@&7'#4 ?IK17P!XK^-%O MX)^$?PKT'0/BCKVIW=[I33G4=-U/2X45DABS#)<3)Y8,98 1 ;R.M86B_M,^ M,_B!X(_9HO=?^)[?#VV\5G7;;7-8A2W1;@VERT$+%I%*1NPC!W#Y06/&,4 ? MHY17SY^R/\1]:\<6'Q T^[\1_P#"<:3X>UY].TCQ2R(O]HP^4CD%HP$V)A F=V";UW M?)F@#WCQ)\6O W@[4CIVO^,_#^AZ@$#FTU+5(+>4*>C;'<'!]<5L>'/%6B^, M=-&HZ!K%AKFGEB@N]-N4N(BPZC>A(R/3-?+O_!0/X8^#M5\!:'XAOO"6A7NO MS>*=$LI-4N=,ADNG@:[16B:5E+%"I(*DX()&*T/%'AJ^\/\ [2G@7X<^ =67 MX:>"9-&O-7O=)\,Z=:V\5S*DT8'R^7A2%UU#G-3^,/&.L^#O$/QZU+1KYK&^D\=> M%K=IE1')CDMK-9%PP(Y4D=,\\4 ?>&>*P/!WCW0/']K?7/A_4HM3@L;R6PN' MB!Q'/&<.AR!R#7RII'Q6O/$_Q!\477B7XW_\*]U31_%"Z59^#C#;[)K<2(L8 M:%U\V8S!N'0@+N'H:\N^)FKZKXSMO &M>(O'-_X>LM-^+M]IIU.)K>".RA D M$4A=XRJE<;0S<88YSUH ^^?B/K=]X:^'_B35M+A$^HV.G3W-O&5W!I$C++QW MY'2OE^&Z\1^&=7U/Q!!J6MSVUK'I]SI_B.YOGEM?$!N$MF>-8LF+:3-(%"*I M&P8+8;&9\0_C9XV^'GC3Q#\--/\ $MSKNK>-S8/X%UEECD,,4H"73!D4*XB" MM,#C'S#J*^D?"O[/_@3PEJMIJUEX>MEU2W8RI-\WE1SM_K)HX,^5$[DL6:-% M)+'UH ]#B8O&C,-K$ D>E.HHH *\(UJ9X/VMHGC8JW_"($9'_7U7N]>"Z_\ M\G:1?]B@?_2JM(=?0#TZ35;L=)V'Y54DUJ^'2Y?]/\*):I2=*(G932?0DDU_ M4!TNW_3_ JM)XCU->EY(/P'^%0R53FK=)'I4X0?1%F3Q1JJ]+Z3\A_A563Q M9K"]+^4?@/\ "JLU4YJV48]CT:=*F_LK[B[)XQUH=-1E'X+_ (55D\;:Z.FI M2C\%_P *H2]ZIR]#6RA'L>E3H4?Y%]R-*3QWKX/&J3?DO^%59?'_ (B7IJTW MY+_A67+UJI-WK=0AV1Z,,-0?_+M?FKS_DO^%57^)'B<#C69_R7 M_"L>:JC'_ M ,!7^1TDOQ?\9KG'B&Z_[Y3_ .)JM)\8_&HZ>(KH?\!3_P")KF)NAJI)6ZHT MOY5]R/2IY;@G_P N(?\ @*_R.HD^-'C@9QXDNQ_P%/\ XFJTOQM\=+T\2W?_ M 'S'_P#$URDG>JME0I?R+[D>C3RS /?#P_P# 8_Y'6R?''QZ.GB>\_P"^ M8_\ XFJTGQV\?CIXHO!_P&/_ .)KCY>]5)JWCAZ/\B^Y'I4\JR][X>'_ (!' M_([&3X]_$(=/%5X/^ Q__$U3?X\?$!)WF7Q3>"5E"%]L>2 20/N^Y_.N-E[U M4E[ULL/1_D7W(]"&49;;_=J?_@$?\CN)/VA/B,.GBV]_[YC_ /B:JO\ M$?$ MD=/%U]_WS'_\37#2]:J24?5J/\B^Y&4LHR[_ *!H?^ 1_P CO9/VC/B6.GC" M^_[YC_\ B*K/^TA\31T\8W__ 'Q%_P#$5P,O>JDG2I^KT?Y%]R.2>59?_P! M\/\ P"/^1Z!)^TK\3QT\9W__ 'Q%_P#$56D_:8^*()QXTU#_ +XB_P#B*\]E MJK+U-+ZO1_D7W(Y997EZ_P"8>'_@,?\ (]$D_:<^*@Z>-M0_[XB_^(JL_P"U M#\5@./&^H?\ ?$7_ ,17G,E5).E+ZO1_D7W(Y)99@/\ GQ#_ ,!C_D>DR?M2 M_%@=/'&H_P#?$7_Q%5G_ &J?BT.GCK4?^^(O_B*\TDZ55DI?5Z/\B^Y')++< M"O\ EQ#_ ,!C_D>F2?M7?%T=/'>I?]\0_P#Q%5#^U7\6XI)'3QUJ*N^-S!(> M<=/X*\REJK+U-3]7H_R+[DJO^U]\ M9@./B#J?_?$/_P 15:3]L+XT#I\0]4_[XA_^-UY1)T-59>II?5Z/\B^Y')+ MX3_GU'_P%?Y'K$G[8_QJ'3XB:I_WQ#_\;JN_[9?QL'3XBZK_ -^X?_C=>1RU M5DZ?C4^PI?R+[D7X?\ QN\!_%*-6\+>*],UB0C/ MV>"X F ]XSAA^5=Q7\[23RVLZ30R/#-&P9)(V*LI'0@CD&O=/A?^VO\ &WP) M<6]CI7B:^\1Q#"1:?J<9OBWHJD_/^ ->35RIK6G+[SY?$,?A+>^'K=Y(O^)HDWE+_ *Q> M3$^'%?4=>)4ING+ED?*U:4J,N25K^3O^04445F8A1110 4444 %%%% !1110 M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110!A^+_ OAOX@:=%I_B?0-,\16$4PN([75;..YB24* MRAPK@@,%=AGKAB.]1>%?AWX5\"V4]GX<\-:1H%I.FPQ$B3B0951][ SZ]ZOQ>!O#D%EHM MG'H.F1VFB%3I<"VD82QVKM7R5QB/"\#;C XK<=O[S_@6:2S^%G@S3]/EL+7PEHEM8RM"\EM%IT*QNT)S"2H7 M!*'[O]WMBNHHH SCXF!?.>'.?++XR4SSMSBL_P . M_#KPKX02]30O#6D:,MZ2;I=/L8H!.3U+[5&[\:Z&B@#CD^#?@*/2K;3$\$^' METVVN#>068TN 113GDRJFW ?@?,!FN-\7?LQ>%_%/CCP'JZVFFV6@^%H]1C_ M .$;33(VM+L7@&_*Y"K\VYS\IW%CG'6O8Z* *&AZ#IGAG3(--TC3[72M.@7; M%:64*PQ1CT55 _"K]%% &?K7A_2_$EK':ZMIUIJ=M'*DZ0WD*RHLB'-?-/X>TN M9KZ>*ZNS)9QL;B:(*(I'R/F9 JA6/(VC'2MZB@#G[_X?>%]4\1VOB"\\.:3= MZ]:C%OJD]E&]S#_NR%=R_@:;>?#KPIJ.B7FC77AK2+G2+V=KFYL)K&)H)Y6. M6D="NUF)Y)(S7144 >+^&_V=)K'XPP^.-?\ %3>(;;2(9K;PSH@TJWM(-%AE MQN16C&92% 52V,#BO:*** "BBB@ KP77_P#D[2+_ +% _P#I57O5>'7\T,/[ M7T)GQM/@YNHS_P O0K2'7T [J6J4G2NO;4-,'7;_ -^S_A4;:KI Z[/^_1_P MI)V.F$FNAQ,E4YJ[UM8T0=0G_?H_X5&VMZ .HC_[\G_"M5)]CNA6DOL,\ZF- M4Y37IK:_X<'41_\ ?@_X5$WB+PP.HC_\!V_PK55'_*=L,5-?\NF>62GK5.7H M:];;Q-X4'41?^ S?X5$WBGP@.HB_\!6_^)K559?RL[88ZHO^7,OZ^1X[*>:I MS'K7M3>+?!@ZB'_P%;_XFHW\8>"!]X0_^ C?_$UJJTOY&=T,QK+_ )AY?=_P M#PZ8BJ4AKWIO&?@0=5@_\ V_^)J)O&_@ =5@_P# )_\ XFM%B)?R,[H9K77_ M #"S^[_@'S_*>:IS$9-?1#>._AX.JV__ ( O_P#$U$WC[X<#JMO_ . +_P#Q M-:K$S_Y]L[89SB%_S!S^Y_Y'SC,1CK5.4CUKZ)U/Q[\.WGT\Q) 42XW2XL7& M$\MQSP,\E>.?IW%EOB+\,!U6V_\ !>__ ,16JQ4U_P NF=L,]Q*_Y@JGW/\ MR/F&8C!YJG(1ZU]2M\2?A8.JVW_@N?\ ^(J-OB9\*!U2U_\ !:__ ,16JQE3 M_GU([8<08I?\P%3[G_D?*4A'/-4YB/6OK5OB?\)!U2U_\%LG_P 143?%3X/C MJEI_X+)/_B*U6-J?\^9'=#B3&+_F75?N?^1\ARD<\U4F(]:^PV^*WP;'5+3_ M ,%&?=Q ML]"O8?4XXT685?\ GQ+^OD=D>*\OVG>4VW9_Q(9SVY_P"6?]!2 M^O5?^?$OZ^1S2S_%?] -3[G_ )'YORL,'D55D8>HK],&_:+_ &8!UCTW_P ) M^;_XU4;?M'?LN#K%IO\ X3T__P :I?7JG_/F7]?(YY9[B7_S!5/N?^1^9$C# M'455E89/(_.OT];]I']ED=8M,_\ "=G_ /C-1M^TI^RJ.L6F?^$[/_\ &:7U MZI_SYE_7R.>6=8A_\P<_N?\ D?EU*P]1561ACJ.OK7ZEM^TO^RB.L6E_^$Y/ M_P#&:C/[37[)PZQ:7_X3<_\ \9I?7:G_ #YE_7R.>6<8A_\ ,)/[G_D?F-H' M@[7?&%XMKH>CWNK7#!M:T%%/_ "ZVVRWE'UC(##\17JZL'4,I#*>A M'>O.K9G53Y8QY?4^=Q>?XE-PA3Y/7?\ 0^*?AM_P2S^'WA\Q7/C#6-2\672X M)MHF^R6N?0A?G;_OH?2OJ/P)\&/ WPQMEA\+^%=+T4 ;3);6RB1O]YSEC^)K MM**\BIB*M7XY-GS%?&8C$O\ >S;_ "^XS/$*AM*8%=P\V+CC_GHOJ#_+\NM: M=9OB$9TMN,_O8N,X_P"6B^X_G^?2M*NZ\<\W\,?VK[;Q)JGC'1_'OA>X^%^L^%;*'4]134]2 MM;RT2TEW;9?M,#L@^Z<9'[L]#\!6_P;\->*/"4F MD0>'+K6!J!NM2R3'=0TUL@!>91W0 @D].:Y?P]^TE\*O%EVUKHWQ#\-ZG<+:F],5MJ43L( NX MR8!Z!>3Z#K7SQX9\$?%[QOX_\*ZGXD^'D?A/3= \&7_A_)U:&Z>XN7BC57 7 M&U&*\=2.^*F\+?LV>(M ^'/[*UG;>%K:PUCP=<6\OB$1-"KVV;1UGW,#\^96 MYVDY)SS0![%\+/VO_A;\6?A_J'C'3_$MKI6E:;*\5^NKW$,,MGB5XD:4*[!5 MD,99#GYE(Z'BNKMOCW\-[SP9/XNA\)_$GA[4X;/4+^UFDD@@D0W/FM M$$CW!5YPHSQC=0!]M^$OC-X#\>:=JE_X=\8:+K-EI>3?7%G?1R):@ DF0@_* M, G)XXKDO$?[6?PJT#X=^(_&D'C+2]=TG08C)=)I%Y#/,S8)6-%+@%WQA02 M3WKQ;]H+]E/Q/\3_ !S\4K?PQ;VWA[2O$O@FTTR"_C98XI;V"\641.B_-@QK MLW;2 '/7I7&^$_V6OB%XU\/?$;_A)-'U'1-* /J>V_:A^%#]-TC4-;\;Z#I=AK$+7&G7-U?QI'=QJ 6:)B<. &7IZBO MEOQAX3^.WB?P+\.[73? \WAJ+3+5](U/2K'4K W;$1QHESYTD;H(6PY9%&[@ M=:\JT/X=>.O@[#^REX6,I+@H&$;HR] . M!QC@ _1KPAXUT#X@:'#K/AK6;'7M*F)$=YI\ZS1,1U&Y21D>E2V/BK1]3U[4 M]$M-2MKC5],6)[VRCE!EMUD!,9=>J[@"1GKBO'/V6?AKXE\(0>/]>\3Z1:^% M;GQ?KC:K%X;L9UE33H_)2/!=0%,C%"S;>,FLCX;?L9:;\/?CUKWQ%7Q7XCOD MNVADL["?5[B10XCD607 9BLR?O,HI&$QQ0!Z5=_&*'3/CG9?#>_TN6UDU+2G MU/3M4,H,5T8W"RP[ZOKVHF".[FD3?+!:JJG?,@(&"<%LCC%3_M:_#?Q5XH\,^'?%OP\M8[SXB># M=4BU/2K:1UC6[C8^7<6S,Q "O&S9R?X?6O/)/V:?$V@_"#X.Z+:6@U3Q#I_B MNV\2>)[KS44O<2,TEU,22-V&;:,9.%% 'T#IWQV^'6K^,I/"5EXWT*Z\31R- M"VE17\;7 D7[R; <[AW'452UW]H_X6>&-?N]#U;X@^'-/UBT8)/97&HQ++$Q MQ\K+G(;D<=>:^/)_@-\>O$7Q:T.\\1:2UQ9:-XR.KF]M+RRBT][5IG(>"!4$ MRN$8%R[Y)+?>S7FGQ&UB3P+\(O%7PB32_"'BN[?Q4\\?BFWUZUEO;F5[]6"M M:#-P;IN!0!^CLGQQ^'L/B>;PY)XTT./7H0[2Z:U]&)T"1^:Y*9R ( M_F)Z (U2/P_J5^L>#7GW[+?P9^+>B?' MK3?&7CO2+VQLXO#I2*DO0U3EZ&KDO0U3EZ&MX MGITRG+U-5)ZMR]352>NB)ZE,IS53EZ&KDU4Y>AK9'J4RG+U-4YNM7)>IJG+U MK='ITRI-5.7O5R:JNB)Z=,IS54E[U;FJI+WK>)ZM,IR]35*:KLO4U2FK: M)Z=(J2U4E_I5N6JDO]*Z(GITRE)TJI)5N3I522MD>C'8J2]ZJ25;E[U4DH,9 M%67H:J25;EZ&JDE2<]5)>E6Y>]5)>E(XY%27H M:JR]ZM2]#567O4G),J2=:J2]ZMR=:J2]ZDXYE26JDO>K](XI%62JDO> MK]2I_#[]KC MXK_"^2,:/XNO);5"/]#OS]HA/MA\UY3+WJI*< DUE.$9JTE<\ZM2IUERU(IK MS/O[X>_\%8+RU\J#QOX.2[3H]WHTVQ_KY;\'Z;A7U3\,_P!M[X-_%,11:?XO MM]+U!_\ F'ZT#9S ^@+_ "-_P%C7Y#> O@=X^^*LJ#PKX3U36(F./M,5N1 / MK(V%_6OI_P"&_P#P2J\<^(3%<>,==L/#5L>6MK;_ $F?Z9&%!_$UX>)PN#CO M+E?]=#XS'8#+:=[RY'Y._P"&I^G.K7EO?Z+YUM/%<1-)$5>-PRD>8O<9K8KY MX^$?[(_AWX Z6)-,U[7]2G#Q!DN[Y_LY_>+SY(^7]*^AZ^>FHJ5H.Z/BZL81 ME:G*Z]+!11169D%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444 M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 M 4444 %%%% !1110 5FWOAO2-2UC3]6N]+LKK5=/$@L[Z:W1Y[8. '$;D;DW M ':1G'-:5% !1110 45Y?I?[1OA#6O%"Z%8KJ]S/8?:(]+F-L)58JP,N MW: """9Y7D^:V[=G;C&WUXH ]LKEC\*_!1\7#Q M6?"&@GQ0/^8W_9D'VW_O_MW_ *UTZ.LB*ZG*L,@CN*I:]K=IX:T2_P!6U"0Q M6-C ]Q/( 3M102QP.O H OT5P?@[XT^&_'NNZ?I>C->W#WVC)KUOJO*EC;/<3'[B>Y6))GMMX\V-'&5+)U7/N*MS31VT,DLKK' M%&I=W8X"@#))H ?17B71DL/#E_>Z48C=17*SPK/<6XS^_CMV82,F% M=@0,D*2!7KVB:S9^(M(L]4T^=;FQO(EGAE7HZ,,@T 7J\(UBTDN_VO+=8\9' M@]CS_P!?0KW>O%9/^3PHO^Q.;_TK%:0Z^@'HLGA^Z;IL_.J[^%[QNGE_]]5U MM%2FT:JI*.QQ3^$;YNGE_P#?55Y/!6H-T\K_ +ZKO:*I3:-EBJD=CSJ3P'J3 M=/*_[[JO)\/-4;IY/_?=>FT52K21M''UH[6/*W^&VK-T,/\ WW5=_A?K#=X/ M^^Z].W)_X#_P3 MXN?]DGQNW0Z?_P"!'_UJH?\ #)_C66^EM VG^;'$DI_TCC#%@.W^P:^X*S(2 M?^$EO!DX^R0<C:9_X$_P#UJ@?]AWXB,.&TO_P*_P#K5^@=%+^U\3Y?<9OCC-G_ M "_^ _\ !/SU?]A?XCMG#:5_X%?_ %J@?]A#XD-_%I7_ (%?_6K]$:*/[6Q/ ME]QF^-%7 MTC?%C=_IGJ,CM7Z:5G6!)U34ADD Q\'/'R_7_"C^U<1Y?<9OB[,G_+]W_!/S M;D_X)X_%)NC:/_X&?_6J!_\ @G7\5&Z-HW_@9_\ 6K]/**7]JXCR^XS?%>8O M^7[O^"?EX_\ P3F^*S=&T;_P,_\ L:@?_@F_\5VZ-HO_ (&?_8U^I5%']JXC MR^XS?%&/?\OW?\$_*Z3_ ()L_%E_XM%_\#?_ +&H'_X)I_%LCAM$_P# W_[& MOU8HI?VIB/+[C-\28Y_R_=_P3\[?AY_P2NN9VCN/&WBQ8$ZM9Z1%N;Z&1N!^ M -?3OP[_ &)O@_\ #AH9K7PE;:M?1$%;O6/]*8$=PK?*#]%KW6BN6IC*]7XI M?H>7B,TQF)^.H[=EI^1'!!%:PI%#&D42#:J1J%51Z #I4E%%<1Y1F^(B!I;9 M( \V+J/^FBUI5F^("1I;$$C][%R,_P#/1?0BM*@ HHHH **** "BBB@ HHHH M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ MHHHH **** "BBB@ HHHH **** "BO'/VFOC9JOP2T#PA<:+9:/>7_B'Q'!H* MOKU\UG9V_F6]Q+YLDJJQ 'D =#]ZN-^&_P"U\+K4?B'9_$"TT;2[3P5I\.J7 MWB#PM?RZMII@D#';N6(/YBA3(3"X#*=K$,<\ UPW@_P#;2^#?CV\M;70O&!OIKNT>\M0= M*O8UN8T7>XB9X0)) _@]^VWX ^*WPMU3QO-_:'A^S MTJ=X;Z"YTZ[D,?[^2*(HRP@3%_+SMBW,NX*P!KI8OVM_A/+\/-3\60#!SG'- 'K]%>6>#OVH?A?X[TOQ M'J.E>+;=;7P[$+C56U&WGL&M(2"1*R7"(WED X< J<<$UR'B7]N3X6Z9\-?% M?BW1]6N->;0+0W3Z6NG7=M<39!\LA9(0PC8C'G;3&.I;% 'T%17BHZ?I^LQEH(?[#U":<,J@R Q) 7VJ3C?M"GJ"15[Q1^UK\)O! M^C>%=5U+Q?%_9_BF&6?19[.RN;L7JQXWA!#&YW#$M8CU?3!*T$D@C>&2&1?O1R1R*KQL,C*NH//2I_#7Q$ M\.^,M1UW3]&U);R\T2Z-C?Q>6Z>5-L5]H+* XVNIW+D<]M MUW:[JA_\FY*XW_A%M+'[:P7^Q[/[-_PAI?'V5-F_[4.>F,UV?[,(_P"+7.?7 M6=3/_DY+7JOV2#[3]H\F/[1MV>;M&_;UQGKCVH _/S0-+\2WOP2_:5\9Q:YX MGO?$5CXPUO3=.MUOIFBM+2*ZC;$$(. =N>0"< 8YSJ>-OC;8?%3XNI9^$_$ M,^MZ##\+-4-\MJSFV-WF/ ;L95!Y'4;AZU]VP6-M:I*D-O%"LKM)(L:!0['J MQQU)[FLZ*TT"SU!-.B@TZ"^>%Y5M$2-9#$2 [!>NW.T$],XS0!^=MIXO^(GA MG1+2'P3-J)U"U^!]O=VMI"K.(YO[2B269(SP95A,A7@G@<'I70?$'Q%X+T?] MFWXGWGPL^)OB_P 0ZZOAVTGNH[C4+BY2&4W$8,N]US%.&;G]K+XA:;JNN:IH.O\ BKPQ:#1YFU:YC,]Q+%*)6B7?M?9@,%P0 MN. ,UK_LZ^-O$_[2GBW3-#\4&_TZ/X=:/B:M8 M/:6&B:AJVF62:58>+)M2FA*6BQS1(TMD(BK2".X?(60*S*I&WI7T#X$\(VW@ M+P=H_AZSEDGM]-MDMUEEQN? Y8XXR3D_C6]10 5XC=W"6W[7T3R':O\ PAQ& M<9_Y>Z]NKP77_P#D[2+_ +% _P#I56D.OH![6=;LUZRG_ODTP^(; =9C_P!\ M'_"N:EJE)TI)7.B%-2W.O/B?3EZSG_OAO\*8?%NEKUN#_P!^V_PKB)*IS5HJ M:9VPPL);MG?GQGI*];D_]^V_PIA\-_P!^7_PKR:7O5.7H:U6'@SLAE-"6 M[?X?Y'L1^)?AY>MZW_?E_P#"F'XH>'%ZWS?]^7_PKQ27K52;O6BPL'U9VPR/ M#2WE+[U_D>YM\5O#*];]O^_$G_Q-1GXN>%AUU!O^_$G_ ,37@DU4Y.E:+!TW MU9V0X=PDMY2^]?Y'T(WQB\*+UU%O_ >3_P")IC?&CPBO74G_ / >3_XFOG*7 MK5.;J:U6 I/J_P"OD=L.%\%+>4OO7^1]$:I\8O"=Q<:"5ZZJ_\ X"R__$TP_'_P.O75G_\ 67_ .)KY/FZ&JDE M:K+*+ZO\/\CLAP7ETMYS^]?_ ")]<']H7P(.NL/_ . DW_Q-1M^T7X"7KK+_ M /@)-_\ $U\?R=ZIS=ZT654'U?X?Y';#@7+);SG]\?\ Y$^R3^TC\/UZZS)_ MX!S?_$4P_M+_ \7KKM7-RVN2>4]O%&/]#F^\K2$\ M>7G^(=_P'?XHE[U4E[UHLFP_=_>O\CKCXNO2 M?^ ,_P#\13#^U;\,AUU^3_P!G_\ B*^"Y>M5)*/[&P_=_>O\B)>'>4K_ )>5 M/OC_ /(GWZ?VLOA@O77Y/_ "?_XBHS^UQ\+AU\02_P#@!II?V/A^[^]?Y&$N LK7VY_?'_ .1/T;/[9'PG'7Q' M+_X+[C_XW3#^V=\)%Z^))?\ P77/_P ;K\W)*J2=*7]CX?N_P_R.=\#9:OMS M^^/_ ,B?I6?VT_A$O7Q++_X+KG_XW3#^VQ\(!U\32_\ @MN?_C=?F9)TJK)2 M_LC#]W^'^1SRX*RY?;G]Z_\ D3].C^V]\'1U\3R_^"VY_P#C=4;;]MGX/07U MY*_BB79*5V_\2VY[#!_Y9?U-?F/+567J:7]D8?N_P_R,)<&Y>OMS^]?_ ")^ MI9_;H^#*]?%,W_@LNO\ XW3#^W;\%AU\53?^"RZ_^-U^5DO0U5DI?V30[O\ M#_(PEPC@%]J?WK_Y$_5H_MY?!0=?%O\ (_6D_M_? ]>OBV;_ ,%=W_\ M&Z:?^"@?P-'7Q=-_X*KO_P"-5^1DM59.GXU/]E4.[_#_ ".>7#&"7VI?>O\ M(_;OP!^TI\,_B<@_X1[QAIUW,?\ EWED\F8?6-\,/RKTJ.194#(P=3T93D&O MY\2[12!T8HZ\AE."/H:])\!?M3?%'X821_V'XOOT@0_\>MT_GPGV*OFN6KE/ M6G+[SR<1PU;6A4^3_P U_D?N/17YJ?#S_@J[K-AY4'C7PE;ZF@P'NM*E\F3Z M[&RI^F17U-\,OV\_@S\31%##XIC\/ZB__+CKR?97!] YS&WX,:\JI@Z]+XH_ M=J?-5\LQ>'^.%UW6I[GXA_Y!;=1^]BZ#/_+1?8_R_+K6E6)J6IVFJ:']HL[J M*[@:2(K+;R*ZD>8O0@X_6MNN(\L**** "BBB@ HHHH **** "BBB@ HHHH * M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH MHH **** "BBB@#P;]K[X1>)?B[X8\#1^&-'T#Q!=:!XJM];N-+\22E+.Z@2U MNHF1L(^3NG3@CH#7D>D_L?>,_%W_ L^?6=/\)_#2W\4^%)?#L.A>#][V;3D MEDNYAL0%E^[@+G:3S7VK10!\A^%_@?\ &77?&_AS6/&<'A6PL]"\)WWAR"'2 M;R:5Y9)(T1)F+H, [.5'W?>M;1_V9O%&F_#W]FC11_9<=[\.[BVEUEHYB%;9 M:-%)Y)V?.2[9YVYY-?4U% 'QGI'[./QH\,? 3Q+\+=&U;1]-MK;5);W1=:LM M0F@NKZ":]DN9H9B$S;DK)L#H6/>N9\)?L4?$33_ ?Q!TS4Y]-N+WQ)K^@:K$ MEUK%Q?E(K216G22>5"[G"_+G@].!7WE10!\J_'_]DC6?C?XY^(M?H_28&: /$_@!\&M<\)6? MC[5?'+:=)KOCC5&U'4-.TEG^QVR^2D(B1C@L2J99\ DGVJG\%_V-/AW\"_&N MO>*M TI8]3O;AY+-_,E_T&%HU1H5RY# [2![N_N7GN;B#47VPC>Q+,+=RXR2G!_*OFO7OV8_&.J_M4V7Q$@^(>KVOA^/2+BV,4;P^;"SW44HM$4Q M']P50DDG=D#WKCT\1+\!/'?CB!KBP?7M!\!:()?%7B*XNKFXOIC-.G[]MS%\ MLN0%7<2V,XP!B>%/V[/%EOX:^(MMKNBV.H^)/#_]E?V=6Y# \=* /N.BODB/X]?&#P)\5M1\%>.8?"EW)#X)OO%$%WHJ3 /) M$X5$97;( .X'^]C((K+'[2OQ4L_@7X0\5:S>^$-*\1>+F2;2[&"PO;UQ!Y.] M@(8@7D?/)Q@*#WH ^RZ*\6_9+^.FH?M ?"VXUW5].CTW5].U:ZT:\2)'C222 M KF14D = P8':PR#D5[30 4444 %>"Z__P G:1?]B@?_ $JKWJO"M6MGNOVN M(HTQN_X0\GG_ *^ZTAU] .^EZ52DZ5T#Z!=-TV?G59_#%XW0Q_\ ?5$6CKIR M2W9SLM4YJZ=_"-\W3R_^^JKR>"]0;IY7_?5;*2[GH4ZU-;LY6:JYZ%/$T5O)'&R]ZIR]#7;O\-]6;IY/_?=5Y/A MAK#=#!_WW6RJ0[GHT\9AUO-'"2]:J3=Z[Z3X4ZTQX-O_ -_*KR?"+7&Z&W_[ M^?\ UJU5:GW/0AC\*MZB^\\]FJG)TKT>3X-Z\W0VW_?S_P"M59_@IX@;H;7_ M +^__6K95Z?\QZ$,SP:WJK[SS67K5.;J:]/?X&^(VZ&U_P"_O_UJKR? ?Q*W M0VG_ ']_^M6RQ%+^9'H0S; +>M'[SRV;I5.6O4+SX%^(X7@1S:AIY/+3$O?: M6]/1339/V>?%+=#9_P#?[_ZU:QQ-'^9'H4\YRY;UX_>>2S=#522O7I/V<_%; M#@V7_?[_ .M5=_V;/%K=[+_O]_\ 6K=8JA_.CT:>>Y8M\1'[SQV3O5.;O7LS M_LR^+VS@V/\ W_\ _K57D_9>\8MT-C_W_P#_ *U;+%X?^='H4^(,J6^(C]YX MK+WJI-7MK_LK^,VZ&P_[_P#_ -:H'_91\:MT.G_^!'_UJV6-P_\ .CT*?$>4 M+?$P^\\,E[U4E[U[L_[)/C=NAT__ ,"/_K52/[)OC:2[DM@VG^8B+(?W_&&+ M =O]DUJL=AO^?B.^/$V3)?[U#[SPN7K522O?7_8]\=L?O:=_X$?_ %J@?]C; MQZW1M-_\"?\ ZU'U[#?\_$92XER9_P#,5#[SY_E[U4DZ5]"/^QCX_;OIO_@3 M_P#6J!_V*OB"W1M,_P# G_ZU+Z]AO^?B.6?$>4/_ )B8?>?.\M59>IKZ*?\ M8D^(;=&TS_P)_P#K5"_[#WQ$;HVE_P#@5_\ 6J?KN&_Y^(YI<0Y2_P#F)C]Y M\X254DZ5])O^PQ\1FZ-I7_@5_P#6JN_["/Q(;^+2O_ K_P"M1]=PW_/Q'++/ M\J_Z"(_>?-,G2JLE?3+_ +!?Q*;^+2?_ +_ /K5 _[ OQ,/1M)_\"__ *U3 M]=PW\Z.66>Y8_P#F(C]Y\PRU5EZFOJ%_^"?WQ.;HVD?^!?\ ]:JG_# /Q-FF MEC5](+1XW?Z7Z_A2^NX?^='++.\M_P"?\?O/EZ7H:JR5]4/_ ,$\OBDW1M'_ M / S_P"M4#_\$[/BHW\6C?\ @9_]C4O&8?\ G1RRSG+G_P OX_>?*II2BHK[W_7R/F/X/_L4^'?@ M):I>6/B7Q%J5XDL1*-?-%;L?,7K$ORG\:^G*S?$(SI;#&?WL7'_;1:TJ\F=2 M55\TW=GSM6M.M+GJ.["BBBLS$**** "BBB@ HHHH **** "BBB@ HHHH *** M* "BBB@ HHHH **** "BBB@ HHHH **** "BBD9E098A1ZDT +12*P<94@CU M!I: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "FR#,;?0 MTZB@#YT_9P^+GAW1]!LO!5^]]9^(VU6_C%M/ITZJ6:[F9?G*;<$$'.<=>,_V M?O _Q U/Q#?Z[I3WMSKVGV^FWS?:9$W0P2/)%LVL-C*SL0ZX/3GBN UC]D+P MCX>\'>-8O"N@QZ[KOB.Q@LKP>+M8O;N.\6%V:,22L[R*5WMAE.1A?05]"44 M?'GP(_8^U/2OB?K7B_QAI4&B65SX;E\-QZ5#XBO-9N+A)7!DEDNI\,JA%")& MO !SU'/M_B+]F;P%XE\(>%?#EQ8W]K:>%E":/=:=J=Q:7EFNS80MQ$ZR8*\' MYN>]>J44 <5\)_@]X6^"?A^\T3PC8RV&G7=_-J4T]:M9 M6MG%WHW*C_3?XO\ KC)TY'/Y_3N-6@ HHHH **** "BBB@ K+@Q_PDU[PN?L M<'/?[\U:E9_/]!0!HT444 %%% M% !1110 4444 %%%% &;XA_Y!;9 /[V+[W3_ %BUI5F^(3C2VY4?O8OO=/\ M6+[C^?Y]*TJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** M"BBB@ HHHH **** "BBB@ HHKRG]I/Q]?^!OAO,FC(\FO:O*NFV B^^)).,K M[@=/>ID^579WX#!5,QQ5/"4OBFTM=EYOR6[/.?VC/VO;;P!=S>&_"!AU+Q!& M=ES=D;X;5O[@_O/ZCH.AYX'S4R?'#XH2-?I!XGU*.0[A)&DD<7/IT&*^K_@# M^RGHWP\L;?6/$D$6M>*95$CM.HDBMF/)"@]6']XU] JH4 = *YO9SJ:S= MO(_6X<4Y-PLOJF2X6->2^*K/[3Z\JW4>VJ^>[_,PS?&WX43"_FC\3:6D9P9) MTDDA/L2)\L5TW]PC^%SV'0_7K].. MBR*590RG@@C(-?-?[0_[)NG>+K*Y\0^#;9-*\36^;C[/;_(EVPYP .%?C@C' M/YT>SG3U@[^1I_K/DO%:^IYSA8T*DM(U8?9?3F6_+WNVO3=?2U%>3?LS?$NY M^)?PQM9]39CKFG2-8WXD7:_F)QEAV)'7W!KUFNF+4E='Y#F&!JY;BZF#K_%! MM/Y=5Y/=>044451YX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ! M1110 4444 %%%% !1110 4444 %>*R?\GA1?]BH4445 !1110 4444 %%%% !11 M10 4444 %%%% &7K7_'WH_('^F=P3_RRD] ?UQ]>QU*R=;(%YHN2HS>\9 Y_ M] &E1110 4444 %%%% !1110 M4444 9WB#_D&-@@?O8NH)_Y:+Z UHUF^(2!I;9( \V+[P&/]8OK6E0 4444 M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4 MC,%4L2 ,DGM2U\Z_MX?&N3X-_ 34(]+NTMO%?BB9/#^B[I A6>?Y6ER2,"- M-S;N@(7UH ]V\/\ BG1?%EI)=:'J]AK-M'(T+S:?'A)K0IBX7*DX\P!B <<**X#XVV'Q*TG_@H# M\1_'GPOE^U:SX1TBQO[O0SG&J6A0"6' ZG;R.^1D7/3=G9KY- M-/\ !GZ M(])\5Z9'J6B:I9ZQITA94N["X2>%BI(8!T)!P00>>"*^#+?XV>%OVDOVN_V= M/%7A^5;BQO= UJ"\L9L>9:S!8Q)!*O8C./<$$<&MO]EK6X?V4?V@/BU\#]>N MOLOAEQ)XT\+S3-A3:N,W$2Y[KMZ>L*=&/B$Z"-7L#K@A^TG3/M M*?:1%D#S/*SNVY(^;&.:SK7XF>#[[7VT*V\5Z)<:VK;#IL6HPMB'M MFO/O!^D_L^_#3PUX9\._&SX$ZW\/-?M?(CN/%-W%,\$URK+F4W43YVLPSAN, M$C&* /T,\!^"/^$0\?\ C>YMHQ%IVKRV]ZJJ, 3%6$F/J0#]375^(/%6B^$[ M>&?7-8L-&@FD$,4NH720+)(>B*7(!8^@YJ2_\0:;IF@3ZW=7L,.DP6QO)+QG M'EK"%W%]WIMYS7YS7_[0?A;XU^+=7^/WCJZ@E^%W@"5XO"/@];J+[7J=PK[7 MOY(&;).?N C@ >ARDK:'7BL54QE3VM75VBO_ &*BOP1^DES>V]G:274\\4% MM&A=YI'"HJ],[62Y\/ZYINNVT;^6\VFW<=PB-_=)0D ^U M?%/[7'CS3_C[X^_9[^'=AK2R> _&6IRW.MQ:?>#-R(DB9+61XSQ_K"2F>I7T M%4?BM\-?#_[)'[7/P!U+X6V2^%;#QG>76A:YHEE*XMKR)1%LD,9)&Y?-)SZJ MAZYRSD/LC5?C9\.]"U&XT_4O'OAC3[^W;9-:W6L6\4L;>C*S@@^QKJ].U*TU MBP@OK"Z@OK*X020W-M()(Y%/1E8$@@^HK\PF\&:;\._&WQ<\5_%_]FG6_'.G MWWB&XU*/Q$+2*:.UL5 7=@N&VX4MP.]?H=\$?$_A'QE\)_#&K^!$CA\(W%FG M]G0Q)L6*('=/<: MGKC6#QR;C\H002;AC!SD=<8KD/\ A.OC_P#]$H\*?^%@_P#\B5HH-J]U]Z ] MRHKF-'U/Q7<>!'O=2T*PL_%@MI7728=0,ML9@&\M/M'E@[6(7+;.,G@XKS3_ M (3KX_\ _1*/"G_A8/\ _(E)0;_X= >Y45Y=X#\4_%K5?$D-OXM\!:!H&B,C MF2^L/$37DJL!\H$1MTR"< G=Q[U/\0_$WQ3TC75@\&^!]#\1:2859KO4=?:R MD$F3E?+$#\ 8YSWZ4%/_"P?_Y$KTMM4\5C MP";Y="L#XN^S;QH_]H'[-YW_ #S^T>7G;_M;/PH<&O\ AP.GHKPW_A.OC_\ M]$H\*?\ A8/_ /(E=5\.O$OQ0UC6I8?&G@C1/#FF"$LEUINO-?2-)D84H8$P M,9YSVZ4W!I7T^] >D45Y=X\\4_%K2O$@/)XW\':-X9M$C!MY=,UMK]I'SRK*8 M8]HQSG)K'\9^+?C#IWB6\M_#/P\\/:UHB%?L]]>^)6M991M!.Z(6[[<'(^\> MF:.1WM^H'K%%>'+XZ^/Q8!OA3X4"YY(\7OP/_ 2O1_&>J^+M-\)QW7AG0-/U MKQ"3'OTZ]U$VL*@CY\3"-\X/3Y>?:AP:T_5 =517AO\ PG7Q_P#^B4>%/_"P M?_Y$KN?AGKOC_6OM_P#PG'A32?#/E[/LO]F:P;_SLYW;LPQ[<<>N#E@XCDR%/_"P?_P"1 M*2@VKZ?>@/-Y(P?E9E^RG:2,'&3CUH4&W;]4![1 M17C.C^-/CE<:M9Q:E\,?#%GI[S(MQ<0^*WE>*,GYF5/LHW$#)QD9]:[3XE:S MXXT:QLW\$>&=,\373R$7$6IZJ;!8TQP5812;CGM@4.#3M^H'945X;_PG7Q__ M .B4>%/_ L'_P#D2O1_AUJWC#5]%FF\9^']/\.:F)2L=KINI&^C:/ PQ,,0K-XN<$CL24+=7EKXH:XEAC[LL?V9=Q'IN'UI^S?=?>@/7Z*X;XF: M[X_T7[!_P@_A32?$_F;_ +5_:>L&P\G&-NW$4F[/.>F,>]<-_P )U\?_ /HE M'A3_ ,+!_P#Y$H4&U?3[T![E17*^#M5\7ZCX2ENO$OA_3]&\1#S-FG6>I&Z@ M; ^3,QC0C)Z_+Q[UYPWCKX_!CCX4^%",\'_A+W_^1*2@W_PZ ]QHKRCP7XL^ M,.I>)+.W\3_#WP]HNB.6^T7UEXD:ZEC&TD;8C;INR<#[PZYK6^)7B'XD:-J% MI'X(\':-XFLWB+7$VIZVU@T;YX55$,FX8P8.._ M[J2M2OGW5?&_Q[>YTLO\+/"J,MUE /%SGM:+JGBRY\!B^ MU/0;"R\6^3(W]D0ZB9;;S06V+]H\L'# *2=G&3P<4.#7_#H#J**\-_X3KX__ M /1*/"G_ (6#_P#R)71> O%/Q9U7Q%%;^+? 6@:!HQ1B][8>(FO)58#Y0(S; MID$]]W%-P:UNOO0'J%%>;_$7Q+\4-'UJ*'P9X(T3Q'I9A#/=:EKS6,BR9.5" M"!\C&.<]^EZ^] >Y45S U3Q7_P ( M"+XZ%8#Q=]FWG1_[0/V;SO\ GG]H\O.W_:V?A7FG_"=?'_\ Z)1X4_\ "P?_ M .1*2@W_ ,.![E69"3_PDMX,G'V2 X[??EKB?AWXE^*6KZX\/C/P/H?AS2A" M66[T[7VOI#)D87RS F 1GG/;I61XW\3_ !7TKX@ZA#X2\"Z%K^DBTM]EU?\ MB!K.0\R$YC%N^/F+#[W0 ]Z.1WM^J ]@HKPW_A.OC_\ ]$H\*?\ A8/_ /(E M>EZUJGBNV\""]TS0K"]\6?9XG.DS:@8K;SCM\Q//\LG"Y;#;.<#@9H<&O^' MZ>BO#?\ A.OC_P#]$H\*?^%@_P#\B5V'PV\1?$K6=2NX_&_@W1O#5DD6Z"?3 M-<:_>23(^4J88]HQDYR>G2FX-*^GWH#T*BO)_&/BWXQ:=XBO+?PW\//#NLZ* MC 6][>>)6M99!CDM&+9MO/\ M&L4>.OC_GGX4>%/_"P?_P"1*/9M]5]Z ]RH MKF/&NJ>*]-\*BY\,:%8:WK^4SI][J!M(<'[_ .]$;].WR\^U>:?\)U\?_P#H ME'A3_P +!_\ Y$I*#E_PX'N5%<-\,]=^(&M'4?\ A.?">D^&/+\O[)_9FL&_ M\[.[?NS#'LQA<=16_CCX]O<1+-\*_"L<)8!W7Q M<[%5SR0/LG/':NR\::MXPTBWO)_!OA^P\1:J9HEDM-1U$V,2IL.6$@C?)!QQ MCOUH<&G;]4!WE%>&_P#"=?'_ /Z)1X4_\+!__D2O0/AKK7CC6K&]?QOX9TSP MS=)(%MXM,U4WZRICEF8Q1[3GC�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anvs-20241231x10k006.jpg GRAPHIC begin 644 anvs-20241231x10k006.jpg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end GRAPHIC 11 anvs-20241231x10k007.jpg GRAPHIC begin 644 anvs-20241231x10k007.jpg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anvs-20241231x10k008.jpg GRAPHIC begin 644 anvs-20241231x10k008.jpg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anvs-20241231x10k009.jpg GRAPHIC begin 644 anvs-20241231x10k009.jpg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

0 '!^8\]O3RLPG*$(CB,3B55@I-4I.*<8S][FA9J,FDW:^[74]R^!GQY^(D?[06L?"_QGJ^C>-[ M6UTYK\:]H<"QB'"JVUPF%YSC&,Y(Y.:]I^%O[0OACXN^$?$'B/1(=1CT_1)I M8+I;R%4D+1IO;: Y!&.F2*^0/V?="2\_:BT_4/@[X,\3>"_AU+I\L&O)KRR" M*4[),$;W*/&UAXJ7M@8K.X%-:/_ 3LTW3O['O_ +>/&9&[52FK3BQD>[$N MTD>0 P#KRG./6O1_B5^V#X+^&4^F6UWIGB/5KV_L8M22VTO2VD:."095G+%5 M!ZY )((YKQG]J.2\^&W[4WPQ^)%YX?U35O#%E8M!ZR?.-I' SAP>2 M,\^E9GQ>^-GB_4_C!I;W>H^+O _PVU'0X;S3KCP_HHEO)IG56\J8[2RD$NI7 M. 0..2:J6)JTW44I:\VFFR^]:&-+)<#C:>#J4J'NNDW)\]N:2;35E&3W@U*U*7,F3+]Y0,%^FX+QFN]U#P4R_\ !,^ULDT1_P"U#9+,UN+4 M^?YOVH_-MQNW8_2DL7B)P4HV7NMO3JG;\2Y\/Y-A<1*E54IIUH4XVFE:,X*5 MWH[\K?E?J?37Q5_:+\$?"#P[I6KZQJ$EZNK@-IEGI\$_M?^ ?'6A>([ZU_M6PO_#]J][?Z)J%B8[Y85&2R1@D/_P !)/3. M,C/R/\4/ASXPT32_@5\2;>#Q VC:7X:MM.OFT&(/J&FNN\[UC<8&1)C)_N$$ MC(KTW]EK0-)^(GQSOO'$5S\0;Z]T_3OL_P#:GBNQA@BNE?*F([,\KD$&RV6*E-S<>9MI[24[*#5G:ZZWOK=*QU?[+7[ M:X^-GBG4_#NNZY-K-JXTEA:1N&VG)9@^ 0?X<^@->7?L@^*9_@_P#$_P >_#OQ!X9U MJWUS6O$$]U87JV1:TV;7(+R9^4':,$ @[ATKQOQOXV\>_$3X<^.-)\9ZCXV7 MQC]IEV^$=.T14TM8597WLX3HN&.<[B57KG-8?7*U.A%\UY:].W1ZGKOAW+L5 MFM6*H\M&U.UI])[SBE%Z*VMVDFM7KI]T?%/]JWP#\(8/"MUK=U=SZ=XDC::R MO]/@$T7E@*=[?,&QAQT!/M69\*/VR_A]\6_%Z^%[(:MH>MS*7M;77+,6YNU M)_=D,P)P"<'!..,XKXX^,4UUX?\ '[)DUQHT^JW=D$D;1WC/F7)2: ^1M(S MEL;<8[UZ+XA\2WO[7'[1OPNO?"/@O7/#NG>%+M+S4]7UFS%LR*DBN8P02#]S M:!G)+= 36GUVJZEDU]G2VKNE?7R.+_5?+X8-3FI6:JWJ$=0U+X:?LH65?\ I21Y7#^ PN/P,*6+D^1U972:6U*4 MKWM?=6[>1]3_ I_;2^'?Q;\;KX3L/[6TC6)U9[./6;/R%O 2?+(9N< D!L M$@<>E>+?\-9#X1_M4?%JP\8ZOKFJZ%;K!#I&AV4;7)639&S^6F0J\9))(ZUO M_M+^&[@_M?? :_T_2Y3#%<>E93J5Y35/FU4K7MTY;[7._#X3*:&'J8M4VZ M=2AS$) MJ-B<9X3=@DCIAL'GD5\]>/?C!=?#/X1?LYZGX>\<>(O^$9O-3G;4;^_8QW%U M;1SQ[UE1&;*J/, 7+S3Z6+5V9P+I6$;KCCWE<^P?AK^VS\ M.?B9XT@\+VW]L:)JEW_QX_VU9?9TO/3RV#'D]MV,_7BO/?"OQ*\-?#;XO_'7 M7V\3^+-;N=*1&N](NK8/:6S,^$\D+(2^#A1\JX4GK7 ?$'QK=_M<_&3X56?@ M_P ":]H"^&M26]U/5=7LA;FW0/&S1@@D;1Y9QD\DC ZUW/P$\-:A-^U3^T0) MK*:"WOT2.">>%EBD)+#AB,'KVKI5>I5G%7O:6CLU]E]/)GBSRS!8##UJCBX. M5-.=-RC)JU6*^+ETYHZK2Z]#?_97_;4M/C)H5W'XL@31]/3X M[6( EC*S'# 9)&>U;.@?MV_#_P 3^(['3--TCQ7=6E]=K96NL)H[&TED9@JX M(;?@DC^'/M7A_P"R5XNLO!WPB\6_"'QGX'\32:P(M3EN[:'3V*7$!A^:%) < M[VPRK@8R00:\[\)>*O%/@?4O#^D_!/4?B+=7!OE5_"/BC2D:Q@0ME@7W%5&> MK*%QR<@UE'&5H4Z;:&RC^5+>$RL78[4^4ZVMKF_LY?M\:%X,^$=A;_ !!U#Q)XG\0_:YFNKV&V-R+:(OB/S)'91TZ! MH.,8.<5\T_L MP^!Q;?L#>.K:\T)HM2O+36'>&>U(FE<0$1G!&2?E7'T&*\IU_P"%'C/5?V2O M@;XBTS3=6N#X8O+V6_L;.+_3($-](RRI&P.2 O<'&0<8KSZ>(Q%&BOM>[=:; M:I:]][GU^-R?)LQS*HU>DE7<)>\K2O&4ERZ6CK'E6^C74^S_ (1_M9>"/C!X MD?P[91ZMH.O^69X=-U^S^S2W$8&2T>&8-@/_ /KA;?\ I5#7=2Q%26'G M4>ZO9^B/E<=D^#HYSA<%334:C@I1;U7-*SLVD]5KJKIG.6O_ 4.^$]SJEA MQUVWTZ[*(-9GTTK9Q.P!*,^[.5/!(4C(."1S79?%G]KCP!\%_$FEZ-XCFO\ MS-2LC?V]U9VXFA:/G:,ALDL1@8!ZCFOC_6?C(WCG]E'P_P#!W2?A7KQ\676G MV,$$@T\"S<#RW6[23.29%&[. ,N26(Z]KK'PLU'1?VE_V<]#UBPDU:+1?#MO M:WMP83) )HHWZMC& RC&?05QK&5Y+W6G\.MGHV]4?1U.&\KI5+UX2@E[7W>> M+,TTM+O2UFGT/H7Q)^V#\/O"7P[\/>+=5DU*V77T9].T86N[49@&*G] MT&PO(ZE@.1SGBM'X,_M3>!?CA=7UAHUQ>:7K5DAEGTG68/LURL8ZN!DAE&>< M$XR,XR*\/_:AT'6?AO\ M+> _BX?#%[XK\'Z;:M:75MIT(FDM'PX#!.WWPP/ M RN,CBN1TS0==_:M_:+UCQQX9\.:IX.\-0^'+K2_[3U>#[-)=3RP21("H)R< MR G!.%3D@D"MGBJ\:O)NTTK6W5OBN>=3R+*Z^ ^M*\8RA*?/SIJ$N9I4G&UV M[6UW;=TK'IOQ'_;Z^'2Z;XKT;0[G6Y[F*SN;:#Q#8V1:QBNO+81XE#;OOXPP M7'0YQS5+X"?M-1^ ?V1-&\??$74-7UYY=1FM'N4 N+AB96"9W,O ]:\6^'/ MQ.N_A+^SYXI^#.N?"OQ#<>,IH[VW40:>)+:8R*P$KR9S\G4%0P(4$$5:@^&' MB7Q7_P $WK/3-/T>\EU6QU62]>P\EA,T:S-N(0C)P&STZ"N2.)K3DYIW:BW: MST=UIYGT-7(\LH48X6<.6G*O3CSN<6YPM+WDTO=3^[[F?9WQ:_:#\,?!GPSX M?UW7H=0DLM;NH[2U%E"KN'="Z[@77 P#T)K+^,_[57@7X'ZK;:/K$M]JNOW" M>:FCZ+;?:+D)V=AD!0>V3D]A7Q7^T+\<-4^/OP_^'>BZ3X \2V":+J-M)J-Y M=V3>4)UCV!(RN21RYR<=!Q7J?CBYU3]FW]L/Q!\2/$'A/5O$_A/Q!8K%:ZCI M-L+F2T?" K@D;2-A')&5;(SR*Z98Z)1X6P]&%)8N+=5J MJ^132MKIM]VEH=?\4OV^_#6G_!F;Q5X&66]ULW:V0T_5;)U^RR @ MLLX5AMRA.TAB"1C/!%4/'O[0?AWXW?LF:WKEYJOB+PI]A:RCU.[TBR*2"9V7 MY8E=UWQDG!.X<>O0T_BEK>J_M&_LI?$6;P_\,M2\,O\ :XKBTAN+=$GU-%F5 MY)5C4;MP4$GKGH"QS7(>//B-!\5/V$]9\.Z3X]]4?0FH?M%^!O@1\(O!$^N:QJFK2:AIT T^ P^=J5\NQ?G9 V > M1DEL9.,FMSX,_M1^!_CC-J%GH,C.,U M\O\ C+1]<^%OCWX'?%N\\*ZAXI\+Z7X6@TR]L[.#S9[&7RY?G"'H?WP(SCE2 M,CBNA^&$FI_'[]KL?%;1O"FI^%/"&D:)+8R3ZI;BWEU&5DE494$@G]X#P3@1 M+D\@5M#%5544/-*UG>UOBN>=7R+ /!U,2VW[LY>TYHV4U)I4^2U[O36^[NM# MM[O_ (*-?"RW@N'CLO$MW-;3O#/;P:J3'+M*LI!PR,IY5@000?2ODO\ 8>\&M:_"'XM?VEHK MPW5WJ-W'BZMBKRQ^2=H&X9(R3^==G_P3BTN^T?\ 9\N+:_M+BRE77+HK#Y1EF&HXEX)24J,X1NY)J2G%O:RM9 MKN_,]$^-'[5?@7X&ZM:Z/K,FH:IKURGFII.C6WVBX"=G8$J%'!ZG)]*S;/\ M;!\">(?A'XD\<:'->70T1 MUIA8C+ D8!YX->+>/M0U'] MG#]L?Q)\2M?\):MXH\*>(],CM[6_TJV%Q+92*D*E0"0!S$>,CA@.O'GQR^+/_",WGA7PQX@T2:RT[2[R'RY;E_+4^:8QW_=$DC^*4X)P34/% M5G5<%W:M;9):2N=4,BRV&!AB9IMNZM=JQ7_88^*W MB'XP_$6\U;Q+X_\ $NI:JT%U<2>'WMBFDK&'15*L#M##?PH4?7BOI/XV?M-^ M#/@!JV@6/BUM0B.LK,T$]I;B6.,1[=V_Y@W\:XP#7G?_ 3MTBZTC]G.VBOK M*:RNO[3NR4N(C&^"5QP0#BN:_;$\.7&O_M&_L_D:9-J%C%?S&X*P&2-!YMN1 MO., <=_2E2E5HX*,T[R=M[]6O,K&T,#F7$]7#5862AH["_TXK<7F3@"%59@3R.&*\'/0'':?!S M]K#P+\;8];31&U&QU+1X6N;K2]4MA##_M?_ M 4*^'MZ-&:73UTC?+<"V)B$B^?M+-C&1\O7VJ/1?"-W)_P4!\'M*ANI[B.X@1;@K;H7DVJ M'()P./F&?:OGS]K#]I"]U_\ 9Z\$^.OAWK&K^'K;5M:\CS WV>=HU$BLK!6( MQN7U]*\A^'7Q.\0_"+]G?Q[\$]1^'?B2Y\6W2:C;136UH7MECFB*/(S=<*-S M J"",]*V8?$&A:W^V;X:N(?%/BB/4;[P MV+Z#0'B5=.,+1O@N=^0W!8KL/S '/:N0_:EN+KX9?M:?##XGWGA_4]7\*V.F M365T^E6OGR+*1<#!7('_ "W0\D9 ..E36-U-XM_;[\&>*;/3+^#1[WP:)$DN M;9H_+W+,0C]E89&1FMW4J>T<)N]IJRMT[GEPP>$6"IXC#4^12PU3FE=-.:O> M+36CTN]G9I+:[ZW5O^"@_P ,]+U#5=/73_$U]J.FW3VL]K9Z:LC_ "$AI ?, MQL!'4D'VK,_:-_:-LO%_[(FM^.OAGXDN;2:.ZM8/M-LS07-JYGC#QN.JG#?0 M@Y!(.:^?_P!G3X[Z=\#_ (A_&"XU7P;K/B&UO]7DC2]T>S6AJBWPM\667[(/QO'AS+L#C:4N1Q4:E&SE*,E4YFN:/+:ZY=^NF M^Z/L?5_VF?"_P@^&/@:Z\67M]J>O:QIEM)#I^GPFYO;MC$I9PN0.IZL1D^M= M/\&/VB?"'QTCU"/0)+RSU33B/MFDZK;_ &>[@!Z,R9((/J"??%?&_P @\+VFG75WX;A62]TZ18FSA'&!G>.N,X89%>H_LA^'M, M\7?%OQ%\0K6[\>75ZEBNGO?^++.*W2^1BIP-G4H8UZGIBNREBJSKJDUIV\K; MW/GL;D66PRN>.C)N33=T]%+GMR.-K)6ZWO?6UCZ&^-GQL\/? 3PA#XD\2QWL MFG2WD=D!8Q+(X=U9@2&91C"'G->9>%_V]/A;XK\<6/AJWEUBT.H2B&RU2^L# M%9W+DX4*Q;< 20 2H'/.*Y[_ (*3Z3>ZU^SY96]A9W%]-_;ULQBMHFD;;Y4V M3A03CD5A?MU^#=O@;X1IHFBL9+#7[:-!8VQ)@B$9R/E'RKE5_(5>(KUX3GR6 MM%)[;W.3)\IRO%8;#+$J7M*TJD;J22CRI-.UG?5]UU/:/C!^U5X(^#.NV^@Z MB-3UOQ#-'YW]DZ%:?:;B./\ ON,J%'MG/M3;']K#P#JOPCU?XB65S>W6CZ0P MCO[-;<+>VTA(&QXV8 'GUQUP37RG\BN'LHA@L-7G-VG[.\KZ7D MTIQ>EH\JOK=M-:K4^J/%?[1WA7P=\%M/^*%]#J3>'+V.WEBCA@1KD"8@)E"X M'?GYJPOB-^V+\/OA5?\ AVV\0MJEL-=TI=7M9HK42(L3 E5;#9#DC& ",D<] MZ^+/B-\:=6\)HM7T=;6'4;R6Q;[/&L+84J1EB6.T8(&.>M> MM>,/"$^L_M/_ +-7VO1YKO3K?PU;?:#);,T4;I'*P#DC (8*<'OBI>-J3_A? MW>G5NS-(\+X+"ZXY-:UW925W"$5*'>S>N^_8]^\1?M>^ /"GPVT'QCJKZE:P M:Z&.G:2;4-J%QAL'$0; [L_#[]H[X>_&!?#=WXK\(Z39?8+RQTZ M'S9;-PTI$JITY\X$'U3!(R*R?AW+J7[1G[8^F?$[0_"6J>&/"&BZ0UE<76K6 MHMWOI"LH *@D$_O1T)P(QD]!6DL3757V=U>Z5K;JWQ''2R7*ZF7_ %SE?*X2 MGS'==T\V>JO>2C36L;.18# M;(A;,SLQ"OP>*W_&/[>_PN\(>)KW1P=:UL6$GE7NH:18>=:VS X(9RRYQSDJ M"..,UY!^R+KT_P ,?'?Q ^%_B'P]K>GZ[K^N74UEJ*61-K&AC?#-)_"#M&" M0=PZ5R?P=^(UU^RY\/O&GPP\7_#+7M6\17=Y%?$?Q+N_A[HKW^KZK#8FZO-0TR-'M+%"A(WREQAN5P #RP]\? M).G^'-=^#W[%MI\.M9\+3^(O&'CB^E-CH\O?BI)>TMO:%VFEI+=:) MG7?LK?$3P9X)^$_CGQ+<^-]=U/0K#5Y/M=[XFC"- ^!\D:J[EMQ(Z\;L$<,V,]MP Z=^*^0O#/P6 M\7^/?V3O&EGI.E7;ZCIOC/\ M8Z7+$R/>PK$R,J*0-Q&_"O#6E?![Q U]; 07=Q?6$<,6DX0*SQN<_*,'.=AQ[G%8T,142A!O ME5ET;O=ZGI9MDV$J5,3B(Q=:?-)-J<(>S48)Q;5K/F=^RTLM3Z,^(_C[3?A? MX(U?Q5K"7$FFZ7"9YUM4#R%<@?*"0">?45X)!_P44^%$US8;H_$,.FW(0/JL MFF?Z+;NP!V2,&)RN<':&'H37MRLF#/CQ\-_BS!X:NO%7A30X3:WUAI\0DD MM6#.PD$?N'R#TRF"1D5#Q.(Y9SM9)I;;7M=^=CHCDF3^UPV&4G*4XSE?F24^ M5S48JZM%SLM6_179ZO\ #7]L3X>_$^/68[)]3TO5M)M)+Z?1]5LS#=O"BEF: M-02'X'0'/M7G'[/'[<\?Q9^*6O>%=8TV2VBFOQ;Z!)9V,@)B_>DFZ)8A&VHF M.!SNKD_!5WJ7[2G[8OA[XC^'_"6K^&O"?A_3C!=WVKVHMWNW_>84@$AB?, P M">$Y[5'\ O$,OP6_:=^*_ACQ'X=UN*X\9ZY$VDZC:6/F6Z*9+@AV?/RKB9.1 MG&#G&*A8FM*5-N7N\S5[:/33_+U.NIDV6T:&*IPHMUO90FH.:5J&HZ/I_GVEHP.&#ON'3OM!KG/V MN_'7A'Q'\*? _B-?&VOZ3H5]JD4EI?>%T#M01R*^6/".F:] M\!K/Q/X#\93_ !'TF26[F,<7A:QAN++5$90NYB_)W =I6V;NU$BNS(ZH. "3^=82Q=:K2J*:Z;=G?;<]. MED&6X#'81X>H]9I*5TU.+@VY:QLG?HKJSL]4?3?Q)_;*^'WP?\;WW@S7AK4N MM6%K%-BVLQ,+DNJLJ(0V2Y!R<@#@\UL?"3]JWP!\8M!U[4],O+G2AH,33ZG: MZO#Y$UM$H),A + KA3R"<8Y XKQ_3?#$MY_P4GUS4KK2Y)K&+P\C0W3"ORL1C=@L/7K7+:5X9BM/VJ/VBSJ7AW4;WPW>>'I%DM;"V<->!H(M\<1 P M78EL8Z$YKL^L5U.[MR\SC:W9.SN?/?V-E53#J$5)5?8TZKES)IN4HJ45&WG= M:[^1[!X7_;I\ ^+O$NG:5I^C^*WMM1NEL[35FT@_9)G9MJX8,6P3W*_7%>[> M*O%.E^"?#FHZ]K=XEAI.GPM/#_$OA/1/@ MUJOQ#U&V-\B7'ACQ5I*FSM(2V7&\EE7J264+CDY!K[U_:"L]*U'X*^+;;7-) MU'7-,ELBL^GZ0A:ZEY&/+ [AL-D\#&3P#6F%Q-2K3G*6Z\M-OG?\SBSW)<)@ M<;AJ5%-4ZCM;FO.W,E=IJ/*VMM7%]'8X#P%^VSX)^(?BS2M"T_0_%=N=5E\F MQU"[TDK:SGD@AE8D# )R0,#DXKDOA+XX\->#/B?\?]=?Q3XKUX:%.UQJ6G:A M$A@M0))25MOWAWXVE1D)\H4?3PWX.^,?&6A?$KP/H'PMUGQYK_AO[2L6H:/X MOTI5M]/M1@$+(2VS:N[E=N,#KG%='X;\/ZHGB/\ ;'9M-NU6\2;[,3 P$_SW M/W./FZCIZUQ1Q-2IRREJTWTT^%O2SU/I:V1X/!NO2I/EA.,-.:\M:T8^\I13 MB[:Z:/=.VAZU#_P4<^$LLFFL4\01V=V0LE\^G#R;1B2-LK!SSCD[ W!^H&K! M^WY\)[GQM;>'X[O5/L]SU/\ VG/!,A_8$^%5MI^AR-J5O%H\ MK0V]J3-&[63F4D 9!+$[O<\U3Q.*C'F;7PJ6W?IN91R3(:M=4(PFKUIT;\ZT MY=5/X?.UMK=3ZPG^/'ANW^-MM\+&BOSXDN+,WR2"%?LWEA2W+[LYPIXVU3;X M^^'M5^)WB7X:V::A'XFTG3'OY9FB46^S:N-K[LD_O%_A'>OG'X^:AK'P2_;! M\+?%6[\-:KKOA>31_L4LFE0>:Z/Y;H5[ ,-RG!(R.]9'P(U_5_B+^V'\0/&% MQX7U;P]I^I^&9OLD>I6S(Y3]R$).,;F"DX!-=#QDU4]D]^:VWV;;GE0X=PTL M)]>CK#V"E?F7\7FLU;?1="O\+OVN?$OP]_8]E\7ZS?7?B?Q5@R,FOFWX2?#SQ!KO_!.WQKHMMHUV^LM?S3Q6+P,LSJK1,=JD9)P#TZX MKK-#^._B6Z_8_N],^'OAG6;+QAX7L+&SO#?Z4""IW+)) K;A(5"9.5XW X]. M2A7JTU'FEIR7M:]WK^)[^:95@,9*LJ%%TK[/;V4IFA9HXBJ@\;6)/W0 O/)KZ!^ OA>4_MR_&?4K M[2I/(\@?9;J>W.PDO&#L8C!X]*TIXNO4M!-:NU[=+7[_ *G'C.'LIP2GB*D9 M-*FY\#ZIXJT?5&L].TG=_:4>I)Y M$MEA2V9!DC& 2""0<$9R"!P6C?M[_"[5]?M;%O[GS/G M Q)DL 3W90!WP*^== ^#OB/QR/VI_#&AV,]A<:A=Q2V$;QF&*Y\JY:7RT) ! MW!2H[989XKBM)"^+_!>@_#;Q1_PMJ2^CF@M)_#\&F0&RMBK@;XV(W84<@8!Z MC/>IECL0E'1=>FC:=K;Z&U'A?*)SK/GDTG'12]Z$904N;X7S6;:ULM-7=GWM M\:?VFO!'P*_L^'7KF[O=4U!=]II6DP?:+F9.F\+D +[DC/.,XJK\-?VJ_ ?Q M4\.:_JFCSWL-QH4#W.H:3?6_DWL**"2=F<'ICACSP<5\^_%'1-3_ &<_VG_# MGQ*O_#NK>-?!BZ!%I N+. 3W%C(D83=MX 8[<]0#YC\\57^&?AO7?C]\>?B3 M\2]*\,7_ (2\,:AX;FT>U74H1!+?SO&J!F7I_#DD$@87D\UT/%5O:\GG:UNE MM[GD1R'+?[/6(DW;D4O:]]=CZ8\,?M'>%?%GP3O\ XI64 M.I+X;LH;B>6.:!!,;E]4>#Q+O_LO M2H+3S+ZXVN4;$8;:,$=2V.1WXKXV\&?%G7O O[+/BKX*7/PZ\33>+"E[ 98[ M(FWCBD8L[L>N5!;H"#QS6[J>@>';7]G/X'2^)],\<:3K6G6UU);:[X7LR\FG MM]H8@2*VWDGD8(88[YK'Z_4E'W;7Y;NZZW29Z3X4P5&LU74N1UG&/+)-NGR2 ME%Z7W:6N]KV5SZ-U[]IBQ^)WP)^)FJ>%+7Q%X9UC0M,=R=4LS:30NRL49&!( M)^4]#D<>M8G[-W[4-C;^ /A+X=\:7>KWOBGQ7;3O;ZO=(LD,[+4ONW# M:JXV]U]:\L^'WBKXD^-?@[\;K'5)]>\2>#8M&9-%U7Q!IXM[^XE(PR8&6<8S MU+8PO3.*-1^%-_KG_!/KP)KEI;S:?XN\%&76;-WC*31A;J4R+@\@%=KX]46I M6(K2DJL>D6]M[2UZ]MF7/*,NHTI8&LDE*M&*:E=QYJ3M=M)V4FN:+2MMNKGU MUK7QS\.Z+\7]'^&IBO[SQ+J=LUVHM85:&WB&[YI6+ KPI/ /;UKT2OC+]DBZ MU+QJWQ)_:)U_29+O5]1BDM]*TZURS+;0)N:.+/4NR(H]U/K7T+\ ?BW=?&KX M>P^);SPY=^&)GGDA^Q7F=Q"G&X$@$@_3L:]3#XCVJO+[5VO0^%SC*/J$G&DK MJERQJ.Z_B--M);V6WJF>D4445W'RP4444 %%%% !1110 4444 %%%% !1110 M 4F!G..?6EHH **** $(##!&1[T$ XR <4M% !1110 4@ 48 'H*6B@!,#. M<<^M&T9S@9]:6B@#R[XK? '2?BSXW\!^)M0U"[M+KPC?KJ%K#;A=DSK)')A\ MC.,Q@<>IKU #H,4M%1&$8MR2U>YU5<56K4Z=&I*\8)J*[)N[_'4****LY0H MHHH **** $ S@8S2T44 )@9S@9]: H!) )ZFEHH *3: 2<#)[TM% !1110 M @4+T 'TKC_B_P##.R^,7PXUKP=J-U/966J)&DD]N!YB!9%D&,\=4 _&NQHJ M914XN,MF;4:U3#U8UJ3M*+33[-:IF)X(\*V_@;P;H'ARUE>>WT?3[?3HII0- M[I%&L:DX[D*":VZ**:22LB)SE4FYS=V]6'6D & ,#T%+13($P,YP,^M+110 M @ '08^E! 88(R/0TM% !2 !>@ ^E+10 =:0 8 P*6B@ HHHH 0@$8(R/>E MHHH **** "BBB@!-HSG SZTM%% "$!A@@$>]+110!Y;\%_V?](^">I>+[S3= M0NK]_$M\+^X6Z"XB<%SA<#I\YZ^E>I445$(1IQY8*R.K$XJMC*KKXB7-)VN_ M167X)!UI HP!@>@I:*LY0HHHH 0@,,$9'H:.E+10 @ &<#&>M+110 4@ P M!@>U+10 F!G..?6@@$@X&1TI:* "BBB@ I "2!@GK2T4 [3X8^ M"\*V,\MU:Z1:K:Q3S@;W M4=SCC-=/14?GMKL=7UJM]7^J\WN7YK>=K7^X****LY1 HP!@>@HP"0<# M([TM% "%0<9 ..E+110 4444 (% )( !/4TM%% "!0I. !GKBEHHH **** $ M(##!&1[TM%% !2 =!BEHH 0*%& ![4M%% !2;1G.!GUI:* $(R,'D4 8&! M2T4 )@9SCGUH(!&",CT-+10 @ P!@5XK\<_V8[;XYZS;7EYXS\1Z'9K;?8[ MC3=+N1';W,6XL0RXY)SWSVKVNBLZE.-6/+-71VX/&U\!55?#2Y9+KI^IA>!_ M!6D?#KPEI?AO0;46>DZ; L%O%G)VCNQ/5B EX-101.SCH 14 anvs-20241231.xsd EX-101.SCH 99900 - Disclosure - Standard And Custom Axis Domain Defaults link:presentationLink link:calculationLink link:definitionLink 995200100 - Statement - Balance Sheets link:presentationLink link:calculationLink link:definitionLink 995200200 - Statement - Statements of Operations link:presentationLink link:calculationLink link:definitionLink 995200400 - Statement - Statements of Cash Flows link:presentationLink link:calculationLink link:definitionLink 99940301 - Disclosure - Fair Value Measurements - Hierarchy (Details) link:presentationLink link:calculationLink link:definitionLink 99940401 - Disclosure - Prepaid Expenses and Other Current Assets (Details) link:presentationLink link:calculationLink link:definitionLink 99940501 - Disclosure - Accrued Expenses (Details) link:presentationLink link:calculationLink link:definitionLink 99940901 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details) link:presentationLink link:calculationLink link:definitionLink 99941001 - Disclosure - Income Taxes - Reconciliation of income tax provision (benefit) (Details) link:presentationLink link:calculationLink link:definitionLink 99941002 - Disclosure - Income Taxes - Deferred taxes (Details) link:presentationLink link:calculationLink link:definitionLink 99941101 - Disclosure - Segment Information (Details) link:presentationLink link:calculationLink link:definitionLink 995200090 - Document - Document and Entity Information link:presentationLink link:calculationLink link:definitionLink 995200105 - Statement - Balance Sheets (Parenthetical) link:presentationLink link:calculationLink link:definitionLink 995200300 - Statement - Statements of Changes in Stockholders' Equity (Deficit) link:presentationLink link:calculationLink link:definitionLink 995210101 - Disclosure - Nature of Business and Management's Plans link:presentationLink link:calculationLink link:definitionLink 995210201 - Disclosure - Summary of Significant Accounting Policies link:presentationLink link:calculationLink link:definitionLink 995210301 - Disclosure - Fair Value Measurements link:presentationLink link:calculationLink link:definitionLink 995210401 - Disclosure - Prepaid Expenses and Other Current Assets link:presentationLink link:calculationLink link:definitionLink 995210501 - Disclosure - Accrued Expenses link:presentationLink link:calculationLink link:definitionLink 995210601 - Disclosure - Commitments and Contingencies link:presentationLink link:calculationLink link:definitionLink 995210801 - Disclosure - Stock-Based Compensation link:presentationLink link:calculationLink link:definitionLink 995210901 - Disclosure - Net Loss Per Share link:presentationLink link:calculationLink link:definitionLink 995211001 - Disclosure - Income Taxes link:presentationLink link:calculationLink link:definitionLink 995211201 - Disclosure - Subsequent Events link:presentationLink link:calculationLink link:definitionLink 99920202 - Disclosure - Summary of Significant Accounting Policies (Policies) link:presentationLink link:calculationLink link:definitionLink 99930303 - Disclosure - Fair Value Measurements (Tables) link:presentationLink link:calculationLink link:definitionLink 99930403 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) link:presentationLink link:calculationLink link:definitionLink 99930503 - Disclosure - Accrued Expenses (Tables) link:presentationLink link:calculationLink link:definitionLink 99930803 - Disclosure - Stock-Based Compensation (Tables) link:presentationLink link:calculationLink link:definitionLink 99930903 - Disclosure - Net Loss Per Share (Tables) link:presentationLink link:calculationLink link:definitionLink 99931003 - Disclosure - Income Taxes (Tables) link:presentationLink link:calculationLink link:definitionLink 99940101 - Disclosure - Nature of Business and Management's Plans (Details) link:presentationLink link:calculationLink link:definitionLink 99940201 - Disclosure - Summary of Significant Accounting Policies (Details) link:presentationLink link:calculationLink link:definitionLink 99940302 - Disclosure - Fair Value Measurements - Canaccord Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 99940601 - Disclosure - Commitments and Contingencies (Details) link:presentationLink link:calculationLink link:definitionLink 99940701 - Disclosure - Stockholders' (Deficit) Equity - Overview (Details) link:presentationLink link:calculationLink link:definitionLink 99940702 - Disclosure - Stockholders' (Deficit) Equity - IPO Warrants (Details) link:presentationLink link:calculationLink link:definitionLink 99940703 - Disclosure - Stockholders' (Deficit) Equity - ATMs and Private Placements (Details) link:presentationLink link:calculationLink link:definitionLink 99940704 - Disclosure - Stockholders' (Deficit) Equity - November 2023 Equity Offering and Warrant Issuance (Details) link:presentationLink link:calculationLink link:definitionLink 99940705 - Disclosure - Stockholders' (Deficit) Equity - Rollforward of warrant liability (Details) link:presentationLink link:calculationLink link:definitionLink 99940706 - Disclosure - Stockholders' Equity - Warrant Summary (Details) link:presentationLink link:calculationLink link:definitionLink 99940707 - Disclosure - Stockholders' (Deficit) Equity - Registered Direct Offerings (Details) link:presentationLink link:calculationLink link:definitionLink 99940708 - Disclosure - Stockholders' (Deficit) Equity - ELOC Purchase Agreement (Details) link:presentationLink link:calculationLink link:definitionLink 99940709 - Disclosure - Stockholders' (Deficit) Equity - Changes in derivative liability (Details) link:presentationLink link:calculationLink link:definitionLink 99940801 - Disclosure - Stock-Based Compensation - Summary of plans (Details) link:presentationLink link:calculationLink link:definitionLink 99940802 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details) link:presentationLink link:calculationLink link:definitionLink 99940803 - Disclosure - Stock-Based Compensation - Stock option activity (Details) link:presentationLink link:calculationLink link:definitionLink 99940804 - Disclosure - Stock-Based Compensation - Additional disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 99940902 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details) link:presentationLink link:calculationLink link:definitionLink 99941003 - Disclosure - Income Taxes - Additional disclosures (Details) link:presentationLink link:calculationLink link:definitionLink 99941201 - Disclosure - Subsequent Events (Details) link:presentationLink link:calculationLink link:definitionLink 995210701 - Disclosure - Stockholders' (Deficit) Equity link:presentationLink link:calculationLink link:definitionLink 995211101 - Disclosure - Segment Information link:presentationLink link:calculationLink link:definitionLink 99930703 - Disclosure - Stockholders' (Deficit) Equity (Tables) link:presentationLink link:calculationLink link:definitionLink 99931103 - Disclosure - Segment Information (Tables) link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 15 anvs-20241231_cal.xml EX-101.CAL EX-101.DEF 16 anvs-20241231_def.xml EX-101.DEF EX-101.LAB 17 anvs-20241231_lab.xml EX-101.LAB EX-101.PRE 18 anvs-20241231_pre.xml EX-101.PRE XML 20 R1.htm IDEA: XBRL DOCUMENT v3.25.1
Document and Entity Information - USD ($)
12 Months Ended
Dec. 31, 2024
Mar. 18, 2025
Jun. 30, 2024
Document and Entity Information      
Document Type 10-K    
Document Annual Report true    
Document Period End Date Dec. 31, 2024    
Document Transition Report false    
Securities Act File Number 001-39202    
Entity Registrant Name ANNOVIS BIO, INC.    
Entity Incorporation, State or Country Code DE    
Entity Tax Identification Number 26-2540421    
Entity Address, Address Line One 101 Lindenwood Drive, Suite 225    
Entity Address, City or Town Malvern    
Entity Address, State or Province PA    
Entity Address, Postal Zip Code 19355    
City Area Code 484    
Local Phone Number 875-3192    
Title of 12(b) Security Common Stock, par value $0.0001 per share    
Trading Symbol ANVS    
Security Exchange Name NYSE    
Entity Current Reporting Status Yes    
Entity Well-known Seasoned Issuer No    
Entity Voluntary Filers No    
Entity Interactive Data Current Yes    
Entity Filer Category Non-accelerated Filer    
Entity Small Business true    
Entity Emerging Growth Company true    
Entity Ex Transition Period true    
ICFR Auditor Attestation Flag false    
Document Financial Statement Error Correction [Flag] false    
Entity Shell Company false    
Entity Public Float     $ 51,312,050
Entity Common Stock, Shares Outstanding   19,486,231  
Document incorporated by reference

Certain portions, as expressly described in this report, of the registrant’s proxy statement for the 2025 Annual Meeting of the Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K.

   
Entity Central Index Key 0001477845    
Current Fiscal Year End Date --12-31    
Document Fiscal Year Focus 2024    
Document Fiscal Period Focus FY    
Amendment Flag false    
Auditor Firm ID 42    
Auditor Name Ernst & Young LLP    
Auditor Location Philadelphia, Pennsylvania    
XML 21 R2.htm IDEA: XBRL DOCUMENT v3.25.1
Balance Sheets - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Current assets:    
Cash and cash equivalents $ 10,551,916 $ 5,754,720
Prepaid expenses and other current assets 3,373,717 4,453,544
Total assets 13,925,633 10,208,264
Current liabilities:    
Accounts payable 2,305,974 1,292,837
Accrued expenses 1,575,013 2,986,273
Total current liabilities 3,880,987 4,279,110
Non-current liabilities:    
Warrant liability 737,000 13,680,000
Total liabilities 4,617,987 17,959,110
Commitments and contingencies (Note 6)
Stockholders' equity (deficit):    
Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding
Common stock - $0.0001 par value, 70,000,000 shares authorized and 14,141,521 and 10,519,933 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively 1,414 1,052
Additional paid-in capital 144,155,694 102,507,189
Accumulated deficit (134,849,462) (110,259,087)
Total stockholders' equity (deficit) 9,307,646 (7,750,846)
Total liabilities and stockholders' equity (deficit) $ 13,925,633 $ 10,208,264
XML 22 R3.htm IDEA: XBRL DOCUMENT v3.25.1
Balance Sheets (Parenthetical) - $ / shares
Dec. 31, 2024
Dec. 31, 2023
Balance Sheets    
Preferred stock, par value (dollars per share) $ 0.0001 $ 0.0001
Preferred stock, shares authorized 2,000,000 2,000,000
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
Common stock, par value (dollars per share) $ 0.0001 $ 0.0001
Common stock, shares authorized 70,000,000 70,000,000
Common stock, shares issued 14,141,521 10,519,933
Common stock, shares outstanding 14,141,521 10,519,933
XML 23 R4.htm IDEA: XBRL DOCUMENT v3.25.1
Statements of Operations - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Operating expenses:    
Research and development $ 19,995,447 $ 38,790,603
General and administrative 6,699,481 6,244,408
Total operating expenses 26,694,928 45,035,011
Operating loss (26,694,928) (45,035,011)
Other income (expense):    
Interest income 331,849 667,898
Other financing costs (1,853,189)  
Change in fair value of warrants 3,625,893 (11,837,200)
Total other income (expense), net 2,104,553 (11,169,302)
Net loss $ (24,590,375) $ (56,204,313)
Net loss per share    
Basic (dollars per share) $ (2.02) $ (6.23)
Diluted (dollars per share) $ (2.31) $ (6.23)
Weighted-average number of common shares used in computing net loss per share    
Basic 12,182,475 9,023,138
Diluted 12,235,444 9,023,138
XML 24 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Statements of Changes in Stockholders' Equity (Deficit) - USD ($)
Common Stock
Additional Paid-in Capital
Accumulated Deficit
Total
Balance at Dec. 31, 2022 $ 816 $ 82,377,488 $ (54,054,774) $ 28,323,530
Balance, shares at Dec. 31, 2022 8,163,923      
Changes in Stockholders' Equity (Deficit)        
Exercise of stock options $ 6 8,379   8,385
Exercise of stock options, shares 59,897      
Stock-based compensation expense   4,628,406   4,628,406
Exercise of common stock warrants, inclusive of warrant reduction $ 5 1,056,196   1,056,201
Exercise of common stock warrants, inclusive of warrant reduction, shares 50,000      
Issuance of common stock, net of issuance costs and warrant liability $ 225 14,436,720   14,436,945
Issuance of common stock, net of issuance costs and warrant liability, shares 2,246,113      
Net loss     (56,204,313) (56,204,313)
Balance at Dec. 31, 2023 $ 1,052 102,507,189 (110,259,087) $ (7,750,846)
Balance, shares at Dec. 31, 2023 10,519,933      
Changes in Stockholders' Equity (Deficit)        
Exercise of stock options, shares       300,000
Cashless exercise of stock options $ 22 (22)    
Cashless exercise of stock options, shares 220,339      
Stock-based compensation expense   3,836,770   $ 3,836,770
Exercise of common stock warrants, inclusive of warrant reduction $ 89 17,342,022   17,342,111
Exercise of common stock warrants, inclusive of warrant reduction, shares 891,667      
Issuance of common stock pursuant to Equity Distribution Agreement, net of issuance costs $ 3 156,766   156,769
Issuance of common stock pursuant to Equity Distribution Agreement, net of issuance costs, shares 26,788      
Issuance of common stock pursuant to ELOC, net of issuance costs $ 205 16,438,012   16,438,217
Issuance of common stock pursuant to ELOC, net of issuance costs, shares 2,051,428      
Issuance of common stock pursuant to registered direct offering, net of issuance costs $ 43 3,874,957   3,875,000
Issuance of common stock pursuant to registered direct offering, net of issuance costs, shares 431,366      
Net loss     (24,590,375) (24,590,375)
Balance at Dec. 31, 2024 $ 1,414 $ 144,155,694 $ (134,849,462) $ 9,307,646
Balance, shares at Dec. 31, 2024 14,141,521      
XML 25 R6.htm IDEA: XBRL DOCUMENT v3.25.1
Statements of Cash Flows - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Cash flows from operating activities:    
Net loss $ (24,590,375) $ (56,204,313)
Adjustments to reconcile net loss to net cash used in operating activities:    
Stock-based compensation expense 3,836,770 4,628,406
Change in fair value of warrants (3,625,893) 11,837,200
Non-cash other financing costs, including change in fair value of derivative 1,803,189
Changes in operating assets and liabilities:    
Prepaid expenses and other current assets 1,079,827 3,190,832
Accounts payable 1,013,138 (2,668,417)
Accrued expenses (1,411,260) (751,012)
Net cash used in operating activities (21,894,604) (39,967,304)
Cash flows from financing activities:    
Proceeds from issuance of common stock, net 18,666,797 16,885,946
Proceeds from exercise of warrants 8,025,003 450,000
Proceeds from exercise of stock options 0 8,385
Net cash provided by financing activities 26,691,800 17,344,331
Net increase (decrease) in cash and cash equivalents 4,797,196 (22,622,973)
Cash and cash equivalents, beginning of year 5,754,720 28,377,693
Cash and cash equivalents, end of year 10,551,916 5,754,720
Supplemental disclosure of cash flow information:    
Other adjustment to value of warrants related to exercises 9,317,108 606,201
Cash paid for financing costs $ 50,000
XML 26 R7.htm IDEA: XBRL DOCUMENT v3.25.1
Nature of Business and Management's Plans
12 Months Ended
Dec. 31, 2024
Nature of Business and Management's Plans  
Nature of Business and Management's Plans

(1) Nature of Business and Management’s Plans

Annovis Bio, Inc. (the “Company” or “Annovis”) was incorporated on April 29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company’s lead product candidate, buntanetap, is a small molecule administered orally that is designed to attack neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby impeding the toxic cascade.

Going Concern

Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has not generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company’s future operations are dependent on the success of the Company’s efforts to raise additional capital.

The Company has a history of incurring net losses and anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company’s primary source of capital has been the issuance of common stock and warrants to purchase common stock.

Since the Company’s inception, the Company has incurred losses and negative cash flows from operations. At December 31, 2024, the Company had cash and cash equivalents of $10.6 million and an accumulated deficit of $134.8 million. The Company’s net loss was $24.6 million and $56.2 million for the years ended December 31, 2024 and 2023, respectively. In addition, the Company’s operating loss was $26.7 million and $45.0 million for the years ended December 31, 2024 and 2023, respectively. The Company follows the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 205-40, Presentation of Financial Statements-Going Concern, or ASC 205-40, which requires management to assess the Company’s ability to continue as a going concern for one year after the date the financial statements are issued. The Company expects that its existing balance of cash and cash equivalents as of December 31, 2024, combined with cash raised in the first quarter of 2025 in connection with its December 2024 ATM with OpCo and February 2025 stock offering with ThinkEquity, is not sufficient to fund operations for the period through one year after the date of this filing and therefore management has concluded that substantial doubt exists about the Company’s ability to continue as a going concern. Management’s plans to mitigate this risk include raising additional capital through equity financings, debt or other potential alternatives. Management’s plans may also include the deferral of certain operating expenses unless and until additional capital is received. However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company, or that the Company will be successful in deferring certain operating expenses. As such, management concluded that such plans do not alleviate the substantial doubt. If the Company is unable to raise sufficient additional capital or defer sufficient operating expenses, the Company may be compelled to reduce the scope of its operations.

The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.

XML 27 R8.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies
12 Months Ended
Dec. 31, 2024
Summary of Significant Accounting Policies  
Summary of Significant Accounting Policies

(2) Summary of Significant Accounting Policies

(a) Basis of Presentation

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).

(b) Use of Estimates

In preparing the financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the accounting for research and development contracts, including clinical trial accruals, common stock warrant liabilities, derivative liabilities and the accounting and fair value measurement of equity awards.

(c) Segment Information

As of December 31, 2024, the Company viewed its operations and managed its business as one operating segment consistent with how the Company's chief operating decision-maker, the Company's Chief Executive Officer, makes decisions regarding resource allocation and assesses performance. As of December 31, 2024, substantially all of the Company's assets were located in the United States. Refer to Note 11 for additional information

(d) Basic and Diluted Net Income per Share

Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options and warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion or exercise of securities that would have an anti-dilutive effect.

(e) Cash and Cash Equivalents

The Company considers all highly-liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents may include bank demand deposits and money market funds that invest primarily in certificates of deposit, commercial paper, and U.S. government agency securities and treasuries. The Company records interest income received on cash and cash equivalents to other income (expense), net in the statements of operations. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse effect on the Company’s financial condition, results of operations, and cash flows.

(f) Issuance Costs Associated with Equity Issuances

Issuance costs incurred in connection with the Company’s equity issuances, which primarily consist of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. Issuance costs related to the Equity Line of Credit (“ELOC”) Purchase Agreement are expensed as incurred as prescribed by ASC 815.

(g) Derivative Liability

The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separate accounting from the underlying agreement under ASC 815 – Derivatives and Hedging. An embedded derivative

that requires separation is accounted for as a separate liability or asset from the host agreement. The separated embedded derivative is accounted for at fair market value, with changes in fair value recognized in the statements of operations within the other financing costs line item. The Company determined that certain features under the ELOC Purchase Agreement (See Note 7 — Stockholders’ Equity (Deficit)) collectively qualified as an embedded derivative. The derivative was accounted for separately from the underlying ELOC Purchase Agreement and is accounted for at fair value. As of December 31, 2024, the liability balance was zero because the ELOC facility had been exhausted and all shares from the equity line had been sold.

(h) Common Stock Warrants

On October 31, 2023, the Company completed an underwritten offering whereby the Company sold (i) 1,250,000 shares of common stock and (ii) warrants to purchase an aggregate of 1,250,000 shares of common stock at an exercise price of $9.00 per share (“Canaccord Warrants”). The warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company’s control or not deemed to be indexed to the Company’s stock. The warrant liabilities are recorded at fair value regardless of the timing of the redemption feature, the redemption price, or the likelihood of redemption. These warrants are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of change in fair value of warrant liability in the statements of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise, expiration, or other settlement of the warrants. The warrants are classified as Level 3 liabilities.

(i) Research and Development

Research and development costs are either expensed as incurred, or recorded separately as a prepaid asset where expense is recognized when the service is performed. These costs are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on the Company’s contracts with its vendors and are realized in the ordinary course of business.

(j) Patent Costs

All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.

(k) Stock-Based Compensation

The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, Compensation—Stock Compensation (“ASC 718”). The Company has issued stock-based compensation awards, including stock options. ASC 718 requires all stock-based payments, including grants of stock options, to be recognized in the financial statements based on their grant date fair values. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. The Company recognizes forfeitures as they occur.

Expense related to stock-based compensation awards granted with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock options have a contractual term of 10 years. Expense for stock-based compensation awards with performance-based vesting conditions is only recognized when the performance-based vesting condition is deemed probable to occur. Expense related to stock-based compensation awards are recorded in research and development expense or general and administrative expense based on the underlying function of the individual that was granted the stock-based compensation award.

Estimating the fair value of stock options requires the input of subjective assumptions, including the expected term of the stock option, stock price volatility, the risk-free interest rate, and expected dividends. The assumptions used in the Company’s Black-Scholes option-pricing model represent Management’s best estimates and involve a number of variables, uncertainties, assumptions,

and the application of Management’s judgment, as they are inherently subjective. If any assumptions change, the Company’s stock-based compensation expense could be materially different in the future.

The assumptions used in the Company’s Black-Scholes option-pricing model for stock options are as follows:

Expected Term. As Annovis does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the expected term of employee stock options subject to service-based vesting conditions is determined using the “simplified” method, as prescribed in SEC’s Staff Accounting Bulletin No. 107, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock option.

Expected Volatility. The expected volatility is based on historical volatilities of Annovis and similar entities within the Company’s industry for periods commensurate with the assumed expected term.

Risk-Free Interest Rate. The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.

Expected Dividends. The expected dividend yield is 0% because Annovis has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.

(l) Income Taxes

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2024 and 2023, the Company had a full valuation allowance against its deferred tax assets.

The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions as of December 31, 2024 or 2023.

(m) Recently Adopted Accounting Pronouncements

Effective January 1, 2024, the Company retrospectively adopted Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) on an annual basis, which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items. ASU 2023-07 also requires public entities with a single reportable segment to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in FASB ASC Topic 280, Segment Reporting. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. See Note 11 for additional disclosures made as a result of adopting ASU 2023-07.

(n) Recent Accounting Pronouncements

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which improves income tax disclosures by requiring: (1) consistent categories and greater disaggregation of information in the rate reconciliation, and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The ASU indicates that all entities will apply the guidance prospectively with an option for retroactive application to each period presented in the financial statements. The Company has not determined the impact ASU 2023-09 may have on the Company’s financial statement disclosures, but it does not anticipate material impacts.

In November 2024, the FASB issued ASU 2024-03, Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires public entities, at annual and interim reporting periods, to disclose in a tabular format additional information about specific expense categories in the notes to the financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is still evaluating the impacts of this ASU on its future financial statements and disclosures.

XML 28 R9.htm IDEA: XBRL DOCUMENT v3.25.1
Fair Value Measurements
12 Months Ended
Dec. 31, 2024
Fair Value Measurements  
Fair Value Measurements

(3) Fair Value Measurements

The Company measures certain assets and liabilities at fair value in accordance with ASC 820, Fair Value Measurements and Disclosures. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows:

Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.

Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.

Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.

The following tables provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of December 31, 2024 and 2023:

    

    

Fair Value Measurement at

December 31, 2024

Carrying Value

Level 1

    

Level 2

    

Level 3

Assets:

Cash equivalents

$

491,006

$

491,006

$

$

Total assets measured and recorded at fair value

$

491,006

$

491,006

$

$

Liabilities:

Warrant liability

$

737,000

$

$

$

737,000

Total liabilities measured and recorded at fair value

$

737,000

$

$

$

737,000

    

    

Fair Value Measurement at

December 31, 2023

Carrying Value

Level 1

    

Level 2

    

Level 3

Assets:

Cash equivalents

$

5,136,677

$

5,136,677

$

$

Total assets measured and recorded at fair value

$

5,136,677

$

5,136,677

$

$

Liabilities:

Warrant liability

$

13,680,000

$

$

$

13,680,000

Total liabilities measured and recorded at fair value

$

13,680,000

$

$

$

13,680,000

The Company did not transfer any financial instruments into or out of Level 3 classification, during the year ended December 31, 2024 or 2023.

(a)Canaccord Warrants

The common stock warrants issued in connection with the Company’s equity financing in November 2023 (“Canaccord Warrants”) were classified as liabilities at the time of issuance due to certain cash settlement adjustment features that are outside of the Company’s control or not deemed to be indexed to the Company’s stock. The Canaccord Warrant liability is remeasured each reporting period with the change in fair value recorded to other income (expense), net in the statements of operations until the warrants are exercised, expired, reclassified, or otherwise settled. From their date of issuance until the period ended June 30, 2024, the fair value of the Canaccord Warrants was estimated using a Monte Carlo simulation model, given the performance conditions outlined further below. However, during the quarter ended September 30, 2024, the Company determined that certain performance conditions could not be met and that going forward, their use as inputs for determining fair value was no longer appropriate. As such, after the period ended June 30, 2024, the fair value of the Canaccord Warrants is estimated using a Black-Scholes option-pricing model.

The estimated fair value of the Canaccord Warrants is determined using Level 3 inputs. Inherent in both a Monte Carlo simulation model and a Black-Scholes option-pricing model are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and other inputs. The Company estimates the volatility of its warrants based on an implied asset volatility calculated and believed to be reasonable for the Company over the holding period remaining. The risk-free interest rate is based on the market yield of U.S. Treasuries over a term commensurate with the remaining term to expiration. Any changes in these assumptions can change the associated valuation significantly.

The following tables provide quantitative information regarding Level 3 fair value measurements inputs as of their respective measurement dates. The table for the year ending December 31, 2024 presents inputs used under a Black-Scholes option-pricing model. The table for the year ending December 31, 2023 presents inputs used under a Monte Carlo simulation model:

    

December 31, 2024

    

December 31, 2023

 

Exercise price

$

9.00

$

9.00

Closing stock price

$

5.03

$

18.70

Number of warrants outstanding

 

308,333

 

1,200,000

Phase III data probability of success

 

%  

 

60

%

Volatility

 

80

%  

 

55

%

Term (time to expiration in years)

 

3.84

 

4.84

Redemption hurdle price

$

$

14.25

Risk-free rate

 

4.3

%  

 

3.9

%

The Canaccord Warrants were exercisable immediately at an exercise price of $9.00 per unit, and redeemable at the Company’s option, in whole or in part, at a redemption price equal to $0.001 per Warrant upon 30 days’ prior written notice, at any time after:

the Company’s public announcement of Positive Topline Data (as defined in the Warrant Agreement) from its Phase 3 in patients with Parkinson’s Disease; and
the date on which (a) the closing price of the Company’s common stock on the principal exchange or trading facility on which it is then traded has equaled or exceeded $14.25 and (b) the average daily trading value (“ADTV”) of the Company’s common stock is equal to or exceeds $2,000,000, for two consecutive Trading Days.

During the year ended December 31, 2024, the Company released topline data from its Phase 3 study in patients with Parkinson’s Disease. It was determined that based on the data, both criteria required for redemption of the Canaccord Warrants were not met. As such, the probability of success and redemption hurdle price inputs were no longer used in the Black-Scholes option-pricing model outlined above for the year ending December 31, 2024.

The Warrants were exercisable immediately and will expire on November 2, 2028, five years from the date of issuance. See Note 7 – Stockholders’ Equity (Deficit) for additional background.

XML 29 R10.htm IDEA: XBRL DOCUMENT v3.25.1
Prepaid Expenses and Other Current Assets
12 Months Ended
Dec. 31, 2024
Prepaid Expenses and Other Current Assets  
Prepaid Expenses and Other Current Assets

(4) Prepaid Expenses and Other Current Assets

Prepaid expenses and other current assets consisted of the following:

As of December 31, 

    

2024

    

2023

Prepaid clinical expenses

$

2,998,811

$

4,391,219

Prepaid other

346,313

23,455

Prepaid insurance

21,098

18,074

Security deposits

 

7,495

 

20,796

Total prepaid expenses and other current assets

$

3,373,717

$

4,453,544

XML 30 R11.htm IDEA: XBRL DOCUMENT v3.25.1
Accrued Expenses
12 Months Ended
Dec. 31, 2024
Accrued Expenses  
Accrued Expenses

(5) Accrued Expenses

Accrued expenses consisted of the following:

As of December 31, 

    

2024

    

2023

Accrued clinical expenses

$

948,695

$

2,645,589

Payroll and related benefits

364,717

96,848

Accrued professional fees and other

 

261,601

 

243,836

Total accrued expenses

$

1,575,013

$

2,986,273

XML 31 R12.htm IDEA: XBRL DOCUMENT v3.25.1
Commitments and Contingencies
12 Months Ended
Dec. 31, 2024
Commitments and Contingencies  
Commitments and Contingencies

(6) Commitments and Contingencies

(a) Research & Development

The Company has entered contracts with CROs and CMOs related the Company’s clinical trials. The contracts require upfront payments, milestone payments, and pass-through cost reimbursements, to be made. While the contracts are generally cancellable with (written) notice, the Company is obligated to make payments for services rendered through the termination date of the project with any applicable CRO/CMO.

(b) Leases

The Company maintains one short-term lease associated with occupying its corporate headquarters. Total rental expense was $0.1 million and $0.1 million for the years ended December 31, 2024 and 2023, respectively.

(c) Employment Agreements

The Company has an agreement with its Chief Executive Officer that provides for severance payments upon termination of the agreement by the Company for any reason other than for cause, death or disability or by the employee for good reason. The maximum aggregate severance payments under the agreement was estimated to be $1.1 million at December 31, 2024.

(d) Litigation

The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows.

For both the years ended December 31, 2024 and December 31, 2023 the Company did not have any pending legal actions deemed to be material.

XML 32 R13.htm IDEA: XBRL DOCUMENT v3.25.1
Stockholders' (Deficit) Equity
12 Months Ended
Dec. 31, 2024
Stockholders' (Deficit) Equity  
Stockholders' (Deficit) Equity

(7) Stockholders’ Equity (Deficit)

(a) Overview

The Company’s Amended and Restated Certificate of Incorporation was adopted on January 31, 2020, in conjunction with the closing of the Company’s initial public offering (the “IPO”) and amended on June 15, 2023 to increase the authorized number of shares. Currently, there are two classes of stock authorized which are designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is 72,000,000, each with a par value of $0.0001 per share. Of these shares, 70,000,000 is designated as common stock and 2,000,000 is preferred stock.

(b) Common Stock

Dividends

Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board of Directors.

Liquidation

Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.

Voting

The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.

(c) Preferred Stock

Preferred stock may be issued from time to time by the Board in one or more series. There was no preferred stock issued or outstanding as of December 31, 2024 or December 31, 2023.

(d) IPO Warrants

In conjunction with the closing of the Company’s Initial Public Offering (“IPO”), the Company granted its underwriters 0.1 million warrants to purchase shares of Company common stock (“IPO Warrants”) at an exercise price of $7.50 per share, which was 125% of the IPO price. The IPO Warrants have a five-year term and were exercisable as of January 29, 2021 and have been classified by the Company as a component of stockholders’ equity. At both December 31, 2024 and December 31, 2023, 2,400 of the IPO Warrants were outstanding. No IPO Warrants were exercised during the years ended December 31, 2024 or 2023.

(e) March 2023 ATM

On March 31, 2023, the Company, entered into an At the Market (“ATM”) Equity Offering Sales Agreement (the “Sales Agreement” or “March 2023 ATM”) with BofA Securities, Inc. (“BofA”) and ThinkEquity LLC (“ThinkEquity” and, together with BofA, the “Sales Agents”), as sales agents, pursuant to which the Company could offer and sell, from time to time through the Sales Agents, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $50.0 million.

On April 4, 2023, the Company delivered written notice to BofA and ThinkEquity to terminate the Sales Agreement, effective April 9, 2023. The Company was not subject to any termination penalties related to the termination of the Sales Agreement.

Prior to termination of the Sales Agreement, the Company sold 0.7 million shares of Common Stock pursuant to the Sales Agreement at a price of $10.88 per share, for gross proceeds of $7.6 million before commissions. As a result of the termination of the Sales Agreement, the Company will not offer or sell any additional shares of Common Stock under the Sales Agreement.

(f) April 2023 Private Placement

On April 7, 2023, the Company sold 0.1 million shares of its common stock in a private placement to individual members of its Board of Directors and management at a price of $12.61 per share, for aggregate proceeds of $1.1 million.

(g) November 2023 Equity Offering and Warrant Issuance

On October 31, 2023, the Company entered into an underwritten offering with a Canaccord Genuity LLC whereby the Company sold (i) 1,250,000 shares of common stock and (ii) warrants (“Canaccord Warrants”) to purchase an aggregate of 1,250,000 shares of common stock at an exercise price of $9.00 per share. The offering closed on November, 2, 2023. The warrants were exercisable immediately on the date of issuance and will expire five years after the date of issuance. The Company received $6.8 million in net cash proceeds after deducting underwriter discount and fees, as well as other third-party costs. The Canaccord Warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company’s control or not deemed to be indexed to the Company’s stock.

The following is a roll forward of the Common Stock Warrant Liability during the years ended December 31, 2023 and 2024, respectively:

Issuance of Canaccord Warrants

$

2,449,001

Exercise of 50,000 warrants

(606,201)

Change in fair value of warrant liabilities

11,837,200

Warrant liability at December 31, 2023

13,680,000

Change in fair value of warrant liabilities

 

(3,625,893)

Exercise of 891,667 warrants

 

(9,317,107)

Warrant liability at December 31, 2024

$

737,000

(h) Warrant Summary

As of December 31, 2024, the Company had the following common stock warrants outstanding:

    

    

Outstanding 

    

    

    

Outstanding 

    

Exercise 

    

December 31,

Exercised or

December 31,

price per

Expiration

Classification

2023

Granted

Expired

2024

share

date

IPO warrants

 

Equity

 

2,400

 

 

 

2,400

$

7.50

January 29, 2026

Canaccord warrants

 

Liability

 

1,200,000

 

 

(891,667)

 

308,333

$

9.00

November 2, 2028

(i) November 2023 Private Placement

On November 27, 2023, the Company sold 0.2 million shares of its common stock in a private placement to individual members of its Board of Directors and management at a price of $6.10 per share, for aggregate proceeds of $1.3 million.

(j) March 2024 Registered Direct Offerings

On March 15, 2024 and March 21, 2024, the Company entered into two separate securities purchase agreements with the same institutional investor. When aggregating the results of both purchase agreements, the Company issued 0.4 million shares for net proceeds of $3.9 million in registered direct offerings.

(k) April 2024 ELOC Purchase Agreement

On April 25, 2024, the Company entered into an ELOC Purchase Agreement with an ELOC Purchaser, whereby we could offer and sell, from time to time at our sole discretion, and whereby the ELOC Purchaser committed to purchase, up to 2.0 million shares of shares of the Company’s common stock. The term of the agreement was until the expiration of the Company’s active S-3 Registration Statement, unless earlier terminated or exhausted. Due to certain pricing and settlement provisions, the ELOC Purchase Agreement qualified as a standby equity purchase agreement and included an embedded put option and embedded forward option. The Company therefore accounted for the ELOC Purchase Agreement as a derivative measured at fair value, with changes in the fair value recognized in the statements of operations within other financing costs. The Company initially recognized a derivative liability of $1.7 million related to the purchased put option at inception of the ELOC Purchase Agreement. The Company then expensed the difference between the discounted purchase price of the settled forward and the fair value of shares on the date of settlement as a noncash financing issuance cost. The Company recognized $1.3 million of noncash financing costs during the year ended December 31, 2024 related to the discounted purchase price of the settled forward and the underlying fair value of the shares issued.

Upon execution of the ELOC Purchase Agreement, the Company agreed to issue to the ELOC Purchaser 33,937 shares of Common Stock as commitment shares (the “Commitment Shares”). The fair value of the Commitment Shares was $0.5 million, which was expensed within other financing costs in the statements of operations during the year ended December 31, 2024. The Company also incurred issuance costs of $0.1 million, consisting of legal costs incurred in connection with the ELOC Purchase Agreement, which were expensed within other financing costs in the statements of operations during the year ended December 31, 2024. The ELOC Purchaser agreed that during the term of the Purchase Agreement, neither it nor any of its affiliates would engage in any short sales or hedging transactions involving the Company’s common stock.

Under the ELOC Purchase Agreement, on any business day (the “Purchase Date”), if the Company’s stock price is greater than or equal to $5.00 per share, the Company could direct the ELOC Purchaser to purchase common stock. The ELOC Purchaser’s committed obligation under any single Fixed Purchase could not exceed the lower of 25,000 shares of Common Stock or $250,000 (“Fixed Purchases”).

In addition, the Company could also direct the ELOC Purchaser, on any trading day in which the Company submitted a Fixed Purchase notice for the maximum amount allowed for such Fixed Purchase, to purchase an additional amount of the Company’s common stock (a “VWAP Purchase”). The ELOC Purchaser’s committed obligation under any single VWAP Purchase could not exceed a number of shares of Common Stock equal to the lesser of (i) 300% of the number of Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Fixed Purchase Notice and (ii) 30% of the trading volume in the Company’s Common Stock on the NYSE during the applicable VWAP Purchase Period on the applicable VWAP Purchase Date (“VWAP Purchase Maximum Amount”).

The Company could also direct the ELOC Purchaser, on any trading day for which a VWAP Purchase had been completed and all of the shares had been placed, to purchase an additional amount of the Company’s common stock (an “Additional VWAP Purchase”). The ELOC Purchaser’s committed obligation under any single Additional VWAP Purchase was the lesser of (i) 300% of the number of Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Fixed Purchase Notice and (ii) a number of Shares equal to (A) the Additional VWAP Purchase Share Percentage multiplied by (B) the trading volume of shares of Common Stock traded during the applicable Additional VWAP Purchase Period on the applicable Additional VWAP Purchase Date for such Additional VWAP Purchase (“Additional VWAP Purchase Maximum Amount”). The applicable pricing structure for each purchase type is outlined below:

The purchase price per share for Fixed Purchases (“Fixed Purchase Price”) equals 95% of the lesser of:

the daily volume weighted average price (“VWAP”) of the Company’s Common Stock on the NYSE for the five (5) Trading Days immediately preceding the applicable Fixed Purchase Date for such Fixed Purchase; and
the Closing Sale Price of a share of Common Stock on the applicable Fixed Purchase Date.

The purchase price per share for VWAP Purchases (“VWAP Purchase Price”) equals 95% of the lesser of:

the VWAP during the applicable VWAP Purchase Period during the applicable VWAP Purchase Date.
the Closing Sale Price of the Common Stock on the applicable VWAP Purchase Date.

The purchase price per share for Additional VWAP Purchases (“Additional VWAP Purchase Price”) equals 95% of the lesser of:

the VWAP for the applicable Additional VWAP Purchase Period during the applicable Additional VWAP Purchase Date; and
the Closing Sale Price of the Common Stock on such applicable Additional VWAP Purchase Date.

In addition to the commitment shares referenced above, a total of 2.0 million shares of the Company’s common stock were issued under the ELOC Purchase Agreement during the year ended December 31, 2024, for net proceeds of $14.6 million. The facility was fully exhausted during 2024 and no further shares are available to issue as of December 31, 2024.

The following is a roll-forward of the ELOC derivative liability from date of execution to December 31, 2024:

Fair value at April 25, 2024

    

1,697,500

Settlements and changes in fair value of ELOC derivative liability

 

(1,192,500)

Fair value at June 30, 2024

 

505,000

Settlements and changes in fair value of ELOC derivative liability

 

(62,500)

Fair value at September 30, 2024

 

442,500

Settlements and changes in fair value of ELOC derivative liability

 

(442,500)

Fair value at December 31, 2024

 

(l) December 2024 ATM

On December 11, 2024, the Company entered into an Equity Distribution Agreement (“Distribution Agreement”) with Oppenheimer & Co. Inc., (“OpCo”) relating to the sale of shares of the Company’s common stock. In accordance with the terms of the Distribution Agreement, The Company may offer and sell shares of its common stock having an aggregate offering price of up to $50.0 million from time to time through or to OpCo, acting as agent or principal.

During the year-ended December 31, 2024, the Company sold 26,788 million shares of common stock pursuant to the Distribution Agreement for gross proceeds of $0.2 million before commissions.

XML 33 R14.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation
12 Months Ended
Dec. 31, 2024
Stock-Based Compensation  
Stock-Based Compensation

(8) Stock-Based Compensation

Effective upon the closing of the Company’s IPO on January 31, 2020, the Company’s 2019 Equity Incentive Plan (the “2019 Plan”) became effective, succeeding the Company’s previous equity incentive plan. No new options may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 12, 2024, the 2019 Plan was amended to increase the number of shares authorized from 2,000,000 to 3,000,000. As of December 31, 2024, the 2019 Plan contained 354,299 shares available for future grants.

The 2019 Plan provides for grants to employees, members of the Board, consultants and advisors to the Company, in the form of stock options, stock awards and other equity-based awards. The amount and terms of grants are determined by the Board, except when they are below previously approved thresholds allowing the Company’s CEO to grant awards on a discretionary basis. The Company’s stock options generally carry a maximum term of 10 years after date of grant and are exercisable in cash, or as otherwise determined by the Board.

Stock-based compensation expense in the statements of operations, including the fair value of stock awards to consultants and advisors for services rendered, for the years ended December 31, 2024 and 2023 was as follows:

Year Ended

December 31, 

    

2024

    

2023

General and administrative

$

2,510,444

$

2,414,867

Research and development

 

1,326,326

2,213,539

$

3,836,770

$

4,628,406

The following table summarizes the Company’s stock option activity:

    

    

    

Weighted

Average

Remaining

Aggregate

Weighted

Contractual

Intrinsic

Number of

Average

Term

Value

Shares

Exercise Price

(Years)

    

(In Thousands)

Outstanding at December 31, 2023

 

1,954,774

$

13.41

6.1

$

17,863

Granted

870,494

6.01

Exercised

(300,000)

3.13

570

Forfeited

(189,248)

20.61

Outstanding at December 31, 2024

 

2,336,020

$

11.39

7.3

$

1,298

Exercisable at December 31, 2024

1,824,122

$

12.80

6.8

$

1,298

The weighted average grant date fair value of stock options granted during the years ended December 31, 2024 and 2023 was $5.16 and $7.39, respectively. During the year ended December 31, 2024 the Company received no cash proceeds from the exercises of stock options. For the year ended December 31, 2023, the Company received $8,385 cash proceeds from the exercises of stock options. As of December 31, 2024, there was unrecognized stock-based compensation expense related to unvested stock option awards, related to service-based options of $2.4 million, which will be recognized over a remaining weighted-average period of 1.0 years.

During the years ended December 31, 2024 and 2023, the Company issued 870,494 and 367,329 options, respectively. Under the grant agreements for the 2024 stock option grants, 382,282 of the options vested immediately and 468,212 of the options vest in substantially equal quarterly installments over two years from the date of grant. There are also 20,000 stock option grants that vest as consulting services are performed and awards are earned. Under the grant agreements for the 2023 stock option grants, 94,624 of the options vested immediately, and 272,705 of the options vest in substantially equal quarterly installments over two years from the date of grant. All of the options have a 10-year term prior to expiration.

The assumptions utilized in the fair value calculations for stock options granted during the years ended December 31, 2024 and 2023, respectively, were as follows:

    

Year Ended

 

Year Ended

 

December 31, 2024

 

December 31, 2023

 

Weighted average risk-free interest rate

 

4.18

%  

4.17

%

Weighted average expected option term (years)

 

5.3

5.5

Weighted average expected volatility

 

123

%  

120

%

Expected dividend yield

 

Related Party Transaction

During the year ended December 31, 2024, the Company issued 20,000 non-qualified stock options to a member of its Board of Directors in consideration for the member’s agreement to serve as a consultant to the Company. The options were issued in one tranche, at a grant price of $5.27 per share. 8,069 of the awards became vested during the year ended December 31, 2024.

XML 34 R15.htm IDEA: XBRL DOCUMENT v3.25.1
Net Loss Per Share
12 Months Ended
Dec. 31, 2024
Net Loss Per Share  
Net Loss Per Share

(9) Net Loss Per Share

The Company has reported a net loss for the years ended December 31, 2024 and 2023, and the basic and diluted net loss per share attributable to common stockholders are the same for both years because all warrants and stock options have been excluded from the computation of diluted weighted-average shares outstanding because such securities would have an antidilutive impact.

The following table sets forth the computation of basic and diluted net loss per common share for the years ended December 31, 2024 and 2023:

Year Ended

December 31, 

    

2024

    

2023

Net loss per share – Basic:

  

 

  

Numerator

Net loss

$

(24,590,375)

$

(56,204,313)

Denominator

 

 

Weighted-average common shares outstanding, basic

12,182,475

9,023,138

Basic net loss per common share

$

(2.02)

$

(6.23)

Net loss per share – Diluted:

Numerator

Net loss

$

(24,590,375)

$

(56,204,313)

Less: gain from change in fair value applicable to dilutive liability-classified warrants

(3,625,893)

Numerator for diluted net loss per share

$

(28,216,268)

$

(56,204,313)

Denominator

Denominator for basic net loss per share

12,182,475

9,023,138

Plus: incremental shares underlying “in the money” liability-classified warrants outstanding

52,969

Denominator for diluted net loss per share

12,235,444

9,023,138

Diluted net loss per common share

$

(2.31)

$

(6.23)

Potentially dilutive securities, whose effect would have been antidilutive, were excluded from the computation of diluted earnings per share for each of the years ended December 31, 2024 and 2023. Total antidilutive securities that were excluded from the computation of diluted weighted-average shares outstanding were as follows:

December 31, 

    

2024

    

2023

Stock options

2,336,020

1,954,774

Warrants

2,400

1,202,400

XML 35 R16.htm IDEA: XBRL DOCUMENT v3.25.1
Income Taxes
12 Months Ended
Dec. 31, 2024
Income Taxes  
Income Taxes

(10) Income Taxes

The federal and state provision (benefit) for income taxes was $0 for the years ended December 31, 2024 and 2023.

A reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements for the years ended December 31, 2024 and 2023 is as follows:

Year Ended

 

December 31, 

 

    

2024

    

2023

 

Federal income tax benefit at statutory rate

 

21.0

%  

21.0

%

State and local tax, net of federal benefit

 

4.0

%  

3.1

%

State and local tax, change in rates

0.0

%

(3.5)

%

Permanent differences

 

(1.9)

%  

(0.4)

%

Research and development credit

4.3

%  

4.5

%

Stock-based compensation

0.0

%  

0.4

%

Change in fair value of warrants

1.5

%

(4.4)

%

Change in valuation allowance

 

(28.9)

%  

(20.7)

%

Effective income tax rate

 

0.0

%  

0.0

%

Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company’s deferred tax assets are comprised of the following:

As of December 31, 

    

2024

    

2023

Net operating loss carryforwards

$

13,634,896

$

9,607,158

Stock compensation

4,390,635

4,245,472

Capitalized R&D

 

1,137,406

 

1,334,494

Section 174

12,802,738

10,793,442

R&D credit carryforwards

 

5,198,123

 

4,132,475

Other

76,757

14,553

Total deferred tax assets

 

37,240,555

 

30,127,594

Less valuation allowance

 

(37,240,555)

 

(30,127,594)

Net deferred taxes

$

$

As of December 31, 2024, the Company had U.S. federal net operating loss (“NOL”) carryforwards of $54.1 million which may be available to offset future income tax liabilities. Federal NOL carryforwards generated in 2017 and prior of $2.8 million will expire beginning in 2032. The remaining federal NOL carryforwards generated in 2018 and later do not expire. As of December 31, 2024, the Company also had U.S. state NOL carryforwards of $56.6 million which may be available to offset future income tax liabilities and will expire beginning in 2028.

The Company has recorded a full valuation allowance against its net deferred tax assets as of December 31, 2024 and 2023 because the Company has determined that is it more likely than not that these assets will not be fully realized due to historic net operating losses incurred. The Company recorded a net change in valuation allowance of $7.1 million and $11.7 million in the years ended December 31, 2024 and 2023, respectively.

As of December 31, 2024, the Company had federal research and development tax credit carryforwards of $5.2 million available to reduce future tax liabilities, which expire beginning in 2028.

Under the provisions of the Internal Revenue Code, the NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of

the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code, or could result in a change in control in the future.

The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The Company’s tax years from 2021 to the present remain open for review. All open years may be examined to the extent that tax credits or NOL carryforwards are used in future periods. To the extent the Company utilizes any tax attributes from a tax period that may otherwise be closed due to statute expiration, the tax authorities may adjust the tax attributes upon their examination of the future period in which the attribute was utilized. The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2024, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company’s statements of operations.

Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (R&E) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&E activities in the US must be amortized over a 5-year period if incurred, and R&E expenses incurred outside the US must be amortized over a 15-year period. R&E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2024, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&E capitalization and amortization to require it to pay cash taxes now or in the near future.

XML 36 R17.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information
12 Months Ended
Dec. 31, 2024
Segment Information  
Segment Information

(11) Segment Information

The Company is a clinical-stage biopharmaceutical company and has not generated any revenue since commencing significant operations in 2008. The Company’s operations are organized and reported as a single reportable segment, which includes all activities related to the discovery, development, and commercialization of our lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. This presentation is consistent with how the Company’s chief operating decision maker (“CODM”), its Chief Executive Officer, assesses the performance of the Company and makes operating decisions. The accounting policies of the segment are the same as those described in the summary of significant accounting policies (see Note 2). The CODM assesses performance and decides how to allocate resources based on net loss as reported on the statements of operations. The CODM uses net loss to monitor actual operating results, assess cash runway, and benchmark against the Company’s competitors. The measure of segment assets is reported on the balance sheets as total assets. The Company’s assets are held in the United States.

When evaluating the Company’s financial performance, the CODM regularly reviews the following expense categories that comprise net loss. The table below sets forth the Company’s segment information as reviewed by the CODM:

Year Ended December 31, 

2024

    

2023

Program expenses related to clinical-stage product candidates

$

(16,723,518)

$

(35,104,702)

Program expenses related to preclinical and discovery programs

(568,214)

(583,154)

Personnel-related expenses (including stock-based compensation)

(6,525,586)

(6,444,920)

General and administrative professional and consultant fees

(1,687,276)

(2,152,485)

Other segment items¹

(1,190,333)

(749,750)

Interest income

331,849

667,898

Other non-cash income (expense) items²

1,772,704

(11,837,199)

Net Loss

$

(24,590,374)

$

(56,204,313)

¹ Other segment items included in net loss include insurance expense, information technology expenses, warrant commissions and other miscellaneous expenses.

² Other non-cash income (expense) items includes financing costs from our ELOC and change in fair value of our liability classified warrants.

XML 37 R18.htm IDEA: XBRL DOCUMENT v3.25.1
Subsequent Events
12 Months Ended
Dec. 31, 2024
Subsequent Events  
Subsequent Events

(12) Subsequent Events

Subsequent to December 31, 2024, the Company sold 0.1 million shares of its common stock under its ATM with OpCo, which the Company entered into in December 2024. The Company received net proceeds of $0.5 million after deducting commissions and fees.

On February 3, 2025, the Company entered into an Underwriting Agreement with ThinkEquity LLC, acting as representative of the underwriters with respect to an underwritten public offering of 5.3 million units of the Company. Each unit sold consisted of one share of common stock and one warrant to purchase one share of common stock (the “ThinkEquity Warrants”), at a per unit price of $4.00 (the “Offering”). Aggregate gross proceeds from the Offering were $21.0 million before deducting underwriting discounts and other estimated offering expenses. The Warrants have an exercise price of $5.00 per share, are immediately exercisable and expire five years from the date of issuance. The shares of Common Stock and Warrants were issued separately. The Company has agreed to suspend sales of its Common Stock under the OpCo ATM Facility for a period of six months after the closing of the Offering.

XML 38 R19.htm IDEA: XBRL DOCUMENT v3.25.1
Pay vs Performance Disclosure - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Pay vs Performance Disclosure    
Net Income (Loss) $ (24,590,375) $ (56,204,313)
XML 39 R20.htm IDEA: XBRL DOCUMENT v3.25.1
Insider Trading Arrangements
3 Months Ended
Dec. 31, 2024
shares
Trading Arrangements, by Individual  
Material Terms of Trading Arrangement

Name and Title

Action

Date

Plan

Aggregate Number of securities to be sold

Plan Expiration Date

Maria Maccecchini, CEO & Director

Adoption

17-Dec-24

Rule 10b5-1

270,000

16-Sep-26

Claudine Bruck, Director

Adoption

17-Dec-24

Rule 10b5-1

21,426

31-Dec-25

Mark White, Director

Adoption

17-Dec-24

Rule 10b5-1

51,426

30-Sep-26

Maria Maccecchini  
Trading Arrangements, by Individual  
Name Maria Maccecchini
Title CEO & Director
Rule 10b5-1 Arrangement Adopted true
Adoption Date 17-Dec-24
Expiration Date 16-Sep-26
Aggregate Available 270,000
Claudine Bruck  
Trading Arrangements, by Individual  
Name Claudine Bruck
Title Director
Rule 10b5-1 Arrangement Adopted true
Adoption Date 17-Dec-24
Expiration Date 31-Dec-25
Aggregate Available 21,426
Mark White  
Trading Arrangements, by Individual  
Name Mark White
Title Director
Rule 10b5-1 Arrangement Adopted true
Adoption Date 17-Dec-24
Expiration Date 30-Sep-26
Aggregate Available 51,426
XML 40 R21.htm IDEA: XBRL DOCUMENT v3.25.1
Insider Trading Policies and Procedures
12 Months Ended
Dec. 31, 2024
Insider Trading Policies and Procedures [Line Items]  
Insider Trading Policies and Procedures Adopted true
XML 41 R22.htm IDEA: XBRL DOCUMENT v3.25.1
Cybersecurity Risk Management and Strategy Disclosure
12 Months Ended
Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]  
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]

Risk Management and Strategy

The Company has adopted processes designed to identify, assess and manage material risks from cybersecurity threats, which are integrated into the Company’s overall risk management systems and processes. Those processes include response to and an assessment of internal and external threats to the security, confidentiality, integrity and availability of our data and information systems, along with other material risks to our operations. The Company references the National Institute of Standards and Technology Cybersecurity Framework to help identify, assess, and manage cybersecurity risks and has adopted and tested a formal cybersecurity incident response plan. As part of our risk management process, the Company engages a third-party provider to conduct periodic maturity assessments. The Company stores data in cloud environments, with security appropriate to the data involved and has adopted controls around, among other things, access and acceptable use, backup and recovery and vendor risk assessment.

Our cybersecurity program is managed by the Annovis Incident Management Committee (the “AIMC”). The AIMC serves as the core team responsible for managing the enterprise-wide cybersecurity policy, maintenance and compliance across all platforms. The AIMC is responsible for the detection and initial assessment of potential cybersecurity threats and incidents. The AIMC classifies detected cyber incidents to allow prioritization, response and escalation. Incidents (if any) are documented for internal reporting processes and regularly shared with senior management.

Our third-party IT service provider is a key part of our cybersecurity program. We partner with a cybersecurity company and leverage their technology and expertise to better protect the Company. From time to time, we engage this vendor to monitor our environment, which includes an outsourced security operations center. We may also from time to time engage partners for periodic penetration testing and vulnerability assessments. We intend to continue to work to formalize our cybersecurity program, including developing processes for third-party service provider cyber-risk oversight and management.

In the event of a potential cybersecurity incident, the AIMC will conduct an assessment to determine the nature and scope of the incident and manages the incident in accordance with our incident response plan until the incident is contained and resolved. The AIMC will document findings and make them available to the Disclosure Committee, which includes cross functional senior management representation from, legal, finance, investor relations and business segments. The Disclosure Committee, in conjunction with third-party experts, including outside legal counsel, is responsible for assessing the materiality of any cybersecurity incident and coordinating external communications and disclosures, including with the Securities and Exchange Commission.

As of December 31, 2024, we are not aware of any cybersecurity threats that have materially affected or are reasonably likely to materially affect the Company's business strategy, results of operations, or financial condition, although we may be materially affected in the future by such risks or future material incidents. See “Risk Factors—Risks Related to Our Business Operations—Disruption, failure or cyber security breaches affecting or targeting computers and infrastructure used by us or our business partners may adversely impact our business and operations” for additional information regarding cybersecurity risks.

Cybersecurity Risk Management Processes Integrated [Flag] true
Cybersecurity Risk Management Processes Integrated [Text Block] The Company has adopted processes designed to identify, assess and manage material risks from cybersecurity threats, which are integrated into the Company’s overall risk management systems and processes. Those processes include response to and an assessment of internal and external threats to the security, confidentiality, integrity and availability of our data and information systems, along with other material risks to our operations.
Cybersecurity Risk Management Third Party Engaged [Flag] true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag] true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag] false
Cybersecurity Risk Board of Directors Oversight [Text Block]

Governance

Roles and Responsibilities

Cybersecurity is an important part of our risk management processes and an area of focus for the Annovis management and Board of Directors. We continue to invest in cybersecurity and enhance our internal controls and processes, which are designed to help protect our systems and the information they contain.

Our Board is actively involved in the assessment, oversight and management of the material risks that could affect the Company. The Board has delegated to the Audit Committee the responsibility to oversee the integrity of the Company’s information technology and cybersecurity risks and to assess the risks and incidents relating to cybersecurity threats. While our Board and Audit Committee oversee cybersecurity risk, management, through the AIMC, is responsible for the implementation and management of cybersecurity risk management systems and processes and for the communication of incidents to senior management and the Audit Committee.

The AIMC meets with the Audit Committee on a quarterly basis and meets with the BOD at least annually. Additionally, the Audit Committee regularly meets with members of the Company’s internal audit function to discuss risk management activities, compliance, best practices, and other related matters.

Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block] Board and Audit Committee
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block] AIMC, is responsible for the implementation and management of cybersecurity risk management systems and processes and for the communication of incidents to senior management and the Audit Committee
Cybersecurity Risk Role of Management [Text Block]

Our cybersecurity program is managed by the Annovis Incident Management Committee (the “AIMC”). The AIMC serves as the core team responsible for managing the enterprise-wide cybersecurity policy, maintenance and compliance across all platforms. The AIMC is responsible for the detection and initial assessment of potential cybersecurity threats and incidents. The AIMC classifies detected cyber incidents to allow prioritization, response and escalation. Incidents (if any) are documented for internal reporting processes and regularly shared with senior management.

In the event of a potential cybersecurity incident, the AIMC will conduct an assessment to determine the nature and scope of the incident and manages the incident in accordance with our incident response plan until the incident is contained and resolved. The AIMC will document findings and make them available to the Disclosure Committee, which includes cross functional senior management representation from, legal, finance, investor relations and business segments. The Disclosure Committee, in conjunction with third-party experts, including outside legal counsel, is responsible for assessing the materiality of any cybersecurity incident and coordinating external communications and disclosures, including with the Securities and Exchange Commission.

Cybersecurity Risk Management Positions or Committees Responsible [Flag] true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block] Annovis Incident Management Committee
Cybersecurity Risk Management Expertise of Management Responsible [Text Block] Our third-party IT service provider is a key part of our cybersecurity program. We partner with a cybersecurity company and leverage their technology and expertise to better protect the Company.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block] the AIMC, is responsible for the implementation and management of cybersecurity risk management systems and processes and for the communication of incidents to senior management and the Audit Committee.The AIMC meets with the Audit Committee on a quarterly basis and meets with the BOD at least annually
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag] true
XML 42 R23.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies (Policies)
12 Months Ended
Dec. 31, 2024
Summary of Significant Accounting Policies  
Basis of Presentation

(a) Basis of Presentation

The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).

Use of Estimates

(b) Use of Estimates

In preparing the financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the accounting for research and development contracts, including clinical trial accruals, common stock warrant liabilities, derivative liabilities and the accounting and fair value measurement of equity awards.

Segment Information

(c) Segment Information

As of December 31, 2024, the Company viewed its operations and managed its business as one operating segment consistent with how the Company's chief operating decision-maker, the Company's Chief Executive Officer, makes decisions regarding resource allocation and assesses performance. As of December 31, 2024, substantially all of the Company's assets were located in the United States. Refer to Note 11 for additional information

Basic and Diluted Net Loss per Share

(d) Basic and Diluted Net Income per Share

Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options and warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion or exercise of securities that would have an anti-dilutive effect.

Cash and Cash Equivalents

(e) Cash and Cash Equivalents

The Company considers all highly-liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents may include bank demand deposits and money market funds that invest primarily in certificates of deposit, commercial paper, and U.S. government agency securities and treasuries. The Company records interest income received on cash and cash equivalents to other income (expense), net in the statements of operations. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse effect on the Company’s financial condition, results of operations, and cash flows.

Issuance Costs Associated with Equity Issuances

(f) Issuance Costs Associated with Equity Issuances

Issuance costs incurred in connection with the Company’s equity issuances, which primarily consist of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. Issuance costs related to the Equity Line of Credit (“ELOC”) Purchase Agreement are expensed as incurred as prescribed by ASC 815.

Derivative Liability

(g) Derivative Liability

The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separate accounting from the underlying agreement under ASC 815 – Derivatives and Hedging. An embedded derivative

that requires separation is accounted for as a separate liability or asset from the host agreement. The separated embedded derivative is accounted for at fair market value, with changes in fair value recognized in the statements of operations within the other financing costs line item. The Company determined that certain features under the ELOC Purchase Agreement (See Note 7 — Stockholders’ Equity (Deficit)) collectively qualified as an embedded derivative. The derivative was accounted for separately from the underlying ELOC Purchase Agreement and is accounted for at fair value. As of December 31, 2024, the liability balance was zero because the ELOC facility had been exhausted and all shares from the equity line had been sold.

Common Stock Warrants

(h) Common Stock Warrants

On October 31, 2023, the Company completed an underwritten offering whereby the Company sold (i) 1,250,000 shares of common stock and (ii) warrants to purchase an aggregate of 1,250,000 shares of common stock at an exercise price of $9.00 per share (“Canaccord Warrants”). The warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company’s control or not deemed to be indexed to the Company’s stock. The warrant liabilities are recorded at fair value regardless of the timing of the redemption feature, the redemption price, or the likelihood of redemption. These warrants are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of change in fair value of warrant liability in the statements of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise, expiration, or other settlement of the warrants. The warrants are classified as Level 3 liabilities.

Research and Development

(i) Research and Development

Research and development costs are either expensed as incurred, or recorded separately as a prepaid asset where expense is recognized when the service is performed. These costs are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on the Company’s contracts with its vendors and are realized in the ordinary course of business.

Patent Costs

(j) Patent Costs

All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.

Stock-Based Compensation

(k) Stock-Based Compensation

The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, Compensation—Stock Compensation (“ASC 718”). The Company has issued stock-based compensation awards, including stock options. ASC 718 requires all stock-based payments, including grants of stock options, to be recognized in the financial statements based on their grant date fair values. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. The Company recognizes forfeitures as they occur.

Expense related to stock-based compensation awards granted with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock options have a contractual term of 10 years. Expense for stock-based compensation awards with performance-based vesting conditions is only recognized when the performance-based vesting condition is deemed probable to occur. Expense related to stock-based compensation awards are recorded in research and development expense or general and administrative expense based on the underlying function of the individual that was granted the stock-based compensation award.

Estimating the fair value of stock options requires the input of subjective assumptions, including the expected term of the stock option, stock price volatility, the risk-free interest rate, and expected dividends. The assumptions used in the Company’s Black-Scholes option-pricing model represent Management’s best estimates and involve a number of variables, uncertainties, assumptions,

and the application of Management’s judgment, as they are inherently subjective. If any assumptions change, the Company’s stock-based compensation expense could be materially different in the future.

The assumptions used in the Company’s Black-Scholes option-pricing model for stock options are as follows:

Expected Term. As Annovis does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the expected term of employee stock options subject to service-based vesting conditions is determined using the “simplified” method, as prescribed in SEC’s Staff Accounting Bulletin No. 107, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock option.

Expected Volatility. The expected volatility is based on historical volatilities of Annovis and similar entities within the Company’s industry for periods commensurate with the assumed expected term.

Risk-Free Interest Rate. The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.

Expected Dividends. The expected dividend yield is 0% because Annovis has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.

Income Taxes

(l) Income Taxes

The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2024 and 2023, the Company had a full valuation allowance against its deferred tax assets.

The Company is subject to the provisions of ASC 740, Income Taxes, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions as of December 31, 2024 or 2023.

Recent Accounting Pronouncements

(m) Recently Adopted Accounting Pronouncements

Effective January 1, 2024, the Company retrospectively adopted Accounting Standards Update (“ASU”) 2023-07, Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures (“ASU 2023-07”) on an annual basis, which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items. ASU 2023-07 also requires public entities with a single reportable segment to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in FASB ASC Topic 280, Segment Reporting. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. See Note 11 for additional disclosures made as a result of adopting ASU 2023-07.

(n) Recent Accounting Pronouncements

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes (Topic 740): Improvements to Income Tax Disclosures (“ASU 2023-09”), which improves income tax disclosures by requiring: (1) consistent categories and greater disaggregation of information in the rate reconciliation, and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The ASU indicates that all entities will apply the guidance prospectively with an option for retroactive application to each period presented in the financial statements. The Company has not determined the impact ASU 2023-09 may have on the Company’s financial statement disclosures, but it does not anticipate material impacts.

In November 2024, the FASB issued ASU 2024-03, Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (“ASU 2024-03”), which requires public entities, at annual and interim reporting periods, to disclose in a tabular format additional information about specific expense categories in the notes to the financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is still evaluating the impacts of this ASU on its future financial statements and disclosures.

XML 43 R24.htm IDEA: XBRL DOCUMENT v3.25.1
Fair Value Measurements (Tables)
12 Months Ended
Dec. 31, 2024
Fair Value Measurements  
Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis

The following tables provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of December 31, 2024 and 2023:

    

    

Fair Value Measurement at

December 31, 2024

Carrying Value

Level 1

    

Level 2

    

Level 3

Assets:

Cash equivalents

$

491,006

$

491,006

$

$

Total assets measured and recorded at fair value

$

491,006

$

491,006

$

$

Liabilities:

Warrant liability

$

737,000

$

$

$

737,000

Total liabilities measured and recorded at fair value

$

737,000

$

$

$

737,000

    

    

Fair Value Measurement at

December 31, 2023

Carrying Value

Level 1

    

Level 2

    

Level 3

Assets:

Cash equivalents

$

5,136,677

$

5,136,677

$

$

Total assets measured and recorded at fair value

$

5,136,677

$

5,136,677

$

$

Liabilities:

Warrant liability

$

13,680,000

$

$

$

13,680,000

Total liabilities measured and recorded at fair value

$

13,680,000

$

$

$

13,680,000

Canaccord Warrants  
Fair Value Measurements  
Schedule of quantitative information regarding Level 3 fair value measurements inputs

The following tables provide quantitative information regarding Level 3 fair value measurements inputs as of their respective measurement dates. The table for the year ending December 31, 2024 presents inputs used under a Black-Scholes option-pricing model. The table for the year ending December 31, 2023 presents inputs used under a Monte Carlo simulation model:

    

December 31, 2024

    

December 31, 2023

 

Exercise price

$

9.00

$

9.00

Closing stock price

$

5.03

$

18.70

Number of warrants outstanding

 

308,333

 

1,200,000

Phase III data probability of success

 

%  

 

60

%

Volatility

 

80

%  

 

55

%

Term (time to expiration in years)

 

3.84

 

4.84

Redemption hurdle price

$

$

14.25

Risk-free rate

 

4.3

%  

 

3.9

%

XML 44 R25.htm IDEA: XBRL DOCUMENT v3.25.1
Prepaid Expenses and Other Current Assets (Tables)
12 Months Ended
Dec. 31, 2024
Prepaid Expenses and Other Current Assets  
Schedule of prepaid expenses and other current assets

Prepaid expenses and other current assets consisted of the following:

As of December 31, 

    

2024

    

2023

Prepaid clinical expenses

$

2,998,811

$

4,391,219

Prepaid other

346,313

23,455

Prepaid insurance

21,098

18,074

Security deposits

 

7,495

 

20,796

Total prepaid expenses and other current assets

$

3,373,717

$

4,453,544

XML 45 R26.htm IDEA: XBRL DOCUMENT v3.25.1
Accrued Expenses (Tables)
12 Months Ended
Dec. 31, 2024
Accrued Expenses  
Schedule of accrued expenses

Accrued expenses consisted of the following:

As of December 31, 

    

2024

    

2023

Accrued clinical expenses

$

948,695

$

2,645,589

Payroll and related benefits

364,717

96,848

Accrued professional fees and other

 

261,601

 

243,836

Total accrued expenses

$

1,575,013

$

2,986,273

XML 46 R27.htm IDEA: XBRL DOCUMENT v3.25.1
Stockholders' (Deficit) Equity (Tables)
12 Months Ended
Dec. 31, 2024
Stockholders' (Deficit) Equity  
Schedule of changes in common stock warrant liabilities

On October 31, 2023, the Company entered into an underwritten offering with a Canaccord Genuity LLC whereby the Company sold (i) 1,250,000 shares of common stock and (ii) warrants (“Canaccord Warrants”) to purchase an aggregate of 1,250,000 shares of common stock at an exercise price of $9.00 per share. The offering closed on November, 2, 2023. The warrants were exercisable immediately on the date of issuance and will expire five years after the date of issuance. The Company received $6.8 million in net cash proceeds after deducting underwriter discount and fees, as well as other third-party costs. The Canaccord Warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company’s control or not deemed to be indexed to the Company’s stock.

The following is a roll forward of the Common Stock Warrant Liability during the years ended December 31, 2023 and 2024, respectively:

Issuance of Canaccord Warrants

$

2,449,001

Exercise of 50,000 warrants

(606,201)

Change in fair value of warrant liabilities

11,837,200

Warrant liability at December 31, 2023

13,680,000

Change in fair value of warrant liabilities

 

(3,625,893)

Exercise of 891,667 warrants

 

(9,317,107)

Warrant liability at December 31, 2024

$

737,000

Schedule of common stock warrants outstanding

As of December 31, 2024, the Company had the following common stock warrants outstanding:

    

    

Outstanding 

    

    

    

Outstanding 

    

Exercise 

    

December 31,

Exercised or

December 31,

price per

Expiration

Classification

2023

Granted

Expired

2024

share

date

IPO warrants

 

Equity

 

2,400

 

 

 

2,400

$

7.50

January 29, 2026

Canaccord warrants

 

Liability

 

1,200,000

 

 

(891,667)

 

308,333

$

9.00

November 2, 2028

XML 47 R28.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation (Tables)
12 Months Ended
Dec. 31, 2024
Stock-Based Compensation  
Schedule of stock-based compensation expense

Stock-based compensation expense in the statements of operations, including the fair value of stock awards to consultants and advisors for services rendered, for the years ended December 31, 2024 and 2023 was as follows:

Year Ended

December 31, 

    

2024

    

2023

General and administrative

$

2,510,444

$

2,414,867

Research and development

 

1,326,326

2,213,539

$

3,836,770

$

4,628,406

Schedule of stock option activity

The following table summarizes the Company’s stock option activity:

    

    

    

Weighted

Average

Remaining

Aggregate

Weighted

Contractual

Intrinsic

Number of

Average

Term

Value

Shares

Exercise Price

(Years)

    

(In Thousands)

Outstanding at December 31, 2023

 

1,954,774

$

13.41

6.1

$

17,863

Granted

870,494

6.01

Exercised

(300,000)

3.13

570

Forfeited

(189,248)

20.61

Outstanding at December 31, 2024

 

2,336,020

$

11.39

7.3

$

1,298

Exercisable at December 31, 2024

1,824,122

$

12.80

6.8

$

1,298

Schedule of weighted average assumptions used to determine fair value of options

    

Year Ended

 

Year Ended

 

December 31, 2024

 

December 31, 2023

 

Weighted average risk-free interest rate

 

4.18

%  

4.17

%

Weighted average expected option term (years)

 

5.3

5.5

Weighted average expected volatility

 

123

%  

120

%

Expected dividend yield

 

XML 48 R29.htm IDEA: XBRL DOCUMENT v3.25.1
Net Loss Per Share (Tables)
12 Months Ended
Dec. 31, 2024
Net Loss Per Share  
Schedule of basic and diluted net loss per share

The following table sets forth the computation of basic and diluted net loss per common share for the years ended December 31, 2024 and 2023:

Year Ended

December 31, 

    

2024

    

2023

Net loss per share – Basic:

  

 

  

Numerator

Net loss

$

(24,590,375)

$

(56,204,313)

Denominator

 

 

Weighted-average common shares outstanding, basic

12,182,475

9,023,138

Basic net loss per common share

$

(2.02)

$

(6.23)

Net loss per share – Diluted:

Numerator

Net loss

$

(24,590,375)

$

(56,204,313)

Less: gain from change in fair value applicable to dilutive liability-classified warrants

(3,625,893)

Numerator for diluted net loss per share

$

(28,216,268)

$

(56,204,313)

Denominator

Denominator for basic net loss per share

12,182,475

9,023,138

Plus: incremental shares underlying “in the money” liability-classified warrants outstanding

52,969

Denominator for diluted net loss per share

12,235,444

9,023,138

Diluted net loss per common share

$

(2.31)

$

(6.23)

Schedule of shares excluded from the computation of diluted weighted-average shares outstanding

Potentially dilutive securities, whose effect would have been antidilutive, were excluded from the computation of diluted earnings per share for each of the years ended December 31, 2024 and 2023. Total antidilutive securities that were excluded from the computation of diluted weighted-average shares outstanding were as follows:

December 31, 

    

2024

    

2023

Stock options

2,336,020

1,954,774

Warrants

2,400

1,202,400

XML 49 R30.htm IDEA: XBRL DOCUMENT v3.25.1
Income Taxes (Tables)
12 Months Ended
Dec. 31, 2024
Income Taxes  
Schedule of reconciliation of income tax provision (benefit)

A reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements for the years ended December 31, 2024 and 2023 is as follows:

Year Ended

 

December 31, 

 

    

2024

    

2023

 

Federal income tax benefit at statutory rate

 

21.0

%  

21.0

%

State and local tax, net of federal benefit

 

4.0

%  

3.1

%

State and local tax, change in rates

0.0

%

(3.5)

%

Permanent differences

 

(1.9)

%  

(0.4)

%

Research and development credit

4.3

%  

4.5

%

Stock-based compensation

0.0

%  

0.4

%

Change in fair value of warrants

1.5

%

(4.4)

%

Change in valuation allowance

 

(28.9)

%  

(20.7)

%

Effective income tax rate

 

0.0

%  

0.0

%

Schedule of significant components of deferred tax assets

Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company’s deferred tax assets are comprised of the following:

As of December 31, 

    

2024

    

2023

Net operating loss carryforwards

$

13,634,896

$

9,607,158

Stock compensation

4,390,635

4,245,472

Capitalized R&D

 

1,137,406

 

1,334,494

Section 174

12,802,738

10,793,442

R&D credit carryforwards

 

5,198,123

 

4,132,475

Other

76,757

14,553

Total deferred tax assets

 

37,240,555

 

30,127,594

Less valuation allowance

 

(37,240,555)

 

(30,127,594)

Net deferred taxes

$

$

XML 50 R31.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information (Tables)
12 Months Ended
Dec. 31, 2024
Segment Information  
Schedule of Segment information

When evaluating the Company’s financial performance, the CODM regularly reviews the following expense categories that comprise net loss. The table below sets forth the Company’s segment information as reviewed by the CODM:

Year Ended December 31, 

2024

    

2023

Program expenses related to clinical-stage product candidates

$

(16,723,518)

$

(35,104,702)

Program expenses related to preclinical and discovery programs

(568,214)

(583,154)

Personnel-related expenses (including stock-based compensation)

(6,525,586)

(6,444,920)

General and administrative professional and consultant fees

(1,687,276)

(2,152,485)

Other segment items¹

(1,190,333)

(749,750)

Interest income

331,849

667,898

Other non-cash income (expense) items²

1,772,704

(11,837,199)

Net Loss

$

(24,590,374)

$

(56,204,313)

¹ Other segment items included in net loss include insurance expense, information technology expenses, warrant commissions and other miscellaneous expenses.

² Other non-cash income (expense) items includes financing costs from our ELOC and change in fair value of our liability classified warrants.

XML 51 R32.htm IDEA: XBRL DOCUMENT v3.25.1
Nature of Business and Management's Plans (Details) - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Nature of Business and Management's Plans    
Revenue $ 0  
Cash and cash equivalents 10,551,916 $ 5,754,720
Accumulated deficit 134,849,462 110,259,087
Net loss 24,590,375 56,204,313
Operating loss $ 26,694,928 $ 45,035,011
XML 52 R33.htm IDEA: XBRL DOCUMENT v3.25.1
Summary of Significant Accounting Policies (Details)
12 Months Ended
Oct. 31, 2023
$ / shares
shares
Dec. 31, 2024
USD ($)
segment
Summary of Significant Accounting Policies    
Number of operating segments | segment   1
Cash and cash equivalents, Federally insured limit | $   $ 250,000
Derivative liability | $   $ 0
Stock option contractual term (in years)   10 years
Expected dividend yield   0.00%
Common stock warrants    
Summary of Significant Accounting Policies    
Number of shares issued | shares 1,250,000  
Number of shares which may be purchased with warrants | shares 1,250,000  
Exercise price of warrants | $ / shares $ 9  
XML 53 R34.htm IDEA: XBRL DOCUMENT v3.25.1
Fair Value Measurements - Hierarchy (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Liabilities:    
Warrant liability $ 737,000 $ 13,680,000
Carrying Value    
Assets:    
Cash equivalents 491,006 5,136,677
Total assets measured and recorded at fair value 491,006 5,136,677
Liabilities:    
Warrant liability 737,000 13,680,000
Total liabilities measured and recorded at fair value 737,000 13,680,000
Fair Value | Level 1    
Assets:    
Cash equivalents 491,006 5,136,677
Total assets measured and recorded at fair value 491,006 5,136,677
Fair Value | Level 3    
Liabilities:    
Warrant liability 737,000 13,680,000
Total liabilities measured and recorded at fair value $ 737,000 $ 13,680,000
XML 54 R35.htm IDEA: XBRL DOCUMENT v3.25.1
Fair Value Measurements - Canaccord Warrants (Details)
Oct. 31, 2023
USD ($)
D
$ / shares
Dec. 31, 2024
$ / shares
shares
Jun. 30, 2024
Dec. 31, 2023
shares
Canaccord warrants        
Fair Value Measurements        
Warrants and Rights Outstanding, Valuation Technique [Extensible Enumeration]   us-gaap:BlackScholesMertonModelMember us-gaap:MonteCarloModelMember  
Number of warrants | shares   308,333   1,200,000
Exercise price of warrants $ 9 $ 9    
Redemption price per share $ 0.001      
Threshold period of notice for redemption 30 days      
Closing price of common stock $ 14.25      
Average daily trading value | $ $ 2,000,000      
Threshold consecutive trading days | D 2      
Term of warrants (in years) 5 years      
Level 3        
Fair Value Measurements        
Number of warrants | shares   308,333   1,200,000
Level 3 | Exercise price        
Fair Value Measurements        
Warrants, measurement input   9   9
Level 3 | Closing stock price        
Fair Value Measurements        
Warrants, measurement input   5.03   18.7
Level 3 | Phase 3 data probability of success        
Fair Value Measurements        
Warrants, measurement input       0.60
Level 3 | Volatility        
Fair Value Measurements        
Warrants, measurement input   0.80   0.55
Level 3 | Term (time to expiration in years)        
Fair Value Measurements        
Warrants, measurement input   3.84   4.84
Level 3 | Redemption hurdle price        
Fair Value Measurements        
Warrants, measurement input       14.25
Level 3 | Risk-free rate        
Fair Value Measurements        
Warrants, measurement input   0.043   0.039
XML 55 R36.htm IDEA: XBRL DOCUMENT v3.25.1
Prepaid Expenses and Other Current Assets (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Prepaid Expenses and Other Current Assets    
Prepaid clinical expenses $ 2,998,811 $ 4,391,219
Prepaid other 346,313 23,455
Prepaid insurance 21,098 18,074
Security deposits 7,495 20,796
Total prepaid expenses and other current assets $ 3,373,717 $ 4,453,544
XML 56 R37.htm IDEA: XBRL DOCUMENT v3.25.1
Accrued Expenses (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Accrued Expenses    
Accrued clinical expenses $ 948,695 $ 2,645,589
Payroll and related benefits 364,717 96,848
Accrued professional fees and other 261,601 243,836
Total accrued expenses $ 1,575,013 $ 2,986,273
XML 57 R38.htm IDEA: XBRL DOCUMENT v3.25.1
Commitments and Contingencies (Details)
$ in Millions
12 Months Ended
Dec. 31, 2024
USD ($)
lease
Dec. 31, 2023
USD ($)
Leases    
Number of short term leases | lease 1  
Rental expense $ 0.1 $ 0.1
Chief Executive Officer    
Employment Agreements    
Maximum aggregate severance payments $ 1.1  
XML 58 R39.htm IDEA: XBRL DOCUMENT v3.25.1
Stockholders' (Deficit) Equity - Overview (Details)
Dec. 31, 2024
Vote
USD ($)
$ / shares
shares
Dec. 31, 2023
$ / shares
shares
Stockholders' (Deficit) Equity    
Number of classes of stock designated | $ 2  
Number of common and preferred shares authorized 72,000,000  
Common stock, par value (dollars per share) | $ / shares $ 0.0001 $ 0.0001
Preferred stock, par value (dollars per share) | $ / shares $ 0.0001 $ 0.0001
Number of common shares authorized 70,000,000 70,000,000
Number of preferred shares authorized 2,000,000 2,000,000
Number of vote for each share of common stock | Vote 1  
Preferred stock, shares issued 0 0
Preferred stock, shares outstanding 0 0
XML 59 R40.htm IDEA: XBRL DOCUMENT v3.25.1
Stockholders' (Deficit) Equity - IPO Warrants (Details) - IPO warrants - $ / shares
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Jan. 31, 2020
Warrants      
Number of shares which may be purchased with warrants     100,000
Exercise price of warrants $ 7.5   $ 7.5
Percentage of exercise price to the share offering price     125.00%
Warrant term     5 years
Warrants outstanding 2,400 2,400  
Number of warrants exercised 0 0  
XML 60 R41.htm IDEA: XBRL DOCUMENT v3.25.1
Stockholders' (Deficit) Equity - ATMs and Private Placements (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Nov. 27, 2023
Apr. 07, 2023
Apr. 04, 2023
Dec. 31, 2024
Dec. 11, 2024
Dec. 31, 2023
Mar. 31, 2023
Stockholders' (Deficit) Equity              
Common stock, par value (dollars per share)       $ 0.0001   $ 0.0001  
March 2023 ATM              
Stockholders' (Deficit) Equity              
Common stock, par value (dollars per share)             $ 0.0001
Aggregate offering price             $ 50,000
Number of shares issued     700,000        
Price per share     $ 10.88        
Gross proceeds from issuance of common shares     $ 7,600        
April 2023 Private Placement              
Stockholders' (Deficit) Equity              
Number of shares issued   100,000          
Price per share   $ 12.61          
Gross proceeds from issuance of common shares   $ 1,100          
November 2023 Private Placement              
Stockholders' (Deficit) Equity              
Number of shares issued 200,000            
Price per share $ 6.1            
Gross proceeds from issuance of common shares $ 1,300            
December 2024 ATM              
Stockholders' (Deficit) Equity              
Aggregate offering price         $ 50,000    
Number of shares issued       26,788      
Gross proceeds from issuance of common shares       $ 200      
XML 61 R42.htm IDEA: XBRL DOCUMENT v3.25.1
Stockholders' (Deficit) Equity - November 2023 Equity Offering and Warrant Issuance (Details) - USD ($)
12 Months Ended
Oct. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Stockholders' (Deficit) Equity      
Net cash proceeds after deducting underwriter discount and fees   $ 18,666,797 $ 16,885,946
November 2023 Equity Offering and Warrant Issuance      
Stockholders' (Deficit) Equity      
Number of shares issued 1,250,000    
Number of shares which may be purchased with warrants 1,250,000    
Exercise price of warrants $ 9    
Term of warrants (in years) 5 years    
Net cash proceeds after deducting underwriter discount and fees $ 6,800,000    
XML 62 R43.htm IDEA: XBRL DOCUMENT v3.25.1
Stockholders' (Deficit) Equity - Rollforward of warrant liability (Details) - USD ($)
2 Months Ended 12 Months Ended
Dec. 31, 2023
Dec. 31, 2024
Dec. 31, 2023
Stockholders' (Deficit) Equity      
Warrant liability, beginning balance   $ 13,680,000  
Change in fair value of warrant liabilities   3,625,893 $ (11,837,200)
Warrant liability, ending balance $ 13,680,000 737,000 13,680,000
Canaccord warrants      
Stockholders' (Deficit) Equity      
Warrant liability, beginning balance 2,449,001 13,680,000  
Change in fair value of warrant liabilities 11,837,200 (3,625,893)  
Exercise of warrants $ (606,201) $ 9,317,107  
Number of warrants exercised 50,000 891,667  
Warrant liability, ending balance $ 13,680,000 $ 737,000 $ 13,680,000
XML 63 R44.htm IDEA: XBRL DOCUMENT v3.25.1
Stockholders' Equity - Warrant Summary (Details) - $ / shares
2 Months Ended 12 Months Ended
Dec. 31, 2023
Dec. 31, 2024
Oct. 31, 2023
Jan. 31, 2020
IPO warrants        
Stockholders' (Deficit) Equity        
Beginning balance   2,400    
Granted      
Exercised or Expired      
Ending balance 2,400 2,400    
Exercise price of warrants   $ 7.5   $ 7.5
Canaccord warrants        
Stockholders' (Deficit) Equity        
Beginning balance   1,200,000    
Granted      
Exercised or Expired (50,000) (891,667)    
Ending balance 1,200,000 308,333    
Exercise price of warrants   $ 9 $ 9  
XML 64 R45.htm IDEA: XBRL DOCUMENT v3.25.1
Stockholders' (Deficit) Equity - Registered Direct Offerings (Details)
shares in Millions
12 Months Ended
Mar. 21, 2024
USD ($)
shares
Dec. 31, 2024
USD ($)
Dec. 31, 2023
USD ($)
Stockholders' (Deficit) Equity      
Proceeds from issuance of common stock, net   $ 18,666,797 $ 16,885,946
Securities Purchase Agreement with an institutional investor      
Stockholders' (Deficit) Equity      
Number of transactions 2    
Number of shares issued | shares 0.4    
Proceeds from issuance of common stock, net $ 3,900,000    
XML 65 R46.htm IDEA: XBRL DOCUMENT v3.25.1
Stockholders' (Deficit) Equity - ELOC Purchase Agreement (Details) - USD ($)
12 Months Ended
Apr. 25, 2024
Dec. 31, 2024
Sep. 30, 2024
Jun. 30, 2024
Stockholders' (Deficit) Equity        
Derivative liability   $ 0    
ELOC Purchase Agreement        
Stockholders' (Deficit) Equity        
Number of authorized shares under terms of the agreement 2      
Derivative liability $ 1,697,500 $ 0 $ 442,500 $ 505,000
Non-cash other financing costs $ 1,300,000      
Number of shares issued   2,000,000    
Value of shares issued, net of issuance costs   $ 14,600,000    
Price per share $ 5      
Commitment Shares        
Stockholders' (Deficit) Equity        
Total commitment shares 33,937      
Value of total commitment shares   500,000    
Issuance costs   $ 100,000    
Fixed Purchase        
Stockholders' (Deficit) Equity        
Purchase price, percentage 95.00%      
Fixed Purchase | Minimum        
Stockholders' (Deficit) Equity        
Total commitment shares 25,000      
Value of total commitment shares $ 250,000      
VWAP Purchase        
Stockholders' (Deficit) Equity        
Maximum percentage of shares directed by Fixed Purchase Notice 300.00%      
Threshold percentage of trading volume 30.00%      
Purchase price, percentage 95.00%      
Additional VWAP Purchase        
Stockholders' (Deficit) Equity        
Maximum percentage of shares directed by Fixed Purchase Notice 300.00%      
Purchase price, percentage 95.00%      
XML 66 R47.htm IDEA: XBRL DOCUMENT v3.25.1
Stockholders' (Deficit) Equity - Changes in derivative liability (Details) - USD ($)
2 Months Ended 3 Months Ended
Jun. 30, 2024
Dec. 31, 2024
Sep. 30, 2024
Stockholders' (Deficit) Equity      
Derivative liability, ending balance   $ 0  
ELOC Purchase Agreement      
Stockholders' (Deficit) Equity      
Derivative liability, beginning balance $ 1,697,500 442,500 $ 505,000
Settlements and changes in fair value of ELOC derivative liability (1,192,500) (442,500) (62,500)
Derivative liability, ending balance $ 505,000 $ 0 $ 442,500
XML 67 R48.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation - Summary of plans (Details) - shares
12 Months Ended
Dec. 31, 2024
Jun. 12, 2024
Jun. 01, 2021
Stock-Based Compensation      
Term of award (in years) 10 years    
2019 Plan      
Stock-Based Compensation      
Shares authorized   3,000,000 2,000,000
Shares available for future grants 354,299    
2019 Plan | Employee Stock Option      
Stock-Based Compensation      
Term of award (in years) 10 years    
2018 Plan | Employee Stock Option      
Stock-Based Compensation      
Shares available for future grants 0    
XML 68 R49.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation - Share-based compensation expense (Details) - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Stock-Based Compensation    
Stock-based compensation expense $ 3,836,770 $ 4,628,406
General and administrative    
Stock-Based Compensation    
Stock-based compensation expense 2,510,444 2,414,867
Research and development    
Stock-Based Compensation    
Stock-based compensation expense $ 1,326,326 $ 2,213,539
XML 69 R50.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation - Stock option activity (Details) - USD ($)
$ / shares in Units, $ in Thousands
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Number of Shares    
Outstanding at beginning of the year 1,954,774  
Granted 870,494 367,329
Exercised (300,000)  
Forfeited (189,248)  
Outstanding at end of the year 2,336,020 1,954,774
Exercisable at end of year 1,824,122  
Weighted Average Exercise Price    
Outstanding at beginning of the year (in dollars per share) $ 13.41  
Granted (in dollars per share) 6.01  
Exercised (in dollars per share) 3.13  
Forfeited (in dollars per share) 20.61  
Outstanding at end of the year (in dollars per share) 11.39 $ 13.41
Exercisable at end of year (in dollars per share) $ 12.8  
Weighted Average Remaining Contractual Term    
Outstanding (in years) 7 years 3 months 18 days 6 years 1 month 6 days
Exercisable (in years) 6 years 9 months 18 days  
Aggregate Intrinsic Value    
Exercised $ 570  
Outstanding 1,298 $ 17,863
Exercisable $ 1,298  
XML 70 R51.htm IDEA: XBRL DOCUMENT v3.25.1
Stock-Based Compensation - Additional disclosures (Details) - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Stock-Based Compensation    
Weighted average grant date fair value $ 5.16 $ 7.39
Proceeds from exercise of stock options $ 0 $ 8,385
Options granted 870,494 367,329
Term of award (in years) 10 years  
Weighted average exercise price $ 6.01  
Estimated fair value of options    
Expected dividend yield 0.00%  
Immediate vesting    
Stock-Based Compensation    
Options granted 382,282 94,624
Vests in equal quarterly installments over two years    
Stock-Based Compensation    
Options granted 468,212 272,705
Vesting period 2 years 2 years
Performance-based vesting conditions    
Stock-Based Compensation    
Options granted 20,000  
Director    
Stock-Based Compensation    
Options granted 20,000  
Weighted average exercise price $ 5.27  
Director | Immediate vesting    
Stock-Based Compensation    
Options granted 8,069  
Employee Stock Option    
Estimated fair value of options    
Expected dividend yield 0.00% 0.00%
Employee Stock Option | Weighted average    
Estimated fair value of options    
Risk-free interest rate 4.18% 4.17%
Expected option terms (years) 5 years 3 months 18 days 5 years 6 months
Expected volatility 123.00% 120.00%
Service-based options    
Stock-Based Compensation    
Unrecognized stock-based compensation expense related to unvested stock option awards $ 2,400,000  
Weighted average recognition period (in years) 1 year  
XML 71 R52.htm IDEA: XBRL DOCUMENT v3.25.1
Net Loss Per Share - Basic and diluted net loss per share (Details) - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Numerator    
Net Income (Loss) $ (24,590,375) $ (56,204,313)
Denominator    
Weighted-average common shares outstanding, basic 12,182,475 9,023,138
Basic net loss per common share $ (2.02) $ (6.23)
Numerator    
Net Income (Loss) $ (24,590,375) $ (56,204,313)
Less: gain from change in fair value applicable to dilutive liability-classified warrants (3,625,893)  
Numerator for diluted net loss per share $ (28,216,268) $ (56,204,313)
Denominator    
Weighted-average common shares outstanding, basic 12,182,475 9,023,138
Plus: Incremental shares underlying "in the money" liability-classified warrants outstanding 52,969  
Denominator for diluted net loss per share 12,235,444 9,023,138
Net loss per share, diluted $ (2.31) $ (6.23)
XML 72 R53.htm IDEA: XBRL DOCUMENT v3.25.1
Net Loss Per Share - Potential shares excluded from calculation (Details) - shares
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Employee Stock Option    
Net Loss Per Share    
Antidilutive securities excluded from computation of earnings per share 2,336,020 1,954,774
Warrants    
Net Loss Per Share    
Antidilutive securities excluded from computation of earnings per share 2,400 1,202,400
XML 73 R54.htm IDEA: XBRL DOCUMENT v3.25.1
Income Taxes - Reconciliation of income tax provision (benefit) (Details) - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income Taxes    
Federal provision (benefit) for income taxes $ 0 $ 0
State provision (benefit) for income taxes $ 0 $ 0
Reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes    
Federal income tax benefit at statutory rate 21.00% 21.00%
State and local tax, net of federal benefit 4.00% 3.10%
State and local tax, change in rates 0.00% (3.50%)
Permanent differences (1.90%) (0.40%)
Research and development credit 4.30% 4.50%
Stock-based compensation 0.00% 0.40%
Change in fair value of warrants 1.50% (4.40%)
Change in valuation allowance (28.90%) (20.70%)
Effective income tax rate 0.00% 0.00%
XML 74 R55.htm IDEA: XBRL DOCUMENT v3.25.1
Income Taxes - Deferred taxes (Details) - USD ($)
Dec. 31, 2024
Dec. 31, 2023
Deferred taxes    
Net operating loss carryforwards $ 13,634,896 $ 9,607,158
Stock compensation 1,137,406 1,334,494
Capitalized R&D 4,390,635 4,245,472
Section 174 12,802,738 10,793,442
R&D credit carryforwards 5,198,123 4,132,475
Other 76,757 14,553
Total deferred tax assets 37,240,555 30,127,594
Less valuation allowance (37,240,555) (30,127,594)
Net deferred taxes $ 0 $ 0
XML 75 R56.htm IDEA: XBRL DOCUMENT v3.25.1
Income Taxes - Additional disclosures (Details) - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Income taxes    
Net change in valuation allowance $ 7,100,000 $ 11,700,000
Accrued interest or penalties 0  
Recognized income tax interest and penalties 0  
Research and development tax credit carryforwards    
Income taxes    
Tax credit carryforward 5,200,000  
U.S. federal    
Income taxes    
Net operating loss carryforwards $ 54,100,000  
R&D amortization period 5 years  
U.S. federal | Generated in 2017 and prior    
Income taxes    
Net operating loss carryforwards $ 2,800,000  
State    
Income taxes    
Net operating loss carryforwards $ 56,600,000  
Outside of the U.S.    
Income taxes    
R&D amortization period 15 years  
XML 76 R57.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Information (Details) - USD ($)
12 Months Ended
Dec. 31, 2024
Dec. 31, 2023
Segment Information    
Interest income $ 331,849 $ 667,898
Net loss (24,590,375) (56,204,313)
Single reportable segment    
Segment Information    
Program expenses related to clinical-stage product candidates (16,723,518) (35,104,702)
Program expenses related to preclinical and discovery programs (568,214) (583,154)
Personnel-related expenses (including stock-based compensation) (6,525,586) (6,444,920)
General and administrative professional and consultant fees (1,687,276) (2,152,485)
Other segment items (1,190,333) (749,750)
Interest income 331,849 667,898
Other non-cash income (expense) items 1,772,704 (11,837,199)
Net loss $ (24,590,374) $ (56,204,313)
XML 77 R58.htm IDEA: XBRL DOCUMENT v3.25.1
Subsequent Events (Details) - USD ($)
$ / shares in Units, $ in Millions
1 Months Ended 12 Months Ended
Feb. 03, 2025
Feb. 01, 2025
Dec. 31, 2024
December 2024 ATM      
Subsequent Events      
Gross proceeds from issuance of common shares     $ 0.2
Number of shares issued     26,788
Subsequent Events      
Subsequent Events      
Temporary suspension of ATM offering 6 months    
Subsequent Events | Public offering      
Subsequent Events      
Number of units to be sold 5,300,000    
Number of common shares included in each unit 1    
Number of warrants included in each unit 1    
Price per share $ 4    
Gross proceeds from issuance of common shares $ 21.0    
Exercise price of warrants $ 5    
Term of warrants 5 years    
Subsequent Events | December 2024 ATM      
Subsequent Events      
Number of shares issued   100,000  
Net proceeds from sale of stock   $ 0.5  
EXCEL 78 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 79 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 80 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 82 FilingSummary.xml IDEA: XBRL DOCUMENT 3.25.1 html 129 287 1 false 54 0 false 8 false false R1.htm 995200090 - Document - Document and Entity Information Sheet http://annovisbio.com/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 995200100 - Statement - Balance Sheets Sheet http://annovisbio.com/role/StatementBalanceSheets Balance Sheets Statements 2 false false R3.htm 995200105 - Statement - Balance Sheets (Parenthetical) Sheet http://annovisbio.com/role/StatementBalanceSheetsParenthetical Balance Sheets (Parenthetical) Statements 3 false false R4.htm 995200200 - Statement - Statements of Operations Sheet http://annovisbio.com/role/StatementStatementsOfOperations Statements of Operations Statements 4 false false R5.htm 995200300 - Statement - Statements of Changes in Stockholders' Equity (Deficit) Sheet http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit Statements of Changes in Stockholders' Equity (Deficit) Statements 5 false false R6.htm 995200400 - Statement - Statements of Cash Flows Sheet http://annovisbio.com/role/StatementStatementsOfCashFlows Statements of Cash Flows Statements 6 false false R7.htm 995210101 - Disclosure - Nature of Business and Management's Plans Sheet http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlans Nature of Business and Management's Plans Notes 7 false false R8.htm 995210201 - Disclosure - Summary of Significant Accounting Policies Sheet http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies Summary of Significant Accounting Policies Notes 8 false false R9.htm 995210301 - Disclosure - Fair Value Measurements Sheet http://annovisbio.com/role/DisclosureFairValueMeasurements Fair Value Measurements Notes 9 false false R10.htm 995210401 - Disclosure - Prepaid Expenses and Other Current Assets Sheet http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets Prepaid Expenses and Other Current Assets Notes 10 false false R11.htm 995210501 - Disclosure - Accrued Expenses Sheet http://annovisbio.com/role/DisclosureAccruedExpenses Accrued Expenses Notes 11 false false R12.htm 995210601 - Disclosure - Commitments and Contingencies Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 12 false false R13.htm 995210701 - Disclosure - Stockholders' (Deficit) Equity Sheet http://annovisbio.com/role/DisclosureStockholdersDeficitEquity Stockholders' (Deficit) Equity Notes 13 false false R14.htm 995210801 - Disclosure - Stock-Based Compensation Sheet http://annovisbio.com/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 14 false false R15.htm 995210901 - Disclosure - Net Loss Per Share Sheet http://annovisbio.com/role/DisclosureNetLossPerShare Net Loss Per Share Notes 15 false false R16.htm 995211001 - Disclosure - Income Taxes Sheet http://annovisbio.com/role/DisclosureIncomeTaxes Income Taxes Notes 16 false false R17.htm 995211101 - Disclosure - Segment Information Sheet http://annovisbio.com/role/DisclosureSegmentInformation Segment Information Notes 17 false false R18.htm 995211201 - Disclosure - Subsequent Events Sheet http://annovisbio.com/role/DisclosureSubsequentEvents Subsequent Events Notes 18 false false R19.htm 995410 - Disclosure - Pay vs Performance Disclosure Sheet http://xbrl.sec.gov/ecd/role/PvpDisclosure Pay vs Performance Disclosure Notes 19 false false R20.htm 995445 - Disclosure - Insider Trading Arrangements Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements Insider Trading Arrangements Notes 20 false false R21.htm 995447 - Disclosure - Insider Trading Policies and Procedures Sheet http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc Insider Trading Policies and Procedures Notes 21 false false R22.htm 995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure Sheet http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure Cybersecurity Risk Management and Strategy Disclosure Notes 22 false false R23.htm 99920202 - Disclosure - Summary of Significant Accounting Policies (Policies) Sheet http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies Summary of Significant Accounting Policies (Policies) Policies http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies 23 false false R24.htm 99930303 - Disclosure - Fair Value Measurements (Tables) Sheet http://annovisbio.com/role/DisclosureFairValueMeasurementsTables Fair Value Measurements (Tables) Tables http://annovisbio.com/role/DisclosureFairValueMeasurements 24 false false R25.htm 99930403 - Disclosure - Prepaid Expenses and Other Current Assets (Tables) Sheet http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables Prepaid Expenses and Other Current Assets (Tables) Tables http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets 25 false false R26.htm 99930503 - Disclosure - Accrued Expenses (Tables) Sheet http://annovisbio.com/role/DisclosureAccruedExpensesTables Accrued Expenses (Tables) Tables http://annovisbio.com/role/DisclosureAccruedExpenses 26 false false R27.htm 99930703 - Disclosure - Stockholders' (Deficit) Equity (Tables) Sheet http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables Stockholders' (Deficit) Equity (Tables) Tables http://annovisbio.com/role/DisclosureStockholdersDeficitEquity 27 false false R28.htm 99930803 - Disclosure - Stock-Based Compensation (Tables) Sheet http://annovisbio.com/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://annovisbio.com/role/DisclosureStockBasedCompensation 28 false false R29.htm 99930903 - Disclosure - Net Loss Per Share (Tables) Sheet http://annovisbio.com/role/DisclosureNetLossPerShareTables Net Loss Per Share (Tables) Tables http://annovisbio.com/role/DisclosureNetLossPerShare 29 false false R30.htm 99931003 - Disclosure - Income Taxes (Tables) Sheet http://annovisbio.com/role/DisclosureIncomeTaxesTables Income Taxes (Tables) Tables http://annovisbio.com/role/DisclosureIncomeTaxes 30 false false R31.htm 99931103 - Disclosure - Segment Information (Tables) Sheet http://annovisbio.com/role/DisclosureSegmentInformationTables Segment Information (Tables) Tables http://annovisbio.com/role/DisclosureSegmentInformation 31 false false R32.htm 99940101 - Disclosure - Nature of Business and Management's Plans (Details) Sheet http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlansDetails Nature of Business and Management's Plans (Details) Details http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlans 32 false false R33.htm 99940201 - Disclosure - Summary of Significant Accounting Policies (Details) Sheet http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails Summary of Significant Accounting Policies (Details) Details http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies 33 false false R34.htm 99940301 - Disclosure - Fair Value Measurements - Hierarchy (Details) Sheet http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails Fair Value Measurements - Hierarchy (Details) Details 34 false false R35.htm 99940302 - Disclosure - Fair Value Measurements - Canaccord Warrants (Details) Sheet http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails Fair Value Measurements - Canaccord Warrants (Details) Details 35 false false R36.htm 99940401 - Disclosure - Prepaid Expenses and Other Current Assets (Details) Sheet http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails Prepaid Expenses and Other Current Assets (Details) Details http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables 36 false false R37.htm 99940501 - Disclosure - Accrued Expenses (Details) Sheet http://annovisbio.com/role/DisclosureAccruedExpensesDetails Accrued Expenses (Details) Details http://annovisbio.com/role/DisclosureAccruedExpensesTables 37 false false R38.htm 99940601 - Disclosure - Commitments and Contingencies (Details) Sheet http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails Commitments and Contingencies (Details) Details http://annovisbio.com/role/DisclosureCommitmentsAndContingencies 38 false false R39.htm 99940701 - Disclosure - Stockholders' (Deficit) Equity - Overview (Details) Sheet http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails Stockholders' (Deficit) Equity - Overview (Details) Details http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables 39 false false R40.htm 99940702 - Disclosure - Stockholders' (Deficit) Equity - IPO Warrants (Details) Sheet http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails Stockholders' (Deficit) Equity - IPO Warrants (Details) Details http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables 40 false false R41.htm 99940703 - Disclosure - Stockholders' (Deficit) Equity - ATMs and Private Placements (Details) Sheet http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails Stockholders' (Deficit) Equity - ATMs and Private Placements (Details) Details http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables 41 false false R42.htm 99940704 - Disclosure - Stockholders' (Deficit) Equity - November 2023 Equity Offering and Warrant Issuance (Details) Sheet http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails Stockholders' (Deficit) Equity - November 2023 Equity Offering and Warrant Issuance (Details) Details http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables 42 false false R43.htm 99940705 - Disclosure - Stockholders' (Deficit) Equity - Rollforward of warrant liability (Details) Sheet http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails Stockholders' (Deficit) Equity - Rollforward of warrant liability (Details) Details http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables 43 false false R44.htm 99940706 - Disclosure - Stockholders' Equity - Warrant Summary (Details) Sheet http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails Stockholders' Equity - Warrant Summary (Details) Details 44 false false R45.htm 99940707 - Disclosure - Stockholders' (Deficit) Equity - Registered Direct Offerings (Details) Sheet http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails Stockholders' (Deficit) Equity - Registered Direct Offerings (Details) Details http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables 45 false false R46.htm 99940708 - Disclosure - Stockholders' (Deficit) Equity - ELOC Purchase Agreement (Details) Sheet http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails Stockholders' (Deficit) Equity - ELOC Purchase Agreement (Details) Details http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables 46 false false R47.htm 99940709 - Disclosure - Stockholders' (Deficit) Equity - Changes in derivative liability (Details) Sheet http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails Stockholders' (Deficit) Equity - Changes in derivative liability (Details) Details http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables 47 false false R48.htm 99940801 - Disclosure - Stock-Based Compensation - Summary of plans (Details) Sheet http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails Stock-Based Compensation - Summary of plans (Details) Details 48 false false R49.htm 99940802 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details) Sheet http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails Stock-Based Compensation - Share-based compensation expense (Details) Details 49 false false R50.htm 99940803 - Disclosure - Stock-Based Compensation - Stock option activity (Details) Sheet http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails Stock-Based Compensation - Stock option activity (Details) Details 50 false false R51.htm 99940804 - Disclosure - Stock-Based Compensation - Additional disclosures (Details) Sheet http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails Stock-Based Compensation - Additional disclosures (Details) Details 51 false false R52.htm 99940901 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details) Sheet http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails Net Loss Per Share - Basic and diluted net loss per share (Details) Details 52 false false R53.htm 99940902 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details) Sheet http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails Net Loss Per Share - Potential shares excluded from calculation (Details) Details 53 false false R54.htm 99941001 - Disclosure - Income Taxes - Reconciliation of income tax provision (benefit) (Details) Sheet http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails Income Taxes - Reconciliation of income tax provision (benefit) (Details) Details 54 false false R55.htm 99941002 - Disclosure - Income Taxes - Deferred taxes (Details) Sheet http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails Income Taxes - Deferred taxes (Details) Details 55 false false R56.htm 99941003 - Disclosure - Income Taxes - Additional disclosures (Details) Sheet http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails Income Taxes - Additional disclosures (Details) Details 56 false false R57.htm 99941101 - Disclosure - Segment Information (Details) Sheet http://annovisbio.com/role/DisclosureSegmentInformationDetails Segment Information (Details) Details http://annovisbio.com/role/DisclosureSegmentInformationTables 57 false false R58.htm 99941201 - Disclosure - Subsequent Events (Details) Sheet http://annovisbio.com/role/DisclosureSubsequentEventsDetails Subsequent Events (Details) Details http://annovisbio.com/role/DisclosureSubsequentEvents 58 false false All Reports Book All Reports anvs-20241231.xsd anvs-20241231_cal.xml anvs-20241231_def.xml anvs-20241231_lab.xml anvs-20241231_pre.xml anvs-20241231x10k.htm anvs-20241231x10k003.jpg anvs-20241231x10k004.jpg anvs-20241231x10k005.jpg anvs-20241231x10k006.jpg anvs-20241231x10k007.jpg anvs-20241231x10k008.jpg anvs-20241231x10k009.jpg http://fasb.org/us-gaap/2024 http://xbrl.sec.gov/cyd/2024 http://xbrl.sec.gov/dei/2024 http://xbrl.sec.gov/ecd/2024 true true JSON 85 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "anvs-20241231x10k.htm": { "nsprefix": "anvs", "nsuri": "http://annovisbio.com/20241231", "dts": { "schema": { "local": [ "anvs-20241231.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/2023/calculation-1.1.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-roles-2024.xsd", "https://xbrl.fasb.org/srt/2024/elts/srt-types-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-gaap-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-roles-2024.xsd", "https://xbrl.fasb.org/us-gaap/2024/elts/us-types-2024.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-af-sub-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-2024.xsd", "https://xbrl.sec.gov/ecd/2024/ecd-sub-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "calculationLink": { "local": [ "anvs-20241231_cal.xml" ] }, "definitionLink": { "local": [ "anvs-20241231_def.xml" ] }, "labelLink": { "local": [ "anvs-20241231_lab.xml" ] }, "presentationLink": { "local": [ "anvs-20241231_pre.xml" ] }, "inline": { "local": [ "anvs-20241231x10k.htm" ] } }, "keyStandard": 225, "keyCustom": 62, "axisStandard": 20, "axisCustom": 0, "memberStandard": 27, "memberCustom": 25, "hidden": { "total": 25, "http://fasb.org/us-gaap/2024": 15, "http://xbrl.sec.gov/dei/2024": 4, "http://annovisbio.com/20241231": 5, "http://xbrl.sec.gov/ecd/2024": 1 }, "contextCount": 129, "entityCount": 1, "segmentCount": 54, "elementCount": 551, "unitCount": 8, "baseTaxonomies": { "http://fasb.org/us-gaap/2024": 391, "http://xbrl.sec.gov/dei/2024": 39, "http://xbrl.sec.gov/ecd/2024": 20, "http://xbrl.sec.gov/cyd/2024": 15 }, "report": { "R1": { "role": "http://annovisbio.com/role/DocumentDocumentAndEntityInformation", "longName": "995200090 - Document - Document and Entity Information", "shortName": "Document and Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R2": { "role": "http://annovisbio.com/role/StatementBalanceSheets", "longName": "995200100 - Statement - Balance Sheets", "shortName": "Balance Sheets", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "2", "firstAnchor": { "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA", "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA", "name": "us-gaap:Assets", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "unique": true } }, "R3": { "role": "http://annovisbio.com/role/StatementBalanceSheetsParenthetical", "longName": "995200105 - Statement - Balance Sheets (Parenthetical)", "shortName": "Balance Sheets (Parenthetical)", "isDefault": "false", "groupType": "statement", "subGroupType": "parenthetical", "menuCat": "Statements", "order": "3", "firstAnchor": { "contextRef": "As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww", "name": "us-gaap:PreferredStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA", "name": "us-gaap:CommonStockSharesIssued", "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "unique": true } }, "R4": { "role": "http://annovisbio.com/role/StatementStatementsOfOperations", "longName": "995200200 - Statement - Statements of Operations", "shortName": "Statements of Operations", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "4", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ResearchAndDevelopmentExpense", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R5": { "role": "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit", "longName": "995200300 - Statement - Statements of Changes in Stockholders' Equity (Deficit)", "shortName": "Statements of Changes in Stockholders' Equity (Deficit)", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "5", "firstAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xG1BLCeWX0u4MxvS-D_F1A", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_xG1BLCeWX0u4MxvS-D_F1A", "name": "us-gaap:StockholdersEquity", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R6": { "role": "http://annovisbio.com/role/StatementStatementsOfCashFlows", "longName": "995200400 - Statement - Statements of Cash Flows", "shortName": "Statements of Cash Flows", "isDefault": "false", "groupType": "statement", "subGroupType": "", "menuCat": "Statements", "order": "6", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ProfitLoss", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R7": { "role": "http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlans", "longName": "995210101 - Disclosure - Nature of Business and Management's Plans", "shortName": "Nature of Business and Management's Plans", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "7", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R8": { "role": "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies", "longName": "995210201 - Disclosure - Summary of Significant Accounting Policies", "shortName": "Summary of Significant Accounting Policies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "8", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R9": { "role": "http://annovisbio.com/role/DisclosureFairValueMeasurements", "longName": "995210301 - Disclosure - Fair Value Measurements", "shortName": "Fair Value Measurements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "9", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:FairValueDisclosuresTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R10": { "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets", "longName": "995210401 - Disclosure - Prepaid Expenses and Other Current Assets", "shortName": "Prepaid Expenses and Other Current Assets", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "10", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R11": { "role": "http://annovisbio.com/role/DisclosureAccruedExpenses", "longName": "995210501 - Disclosure - Accrued Expenses", "shortName": "Accrued Expenses", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "11", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R12": { "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingencies", "longName": "995210601 - Disclosure - Commitments and Contingencies", "shortName": "Commitments and Contingencies", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "12", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R13": { "role": "http://annovisbio.com/role/DisclosureStockholdersDeficitEquity", "longName": "995210701 - Disclosure - Stockholders' (Deficit) Equity", "shortName": "Stockholders' (Deficit) Equity", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "13", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R14": { "role": "http://annovisbio.com/role/DisclosureStockBasedCompensation", "longName": "995210801 - Disclosure - Stock-Based Compensation", "shortName": "Stock-Based Compensation", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "14", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R15": { "role": "http://annovisbio.com/role/DisclosureNetLossPerShare", "longName": "995210901 - Disclosure - Net Loss Per Share", "shortName": "Net Loss Per Share", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "15", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:EarningsPerShareTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R16": { "role": "http://annovisbio.com/role/DisclosureIncomeTaxes", "longName": "995211001 - Disclosure - Income Taxes", "shortName": "Income Taxes", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "16", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R17": { "role": "http://annovisbio.com/role/DisclosureSegmentInformation", "longName": "995211101 - Disclosure - Segment Information", "shortName": "Segment Information", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "17", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:SegmentReportingDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R18": { "role": "http://annovisbio.com/role/DisclosureSubsequentEvents", "longName": "995211201 - Disclosure - Subsequent Events", "shortName": "Subsequent Events", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "18", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:SubsequentEventsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R19": { "role": "http://xbrl.sec.gov/ecd/role/PvpDisclosure", "longName": "995410 - Disclosure - Pay vs Performance Disclosure", "shortName": "Pay vs Performance Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "19", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true }, "uniqueAnchor": null }, "R20": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "longName": "995445 - Disclosure - Insider Trading Arrangements", "shortName": "Insider Trading Arrangements", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "20", "firstAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_MGlUmH3MfkWLfNYZY2PITw", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_10_1_2024_To_12_31_2024_MGlUmH3MfkWLfNYZY2PITw", "name": "ecd:MtrlTermsOfTrdArrTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R21": { "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc", "longName": "995447 - Disclosure - Insider Trading Policies and Procedures", "shortName": "Insider Trading Policies and Procedures", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "21", "firstAnchor": null, "uniqueAnchor": null }, "R22": { "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure", "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure", "shortName": "Cybersecurity Risk Management and Strategy Disclosure", "isDefault": "false", "groupType": "disclosure", "subGroupType": "", "menuCat": "Notes", "order": "22", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R23": { "role": "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies", "longName": "99920202 - Disclosure - Summary of Significant Accounting Policies (Policies)", "shortName": "Summary of Significant Accounting Policies (Policies)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "policies", "menuCat": "Policies", "order": "23", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:BasisOfAccounting", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:BasisOfAccounting", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R24": { "role": "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables", "longName": "99930303 - Disclosure - Fair Value Measurements (Tables)", "shortName": "Fair Value Measurements (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "24", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R25": { "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables", "longName": "99930403 - Disclosure - Prepaid Expenses and Other Current Assets (Tables)", "shortName": "Prepaid Expenses and Other Current Assets (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "25", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R26": { "role": "http://annovisbio.com/role/DisclosureAccruedExpensesTables", "longName": "99930503 - Disclosure - Accrued Expenses (Tables)", "shortName": "Accrued Expenses (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "26", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R27": { "role": "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables", "longName": "99930703 - Disclosure - Stockholders' (Deficit) Equity (Tables)", "shortName": "Stockholders' (Deficit) Equity (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "27", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "anvs:ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "anvs:ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R28": { "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationTables", "longName": "99930803 - Disclosure - Stock-Based Compensation (Tables)", "shortName": "Stock-Based Compensation (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "28", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R29": { "role": "http://annovisbio.com/role/DisclosureNetLossPerShareTables", "longName": "99930903 - Disclosure - Net Loss Per Share (Tables)", "shortName": "Net Loss Per Share (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "29", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R30": { "role": "http://annovisbio.com/role/DisclosureIncomeTaxesTables", "longName": "99931003 - Disclosure - Income Taxes (Tables)", "shortName": "Income Taxes (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "30", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R31": { "role": "http://annovisbio.com/role/DisclosureSegmentInformationTables", "longName": "99931103 - Disclosure - Segment Information (Tables)", "shortName": "Segment Information (Tables)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "tables", "menuCat": "Tables", "order": "31", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R32": { "role": "http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlansDetails", "longName": "99940101 - Disclosure - Nature of Business and Management's Plans (Details)", "shortName": "Nature of Business and Management's Plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "32", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "-6", "ancestors": [ "p", "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R33": { "role": "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails", "longName": "99940201 - Disclosure - Summary of Significant Accounting Policies (Details)", "shortName": "Summary of Significant Accounting Policies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "33", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_IBXfWvS8o0ORI540t7gqug", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:NumberOfOperatingSegments", "unitRef": "Unit_Standard_segment_IBXfWvS8o0ORI540t7gqug", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:SegmentReportingPolicyPolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R34": { "role": "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails", "longName": "99940301 - Disclosure - Fair Value Measurements - Hierarchy (Details)", "shortName": "Fair Value Measurements - Hierarchy (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "34", "firstAnchor": { "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA", "name": "anvs:WarrantLiabilityNoncurrent", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_CarryingReportedAmountFairValueDisclosureMember_c0ZCp4j2MkO7y0Djf-eKnA", "name": "us-gaap:CashAndCashEquivalentsFairValueDisclosure", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "us-gaap:FairValueDisclosuresTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "unique": true } }, "R35": { "role": "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails", "longName": "99940302 - Disclosure - Fair Value Measurements - Canaccord Warrants (Details)", "shortName": "Fair Value Measurements - Canaccord Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "35", "firstAnchor": { "contextRef": "As_Of_12_31_2024_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_fC7oQbTiCkKetGBK6EOq-Q", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_dT2gLJszR029SS3nhdL4Fw", "name": "anvs:ClassOfWarrantOrRightRedemptionPricePerShare", "unitRef": "Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw", "xsiNil": "false", "lang": null, "decimals": "3", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "unique": true } }, "R36": { "role": "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "longName": "99940401 - Disclosure - Prepaid Expenses and Other Current Assets (Details)", "shortName": "Prepaid Expenses and Other Current Assets (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "36", "firstAnchor": { "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA", "name": "anvs:PrepaidResearchAndDevelopmentExpenseCurrent", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA", "name": "anvs:PrepaidResearchAndDevelopmentExpenseCurrent", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "anvs:DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R37": { "role": "http://annovisbio.com/role/DisclosureAccruedExpensesDetails", "longName": "99940501 - Disclosure - Accrued Expenses (Details)", "shortName": "Accrued Expenses (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "37", "firstAnchor": { "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA", "name": "anvs:AccruedClinicalLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA", "name": "anvs:AccruedClinicalLiabilitiesCurrent", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock", "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R38": { "role": "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails", "longName": "99940601 - Disclosure - Commitments and Contingencies (Details)", "shortName": "Commitments and Contingencies (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "38", "firstAnchor": { "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA", "name": "anvs:NumberOfShortTermLeases", "unitRef": "Unit_Standard_lease_oDj-5JhEt0KT8kr98NxE0Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA", "name": "anvs:NumberOfShortTermLeases", "unitRef": "Unit_Standard_lease_oDj-5JhEt0KT8kr98NxE0Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R39": { "role": "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails", "longName": "99940701 - Disclosure - Stockholders' (Deficit) Equity - Overview (Details)", "shortName": "Stockholders' (Deficit) Equity - Overview (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "39", "firstAnchor": { "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA", "name": "anvs:NumberOfClassesOfStockDesignated", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA", "name": "anvs:NumberOfClassesOfStockDesignated", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R40": { "role": "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails", "longName": "99940702 - Disclosure - Stockholders' (Deficit) Equity - IPO Warrants (Details)", "shortName": "Stockholders' (Deficit) Equity - IPO Warrants (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "40", "firstAnchor": { "contextRef": "As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_zGLH0xz4SUuuN7zhmxY00w", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_1_31_2020_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_zGLH0xz4SUuuN7zhmxY00w", "name": "us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R41": { "role": "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails", "longName": "99940703 - Disclosure - Stockholders' (Deficit) Equity - ATMs and Private Placements (Details)", "shortName": "Stockholders' (Deficit) Equity - ATMs and Private Placements (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "41", "firstAnchor": { "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "us-gaap:CommonStockParOrStatedValuePerShare", "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_3_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_March2023AtMarketEquityOfferingMember_DM9G2OExTE29vPXXRQzbhQ", "name": "us-gaap:CommonStockParOrStatedValuePerShare", "unitRef": "Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "unique": true } }, "R42": { "role": "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails", "longName": "99940704 - Disclosure - Stockholders' (Deficit) Equity - November 2023 Equity Offering and Warrant Issuance (Details)", "shortName": "Stockholders' (Deficit) Equity - November 2023 Equity Offering and Warrant Issuance (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "42", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_10_31_2023_us-gaap_SubsidiarySaleOfStockAxis_anvs_November2023EquityOfferingAndWarrantIssuanceMember_ztvL4dJrEki0TQD2nUkWvw", "name": "us-gaap:WarrantsAndRightsOutstandingTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "anvs:ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "unique": true } }, "R43": { "role": "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails", "longName": "99940705 - Disclosure - Stockholders' (Deficit) Equity - Rollforward of warrant liability (Details)", "shortName": "Stockholders' (Deficit) Equity - Rollforward of warrant liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "43", "firstAnchor": { "contextRef": "As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww", "name": "anvs:WarrantLiabilityNoncurrent", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_10_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsLiabilitiesMember_dT2gLJszR029SS3nhdL4Fw", "name": "anvs:WarrantLiabilityNoncurrent", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "anvs:ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "unique": true } }, "R44": { "role": "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails", "longName": "99940706 - Disclosure - Stockholders' Equity - Warrant Summary (Details)", "shortName": "Stockholders' Equity - Warrant Summary (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "44", "firstAnchor": { "contextRef": "As_Of_12_31_2023_us-gaap_ClassOfWarrantOrRightAxis_anvs_WarrantsClassifiedAsEquityMember_g2Axm8rylUWspyA6FuMXng", "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true }, "uniqueAnchor": null }, "R45": { "role": "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails", "longName": "99940707 - Disclosure - Stockholders' (Deficit) Equity - Registered Direct Offerings (Details)", "shortName": "Stockholders' (Deficit) Equity - Registered Direct Offerings (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "45", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_3_15_2024_To_3_21_2024_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_PrivatePlacementMember_3kCBCp5ZA0uFygJdADIVew", "name": "anvs:NumberOfSaleOfStockTransactions", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "unique": true } }, "R46": { "role": "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails", "longName": "99940708 - Disclosure - Stockholders' (Deficit) Equity - ELOC Purchase Agreement (Details)", "shortName": "Stockholders' (Deficit) Equity - ELOC Purchase Agreement (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "46", "firstAnchor": { "contextRef": "As_Of_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_0gUFcL1MOE27UglgyHqIog", "name": "anvs:CommonStockPurchaseAgreementSharesAuthorized", "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_0gUFcL1MOE27UglgyHqIog", "name": "anvs:CommonStockPurchaseAgreementSharesAuthorized", "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R47": { "role": "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails", "longName": "99940709 - Disclosure - Stockholders' (Deficit) Equity - Changes in derivative liability (Details)", "shortName": "Stockholders' (Deficit) Equity - Changes in derivative liability (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "47", "firstAnchor": { "contextRef": "As_Of_4_25_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_0gUFcL1MOE27UglgyHqIog", "name": "us-gaap:DerivativeLiabilitiesNoncurrent", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_4_26_2024_To_6_30_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_CommonStockPurchaseAgreementMember_4nudJCrUe0q5HzKyVLPtIw", "name": "anvs:FairValueAdjustmentOfDerivativeLiabilities", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "unique": true } }, "R48": { "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails", "longName": "99940801 - Disclosure - Stock-Based Compensation - Summary of plans (Details)", "shortName": "Stock-Based Compensation - Summary of plans (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "48", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "As_Of_6_12_2024_us-gaap_PlanNameAxis_anvs_EquityIncentivePlan2019Member_VGsJvkPfqEiFabjsYECyuw", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "unique": true } }, "R49": { "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails", "longName": "99940802 - Disclosure - Stock-Based Compensation - Share-based compensation expense (Details)", "shortName": "Stock-Based Compensation - Share-based compensation expense (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "49", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ShareBasedCompensation", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_gvgCPSCuP0eTU2Ad-DzdLg", "name": "us-gaap:ShareBasedCompensation", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "unique": true } }, "R50": { "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "longName": "99940803 - Disclosure - Stock-Based Compensation - Stock option activity (Details)", "shortName": "Stock-Based Compensation - Stock option activity (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "50", "firstAnchor": { "contextRef": "As_Of_12_31_2023_pr6_3Itio0m7E2yLgfzDww", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q", "xsiNil": "false", "lang": null, "decimals": "INF", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "unique": true } }, "R51": { "role": "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails", "longName": "99940804 - Disclosure - Stock-Based Compensation - Additional disclosures (Details)", "shortName": "Stock-Based Compensation - Additional disclosures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "51", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "unitRef": "Unit_Divide_USD_shares_upMnl7CsKkaQaDWppvDpIw", "xsiNil": "false", "lang": null, "decimals": "2", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R52": { "role": "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "longName": "99940901 - Disclosure - Net Loss Per Share - Basic and diluted net loss per share (Details)", "shortName": "Net Loss Per Share - Basic and diluted net loss per share (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "52", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:NetIncomeLoss", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:DilutiveSecurities", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "unique": true } }, "R53": { "role": "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails", "longName": "99940902 - Disclosure - Net Loss Per Share - Potential shares excluded from calculation (Details)", "shortName": "Net Loss Per Share - Potential shares excluded from calculation (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "53", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_MqKVJkeET0yOdt3W5Sha6w", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_MqKVJkeET0yOdt3W5Sha6w", "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "unitRef": "Unit_Standard_shares_0PiblLn_KE-aEMT1_CR32Q", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "us-gaap:EarningsPerShareTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R54": { "role": "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails", "longName": "99941001 - Disclosure - Income Taxes - Reconciliation of income tax provision (benefit) (Details)", "shortName": "Income Taxes - Reconciliation of income tax provision (benefit) (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "54", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "us-gaap:StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R55": { "role": "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails", "longName": "99941002 - Disclosure - Income Taxes - Deferred taxes (Details)", "shortName": "Income Taxes - Deferred taxes (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "55", "firstAnchor": { "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "As_Of_12_31_2024_q9uvV6AGoEK-Cg0ZHNa9UA", "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R56": { "role": "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails", "longName": "99941003 - Disclosure - Income Taxes - Additional disclosures (Details)", "shortName": "Income Taxes - Additional disclosures (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "56", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true, "unique": true } }, "R57": { "role": "http://annovisbio.com/role/DisclosureSegmentInformationDetails", "longName": "99941101 - Disclosure - Segment Information (Details)", "shortName": "Segment Information (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "57", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_VexRgTJmFEqNDNyjMNMzQg", "name": "us-gaap:InvestmentIncomeInterest", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_StatementBusinessSegmentsAxis_anvs_SingleReportableSegmentMember_9S2GWn_L1EyW1s3TdWoM_A", "name": "anvs:ProgramExpensesRelatedToClinicalStageProductCandidates", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "0", "ancestors": [ "p", "td", "tr", "table", "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock", "us-gaap:SegmentReportingDisclosureTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "unique": true } }, "R58": { "role": "http://annovisbio.com/role/DisclosureSubsequentEventsDetails", "longName": "99941201 - Disclosure - Subsequent Events (Details)", "shortName": "Subsequent Events (Details)", "isDefault": "false", "groupType": "disclosure", "subGroupType": "details", "menuCat": "Details", "order": "58", "firstAnchor": { "contextRef": "Duration_1_1_2024_To_12_31_2024_us-gaap_SubsidiarySaleOfStockAxis_anvs_December2024AtMarketEquityOfferingMember_Ajz0lNfoHESRCWcXvDKjFw", "name": "anvs:GrossProceedsFromIssuanceOfCommonStock", "unitRef": "Unit_Standard_USD_jstSbnFSCU2_eqx5S_UA7A", "xsiNil": "false", "lang": null, "decimals": "-5", "ancestors": [ "p", "ix:continuation", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "first": true }, "uniqueAnchor": { "contextRef": "Duration_2_3_2025_To_2_3_2025_us-gaap_SubsequentEventTypeAxis_us-gaap_SubsequentEventMember_Ks4SJs0ZpUGHrUcFBn_hhg", "name": "anvs:SaleOfStockAtMarketOfferingTemporarySuspensionTerm", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "p", "us-gaap:SubsequentEventsTextBlock", "div", "div", "div", "body", "html" ], "reportCount": 1, "baseRef": "anvs-20241231x10k.htm", "unique": true } } }, "tag": { "us-gaap_AccountingPoliciesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountingPoliciesAbstract", "lang": { "en-us": { "role": { "label": "Summary of Significant Accounting Policies" } } }, "auth_ref": [] }, "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpenses" ], "lang": { "en-us": { "role": { "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]", "terseLabel": "Accrued Expenses", "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period." } } }, "auth_ref": [ "r42", "r44", "r47", "r819" ] }, "us-gaap_AccountsPayableCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccountsPayableCurrent", "crdr": "credit", "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Accounts Payable, Current", "terseLabel": "Accounts payable", "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r42", "r621" ] }, "anvs_AccruedClinicalLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "AccruedClinicalLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": { "parentTag": "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical liabilities.", "label": "Accrued Clinical Liabilities, Current", "terseLabel": "Accrued clinical expenses" } } }, "auth_ref": [] }, "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0, "order": 2.0 }, "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Includes accrued interest and obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits.", "label": "Accrued Liabilities and Interest, and Employee-Related Liabilities, Current", "terseLabel": "Accrued expenses", "totalLabel": "Total accrued expenses" } } }, "auth_ref": [] }, "us-gaap_AccruedLiabilitiesAndOtherLiabilitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedLiabilitiesAndOtherLiabilitiesAbstract", "lang": { "en-us": { "role": { "label": "Accrued Expenses" } } }, "auth_ref": [] }, "us-gaap_AccruedProfessionalFeesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AccruedProfessionalFeesCurrent", "crdr": "credit", "calculation": { "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": { "parentTag": "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Accrued Professional Fees, Current", "terseLabel": "Accrued professional fees and other", "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r44" ] }, "ecd_Additional402vDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Additional402vDisclosureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Additional 402(v) Disclosure [Text Block]", "terseLabel": "Additional 402(v) Disclosure" } } }, "auth_ref": [ "r686" ] }, "us-gaap_AdditionalPaidInCapital": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapital", "crdr": "credit", "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Additional Paid in Capital", "terseLabel": "Additional paid-in capital", "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock." } } }, "auth_ref": [ "r52", "r621", "r883" ] }, "us-gaap_AdditionalPaidInCapitalMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdditionalPaidInCapitalMember", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Additional Paid-in Capital [Member]", "terseLabel": "Additional Paid-in Capital", "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders." } } }, "auth_ref": [ "r512", "r767", "r768", "r769", "r770", "r830", "r886" ] }, "ecd_AdjToCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation Amount", "terseLabel": "Adjustment to Compensation, Amount" } } }, "auth_ref": [ "r699" ] }, "ecd_AdjToCompAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToCompAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Compensation [Axis]", "terseLabel": "Adjustment to Compensation:" } } }, "auth_ref": [ "r699" ] }, "ecd_AdjToNonPeoNeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToNonPeoNeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]", "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote" } } }, "auth_ref": [ "r699" ] }, "ecd_AdjToPeoCompFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AdjToPeoCompFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Adjustment To PEO Compensation, Footnote [Text Block]", "terseLabel": "Adjustment To PEO Compensation, Footnote" } } }, "auth_ref": [ "r699" ] }, "us-gaap_AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsNoncashItemsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Adjustments, Noncash Items, to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "auth_ref": [] }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "APIC, Share-Based Payment Arrangement, Option, Increase for Cost Recognition", "terseLabel": "Stock-based compensation expense", "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for option under share-based payment arrangement." } } }, "auth_ref": [] }, "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table" } } }, "auth_ref": [ "r744" ] }, "ecd_AggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Amount", "terseLabel": "Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r657", "r668", "r678", "r711" ] }, "ecd_AggtErrCompNotYetDeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtErrCompNotYetDeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]", "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined" } } }, "auth_ref": [ "r660", "r671", "r681", "r714" ] }, "ecd_AggtPnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AggtPnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Pension Adjustments Service Cost [Member]", "terseLabel": "Aggregate Pension Adjustments Service Cost" } } }, "auth_ref": [ "r745" ] }, "ecd_AllAdjToCompMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllAdjToCompMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Adjustments to Compensation [Member]", "terseLabel": "All Adjustments to Compensation" } } }, "auth_ref": [ "r699" ] }, "ecd_AllExecutiveCategoriesMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllExecutiveCategoriesMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Executive Categories [Member]", "terseLabel": "All Executive Categories" } } }, "auth_ref": [ "r706" ] }, "ecd_AllIndividualsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllIndividualsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "All Individuals [Member]", "terseLabel": "All Individuals" } } }, "auth_ref": [ "r661", "r672", "r682", "r706", "r715", "r719", "r727" ] }, "ecd_AllTradingArrangementsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AllTradingArrangementsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "All Trading Arrangements [Member]", "terseLabel": "All Trading Arrangements" } } }, "auth_ref": [ "r725" ] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount", "terseLabel": "Antidilutive securities excluded from computation of earnings per share", "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented." } } }, "auth_ref": [ "r142" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities [Axis]", "documentation": "Information by type of antidilutive security." } } }, "auth_ref": [ "r18" ] }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]", "terseLabel": "Net Loss Per Share", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_AntidilutiveSecuritiesNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AntidilutiveSecuritiesNameDomain", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Securities, Name [Domain]", "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented." } } }, "auth_ref": [ "r18" ] }, "anvs_April2023PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "April2023PrivatePlacementMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the April 2023 Private Placement.", "label": "April 2023 Private Placement [Member]", "terseLabel": "April 2023 Private Placement" } } }, "auth_ref": [] }, "us-gaap_Assets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Assets", "crdr": "debit", "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets", "totalLabel": "Total assets", "documentation": "Amount of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r75", "r82", "r92", "r111", "r147", "r154", "r179", "r183", "r222", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r380", "r384", "r419", "r469", "r536", "r588", "r589", "r621", "r635", "r789", "r790", "r842" ] }, "us-gaap_AssetsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsAbstract", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets [Abstract]", "terseLabel": "Assets" } } }, "auth_ref": [] }, "us-gaap_AssetsCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsCurrentAbstract", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Assets, Current [Abstract]", "terseLabel": "Current assets:" } } }, "auth_ref": [] }, "us-gaap_AssetsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosure", "crdr": "debit", "calculation": { "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure", "totalLabel": "Total assets measured and recorded at fair value", "documentation": "Fair value portion of asset recognized for present right to economic benefit." } } }, "auth_ref": [ "r398", "r399", "r611" ] }, "us-gaap_AssetsFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AssetsFairValueDisclosureAbstract", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Assets, Fair Value Disclosure [Abstract]", "terseLabel": "Assets:" } } }, "auth_ref": [] }, "anvs_AtMarketEquityOfferingCommonStockAuthorizedValue": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "AtMarketEquityOfferingCommonStockAuthorizedValue", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails" ], "lang": { "en-us": { "role": { "documentation": "The authorized value of common shares which may be sold under the terms of the At the Market (ATM) Equity Offering.", "label": "At the Market Equity Offering, Common Stock, Authorized Value", "verboseLabel": "Aggregate offering price" } } }, "auth_ref": [] }, "dei_AuditorFirmId": { "xbrltype": "nonemptySequenceNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorFirmId", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Firm ID", "documentation": "PCAOB issued Audit Firm Identifier" } } }, "auth_ref": [ "r640", "r641", "r664" ] }, "dei_AuditorLocation": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorLocation", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Location" } } }, "auth_ref": [ "r640", "r641", "r664" ] }, "dei_AuditorName": { "xbrltype": "internationalNameItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AuditorName", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Auditor Name" } } }, "auth_ref": [ "r640", "r641", "r664" ] }, "anvs_AverageDailyTradingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "AverageDailyTradingValue", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of average daily trading value.", "label": "Average Daily Trading Value", "terseLabel": "Average daily trading value" } } }, "auth_ref": [] }, "ecd_AwardExrcPrice": { "xbrltype": "perShareItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardExrcPrice", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Exercise Price", "terseLabel": "Exercise Price" } } }, "auth_ref": [ "r722" ] }, "ecd_AwardGrantDateFairValue": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardGrantDateFairValue", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Grant Date Fair Value", "terseLabel": "Fair Value as of Grant Date" } } }, "auth_ref": [ "r723" ] }, "ecd_AwardTmgDiscLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgDiscLineItems", "lang": { "en-us": { "role": { "label": "Award Timing Disclosures [Line Items]", "terseLabel": "Award Timing Disclosures" } } }, "auth_ref": [ "r718" ] }, "ecd_AwardTmgHowMnpiCnsdrdTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgHowMnpiCnsdrdTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing, How MNPI Considered [Text Block]", "terseLabel": "Award Timing, How MNPI Considered" } } }, "auth_ref": [ "r718" ] }, "ecd_AwardTmgMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Method [Text Block]", "terseLabel": "Award Timing Method" } } }, "auth_ref": [ "r718" ] }, "ecd_AwardTmgMnpiCnsdrdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiCnsdrdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Considered [Flag]", "terseLabel": "Award Timing MNPI Considered" } } }, "auth_ref": [ "r718" ] }, "ecd_AwardTmgMnpiDiscTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgMnpiDiscTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing MNPI Disclosure [Text Block]", "terseLabel": "Award Timing MNPI Disclosure" } } }, "auth_ref": [ "r718" ] }, "ecd_AwardTmgPredtrmndFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardTmgPredtrmndFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Timing Predetermined [Flag]", "terseLabel": "Award Timing Predetermined" } } }, "auth_ref": [ "r718" ] }, "us-gaap_AwardTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "AwardTypeAxis", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails", "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Type [Axis]", "terseLabel": "Award Type", "documentation": "Information by type of award under share-based payment arrangement." } } }, "auth_ref": [ "r299", "r300", "r301", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r323", "r324", "r325", "r326", "r327" ] }, "ecd_AwardUndrlygSecuritiesAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardUndrlygSecuritiesAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Award Underlying Securities Amount", "terseLabel": "Underlying Securities" } } }, "auth_ref": [ "r721" ] }, "ecd_AwardsCloseToMnpiDiscIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r720" ] }, "ecd_AwardsCloseToMnpiDiscTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table]", "terseLabel": "Awards Close in Time to MNPI Disclosures" } } }, "auth_ref": [ "r719" ] }, "ecd_AwardsCloseToMnpiDiscTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "AwardsCloseToMnpiDiscTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]", "terseLabel": "Awards Close in Time to MNPI Disclosures, Table" } } }, "auth_ref": [ "r719" ] }, "us-gaap_BasisOfAccounting": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "BasisOfAccounting", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Basis of Accounting [Text Block]", "terseLabel": "Basis of Presentation", "documentation": "The entire disclosure for the basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)." } } }, "auth_ref": [ "r63" ] }, "us-gaap_CarryingReportedAmountFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CarryingReportedAmountFairValueDisclosureMember", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Reported Value Measurement [Member]", "terseLabel": "Carrying Value", "documentation": "Measured as reported on the statement of financial position (balance sheet)." } } }, "auth_ref": [ "r39", "r40" ] }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsAtCarryingValue", "crdr": "debit", "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlansDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, at Carrying Value", "terseLabel": "Cash and cash equivalents", "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation." } } }, "auth_ref": [ "r15", "r91", "r578" ] }, "us-gaap_CashAndCashEquivalentsFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsFairValueDisclosure", "crdr": "debit", "calculation": { "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails": { "parentTag": "us-gaap_AssetsFairValueDisclosure", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Fair Value Disclosure", "terseLabel": "Cash equivalents", "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r832", "r833" ] }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashAndCashEquivalentsPolicyTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Cash and Cash Equivalents, Policy [Policy Text Block]", "terseLabel": "Cash and Cash Equivalents", "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value." } } }, "auth_ref": [ "r16" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "crdr": "debit", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents", "periodEndLabel": "Cash and cash equivalents, end of year", "periodStartLabel": "Cash and cash equivalents, beginning of year", "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r15", "r60", "r108" ] }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "crdr": "debit", "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Cash, Cash Equivalents, Restricted Cash, and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect", "totalLabel": "Net increase (decrease) in cash and cash equivalents", "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates." } } }, "auth_ref": [ "r5", "r60" ] }, "us-gaap_CashFDICInsuredAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CashFDICInsuredAmount", "crdr": "debit", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Cash, FDIC Insured Amount", "terseLabel": "Cash and cash equivalents, Federally insured limit", "documentation": "The amount of cash deposited in financial institutions as of the balance sheet date that is insured by the Federal Deposit Insurance Corporation." } } }, "auth_ref": [] }, "anvs_CashPaidForFinancingCostsDuringPeriod": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "CashPaidForFinancingCostsDuringPeriod", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The amount of cash paid during the current period for financing costs related to the issuance of shares.", "label": "Cash Paid for Financing Costs During the Period", "terseLabel": "Cash paid for financing costs" } } }, "auth_ref": [] }, "ecd_ChangedPeerGroupFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChangedPeerGroupFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Changed Peer Group, Footnote [Text Block]", "terseLabel": "Changed Peer Group, Footnote" } } }, "auth_ref": [ "r697" ] }, "srt_ChiefExecutiveOfficerMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "ChiefExecutiveOfficerMember", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Chief Executive Officer [Member]", "terseLabel": "Chief Executive Officer" } } }, "auth_ref": [ "r778" ] }, "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]", "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year" } } }, "auth_ref": [ "r694" ] }, "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]", "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested" } } }, "auth_ref": [ "r692" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "us-gaap_ClassOfStockLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfStockLineItems", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails", "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails", "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Class of Stock [Line Items]", "terseLabel": "Stockholders' (Deficit) Equity", "verboseLabel": "Summary of Significant Accounting Policies", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r93", "r94", "r95", "r149", "r268", "r269", "r270", "r272", "r275", "r280", "r282", "r505", "r506", "r507", "r508", "r600", "r750", "r763" ] }, "us-gaap_ClassOfWarrantOrRightAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightAxis", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails", "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Axis]", "documentation": "Information by type of warrant or right issued." } } }, "auth_ref": [ "r32" ] }, "us-gaap_ClassOfWarrantOrRightDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightDomain", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails", "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Domain]", "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails", "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails", "http://annovisbio.com/role/DisclosureSubsequentEventsDetails", "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights", "terseLabel": "Exercise price of warrants", "documentation": "Exercise price per share or per unit of warrants or rights outstanding." } } }, "auth_ref": [ "r283" ] }, "us-gaap_ClassOfWarrantOrRightLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightLineItems", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Line Items]", "terseLabel": "Warrants", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails", "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights", "terseLabel": "Number of shares which may be purchased with warrants", "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares." } } }, "auth_ref": [ "r283" ] }, "anvs_ClassOfWarrantOrRightNumberOfWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "ClassOfWarrantOrRightNumberOfWarrantsExercised", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants exercised.", "label": "Class of Warrant or Right, Number of Warrants Exercised", "terseLabel": "Number of warrants exercised" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightOutstanding", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails", "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right, Outstanding", "periodEndLabel": "Ending balance", "periodStartLabel": "Beginning balance", "terseLabel": "Warrants outstanding", "verboseLabel": "Number of warrants", "documentation": "Number of warrants or rights outstanding." } } }, "auth_ref": [] }, "anvs_ClassOfWarrantOrRightRedemptionPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "ClassOfWarrantOrRightRedemptionPricePerShare", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Redemption price per share or per unit of warrants or rights outstanding.", "label": "Class of Warrant or Right, Redemption Price Per Share", "terseLabel": "Redemption price per share" } } }, "auth_ref": [] }, "us-gaap_ClassOfWarrantOrRightTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ClassOfWarrantOrRightTable", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Class of Warrant or Right [Table]", "documentation": "Disclosure of information about warrant or right issued that give holder right to purchase security from issuer at specific price within certain time frame." } } }, "auth_ref": [ "r32" ] }, "anvs_ClaudineBruckMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "ClaudineBruckMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Claudine Bruck.", "label": "Claudine Bruck [Member]", "terseLabel": "Claudine Bruck" } } }, "auth_ref": [] }, "ecd_CoSelectedMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Amount", "terseLabel": "Company Selected Measure Amount" } } }, "auth_ref": [ "r698" ] }, "ecd_CoSelectedMeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CoSelectedMeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Company Selected Measure Name", "terseLabel": "Company Selected Measure Name" } } }, "auth_ref": [ "r698" ] }, "us-gaap_CommitmentsAndContingencies": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingencies", "crdr": "credit", "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies.", "terseLabel": "Commitments and contingencies (Note 6)", "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur." } } }, "auth_ref": [ "r48", "r76", "r470", "r523" ] }, "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Commitments and Contingencies" } } }, "auth_ref": [] }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingencies" ], "lang": { "en-us": { "role": { "label": "Commitments and Contingencies Disclosure [Text Block]", "terseLabel": "Commitments and Contingencies", "documentation": "The entire disclosure for commitments and contingencies." } } }, "auth_ref": [ "r65", "r250", "r251", "r574", "r786", "r788" ] }, "anvs_CommonStockAndPreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "CommonStockAndPreferredStockSharesAuthorized", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of shares permitted to be issued by an entity's charter and bylaws.", "label": "Common Stock And Preferred Stock, Shares Authorized", "terseLabel": "Number of common and preferred shares authorized" } } }, "auth_ref": [] }, "us-gaap_CommonStockMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockMember", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Common Stock [Member]", "terseLabel": "Common Stock", "documentation": "Stock that is subordinate to all other stock of the issuer." } } }, "auth_ref": [ "r625", "r626", "r627", "r629", "r630", "r631", "r632", "r767", "r768", "r770", "r830", "r881", "r886" ] }, "us-gaap_CommonStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockParOrStatedValuePerShare", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Par or Stated Value Per Share", "terseLabel": "Common stock, par value (dollars per share)", "documentation": "Face amount or stated value per share of common stock." } } }, "auth_ref": [ "r51" ] }, "anvs_CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to additional Volume-Weighted Average Price (VWAP) shares issued as defined under terms of a Common Stock Purchase Agreement (the \"Purchase Agreement\") with an Equity Line investor (the \"ELOC Purchaser\").", "label": "Common Stock Purchase Agreement, Additional Volume-Weighted Average Price Purchase [Member]", "terseLabel": "Additional VWAP Purchase" } } }, "auth_ref": [] }, "anvs_CommonStockPurchaseAgreementCommitmentSharesMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "CommonStockPurchaseAgreementCommitmentSharesMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the \"Commitment Shares\" issued under terms of a Common Stock Purchase Agreement (the \"Purchase Agreement\") with an Equity Line investor (the \"ELOC Purchaser\").", "label": "Common Stock Purchase Agreement, Commitment Shares [Member]", "terseLabel": "Commitment Shares" } } }, "auth_ref": [] }, "anvs_CommonStockPurchaseAgreementFixedPurchaseMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "CommonStockPurchaseAgreementFixedPurchaseMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Fixed Purchase shares issued as defined under terms of a Common Stock Purchase Agreement (the \"Purchase Agreement\") with an Equity Line investor (the \"ELOC Purchaser\").", "label": "Common Stock Purchase Agreement, Fixed Purchase [Member]", "terseLabel": "Fixed Purchase" } } }, "auth_ref": [] }, "anvs_CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice": { "xbrltype": "percentItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "CommonStockPurchaseAgreementMaximumPurchaseOfSharesAsPercentageOfFixedPurchaseNotice", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The maximum purchase of shares in a single transaction as a percentage of the Fixed Purchase Notice shares directed.", "label": "Common Stock Purchase Agreement, Maximum Purchase of Shares as a Percentage of Fixed Purchase Notice", "terseLabel": "Maximum percentage of shares directed by Fixed Purchase Notice" } } }, "auth_ref": [] }, "anvs_CommonStockPurchaseAgreementMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "CommonStockPurchaseAgreementMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to a Common Stock Purchase Agreement (the \"Purchase Agreement\") with an Equity Line investor (the \"ELOC Purchaser\").", "label": "Common Stock Purchase Agreement [Member]", "verboseLabel": "ELOC Purchase Agreement" } } }, "auth_ref": [] }, "anvs_CommonStockPurchaseAgreementPurchasePricePercentage": { "xbrltype": "percentItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "CommonStockPurchaseAgreementPurchasePricePercentage", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The purchase price as a percentage of the lesser of certain criteria as defined in the purchase agreement..", "label": "Common Stock Purchase Agreement, Purchase Price, Percentage", "terseLabel": "Purchase price, percentage" } } }, "auth_ref": [] }, "anvs_CommonStockPurchaseAgreementSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "CommonStockPurchaseAgreementSharesAuthorized", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of shares of authorized under terms of a common stock purchase agreement.", "label": "Common Stock Purchase Agreement, Shares Authorized", "terseLabel": "Number of authorized shares under terms of the agreement" } } }, "auth_ref": [] }, "anvs_CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume": { "xbrltype": "percentItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "CommonStockPurchaseAgreementThresholdPercentageOfTradingVolume", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The threshold percentage of trading volume.", "label": "Common Stock Purchase Agreement, Threshold Percentage of Trading Volume", "terseLabel": "Threshold percentage of trading volume" } } }, "auth_ref": [] }, "anvs_CommonStockPurchaseAgreementTotalCommitment": { "xbrltype": "sharesItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "CommonStockPurchaseAgreementTotalCommitment", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The aggregate number of shares of committed under terms of a common stock purchase agreement.", "label": "Common Stock Purchase Agreement, Total Commitment", "terseLabel": "Total commitment shares" } } }, "auth_ref": [] }, "anvs_CommonStockPurchaseAgreementTotalCommitmentValue": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "CommonStockPurchaseAgreementTotalCommitmentValue", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "The aggregate value of shares of committed under terms of a common stock purchase agreement.", "label": "Common Stock Purchase Agreement, Total Commitment Value", "terseLabel": "Value of total commitment shares" } } }, "auth_ref": [] }, "anvs_CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Volume-Weighted Average Price (VWAP) shares issued as defined under terms of a Common Stock Purchase Agreement (the \"Purchase Agreement\") with an Equity Line investor (the \"ELOC Purchaser\").", "label": "Common Stock Purchase Agreement, Volume-Weighted Average Price Purchase [Member]", "terseLabel": "VWAP Purchase" } } }, "auth_ref": [] }, "us-gaap_CommonStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesAuthorized", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares Authorized", "terseLabel": "Common stock, shares authorized", "verboseLabel": "Number of common shares authorized", "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r51", "r524" ] }, "us-gaap_CommonStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesIssued", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Issued", "terseLabel": "Common stock, shares issued", "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury." } } }, "auth_ref": [ "r51" ] }, "us-gaap_CommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockSharesOutstanding", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Common Stock, Shares, Outstanding", "terseLabel": "Common stock, shares outstanding", "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation." } } }, "auth_ref": [ "r9", "r51", "r524", "r542", "r886", "r887" ] }, "us-gaap_CommonStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "CommonStockValue", "crdr": "credit", "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Common Stock, Value, Issued", "verboseLabel": "Common stock - $0.0001 par value, 70,000,000 shares authorized and 14,141,521 and 10,519,933 shares issued and outstanding at December 31, 2024 and December 31, 2023, respectively", "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r51", "r472", "r621" ] }, "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Company Selected Measure" } } }, "auth_ref": [ "r703" ] }, "ecd_CompActuallyPaidVsNetIncomeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsNetIncomeTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Net Income [Text Block]", "terseLabel": "Compensation Actually Paid vs. Net Income" } } }, "auth_ref": [ "r702" ] }, "ecd_CompActuallyPaidVsOtherMeasureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsOtherMeasureTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Other Measure [Text Block]", "terseLabel": "Compensation Actually Paid vs. Other Measure" } } }, "auth_ref": [ "r704" ] }, "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]", "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return" } } }, "auth_ref": [ "r701" ] }, "anvs_ConversionOfWarrantsNumberOfWarrantsConverted": { "xbrltype": "sharesItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "ConversionOfWarrantsNumberOfWarrantsConverted", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails", "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of warrants converted in a noncash (or part noncash) transaction.", "label": "Conversion of Warrants, Number of Warrants Converted", "negatedLabel": "Exercised or Expired", "verboseLabel": "Number of warrants exercised" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Document and Entity Information", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r649", "r738" ] }, "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]" } } }, "auth_ref": [ "r649", "r738" ] }, "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]" } } }, "auth_ref": [ "r651", "r740" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]" } } }, "auth_ref": [ "r651", "r740" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]" } } }, "auth_ref": [ "r653", "r742" ] }, "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r651", "r740" ] }, "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]" } } }, "auth_ref": [ "r644", "r733" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Flag]" } } }, "auth_ref": [ "r645", "r734" ] }, "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Processes Integrated [Text Block]" } } }, "auth_ref": [ "r645", "r734" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract", "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]" } } }, "auth_ref": [ "r643", "r732" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]" } } }, "auth_ref": [ "r643", "r732" ] }, "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]" } } }, "auth_ref": [ "r643", "r732" ] }, "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Management Third Party Engaged [Flag]" } } }, "auth_ref": [ "r646", "r735" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]" } } }, "auth_ref": [ "r648", "r737" ] }, "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]" } } }, "auth_ref": [ "r648", "r737" ] }, "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]" } } }, "auth_ref": [ "r649", "r738" ] }, "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]" } } }, "auth_ref": [ "r652", "r741" ] }, "cyd_CybersecurityRiskRoleOfManagementTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskRoleOfManagementTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Role of Management [Text Block]" } } }, "auth_ref": [ "r650", "r739" ] }, "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag", "presentation": [ "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure" ], "lang": { "en-us": { "role": { "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]" } } }, "auth_ref": [ "r647", "r736" ] }, "anvs_December2024AtMarketEquityOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "December2024AtMarketEquityOfferingMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails", "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the December 2024 ATM Equity Offering.", "label": "December 2024 At the Market Equity Offering [Member]", "terseLabel": "December 2024 ATM" } } }, "auth_ref": [] }, "us-gaap_DeferredCompensationArrangementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCompensationArrangementsAbstract", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Compensation Arrangements [Abstract]", "terseLabel": "Employment Agreements" } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Prepaid Expenses and Other Current Assets" } } }, "auth_ref": [] }, "us-gaap_DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredCostsCapitalizedPrepaidAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsTables" ], "lang": { "en-us": { "role": { "label": "Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Table Text Block]", "terseLabel": "Schedule of prepaid expenses and other current assets", "documentation": "Tabular disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs." } } }, "auth_ref": [] }, "anvs_DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "DeferredCostsCapitalizedPrepaidExpensesAndOtherAssetsDisclosureTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssets" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure of the amounts paid in advance for capitalized costs that will be expensed with the passage of time or the occurrence of a triggering event, and will be charged against earnings within one year or the normal operating cycle, if longer; the aggregate carrying amount of current assets, not separately presented elsewhere in the balance sheet; and other deferred costs.", "label": "Deferred Costs, Capitalized, Prepaid Expenses, and Other Assets Disclosure [Text Block]", "terseLabel": "Prepaid Expenses and Other Current Assets" } } }, "auth_ref": [] }, "anvs_DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "DeferredTaxAssetsAmortizationOfResearchExperimentalExpenditures", "crdr": "debit", "calculation": { "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to amortization of research and experimental expenditures (Section 174).", "label": "Deferred Tax Assets, Amortization of Research & Experimental Expenditures", "terseLabel": "Section 174" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsGross": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsGross", "crdr": "debit", "calculation": { "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Gross", "totalLabel": "Total deferred tax assets", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r358" ] }, "us-gaap_DeferredTaxAssetsNet": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNet", "crdr": "debit", "calculation": { "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance", "totalLabel": "Net deferred taxes", "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards." } } }, "auth_ref": [ "r826" ] }, "us-gaap_DeferredTaxAssetsNetOfValuationAllowanceAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsNetOfValuationAllowanceAbstract", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Net of Valuation Allowance [Abstract]", "terseLabel": "Deferred taxes" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOperatingLossCarryforwards", "crdr": "debit", "calculation": { "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards." } } }, "auth_ref": [ "r828" ] }, "us-gaap_DeferredTaxAssetsOther": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsOther", "crdr": "debit", "calculation": { "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Other", "terseLabel": "Other", "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other." } } }, "auth_ref": [ "r828" ] }, "anvs_DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsCapitalizedResearchAndDevelopment", "crdr": "debit", "calculation": { "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized research and development.", "label": "Deferred Tax Assets, Tax Credit Carryforwards, Capitalized Research and Development", "terseLabel": "Capitalized R&D" } } }, "auth_ref": [] }, "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch", "crdr": "debit", "calculation": { "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research", "terseLabel": "R&D credit carryforwards", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards." } } }, "auth_ref": [ "r828" ] }, "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost", "crdr": "debit", "calculation": { "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsGross", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost", "terseLabel": "Stock compensation", "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation." } } }, "auth_ref": [ "r828" ] }, "us-gaap_DeferredTaxAssetsValuationAllowance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DeferredTaxAssetsValuationAllowance", "crdr": "credit", "calculation": { "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails": { "parentTag": "us-gaap_DeferredTaxAssetsNet", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesDeferredTaxesDetails" ], "lang": { "en-us": { "role": { "label": "Deferred Tax Assets, Valuation Allowance", "negatedLabel": "Less valuation allowance", "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized." } } }, "auth_ref": [ "r359" ] }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativeLiabilitiesNoncurrent", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails", "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Derivative Liability, Noncurrent", "periodEndLabel": "Derivative liability, ending balance", "periodStartLabel": "Derivative liability, beginning balance", "terseLabel": "Derivative liability", "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset." } } }, "auth_ref": [ "r96" ] }, "us-gaap_DerivativesEmbeddedDerivatives": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesEmbeddedDerivatives", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Derivatives, Embedded Derivatives [Policy Text Block]", "terseLabel": "Derivative Liability", "documentation": "Disclosure of accounting policy for embedded derivatives, including how such derivatives are identified and analyzed for possible separation from their host contracts." } } }, "auth_ref": [ "r0", "r2", "r3", "r4" ] }, "us-gaap_DerivativesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DerivativesPolicyTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Derivatives, Policy [Policy Text Block]", "terseLabel": "Common Stock Warrants", "documentation": "Disclosure of accounting policy for its derivative instruments and hedging activities." } } }, "auth_ref": [ "r10", "r35", "r36", "r37", "r38", "r114", "r128" ] }, "us-gaap_DilutiveSecurities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DilutiveSecurities", "crdr": "credit", "calculation": { "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Dilutive Securities, Effect on Basic Earnings Per Share", "terseLabel": "Less: gain from change in fair value applicable to dilutive liability-classified warrants", "documentation": "Amount of increase (decrease) to net income used for calculating diluted earnings per share (EPS), resulting from the assumed exercise stock options, restrictive stock units (RSUs), convertible preferred stock of an employee stock ownership plan (ESOP), and other dilutive convertible securities." } } }, "auth_ref": [ "r17" ] }, "srt_DirectorMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "DirectorMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Director [Member]", "terseLabel": "Director" } } }, "auth_ref": [ "r778", "r882" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensation" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "The entire disclosure for share-based payment arrangement." } } }, "auth_ref": [ "r295", "r298", "r328", "r329", "r331", "r605" ] }, "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract", "lang": { "en-us": { "role": { "label": "Stock-Based Compensation" } } }, "auth_ref": [] }, "anvs_DisclosureOfEarningsPerShareBasicAndDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "DisclosureOfEarningsPerShareBasicAndDilutedAbstract", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Disclosure of Earnings Per Share, Basic and Diluted [Abstract]", "terseLabel": "Net loss per share" } } }, "auth_ref": [] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentAnnualReport", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r640", "r641", "r664" ] }, "dei_DocumentFinStmtErrorCorrectionFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFinStmtErrorCorrectionFlag", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Financial Statement Error Correction [Flag]", "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction." } } }, "auth_ref": [ "r640", "r641", "r664", "r707" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentTransitionReport", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r685" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "terseLabel": "Document incorporated by reference", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r638" ] }, "us-gaap_DomesticCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "DomesticCountryMember", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Domestic Tax Jurisdiction [Member]", "terseLabel": "U.S. federal", "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction." } } }, "auth_ref": [ "r343" ] }, "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]", "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year" } } }, "auth_ref": [ "r696" ] }, "us-gaap_EarningsPerShareAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareAbstract", "lang": { "en-us": { "role": { "label": "Net Loss Per Share" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareBasic": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareBasic", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Basic", "terseLabel": "Basic (dollars per share)", "verboseLabel": "Basic net loss per common share", "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period." } } }, "auth_ref": [ "r103", "r120", "r121", "r122", "r123", "r124", "r125", "r130", "r132", "r139", "r140", "r141", "r146", "r375", "r378", "r395", "r396", "r467", "r479", "r580" ] }, "anvs_EarningsPerShareBasicDenominatorAbstract": { "xbrltype": "stringItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "EarningsPerShareBasicDenominatorAbstract", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Earnings Per Share, Basic, Denominator [Abstract]", "terseLabel": "Denominator" } } }, "auth_ref": [] }, "anvs_EarningsPerShareBasicNumeratorAbstract": { "xbrltype": "stringItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "EarningsPerShareBasicNumeratorAbstract", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Earnings Per Share, Basic, Numerator [Abstract]", "terseLabel": "Numerator" } } }, "auth_ref": [] }, "us-gaap_EarningsPerShareDiluted": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareDiluted", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Diluted", "terseLabel": "Diluted (dollars per share)", "verboseLabel": "Net loss per share, diluted", "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period." } } }, "auth_ref": [ "r103", "r120", "r121", "r122", "r123", "r124", "r125", "r132", "r139", "r140", "r141", "r146", "r375", "r378", "r395", "r396", "r467", "r479", "r580" ] }, "anvs_EarningsPerShareDilutedDenominatorAbstract": { "xbrltype": "stringItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "EarningsPerShareDilutedDenominatorAbstract", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Earnings Per Share, Diluted, Denominator [Abstract]", "terseLabel": "Denominator" } } }, "auth_ref": [] }, "anvs_EarningsPerShareDilutedNumeratorAbstract": { "xbrltype": "stringItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "EarningsPerShareDilutedNumeratorAbstract", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Earnings Per Share, Diluted, Numerator [Abstract]", "terseLabel": "Numerator" } } }, "auth_ref": [] }, "us-gaap_EarningsPerSharePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerSharePolicyTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share, Policy [Policy Text Block]", "terseLabel": "Basic and Diluted Net Loss per Share", "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements." } } }, "auth_ref": [ "r18", "r19", "r143" ] }, "us-gaap_EarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EarningsPerShareTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShare" ], "lang": { "en-us": { "role": { "label": "Earnings Per Share [Text Block]", "terseLabel": "Net Loss Per Share", "documentation": "The entire disclosure for earnings per share." } } }, "auth_ref": [ "r129", "r142", "r144", "r145" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperations", "calculation": { "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent", "totalLabel": "Effective income tax rate", "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations." } } }, "auth_ref": [ "r343", "r608" ] }, "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]", "terseLabel": "Reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes" } } }, "auth_ref": [] }, "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate", "calculation": { "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent", "terseLabel": "Federal income tax benefit at statutory rate", "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)." } } }, "auth_ref": [ "r113", "r343", "r367", "r608" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance", "calculation": { "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 8.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent", "terseLabel": "Change in valuation allowance", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets." } } }, "auth_ref": [ "r348", "r608", "r766", "r822" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationChangeInEnactedTaxRate", "calculation": { "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Change in Enacted Tax Rate, Percent", "terseLabel": "State and local tax, change in rates", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the income tax rates." } } }, "auth_ref": [ "r347", "r608", "r766", "r822" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense", "calculation": { "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent", "terseLabel": "Permanent differences", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses." } } }, "auth_ref": [ "r349", "r350", "r766", "r822" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseImpairmentLosses", "calculation": { "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Impairment Losses, Percent", "terseLabel": "Change in fair value of warrants", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to impairment loss." } } }, "auth_ref": [ "r608", "r766", "r822", "r823" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseResearchAndDevelopment", "calculation": { "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Percent", "terseLabel": "Research and development credit", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research and development expense." } } }, "auth_ref": [ "r766", "r822", "r823" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost", "calculation": { "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 5.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent", "terseLabel": "Stock-based compensation", "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement." } } }, "auth_ref": [ "r608", "r766", "r822", "r823" ] }, "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes", "calculation": { "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails": { "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent", "terseLabel": "State and local tax, net of federal benefit", "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)." } } }, "auth_ref": [ "r346", "r608", "r766", "r822" ] }, "us-gaap_EmployeeRelatedLiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeRelatedLiabilitiesCurrent", "crdr": "credit", "calculation": { "http://annovisbio.com/role/DisclosureAccruedExpensesDetails": { "parentTag": "anvs_AccruedLiabilitiesAndInterestAndEmployeeRelatedLiabilitiesCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesDetails" ], "lang": { "en-us": { "role": { "label": "Employee-related Liabilities, Current", "terseLabel": "Payroll and related benefits", "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)." } } }, "auth_ref": [ "r44" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition", "terseLabel": "Weighted average recognition period (in years)", "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r330" ] }, "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions", "crdr": "debit", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Nonvested Award, Option, Cost Not yet Recognized, Amount", "terseLabel": "Unrecognized stock-based compensation expense related to unvested stock option awards", "documentation": "Amount of cost to be recognized for option under share-based payment arrangement." } } }, "auth_ref": [ "r818" ] }, "us-gaap_EmployeeStockOptionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EmployeeStockOptionMember", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails", "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails", "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Employee Stock Option [Member]", "terseLabel": "Employee Stock Option", "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r637" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r637" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityExTransitionPeriod", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Ex Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r749" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Securities Act File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFilerCategory", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r637" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r747" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r637" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityShellCompany", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r637" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntitySmallBusiness", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r637" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r637" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityVoluntaryFilers", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r748" ] }, "ecd_EqtyAwrdsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Footnote [Text Block]", "terseLabel": "Equity Awards Adjustments, Footnote" } } }, "auth_ref": [ "r690" ] }, "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]", "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table" } } }, "auth_ref": [ "r743" ] }, "ecd_EqtyAwrdsAdjsMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsAdjsMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Awards Adjustments [Member]", "terseLabel": "Equity Awards Adjustments" } } }, "auth_ref": [ "r743" ] }, "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]", "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table" } } }, "auth_ref": [ "r743" ] }, "us-gaap_EquityComponentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EquityComponentDomain", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Component [Domain]", "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc." } } }, "auth_ref": [ "r9", "r87", "r100", "r101", "r102", "r115", "r116", "r117", "r119", "r124", "r126", "r128", "r148", "r223", "r224", "r243", "r284", "r365", "r366", "r372", "r373", "r374", "r376", "r377", "r378", "r386", "r387", "r388", "r389", "r390", "r391", "r394", "r420", "r421", "r422", "r423", "r424", "r425", "r427", "r428", "r429", "r477", "r495", "r496", "r497", "r512", "r562" ] }, "anvs_EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "EquityDistributionAgreementValueOfStockIssuedDuringPeriodNetOfIssuanceCosts", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued under terms of an equity distribution agreement during the period, net of issuance costs.", "label": "Equity Distribution Agreement, Value of Stock Issued During Period, Net of Issuance Costs", "terseLabel": "Issuance of common stock pursuant to Equity Distribution Agreement, net of issuance costs" } } }, "auth_ref": [] }, "anvs_EquityIncentivePlan2018Member": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "EquityIncentivePlan2018Member", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Pertaining to the 2018 Equity Incentive Plan.", "label": "2018 Plan" } } }, "auth_ref": [] }, "anvs_EquityIncentivePlan2019Member": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "EquityIncentivePlan2019Member", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the Company's 2019 Equity Incentive Plan.", "label": "2019 Plan" } } }, "auth_ref": [] }, "anvs_EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "EquityLineOfCreditValueOfStockIssuedDuringPeriodNetOfIssuanceCosts", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued under terms of an equity line of credit, net of issuance costs.", "label": "Equity Line of Credit, Value of Stock Issued During Period, Net of Issuance Costs", "terseLabel": "Issuance of common stock pursuant to ELOC, net of issuance costs" } } }, "auth_ref": [] }, "ecd_EquityValuationAssumptionDifferenceFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "EquityValuationAssumptionDifferenceFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Equity Valuation Assumption Difference, Footnote [Text Block]", "terseLabel": "Equity Valuation Assumption Difference, Footnote" } } }, "auth_ref": [ "r700" ] }, "ecd_ErrCompAnalysisTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompAnalysisTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneous Compensation Analysis [Text Block]", "terseLabel": "Erroneous Compensation Analysis" } } }, "auth_ref": [ "r657", "r668", "r678", "r711" ] }, "ecd_ErrCompRecoveryTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ErrCompRecoveryTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Erroneously Awarded Compensation Recovery [Table]", "terseLabel": "Erroneously Awarded Compensation Recovery" } } }, "auth_ref": [ "r654", "r665", "r675", "r708" ] }, "us-gaap_EstimateOfFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "EstimateOfFairValueFairValueDisclosureMember", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Estimate of Fair Value Measurement [Member]", "terseLabel": "Fair Value", "documentation": "Measured as an estimate of fair value." } } }, "auth_ref": [ "r265", "r418", "r598", "r599" ] }, "ecd_ExecutiveCategoryAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ExecutiveCategoryAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Executive Category [Axis]", "terseLabel": "Executive Category:" } } }, "auth_ref": [ "r706" ] }, "anvs_FairValueAdjustmentOfDerivativeLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "FairValueAdjustmentOfDerivativeLiabilities", "crdr": "debit", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of derivative liability.", "label": "Fair Value Adjustment of Derivative Liabilities", "negatedLabel": "Settlements and changes in fair value of ELOC derivative liability" } } }, "auth_ref": [] }, "us-gaap_FairValueAdjustmentOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAdjustmentOfWarrants", "crdr": "debit", "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Fair Value Adjustment of Warrants", "negatedLabel": "Change in fair value of warrant liabilities", "terseLabel": "Change in fair value of warrants", "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability." } } }, "auth_ref": [ "r1", "r8" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails", "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]", "terseLabel": "Fair Value Measurements", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r398", "r399", "r409", "r611" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails", "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value, Recurring and Nonrecurring [Table]", "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis." } } }, "auth_ref": [ "r398", "r399", "r409", "r611" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesLineItems", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Line Items]", "terseLabel": "Fair Value Measurements", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r400", "r401", "r402", "r614" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTable", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table]", "documentation": "Disclosure of information about input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r400", "r401", "r402", "r614" ] }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Fair Value Measurement Inputs and Valuation Techniques [Table Text Block]", "terseLabel": "Schedule of quantitative information regarding Level 3 fair value measurements inputs", "documentation": "Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis." } } }, "auth_ref": [ "r400", "r401", "r614" ] }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByFairValueHierarchyLevelAxis", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails", "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Axis]", "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient." } } }, "auth_ref": [ "r265", "r288", "r289", "r290", "r291", "r292", "r293", "r397", "r399", "r400", "r401", "r402", "r408", "r409", "r411", "r436", "r437", "r438", "r598", "r599", "r601", "r602", "r603", "r611", "r614" ] }, "us-gaap_FairValueByMeasurementBasisAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueByMeasurementBasisAxis", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Basis [Axis]", "documentation": "Information by measurement basis." } } }, "auth_ref": [ "r265", "r598", "r599" ] }, "us-gaap_FairValueDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresAbstract", "lang": { "en-us": { "role": { "label": "Fair Value Measurements" } } }, "auth_ref": [] }, "us-gaap_FairValueDisclosuresTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueDisclosuresTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurements" ], "lang": { "en-us": { "role": { "label": "Fair Value Disclosures [Text Block]", "terseLabel": "Fair Value Measurements", "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information." } } }, "auth_ref": [ "r404", "r406", "r407", "r408", "r411", "r412", "r413", "r414", "r415", "r466", "r611", "r615" ] }, "us-gaap_FairValueInputsLevel1Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel1Member", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 1 [Member]", "terseLabel": "Level 1", "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date." } } }, "auth_ref": [ "r265", "r288", "r293", "r399", "r409", "r436", "r601", "r602", "r603", "r611" ] }, "us-gaap_FairValueInputsLevel3Member": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueInputsLevel3Member", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails", "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value, Inputs, Level 3 [Member]", "terseLabel": "Level 3", "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing." } } }, "auth_ref": [ "r265", "r288", "r289", "r290", "r291", "r292", "r293", "r399", "r400", "r401", "r402", "r409", "r438", "r598", "r599", "r601", "r602", "r603", "r611", "r614" ] }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FairValueMeasurementsFairValueHierarchyDomain", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails", "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Fair Value Hierarchy and NAV [Domain]", "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value." } } }, "auth_ref": [ "r265", "r288", "r289", "r290", "r291", "r292", "r293", "r397", "r399", "r400", "r401", "r402", "r408", "r409", "r411", "r436", "r437", "r438", "r598", "r599", "r601", "r602", "r603", "r611", "r614" ] }, "us-gaap_FederalIncomeTaxExpenseBenefitContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FederalIncomeTaxExpenseBenefitContinuingOperations", "crdr": "debit", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "label": "Federal Income Tax Expense (Benefit), Continuing Operations", "terseLabel": "Federal provision (benefit) for income taxes", "documentation": "Amount of current and deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred national tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r112", "r341", "r342" ] }, "us-gaap_FinancialInstrumentAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "FinancialInstrumentAxis", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Financial Instrument [Axis]", "documentation": "Information by type of financial instrument." } } }, "auth_ref": [ "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r225", "r226", "r227", "r228", "r229", "r230", "r231", "r232", "r266", "r280", "r392", "r416", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r478", "r595", "r611", "r612", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r622", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r779", "r780", "r781", "r782", "r831", "r834", "r835", "r836", "r837", "r838" ] }, "anvs_FinancingCostsFromIssuanceOfShares": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "FinancingCostsFromIssuanceOfShares", "crdr": "debit", "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Represents the charge against earnings during the period for transaction costs related to the issuance of shares.", "label": "Financing Costs from Issuance of Shares", "negatedLabel": "Other financing costs" } } }, "auth_ref": [] }, "us-gaap_ForeignCountryMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ForeignCountryMember", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Foreign Tax Jurisdiction [Member]", "terseLabel": "Outside of the U.S.", "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile." } } }, "auth_ref": [ "r343", "r344" ] }, "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount", "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount" } } }, "auth_ref": [ "r661", "r672", "r682", "r715" ] }, "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Expense of Enforcement, Amount", "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount" } } }, "auth_ref": [ "r661", "r672", "r682", "r715" ] }, "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery due to Violation of Home Country Law, Amount", "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount" } } }, "auth_ref": [ "r661", "r672", "r682", "r715" ] }, "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Explanation of Impracticability [Text Block]", "terseLabel": "Forgone Recovery, Explanation of Impracticability" } } }, "auth_ref": [ "r661", "r672", "r682", "r715" ] }, "ecd_ForgoneRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "ForgoneRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Forgone Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r661", "r672", "r682", "r715" ] }, "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]", "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year" } } }, "auth_ref": [ "r695" ] }, "anvs_GainLossOnChangesInFairValueOfWarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "GainLossOnChangesInFairValueOfWarrantLiability", "crdr": "credit", "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) from changes in fair value of warrant liabilities.", "label": "Gain (Loss) on Changes in Fair Value of Warrant Liability", "terseLabel": "Change in fair value of warrants" } } }, "auth_ref": [] }, "us-gaap_GeneralAndAdministrativeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpense", "crdr": "debit", "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense", "terseLabel": "General and administrative", "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line." } } }, "auth_ref": [ "r58", "r546" ] }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "GeneralAndAdministrativeExpenseMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "General and Administrative Expense [Member]", "terseLabel": "General and administrative", "documentation": "Primary financial statement caption encompassing general and administrative expense." } } }, "auth_ref": [ "r58" ] }, "anvs_GeneralAndAdministrativeExpenseProfessionalAndConsultantFees": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "GeneralAndAdministrativeExpenseProfessionalAndConsultantFees", "crdr": "debit", "calculation": { "http://annovisbio.com/role/DisclosureSegmentInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 4.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "General and administrative expenses classified as professional and consultant fees.", "label": "General and Administrative Expense, Professional and Consultant Fees", "negatedLabel": "General and administrative professional and consultant fees" } } }, "auth_ref": [] }, "anvs_GeneratedIn2017AndPriorMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "GeneratedIn2017AndPriorMember", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to tax years 2017 and prior.", "label": "Generated in 2017 and prior" } } }, "auth_ref": [] }, "anvs_GrossProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "GrossProceedsFromIssuanceOfCommonStock", "crdr": "debit", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails", "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "The gross proceeds from the additional capital contribution to the entity through the issuance of common stock.", "label": "Gross Proceeds from Issuance of Common Stock", "terseLabel": "Gross proceeds from issuance of common shares" } } }, "auth_ref": [] }, "dei_IcfrAuditorAttestationFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "IcfrAuditorAttestationFlag", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "ICFR Auditor Attestation Flag" } } }, "auth_ref": [ "r640", "r641", "r664" ] }, "us-gaap_IncomeStatementAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementAbstract", "lang": { "en-us": { "role": { "label": "Statements of Operations" } } }, "auth_ref": [] }, "us-gaap_IncomeStatementLocationAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationAxis", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Axis]", "documentation": "Information by location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r244", "r246", "r247", "r403", "r405", "r410", "r492", "r494", "r547", "r577", "r613", "r852" ] }, "us-gaap_IncomeStatementLocationDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeStatementLocationDomain", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Statement of Income Location, Balance [Domain]", "documentation": "Location in statement of income where disaggregated amount has been reported." } } }, "auth_ref": [ "r246", "r247", "r403", "r405", "r410", "r492", "r494", "r547", "r577", "r613", "r852" ] }, "us-gaap_IncomeTaxAuthorityAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityAxis", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Axis]", "documentation": "Information by income tax jurisdiction." } } }, "auth_ref": [ "r107", "r343", "r344", "r354", "r362", "r608", "r827" ] }, "us-gaap_IncomeTaxAuthorityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxAuthorityDomain", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Jurisdiction [Domain]", "documentation": "Income tax jurisdiction." } } }, "auth_ref": [ "r107", "r343", "r344", "r354", "r362", "r608", "r827" ] }, "us-gaap_IncomeTaxDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureAbstract", "lang": { "en-us": { "role": { "label": "Income Taxes" } } }, "auth_ref": [] }, "us-gaap_IncomeTaxDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxDisclosureTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxes" ], "lang": { "en-us": { "role": { "label": "Income Tax Disclosure [Text Block]", "terseLabel": "Income Taxes", "documentation": "The entire disclosure for income tax." } } }, "auth_ref": [ "r113", "r338", "r343", "r351", "r352", "r353", "r355", "r361", "r368", "r369", "r370", "r371", "r510", "r608" ] }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestAccrued": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExaminationPenaltiesAndInterestAccrued", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Examination, Penalties and Interest Accrued", "terseLabel": "Accrued interest or penalties", "documentation": "The amount of estimated penalties and interest accrued as of the balance sheet date arising from income tax examinations." } } }, "auth_ref": [ "r824" ] }, "us-gaap_IncomeTaxExaminationPenaltiesAndInterestExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxExaminationPenaltiesAndInterestExpense", "crdr": "debit", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Income Tax Examination, Penalties and Interest Expense", "terseLabel": "Recognized income tax interest and penalties", "documentation": "The sum of the amounts of estimated penalties and interest recognized in the period arising from income tax examinations." } } }, "auth_ref": [ "r824" ] }, "us-gaap_IncomeTaxPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncomeTaxPolicyTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Income Tax, Policy [Policy Text Block]", "terseLabel": "Income Taxes", "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements." } } }, "auth_ref": [ "r99", "r339", "r340", "r355", "r356", "r360", "r364", "r504" ] }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccountsPayable", "crdr": "debit", "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accounts Payable", "terseLabel": "Accounts payable", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInAccruedLiabilities", "crdr": "debit", "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Accrued Liabilities", "terseLabel": "Accrued expenses", "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid." } } }, "auth_ref": [ "r7" ] }, "anvs_IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "IncreaseDecreaseInFairValueOfWarrantsAttributableToExerciseOfWarrants", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails" ], "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the period in the fair value of warrants attributable to the exercise of warrants.", "label": "Increase (Decrease) in Fair Value of Warrants Attributable to Exercise of Warrants", "terseLabel": "Exercise of warrants" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Operating Capital [Abstract]", "terseLabel": "Changes in operating assets and liabilities:" } } }, "auth_ref": [] }, "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets", "crdr": "credit", "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Prepaid Expense and Other Assets", "negatedLabel": "Prepaid expenses and other current assets", "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other." } } }, "auth_ref": [ "r7" ] }, "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "IncreaseDecreaseInStockholdersEquityRollForward", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]", "terseLabel": "Changes in Stockholders' Equity (Deficit)", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "ecd_IndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "IndividualAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure", "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure", "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Individual [Axis]", "terseLabel": "Individual:" } } }, "auth_ref": [ "r661", "r672", "r682", "r706", "r715", "r719", "r727" ] }, "ecd_InsiderTradingArrLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingArrLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Arrangements [Line Items]", "terseLabel": "Insider Trading Arrangements:" } } }, "auth_ref": [ "r725" ] }, "ecd_InsiderTradingPoliciesProcLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTradingPoliciesProcLineItems", "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures [Line Items]", "terseLabel": "Insider Trading Policies and Procedures:" } } }, "auth_ref": [ "r642", "r731" ] }, "ecd_InsiderTrdPoliciesProcAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Adopted [Flag]", "terseLabel": "Insider Trading Policies and Procedures Adopted" } } }, "auth_ref": [ "r642", "r731" ] }, "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" ], "lang": { "en-us": { "role": { "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]", "terseLabel": "Insider Trading Policies and Procedures Not Adopted" } } }, "auth_ref": [ "r642", "r731" ] }, "anvs_IntangibleAssetsPatentCostsPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "IntangibleAssetsPatentCostsPolicyTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the treatment of patent costs.", "label": "Intangible Assets, Patent Costs [Policy Text Block]", "terseLabel": "Patent Costs" } } }, "auth_ref": [] }, "us-gaap_InvestmentIncomeInterest": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "InvestmentIncomeInterest", "crdr": "credit", "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "parentTag": "us-gaap_NonoperatingIncomeExpense", "weight": 1.0, "order": 1.0 }, "http://annovisbio.com/role/DisclosureSegmentInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 6.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureSegmentInformationDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Investment Income, Interest", "terseLabel": "Interest income", "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities." } } }, "auth_ref": [ "r147", "r157", "r183", "r588", "r762" ] }, "anvs_IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "IssuanceCostsAssociatedWithEquityIssuancesPolicyTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for issuance costs associated with equity issuances.", "label": "Issuance Costs Associated with Equity Issuances [Policy Text Block]", "terseLabel": "Issuance Costs Associated with Equity Issuances" } } }, "auth_ref": [] }, "us-gaap_LaborAndRelatedExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LaborAndRelatedExpense", "crdr": "debit", "calculation": { "http://annovisbio.com/role/DisclosureSegmentInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 3.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Labor and Related Expense", "negatedLabel": "Personnel-related expenses (including stock-based compensation)", "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit." } } }, "auth_ref": [ "r761" ] }, "us-gaap_LeaseCostAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LeaseCostAbstract", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Lease, Cost [Abstract]", "terseLabel": "Leases" } } }, "auth_ref": [] }, "us-gaap_Liabilities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "Liabilities", "crdr": "credit", "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities", "totalLabel": "Total liabilities", "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others." } } }, "auth_ref": [ "r14", "r43", "r44", "r45", "r46", "r47", "r48", "r49", "r111", "r222", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r381", "r384", "r385", "r419", "r522", "r581", "r635", "r789", "r842", "r843" ] }, "us-gaap_LiabilitiesAndStockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquity", "crdr": "credit", "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity", "totalLabel": "Total liabilities and stockholders' equity (deficit)", "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any." } } }, "auth_ref": [ "r56", "r77", "r474", "r621", "r764", "r783", "r839" ] }, "us-gaap_LiabilitiesAndStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesAndStockholdersEquityAbstract", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities and Equity [Abstract]", "verboseLabel": "Liabilities and stockholders' equity (deficit)" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrent", "crdr": "credit", "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current", "totalLabel": "Total current liabilities", "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer." } } }, "auth_ref": [ "r45", "r90", "r111", "r222", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r381", "r384", "r385", "r419", "r621", "r789", "r842", "r843" ] }, "us-gaap_LiabilitiesCurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesCurrentAbstract", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Current [Abstract]", "terseLabel": "Current liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesFairValueDisclosure": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosure", "crdr": "credit", "calculation": { "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure", "totalLabel": "Total liabilities measured and recorded at fair value", "documentation": "Fair value of financial and nonfinancial obligations." } } }, "auth_ref": [ "r399", "r832" ] }, "us-gaap_LiabilitiesFairValueDisclosureAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesFairValueDisclosureAbstract", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Liabilities, Fair Value Disclosure [Abstract]", "terseLabel": "Liabilities:" } } }, "auth_ref": [] }, "us-gaap_LiabilitiesNoncurrentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "LiabilitiesNoncurrentAbstract", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Liabilities, Noncurrent [Abstract]", "terseLabel": "Non-current liabilities:" } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "anvs_March2023AtMarketEquityOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "March2023AtMarketEquityOfferingMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the March 2023 ATM Equity Offering.", "label": "March 2023 At the Market Equity Offering [Member]", "terseLabel": "March 2023 ATM" } } }, "auth_ref": [] }, "anvs_MariaMaccecchiniMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "MariaMaccecchiniMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Maria Maccecchini.", "label": "Maria Maccecchini [Member]", "terseLabel": "Maria Maccecchini" } } }, "auth_ref": [] }, "anvs_MarkWhiteMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "MarkWhiteMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to Mark White.", "label": "Mark White [Member]", "terseLabel": "Mark White" } } }, "auth_ref": [] }, "anvs_MaximumAggregateSeverancePayments": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "MaximumAggregateSeverancePayments", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "The maximum aggregate severance payments payable to executive officers under the terms of employment agreements.", "label": "Maximum Aggregate Severance Payments", "terseLabel": "Maximum aggregate severance payments" } } }, "auth_ref": [] }, "ecd_MeasureAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure [Axis]", "terseLabel": "Measure:" } } }, "auth_ref": [ "r698" ] }, "ecd_MeasureName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MeasureName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Measure Name", "terseLabel": "Name" } } }, "auth_ref": [ "r698" ] }, "us-gaap_MeasurementInputConversionPriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputConversionPriceMember", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Conversion Price [Member]", "terseLabel": "Redemption hurdle price", "documentation": "Measurement input using price per share at which convertible share can be converted into common stock." } } }, "auth_ref": [ "r834", "r835", "r836" ] }, "us-gaap_MeasurementInputExercisePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExercisePriceMember", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Exercise Price [Member]", "terseLabel": "Exercise price", "documentation": "Measurement input using agreed upon price for exchange of underlying asset." } } }, "auth_ref": [ "r834", "r835", "r836" ] }, "us-gaap_MeasurementInputExpectedTermMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputExpectedTermMember", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Expected Term [Member]", "terseLabel": "Term (time to expiration in years)", "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date." } } }, "auth_ref": [ "r834", "r835", "r836" ] }, "us-gaap_MeasurementInputPriceVolatilityMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputPriceVolatilityMember", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Price Volatility [Member]", "terseLabel": "Volatility", "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns." } } }, "auth_ref": [ "r614", "r834", "r835", "r836" ] }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputRiskFreeInterestRateMember", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Risk Free Interest Rate [Member]", "terseLabel": "Risk-free rate", "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss." } } }, "auth_ref": [ "r834", "r835", "r836" ] }, "us-gaap_MeasurementInputSharePriceMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputSharePriceMember", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input, Share Price [Member]", "terseLabel": "Closing stock price", "documentation": "Measurement input using share price of saleable stock." } } }, "auth_ref": [ "r834", "r835", "r836" ] }, "anvs_MeasurementInputSuccessRateMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "MeasurementInputSuccessRateMember", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using probability of success rate.", "label": "Measurement Input, Success Rate [Member]", "terseLabel": "Phase 3 data probability of success" } } }, "auth_ref": [] }, "us-gaap_MeasurementInputTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeAxis", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Axis]", "documentation": "Information by type of measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r400", "r401", "r402", "r614" ] }, "us-gaap_MeasurementInputTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "MeasurementInputTypeDomain", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Measurement Input Type [Domain]", "documentation": "Measurement input used to determine value of asset and liability." } } }, "auth_ref": [ "r400", "r401", "r402", "r614" ] }, "srt_MinimumMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "MinimumMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]", "terseLabel": "Minimum" } } }, "auth_ref": [ "r252", "r253", "r254", "r255", "r294", "r336", "r402", "r464", "r491", "r493", "r500", "r514", "r515", "r567", "r568", "r569", "r570", "r571", "r575", "r576", "r594", "r600", "r604", "r614", "r615", "r619", "r623", "r791", "r844", "r845", "r846", "r847", "r848", "r849" ] }, "ecd_MnpiDiscTimedForCompValFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MnpiDiscTimedForCompValFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "MNPI Disclosure Timed for Compensation Value [Flag]", "terseLabel": "MNPI Disclosure Timed for Compensation Value" } } }, "auth_ref": [ "r718" ] }, "ecd_MtrlTermsOfTrdArrTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "MtrlTermsOfTrdArrTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Material Terms of Trading Arrangement [Text Block]", "terseLabel": "Material Terms of Trading Arrangement" } } }, "auth_ref": [ "r726" ] }, "ecd_NamedExecutiveOfficersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NamedExecutiveOfficersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Named Executive Officers, Footnote [Text Block]", "terseLabel": "Named Executive Officers, Footnote" } } }, "auth_ref": [ "r699" ] }, "anvs_NatureOfBusinessAndLiquidityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "NatureOfBusinessAndLiquidityAbstract", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlansDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Nature of Business and Liquidity [Abstract]", "verboseLabel": "Nature of Business and Management's Plans" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivities", "crdr": "debit", "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities", "totalLabel": "Net cash provided by financing activities", "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit." } } }, "auth_ref": [ "r106" ] }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]", "terseLabel": "Cash flows from financing activities:" } } }, "auth_ref": [] }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivities", "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities", "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities." } } }, "auth_ref": [ "r60", "r61", "r62" ] }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]", "terseLabel": "Cash flows from operating activities:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLoss", "crdr": "credit", "calculation": { "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails": { "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted", "weight": 1.0, "order": 1.0 }, "http://annovisbio.com/role/StatementStatementsOfOperations": { "parentTag": null, "weight": null, "order": null, "root": true }, "http://annovisbio.com/role/DisclosureSegmentInformationDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlansDetails", "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/DisclosureSegmentInformationDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit", "http://annovisbio.com/role/StatementStatementsOfOperations", "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "negatedLabel": "Net loss", "totalLabel": "Net loss", "verboseLabel": "Net loss", "label": "Net Income (Loss)", "terseLabel": "Net Income (Loss)", "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent." } } }, "auth_ref": [ "r57", "r62", "r78", "r89", "r97", "r98", "r102", "r111", "r118", "r120", "r121", "r122", "r123", "r124", "r127", "r128", "r137", "r222", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r375", "r378", "r396", "r419", "r476", "r544", "r560", "r561", "r633", "r789" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasicAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersBasicAbstract", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Basic [Abstract]", "terseLabel": "Net loss per share - Basic:" } } }, "auth_ref": [] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDiluted": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDiluted", "crdr": "credit", "calculation": { "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted", "totalLabel": "Numerator for diluted net loss per share", "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities, and addition from assumption of issuance of common shares for dilutive potential common shares; of income (loss) available to common shareholders." } } }, "auth_ref": [ "r104", "r131", "r133", "r134", "r135", "r136", "r138", "r141" ] }, "us-gaap_NetIncomeLossAvailableToCommonStockholdersDilutedAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NetIncomeLossAvailableToCommonStockholdersDilutedAbstract", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss) Available to Common Stockholders, Diluted [Abstract]", "terseLabel": "Net loss per share - Diluted:" } } }, "auth_ref": [] }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "New Accounting Pronouncements, Policy [Policy Text Block]", "terseLabel": "Recent Accounting Pronouncements", "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact." } } }, "auth_ref": [] }, "anvs_NonCashFinancingCostsFromIssuanceOfShares": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "NonCashFinancingCostsFromIssuanceOfShares", "crdr": "debit", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of non-cash financing costs attributable to shares issuance costs.", "label": "Non-Cash Financing Costs from Issuance of Shares", "terseLabel": "Non-cash other financing costs" } } }, "auth_ref": [] }, "anvs_NonCashFinancingCostsIncludingChangeInFairValueDerivative": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "NonCashFinancingCostsIncludingChangeInFairValueDerivative", "crdr": "debit", "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "Amount of non-cash financing costs, including change in fair value of derivative.", "label": "Non-Cash Financing Costs, Including Change in Fair Value Derivative", "terseLabel": "Non-cash other financing costs, including change in fair value of derivative" } } }, "auth_ref": [] }, "anvs_NonCashTransactionValueOfConsiderationWarrantExercises": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "NonCashTransactionValueOfConsiderationWarrantExercises", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "documentation": "The value of the noncash consideration recognized as a reduction in warrant value related to exercise of warrants.", "label": "Non-Cash Transaction, Value of Consideration, Warrant Exercises", "terseLabel": "Other adjustment to value of warrants related to exercises" } } }, "auth_ref": [] }, "ecd_NonGaapMeasureDescriptionTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonGaapMeasureDescriptionTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-GAAP Measure Description [Text Block]", "terseLabel": "Non-GAAP Measure Description" } } }, "auth_ref": [ "r698" ] }, "ecd_NonNeosMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonNeosMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-NEOs [Member]", "terseLabel": "Non-NEOs" } } }, "auth_ref": [ "r661", "r672", "r682", "r706", "r715" ] }, "ecd_NonPeoNeoAvgCompActuallyPaidAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgCompActuallyPaidAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Compensation Actually Paid Amount", "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount" } } }, "auth_ref": [ "r689" ] }, "ecd_NonPeoNeoAvgTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoAvgTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO Average Total Compensation Amount", "terseLabel": "Non-PEO NEO Average Total Compensation Amount" } } }, "auth_ref": [ "r688" ] }, "ecd_NonPeoNeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonPeoNeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Non-PEO NEO [Member]", "terseLabel": "Non-PEO NEO" } } }, "auth_ref": [ "r706" ] }, "ecd_NonRule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r726" ] }, "ecd_NonRule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "NonRule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r726" ] }, "us-gaap_NonoperatingIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpense", "crdr": "credit", "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense)", "totalLabel": "Total other income (expense), net", "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)." } } }, "auth_ref": [ "r59" ] }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NonoperatingIncomeExpenseAbstract", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Nonoperating Income (Expense) [Abstract]", "terseLabel": "Other income (expense):" } } }, "auth_ref": [] }, "anvs_November2023EquityOfferingAndWarrantIssuanceMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "November2023EquityOfferingAndWarrantIssuanceMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails", "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the November 2023 Equity Offering and Warrant Issuance.", "label": "November 2023 Equity Offering and Warrant Issuance [Member]", "terseLabel": "November 2023 Equity Offering and Warrant Issuance", "verboseLabel": "Common stock warrants" } } }, "auth_ref": [] }, "anvs_November2023PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "November2023PrivatePlacementMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to the November 2023 Private Placement.", "label": "November 2023 Private Placement [Member]", "terseLabel": "November 2023 Private Placement" } } }, "auth_ref": [] }, "anvs_NumberOfClassesOfStockDesignated": { "xbrltype": "integerItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "NumberOfClassesOfStockDesignated", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of classes of stock designated.", "label": "Number of classes of stock designated", "terseLabel": "Number of classes of stock designated" } } }, "auth_ref": [] }, "us-gaap_NumberOfOperatingSegments": { "xbrltype": "integerItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "NumberOfOperatingSegments", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Number of Operating Segments", "terseLabel": "Number of operating segments", "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues." } } }, "auth_ref": [ "r589", "r773" ] }, "anvs_NumberOfSaleOfStockTransactions": { "xbrltype": "integerItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "NumberOfSaleOfStockTransactions", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the number of sale of stock transactions.", "label": "Number of Sale of Stock Transactions", "terseLabel": "Number of transactions" } } }, "auth_ref": [] }, "anvs_NumberOfSharesIncludedInEachUnit": { "xbrltype": "sharesItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "NumberOfSharesIncludedInEachUnit", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of shares included in each unit.", "label": "Number of Shares Included in Each Unit", "terseLabel": "Number of common shares included in each unit" } } }, "auth_ref": [] }, "anvs_NumberOfShortTermLeases": { "xbrltype": "integerItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "NumberOfShortTermLeases", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of short-term leases.", "label": "Number of Short-Term Leases", "terseLabel": "Number of short term leases" } } }, "auth_ref": [] }, "anvs_NumberOfVotesForEachShareOfCommonStock": { "xbrltype": "integerItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "NumberOfVotesForEachShareOfCommonStock", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of vote for each share of common stock.", "label": "Number of Votes for Each Share of Common Stock", "terseLabel": "Number of vote for each share of common stock" } } }, "auth_ref": [] }, "anvs_NumberOfWarrantsIncludedInEachUnit": { "xbrltype": "sharesItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "NumberOfWarrantsIncludedInEachUnit", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants included in each unit.", "label": "Number of Warrants Included in Each Unit", "terseLabel": "Number of warrants included in each unit" } } }, "auth_ref": [] }, "anvs_NumberOfWarrantsIssuedDuringPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "NumberOfWarrantsIssuedDuringPeriod", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "Number of warrants issued during the period.", "label": "Number of Warrants Issued During the Period", "terseLabel": "Granted" } } }, "auth_ref": [] }, "us-gaap_OperatingExpenses": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpenses", "crdr": "debit", "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses", "totalLabel": "Total operating expenses", "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense." } } }, "auth_ref": [] }, "us-gaap_OperatingExpensesAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingExpensesAbstract", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Expenses [Abstract]", "terseLabel": "Operating expenses:" } } }, "auth_ref": [] }, "us-gaap_OperatingIncomeLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingIncomeLoss", "crdr": "credit", "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlansDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Operating Income (Loss)", "negatedLabel": "Operating loss", "totalLabel": "Operating loss", "documentation": "The net result for the period of deducting operating expenses from operating revenues." } } }, "auth_ref": [ "r81", "r582", "r772", "r774", "r775", "r776", "r777" ] }, "us-gaap_OperatingLeaseExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLeaseExpense", "crdr": "debit", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Operating Lease, Expense", "terseLabel": "Rental expense", "documentation": "Amount of operating lease expense. Excludes sublease income." } } }, "auth_ref": [ "r840" ] }, "us-gaap_OperatingLossCarryforwards": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwards", "crdr": "debit", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards", "terseLabel": "Net operating loss carryforwards", "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r363" ] }, "us-gaap_OperatingLossCarryforwardsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsLineItems", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Line Items]", "terseLabel": "Income taxes", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r363" ] }, "us-gaap_OperatingLossCarryforwardsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OperatingLossCarryforwardsTable", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Operating Loss Carryforwards [Table]", "documentation": "Disclosure of information about operating loss carryforward. Includes, but is not limited to, tax authority, amount and expiration date of operating loss carryforward, and likelihood of utilization." } } }, "auth_ref": [ "r363" ] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract", "lang": { "en-us": { "role": { "label": "Nature of Business and Management's Plans" } } }, "auth_ref": [] }, "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlans" ], "lang": { "en-us": { "role": { "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]", "terseLabel": "Nature of Business and Management's Plans", "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure." } } }, "auth_ref": [ "r41", "r74", "r501", "r502" ] }, "us-gaap_OtherCommitmentsLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsLineItems", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Line Items]", "terseLabel": "Commitments and Contingencies", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_OtherCommitmentsTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherCommitmentsTable", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails" ], "lang": { "en-us": { "role": { "label": "Other Commitments [Table]", "documentation": "Disclosure of information about obligations resulting from other commitments." } } }, "auth_ref": [] }, "us-gaap_OtherNoncashIncomeExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherNoncashIncomeExpense", "crdr": "credit", "calculation": { "http://annovisbio.com/role/DisclosureSegmentInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0, "order": 7.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Other Noncash Income (Expense)", "terseLabel": "Other non-cash income (expense) items", "documentation": "Amount of income (expense) included in net income that results in no cash inflow (outflow), classified as other." } } }, "auth_ref": [ "r62" ] }, "ecd_OtherPerfMeasureAmt": { "xbrltype": "decimalItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OtherPerfMeasureAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Other Performance Measure, Amount", "terseLabel": "Other Performance Measure, Amount" } } }, "auth_ref": [ "r698" ] }, "us-gaap_OtherPrepaidExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "OtherPrepaidExpenseCurrent", "crdr": "debit", "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Other Prepaid Expense, Current", "terseLabel": "Prepaid other", "documentation": "Amount of asset related to consideration paid in advance for other costs that provide economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r759", "r784" ] }, "ecd_OutstandingAggtErrCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingAggtErrCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Aggregate Erroneous Compensation Amount", "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount" } } }, "auth_ref": [ "r659", "r670", "r680", "r713" ] }, "ecd_OutstandingRecoveryCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery Compensation Amount", "terseLabel": "Compensation Amount" } } }, "auth_ref": [ "r662", "r673", "r683", "r716" ] }, "ecd_OutstandingRecoveryIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "OutstandingRecoveryIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Outstanding Recovery, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r662", "r673", "r683", "r716" ] }, "ecd_PayVsPerformanceDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PayVsPerformanceDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Line Items]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r687" ] }, "ecd_PeerGroupIssuersFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupIssuersFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Issuers, Footnote [Text Block]", "terseLabel": "Peer Group Issuers, Footnote" } } }, "auth_ref": [ "r697" ] }, "ecd_PeerGroupTotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeerGroupTotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Peer Group Total Shareholder Return Amount", "terseLabel": "Peer Group Total Shareholder Return Amount" } } }, "auth_ref": [ "r697" ] }, "ecd_PeoActuallyPaidCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoActuallyPaidCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Actually Paid Compensation Amount", "terseLabel": "PEO Actually Paid Compensation Amount" } } }, "auth_ref": [ "r689" ] }, "ecd_PeoMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO [Member]", "terseLabel": "PEO" } } }, "auth_ref": [ "r706" ] }, "ecd_PeoName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoName", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Name", "terseLabel": "PEO Name" } } }, "auth_ref": [ "r699" ] }, "ecd_PeoTotalCompAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PeoTotalCompAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "PEO Total Compensation Amount", "terseLabel": "PEO Total Compensation Amount" } } }, "auth_ref": [ "r688" ] }, "anvs_PercentageOfExercisePriceToShareOfferingPrice": { "xbrltype": "percentItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "PercentageOfExercisePriceToShareOfferingPrice", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Percentage of exercise price to the share offering price.", "label": "Percentage of Exercise Price to the Share Offering Price", "terseLabel": "Percentage of exercise price to the share offering price" } } }, "auth_ref": [] }, "anvs_PerformanceBasedVestingConditionsMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "PerformanceBasedVestingConditionsMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to performance-based vesting conditions.", "label": "Performance-based vesting conditions" } } }, "auth_ref": [] }, "us-gaap_PlanNameAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameAxis", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Axis]", "documentation": "Information by plan name for share-based payment arrangement." } } }, "auth_ref": [ "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817" ] }, "us-gaap_PlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PlanNameDomain", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" ], "lang": { "en-us": { "role": { "label": "Plan Name [Domain]", "documentation": "Plan name for share-based payment arrangement." } } }, "auth_ref": [ "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817" ] }, "ecd_PnsnAdjsPrrSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsPrrSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Prior Service Cost [Member]", "terseLabel": "Pension Adjustments Prior Service Cost" } } }, "auth_ref": [ "r690" ] }, "ecd_PnsnAdjsSvcCstMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnAdjsSvcCstMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Adjustments Service Cost [Member]", "terseLabel": "Pension Adjustments Service Cost" } } }, "auth_ref": [ "r746" ] }, "ecd_PnsnBnftsAdjFnTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PnsnBnftsAdjFnTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pension Benefits Adjustments, Footnote [Text Block]", "terseLabel": "Pension Benefits Adjustments, Footnote" } } }, "auth_ref": [ "r689" ] }, "us-gaap_PortionAtFairValueFairValueDisclosureMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PortionAtFairValueFairValueDisclosureMember", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails" ], "lang": { "en-us": { "role": { "label": "Portion at Fair Value Measurement [Member]", "documentation": "Measured at fair value for financial reporting purposes." } } }, "auth_ref": [ "r417" ] }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockParOrStatedValuePerShare", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Par or Stated Value Per Share", "terseLabel": "Preferred stock, par value (dollars per share)", "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer." } } }, "auth_ref": [ "r50", "r268" ] }, "us-gaap_PreferredStockSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesAuthorized", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Authorized", "terseLabel": "Preferred stock, shares authorized", "verboseLabel": "Number of preferred shares authorized", "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws." } } }, "auth_ref": [ "r50", "r524" ] }, "us-gaap_PreferredStockSharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesIssued", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Issued", "terseLabel": "Preferred stock, shares issued", "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt." } } }, "auth_ref": [ "r50", "r268" ] }, "us-gaap_PreferredStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockSharesOutstanding", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityOverviewDetails", "http://annovisbio.com/role/StatementBalanceSheetsParenthetical" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Shares Outstanding", "terseLabel": "Preferred stock, shares outstanding", "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased." } } }, "auth_ref": [ "r50", "r524", "r542", "r886", "r887" ] }, "us-gaap_PreferredStockValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PreferredStockValue", "crdr": "credit", "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Preferred Stock, Value, Issued", "verboseLabel": "Preferred stock - $0.0001 par value, 2,000,000 shares authorized and 0 shares issued and outstanding", "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity." } } }, "auth_ref": [ "r50", "r471", "r621" ] }, "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "crdr": "debit", "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "parentTag": "us-gaap_Assets", "weight": 1.0, "order": 2.0 }, "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer. Includes security deposits.", "label": "Prepaid Expense, Security Deposits, and Other Assets, Current", "terseLabel": "Prepaid expenses and other current assets", "totalLabel": "Total prepaid expenses and other current assets" } } }, "auth_ref": [] }, "us-gaap_PrepaidInsurance": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrepaidInsurance", "crdr": "debit", "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Prepaid Insurance", "verboseLabel": "Prepaid insurance", "documentation": "Amount of asset related to consideration paid in advance for insurance that provides economic benefits within a future period of one year or the normal operating cycle, if longer." } } }, "auth_ref": [ "r579", "r596", "r784" ] }, "anvs_PrepaidResearchAndDevelopmentExpenseCurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "PrepaidResearchAndDevelopmentExpenseCurrent", "crdr": "debit", "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for research and development expense that provides economic benefits within a future period of one year or the normal operating cycle, if longer.", "label": "Prepaid Research and Development Expense, Current", "terseLabel": "Prepaid clinical expenses" } } }, "auth_ref": [] }, "us-gaap_PrivatePlacementMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "PrivatePlacementMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails" ], "lang": { "en-us": { "role": { "label": "Private Placement [Member]", "terseLabel": "Securities Purchase Agreement with an institutional investor", "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts." } } }, "auth_ref": [] }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfCommonStock", "crdr": "debit", "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Common Stock", "terseLabel": "Proceeds from issuance of common stock, net", "verboseLabel": "Net cash proceeds after deducting underwriter discount and fees", "documentation": "The cash inflow from the additional capital contribution to the entity." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromIssuanceOfWarrants": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromIssuanceOfWarrants", "crdr": "debit", "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Issuance of Warrants", "terseLabel": "Proceeds from exercise of warrants", "documentation": "The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt)." } } }, "auth_ref": [ "r6" ] }, "us-gaap_ProceedsFromStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProceedsFromStockOptionsExercised", "crdr": "debit", "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Proceeds from Stock Options Exercised", "terseLabel": "Proceeds from exercise of stock options", "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement." } } }, "auth_ref": [ "r6", "r13" ] }, "us-gaap_ProfessionalFees": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfessionalFees", "crdr": "debit", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Professional Fees", "terseLabel": "Issuance costs", "documentation": "A fee charged for services from professionals such as doctors, lawyers and accountants. The term is often expanded to include other professions, for example, pharmacists charging to maintain a medicinal profile of a client or customer." } } }, "auth_ref": [ "r588", "r633", "r884", "r885" ] }, "us-gaap_ProfitLoss": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ProfitLoss", "crdr": "credit", "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest", "terseLabel": "Net loss", "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest." } } }, "auth_ref": [ "r89", "r97", "r98", "r105", "r111", "r118", "r124", "r127", "r128", "r222", "r256", "r257", "r258", "r259", "r260", "r261", "r262", "r263", "r264", "r375", "r378", "r379", "r382", "r383", "r396", "r419", "r468", "r475", "r511", "r544", "r560", "r561", "r609", "r610", "r634", "r760", "r789" ] }, "anvs_ProgramExpensesRelatedToClinicalStageProductCandidates": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "ProgramExpensesRelatedToClinicalStageProductCandidates", "crdr": "debit", "calculation": { "http://annovisbio.com/role/DisclosureSegmentInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 1.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of program expenses related to clinical-stage product candidates.", "label": "Program Expenses Related to Clinical-Stage Product Candidates", "negatedLabel": "Program expenses related to clinical-stage product candidates" } } }, "auth_ref": [] }, "anvs_ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "ProgramExpensesRelatedToPreclinicalAndDiscoveryPrograms", "crdr": "debit", "calculation": { "http://annovisbio.com/role/DisclosureSegmentInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 2.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "The amount of program expenses related to preclinical and discovery programs.", "label": "Program Expenses Related to Preclinical and Discovery Programs", "negatedLabel": "Program expenses related to preclinical and discovery programs" } } }, "auth_ref": [] }, "ecd_PvpTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance Disclosure [Table]", "terseLabel": "Pay vs Performance Disclosure" } } }, "auth_ref": [ "r687" ] }, "ecd_PvpTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "PvpTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Pay vs Performance [Table Text Block]", "terseLabel": "Pay vs Performance Disclosure, Table" } } }, "auth_ref": [ "r687" ] }, "srt_RangeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeAxis", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "auth_ref": [ "r252", "r253", "r254", "r255", "r287", "r294", "r324", "r325", "r326", "r336", "r402", "r439", "r448", "r464", "r491", "r493", "r500", "r514", "r515", "r567", "r568", "r569", "r570", "r571", "r575", "r576", "r594", "r600", "r604", "r614", "r615", "r619", "r620", "r623", "r627", "r787", "r791", "r835", "r845", "r846", "r847", "r848", "r849" ] }, "srt_RangeMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "RangeMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "auth_ref": [ "r252", "r253", "r254", "r255", "r287", "r294", "r324", "r325", "r326", "r336", "r402", "r439", "r448", "r464", "r491", "r493", "r500", "r514", "r515", "r567", "r568", "r569", "r570", "r571", "r575", "r576", "r594", "r600", "r604", "r614", "r615", "r619", "r620", "r623", "r627", "r787", "r791", "r835", "r845", "r846", "r847", "r848", "r849" ] }, "ecd_RecoveryOfErrCompDisclosureLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RecoveryOfErrCompDisclosureLineItems", "lang": { "en-us": { "role": { "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]", "terseLabel": "Recovery of Erroneously Awarded Compensation Disclosure" } } }, "auth_ref": [ "r654", "r665", "r675", "r708" ] }, "anvs_RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "RegisteredDirectOfferingValueOfStockIssuedDuringPeriodNetOfIssuanceCosts", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued under terms of a registered direct offering, net of issuance costs.", "label": "Registered Direct Offering, Value of Stock Issued During Period, Net of Issuance Costs", "terseLabel": "Issuance of common stock pursuant to registered direct offering, net of issuance costs" } } }, "auth_ref": [] }, "anvs_ResearchAndDevelopmentAmortizationPeriodTerm": { "xbrltype": "durationItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "ResearchAndDevelopmentAmortizationPeriodTerm", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "documentation": "Period of time for amortization of research and development expenses, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Research and Development Amortization Period, Term", "terseLabel": "R&D amortization period" } } }, "auth_ref": [] }, "us-gaap_ResearchAndDevelopmentExpense": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpense", "crdr": "debit", "calculation": { "http://annovisbio.com/role/StatementStatementsOfOperations": { "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense", "terseLabel": "Research and development", "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity." } } }, "auth_ref": [ "r337", "r577", "r588", "r850" ] }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchAndDevelopmentExpenseMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails" ], "lang": { "en-us": { "role": { "label": "Research and Development Expense [Member]", "terseLabel": "Research and development", "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included." } } }, "auth_ref": [] }, "us-gaap_ResearchDevelopmentAndComputerSoftwarePolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchDevelopmentAndComputerSoftwarePolicyTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Research, Development, and Computer Software, Policy [Policy Text Block]", "terseLabel": "Research and Development", "documentation": "Disclosure of accounting policy for its research and development and computer software activities including the accounting treatment for costs incurred for (1) research and development activities, (2) development of computer software for internal use, (3) computer software to be sold, leased or otherwise marketed as a separate product or as part of a product or process and (4) in-process research and development acquired in a purchase business combination." } } }, "auth_ref": [ "r785", "r820", "r888" ] }, "us-gaap_ResearchMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ResearchMember", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Research Tax Credit Carryforward [Member]", "terseLabel": "Research and development tax credit carryforwards", "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes." } } }, "auth_ref": [ "r827" ] }, "ecd_RestatementDateAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDateAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date [Axis]", "terseLabel": "Restatement Determination Date:" } } }, "auth_ref": [ "r655", "r666", "r676", "r709" ] }, "ecd_RestatementDeterminationDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDeterminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Determination Date", "terseLabel": "Restatement Determination Date" } } }, "auth_ref": [ "r656", "r667", "r677", "r710" ] }, "ecd_RestatementDoesNotRequireRecoveryTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "RestatementDoesNotRequireRecoveryTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Restatement Does Not Require Recovery [Text Block]", "terseLabel": "Restatement does not require Recovery" } } }, "auth_ref": [ "r663", "r674", "r684", "r717" ] }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsAccumulatedDeficit", "crdr": "credit", "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlansDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Retained Earnings (Accumulated Deficit)", "negatedLabel": "Accumulated deficit", "terseLabel": "Accumulated deficit", "documentation": "Amount of accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r53", "r70", "r473", "r498", "r499", "r509", "r525", "r621" ] }, "us-gaap_RetainedEarningsMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RetainedEarningsMember", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Retained Earnings [Member]", "terseLabel": "Accumulated Deficit", "documentation": "Accumulated undistributed earnings (deficit)." } } }, "auth_ref": [ "r87", "r115", "r116", "r117", "r119", "r124", "r126", "r128", "r223", "r224", "r243", "r365", "r366", "r372", "r373", "r374", "r376", "r377", "r378", "r386", "r388", "r389", "r391", "r394", "r427", "r428", "r495", "r497", "r512", "r886" ] }, "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "RevenueFromContractWithCustomerExcludingAssessedTax", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/DisclosureNatureOfBusinessAndManagementSPlansDetails" ], "lang": { "en-us": { "role": { "label": "Revenue from Contract with Customer, Excluding Assessed Tax", "terseLabel": "Revenue", "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise." } } }, "auth_ref": [ "r79", "r80", "r147", "r155", "r156", "r177", "r183", "r187", "r189", "r190", "r285", "r286", "r465" ] }, "ecd_Rule10b51ArrAdoptedFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrAdoptedFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Adopted [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Adopted" } } }, "auth_ref": [ "r726" ] }, "ecd_Rule10b51ArrTrmntdFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "Rule10b51ArrTrmntdFlag", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Rule 10b5-1 Arrangement Terminated [Flag]", "terseLabel": "Rule 10b5-1 Arrangement Terminated" } } }, "auth_ref": [ "r726" ] }, "anvs_SaleOfStockAtMarketOfferingTemporarySuspensionTerm": { "xbrltype": "durationItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "SaleOfStockAtMarketOfferingTemporarySuspensionTerm", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Period of time for temporary suspension of sale of stock under the At the Market Equity Offering Sales Agreements after the start of the secondary public offering, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Sale of Stock, At The Market Offering, Temporary Suspension, Term", "terseLabel": "Temporary suspension of ATM offering" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockConsiderationReceivedOnTransaction": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockConsiderationReceivedOnTransaction", "crdr": "debit", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Consideration Received on Transaction", "terseLabel": "Net proceeds from sale of stock", "documentation": "Cash received on stock transaction after deduction of issuance costs." } } }, "auth_ref": [] }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockNameOfTransactionDomain", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails", "http://annovisbio.com/role/DisclosureSubsequentEventsDetails", "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Domain]", "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement." } } }, "auth_ref": [] }, "anvs_SaleOfStockNumberOfUnitsAuthorizedForIssuance": { "xbrltype": "sharesItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "SaleOfStockNumberOfUnitsAuthorizedForIssuance", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "The number of units authorized for issuance. Each unit consists of one share of common stock and one warrant to purchase one share of common stock at a per unit price.", "label": "Sale of Stock, Number of Units Authorized for Issuance", "terseLabel": "Number of units to be sold" } } }, "auth_ref": [] }, "us-gaap_SaleOfStockPricePerShare": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SaleOfStockPricePerShare", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails", "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock, Price Per Share", "terseLabel": "Price per share", "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureAccruedExpensesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Accrued Liabilities [Table Text Block]", "terseLabel": "Schedule of accrued expenses", "documentation": "Tabular disclosure of the components of accrued liabilities." } } }, "auth_ref": [] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "lang": { "en-us": { "role": { "label": "Antidilutive Security, Excluded EPS Calculation [Table]", "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS." } } }, "auth_ref": [ "r18" ] }, "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]", "terseLabel": "Schedule of shares excluded from the computation of diluted weighted-average shares outstanding", "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities." } } }, "auth_ref": [ "r18" ] }, "anvs_ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "ScheduleOfChangesInCommonStockWarrantLiabilitiesTableTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of changes in common stock warrant liabilities.", "label": "Schedule of Changes in Common Stock Warrant Liabilities [Table Text Block]", "terseLabel": "Schedule of changes in common stock warrant liabilities" } } }, "auth_ref": [] }, "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]", "terseLabel": "Schedule of significant components of deferred tax assets", "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets." } } }, "auth_ref": [ "r826" ] }, "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]", "terseLabel": "Schedule of basic and diluted net loss per share", "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations." } } }, "auth_ref": [ "r771" ] }, "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]", "terseLabel": "Schedule of reconciliation of income tax provision (benefit)", "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations." } } }, "auth_ref": [ "r345", "r608", "r822" ] }, "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]", "terseLabel": "Schedule of stock-based compensation expense", "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement." } } }, "auth_ref": [ "r34" ] }, "us-gaap_ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfFairValueAssetsAndLiabilitiesMeasuredOnRecurringBasisTableTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]", "terseLabel": "Schedule of carrying value and fair value of financial assets and liabilities measured at fair value on a recurring basis", "documentation": "Tabular disclosure of assets and liabilities, including [financial] instruments measured at fair value that are classified in stockholders' equity, if any, that are measured at fair value on a recurring basis. The disclosures contemplated herein include the fair value measurements at the reporting date by the level within the fair value hierarchy in which the fair value measurements in their entirety fall, segregating fair value measurements using quoted prices in active markets for identical assets (Level 1), significant other observable inputs (Level 2), and significant unobservable inputs (Level 3)." } } }, "auth_ref": [ "r832", "r833" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTable", "presentation": [ "http://annovisbio.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table]", "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment." } } }, "auth_ref": [ "r23", "r24", "r25" ] }, "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureSegmentInformationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]", "terseLabel": "Schedule of Segment information", "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss." } } }, "auth_ref": [ "r23", "r24", "r25" ] }, "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails", "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails", "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]", "documentation": "Disclosure of information about share-based payment arrangement." } } }, "auth_ref": [ "r296", "r297", "r299", "r300", "r301", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r323", "r324", "r325", "r326", "r327" ] }, "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]", "terseLabel": "Schedule of stock option activity", "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value." } } }, "auth_ref": [ "r11", "r12", "r71" ] }, "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]", "terseLabel": "Schedule of weighted average assumptions used to determine fair value of options", "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions." } } }, "auth_ref": [ "r73" ] }, "us-gaap_ScheduleOfStockByClassTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockByClassTable", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails", "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails", "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Stock, Class of Stock [Table]", "documentation": "Disclosure of information about stock by class. Includes, but is not limited to, common, convertible, and preferred stocks." } } }, "auth_ref": [ "r26", "r27", "r28", "r29", "r30", "r31", "r66", "r68", "r69", "r70", "r93", "r94", "r95", "r149", "r268", "r269", "r270", "r272", "r275", "r280", "r282", "r505", "r506", "r507", "r508", "r600", "r750", "r763" ] }, "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityTables" ], "lang": { "en-us": { "role": { "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]", "terseLabel": "Schedule of common stock warrants outstanding", "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable." } } }, "auth_ref": [ "r32" ] }, "anvs_SecondaryOfferingMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "SecondaryOfferingMember", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Secondary sale of stock to the public.", "label": "Secondary Offering [Member]", "terseLabel": "Public offering" } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r636" ] }, "us-gaap_SecurityDeposit": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SecurityDeposit", "crdr": "debit", "calculation": { "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails": { "parentTag": "anvs_PrepaidExpenseSecurityDepositsAndOtherAssetsCurrent", "weight": 1.0, "order": 4.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosurePrepaidExpensesAndOtherCurrentAssetsDetails" ], "lang": { "en-us": { "role": { "label": "Security Deposit", "terseLabel": "Security deposits", "documentation": "The amount of an asset, typically cash, provided to a counterparty to provide certain assurance of performance by the entity pursuant to the terms of a written or oral agreement, such as a lease." } } }, "auth_ref": [ "r758" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SecurityExchangeName", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r639" ] }, "us-gaap_SegmentDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentDomain", "presentation": [ "http://annovisbio.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Domain]", "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity." } } }, "auth_ref": [ "r79", "r80", "r81", "r82", "r147", "r151", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r167", "r168", "r169", "r177", "r178", "r179", "r180", "r181", "r183", "r184", "r185", "r190", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r248", "r249", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r585", "r588", "r589", "r597", "r624", "r851", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880" ] }, "us-gaap_SegmentReportingAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingAbstract", "lang": { "en-us": { "role": { "label": "Segment Information" } } }, "auth_ref": [] }, "us-gaap_SegmentReportingDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingDisclosureTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureSegmentInformation" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Disclosure [Text Block]", "terseLabel": "Segment Information", "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments." } } }, "auth_ref": [ "r82", "r147", "r150", "r151", "r152", "r153", "r154", "r166", "r168", "r169", "r181", "r182", "r183", "r184", "r185", "r187", "r188", "r190", "r583", "r586", "r587", "r588", "r590", "r592", "r593" ] }, "us-gaap_SegmentReportingInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingInformationLineItems", "presentation": [ "http://annovisbio.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting Information [Line Items]", "terseLabel": "Segment Information", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "us-gaap_SegmentReportingOtherItemAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingOtherItemAmount", "crdr": "debit", "calculation": { "http://annovisbio.com/role/DisclosureSegmentInformationDetails": { "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0, "order": 5.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Other Segment Item, Amount", "negatedLabel": "Other segment items", "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)." } } }, "auth_ref": [ "r147", "r168", "r169", "r183", "r588" ] }, "us-gaap_SegmentReportingPolicyPolicyTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SegmentReportingPolicyPolicyTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Segment Reporting, Policy [Policy Text Block]", "terseLabel": "Segment Information", "documentation": "Disclosure of accounting policy for segment reporting." } } }, "auth_ref": [ "r170", "r171", "r172", "r173", "r174", "r175", "r176", "r186", "r189", "r584", "r585", "r591" ] }, "anvs_ServiceBasedOptionsMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "ServiceBasedOptionsMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "documentation": "Share-based payment arrangement awarded for meeting service requirements.", "label": "Service-Based Options [Member]", "terseLabel": "Service-based options" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensation": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensation", "crdr": "debit", "calculation": { "http://annovisbio.com/role/StatementStatementsOfCashFlows": { "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails", "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement, Noncash Expense", "terseLabel": "Stock-based compensation expense", "verboseLabel": "Stock-based compensation expense", "documentation": "Amount of noncash expense for share-based payment arrangement." } } }, "auth_ref": [ "r7" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Period", "terseLabel": "Vesting period", "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition." } } }, "auth_ref": [ "r605" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions and Methodology [Abstract]", "verboseLabel": "Estimated fair value of options" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails", "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate", "terseLabel": "Expected dividend yield", "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term." } } }, "auth_ref": [ "r325" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate", "terseLabel": "Expected volatility", "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period." } } }, "auth_ref": [ "r324" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": { "xbrltype": "percentItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate", "terseLabel": "Risk-free interest rate", "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares." } } }, "auth_ref": [ "r326" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails", "http://annovisbio.com/role/DisclosureStockBasedCompensationShareBasedCompensationExpenseDetails", "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]", "terseLabel": "Stock-Based Compensation", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r296", "r297", "r299", "r300", "r301", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r323", "r324", "r325", "r326", "r327" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Authorized", "verboseLabel": "Shares authorized", "documentation": "Number of shares authorized for issuance under share-based payment arrangement." } } }, "auth_ref": [ "r607" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant", "terseLabel": "Shares available for future grants", "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]", "terseLabel": "Aggregate Intrinsic Value" } } }, "auth_ref": [] }, "anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCashlessExercisesInPeriod", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Number of share options (or share units) exercised during the current period in a cashless transaction.", "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Cashless Exercises in Period", "terseLabel": "Cashless exercise of stock options, shares" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number", "terseLabel": "Exercisable at end of year", "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan." } } }, "auth_ref": [ "r305" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price", "terseLabel": "Exercisable at end of year (in dollars per share)", "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan." } } }, "auth_ref": [ "r305" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue", "crdr": "debit", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value", "verboseLabel": "Exercised", "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares." } } }, "auth_ref": [ "r318" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period", "negatedLabel": "Forfeited", "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan." } } }, "auth_ref": [ "r309" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails", "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross", "terseLabel": "Granted", "verboseLabel": "Options granted", "documentation": "Gross number of share options (or share units) granted during the period." } } }, "auth_ref": [ "r307" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value", "terseLabel": "Weighted average grant date fair value", "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology." } } }, "auth_ref": [ "r317" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue", "crdr": "debit", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value", "terseLabel": "Outstanding", "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding." } } }, "auth_ref": [ "r33" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number", "periodEndLabel": "Outstanding at end of the year", "periodStartLabel": "Outstanding at beginning of the year", "documentation": "Number of options outstanding, including both vested and non-vested options." } } }, "auth_ref": [ "r303", "r304" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]", "terseLabel": "Number of Shares", "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period." } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price", "periodEndLabel": "Outstanding at end of the year (in dollars per share)", "periodStartLabel": "Outstanding at beginning of the year (in dollars per share)", "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan." } } }, "auth_ref": [ "r303", "r304" ] }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]", "terseLabel": "Weighted Average Exercise Price" } } }, "auth_ref": [] }, "anvs_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract": { "xbrltype": "stringItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsWeightedAverageRemainingContractualTermAbstract", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "documentation": "No definition available.", "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Options, Weighted-Average Remaining Contractual Term [Abstract]", "terseLabel": "Weighted Average Remaining Contractual Term" } } }, "auth_ref": [] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails", "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails", "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "All Award Types", "terseLabel": "All Award Types", "documentation": "Award under share-based payment arrangement." } } }, "auth_ref": [ "r299", "r300", "r301", "r303", "r304", "r305", "r306", "r307", "r308", "r309", "r310", "r311", "r312", "r313", "r314", "r315", "r316", "r317", "r318", "r319", "r320", "r323", "r324", "r325", "r326", "r327" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price", "terseLabel": "Exercised (in dollars per share)", "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares." } } }, "auth_ref": [ "r308" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price", "terseLabel": "Forfeited (in dollars per share)", "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated." } } }, "auth_ref": [ "r309" ] }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails", "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price", "terseLabel": "Granted (in dollars per share)", "verboseLabel": "Weighted average exercise price", "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options." } } }, "auth_ref": [ "r307" ] }, "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Share-Based Payment Arrangement [Policy Text Block]", "terseLabel": "Stock-Based Compensation", "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost." } } }, "auth_ref": [ "r295", "r302", "r321", "r322", "r323", "r324", "r327", "r332", "r333", "r334", "r335" ] }, "anvs_ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "documentation": "Vesting period of equal quarterly installments over two years for award under share-based payment arrangement.", "label": "Vests in Equal Quarterly Installments Over Two Years [Member]", "terseLabel": "Vests in equal quarterly installments over two years" } } }, "auth_ref": [] }, "anvs_ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "documentation": "Immediate vesting of awards under share-based payment arrangement.", "label": "Immediate Vesting [Member]", "terseLabel": "Immediate vesting" } } }, "auth_ref": [] }, "us-gaap_SharePrice": { "xbrltype": "perShareItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharePrice", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Share Price", "verboseLabel": "Closing price of common stock", "documentation": "Price of a single share of a number of saleable stocks of a company." } } }, "auth_ref": [] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails", "http://annovisbio.com/role/DisclosureStockBasedCompensationSummaryOfPlansDetails", "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Expiration Period", "terseLabel": "Term of award (in years)", "verboseLabel": "Stock option contractual term (in years)", "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r606" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term", "terseLabel": "Expected option terms (years)", "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r323" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1", "crdr": "debit", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value", "terseLabel": "Exercisable", "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable." } } }, "auth_ref": [ "r33" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term", "terseLabel": "Exercisable (in years)", "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r33" ] }, "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term", "terseLabel": "Outstanding (in years)", "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r72" ] }, "us-gaap_SharesIssued": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SharesIssued", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Shares, Issued", "periodEndLabel": "Balance, shares", "periodStartLabel": "Balance, shares", "documentation": "Number of shares of stock issued as of the balance sheet date, including shares that had been issued and were previously outstanding but which are now held in the treasury." } } }, "auth_ref": [ "r9" ] }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SignificantAccountingPoliciesTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPolicies" ], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies [Text Block]", "terseLabel": "Summary of Significant Accounting Policies", "documentation": "The entire disclosure for all significant accounting policies of the reporting entity." } } }, "auth_ref": [ "r63", "r109" ] }, "anvs_SingleReportableSegmentMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "SingleReportableSegmentMember", "presentation": [ "http://annovisbio.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to a single reportable segment.", "label": "Single Reportable Segment [Member]", "terseLabel": "Single reportable segment" } } }, "auth_ref": [] }, "us-gaap_StateAndLocalIncomeTaxExpenseBenefitContinuingOperations": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StateAndLocalIncomeTaxExpenseBenefitContinuingOperations", "crdr": "debit", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesReconciliationOfIncomeTaxProvisionBenefitDetails" ], "lang": { "en-us": { "role": { "label": "State and Local Income Tax Expense (Benefit), Continuing Operations", "terseLabel": "State provision (benefit) for income taxes", "documentation": "Amount of current and deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current and deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction." } } }, "auth_ref": [ "r342", "r765", "r821", "r829" ] }, "us-gaap_StateAndLocalJurisdictionMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StateAndLocalJurisdictionMember", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "State and Local Jurisdiction [Member]", "terseLabel": "State", "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax." } } }, "auth_ref": [ "r343" ] }, "us-gaap_StatementBusinessSegmentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementBusinessSegmentsAxis", "presentation": [ "http://annovisbio.com/role/DisclosureSegmentInformationDetails" ], "lang": { "en-us": { "role": { "label": "Segments [Axis]", "documentation": "Information by business segments." } } }, "auth_ref": [ "r79", "r80", "r81", "r82", "r88", "r147", "r151", "r154", "r155", "r156", "r157", "r158", "r159", "r160", "r161", "r162", "r163", "r164", "r165", "r167", "r168", "r169", "r177", "r178", "r179", "r180", "r181", "r183", "r184", "r185", "r190", "r233", "r234", "r235", "r236", "r237", "r238", "r239", "r240", "r241", "r242", "r245", "r248", "r249", "r480", "r481", "r482", "r483", "r484", "r485", "r486", "r487", "r488", "r489", "r490", "r585", "r588", "r589", "r597", "r624", "r851", "r853", "r854", "r855", "r856", "r857", "r858", "r859", "r860", "r861", "r862", "r863", "r864", "r865", "r866", "r867", "r868", "r869", "r870", "r871", "r872", "r873", "r874", "r875", "r876", "r877", "r878", "r879", "r880" ] }, "us-gaap_StatementEquityComponentsAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementEquityComponentsAxis", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Equity Components [Axis]", "documentation": "Information by component of equity." } } }, "auth_ref": [ "r9", "r51", "r54", "r55", "r87", "r100", "r101", "r102", "r115", "r116", "r117", "r119", "r124", "r126", "r128", "r148", "r223", "r224", "r243", "r284", "r365", "r366", "r372", "r373", "r374", "r376", "r377", "r378", "r386", "r387", "r388", "r389", "r390", "r391", "r394", "r420", "r421", "r422", "r423", "r424", "r425", "r427", "r428", "r429", "r477", "r495", "r496", "r497", "r512", "r562" ] }, "us-gaap_StatementLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementLineItems", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [ "r115", "r116", "r117", "r148", "r428", "r465", "r503", "r513", "r516", "r517", "r518", "r519", "r520", "r521", "r524", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r537", "r538", "r539", "r540", "r541", "r543", "r545", "r546", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r562", "r628" ] }, "us-gaap_StatementOfCashFlowsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfCashFlowsAbstract", "lang": { "en-us": { "role": { "label": "Statements of Cash Flows" } } }, "auth_ref": [] }, "us-gaap_StatementOfFinancialPositionAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfFinancialPositionAbstract", "lang": { "en-us": { "role": { "label": "Balance Sheets" } } }, "auth_ref": [] }, "us-gaap_StatementOfStockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementOfStockholdersEquityAbstract", "lang": { "en-us": { "role": { "label": "Statements of Changes in Stockholders' Equity (Deficit)" } } }, "auth_ref": [] }, "us-gaap_StatementTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StatementTable", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Statement [Table]", "documentation": "Disclosure of information about statement of comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity." } } }, "auth_ref": [ "r115", "r116", "r117", "r148", "r191", "r428", "r465", "r503", "r513", "r516", "r517", "r518", "r519", "r520", "r521", "r524", "r527", "r528", "r529", "r530", "r531", "r532", "r533", "r534", "r535", "r537", "r538", "r539", "r540", "r541", "r543", "r545", "r546", "r548", "r549", "r550", "r551", "r552", "r553", "r554", "r555", "r556", "r557", "r558", "r559", "r562", "r628" ] }, "ecd_StkPrcOrTsrEstimationMethodTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "StkPrcOrTsrEstimationMethodTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Price or TSR Estimation Method [Text Block]", "terseLabel": "Stock Price or TSR Estimation Method" } } }, "auth_ref": [ "r658", "r669", "r679", "r712" ] }, "us-gaap_StockAppreciationRightsSARSMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockAppreciationRightsSARSMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Stock Appreciation Rights (SARs) [Member]", "terseLabel": "Stock Appreciation Rights (SARs)", "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period." } } }, "auth_ref": [] }, "anvs_StockIssuedDuringPeriodSharesEquityDistributionAgreement": { "xbrltype": "sharesItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "StockIssuedDuringPeriodSharesEquityDistributionAgreement", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Shares of stock issued during the period under terms of an equity distribution agreement.", "label": "Stock Issued During Period, Shares, Equity Distribution Agreement", "terseLabel": "Issuance of common stock pursuant to Equity Distribution Agreement, net of issuance costs, shares" } } }, "auth_ref": [] }, "anvs_StockIssuedDuringPeriodSharesEquityLineOfCredit": { "xbrltype": "sharesItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "StockIssuedDuringPeriodSharesEquityLineOfCredit", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Shares of stock issued during the period under terms of an equity line of credit.", "label": "Stock Issued During Period, Shares, Equity Line of Credit", "terseLabel": "Issuance of common stock pursuant to ELOC, net of issuance costs, shares" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesNewIssues", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails", "http://annovisbio.com/role/DisclosureSubsequentEventsDetails", "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Shares, New Issues", "verboseLabel": "Number of shares issued", "documentation": "Number of new stock issued during the period." } } }, "auth_ref": [ "r9", "r50", "r51", "r70", "r505", "r562", "r572" ] }, "anvs_StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability": { "xbrltype": "sharesItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "StockIssuedDuringPeriodSharesNewIssuesExcludingWarrantLiability", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period, excluding warrant liability.", "label": "Stock Issued During Period, Shares, New Issues Excluding Warrant Liability", "terseLabel": "Issuance of common stock, net of issuance costs and warrant liability, shares" } } }, "auth_ref": [] }, "anvs_StockIssuedDuringPeriodSharesRegisteredDirectOffering": { "xbrltype": "sharesItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "StockIssuedDuringPeriodSharesRegisteredDirectOffering", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Shares of stock issued during the period under terms of a registered direct offering.", "label": "Stock Issued During Period, Shares, Registered Direct Offering", "terseLabel": "Issuance of common stock pursuant to registered direct offering, net of issuance costs, shares" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationStockOptionActivityDetails", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period", "negatedLabel": "Exercised", "verboseLabel": "Exercise of stock options, shares", "documentation": "Number of share options (or share units) exercised during the current period." } } }, "auth_ref": [ "r9", "r50", "r51", "r70", "r308" ] }, "anvs_StockIssuedDuringPeriodSharesWarrantsExercised": { "xbrltype": "sharesItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "StockIssuedDuringPeriodSharesWarrantsExercised", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Shares of stock issued as a result of the exercise of warrants.", "label": "Stock Issued During Period, Shares, Warrants Exercised", "terseLabel": "Exercise of common stock warrants, inclusive of warrant reduction, shares" } } }, "auth_ref": [] }, "anvs_StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "StockIssuedDuringPeriodValueCashlessExerciseOfStockOptions", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Value of stock issued as a result of the cashless exercise of stock options.", "label": "Stock Issued During Period, Value, Cashless Exercise of Stock Options", "terseLabel": "Cashless exercise of stock options" } } }, "auth_ref": [] }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueNewIssues", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, New Issues", "terseLabel": "Value of shares issued, net of issuance costs", "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering." } } }, "auth_ref": [ "r9", "r50", "r51", "r70", "r512", "r562", "r572", "r634" ] }, "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockIssuedDuringPeriodValueStockOptionsExercised", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Stock Issued During Period, Value, Stock Options Exercised", "verboseLabel": "Exercise of stock options", "documentation": "Value of stock issued as a result of the exercise of stock options." } } }, "auth_ref": [ "r9", "r51", "r54", "r55", "r70" ] }, "anvs_StockIssuedDuringPeriodValueWarrantsExercised": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "StockIssuedDuringPeriodValueWarrantsExercised", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "The value of stock issued in the cashless exercise of warrants.", "label": "Stock Issued During Period, Value, Warrants Exercised", "terseLabel": "Exercise of common stock warrants, inclusive of warrant reduction" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquity": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquity", "crdr": "credit", "calculation": { "http://annovisbio.com/role/StatementBalanceSheets": { "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0, "order": 3.0 } }, "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets", "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders' equity (deficit)", "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest." } } }, "auth_ref": [ "r51", "r54", "r55", "r64", "r526", "r542", "r563", "r564", "r621", "r635", "r764", "r783", "r839", "r886" ] }, "us-gaap_StockholdersEquityAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityAbstract", "presentation": [ "http://annovisbio.com/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "label": "Equity, Attributable to Parent [Abstract]", "terseLabel": "Stockholders' equity (deficit):" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteAbstract", "lang": { "en-us": { "role": { "label": "Stockholders' (Deficit) Equity" } } }, "auth_ref": [] }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "StockholdersEquityNoteDisclosureTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquity" ], "lang": { "en-us": { "role": { "label": "Equity [Text Block]", "terseLabel": "Stockholders' (Deficit) Equity", "documentation": "The entire disclosure for equity." } } }, "auth_ref": [ "r67", "r110", "r267", "r269", "r271", "r272", "r273", "r274", "r275", "r276", "r277", "r278", "r279", "r281", "r284", "r393", "r565", "r566", "r573" ] }, "us-gaap_SubsequentEventLineItems": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventLineItems", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Line Items]", "terseLabel": "Subsequent Events", "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event." } } }, "auth_ref": [ "r426", "r431" ] }, "us-gaap_SubsequentEventMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventMember", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Member]", "terseLabel": "Subsequent Events", "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r426", "r431" ] }, "us-gaap_SubsequentEventTable": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTable", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event [Table]", "documentation": "Disclosure of information about significant event or transaction occurring between statement of financial position date and date when financial statements were issued." } } }, "auth_ref": [ "r426", "r431" ] }, "us-gaap_SubsequentEventTypeAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeAxis", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Axis]", "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r426", "r431" ] }, "us-gaap_SubsequentEventTypeDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventTypeDomain", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "label": "Subsequent Event Type [Domain]", "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued." } } }, "auth_ref": [ "r426", "r431" ] }, "us-gaap_SubsequentEventsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsAbstract", "lang": { "en-us": { "role": { "label": "Subsequent Events" } } }, "auth_ref": [] }, "us-gaap_SubsequentEventsTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsequentEventsTextBlock", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEvents" ], "lang": { "en-us": { "role": { "label": "Subsequent Events [Text Block]", "verboseLabel": "Subsequent Events", "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business." } } }, "auth_ref": [ "r430", "r432" ] }, "us-gaap_SubsidiarySaleOfStockAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SubsidiarySaleOfStockAxis", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityAtmsAndPrivatePlacementsDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityChangesInDerivativeLiabilityDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityElocPurchaseAgreementDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRegisteredDirectOfferingsDetails", "http://annovisbio.com/role/DisclosureSubsequentEventsDetails", "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesDetails" ], "lang": { "en-us": { "role": { "label": "Sale of Stock [Axis]", "documentation": "Information by type of sale of the entity's stock." } } }, "auth_ref": [] }, "us-gaap_SupplementalCashFlowInformationAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "SupplementalCashFlowInformationAbstract", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfCashFlows" ], "lang": { "en-us": { "role": { "label": "Supplemental Cash Flow Information [Abstract]", "terseLabel": "Supplemental disclosure of cash flow information:" } } }, "auth_ref": [] }, "ecd_TabularListTableTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TabularListTableTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Tabular List [Table Text Block]", "terseLabel": "Tabular List, Table" } } }, "auth_ref": [ "r705" ] }, "us-gaap_TaxCreditCarryforwardAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardAmount", "crdr": "debit", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Amount", "terseLabel": "Tax credit carryforward", "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws." } } }, "auth_ref": [ "r363" ] }, "us-gaap_TaxCreditCarryforwardAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardAxis", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward [Axis]", "documentation": "Information by specific tax credit related to an unused tax credit." } } }, "auth_ref": [ "r363" ] }, "us-gaap_TaxCreditCarryforwardNameDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxCreditCarryforwardNameDomain", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Tax Credit Carryforward, Name [Domain]", "documentation": "The name of the tax credit carryforward." } } }, "auth_ref": [ "r363" ] }, "us-gaap_TaxPeriodAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxPeriodAxis", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Tax Period [Axis]", "documentation": "Information by period subject to enacted tax law." } } }, "auth_ref": [ "r825" ] }, "us-gaap_TaxPeriodDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TaxPeriodDomain", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Tax Period [Domain]", "documentation": "Identified tax period." } } }, "auth_ref": [ "r825" ] }, "anvs_ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded": { "xbrltype": "integerItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "ThresholdConsecutiveTradingDaysOfWhichAverageDailyTradingValueIsTraded", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the threshold consecutive trading days for which average daily trading value is traded.", "label": "Threshold Consecutive Trading Days of Which Average Daily Trading Value is Traded", "terseLabel": "Threshold consecutive trading days" } } }, "auth_ref": [] }, "srt_TitleOfIndividualAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualAxis", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Axis]" } } }, "auth_ref": [ "r778", "r841" ] }, "srt_TitleOfIndividualWithRelationshipToEntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "TitleOfIndividualWithRelationshipToEntityDomain", "presentation": [ "http://annovisbio.com/role/DisclosureCommitmentsAndContingenciesDetails", "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Title and Position [Domain]" } } }, "auth_ref": [] }, "ecd_TotalShareholderRtnAmt": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Amount", "terseLabel": "Total Shareholder Return Amount" } } }, "auth_ref": [ "r697" ] }, "ecd_TotalShareholderRtnVsPeerGroupTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TotalShareholderRtnVsPeerGroupTextBlock", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Total Shareholder Return Vs Peer Group [Text Block]", "terseLabel": "Total Shareholder Return Vs Peer Group" } } }, "auth_ref": [ "r704" ] }, "ecd_TradingArrAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrAxis", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement [Axis]", "terseLabel": "Trading Arrangement:" } } }, "auth_ref": [ "r725" ] }, "ecd_TradingArrByIndTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TradingArrByIndTable", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangements, by Individual [Table]", "terseLabel": "Trading Arrangements, by Individual" } } }, "auth_ref": [ "r727" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://annovisbio.com/role/DocumentDocumentAndEntityInformation" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables" ], "lang": { "en-us": { "role": { "label": "Financial Instruments [Domain]", "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms." } } }, "auth_ref": [ "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213", "r214", "r215", "r216", "r217", "r218", "r219", "r220", "r221", "r266", "r280", "r392", "r416", "r433", "r434", "r435", "r436", "r437", "r438", "r439", "r440", "r441", "r442", "r443", "r444", "r445", "r446", "r447", "r449", "r450", "r451", "r452", "r453", "r454", "r455", "r456", "r457", "r458", "r459", "r460", "r461", "r462", "r463", "r478", "r611", "r612", "r614", "r615", "r616", "r617", "r618", "r619", "r620", "r622", "r751", "r752", "r753", "r754", "r755", "r756", "r757", "r779", "r780", "r781", "r782", "r831", "r834", "r835", "r836", "r837", "r838" ] }, "ecd_TrdArrAdoptionDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrAdoptionDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Adoption Date", "terseLabel": "Adoption Date" } } }, "auth_ref": [ "r728" ] }, "ecd_TrdArrDuration": { "xbrltype": "durationItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrDuration", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Duration", "terseLabel": "Arrangement Duration" } } }, "auth_ref": [ "r729" ] }, "ecd_TrdArrExpirationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrExpirationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Expiration Date", "terseLabel": "Expiration Date" } } }, "auth_ref": [ "r729" ] }, "ecd_TrdArrIndName": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndName", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Name", "terseLabel": "Name" } } }, "auth_ref": [ "r727" ] }, "ecd_TrdArrIndTitle": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrIndTitle", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Individual Title", "terseLabel": "Title" } } }, "auth_ref": [ "r727" ] }, "ecd_TrdArrSecuritiesAggAvailAmt": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrSecuritiesAggAvailAmt", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement, Securities Aggregate Available Amount", "terseLabel": "Aggregate Available" } } }, "auth_ref": [ "r730" ] }, "ecd_TrdArrTerminationDate": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "TrdArrTerminationDate", "presentation": [ "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" ], "lang": { "en-us": { "role": { "label": "Trading Arrangement Termination Date", "terseLabel": "Termination Date" } } }, "auth_ref": [ "r728" ] }, "ecd_UndrlygSecurityMktPriceChngPct": { "xbrltype": "pureItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "UndrlygSecurityMktPriceChngPct", "presentation": [ "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" ], "lang": { "en-us": { "role": { "label": "Underlying Security Market Price Change, Percent", "terseLabel": "Underlying Security Market Price Change" } } }, "auth_ref": [ "r724" ] }, "us-gaap_UseOfEstimates": { "xbrltype": "textBlockItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "UseOfEstimates", "presentation": [ "http://annovisbio.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" ], "lang": { "en-us": { "role": { "label": "Use of Estimates, Policy [Policy Text Block]", "terseLabel": "Use of Estimates", "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles." } } }, "auth_ref": [ "r20", "r21", "r22", "r83", "r84", "r85", "r86" ] }, "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": { "xbrltype": "monetaryItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/DisclosureIncomeTaxesAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount", "terseLabel": "Net change in valuation allowance", "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset." } } }, "auth_ref": [ "r357" ] }, "anvs_ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "ValueOfStockIssuedDuringPeriodNetOfIssuanceCostsAndWarrantLiability", "crdr": "credit", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfChangesInStockholdersEquityDeficit" ], "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period, net of issuance costs and warrant liability.", "label": "Value of Stock Issued During Period, Net of Issuance Costs and Warrant Liability", "terseLabel": "Issuance of common stock, net of issuance costs and warrant liability" } } }, "auth_ref": [] }, "us-gaap_VestingAxis": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingAxis", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Axis]", "documentation": "Information by vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817" ] }, "us-gaap_VestingDomain": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "VestingDomain", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Vesting [Domain]", "documentation": "Vesting schedule of award under share-based payment arrangement." } } }, "auth_ref": [ "r792", "r793", "r794", "r795", "r796", "r797", "r798", "r799", "r800", "r801", "r802", "r803", "r804", "r805", "r806", "r807", "r808", "r809", "r810", "r811", "r812", "r813", "r814", "r815", "r816", "r817" ] }, "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]", "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year" } } }, "auth_ref": [ "r693" ] }, "anvs_WarrantLiabilityNoncurrent": { "xbrltype": "monetaryItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "WarrantLiabilityNoncurrent", "crdr": "credit", "calculation": { "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails": { "parentTag": "us-gaap_LiabilitiesFairValueDisclosure", "weight": 1.0, "order": 1.0 }, "http://annovisbio.com/role/StatementBalanceSheets": { "parentTag": "us-gaap_Liabilities", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsHierarchyDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails", "http://annovisbio.com/role/StatementBalanceSheets" ], "lang": { "en-us": { "role": { "documentation": "Fair value of warrant liabilities which are expected to be settled after one year or the normal operating cycle, if longer.", "label": "Warrant Liability, Noncurrent", "periodEndLabel": "Warrant liability, ending balance", "periodStartLabel": "Warrant liability, beginning balance", "terseLabel": "Warrant liability" } } }, "auth_ref": [] }, "us-gaap_WarrantMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantMember", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsTables", "http://annovisbio.com/role/DisclosureNetLossPerSharePotentialSharesExcludedFromCalculationDetails" ], "lang": { "en-us": { "role": { "label": "Warrant [Member]", "terseLabel": "Warrants", "verboseLabel": "Canaccord Warrants", "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount." } } }, "auth_ref": [ "r625", "r626", "r629", "r630", "r631", "r632" ] }, "anvs_WarrantTerm": { "xbrltype": "durationItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "WarrantTerm", "presentation": [ "http://annovisbio.com/role/DisclosureSubsequentEventsDetails" ], "lang": { "en-us": { "role": { "documentation": "Period of time in which warrants may be exercised, in PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.", "label": "Warrant, Term", "terseLabel": "Term of warrants" } } }, "auth_ref": [] }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "xbrltype": "decimalItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingMeasurementInput", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Measurement Input", "terseLabel": "Warrants, measurement input", "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r834", "r835", "r836" ] }, "us-gaap_WarrantsAndRightsOutstandingTerm": { "xbrltype": "durationItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingTerm", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityNovember2023EquityOfferingAndWarrantIssuanceDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Term", "terseLabel": "Warrant term", "verboseLabel": "Term of warrants (in years)", "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days." } } }, "auth_ref": [ "r834", "r835", "r836" ] }, "us-gaap_WarrantsAndRightsOutstandingValuationTechniqueExtensibleList": { "xbrltype": "enumerationSetItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WarrantsAndRightsOutstandingValuationTechniqueExtensibleList", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" ], "lang": { "en-us": { "role": { "label": "Warrants and Rights Outstanding, Valuation Technique [Extensible Enumeration]", "documentation": "Indicates valuation technique for measuring outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur." } } }, "auth_ref": [ "r834" ] }, "anvs_WarrantsClassifiedAsEquityMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "WarrantsClassifiedAsEquityMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityIpoWarrantsDetails", "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to warrants classified as equity.", "label": "Warrants Classified as Equity [Member]", "terseLabel": "IPO warrants" } } }, "auth_ref": [] }, "anvs_WarrantsClassifiedAsLiabilitiesMember": { "xbrltype": "domainItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "WarrantsClassifiedAsLiabilitiesMember", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails", "http://annovisbio.com/role/DisclosureStockholdersDeficitEquityRollforwardOfWarrantLiabilityDetails", "http://annovisbio.com/role/DisclosureStockholdersEquityWarrantSummaryDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents information pertaining to warrants classified as liabilities.", "label": "Warrants Classified as Liabilities [Member]", "terseLabel": "Canaccord warrants" } } }, "auth_ref": [] }, "anvs_WarrantsThresholdPeriodOfNoticeForRedemption": { "xbrltype": "durationItemType", "nsuri": "http://annovisbio.com/20241231", "localname": "WarrantsThresholdPeriodOfNoticeForRedemption", "presentation": [ "http://annovisbio.com/role/DisclosureFairValueMeasurementsCanaccordWarrantsDetails" ], "lang": { "en-us": { "role": { "documentation": "Represents the threshold period of notice of warrants for redemption.", "label": "Warrants, Threshold Period of Notice for Redemption", "terseLabel": "Threshold period of notice for redemption" } } }, "auth_ref": [] }, "srt_WeightedAverageMember": { "xbrltype": "domainItemType", "nsuri": "http://fasb.org/srt/2024", "localname": "WeightedAverageMember", "presentation": [ "http://annovisbio.com/role/DisclosureStockBasedCompensationAdditionalDisclosuresDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]", "terseLabel": "Weighted average" } } }, "auth_ref": [ "r402", "r448", "r575", "r576", "r614", "r844", "r846", "r849" ] }, "us-gaap_WeightedAverageNumberDilutedSharesOutstandingAdjustment": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberDilutedSharesOutstandingAdjustment", "calculation": { "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 2.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted, Adjustment", "terseLabel": "Plus: Incremental shares underlying \"in the money\" liability-classified warrants outstanding", "documentation": "The sum of dilutive potential common shares or units used in the calculation of the diluted per-share or per-unit computation." } } }, "auth_ref": [ "r771" ] }, "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfDilutedSharesOutstanding", "calculation": { "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails": { "parentTag": null, "weight": null, "order": null, "root": true } }, "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Diluted", "terseLabel": "Diluted", "totalLabel": "Denominator for diluted net loss per share", "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period." } } }, "auth_ref": [ "r131", "r141" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "xbrltype": "sharesItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "calculation": { "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails": { "parentTag": "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding", "weight": 1.0, "order": 1.0 } }, "presentation": [ "http://annovisbio.com/role/DisclosureNetLossPerShareBasicAndDilutedNetLossPerShareDetails", "http://annovisbio.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding, Basic", "terseLabel": "Basic", "verboseLabel": "Weighted-average common shares outstanding, basic", "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period." } } }, "auth_ref": [ "r130", "r141" ] }, "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": { "xbrltype": "stringItemType", "nsuri": "http://fasb.org/us-gaap/2024", "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract", "presentation": [ "http://annovisbio.com/role/StatementStatementsOfOperations" ], "lang": { "en-us": { "role": { "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]", "terseLabel": "Weighted-average number of common shares used in computing net loss per share" } } }, "auth_ref": [] }, "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/ecd/2024", "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember", "presentation": [ "http://xbrl.sec.gov/ecd/role/PvpDisclosure" ], "lang": { "en-us": { "role": { "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]", "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested" } } }, "auth_ref": [ "r691" ] } } } }, "std_ref": { "r0": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "SubTopic": "15", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481116/815-15-25-1" }, "r1": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "13", "SubTopic": "10", "Topic": "480", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481766/480-10-25-13" }, "r2": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "5B", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480588/815-10-25-5B" }, "r3": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480526/815-10-35-1" }, "r4": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1", "SubTopic": "15", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481051/815-15-35-1" }, "r5": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "SubTopic": "230", "Topic": "830", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1" }, "r6": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "14", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-14" }, "r7": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r8": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "230", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r9": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "505", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r10": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "SubTopic": "10", "Topic": "815", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-2" }, "r11": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r12": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r13": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Subparagraph": "(a)", "SubTopic": "10", "Topic": "718", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2A" }, "r14": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(22))", "SubTopic": "10", "Topic": "210", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r15": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4" }, "r16": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "230", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1" }, "r17": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r18": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r19": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "260", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r20": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4" }, "r21": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-8" }, "r22": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "275", "SubTopic": "10", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9" }, "r23": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r24": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r25": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "280", "SubTopic": "10", "Section": "50", "Paragraph": "30", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r26": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481142/505-10-45-2" }, "r27": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-10" }, "r28": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r29": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-4" }, "r30": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-5" }, "r31": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "505", "SubTopic": "10", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8" }, "r32": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-1" }, "r33": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r34": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "718", "SubTopic": "10", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r35": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1" }, "r36": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "1A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-1A" }, "r37": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4" }, "r38": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "815", "SubTopic": "10", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7" }, "r39": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11" }, "r40": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Name": "Accounting Standards Codification", "Topic": "825", "SubTopic": "10", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-12" }, "r41": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "205", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/205/tableOfContent" }, "r42": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r43": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r44": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r45": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r46": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r47": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(24))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r48": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r49": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(26))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r50": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r51": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r52": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r53": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r54": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(30))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r55": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(31))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r56": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(32))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r57": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(20))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r58": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r59": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r60": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r61": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25" }, "r62": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28" }, "r63": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "235", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/235/tableOfContent" }, "r64": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 4.E)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2" }, "r65": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "440", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/440/tableOfContent" }, "r66": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "480", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1" }, "r67": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/505/tableOfContent" }, "r68": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6" }, "r69": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7" }, "r70": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r71": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r72": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(e)(1)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r73": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "718", "SubTopic": "10", "Subparagraph": "(f)(2)", "Name": "Accounting Standards Codification", "Paragraph": "2", "Section": "50", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r74": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "810", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/810/tableOfContent" }, "r75": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(11))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r76": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r77": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-03(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1" }, "r78": { "role": "http://fasb.org/us-gaap/role/ref/legacyRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r79": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r80": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r81": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r82": { "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r83": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r84": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1" }, "r85": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-11" }, "r86": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "SubTopic": "10", "Topic": "275", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12" }, "r87": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "105", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6" }, "r88": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1" }, "r89": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "205", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7" }, "r90": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5" }, "r91": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r92": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r93": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(27)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r94": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(28))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r95": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(29))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r96": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "210", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3" }, "r97": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A" }, "r98": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B" }, "r99": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1" }, "r100": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4" }, "r101": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5" }, "r102": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r103": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r104": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "5", "Subparagraph": "(SAB Topic 6.B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-5" }, "r105": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-2" }, "r106": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24" }, "r107": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A" }, "r108": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "230", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8" }, "r109": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1" }, "r110": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(e)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r111": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r112": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r113": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r114": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(n))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r115": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r116": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r117": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r118": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r119": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1" }, "r120": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r121": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11" }, "r122": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3" }, "r123": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4" }, "r124": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r125": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r126": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7" }, "r127": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8" }, "r128": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9" }, "r129": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/260/tableOfContent" }, "r130": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10" }, "r131": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16" }, "r132": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2" }, "r133": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r134": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r135": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r136": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "40", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-40" }, "r137": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r138": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r139": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "60B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B" }, "r140": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7" }, "r141": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r142": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r143": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r144": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2" }, "r145": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3" }, "r146": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15" }, "r147": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r148": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1" }, "r149": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482987/272-10-50-1" }, "r150": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/280/tableOfContent" }, "r151": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15" }, "r152": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r153": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21" }, "r154": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r155": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r156": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r157": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r158": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r159": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r160": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r161": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r162": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r163": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Subparagraph": "(j)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r164": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r165": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25" }, "r166": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26" }, "r167": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A" }, "r168": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B" }, "r169": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "26C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C" }, "r170": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r171": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r172": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r173": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r174": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r175": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r176": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "29", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-29" }, "r177": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r178": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r179": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r180": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r181": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r182": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r183": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r184": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r185": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "34", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34" }, "r186": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "36", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-36" }, "r187": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "40", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40" }, "r188": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r189": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "41", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41" }, "r190": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "42", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42" }, "r191": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r192": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r193": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r194": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r195": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r196": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r197": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r198": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2" }, "r199": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r200": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r201": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r202": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r203": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3" }, "r204": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r205": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r206": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(aaa)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r207": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r208": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r209": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r210": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r211": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r212": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r213": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5" }, "r214": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r215": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r216": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A" }, "r217": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r218": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r219": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r220": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r221": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B" }, "r222": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r223": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "4", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4" }, "r224": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "5", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5" }, "r225": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11" }, "r226": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13" }, "r227": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14" }, "r228": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16" }, "r229": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5" }, "r230": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4" }, "r231": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7" }, "r232": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9" }, "r233": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r234": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r235": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r236": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r237": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r238": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r239": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r240": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r241": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1" }, "r242": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3" }, "r243": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "350", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1" }, "r244": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r245": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "360", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3" }, "r246": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "405", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1" }, "r247": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r248": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1" }, "r249": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "420", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 5.P.4.d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2" }, "r250": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r251": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "440", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4" }, "r252": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4" }, "r253": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9" }, "r254": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r255": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "450", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1" }, "r256": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r257": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r258": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r259": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r260": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r261": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r262": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r263": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r264": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1B", "Subparagraph": "(SX 210.13-02(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B" }, "r265": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1D", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D" }, "r266": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1I", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I" }, "r267": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r268": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r269": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r270": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r271": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r272": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r273": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r274": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r275": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r276": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-14" }, "r277": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "16", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-16" }, "r278": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r279": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r280": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r281": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18" }, "r282": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2" }, "r283": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3" }, "r284": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.3-04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1" }, "r285": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4" }, "r286": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "606", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5" }, "r287": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r288": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r289": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r290": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(A)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r291": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(B)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r292": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(02)(C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r293": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r294": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5" }, "r295": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/718/tableOfContent" }, "r296": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "1D", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D" }, "r297": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3" }, "r298": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r299": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r300": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r301": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r302": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r303": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r304": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r305": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r306": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r307": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r308": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r309": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r310": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r311": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r312": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r313": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r314": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r315": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r316": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r317": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r318": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r319": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r320": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r321": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r322": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r323": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r324": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r325": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r326": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r327": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r328": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r329": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r330": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r331": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(l)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r332": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.C.Q3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r333": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.1.Q5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r334": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.2.Q6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r335": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 14.D.3.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1" }, "r336": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "720", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1" }, "r337": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "730", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1" }, "r338": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/740/tableOfContent" }, "r339": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25" }, "r340": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "28", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28" }, "r341": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r342": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10B" }, "r343": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r344": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r345": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r346": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r347": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r348": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r349": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r350": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r351": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B" }, "r352": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C" }, "r353": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "14", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14" }, "r354": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r355": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "17", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17" }, "r356": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19" }, "r357": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r358": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r359": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r360": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "20", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20" }, "r361": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "21", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21" }, "r362": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "23", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23" }, "r363": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r364": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9" }, "r365": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r366": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(d)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8" }, "r367": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.1.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r368": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.5.Q1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r369": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SAB Topic 11.C)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2" }, "r370": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "270", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1" }, "r371": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2" }, "r372": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r373": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r374": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r375": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r376": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "740", "SubTopic": "323", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2" }, "r377": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r378": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "805", "SubTopic": "60", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1" }, "r379": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "19", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19" }, "r380": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r381": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "25", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25" }, "r382": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r383": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1A", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A" }, "r384": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r385": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3" }, "r386": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r387": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r388": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r389": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r390": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(h)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r391": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "6", "Subparagraph": "(i)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6" }, "r392": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5" }, "r393": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-6" }, "r394": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r395": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r396": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r397": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r398": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r399": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r400": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r401": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r402": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r403": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r404": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r405": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r406": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(g)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r407": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r408": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r409": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r410": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3" }, "r411": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r412": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r413": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r414": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r415": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(h)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r416": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B" }, "r417": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-2" }, "r418": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10" }, "r419": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r420": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17" }, "r421": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r422": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r423": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r424": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "20", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20" }, "r425": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1" }, "r426": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "830", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-2" }, "r427": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "8", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8" }, "r428": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "12A", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A" }, "r429": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "848", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(a)(3)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2" }, "r430": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/855/tableOfContent" }, "r431": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r432": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "855", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483399/855-10-50-2" }, "r433": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r434": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r435": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r436": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r437": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r438": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(bb)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r439": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r440": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r441": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r442": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r443": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r444": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r445": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r446": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1" }, "r447": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r448": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7" }, "r449": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r450": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r451": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r452": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(4)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3" }, "r453": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r454": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r455": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r456": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r457": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r458": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r459": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(a)(7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r460": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r461": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r462": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r463": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "860", "SubTopic": "50", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4" }, "r464": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "910", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6" }, "r465": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "924", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 11.L)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1" }, "r466": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "940", "SubTopic": "820", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1" }, "r467": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-04(27))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1" }, "r468": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "942", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.9-05(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1" }, "r469": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(12))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r470": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r471": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(21))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r472": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(22))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r473": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r474": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-03(a)(25))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1" }, "r475": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(16))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r476": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r477": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r478": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r479": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.7-04(23))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1" }, "r480": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column A))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r481": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column B))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r482": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column C))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r483": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column D))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r484": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column E))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r485": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column F))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r486": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column G))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r487": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column H))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r488": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column I))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r489": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column J))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r490": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-16(Column K))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1" }, "r491": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r492": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r493": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r494": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9" }, "r495": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r496": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r497": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(f)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r498": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(g)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r499": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "2", "Subparagraph": "(h)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2" }, "r500": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 5.W.Q2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1" }, "r501": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-1" }, "r502": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480424/946-10-50-2" }, "r503": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r504": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(h)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r505": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r506": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r507": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r508": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-03(i)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3" }, "r509": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11" }, "r510": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13" }, "r511": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-3" }, "r512": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r513": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4" }, "r514": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r515": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r516": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r517": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r518": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r519": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r520": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r521": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r522": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(14))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r523": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(15))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r524": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(16)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r525": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r526": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(19))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r527": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r528": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r529": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r530": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r531": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(3)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r532": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r533": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r534": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r535": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(6)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r536": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(8))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r537": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r538": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(c))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r539": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r540": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(9)(e))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r541": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r542": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.6-05(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2" }, "r543": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r544": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "7", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7" }, "r545": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r546": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r547": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r548": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r549": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r550": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r551": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r552": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r553": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r554": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r555": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r556": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r557": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r558": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r559": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r560": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(9))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r561": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(1)(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r562": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r563": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(6))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r564": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r565": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r566": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "235", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477968/946-235-50-2" }, "r567": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r568": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r569": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r570": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r571": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r572": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2" }, "r573": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "946", "SubTopic": "505", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-6" }, "r574": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "954", "SubTopic": "440", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1" }, "r575": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "976", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1" }, "r576": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "978", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1" }, "r577": { "role": "http://www.xbrl.org/2003/role/disclosureRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2" }, "r578": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r579": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(g)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1" }, "r580": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "52", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52" }, "r581": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r582": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "31", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31" }, "r583": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r584": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r585": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(bb)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r586": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r587": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "47", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47" }, "r588": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "48", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48" }, "r589": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "49", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49" }, "r590": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r591": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r592": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r593": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "54", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54" }, "r594": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12A", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A" }, "r595": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "326", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8" }, "r596": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "05", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482955/340-10-05-5" }, "r597": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "350", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24" }, "r598": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B" }, "r599": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "69C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C" }, "r600": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "505", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "13", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13" }, "r601": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r602": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(d)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1" }, "r603": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "17", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17" }, "r604": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "715", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "8", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8" }, "r605": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r606": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r607": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r608": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "231", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231" }, "r609": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4J", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4J" }, "r610": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "810", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4K", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481175/810-10-55-4K" }, "r611": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "100", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100" }, "r612": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "101", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101" }, "r613": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "102", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102" }, "r614": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "103", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103" }, "r615": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r616": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r617": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r618": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r619": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r620": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "107", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107" }, "r621": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10" }, "r622": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "860", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "4", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4" }, "r623": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "29F", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F" }, "r624": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "9C", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C" }, "r625": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1" }, "r626": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6" }, "r627": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1" }, "r628": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1" }, "r629": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1" }, "r630": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2" }, "r631": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3" }, "r632": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "320", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "6", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6" }, "r633": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10" }, "r634": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "11", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11" }, "r635": { "role": "http://www.xbrl.org/2003/role/exampleRef", "Topic": "946", "SubTopic": "830", "Name": "Accounting Standards Codification", "Section": "55", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12" }, "r636": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r637": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r638": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r639": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r640": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r641": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r642": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16", "Subsection": "J", "Paragraph": "a" }, "r643": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K" }, "r644": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1" }, "r645": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r646": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r647": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r648": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "b", "Paragraph": "2" }, "r649": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "1" }, "r650": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2" }, "r651": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r652": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r653": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "16K", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r654": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1" }, "r655": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i" }, "r656": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r657": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r658": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r659": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r660": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r661": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "ii" }, "r662": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "1", "Subparagraph": "iii" }, "r663": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Section": "6", "Subsection": "F", "Paragraph": "2" }, "r664": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r665": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a" }, "r666": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1" }, "r667": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r668": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r669": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r670": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r671": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r672": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "2" }, "r673": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "a", "Subparagraph": "3" }, "r674": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Section": "19", "Paragraph": "b" }, "r675": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a" }, "r676": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1" }, "r677": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "i" }, "r678": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "ii" }, "r679": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iii" }, "r680": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "iv" }, "r681": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "1", "Sentence": "v" }, "r682": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "2" }, "r683": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "a", "Subparagraph": "3" }, "r684": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form N-CSR", "Section": "18", "Paragraph": "b" }, "r685": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r686": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v" }, "r687": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "1" }, "r688": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "ii" }, "r689": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii" }, "r690": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "ii" }, "r691": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "i" }, "r692": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "ii" }, "r693": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iii" }, "r694": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "iv" }, "r695": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "v" }, "r696": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1", "Subclause": "vi" }, "r697": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iv" }, "r698": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "vi" }, "r699": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "3" }, "r700": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "4" }, "r701": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "i" }, "r702": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "ii" }, "r703": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iii" }, "r704": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "5", "Subparagraph": "iv" }, "r705": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6" }, "r706": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "v", "Paragraph": "6", "Subparagraph": "i" }, "r707": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w" }, "r708": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1" }, "r709": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i" }, "r710": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "A" }, "r711": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "B" }, "r712": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "C" }, "r713": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "D" }, "r714": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "i", "Sentence": "E" }, "r715": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "ii" }, "r716": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "1", "Subparagraph": "iii" }, "r717": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "w", "Paragraph": "2" }, "r718": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "1" }, "r719": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2" }, "r720": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "A" }, "r721": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "C" }, "r722": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "D" }, "r723": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "E" }, "r724": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "402", "Subsection": "x", "Paragraph": "2", "Subparagraph": "ii", "Sentence": "F" }, "r725": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a" }, "r726": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "1" }, "r727": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "A" }, "r728": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "B" }, "r729": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "C" }, "r730": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "a", "Paragraph": "2", "Subparagraph": "D" }, "r731": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Number": "229", "Section": "408", "Subsection": "b", "Paragraph": "1" }, "r732": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106" }, "r733": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1" }, "r734": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "i" }, "r735": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "ii" }, "r736": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "1", "Subparagraph": "iii" }, "r737": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "b", "Paragraph": "2" }, "r738": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "1" }, "r739": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2" }, "r740": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "i" }, "r741": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "ii" }, "r742": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "106", "Subsection": "c", "Paragraph": "2", "Subparagraph": "iii" }, "r743": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Number": "229", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "C", "Clause": "1" }, "r744": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "A", "Number": "229" }, "r745": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Number": "229" }, "r746": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-K", "Section": "402", "Subsection": "v", "Paragraph": "2", "Subparagraph": "iii", "Sentence": "B", "Clause": "1", "Subclause": "i", "Number": "229" }, "r747": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r748": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r749": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" }, "r750": { "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef", "Topic": "272", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-3" }, "r751": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "a", "Publisher": "SEC" }, "r752": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(1)", "Publisher": "SEC" }, "r753": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(2)", "Publisher": "SEC" }, "r754": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "b", "Subparagraph": "(3)", "Publisher": "SEC" }, "r755": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(i)", "Publisher": "SEC" }, "r756": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(ii)", "Publisher": "SEC" }, "r757": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Name": "Regulation S-K (SK)", "Number": "229", "Section": "1402", "Paragraph": "c", "Subparagraph": "(2)(iii)", "Publisher": "SEC" }, "r758": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(17))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r759": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "210", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.5-02(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1" }, "r760": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6" }, "r761": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(4))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r762": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "220", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "2", "Subparagraph": "(SX 210.5-03(7)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2" }, "r763": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(d))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r764": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r765": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r766": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "235", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.4-08(h)(2))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1" }, "r767": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "23", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23" }, "r768": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "24", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24" }, "r769": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5" }, "r770": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "250", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6" }, "r771": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "260", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1" }, "r772": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "270", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1" }, "r773": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "18", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18" }, "r774": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "22", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22" }, "r775": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "30", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30" }, "r776": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(ee)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r777": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "280", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "32", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32" }, "r778": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "310", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "13", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13" }, "r779": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "320", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "9", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9" }, "r780": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r781": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r782": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "321", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3" }, "r783": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "323", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3" }, "r784": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "340", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483032/340-10-45-1" }, "r785": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "350", "SubTopic": "40", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/350-40/tableOfContent" }, "r786": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "405", "SubTopic": "30", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/405-30/tableOfContent" }, "r787": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "410", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10" }, "r788": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "450", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/450/tableOfContent" }, "r789": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r790": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1A", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A" }, "r791": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "470", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "1B", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B" }, "r792": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r793": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r794": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r795": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r796": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r797": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r798": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r799": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r800": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r801": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r802": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(1)(iv)(04)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r803": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r804": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r805": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r806": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(01)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r807": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(02)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r808": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)(2)(iii)(03)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r809": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r810": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(d)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r811": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r812": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(e)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r813": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r814": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(ii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r815": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iii)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r816": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(iv)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r817": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(f)(2)(v)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r818": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "718", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2" }, "r819": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "720", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1" }, "r820": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "730", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/730/tableOfContent" }, "r821": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "10", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10" }, "r822": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12" }, "r823": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "12A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A" }, "r824": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r825": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "15", "Subparagraph": "(e)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15" }, "r826": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2" }, "r827": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3" }, "r828": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6" }, "r829": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "740", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SAB Topic 6.I.7)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1" }, "r830": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "815", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "65", "Paragraph": "1", "Subparagraph": "(e)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1" }, "r831": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "35", "Paragraph": "54B", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B" }, "r832": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r833": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r834": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r835": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r836": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(bbb)(2)(i)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2" }, "r837": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2E", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E" }, "r838": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "820", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A" }, "r839": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "825", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "28", "Subparagraph": "(f)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28" }, "r840": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "842", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-4" }, "r841": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "850", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-2" }, "r842": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r843": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "852", "SubTopic": "10", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7" }, "r844": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r845": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r846": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(c)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3" }, "r847": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r848": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r849": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "860", "SubTopic": "20", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4" }, "r850": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "912", "SubTopic": "730", "Name": "Accounting Standards Codification", "Section": "25", "Paragraph": "1", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1" }, "r851": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "30", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B" }, "r852": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "310", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "3", "Subparagraph": "(a)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3" }, "r853": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r854": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B" }, "r855": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4C", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C" }, "r856": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4D", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D" }, "r857": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "4G", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G" }, "r858": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r859": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r860": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r861": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "5", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5" }, "r862": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r863": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r864": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r865": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r866": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(4)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r867": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(5)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r868": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(b)(6)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r869": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "6", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6" }, "r870": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r871": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(1)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r872": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(2)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r873": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(b)(3)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r874": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r875": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7A", "Subparagraph": "(d)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A" }, "r876": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r877": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r878": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "40", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "7B", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B" }, "r879": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(b)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r880": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "944", "SubTopic": "80", "Name": "Accounting Standards Codification", "Section": "50", "Paragraph": "2", "Subparagraph": "(c)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2" }, "r881": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "205", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "4", "Subparagraph": "(a)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4" }, "r882": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r883": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "210", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-04(18))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1" }, "r884": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "45", "Paragraph": "3", "Subparagraph": "(k)", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3" }, "r885": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "1", "Subparagraph": "(SX 210.6-07(2)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1" }, "r886": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(4)(b))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r887": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "946", "SubTopic": "220", "Name": "Accounting Standards Codification", "Section": "S99", "Paragraph": "3", "Subparagraph": "(SX 210.6-09(7))", "Publisher": "FASB", "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3" }, "r888": { "role": "http://www.xbrl.org/2009/role/commonPracticeRef", "Topic": "985", "SubTopic": "20", "Name": "Accounting Standards Codification", "Publisher": "FASB", "URI": "https://asc.fasb.org/985-20/tableOfContent" } } } ZIP 86 0001558370-25-003482-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001558370-25-003482-xbrl.zip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
$IQ+-Q& $R6"N&D'F;,F\?-:X/E_R5O8-R]2O(S+0Z-(SUVW:
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M-W>Z+7V.OG,C$[_%,IVVXGIHK\TVR$]-0
MSA]A#I$:'WW+U!8EKO&M7^3=KNR%98)*HO\8]S?6
MD.!4M\QZW:2!.MT%+?*N.G%@J@05G %6IZ>O_/"#L*:D@VKAT'JG\6E[=HB+Y6RHT/$5/E?4_5*20\
MJ6]W[C1J6YCX.FJO?VC8[.D:6M0[JK
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MTF2KW4)36<3;B[?.0+N%;EUVWE64*OXTTN )W2D@L#@L3;\3[,LE]:54/MX!7X=W)A#B@#.%QBK1WNW"GF)TE:^9I8NT\9T !
M%E"$S7?+D("*95)T:_J;Q"A+;+6['W?.<;%R;M^%]OBG8RH,R(.D0D TL_"T
MRF?$T?0X8"P++EDBVM^*0GT(QC0!!"F.2>Q+[SN,7@.4 !2!"D#XYZS'GD>>
MZ?ZRYILBKW:
MJG\;Y,T
M\6LP W+$YE)A>:XW<>5(\:6@:7:>%6'4F>+?9KP8<87YJ-J[?XX$#*II [-3
MTTVT^4MKI-4(\>XO>%/=.2%W*.W5Z/U5-#*HL%!,9PP@E-BYFH&FI'RF9Q02
M9+_!>3O3*&.[PPO:"]+LHN6>!NJ@WQ?HK;=,B%NF+5V_!P9>66Z\H=*]
MK)[
M1VRUB+LX3TC(:K#!"CW?"Q$]70+MDM56?COO>!]%6S%HQ5C*UL1*Q!A3H#N&L<$D !)QCL6&@(5WH
MIL/^6C+#8B.P8'_1BZ8Z?]GQ[XM!/6^*?_CSIM]+A5Z5/=ONQG_Y)T/KA)C'
MO'W_ (ISCDUN[Z<; 2$SPO R8%_@(?25*%J
M?VY0)O!I.A<@ )V],1J"\6IFGF,"+I9;R6CT1/8'W;HXI,;G&C2D#:-FY8]F
MNK.U?H_JU"OA;VG
MU)O,SED;C>NVT48C3PWI_&V$0Z2' "@%RP-E-#"X$#X4&\#?0[XL?^?)O@K;
MAA#Q/L9P';,0,@4;7KU84I!S\_V #*O=W
M/K L;QS5RYFQPR?T5!8%F^TO93A^F8"=/ZR G16P\Q(!.[]Y]>*'(\U@=Z:T
M!'H=_WJH_A[K48'_A;6K>'8\5[UM,)P!_$.PHA_,7VG[GTBC:I:'8*C$R7-[$;@@(,G6MN_-TTTC>O5'T\=I*V[D W
M)7RGVI!CI2XS
M?<X^];XAWR"^EUP>;S (G3<841+TC[=J%GAJ1
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MN;^O[*:,?8M X828@8+ NZI71&;D[R_$\K@=]_!)(PN2Y'-1*,6O7RG4:XJGAR(OI"-X'LQO^.C]K$U [';R[6RIQ-#><8< V_3]U
M-T++-^EK)Z$0,0[3%PHM$YQSISL[T@/M!$:V$Z/;@P=KV%)"@M8"Z@8XEC^U
M;FGO^+/1NV>?B=*7$'Y5.WRZH(\*.(?M8IY2!Z+:\$)5ZSG+GS^2
M8H! DKI(,2B$S20E#',1,"IW5..@1&1 (+RR;N?)[S9:S.,5J]+FR^D(&+'"J5K#1%WR,FC)6M&$LLZ
M0TL[S1$*WRB]X/ZMLNI,,3/RBLN<&_
MT)OL[7^3@=#-TN(3CE?2J/MD($>7_X'H,&>QS3YW(:WZ; A^W1/LADI)$>Z;
M/GSF49\M#^HPQ9."H$70#H3< 0<,D;CY"-#<,[&H8CT/9)ED,'N.3?UA.CS"
MB0']4I(^Z$:5E3_S[_Y_3AI!($YFJ<
M!1T(>U6EZJ$3^M)N?YEMT?]:VZ)K6W1MBS[B4.R)P]G3PG,6C?XCFK<@_T@Q:@C)&^X!C>1YZ:CLJ0/D@ATM&1>H
M]?PL53I1QS\DB8>?O6)>Z-@6Z0<>0,2'.>-D;Y\,7$DZ-&FYQK%G%@L)B8'4
M$Q9".(I7B9*;'TU+!BCGD8-O[##:/"]?*'*$P)Y483FK$''"&L&Z:CN'C+?J
M^@$:&CQF)Z+<1[PZ4JCM_^UW'__AHR^F*J!,S#ROUO'HC7]G_N[PHQ1!\23G
MKJ1I8O2H;7@D"8SJ52/9CO=2
MW$A%YL-\?I0? @T]&Q1]L:)6'FT"42=%O:A52GI.0.D+8T\F"K;N?5*%
M0-2-ND/XF2)\V_6YKS J.B[H7=F=0^DCZ $='=E+U1^1R'.3[+!A!Q :(YO^
M[+31RUKRAX3):23*20QP#A41AD)P=($3.YR6VDVZ9)M_9P2%^G "
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M6F<9J&6JL,D)$6NZT]'NR^2W3WV_#1$UBWZYONN;":W1+WOG89G.(UF0KF!=D"XCZ0@'DY:6P6.#+ X947&!LZ!#UON!L&+.8@"@AI]^KR+
MWG@JK&T05YCEC^J47$U/88>+]O00!@8&L##2DFHW
M&ARK.?K6R;K5HJ)%B:9Q$++D4W.I']BYX,56,UK-*)H1SJ9$PVV@[!Q==9GW
M.+4G3?1C1!Z_AS.75 F)^V,C120N(5(<\]6;5U&LUMQGK
M18K69^A?,J9T$%G@36G8_>ZT>;%:TFI)UG%%*"=F@,L^A^E<$\+5K)YB5E2;
M\K>@<13Z!PCEL
MKVK''[J4U7:$W0D&YH+MO$R\X>ZQE:H^.?:XR$RW(<-4>KD[MCOJP#!^9CL\FZ;4TELMM
MK^ 6B\)ZFOW^V^\^_^-GJQ&O1AR-F(1_:/14$G+0/(ESY!+A2H6[&LY,4 [S
MY5$]6-'.&5C_T-XX=,W8LS&:.]*I(((WA],XQ(10PQ0SQ/PB1WL5Q0?!7S;&M#*0FZI=4)9#GD7APQXXQ
M0O?(C 4(/41SPVQK.C!"PP_^)NCY\D#OA0F2.!H(\145#)RZ*CNN;P&_46DE
M<%Q0M,ZC=0%2_;X ]W-$F9':!!957"J7[\I3D*:<\M
M;"F3@R0O=NA*_ZCC#M!YW0&S-2'2!;LD"5UF$::$% V24-*RB3#=)/TW4W T
MR1@,JV6RRJQ>Z&J&2MJW^'Z+*46<(899DN=7'F;P>\3,QA1O[M_XZ!]L.U8U
M"_[)^M@E2523>$H(S,T1K->TWJ>J>%)B5!O,8"A;M=,A)A4\PSK\H]];IE]]5&RYN+L3W*V],&9#::
M.*J(P94RG7:'NB;?@2H/FI&"0EEUMN$[.><(TK_LG;_TE0*63S
MJ1]A,]>OM9WHJ5I1!9JLHN06*,[P_&+HM_EO+_%9VEU"T:>-"FB:#E-<>QX>
M[OK131XIH4]/3P]&W$S?V(+K8^JXI=?T192,'4 W) *O\SG[##]6=.F6WW:R
M4M-G05V4[D\NXFVZ;PO^C4@H W\9I5/82/V#8/_]M4TX@.3NXGQ*NI$/@<8Z
M=]840I@G$0ES1M-X43+T,IZ48%C" )1B=Q.?$=SRI77$U_0RNJ*_SAG^!.>2
M.[&C]Z5Y;_,*F,S^IAU '59>V(OA?'N _SD<\EO'/[%G>73B@\*^"06"[(7H
M(WK4R"PN]LFN/87@4>+8Q!;(N%C_6KB]E2I69BGY$ .)G8\+,9Q) >!>P
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M=+UYTW+12&YB=O'FKJV):<8"9&*PZD&
M\U]SJ*EWKBQ[1#E#_U&7]_UFPN,6Z7/!*[L[IW\6[2
MHR^(]:QNF>2'OV"V@T3JG 4L$-;JEB%6#"(2E$_Z!R$FFK65O^X"U2V5ELWV
M+'T5379M\2[CB_L+_)"H:-(!2@JH_QB] ]Z+8:]VM]J=P))B,<4&#CXD=,0U
M,FG)H7#(I8C5A%838A-BTKD+ EQD6RY2:V$EP?91X]7_N$-7=>^.3&NZ7Z)#YJ"0*BV]
M8>D)9.) !53/6/'7"H">6UGMZKX5O#]RYQ[+SI[:N^)&%/*JFUU+!5,W6[
MMFF/0"-1#U&PZK'>?%_2=_PWN]9;[U&X-?4*8T.5/PP;HK\&&%]%6!^_,[;M
M>>=MP'_=FZQ/9FK5!/,N>^],\2^4Q&T9<;7AU88E A4X&>L[(H\1ZRQ$%(>I
MD8OX"93WNA)BIO[_-[WA5@S*=>N@Q6IDPZ I"..ZB D[ &(J.2
M(^*Y)' 0!Z&$\XB6IDHDD$*(T%>#W0IJN0>:6*"42N"TI[&[JT@D3T1GKG^X
MWGPE <#KMNO&T[#YKJ,K$23IU8XH^4EAHFW?:E^'U#UZEE_HN2]#6$@$%D-U
MM26ZH>YL_O[2ID<2@)8P@TO[.E6OPEB&89!/_M O!HJ("QP0>)-44>)
MYTD8R$5=@P@0>M?#$(_K]'\/T_P^*G/2\,@;H$AYAK_90-)X\QUC1M^7D0W,
MN*!)Z&1/T"OGVQYXV\R9WD^=_]_5J:Q%,;:Z*?DCK[__MNQ,Q&]X^
M3],VQLN(HF1P0C3,M"]I!_-NCEU3Q6WN9.:(T&P!L/$ (O$WPFN\\U><>[F_
MVKN]-)' BYY[[_8Y@+9G_T+-[]U;2$,PD-D?G+(":BUC4X[#K0^O?W+SP^&N
M:FEW_V^6ZGMNG_L9>?DX./I\1X] ,T
M(SP','0C8 94(Q1AWNQQR/,*M_;WOJ#JX4B.>^PP^*,6_\7&+W:I( 2?JSM_
M0:0EAZX<.6LNM]2YC2F$4\N"3X(0I@X&7K$CL]&VU>TL(
M2BJ#4,V5\-1ZAV(5=*-@5I4(0[7'LS_+8X2B2\:*3[?5MB(M^'MB]<"C@KB&
MU9LP685*BDQ3V27R7SZV[&$Y8J+M6?4]_F7G5Z4] EY.$%*1>F9
M],["SGJYP-C??[0"8U=@[(<+C%V.*8V;'**OXO,: RJ"K]2"+8=FP/]TY![]
M.4 3C$T4:K!N?BK:ZJ_;,70H2,\.%']1B$#-^Q)D>,,PW2CBZJU0[^
MN)4!T?0RR-7JVMU0-Z/J 5SR[C-<& -($J"D 2'G)YL4^-27,F; $0^K!#K&
M."$](NP4DIO3R N@>ND8 857V/@WW%HQ!B2JB"''):[\ ]DT_18
MU?B]&8DH) =0X=9M5.!$_X[$S'3>:8]1-=!S(7A3&T*(XM=B&"GOU'F4L=>I
M+/H O9ET!&CO#HYQU=@\P#K3,)E_!Q* D04")U5(!*J_F.0ZEJI .R_-G'"4.>F[<(X:MA#[D=_&R@[B+AV)V/6]$]^L;X!UP/-,_/_JGP0QR\-M:"#
MVY,*I T:0R34=ME_#A+#":BQ@,C17;4G_!"YQZ
M]7[HLDN7LQ*0\PNF]!6H(NV3*A(N3?Z6]EO%O_"H/%J'99<4)W7_3C=O3+9T
M?S[?J G0_Z.20O"DN/D\T5[X2%\SE%,2<7BOQ=W;>\",C,
M61 Y?'OR%N)MA4GSR._T'%O@KR!'"H;K8\?](]\0\ZH@6#BQ%/#V'(I5VF8I
M>>Q:X0VF0N3?ZVU5@[I%%PU4$N2QF8[-^EI;9;TW]"7[.)6L#1DF='"[P':S
M="5_OU)#[I GZ.BQ=U,!]1VKFE2BH)4(.W):W\6>3 IQNF^3Q5PJ/TXTF!^*
M"B_HLD^V"#TT16<$.U&&B\3K6[#+A$E$=.][;\X$5.>4B8]
M@L4&U$8Z/5#,ECEI&#(9FWB@OB,S+U0K+D2@_2CSU(;I[T]MF=:0DF3G'ME!/$^Z3V+3WV5SZ=\%G+
M$4Q0(>R@$B<1X?SH=RP^%/>@7>6M.[<-L]/(!D-!
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MS<9F=_MHQKFV,]54GT/XDV^0OB__>'HL2&X\Q*50P9 :F[$9V4J/"[-?<'OPX[4]N+8'
M/]SVX!/"A:\J[D50@(:0H.T6@H!(S&(X],B3&F06JE%"#"L".$S8&4[40[M#
M &>/-69O]/'?<#XQ<(0"0\(K\VE/M<76>\);1^>/W"D?:*"BNV^[M]>;5S5Q
MD]W:*-K9 F:I/K[N04F
MTM1!- +E8[]("VWQ@%[FTP[U-)QPR:T4H@L36S)\IL^._TMYPSQ\FAWY>.F3:LIK$S#T@H@V0NJ7O@X/GM@;0]VD]R1E;=XTY)
M4^HJ)RSD<>M0U,#5:UYTV_R4'AV7MCG^/1%M%<760MRH,+7>5)L6MBGRVYZS
MVPCNDBZ_,L=,$ZP#I?FN?_#GYUU_KD<"MB9,SH)VJ2A
MJ\J2)()'P/UR=\Y5R.W\O]L8]-D+#^]OQXZ;9J8UD/&U5Q,7G)*8EUU'J=L@.R_IL(Y<>>+J%^H4RB0)BAOO
MJGMO4CT7*1#+-T2M7 UB@!,Q@N=-RXOEI!Q,W SB]O_W2M? >PR+])V<4_Z$
MY#?D&AZ0C+L=[LC??AU\M7JQV:OZ%I@7TZCZ7BOW^LFDRQE+'C*2;"I"(9$7
MV(*V(LYNX'[>D?=:?Z(C1
M]L^MCXC^KQ*CG\,43.BN__G_?A>:Z[->"[NP.0*+;N//KS/-F6R?CSTN'6[3
MRNC-Z*.%FO:;\+3,>U[(I"E'#T^Y/3^RZHZ>V/?9?]>?FS_%<-LA.N1@DB<]
M3TY!2P?=3V26P-HO@/ 7-Z$6)66Q> OYPWCZ\J8W5J0Q'_!Q6BS9Z[#_-+H2
MAMP]55+W&#\E\2YAJ']R%Z-RJ0C*F"@QV'!_1H $R\X84+-=?
M+W.T@^X]OA.R!K\0I(N1;;S(['JV)R,L\ER,ELL;PLIYF7?Y[4PRE>R[D.YN
M]$^XDD8($F#36R(ICUGODQ#9Y,O\@M$94!TNFX^4/:>]P"P!^,F5P]*NO9^4
M!W/1CY1BG\DK?JO+H#"ZUL[23&$E>OSX))$#P@[_C'C!'UXMV*.CCJNFHU'
M0_JPV;,1MY%2O*?J%T9LT=19G]Z?\NE4--)B09%W\JU
M8?GG (S(G\[3"2D)A*S26D 548W>1U N=JTHN@_Y6S*;0V,+-?,Q,&9X!LM=
M9.2B7>&*=\7::C<\\%EA0ET(3GEV2EPRF=;=5N%
MYG](:2!-T];MS1G^.FRUGQ>5XC5L:P7#%F'''IU_@)#Q[5VYKQD'&:+8T)EN
M.YFMV06P2WH8P"XD1ZG86W6M7W6Z\!@D96Q?A13+K/SZ?
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M\9J ^$@W("N2>"B\C6.+(E9/,<
M^E.]92EJ#G4X_9<+=2(SRHEC&P^^.3O$?/&H#,Y7D?**P7LQW9T&- 'BOI]K.N::UHD,V(F
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M@Y!:NP64K_/:;.78@(#SF]]!C#W<8=*]-E5V-NL6MHJ?1_(YZM@;*X$20.":\:GI5O;Z"")9%TV=SO#6=]O(0F_X:8P\][F :-+P>(T
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M=4O^BJ/&'*6DQ0](Z:A,/!3FTMXP RF!-I@5];(%,;0 7X .]&D)#:C:_+4ZF"] ^OAQF0&?^/#_4-0F'I3'U5WNEF82
M+IQ01H?[/@\+:&N[R$<+M/T(YH96*C.BIYOWQ)9HSSL"&4&'@."?2<9!3SZ&
MI7[XY,-/M>O(F2HSOZ$W*CB%0$7JVL"&_3]U=PS^87Q('MGGX3RFT'7Q??U3
M&)PP!,1#U&S<&'^(R:$H%X,U'U^OH '':K !3I_\KVXXT)X< E+M7;IIH/1.L -V@'_;$W@0X'DE$AT=<
M$U5'/=IXU;'!J XN=E\CE1L^.Q",=J=&20D@)4.,."RELL9?6EHP?-$TF2(<
MQ-JK[=.W9NF.5<^Y-7RV  6B:><4/]C1"N3SS'D42D6LD@X.R9HBK7X9-KOS
MY.L%N,YU/?*.)D8$$?#,^1((^4YVA(9(G1S&*9EQ"H$]K53*RK X-]':X(\"!0Y;-
MX98=0=[2.'ZW_M@H7YH0T?/!ENB=2FHT54;=-8?K?DTI?4OET],]7OPUO"=]
MN3)]P/2CXMN[\I05B[JY[$<67[NX%T9&%KDMDX3V1>N*NA:2A<)]>"')=^B
MWJ_2$6 EBVJ!0$Q+A*IWB*HQZJ>M'@K8+?C3I%
M?&]@>P<0 NVH],[#!@=:.V+"@YH?LSQN7RGI%.A>D5=EV/$:65@M7V(X\4JZ
M^'6!+$])WW@44=:>!3#4K4/?6,<1BYFJ13Y"'^YL
M\0C;6[9KL88^K$[L*<("S]ULM[0Y9#:6K'O-)&DOO>Y(;&BV);7#]#R8Q ,)
M=38%*.UH^X@=+Z1Y3?G]^^TD^^/!M@XMZV2+XN$2OZ*83$T_(WA6-],=IF)2I_K @#E+M=$=,W.46ILY7DW O
MKVR)-_U&B5,B(8;7Y$5I6TZ"6Y]3=WVT=ZE:(=^-KK#!%8_K=;W/70&C/,R;
MG7#LTE$M)6H*OO//D,[KRG$0\,,AT9<^G38JZI.4*%@COV1UCIEV"]K_[E1$
M1-F$Q,@QLD*FO5;*<8D''O5DY4MGYF]#6*T^_YCMT6W6^IR,@2#Q$FT&F$?7N6,($;D(*#]AQ
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M.^Y9%D8J3J&$-QL4*.'# .UN/K#(,1AXJ^!.X3^P+GI:8.GR2G)!,T7[DI0.,X^/
M:3E!=7H>+YX[.298Q2E2HBMXBZ-S1A*3K6R;]96YW5;:B?3XHBE*7Q5)4$+3
M4CO3@&I*KZS"NUU[ !I&/@?/\OM[V;PO$H2H*WC0@@TR\'BRRUMJ+(W)?'9L
M9%*M!G# ZUJ0$55+O,TQ25-U<#XPU_A&B_X&@"U"(;E*X]AF2\70U.L297#
M^,I.,,S?F%TC_DBX[GC8-LL0W3&9B]IZ^RN$*C:N(0Y<'.K=?W[0_OISJJ)O
ME5$@QN,C.VC##_&YT/42)Q%\Z;I:-_K'AT^Q,BKE2X]D@'WE2D&X:@Z)8
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MS*_L3KZ_*7,R*]'B[J3EP!A\
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MZ3G)_^.QBPT >D001GK\PX<;I0Y PYZ^A])@
M'X?QB+R%WM(_YF7OO^S],87]E9C(5RAO?:& M!?]N&N(I"-)0G_Q8N*(WU&D
M9*P/=94-AE@*F^QRJ(7":<.PX\KPFH*:1$4+A%2T$UUL]F*S,V47#X);[3Y[>22(2"?MQXWV\B>:5+''E7II[_).C-A8
MC]*L(FG6+G;MS+Y*[-[D32WGKP!(EW:-+01: +;Z]HOK=KL>FLY88::1N,2F
MK%I ]%TUR+PB59?+SGI?9XC$#09[UA&-0!^X4QMY:6*DP=&[UTD0]"1QSF2]
MB#36,.'73
M7WA<+YM,W&3JX$'V5\&_YJU&.OX*>#573/VCNHZ4 5!P#.,*?&'8PQ%1E5)\
M0]*L;MV+YYFN*P=1,T0:D\<1)Y$BG8U#) ?*R3-%-]^S'>2)CPC!QHHSH+!'
M$6:M%0D3PC,_CMC65/LF0W%$@K&"!E/V60('A?<^V3X7WH3RB0GJUTLC*8=6
MV,6:&^4989N3S66V9IO0YFD7A&O/5MRP%EXI+U,,UVSK]!*.
M@F42'K%G9TPQ'5)T%J2'C\8LO-OGQ)"^Q4SMQ>WZDP..B/.0B;MJ-\G&GV#&
M^-QL=NX4D#=>3P^ZY9>G$=?HU*)YB5:DH#>J$J2DZN-C3JK
M=E@==\3[@46V2WK$B)JGD8HVZZ+AS2@R=@1U5"/C]]XJFT3UP_7A.JK$FXV"5"ML
M/72:QPPR)S0)H-W\) R+B4G37\9Z UF/)1@9C2W,L;H*D@8\(::]S20WU#DU
MH6QT?%VY/%"GQ7Y'@>>M>H)]SWR94@N/DC#HPT!S2,EFF3>R5P+)7L> +:6!
MPF+?*9M".[CF0J.93)LPF6!%QB=CP;/A>KSX,A'^8T:!"= <+E:7D A(*YF.
MY02)GC9F)'JK19!^<1<#Q%_82B?B(:-RPJ1SG9+PN#XPY8 "X].ST N.$5X([6,_!X:Z*["QW_Z[$X;#)T/,..
M"%(@(**P&29P&%>.PJ/G'GC2>Y1,V/QAEOA'CM U-7RZ);+"K3X+TEU56AO,
MVJ1<8E$R=O"@KOI!16XM![EA%2DSN;!?;8^C]5LR?5>[MR-F&I6Y_:'0S1R)
M_!Q6F?BWVK%77)CC_K7'#>?XD4N#=+W@%=$;X"6OTC7]+!4>PX*Y.0
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MCZ(2D3/S$C\AB<:],YW SZD9/A58M@GW'9-#%.7(%1@:3\DL_9I??OF
M_(MOO]/Z&S=6T6]XFPCC$5Z25MDPD#AKY'VVFL6XH.14B-G(=]*-#BY@)CPN
M&L2FO,U0L:TD\WE!B5*JVT^X <[()J^#W2U,Y9T)*H"!X_1'-V*?H7W']U@P
M(2#(4X0O([W;T"^/"8O**"V">H4*7FG8GYKK$$(SQXQYU=!VQ;$T@D-DUU3\
M.VIH'@XIB8E+,_E:!CXO5(5A;H\$N0N;T]\[/U-?_MU0+K3]30@7*"=P37]YSXDGR?),=X3(7L
MD'GTPDX;'/E^$(&69/C%&NADL!]=*.%525I=1BRPD22*HW7-H/3D$^+2)X_@
MS%Y.7]F!O_R[5'*4F A]ZB-ET$) ),9$9/G%
MKB&[61@SE'QX2CF5'8S:'#]>XXQ-!AM82/JFY-E,UA8&SY-L@LI*_Q)&F&IF
M"A2)Z?OHK.C?-'&J=F?)4^/5FM%"Y^&?DT-WVUMX2S&(1&4H,A:P:7ON1[)Z
MKC6 AY%@H&/D%<'=B97YEM%($^O\@(D!V':/>^D=^>B3CY]]^(1QJN$ V0H.
M@?_^\?]1%^_04SKBMA^VZULBHN%ZZ(*ZC)FY5,4YFE4#"S *@LA3*G-.A*R4
MIZ)-D#P<5]1,DGM2@%E&3OYT+U,"T 7#:]%X/(G[>1VZLH%($*:>+O4O4S[L
MESI7SSO@GN[<<=O1/);*JO.<;MH?P
M?#W7Q0YM\!\'U6:T30%_8#SUMD8B%=QD1:J*%^5\PST7SU*#IT3)F\DB/&DG9S
M4O53?.:1_POD#!D_3*P6/69<_V3#T#J)T!48$PY3UP$7
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M61$Q)=9N^?Q+91XA>_5SV7R2LI&Z73@<8-6T^&0QH.0TVU-C*1PM!_.&<5J
M;,I:D>R ]Y&_H@&B]LIMXT6D*(2E1SSD=_$"42Q%$+Y->\O)'
MQ)0WK;:69&RQ&>T _$(YERJWC,5(E?;I$)ZZ$9@)H]3TSH^SGSE =KR%@\M#
MLL((<1.('87GVY$WR1"J;A/6%6_E.;%L)K22N+6B6)3*U:GX9)I3"QN0),V9
MM)'3O=(JLY1DJWNW5 ;.AZ;3,"!QQ6B,Z5K3J:I,R43:[^?ADSG8DF0[UW%*Y$O!@B!6UDBA]/PN6GUP*EI>"Y6^W
M8/E6-9M"B-S=M$,ON!KM&>2-K]XTA]-,)%A'^EK!>#"_YYIS>#ZYX#T,41TM
M9G&3)_%^%$(.1N"WB8#FP\DCJ^=GKDH*F^77-F+O)B%"CF/?'4,@@=S FTQ"
MPGN:.WWL LSW5UE]9DU)T0H\=5OA=@2[(:ZX;L68V\ $0
MP0AUPG7]SWI8TTMIJ[U@ ".UOOTA-JX2.0+WL!#(!W[+]3&,:3@GM^"AK4/
MU?4A!@A''ID&;?"$P0V>8/9+*3CH3]&/J<.0_Q0^*8)>*(B(-P6_TD*'D^=T
MQV%+IDUN",'8MGV_#@?BT!&C00@;PNTIY+ENMXV,C[ZV))RUP.R <84>V8T;
M.?B]VWJWPR;IABNZ%3I@YP8WACJJ+"E^EQ#8?%#-:W"ZY%%ZZ*_.4:2!AJ;BIU&&K=%B'=>(_0[B+[QKRD3E>HS@Z5PSV$LZE
M.* @G#$CLL'[ M'K;K;][4.MX<2]]'UB^Z%YA$ZQ?_NO;T1*=O'AIQ5)-(J2
M[(L^&%D=3"VLE.?4Z*UR7R\YVG5E"9DH,+O[VS5_HD!M.0-#*P(?-9FS"N)"72CMM_1,.A[#ZR/G"!BV_@O1AL.,PG$A*+0%:HE%Y^GCQ+0E'
MA8V#DK3AGLI5@!Y6BG\67P3K0DG\HZ!& /E%>&K0-^>-;9D(,*$M6M]C?!EB<'CE.">23(F?9OK>AU.6FGEG)T7;3CGHY
MHDH9N>H>83ID@CS=:4_XM%)'W_A:NVN^HT1QL*^72B)>$BMK@L%U7" 0QE338^9#0>PUYH[C^V>$GMPJ
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M[BF6(I'QAJ>LWB;-2@H]/8B(_8S!._(+1![4
M9NW#CP0F/YTSR_.@2&I NYJ"EN#*$'6)>F?QP2M+@^3VRS9PA;7+BH/T7,-"
M\8+E=Y!'"[X*-[@E#%W?( #DBZV;$/RM$?MMJ=HDO"C=!-Y?VD@8.E]8L$5I
M,E_VTP)3KO1\=K5H%F]VN3Q>:,?RK13>N>$36 ^P(V(4MHM-L(AUO_-]"\0'
M<1I;968_1%HY$7VV)PM; X6^'SYY\EF5+\';FEMQ]0+M.![#]_D;!V;-!C=Y
M$O"B T^XRQEPLD$4C^+86VT@*0#,A9JS8+6?:^M"_D&8U4B8ADC.W/(3 (<9
MJ";CJZB;LJ2^3%"&BH%)KTP"O)^:F*!!?&KF[:S*4Z2WJB YCL:] >5<1J,2
M6G=QKW,8W07),>PW@U11\S4S *:H&?UB-_%4@4=V)$8N[V==\=-+7?%25_SM
MUA5_9K_KA1/UC$);LC4A]VP<%6EX?-=9G[3$X*S4#O;\\/%'0]&KJ
MD+0#U:0VABRYG4O*LR'A+KT(HQPE+UV^7A@*9CM)@QR F:ZV-[-+'0*<_'DA5F@RPW3DWIN#P2]):8,"^=8\,@DBQPLP]WQ*#\M5U
MUDA*G!"99/J9$(YY>52W^-HXU34T\E]=F"O_!N\=J]T9M-6[[@F$-4>[II6L
M3)TUA/3MF.)AL^45.]/'QMX8"0&&7M*ND!$9R3 V_.@R?S(W=6&)D!$181BC
M_(D.&,;;>?I)?@H] 4EBM1@2!M376KZU:>4FELXD4$U_HZ<5S)
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MB>[I@:2I'451H_H=(1NZ$:4N=XJ@XQ"MI3KZ/&I
MX!,1@1)&&1=+F#V,%5,):'VO9.'L2O&;G<]_G\EM/U>*H.!CH\RM'=8 KDXW
M*8=B+?)3\8N=E T"   T1+?CX=>CA'P>')\;HC2H)2R@&'TXD#^*&RIA2,%>
MS^\V9^S@<5A:6^&"(1BSORBTS]%-F;563QOHM9:-OFH!364(2IJ+->?.M&"\,X1_MZCK+#Y\0D M#L?CTQ_S_1#/Y%,'/L<*P::.?RQ*TC)'G4@H]:M^?D78:B_<)YTUQR#
M(3>":6K1E3HBHQT5Y_]\!,#ET$=1@?"A!@!."ATZ_1%2(*?^$/;3:PH(R. )
M#K[:-N$<;6D"ZF-/@&LX_V&UADB?I/;Z 8H?0-+4U>(OS6WP+/HU2_G(G9 !
MN Y?"5<.@?21ZI:K!<5'^^ /X:HAS%R" $<6%,')M.=,XWI$;\^/5T0F1!@U
MUX3^K4QGN-'W5$FFNKCVY"NB\.\OO_W^&T,3BL?D_$8Y_G3-J#9MC1?>2#US)5K97/>G!'!(7$B14A$^60'^"4&@%\;30<8"A*LPB6(
MC\:8*^CS,H[QE15BRG%C^-J))^;O+]/=EMC_#\&=P//7XROTJ'"Z*,0/5%M'
M3L!GG2CMMX$OTS)*DV!Z?N2?^JJ9PQNOVX0_^,A85N_Z7[ZO EJ:XU3T=Y[^5N@?N9XF=O
M8HKQ^'+#C)>BW+$; H)*>VOS!ORA^&%V_,C;R2C,OYG="A
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M![O)ZTR0OKZTA;;;+7):;SY%_U-W1TK-A@GZV$]0I\TTDNSYW; [?-=O..C/+957!FX#'N7S7+07V)/[P7(W_=HM)V[\&G(R5$
MM-IZN8F5K-]Q+O+#WS^CU-VZV07O +(10J_3'I3O\S@BX,5EM /ATV_;?O'DWJ;0$L.UXW-,@CWKGM.+1LU
MR_2FY"-QNU?+\BQGZ76,LA9BB3Y[]$%Z8"N'?[-M.2D,?/GVFR&BMN>)5%8 Y]"0C$*VY682'
MF^23-R$X'AC$39RWHHD*^P.:4-14F!S?K[?)ZP'&19S1 H&BG =QJC)?AXP;
M>]*L@,OH)T9UG8-T:"59*8?C+\?%WW3DZ /?@;*26KZ).;AXS?)(/%X\E\7J
M8NYR 3UR3-TUO\I%//Y2<40RL*@ZNM$%Q(92:2^4 ^Q+4L42,G!NG\S?0!Z!
M32G\LF_UY &G*S1,G06)8]U(1+P3P\G:L[O,9V&K92
MH<&^$;!=Q((PC"-N*MKQQSHZ5.1*@04E7,'C9%#'!M-I9>/2P]5CI/0VF_:=
M&GAN?18L+-H*TP.TB(%.IF@CC_?7GHTF-H]4;$,??GSW+EC?L0O[%*H'=.W>!S^5?U)@4
MQ!3LG4NT[\LN]SI;UQ_>J/I>D Z>;8FQ1?7&K3'R@,RXA&\%4T)PR?\"W07?WZI@%XJH+_="NA;(=;1H2F[U+21 2R388L:J]B0J;A-
M\&/RGLI;2Z9Q*DA!WQ 0]T?I;^$."9S-W*0K2@^N28+C/L6ONS:,^',,6<-A
M"UBKN3S'3MIY85V=]D&YS5[CH\JP]+HW'V7?=LVWTIQ,WBZW3#!'&P^7;LK2
MAX'3CI7NS[63WHO$Z%+B:"?70FPN_N$>F5N8V<19P\":@RI6*=Q..H/B
MRE2SFRKZ\4W$$:[DTY'7E9$,'P$2/XO8$ "70JH'L>$
ME*7<6L\.324TP /^&YRMX":'QZFD#<:O/WJ"2#/#7+:M0!X+$L+;]A5U#%&/
M $GC'!(=85,/YF7%P'RBV+6FHI@46V-76AVT338LDW#*[Q3WY[HEHSJQ2HJV
MU-4.(B)A)6V5["Y[G:EBFW8>J(!QO[<^%@X^7"]^ZM?I+]&XMCPEO6L'DJDT
M;C12M\!6%38U,9,HC:3MJ%QI2U,T%$00[U*KWT71P(!NA\!V9
MM74JJR3@?E*_,V).)^S%76+$<\9A:>;-0L2GT"YE7#G@M"3T_X/T@?W"VZ2+
M/LQN*#QH>]=QC5XB,KUZA;2Z4#YSXTTT3M&^)+*V3CIE*TEC-:R!N6U^$AHT
MI!VD+?@?1U*1T[Z[ZUHF&BS)2H;;2,^Q;$M4FZ=M*>H*9:W9!U53"I^.9"DF,CRZ/A3G=KCL1U)=H \S
MI@T\@':VNA+*1A,&D%HW*GT T?OL6;([T68DU'EI 277J7P;J:\A#GGD//4
MN"U_EIFFG(M :YV)0\0686'.XR1K(]G&%AFWB1L0O03':V8^C3K6?/+P(9SU
M3!>C!"X)'0=I0$\#A3O:,LD6*430"XZ9)R574VW>0K3W3JC$CV&.#OQZ;E;C8ER$^>^[--GN[<$  ]TB)WMT9UZG#(+.ED*J/2&
M5@S6#K.DM?]:L?RZF=I&M6SADD_B!
M66HBU[;G965BB'/4PM1VTMD\TW,]TA_PU=N.);G/W",[F<2SQ+,G]J-12=CF
MV[#C2]C,TG=8:$[8GC4-=;@<$RO1#3$_)YP5#NAG>VZMO/$R*$W"'^
MB_DY.M'1 4=[,WA7E:N+O7YW:$S74[J6AM>XOT35HI9(83W4YXOP8W
M#J(?[.JERQG_$&3]*$R4/OR?9ZJ_C$*G+#=E854Z<#+7R>!%=WB2#$MT0H-W
M),)#U)UND2L/>2%XY5>PW8.#3E5O,!1(L>7]CH;W?QU:CA\2-36W#R>[J !A
M=$G2@I3UR(1VSO-OT]/-&Y!:-.5#A)^C$5;B1M0\XH9$;N6Q3XW;$#C;Q)Q?$XL[4TQOKBRV%IB=-E 6;6"5WJ>)@YT:=O3M5<
M4G3Z]9@0OCEZQRMGRW8DQ> ISWPY&1G/&]Q4EI.@Y% F8>V'1A->,!7F^9&X
MV=M,N%P[(B,2ADI&6_=HTQE.XXTYLQ)(6K39Y/A),W;>:(?"(\2B[WG_3&^M
MD*(TV8"=*LE(A'DZCJ+BCM3"CIFB-1EGW2WN 74=\+X^*,-:Y5)F*JA%[H.R
MS/MT98); 2@UN
M!F8 X 3K3XKUW?J)N:H']_)W^L0RYEGB9,>L(YK=:;OREQ^QY?,@ZUSX&: Q
MNC.+Y+^*]Y%'9_5X\7?5+.1$A35
MXLN_*P(&LY:5U/'(YXC.>/K \:YIU(RT$8PMAIAL0^R8SCNR#-%E+''+O 2?
M#!T8M<;&&*SWMYK^R9-+-?U23?_M5M/GO4CGIF]/BRNP4@VN#H6\+ N#,L]H
MPL,WAMVTMDS9>)#0E1/O=VZIR''J+=<-,>/SG?:.)6_9@K'K3UTHHD/D5?;N ]U.]\\7RG$-[,W&U*BI''1ZA;QDR
M<.%5:&;^LRUL4A*L_=M_X=H8GR9L1NU_Z3FC299(WYAF92Q>:\MJ[6!H;M[Z2Q=5A+!ID?FV38
MO;D*=[JG'&:LO+"F&UX45X2JZB:F8K(DO&XNRVV_>G6>(.\0>7U />1:72$N*"1E5JU7 *#5#)9/@YBG:![W!
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M1@Y8]FA_&7?XZ&@DVR# /M)2V$RBDKO:4VYZ:8"11;YN&<2'VW5GJ;D[*
MT\[-*P&;+2/JL(.[T,50'FDC0+/I+M*2R)A6$R<$80YY>WSUJ0-1.
MEZ1$<((&9JE'/.2=B'2%)Y%J!Q",ZT$5=FC/X,)VL@VH2:#Q[5
M_V1/B!9D31G\;=@96E5AYF-D;3J'>GW.9RO7->\<9LFQBRD2NLD"H>#"B'6ZLC
M5Z0XB3UH@SS,^9 ,K"YP;W(.C,&Y#M$5%'NO. *,GBNYEHH0H$<&/4."(+%1G?HJ]VW;X&:7:8#H''0?
M($8'D>72;'NP*K#SC5^GBV(*#A^^0Z3$4-9UO__S\W;0>H5EO
MAN\R,"=805CS.H,,>-5>:0E>:CK<:H5;)S@1BT2ACJFX? 3EKB4N!D@VY"XT
M(MJEL!-R^"7BWAS(S[Z=%%5=]D@/G?M45,Y?FZL'7O'1JB0@V;$M_CVNWSZ]
MU&\O]=M+_7;JSO$Q5*[BQEW,-B\2NY% 1-)Q=-P 1R2'FJ8,E)-/E+=R?%7I
MW)[NY@KA+F,RT[(.-#1EYV/ $H??[QC>$@IZ2N!AX6VIU-"K?#( 6ZO#]A3;
M<>2LQ[=7C76Q('C] J26MIOR=:YRH?<>T6.)(YKU'4GNI]<-)!'I/ZT6BAA&L1E
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M,5\72YLNVWO=4NQX8CZ'\MWL<--WG+X TNFE34IB(CLY/1F%!J1TFN[V]?3
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M,,*:V#:Q^R[9:(EAB_:U$I
M4 N2?%8E]0E&4I$ZVB]J>"OIVIVTB;);A*+86G%$LSVC 'M #', ,R5@S6%7
M8/\E+#0('%#-N,2E=>X@XYPLL4X)X61EQ8WX;&&:N; U<["-O0ULUROP6@>)
MUNCA.EWCY[M[WG?\RKN2;W#\'AFIA_R(&&H_'-= 7FHIHT3081%)I_N^U"26
M? BVYI&[<]#73-^9P^_YJ'@P(G>171<^U;+M"UU\R5+5NB(GF>^.D]/W7L_IVPVYLW9!25#7R*UOLVU^
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M0W^SO =I9(,
M-$@^9M+^FW':BV5@N*7JO-UJEN@]+N5^>"GE7DJYEU+NU"]P#HI&3-P%IEHX
M?)X4O(#'BS]%E$>MP: _;IL;*5(,T$GIUC74Z>6<3 NWP44>8F%L]IOTM)L0
M6@YP.L&2EW!$Q0:T+&5=99!S.7V4^8E#8NRG?.^5I*?S9TT .Y)D%DVDGCO,
M:LV1"\A)F.;H
MH3Q-3U>9#CHZ"0^4EE#Z*3=^&./U<6C&[/6GS88<9V/D#$B%:HKO/[2Q(*38B6/G,<(K,!M+QM*^$\[L^:-]?I8E=/?/A7.')))EA%$]ZG,;F%6,V
M-8>!(IL#V+<84>\AJ89/0Q$G059P4IH 7.-QP(&F7FX&F[]'33MUJ"67)IAL
MY<+!N,4RTMP54\*1A[++I$1GP5G*WDJ\K<-QRVEB;9M0XT,GO+'V\F[(U+W"
MA1J9]TM5>Z]B9%A!QV6;NL=@O:I?-9U>+C;()YVI_@KA*#EJ"OCK-'"VJR(DA\4'I@!G!>:>ML
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MHCVG26DZ/")3VG1'B-B1RF#?%5(=W*^FK=#[NK5X(_+=$>(7&L;8F9)(?Z9LR#E@#%-OS$V+I72IWQ]
M\DM_0/4864@@/O%)WV,:]BR[H;8,\/@/"K#=GAS:RSW""I<5)CYX5DNT.+-U
MNXO6+"]'[Q:NNE1E#V;%(W<=\49BJ9YG@KRY4;MAP#=H3M+"*.KP<,'LDU%'
M74I1Z0=+REV\6_I
M"A6ORSDE\<'G'KH^^\C&\^!F6_@?L=TC4J6#3@Y5&GDZFL-G5D.[;%B%AL^*
ML<*.XJ84)L+B&'9UKG0%:T%%B?K=P8M%^R,S>Q-1AAC['?<[S\P,N^7]/,5@
MS+3])^#!,IJN+=\N%H#AV=R'[8:W)IDSWIPQ8]6TA0=NH:LL(P>ZB$!V!41Q
MG'P-RAEW#6JO,C&4V);&E=D)3[_'.J2L!.-1FD8B$DCP\11H8<#E&G6B:,>,AFKI1#K/'D&&B!O%8
MMDK5U5@.+SPV:9#'+<$UB 7_Y($F+\2/.'DJ+K/Y'(WDJT*0
M%R*Q'F0%?$S,R9LR"!-5_+&)3P;TL[3+&.JL!*'61YV=@]=J5_=KQWH-P>>2
MY$H=0??.\$QD&MW5KU<:3/P^0]RM .3O=4M?F""S!%?MC,2RT3"C ,YH;.8)
M=+EH2KA04X9=E /+Y)JMJ$U$C(F[0(3,$B$&JS%.O:/DL?C1H*RHZ'3L2
MQLM3!M7B1? M:DZ-++CN1^P^_DFF#\*F_QZ72#^ZE$@O)=)+B;3 5AS\.\"[
MMEMC(^&B4=ANJ%2P1A"RUQSXCG+%U)@ULN);K7U/B_5PO,IV.$ CVQ7^Y-N.
MO$)1WKF?"*O>K45VOWK/6,F[H40P3J,9A!A7-:?$)=-<+;:@5=-V"(+IW=6E
M^WCQW_/O[$1BJL78-*], ).)L AQ6!^[<"CIP%$CJG(O^7X"+=ZZ#\
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M[RF7KF:/K!U,69-Z[:3E0JMF
M>?*H*!Z0N+O6CXC:W?JUN8SL(1RLYJE9[_
M4AF/^4HB!Q=/044HQ%)"G-.80R1M4ZC%)$>.>.H$PDV7TKM2)>%I%/?ZL+I^]$/]$XF_4TL6HY;6KFA-[,GCUMIL)AKML:?08WGQ
M!(9]Q$-!&$&]:Q5'!5Z@GR/*J%)CD+EU#B$UK/UJ_)83-TH\#I$B52^60 F4
M\E$O.#\/Z&@.Z]:C)[@<.W!O#[H+6U$!@OH["QPD_% QMVRAQN+#)QX1R1U"
MI%VB!"] 6Z(0K"  --4:Z\OCQ?\*4L;L)Q(5*EZ2*QP*OO /XXKL,5BG5AG:
M92%>.>H814&;^U:LL/%(,4CPB2Z>P*-'^_'CQW^V-, Q$ZEQ4PHTU5],4B61">"<+TR5%P*S@X.4D
M5Y. 7(4%H0/F0GT^C^)8<8% )&NDB$$5&XI)0!A&&WW^):4_MV-G#74KU9#G
ME'.1R@KT
MP,S:T29[8L[LZ>VDW.2<[36O(QA<:3>8!"KFZ#P@$6^$[$(I5OH&<1P3;LGS
M_*U%DS2\TU=?/'=[M"7^SI#_QY5E*(B?V*]TV_ZTKQ)%LVG*+AY,7U!F\ELP
MSKYP2Y4>69BUOJ>+?P+G?TZ
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MV8\O==E+7?92EYT&0)K-4S\AIF *E9.Q[X/[7' JD9V:*4D3'>1
M9$P\).]5/5__>!RA4F@4+=]^;Q0MKI2:%S@Q"-S*HNTYC+TG@Z=/->R*A:O1
MZ>2Y-KG7B]L(Y"2C3SE\DKN:"8,DC:4)+V,6$&B277(;1Y37[.N5/94,>+$U
M0]U_+BJX*H^;WMIJPY&-+MI[TDY YI^U1D[H&B8Y6:SE?
M5LZH3",557"SF?+9R=*H:S.OH@_/OB7WJ!6&^-W)L)W+5XI-A=D94!X,/I#E
MOA8L1C=J,Z?/*UAUXX$VJ^^1A0!Q(?4 & VO-<4B4R-HP#L3X6-L;S2YB;/?
MB+5>'S>KW^_$-7QX'@-R(=!K#U+2MYK!_#!CIXHQB, .A:9RNR6R+:S0/V(^
MN+M4W3JX8(^@%K@?FS_J/Y[]#&>INKV)SZLK\)5%W^JM+0R2W$MV5.Y:D8L
M?%":B3$]Q6,M6.0O5?O2E2R>F3]+@_P!F<8'L*6+7?]V[=J!SK<&Z_-YU'H;
MO(J.I9Z2WHPD$\+>[ UGD S-F'R^I(YWQPERL=B+Q;+%9[5V]@W(4KKXN.+%BZ-5^,
M^V+<;-S,QJU,S8NH-7!&HL(42;0I*.7ON1C7Q;C$N!*[2-S$N3JLPLLGT5*E
M&A;!&X:*\YQ(=\6478+Q),55IB#6M,"H\:.+^"\F>S%9<4^+;?2JITFL>L1T
M*/T+)0G/A>]'B"VZOO*?5*TJ1OU.OC-[J[$&FF18HO?_=F26*(.W=$:;Y\6*
MJ5C0*1*.\XOQB5VOUMU17R@^>
M?06@1_95JGO HAT9V9PYEHO3V).L+/X.E!&^07U32((0?OJ!M%96Z5&[!LJ1
M4BN^'TY+2LH/*/I[""BDR*(Q1=I'I^",73NB1+L?6FV"$0TX14=[.4-P%U*-
M(/+\+)K=?MN?E#,H?8EB_IY;+9S2'%G$I,G/\OS:H6IM=.YD?:!:2<;>29VP
M+EIS19-Y]+*^H[V5SY@9Y@GML0,-&]W)C5%2F3D_21FD\=@)H?UZ\2KL/X^N
M>Y( M%[8RK.?E0>=Y_E,C46A!ZS8I-IPR[?(IC=R9VV4CY0<%-$(,*V<'<3K7+3%L;-OFAL]/4VR@&$C0WZBRQBKN
M;2.=&X0A$C<+)J6)\[CR/'/T_0R0 ';H3W'J;+;*@/2,WWK\'H/F_G !
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MAT@'G6Y9.\I]Q+\&+J[3O%R$R;D4&:(8R(;MSJ0%(EUOI\Z+>(BRT"_+T
M5]'%Y9G+>U8I;PN@\#W^YO6;^%":3"&[
MB@[@-NR76&JR#4"%W.WC0_GD;]3C(G'.U]]*[[]%YMNCXN8G>>%?9"\XW^TR
M%T#-985!9FU,QJ?F &;8D?T0&R2J[,TPP\WRN43.=J*Z&D3@G*\^)%(A.;!_
M)KW^$#OK+S0X2=='TK:@-\@N;XG8 @D*7%533<8"6_H&33GKJO221HDD05NV
M87ENL[/S4VRFVDI"!U+\6;YD57*'?(>5BI?#LV/Z$ZIC+QY^CJ.^BD21FB&3?I-
M>-I(V4H:J.+4^1?Q HFSW(U*B))3I&EZFI&)_.1LHC]PG^\5W-VPI43]V%.F
M\L C$;_+Y!ME1GO:?^'9RV80[Y?X,*E2,LBDF&URD'A(R/U4&63F]:8U('J+
ML;'*X,R0IF7"@1E&Z9RA"MFV/*6/%]_L[90@7Q6?W4[G2*R$=:=U]>6K71=5
M^0&C_03G_J:]:4PVQ=A3WP%'%&&G"X\Z8B(5LZ#?BP^  @0=W'>U+)Q+YI2Q-JV'/SJ7RIED6&MI9W*N"8RQC]O8T$2L
M@A8OAO-'&18PL M*NH5K I&Q!BF5-!V1T!E3NA476=B]?FQ$DR#=GJ>CDKU0
M).4P$AKF/FBZE!_,,6&%72=KE'D]?A-TA"KJ(W')^;G5IO-D1;WN22'965GJQKIV0&*?
MBAQX(6!M++?O_':>N.4 CPL;JC1+&Y4!0?W%,182A?>X^OO)I?I[J?[^=JN_
M\P>_N9"_1EAV;NN<#=>FJN/]/:.T[X&:,G*./%>*4\MOHRD7OS0^+Y$"/J R
MQ?+:6ER:B??3C5FDM:Q>!?'7.CF9[N=69 5&$\J,M*?A\4KRM/7<^7FN,*HR
M[AJTUO"PB:^K.Q2&28C%8]C%A/J@VAN;KO5C$J)GDTLE+X%92MH"W=A]LF53
M/S7\')R'FDL4$\\$Q3K-WYYS=?-WO(+RL7L(YY0JCBH[T?9%%_EZ<^('XZHYNID!CR2)E
MI>+B>Y)7_[H3SX_3'"R/ZW*D<_QUV@F4@ ^BU7O=G,C5/VF4\%?ALY+&?Q@]
MJ8I9I6<)5>L67UX;B+4$5S89X<%/[L^ZK,'?->$/OVJ4J5?;^::_[U(M $(.
M]+(+$"[R%Z@+W&-:7R,7]B;.S/.T95'YDZ*2HHI,GD4I1K?OZ%+\I,L]#?ZJWVIA!OE=^=)4Y
MWWGO=]8O67Z?4!WY+#Z_IIS\RKR&K^Q\++C!(7JBRH&&TZS+M)S&$M(Y,_WI
M G'Q8ZV8NF"=E3OQ;FN&%[%"[JS !$+C#47'IKG)F]8U/V)*
MW^^3K^&[4S1U@MRPEH#K'BVXA6?S&LDWVN^E\-1JDGTG6]]*,,P"VWOS1G*PWO@L.UY4YDS%RXZ(L'3KRE%KJ6EJ>K!
MP&K69%;0JF,-I%P"*?4NW/A-9LUG_<&5^0 '_%DH@)B$9X3D>-#@@&7X:P:N
M2:!4J#;=DN@RAS3',6M^F\=3\@IL<^RMUX2<]$2JRA-",YB%[]&]%30JU\:H
MA"6$^F4C?J J(\FOXU5I4-L0IH9GHG[YGOH=W-?"M!"7!
M:F_[X96AM)+>8H)I#V\%MX6:#2OCS1K=>XQW"*Y-]B\NO_.KG!^$J:+\
MV&PWC^SY*^6T=Q?+8*OA.PP.S72="/5AI^L2BR\3W9N&\*R.FJP$X"5Q/19C
ML"1 Q10>4B:,*;?SNWMY9]<:(;S\^55YWY-'(9/Q>:RP*[4^B+_X2\QL3
MKQSOAP&Q'*1YHL@V7_5Q5#77&]96U[N6BYA.64 4=A,UH,;&8F6DMZ.@0_))
M(W_6#[=I'W8(@.ECN[[C35&D$&U]H)T%$([E]KQ_J#[T:%I4R9P.$61[)%%!
M]7K%H_22ERYM=%-B5J1#
M@C4FLT)*/-3)16A52M+)&OZUL%2<,L2B)?T_>NB8L4M)AN'UPV0XRW8@GWZD
M#@AD:PF"[\/OF?A\M6T[5B="UQM_RX^9\Q]<9UCX]@@P#I#^2*7(;RBGRS"<
M5@Q[#W\^["LR'F0KB2!%TNO$K9H+ULF2?QN
MW+7C:&YSF[P5V"%HAK4?,-0[;G[YJ:^N6D
M.RAI,TD[(RF_7H?#\'?=?B'N$?J&B[61T[V
MR+:W:(:A'VCOVF["4S 9CWI3X2 >CGMY\A=2B]DT:Q)5##X"P5T3G+>3// .C:L@CZJ4'"FXOY7U\;$TN4WXL2L3!^5W3;Z &GJN>U88W]SD9
MTIR0."5(8-F-"!,:KMBMC-"$AI&;0H/#LY80V<7+:%*Z"F_T3^,J16@L0#5X
MHW!=Z?"D"OQ5NQ+4?_@T,6G$\+_2 X%BV6VSON(&%'U(6*K=,U.'PR<=UF."3@0L+6F]:?Z_$
M8]>9'YK]\2 /P:5N1.C2*8B_(S_*,9?Y14RN4]OX:5)A!;CZL=@ZH\0RJ:-T
MGX:<^)!"$;.M3ZG/E24!RAG@!\KI)2>DIZ;;#\TCD-,!CXQ5DRTI!V=889>I
M#,U?L\_+HAS((JRKO$C1'F14'1XA'%ZY.A3N2>='(A2O6 @U^S;%
M[_-2X99E^@ORX(I]=482_G(<)*W\4Q@=D4JF'3K,@$F93Y\&! :MKM-1( 7^
MPF8:OL#)SBT>?ZG?7>WM52'#;;9K@A6GH!@F5'K'3C:_+U
M]QQ&\[J*WXGV[!*J9VOK!Q@>UJ6RZZC"6ZD]S??"XQ: S:1J.CQ
MT1\S2N0B/%YPH](T5D\FB(Y!<7J8[F$L:7[1, 4GOMX%'W^W9%2_$D\$5VD@
MH*E+MQG\/3S-YI#"/ #J:EW33M0C6D92G31P$
MP*5!UI0Y93QKG RWL]E9O\.N%+9[0T+>5U:5V;86HKA(@78G7HDB=X_Y%R)5
ML8!Z'/L5$W0R3_L"E+I:=*"LR]6@70-F#Z;%8J-O=9,>F5^2O[9?)00ZBQ_N
MVR:VJO4N)H[7RO23\N/@!)23<1KTB"/>\O8'[.NJ&7F:XEKH
MLU-8CSA?57"Y65D:[;:I5 ?X$-5^D$@\_M@
M'+36N2V5&HWM>P^'L: *TG48'W#!:%E]2L1:N2.G*O@O*":I?7IW!XF30\L+
MYZ_4 ;'XR^/PCS#"J]5UB"HJ%FG_]OH+B'G<-MLM_13;D_0 GRJZ
M@&*1*ISHJY9=PA4[6!:OA-,H0WDP"1O,-*OKABT=Q:%M1SP=C?3?I=1,3O=5"7($>(<:KL09.&[$'Q\7$A$06/2ANOQ18&1.OBFH
M;/KB ((T)U_@R19-JS#5# _&N;E3INQJ;BNIPP/G0R$T]5 DD.)P9FSK%4MJ
M3AZ)3"%Y)O4R(N>MLJ$=2&R1FLU5WUA4Z:F.1"K'*BLJ96@EJ>J.<#.1-XM>
MH6P-X5>DZWDR;F$:>T13#.^N:E'Y0+2%
M&%/0([5E2"UHHMNU!]XY1H\KP)]=*L"7"O!OMP+\&L[,-^Q)SJ" L\*A-GG2IE_PU7F;NB)I]<8W-192
M$A4+!&24 *#F8."Q]\,K+6W@COV>/&2@/W6ZA$^3?MJ&/-P
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MG>3NXQ#[L9W2"'CJ3)DCK@=J 7@RG5P'?=VA^/Z.B\(_%EW?0Q^^<7\<[2/<44P[K='CT8._@&JU?4@RM9%I$53RD5XJ@_&"ED[.=UV[;U
M. *=6Z^LQ4C7OW1L6;:]BHGQ?DATRARCKA$!&@U@KO@T770[RO (#,I-"D7W
M]4T_%)M1V823S^/BK^(=PLD6,#%Q-8-%=HC'&3=+ _,U!.6_BK64.K$!KEC?#Q:2^N.(6:K
M5['J3AFH@P%P!$Z!DR:QPXTX19*ODNW0B.*D*&RP#=0_(.Z\F B&QDJ!GD(>;"E;]H(
M$D9"V@_3K$W!ZI(DGGFWZ:/9CETE]L[N8=RML8R2\7+8?2'*Y&.%!1)$::$C
MLA4&D=S0(X8;A4=_[FW:JLRRU?MM_B":+5*)JD\AVGZT!AV$E,@]^BDB>13Z
M)%DOV[)6=?#28V?X)H%=N2#J"$&2'TQ-1=0=G$^$MY2L$.U9CO0D7>&TV;#&2N>/&!;S(9::J=A+%E28E5I5C->N(G--/D5BSX3S-84)
M;"*Y^M!P]I9]1[+7IFLV[<%>3J%'#D]R[.S3R;H8$(I.VK13!)/N11F$JYC>M#9!W"C#T
MR?M R63*^N]J(9@85T.[)"S&LK\19.[<5_4QUGV\57F8S@.]JO)X544F)%_C
M?F_HC^0PTL9I=]Q'H!F_LA(AWN@$60'\(0KD8__K
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ML)"S0[M)[LS\[+;Z^1 E!O,I7$D'G'GA[_%,-;JL!3# "V&D_B;'<$GKO5Z4P'\=FYYF;H;%L[F(2MGIK8X1?'O>.9I)[X&&-QW2T!
MH6=\=*13WM&K7<<&ZDA6[8B> *DX8DT0T*.*YJ C5LUT7O=E8IR>-AH:(@S3Q#UP(/UVH:!I
M @<=Q?/2!(%GJ35NII1O"1=>4XX!^9G^WD[U3(<=L#$N]0V1!U:>Y3/+<>]E
M/CX>!-#WOO-^4?+ "J2/D7V^ZX;Q)Z"/1%&=;-;,:"-,PC1S'&=E3^$S+\M(
M#$MC1^QQVVU_RV60Z/*Y(X';#U8,%M-)D_JI."X8 ]9="A$OP$LA,"$OO5<1
MEQ^/(Z&:PJ?R(Z>\4O+9A2L#>0X*5M<-EL6^\:R*P+:D1C;+9A'D"X
M6O.?_L>1.C1ZD?[BKVPY55EW4;]H^ETA2 W//F[0FG7BQ'1LNTO]!:JIE7UQ
MYSZX%!4*M\/Q:MI0Q%E!J]#HT4,\"J;0'P]_W+0_-6M_T*BSPB?U80C_
M6UO/"#Z&D?ZW#_P?WNJ)*55-0![QX#"IX5F?^0Z5KD=_BCSG9_$ E0?]CW__
M_)-//W_VGQ\EA9O!GO]ULEX1V;;'<,1\OG'S\SSXB&Y@.:T ]@ 1=K_$U;HVE'1.^"I'0=
MU4@]QCJ%55(O-G6Q*6=3UIC,V9;(>Y>F>5+3<])^VDRC^1*W@85M,&9&+GO9
MQ>[NL9<=!\KVW\N[%6&"W,7CLK*$."4"#)' :$#H1S=E'A@&N@'50U[[G0%G
M3(*KG$U&VB$EQPJ@WZO&ZFC%X#$&"9M^Q91+KC1_!!%FQ
M^A1@4FF=!#B"Z'[0NP QK5X_$4H-;<_%E%0N.L:SLVB5:.1+L &7 (2T&D7;<+J['J;EP/GLK+\RBI8MD.5 E7K\B/*
MOY'!=X6K,E-Q&),5H(W@+>MM%.[;+-99;-C=UENP9MMMLFH$[>E27(NGIY28)Z52+M*]#9#,RT3)#XU7W
M E*4\'A\-^U1=#BXO/M$M1PQ1O1'Z;&= ?GQ=1VS=>NI$^MAV8I6=J7B,[ZO
M*2S[ J:6.UZ"FW=9Q)=%?'?.&4A4DJ]CH=DJ E:B(A1ZD :)&,Y*64EZ66'1
M]J4Y>1S%Q=2+6VK^$B3]#6&)W5IP':L_-OV^'M;HLT)#HFCFGA,,FV?.Y9PR
M$!$B)VP(UGC[N];1>XDC_?3)!4=ZP9&^CSC2R['U&S^V5&Z^2AFLHX@(=#:9
M_[LQJNCY(VN3YZ5CRBLY&]R!A&88=U0(P/;B<5U,]SX>%ZJ%&B6X'OF:5$*8
MASNZ**R@B="J3&I4CF1(I^DH14 IQ9=E79P4R90B1269$RY=%:[1Q]V"PKU9
MU>,AI0+AIN/!7EE>-9&Z*I"+Q#?&[8^'1X+B+H"2+ZF*RYK+$%T%"G\F/\AH
MER*GQ$RKQX3 BS,60'JE?#&.=NUBCQ=[3%-GI-2;+YG#;- 4XE"B*
M^/TOX:C1#'"42Y]W;K3/QVET:QXMO>\%:7VQV5F_!;YN*CA.+HPF0M\LG:H6
MN2-]P,8J;$P)=(%J7XRR:)3M9I&5@QE%,)H6&*I@U!?%FUX=3^=@F$NI"52R
M_3'B=^:-B"^M6::FOM>"V]=E*;:-9LW'37=\C
MGUSL^QW9= W4$RW&U]B4;">8\4W3&5MH[E!4C&U&C#4P%8;P>[9#4B##%K^6
M3P#(%@P3W=#^_N):APAO34*6POFL"A8I[="D55@IT#+'?):3F'+Q#([
MDNO$?8VNTFK"G_J+=N?.->:>YY&[BR"MP(0VPYK&+'-JW?IBOPQEFMLYWDQ(
MR@[ C,*1R\>$;H+=\*YP(XSBPO?GFXS/Z),;P[)7)I-:-:N=9]*>#ZLQ)?1;
MX )T2E/8^>YZPTR&'; O4O6D[77/I JIONHWQZE>:Z8NY?117WSWC2>C\P*H
MPD:M^B857B75?QM,,1S#H%W=.*.0E)7[<=PVM1XNUW\8BY)@JS
ML#";\?=5(F6Y(T0JF@Y(,WA'?)^L)7_ ?]MQ%Y8B$<81[P6U&85%(;Z;
MZIF_D?"MBNQ6;R^!:ZQT13]B4SCJ3/4W@X_FWGTPV@/Q:2"I'UY?55JU*33$
ML.'&U&[&%(+]/?91YKEW'^&GGY%1+N@F8[)-0Z3YB?K?MAP#@9^F,LI%^04\
MB,BS3UM)OW#R'C&T,E[?]X46] NSXLI8;&G)GDB^;ZJV&G4WPR@372,+0\AF
M:E/CSP"5_^5"2\H5KZR(2/R5JBTSI_-#D(GO[)1R#Q
M@3>Y_HSQ%6/UUZQ&&2_' -4V4I4S93=W^!Q&*A5-QE$,=S7T(TO #9UJ/G 8
M:N2=IHS.[3I.KQCK#;LU?V:Q(6#LL[!Z;QMF]G[&UD&U@7KU*@$VVF&Z(W +
M>=?[ZQ#9HS65.('Z'?_6G8/,M#?<-&UPM*&E7#R(=V3 I"X8UMWFP%>!R)V\
M'V^69$+8I3&FJF)MYKOT^H*:*I828^&>U^'U"%M,C^F??G]]&O5LXX.Z#R.V
M8&Q/RZS! ]]AXC]0-RX(/5;7(.+4,71.3;+T0&[*'$]PV*ZX+G>A_Q
M7+\T+R"[+=I9,0D#C.0C5;G17<>'M<7S_1D.L.#Q4R*+51EX>U,5,?S32SZJ
M'FIT;$6W7K4V4L=6=_7TMXY7;>CI?(O]M-KG[:/)\.DU'FUH(#"<5:\'\[C#
M9[J1NP3IG$D)P10E=4K=\@S0B]0.] =&D.1]%\Z16DN/][@$;\PZ5:*XFRFS
M5^*NR:\]6W=40E)Z8T'%>R273$5!DKDEKYBB)'J$[A2#GUUX"2'ECHG8
MUBJ@.^?:F\1[3^>\BCX1XSB@%'69RU? *DP#-
M*L7.-,5^_3/:UX@R\.I8#VL]%66TV#TK3]/;6\;B=TK>43+\WTNCW4;$D=OQ
M"!I'E^6CS-5QZ)QW?0^C2)FOZ=*<+.Q^[B0A%$:&8Q<.SO>G
M5/U-O6VB."$'"X00:QH>Z=M^>"42>E%.T"( $6 !J38[<=<-S]VZP=$ V<0C
ME!B"(W?;NW'.Q(DW*@%.Q]W,QQ#H59+8R:YO 7QN,&&MB\J S_2@_T$2YRR]
MPRUYX+.G*&C+3!T+DKMT":40XW2TE-?@ /F5X[G<"-[M*:6G6]:(C>P:P@*K
M5^ D&#I4?EKAAC1'7S7!]0R7^T)N^'6G<<.+?M@K=.%WU%SYX9-G7WWQ]0O\
M\^FSW]/1&5XG;';VM*U]F56:G3;W%>53.F1&:(,,L49#6H?7S:Z96J04H&8,
ML^UB7H:0CKP=P41@M*RP-?IXU;,MZNYD>T^4)K'[,;W1FHIS*(J,+BV61L(U
M"\&&)U9K+UDSGC S9RGB)=>R9<*+ \ODGI=C!EG\A9\DQ.'U"D\65QJ;!-_^
M#'QU#$'N@54TMFVP\K6F_SRN54U\:LZ.//"!BA1)TCF,V5^A(?#T217\[P\_
MJA8OPVN$^5_\;QC=YK3X4]V],AM_^;]_4A/'.[\,ML.B0_2QBI.VE&+EC!7!
M@QU#6!3OH+6RN"7G<;\GK9AFS94*^O"J(4(M9BPF/V,9KLR+&-]B:JVU,JB0
MH0SM^JK!YP1SR:32M.Q@=>&I"T\K&6;*2T@7J&S-R?68>*465SUXPC!IVB4X
M1JDPS+VRYX5HS >N]?
M;X_5C#L?;K=.C8R!U9"1TM2);.M84W'_@FA#T\'_Y/H?1*V$*9M;5 _J/,5%
M:I/%RBJR+8I\V\]=Z[Q?9?,[\!5_%ZO55&=[P2*"+PE'_JZ48+^WZC2EZZ*B
M:R)X>%T355'3+6ZH7Z7=LLEMMI1AEM6TI!/KP+&0[/E[PMJK%I47JG4:<')!
MW03==>SRR3&BFIG.PXX5'O]M$9SAI23@\
M#*D.?%;T0Q7O?X[A T^Q_WY,P_M5LQR.5'OZ\#/\\@^")PM#(ER",[<3[ V]
M[_\?%CX;ZN++GY@><0'*^S7?,QC$MK^E__Q_3Q]_BMO6_+#\NS\\_O@3J3ZW
MQ%H50GODI_OM<9=>Z9-/JX^>/ GG8CTP<\^=#YF%?21U.K]2&V,AN:
MB0(;U ]9GB[5MM3,@UCYV*R8=N6"+K[8HMIBUOW6=$.88MWOS((4]Y5:ZL64
M+J;D.WX8PT.(VXX.#1D@(8^)%(!09F,7\[J8E["'>3QOV*!V
M[4%8Z!9_^^*YH7LT792AIJ%_WE)07/I SEK$@>]SHR@;&E:(W'"$&>YWLMFDWZ(E$?X)[&>_%W)L#FTIZ8&24S\8B;V6!&P#=Z\DBT,$;R].P65UN-6A
M\,-<'$_IL?,^B>9U5L6_'#?5AQ_TBL5!4AN06WZ4+1AA!O0GC2KBY'Z,6X?8 J^4:R
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M#TFBF%H!&(F-_CM6/'+*8I6JB;-HB!E>4H-E8Z8>NEYYE"?ZNODMPZ^\&%_9^(3-BMPQ99\B
MOD;A ZP65\=VW6R)9XY9(X?]T!Q;R7==O! 54BY3"OB54S=/AUNUN2H*H4?\-3U*1([[#*X'9HF?9?
MZL= 3)%0]O9NUI#WLW/SHTOGYJ5S\]*Y>3FKWO&SRM!)_U?6J1ZQ1Q7(4S17.S*BPD ]7*?^ J]?#&O)S\G>-
M1$OO^AI_S*U#N=(]=0S+%,O6E+ G"W<\]^GK,0#, G$.C:
MRY(I<5T"(]>ZO4W:?%"]6JNIJ%>@Q1H\+MO&/ HSVD[IK3QU.ERY71K1R<@/
M?F6TWAMLQRV8PYVX@!?XJ;#2@!
MVJ8KZWZM8:X4AQY,!V0NZ,+F\--B:O"#AV$@E.]\I'$E+4J5_F"%D/OHLBYPS4/^H[@3OP6=5P
MSQ0WC[MM8@<2T[V@EJV2OLH;(&&K.(F;U8GSAVY-X%^A7>6'B']_5;XHBN8@S4TR35F/0NO4>-F^PI
MPM4[FLTPQ>99.9-XECO>/8/M33>4Q'4E$]ZP%);+=G!4!$#)I78.\+^.2Q#=
MB1>86X7)2 4"YW/_QG+>LYW$@MKHYF=1!I;,PL'*)^,./5W>7/G8572?2H-I
MYO@;#WN&!]X^/$,-L7L,#P__Q4XWR[:0;B<"(4HSAW$8:Z23)'"<&J<\X3YCM/-\[)>38EN>]Q%X5U0F@NASG
M?AJ2IS6;AAEV!D'.@7Y5H)"/8.O"SDCS#'XW'(^Y[0TP6IH[:ISJZDM4VY';
M;2= O:H;2";8742;X#9'R*@[F+06NR$)V*^1DOSV_K62R2YTLA!HZ(QX)=C6>:TFA3BZY^8>].X0C&V,=
M_#*= (Y]S )\-$D2Z0E //=,H76+_7Y!"UI@H@$G(W-36BH[WY!FB MGCT?F8HSIT1Q-LX043LDM+*G;@.''(HMS<@SM*N0:C0XB:[*3W
M(E8EZ(9!W$= B=@9
MNG"AI*$$:@97@S(*J):GH1T=9D.9H?..8@^%CX"NK3E8[!]:!8K
MV%H>&+MROM*4=E[6@:0WIHS(_>A*63NNZYB;2FI_HKSD%+7C!#@J-4U2;8C9
MY5Q.$DYL0.LD@'MZ1CVD%SM;Z2)2L>,T_=2[+HJT9'>5/%":6)PV>\[,G(6#
MENJ32YS3+O"!P@#R3PO28
M.*UI=4NQGPL0\4/CT2FWZ;3=<1W7 'N2J@P*E<^R8",/^U>5:E?OP^W;>K\4
M+]FED2XV#12!$;E]S)S;0P-9(!A8D&EG2+EKHFQE@F)2$95K+X_I8PKV"_KK
MI$D\&3'6V*?0;H+I#.2\H60+\B/55/6LMG.V=CS'ZH(*,$= ?!S!G?EA<,,-
M(Y$NIC1&3^V^Z];;M#&8[8^;P-Y\X 2(V046SAN7H>V8Y:>O1YY\: I F-#]4YC"BR!89.-C5W2AX 4HB+ #N-LFT!^#G1.QXG3&)S5
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MOC16VG#F[^"=.X9B6D1*^P;/3'NI<#HC%048<5)DE1%C;E3.R@VY7MVC"LO
MLP)3YI-"--6-)(B-J%@G$!D_B!L_HH83;G0#KHY;T!QHL3T-Z?)9LI#(#N,2/65]=F/B\L@K;H7/*#J!$"
MGQ99FSBWYH@H15,HOA;-:UW(]7-"T4VX
M0F>I$D\)4AB\CS!76%W)U)7IU)  XYJ5Y#"C#8A)G/!;LF2?24;VO]93PN4BQ9
MIMT\$9[6;_?QE(!#$C?&G7=%VAC(AYQ4PF0TZ.HB-22Z1"?'D:.R,\K>,,.K
M0-V=8 O[2QQPR@T KQ<4XM1WI\@+YW]#:?$[LY KQ%%)'K^
M<'5P9)B@@T,*CW4DTSA,IRUO10WL1;>8$[F#3F)(&,S)D"?7Q3!R'3JAY*7S)> )ADKGISK[(=[AW=7
MV0DX07Q9!<86,0)%'#A"T<'7A_HG42X)7#C,G;A$>8SM639Y,TD
M /;1W*1+W&S59M(FJ4ZG9^EW99\5*YPSAN"!I350HR= ;!B?DF,\)%^6U7[N
M"%I, @$&@BN60I&V/ U_-A94$3-F7^\K2F@M5#1T_-*V]^8_=5!C:7
MEPJ_YPLX_"67,U-)&.5;X3U(SDG%RIO
MGA2\'MXU=X\6!F>_NZL4!VJ,* #QJ%03>_;LW^D=>H=(KN%)Q=-7?(T-.R YW?_C@3DZE*$QC"%%'%A>US93NWFB5#
MX(+25IV<=RQ$0I-_9*+DI6)7Z3BN8BGJM
M=Z/V4#D='_;A$<=J-]:QVG6L=AVK790=98XMSL&*3+0< '7EI5S=]78:%L,<
MIJ[BQ8UK+'C>U'B:JM1/KUK%)LY2R$V=N$*[,^EBFE0?%
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MM0U$O58]41&9M%C395*Y,^E+DGG?;;7;WE3FYIL(A2+GL< !HQEIE\^.O!1)=9?$7\:^\ G0!>Q'V^P&; ,7F\54@8\WG.*^@2V2
MX?%SX,NJ272 Y3=)<$\Y@%<6EA>4#4L:E&A%C2OT22PEI Q@:=X-STC7!'+3
MHINF!M=/[@MERFHO-)=PVT=\Z@((M -[=8&GX%1W:^]%F,(H"3+1.:>9PWAX
MF]'ZOL \-VP3HJ(+)32 )F^9/]YDLN1GSVW6OO;QE.TWRMI #\Z-/IG]/8Z_
M(D+YH+1;!_AE@/99.'8,;-H54,*#ZZV+H#0E!V
ME)L-4(V+I,J4,,BS8N;<(!'65- [24_R,6(!4AGW:)*=CC' D[F8=BDI HIK
MF\A)DTOYG YT:A%+E1KB?35O#><(Y,Y(8<0^]H$E7.)FP?^X43B,5=A.%PYO
M%\.)!0%O+:?+D_M!ZEG*I1.5F[%>2]TV[O%)N"+E%9I'/V6M4DR(F
ML93TV #/:A,1_LY1D3_RBN,B5H,7<:HZ%ZBXO5_Y4Q[2=?<)3&Z<%]P(I$0B""]S1S<3WI8JG/KJ_[,.5Y=2%
M['>GZ/EAJL6 S5E6L\K0.-]1=3$Y)F*UD-$%LI(KA)$1.J^.&5 +C% @)E9%
M%NKR\,BQ@)0O=*ZUUJ7_U$0>_8^Z4DXI]93L1ZHC$Q6-Z@NQ+(U00]#6+J2\4I1[
MGAM6ZU'1O&2/62.#9^Z6C1EF1EO"LY66P\&M9XN:/2D^?*&12]LY2[)(9HQ?
M'2DW$4HN25P1.;TJ4KR)4U*_;RX$;R_@"$9AK/5PLV7L_LTD"_82@RS,T4GI
M-Y>// T@'2B6DDLF4\'\$2BU2"FQ:V^"G,':]0NTNI@(S@X48#:9^2B1UC3)
M,OEAQ]0W8I"1=6=.@6(4J:E:#&3US@WB*.J-JD4
M)$>6ZVB>E 2[.+LX_+JF?=8E7=#)%530
M*T7-(64)@WQCI8*O$RM^L6RLZ3'FN$*%\RW2;(-2// *L0Y&5B#=XN4K1273
MUS&A6["-A.NGG6EAJF!L=CM2C,^!%9 :2?!1&'X8"1/E/U 8C^<:TV#ZUL[KEU2*Q[WP!$2_)'?6LY>(39
M@D:EG:[I):;%MC@!'( ""P*1>J"\1LE.>OG\3-?N%P2TW:C-74>#Y\3492'4U:,'G% =G,=
MD%T'9-Y45GCQIU"H]
MFO\FXT8=,H*VGX)%QL\.#ZLDBN>?*Z"<0CM=HI8E(P>@R5H"I';IH@&CRWXL
MTC##B 271KC*@D!X6&#>Z^'+R/-4DY))AA(%NM3";CH1#6U*H5?*/T=JR3GF
M(" .I4SA(='/R.3T%ZD(5:KU8H2=L6)[/BC$K+I0CL''IL@L4JX!LS">1:A)(I316\T6L&-9P%C#K*.$44-.+>*/19;KDID\CS2XJZ0\6O-2
M<;IT8HF4TR-%51&"JVXO.2FG"6:/BP:J74"[<$>F& %T51,T5H081P29I1WA
M5 6GGUKF1<+X(6=3"A(I!S?YSM"N5#ULOA<&_WLR:&]M;W>'&VK@J_;FH-_I
MMP<[&\/N0'7ZW6#?E^YCI6P6@9(W'>]1 /L\&&QN;
M&UL=>>$.L7=NB+0#<_O/OSJ;[1>=ERW/SM&C27IZEO<'7/,VN5M @=+'2V+8
M(B,\GX0!3(>@\+>[[=X+5^>74]_9V=II=[JC07>\M3/H]\;#P;"W.1JT-_S-
M4=?O[;3;FXNGOK]L\JS]CI[+:\T*=[L\!,H'O%;K JE
M4'6,I_0.%9C]@B_-H /_O]ON]@>GR:#3'?3DI]_4IW=GIS]/7QW\]7;_[?SC
MF[=O/O]Z]L2+X3:"2C(/GI>&0ZS^-\:]?ZS+1UXEZ2[5K@"'. RH1RX6Q.W&
M 3T,_SP%?_OAN'KSW#TY?3Z+IWJ^O?O_U
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MIL1S1I@4 ,O2#HO[P]%,JXOWW---$9E14<]>JB/1J)J'8%*$><%NG1,WX+S7F&9&A46PB0F*IHM4$;#)8TR&?#LJ=37(3BJ<5", \^7(:J\QY";
M5) D)X=5C02,@O$#O:E5,I&3;W@/[=*>3L(T.(:9SP^HI+-Z9?W+SYUX_+GY
MZ[EJQQ>;DZT/&Y<[OW+C&WVH7 R*@]]E!1P(>*+,$UB4?")2LU).76>^I[(RQ>L/%8/WZGV
M1+<38L$NAMZE]HP-QJ>.BQ*F:2X$)P=WSI+D#?3X0D[')7H-&\
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M&:1QO_*@&UR+E.#(0!%C&.A?A)3V1*!,%@-Q&+^D&Y/N%N8 T68&8%53)S">@Z2M1Z(5FAU
MP2/J[0%V_&X;KG]/P77CZ^3+9I41] I3'
M1-5Q=8_U_LKA2[*AUA%G*E8ZD4;#P',O\AYFQI?X%TJ?/-MFWK#?2L42$,568DFB#,FE)@[M&*P-5
M:S5%.GFYJ=KH3'[.)*D+.2$Z8#+
MTS.PHYDZDYMSNG1JG"KU4>:BBS%FO1N[4Z5
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M31)]X2P6C#\$['UZ2%:%9!3R8DXU'A6T0
MH'VH%3SHE[KL<-\F\GTHXTRQ(4&V0&F2Y'.))PQ>70/?5@F,NE%7-Z1+T3OM
MIZ%\:R>LRH:9%7TS_6/"F\D'BSE3.;<%)J4]L<<<;I4:7
M&LSV?K=,7(.P)8=$+'"PUNM\LV@0.[LN?CS^,?VIWSQXKSX<_3H]V=O>*=KU
M(=V>J/;T[/2G^;Y_/OFS^^M"M.SPS5ZM
MPX4NNX;,M @-98:T2%_7IKSH&G )HCD^&"EKLQ&C15^6YO+7T'^]T_0^\CT?
MAG_^YD'6=Q0V.TV(XBH^E>:GH]V=X2#Y<.!?[A6_7&XE\3#Y=8E"?JFGLZ_H8]HAJ_'^BRQ;N!VV0T7#B?WRT7>V&K#G_K]03<8JT%_4XT'?F=S>] )_,X8?K6S
MK=H+N^-'Z%IU?".
M51QG\^C"CT,?=6I",AQT6[S"C.\F2 ?
ML ,/6A@TJ@]E$^ K30S2\#BVA5BE=%] P,?^2,PJAM$EA'].
MR*)&IRZ>"C8AN-/]O>*T:^W8LE?E;U^ SJ:_-1[V_,%PH[T]Z(\VQX.=X?;V
M(.CVQVV_/1QU:Y+Q>Z\Q9G)LZY,&&SO=?G_UMZ#7\FAJGC.W58%PU,;JV5L^
M0H@V!PS/*1HB6X4+VWS@V@X@/\>1TCE5 7&ID_8<![\H;=>!
M,U^"0; L7C&3ONT5K?(>XVMK8=%HS
M\8K: $6IIFB[/1X'F^V=P4[;[PWZJ-WL##=W!OU M?NC[78'3-4%@NZ_@2%/
M_+'*YS:^",R]O]U[",R]W_)P@A[/T F!KHJXWR*-F/+'!U5D]#@#'-OK ,
M'@ZV^UL[W>[7Y;!++V(-8\-I,<\]/'2D"K+BC3<$(P@FL(W9QB3SAJ#$M&*+_K
M9*34DS%63S)+GLU0U+U-_)H92N>]U1OU!,;>#
M];LE'4$=A.EL/H4=,9GB;W\[D1R!EN;
MTG4Z\%'28344>G='0Z&[('Q78*LW4/&TG]WBSS86 8-QDLX^_'%RX.V21P%K
MED"5#SFCM78B:%/ZU#191J\@$S/ Y]W'^&Y!IC\)(@_LUCN%^7XK:](+,X [
M,YKH,]XP6XC_*5O>W9XWL1-/:>)4S[\4?U5 A.*"SCM(%/<* *$:Z=B0 U+L
M?'RQJ_4DH;_KP1 ^C%OOHN/11 Z&:7+.:=:"&IY9[-PXP0S-E;&F2I?L;Z??
MO,U3@QQ@Z]?UU7-V%=#,TZ&YZZ&T^!P!0IAVIKW) M$_NZY_3R.(S_.
M5M1;M!+Z1@01F3B5>86(Z**F;N,37D"I(0DF.1-04 G]=NA4X^+98N*_UL\.
M&_(O"[S1-8T+=AG]]YUI[_H*YB=/M9N_K.B(;Z1-K_+5]B*^PQHJ(V=S?%X9VNPV4:G5[??'FSO=(:#47^DQNW.
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MN.<7%%T&&^DM' LO\)V1NJ]DV-Z4C3W9;G9M_?]$ %QMTY*TRN
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MFF7$ZY2>4&D".U-=]H724P7UX*49B@$.LGD,[^8"[VY?$^Z0Z#U!=-.TYQ3B> ,H)Z)F4$V61(N"6"
MU4J=9,21C1,25956DB>?L)@>D^NQ/;U4[GF[Q\??[_[G7SO]S1?VS(Z/]1DT
MO-POOI]-D@S^KXD_F*?@WZ6CQ8]LO&B>S.,"^"$L23_(?SCYXZUY7 ]N>@MF
MCGY*K4U)7[&3=ZFOY?T$U$T $-'2Y1&-D N-3\+_1*5]U,P&U22'0NI28\N9
MJT.57V*?"4KA"!$""L9,,>E"11$EIZM8*UON>U0]/H4Y3;'Q8D.2;N$!)B'XWUO!K,UE@<&5.I>G88"7I.:4EJ'%$&K(U?"XE'H<\(#D13_<"HM
M?18/11\7V B1/YT*MZ&O.]L!E]H7UZ7]EBZ)U+?LG/+&5NK+]KR#SX38'GBJJ-5.HRE<#^@RZ*'7&1
M^4IO* ;<#O%,QU$1DGUJB*L$ZP#&(_%:\U=G:GHBUJ0VA^PT)L8L*G1 Z&2!Q("U[W%5K%Q(<#&*&%@UP^
ML]+J%]O3>%R20'@*N_O?P_TZ1=+N7 VJ!)MM88H-
MHY,"6&1S",P!>!DUKALF32GP0GXE9]*M
MIS3CA8??'^^_.VF!5:SI@5*LE:XSJ*Z'$@.S8D@IX(&%NY0ZJ?PJQ5@,?JZO9X<0=T7:?N+LP(.LMON=KVGN F:B.5M>/P$
M/V 5,,%XJ3[0J/D^!3@#-6:H%-T^&6CAIT1-8N\__G3VPOO#GV# F)!:$+,"
M_0D]VLFC5Z\HAY.(7]K"873]$N.4!;;EP@";/V^9)SEL08R%L8(R9"M$-].$
MVLG'P?=)2JVO^1?9?#K+DRD,,4)4>RW6I]@YF,\Y2#)IYTRWU9*,+\T1&8TV
M3\!^-\J"X45TAX&K4ELPH'4A+SA!)FINL,=]/@E+"+DA.T&HK30E>BXYV^[W
MSNF"] H8@L/[D!<'KS9N3 X3M
M07@*V>].GW:CVV]13D65N-A.6)B$A^ 1H.H@;$T840TJE66$4_$>?97V1ZN7
M^+5;5(K@^=6=0*TRIZLSA2].N%.HZY36S>.I02EENG)R"*2"Y?9DT:7$\&L[#A,C!/-,C5=:M2US=-=!]D[NG 03K>!Y2
MMMV'!5PI;JZG+K!O"O8-U+U7'8;!^\F7F#>.9!;/U&#Y]'GS3<)XJJ22@UA-
M,J,M,).BEH/^:,[; -_YN<#,$H8#<@>DOXM8%AHU7DX1&+'ZW3_7=8UR:Z,T',_)Y8AKV(+%(P/+UEL2:GR21@T
M X7)^51.BYHQJ 1BY*,23G!XL,)+E$L?N$<*!S)T65B%DIA8'='.;711#6PF
MXR8?E=9@@X+B/9A%U/+V^0?N3L8/,.4B@SX47
M>*QFLCDJ3M\D0_U0B3DMDWF7+G.\ 2/!VW,X
M*6+N"L0\J,1Z>-0Z)F-\#E:9K[M[6OWO=.HNGS?VLXF^^;B0Y7>1Y(E8)YST
M1-VK1'A\DQ1]9 FOT]9GYB*SH]59XCJXQ8;KS)A6K.5LV1?V?BV1DND2@.Y4
MK/GCDEXNJB6+%ET#.BC8,E C.JB-@W.14L1.#'K=957Z?9=*\N22^@"P,1J)
M2P./B(TUV]S76N9O]WXUHY1IBF^ >
M&0<%*\I4Q92S6C'N=\GAIC$OL3&.$,&+TW5(-H29@K6L]#3DN8JM
MSUNG]TH_&X[)$](T4V>-"GZC/JE1D:.M)=AZ66%:-SL9E# OH"*AN$8I5"!N
M8#Q";)ZN)[*Y9.+:H.-2ND=>2K7=7D>YUU'N?WB4>Z4"WQ@#:ID,1Z&&84XM
MGPKCX!2J%6F[W"
M0 S'<-JC=)[EW%YU6K:0ODDML>KTEV)TDLIQ9-'UG6B[SZ?(Q,1^N7U1["N]
MN"3T3*U7R7&+DK$F&FB:[0"E8F54F$UM3];2)U-"K':CH#I>2";5//9GJ-@(
MS@KH:R_G8DV0.D1!=1T X6C,68+@KIGU1TQ!CP&-E?P+7 ";F5SJ(FWN)
ML$&MW7-,?:#T!@Q"F!P%Y&T<#M#>EB"AM,;$UEM)25]E$RUH1$W* GIQL2DN
M)EJZA"B7C9,Y*>QIU6?:1FW.[+^QB334'J%D9RR,B+Y8:9&A0\(EJBN1(5*>
M3HA ZSW3]]E1L:=)EI,O\L(GC):%E(L6^4TP%DWVW1@50-Y RSHTOZ&/2:G0
M\C0;[=W#\)P$4,CI"@NB'L(JHA!?ECM..2NF :"#JQ&K'+&-,&<&"DL$RRR$?U%S2SQP]$5TX++>P(J9\_1
MW;G0[X1" =]U>OW6-J8H1/2!4AR.AM1C+:]'-M%6_2:1B[S>D9YPX9NX7$
MIG!W*<<3=BRL--.;?F4K'/%GBB
M_IH_FI"X(2C7D I^S.&'TGQX3&'.:$7QQ"L0Y$S]G:U2_!H5 -I5Y1:=7EVR
M>KJL6BI#S%*NPA-*X(3Q6$D2(4-RF!JL<@FBFQSH%HF)%X] >24+YWBKI=VP]/A;
M$13EOE6"*-EQPLQX\21#LX)=H?O:ENM ,U+;+(RA=#+383;\)W%&4%18KP%F
M-7:>#T 5Q'O5Q%9MPIGWZ)D#BA&ABG%$.*AI@]JY9>:5S(%;P+9PV-Z1VJ".
MK,Y@^YK!B$27P+^I2_@5VY 50\S<%C4#HV5RK?%K.M^.AK&5E>]!9R:,*18D
M*$0GR@\$:IE15YU7:A%D'QIW?@2U(G_FM\9O2B,2Q\K67PZT]]MEE"O1SCN^>>T1:R&Z? AJI* !.Z_R
M0XM\\@YNTU5,UM!553VT-IPE,BMF< W?X\Y_3T?U6(/3G75P>AV^=%-MK2EPA)?KSJ2[1=#LZ4VD?N@6,MIND9V H?*YD6NZ]
M.W(R+38AWR\R'49+E;*RID!8LEYKJJHR90(V\T;F-19<*#HOQ1"E2-DL5
M0T^BK2@]089S_1VN=Z<0"R(?7G+ANC*]Z\-,&ZJ82+Y7HR]:JT6#,BT:( (V
MX69E&Q^502.5;A]++2D]#G5=J0X0ZAS6*I:%\P$.$J )3<[G"1"]NL)R,^OB
MND/VA''Z>JA,T2+,ON1NLU= !&">DP/6C@72-
MTAY?LQ JO^!*1"3R.6OOJ]+;JKI\EC88H0%&Y<&-F3*:6[+;!J:%77AP)&%>"7+
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M@SX"W&6U\0YW8GYY8MJ,^Y&B';O+HQU6/-(')S71G2?$(G'FI)
M9 APF:N#(02,MX4U0N[YAC='Z3!?0Z/C-W2O RKZJEFUSD,3'>)L^?Y8K14+
MY06=EK(C%.,_1]ALD953[O:F]=72RK$?7%[C)L+=Q5M,C4#\3R;KB>=>^E8&
M3(36EFK9HZ=MR@T=BZM&Y;C)*J4TTJ;*5!F/+4Y?*A*M-%^\TE?(IH=RBP]C
MJN$^]3^MZKJ68\N>#2N[!<&(B4"9:V,5T+%B1I:-BE.2JRFD/7IM+O;(3].Y
M%/?2.-]M]%L=G7NETP*EJ-+VK,!0Y7A,^-%6G"_Q
M&W/(E Y4,TLZO\W6YEV=GZUR7MA\MD>V[P_S'U=+J@1,<80);WEE\17M'Z%;
M8&AF01FC0?H!)OD0:Q*PZT/="/H=:R#>B3C.GN)?-;S)NY,22%A]1U+$WV"4
M[PCLBKP$HD=@CZ1FZQ0O3H=$;LOYQ";?%6QP$&V3<,99VXK5<]?U1AU^3"\@
M5,A]#[N,JB95+IL"93@TZA ,KV\ *?J9P73B_E@G7+:7>;WM+JVKM]W3LUC8
ME[TD4-*MB '(RTDMM&1.M35IAR3!;J+J#B"S^FA@O4(H=B[\J"#\3B FUM-GNF]6^2#XA%K>B35C
M[1\?<=EW=QU97T?6'V-D_:LK?@^7/Y>EN8F/O7X#_+2L0]ML4:!L [;W=Y7RD9>J@$=
M&77>FJ%.()7$Y%/YTS/V;Q/%$5" !E;1*>C/'UNSIEND,/#,<"(BGY![C9@]
MEEB>7^1)F=_1;TH\:I%%6=F]+8D^J9Z7C->1+ :3$%#)->#ERTYK_=
M/:ND#SCJY&$LV?9E"1Z]5K>S/H@'WT2#^ D
MUKSI@1S$FC<]D(, WM1='\0#.(ANJ]U;'\2#.(@U:WH0![%6F^[X)"@#O%P4
M\+=,ZOM;]?8M5OU5%<0'O>11$N$O__=DX\F7+K_]51>_?55L1089E@99]"AZ
M!^10_._WP[LX[^ND[OV>]\*2[X7FKQ-X_X0]N%;6/*)-6+/Y-9N_GLV+\U_'
M$&:?/-!LPL#3\>D'+ 86$$+X'VN1L!8)=R\25GA/UB+CGR0RMJLK9JZV^-]Z
M8=#]4F'0Z;5Z6X]:'F ^P1TQ_V_YE/N/_9![:PF_EO#?E(3_NY=BCW+(B=+W*73-NREM-+OUQK"0Y =]V)4;G^IA.EOM/I?7W;^G=OR-(Q9
MMN:3I,C\.,B>U5Z=6Q*YBVPZ&BE51C:]!R*X:LV+Z8[/[U156OGB5WSI68X^
MX%U8K6B]_WVYCD$\M)UZ\-=HE?KI>EMJTW76VU)KT:VW97V)'HUPHBJ(M7<7
MOVDJ*@F;=F-KIW/7*MN:B!\Q$:^8%=^4FG7.W&5Z;3J/)D[%G>;CAO--J]._29K]V-_Z1E/WPQ
M<1OG9:_?^2:6O?%$65J^[=A.N"?X?DW6X
MN;F]]@&NZ?UQ,O@;^_AZO6\R.Y']>=P_E#H68W/2M:]B;8[]4\VQY4[^QO9&
M;Y$%K&_(^H9\T]Z\+U$)FVN_WOJ:K 7)K03)(_/M,:P5M87T0]UB-AE[EWZ:
M^O$=ZI#_..K^9]N"#S@?Y(N<@8W-[N;:';B^$M]DUN#-91X(O=[6'5I/:S_A
M/VG9WZ9LZ&PT^IN];\&IN#0QL.'%ZNY 8=:VS]H*_ <6E'4;G?:=0].L*6A]
MEQYWG?-ME,_.YLZ=*Y]KNEG?H'^@-.KT&MVMQ4+(A^Z^?'%-8(?!6^>;WX.8'
M23&,U&.]^MU^8V/[SA%WUI?D'WM)%KR;C_^.;&PVNNT[A])Y2'=D3>7?F"BX
M>0YDI['9V5@2NOX^]V$]7Q^=_(;D=S?3X!_Q0\_#''9OM(CR78F0=[J&7Y1
MLO[VR#^P"]'J?(S%7C#N?==9[NU
M[<&LHC")O7&2>OE$>7-L\ZVHS;=N]>H!>7C8Y\\;)=.9G\*?\N2ZAWLM[Q2>
MT"-ZEW[FS=(09@_;0"^G*BNB'%,+DB+UCB?X5,\[WJ?I\X_=[WO>[C[L8Q&$
M,/VAPDQ6?X08FUY0I/@3?FGJ?TQ2H!O\%@[=\"XG"H?E6>/KQ(?-4BJFM4N(_%SV
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MQS<$M>CRP7 1FVWY"M?[F\ZV_.!F6WYUZKI!VB>?J7?FPQ/PZ^]ZK63I.V!&627T)D069E=1&7[!60 J='Y6L%['1 )L::9&.3Z,=!2%/AL=S5$$
M=!:.0QAX#U2@T0@L.W,.6ASQK3FM""5>3JKP%7@]Y)6@2D<#TTH%@!-E7)E7
MLKD5A!?ZO_ ??>"C"+Z.INA$3LL8FGAJ8HBVV_^^!\NYVW=2A9EFMGO5N?\?
M=_(V9-(<)5&2/MOX3#6'($W.F_X8!G[N1Y?^/)-5;F^WNJ:)
M]G-C5N,^>!NM[>U_>_:?N!L+6SGU/S6=#1-;O!FI^2J>2)[/GW4YK\RL=2H5_]!S7E>]-4C7^WY-_G1[MU?D\F3'%
MH(;[48DQR:^>_'!*=PU?
MV%?^(Q@\HZ?XA/?_X*[AF\\J.UXZN([C5I$!^5=+/O]5C\5AZP&(,; 9A_,%
M91=L3S\ D99[$YBNPE;1R>@R]*,VJS/I>W4 7:%0^N'0&2W4$6"Y^
MXJ;,&97&W#4^EJ^"!$2"NH#>VSO7!6XF^5^'H $'Z) @ ]^?H?+@O5,93&ZT
M*IOR)*3=+\A?H&9XA7 ON^WV=@-= Q,?/2\*;'8XB"DH/9YDN
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M7!72,$EC1MW],O$R]A/"C5! V\0&O)F8\A@TB:WNG]E "/I1$'\I=TOE=D=,N7.R(SZED/WN[>D>^(B5=(Y& E&1Z
M&\OHIFKVVVDO=0M0? "U,W1'%%' YT-4FJDH:@AGAD6(6Y\T-E(ID@A=)ADH
M&DANPO3EY:'8MYE+?$"36L,K9OASM]6NTA;&#LR_Q.UNQ!8K>;#TJ=:0
M?+M48+\%B)R(?J\^S4)F\OH[$C8Y:?:$9\B?3[25"I.*00IE'HCM*(2IXSC
M!7'N0/#JT\0O,HQ_K(80;A+)?#^#!8&F/2KTRA=.Q!('$1+M7Z!U3^7U>HV=
MWI9S!&6M(9/SI!V7A\3K4#[WEG<(G ?L$IJ(/++X+IAN0#FDVOC#Y ((P\_T
MM*_TIFA%!<@Q6$)&5>*!XPT4*Q6++(_(&#B5 AH)%IE;I^](:B3"%-Y-44^R
M*]&61Y[0'3+#A9D[#%KV=8Y(S[O[(.]=\<>?_1A,!5;4?RY VZ0C$.O#.]"6
MWEJ &^:1?[\>1A'8:R:PPB.7J=E<86W;/0^&T2T(&->MAUOG-"0M;>L
M+Q#/7UNT ;+&[W9:[38&_)@>T&CP/5P7TR(PFSA##@1*)S,Q:P^S/&:WV5F*
MCK02Z6W9H)6F/!K>C[($IMLQTS6SLQ.#+^JS,RM$X5TS3+LT#,4DM>GNAJ=F
M_EP;JW9?;$35KLHHN%)R%AY9%?U&?OP'>&G,).FR[)Z^
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MMU'+#=ZC G.)1B@00,6F2[ZIFJ'+)L[9^R+WL- ?4VFV$(B"P+_C&AA/++^(P-Q=\#^-J\;SE'?@@6O!/3((C( 8T0@.ZS;$2
MP?R(HTW]=;1I'6U:1YL6N6^==)3%ZBJ@
M[_NDZQ.W,;+_NS[: .YG-'O7K[: C6K=H2+9C"MQ'6)B2"2\_=AFI=EU;91LFP99ON%T
MJ@+,20'K25XARL:AR?F"48L+5AJZ'K2< =2]4SKU7_H@B;:1UT.F&"8F.+/SD
MP9OY)!/CG3P9$9 \"R;WS!Z,$_\514JX7D,2XNK68QS
M ^4S/#_Z)_3/M%DB%I]FL-S^"C8A)Y  [^RFYA$6D%'U'H\!'
MAHDN.A^X1DHV(IWFI7*.:C12638N,&I"&T>?7=PNHCYX%UZ8Z%\VO'#L^1=^
M&"'G:YB/HL.33%!Z YDE6*EJ9J+\!UQ058_U[?6Z&>NKG$:#/U'UL
MD;",>3LDVV@&IJV0!DH./G"0%3.E#]5>-!!19%+#YZ*YM>I FQY%!9I^L@V6
MN+#>!_,[PBQ?U.S)EN4">FE$9,IDLXQQ).)HWI55[-*1R(?6G,W1!$+^*PICJ)]R;#9?W#!YBSC-49^BF-/D&-"-[
M[[W(+^(1GJ8/U "WA*:%5,53BTG9("U(EA [!!B$2)]%A!_F/'JXUDQBR 0B
ML#4<-468*^@217P>)Y>8,S/*DU3N$,>H_ !N=X8*AP_\9,1L>5AD/+D5N=9@
M"GQHQ.@Y+_>L
M%<%VT_I^K.^'O1\EIUKY3KCTAR8Q: R.[^5C 0P["#E[!_\N62RL$(#=>^[Y
M,V#D%T+V->K*4D6%;6"J.]79\H&^P/@M_#I=9CV 5L5+D_K/O[9W^FMJ7U.[
MHU^3-0AD/@XC,@^!?C)*#,4?T(<8!UI**'3@C+2NC#2(?N[(#\51A)F-N60W
MEI]/Q V5HX=QE!= H# .\&LIZ\$?TA"N EPR"ABNE>,UE3I4JLB1IS.$9HHS
MP-1H$B=1/ZR[$:P7Y$,>TIN&H-9EE9\:@Z=-APUHX$P1@V,WT6Z[-'QMINI
MK87YFKSKR3L.'(0M<@AC '?*J781KTN 0 TN9C,PO$83!,B@.%RF[;XDYHJ/),W]
M,Y6]\-:TO:;M*VG;N'_Q9TKC:8@.H%70P$T9'ODSCC'K(&8M7?.?2K:;=N:Z
MIJ 86E=1Z>-,']U8IX^NTT!)S4+*JXI'"
MX#=L"/ D0=10H&3GR-?#Z;!(,ZDGX234, V:,Q\]%#,X3='=S2OR;4X1%A:HG53,@G<_"4"WO%:>"8FBT44DSYW06/-#R3G PRL U42*B2Q?)*E-
MD?<$(-T]V17E^.YJW5!G^.)*<,I#9=/_]:SC4K(_5Z*G5#$612T/TX5MC@3L
MGB4 WB1]A2X1N0EOE@J$FW"1DT4U ]+TD=Z8DFQ*/&RQH*Z8T+(=A"JO5=G3
M34@XZHP YY:7)2Q<2JKTI7L>F'(#78%"^=T-J39HL*P1+!TO(R:6,\^')I8?&+"5)/6,R(+%<:R15KS(G1W:AVD!&TD8I@,#F8%-$M2E(HR/
MA$SVDLOBJ/Z"5DFS7RB7H2EDV%FIM*/NG)G#$-S7J''%?859
M19UV\Q<0Q#F6R$C=YKLP.\>*0$S&E]I-MO_L)4CAD47A1JMS:F/J).*#*1+<
MPP*V5XB+>&_0 Z=4[Q+!F!3H9<.DF"*(Y6?EP".48#\[GT9V#1*!W1/],2&?/V?%\"7MPK<_7
M,4G-H_X0%)TBOYN71A8NMS>7CG
MTNFVMOOK@WEX![-F9 _S7-:,[&&>"S*R[OI@OMK!W+)A_'7Z\_("]
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M2?2^B$ET-QN;.]V[EG/K"_2/OT#U9M>JEW_W%ZBSU>CU^W$\#Q?]Z1K5*RQH.K?7BO\,<2E>A!UY[&M9_J(Q7 9LQFN;C
M4_\C(K3/I>UA#^N&%QC\P&LPH7Y
MXGY0=;DW\;$9FHK=TEU$[)#^B+1,NQ,I=U]-8MH*7:ANAI8Y\ZQ*""!<#E]M
M!DF;.2S2F ZAB6GU3?Q7RUMU&[NZ8ZY4VR8>-N_S_#-&FK D0IW._:Q$>DRV
M 8.,^+$,0Y^W+Y8W1UK>5E $U@@V6UM&[CN"]6HE0S"12H+=SQEZ5P-[E'N8Z\[>"_W5"6Y*
M=_.F5J,:' ,!9DI02_)Y=2ED77GXIPZ6ZW>+<^IMZIS*G\1MUR0G^SR2%[;@WB0AU?#IYVS6\:8E_$-
ML"3&X^9+/Z+=/9D@7MJN@^5S]V;/+?NPAX%MQ,XX=N/F4*:;T71+T$,.#2*F
M6A+@T:D,-8S @,A)NF7P=""!20"VN99#,4D=+=R0B6FQ'3&/'^Y&#O
MSO%S;HB6@WASJ.EC?^PB)O7T.(D0DI9G^SZCNW20Y2'"&*U((MS$>_!!FGI+
MI\L"H9QBGT\$;?/.UHN,V@\66::!Q."!:)Z%TE*H'FS,Z3OK6(4+"&6V:;?F
M6SP;M,!@EFPO4&=JO/Y$.(Q?:3<>F!Q\:X:$%.&"%8(@(CH>DJ?L@!>,3P5F[R(+@7C
M^E.<+0U,2'J9-+>W4/6$ #GA3H]@Z2 N(3%C6B,U@%_R7F[;HLN]J&^);IEM
M:68":4=XQ'"6W+,=*"=DU#%UX4<$CD?S2N/!"!:1LJ%ZD-6[VKE.G5Q3=-%:-:PJ1:
MWB$H,XI1 $DMX(-TCE0$MQV.-![R$-CD!:T_C&<%
M:@9'U5_)\/1/NJ)\DAXB?U.C/:0BQO8KV/.  ^@+P-"7!"JH0?),6V#Y$)"(
M#S/!DX7?LTH5UX8.''2:5C5=%2$S1>H/B#CE<@=F_ISOO?W"RP@,^>;):)(@JTQF-)!>Z#0)%$&ZRO7B
MO_IP-"#BF3$;UN>6F1H_M8J7]!PC.8*0@=JW%W1D6C^[F5Q-F\9+[OAQ2-26%AX
M:[6JYB2,6"PX;M"2$#?:$Q  ]78=%[PLTCSXL-_"Y?>ZY&E$Q$H@,"2:>G$W
MFX&-1+R:6:!"7G$M]B,QGJ&*J,L L8J\A%*X;,8CK1 *0C39,QG)>U 1J'.-
MLVXC#)GZ#?F)KE+11I8I3"O2?:\Q@9[\\ ZNEY^..$]AWY$;!XZ<\?:T9#E%
M D9%.H4SN5^#""8+MQ6E@&9*SKGQ*1B^4D=DS.50@D:9HA $'^'U)+:  2LT
MX(H%1^\QO8I\+X+98V_EE+DG?6]N^X1O90&*@BFE^<(L8 9$+=9
M;F17P>1MN"8:=DZB<$E(DHD5 "W\#9XZSR=)S_PX_*P!LE'=Q:[H3JUJLS"?"0\
MY;"B<<>EX!(Y<>@?&!">/'*ODD+EJ]MI>G_I:
M^=!-=12V#8;O2Q-"]_K+D=#VC2,=\;O2:B4^' ;F9\E;%$5(#8X*"[.+.ODR%YXD^02OI@V\# * G9FET?-CKAT
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MNU:CN;/9*XKH_\U]--0Q7H#CU3E4\2CF8AX8_2<,CG>G*P9\+:($+'8U>F
MOBPB=$J@I[GE==I;DE@\G-=,$_N 1%(>@>-?2&OB>P
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M\==%41LEG9@=Y_*XL0TDD]+QRLG'L3*#9-Y4>C:SX:N"IA8 9ZYO>8SMC.D_1*[[638;0::_MT07>_=J)U2H)_ R6N!21F?>^BR:8)
M/%,VZD3EX_+KJ](.ZF;J6!O87!6N.C=#=!('XFIS7JNADU9*35--^1*/QM;K
M!$X=5?;4 YV3/-9^K'O1Z]HZ*+7:'UN[V?D\;%NL/?&VX:2K(FV@_967J&.U,[W
M1#'MOC-G_I0]>-WM]K/GWN$4C2[;"Y8?(V:BW]PW2:3(OL,;[)&S$+T LZ"$
M"9PS&G2V9SDE;%8,83E68T=W%L\![P^&)\5',TR*7!QGJ9UWQO/.Q#(K)R%<& RGV3ES4^"ET^+480]Y5:1J)D 1V=E,"E:=5-Q2%W.XL,Z0
MI2(4]$2J3R$;??JC@7,:.K\CQAH6WI/JM]'A2SY.<^AW2$HWHP;DV<#?378A
M_%N92X0ZW;*F1X\G+KF]CDNNXY+KN.27%(W4LHPQ,#D0#VSH#15\G+1IN@[6
MA.ML<)&:N)PQ"CDU;AQQ\]SJ2_V61RV^*36TTZEVYG99[]0/E)O=3H%2E/%4
MO&D9^E?(E+VUAK5JO:HZJ\/8[CQ;ZA3'1$DE@3[<0/2:\B;N7!=I/(PQ@NV=
M^I^P)%\"E/TZ]<8^Z:HUE2"D/KP=K;1H#27DKU$&$GXFA\^X1#&<96V=93LD^-O\1Z?4,&#S2(+SOG\$/9\:&=E4<7;F&ZF%9TK-KZ&GWF3,9
M5%(PN\GY)B=R?2S2,,,"#LH4/,Q9LY$T3; AV8@1AK*J&
M&I71Q8PJ,BOIZ*S0Q;J8 .=*:KQ88VY$"F,0:$F)8\:4+5YE71JKF0R$"3 /
MM/LJ@G8#T@-\H)^3(?&
M]\O7V;6=GIX4PYRU\&Z[2>QI?^'R+\S#Y+EK_G0SI=O9E"_=$LW];C;@=59<
M X,";U0$=BHV'L@8L&L*C"&PWS1%]I1V&>E8L
M7R6>&S9FUEMW+],81*
M!+[OA<'_G@QZ&T%[8Z.W.=@<[_B#?J^_/=CQM]J#S;[J;XW]CK^SV7G"AC"_
M<0A,86OWUP)+E7,R+&%>\&,D/VFY)R_=.WO ^0G][[8\=Y[$QIR9ED3T+HF0
M-QRFP$CZBM0BW5-_O; YVU% -^MV-
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MVR0NG]R&VNJJTD&W,VJW-WK;BR>WBV[3-(F0
M6QQC76& +'70V^IL=/H/X,Q #N@9,DBHF>.*PI\'I9I&2P;+IGEO0="C$FY/
MPZ9E&8@+-RMW;Q*J,9BIH%"2/#W"5$\L9$,/AP9Q">K]1_B^$Q@;N0N?F85[
M3WU$1L'43\QK#$O 3N\(U*G3\YN=C4-ZL;,1P+^?JF=.Q=W!)TF& &67(#FU
M1JT+^4V.S0BS<=AK=DWM=0L4!;U)-IW':/OS99.EP5<><8AV9QVB78=H
MUR':137$952WX5$(?C M..F5LAB3Z;2(*003:%0=5XLH@[ NU1J0Q5-JOH1S
M&8\/)+"UI 1+0JO3B7X5?398)T-L$/, @?]E4IMUYJ\)=J?$_'SUR=;[Q,YVMY1YJH;C0B
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M#5'#,G/R5EREKB#$L5>D% F^SB+,L:*66R3= ;--P,!^/^YFC0W_2' ]\?]@9^
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M#\.PFX]WX7[:/_S8.QNVU7FS\_+]4=S[^9?-[;-!;_&;O[]\/T@NWQYM
MOU?!CQ\=^G9&[#PJ^]46O3.+;LL\U:/*USJ\AJ5M)*>PBDA=T2VSV^KTKVH1ZCB3
MG"%1V(V!B^I=TC]31OUS]DMB0LZU+D'S=W^8)5&1JQ?H'=R U5*&$:\*=G7]D_50_I10_.;MSUT?517]WI\[HCZO1:O>[ZB![T$?5;OUL;T^CX=P'DOOR_J([NF(J*TU_=_?5.)JJB+*[<$[
M+6S%#=L9!J8_N#S! <+9I_J_2K!PV9_Q9!;_>(^=Q\O!=TDJPSQF#&^Z6_%O V^YB;SOKC2UO[''DWX9H78FX
MWLC2_==5OMY;@[/J /)Q!A?,.+@+,EX?0#TE8XEF*,'[,LNXN6ZQ6D5BQ9OX
M=_RA:A0,#@W(\^ZG,!OX\44V>(-HPV\P 6(TFH1Q^(9B$8/3]D:O_V;PZ^[[
M#^W1[MO1UN?1+[^7W*?L,X5/H@;#'M.W?IH.!D?#']\>[*7C=O?X].7EP?3'
M\>7G2XRO8Q#=&>F_WY>6\T.#8S4/@BY4HW2LF"B=J_9@5OH=QM5XAF#KJ=$4<\L7"MM\#C=HXH/:R
MV:!]' ZCU_'@EX.F?_#FM#/8>]?K_OJD="-WL\'1^&_
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�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end XML 87 anvs-20241231x10k_htm.xml IDEA: XBRL DOCUMENT 0001477845 anvs:WarrantsClassifiedAsLiabilitiesMember 2024-06-30 0001477845 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputSharePriceMember 2024-12-31 0001477845 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2024-12-31 0001477845 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2024-12-31 0001477845 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2024-12-31 0001477845 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExercisePriceMember 2024-12-31 0001477845 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputSharePriceMember 2023-12-31 0001477845 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-12-31 0001477845 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputPriceVolatilityMember 2023-12-31 0001477845 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExpectedTermMember 2023-12-31 0001477845 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputExercisePriceMember 2023-12-31 0001477845 us-gaap:FairValueInputsLevel3Member us-gaap:MeasurementInputConversionPriceMember 2023-12-31 0001477845 us-gaap:FairValueInputsLevel3Member anvs:MeasurementInputSuccessRateMember 2023-12-31 0001477845 us-gaap:ResearchMember 2024-12-31 0001477845 anvs:CommonStockPurchaseAgreementMember 2024-01-01 2024-12-31 0001477845 us-gaap:RetainedEarningsMember 2024-12-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0001477845 us-gaap:RetainedEarningsMember 2023-12-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2023-12-31 0001477845 us-gaap:RetainedEarningsMember 2022-12-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001477845 us-gaap:CommonStockMember 2024-12-31 0001477845 us-gaap:CommonStockMember 2023-12-31 0001477845 us-gaap:CommonStockMember 2022-12-31 0001477845 srt:DirectorMember anvs:ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember 2024-01-01 2024-12-31 0001477845 srt:DirectorMember 2024-01-01 2024-12-31 0001477845 anvs:ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember 2024-01-01 2024-12-31 0001477845 anvs:PerformanceBasedVestingConditionsMember 2024-01-01 2024-12-31 0001477845 anvs:ShareBasedPaymentArrangementVestingPeriodImmediateVestingMember 2023-01-01 2023-12-31 0001477845 us-gaap:EmployeeStockOptionMember anvs:EquityIncentivePlan2018Member 2024-12-31 0001477845 anvs:EquityIncentivePlan2019Member 2024-12-31 0001477845 anvs:EquityIncentivePlan2019Member 2024-06-12 0001477845 anvs:EquityIncentivePlan2019Member 2021-06-01 0001477845 srt:WeightedAverageMember us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0001477845 srt:WeightedAverageMember us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001477845 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0001477845 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001477845 us-gaap:EmployeeStockOptionMember anvs:EquityIncentivePlan2019Member 2024-01-01 2024-12-31 0001477845 anvs:ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember 2024-01-01 2024-12-31 0001477845 anvs:ShareBasedPaymentArrangementVestingPeriodEqualQuarterlyInstallmentsOverTwoYearsMember 2023-01-01 2023-12-31 0001477845 us-gaap:ResearchAndDevelopmentExpenseMember 2024-01-01 2024-12-31 0001477845 us-gaap:GeneralAndAdministrativeExpenseMember 2024-01-01 2024-12-31 0001477845 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-12-31 0001477845 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-12-31 0001477845 anvs:November2023PrivatePlacementMember 2023-11-27 0001477845 anvs:April2023PrivatePlacementMember 2023-04-07 0001477845 anvs:March2023AtMarketEquityOfferingMember 2023-04-04 0001477845 us-gaap:SubsequentEventMember anvs:December2024AtMarketEquityOfferingMember 2025-01-01 2025-02-01 0001477845 anvs:CommonStockPurchaseAgreementCommitmentSharesMember 2024-01-01 2024-12-31 0001477845 anvs:November2023EquityOfferingAndWarrantIssuanceMember 2023-10-31 2023-10-31 0001477845 us-gaap:DomesticCountryMember anvs:GeneratedIn2017AndPriorMember 2024-12-31 0001477845 us-gaap:StateAndLocalJurisdictionMember 2024-12-31 0001477845 us-gaap:DomesticCountryMember 2024-12-31 0001477845 us-gaap:RetainedEarningsMember 2024-01-01 2024-12-31 0001477845 us-gaap:RetainedEarningsMember 2023-01-01 2023-12-31 0001477845 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001477845 anvs:ServiceBasedOptionsMember 2024-12-31 0001477845 anvs:ServiceBasedOptionsMember 2024-01-01 2024-12-31 0001477845 anvs:CommonStockPurchaseAgreementMember 2024-12-31 0001477845 anvs:CommonStockPurchaseAgreementMember 2024-09-30 0001477845 anvs:CommonStockPurchaseAgreementMember 2024-06-30 0001477845 us-gaap:FairValueInputsLevel3Member 2024-12-31 0001477845 us-gaap:FairValueInputsLevel3Member 2023-12-31 0001477845 anvs:WarrantsClassifiedAsEquityMember 2023-12-31 0001477845 anvs:WarrantsClassifiedAsEquityMember 2024-12-31 0001477845 anvs:November2023EquityOfferingAndWarrantIssuanceMember 2023-10-31 0001477845 2022-12-31 0001477845 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-12-31 0001477845 us-gaap:FairValueInputsLevel1Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0001477845 us-gaap:WarrantMember 2024-01-01 2024-12-31 0001477845 us-gaap:EmployeeStockOptionMember 2024-01-01 2024-12-31 0001477845 us-gaap:WarrantMember 2023-01-01 2023-12-31 0001477845 us-gaap:EmployeeStockOptionMember 2023-01-01 2023-12-31 0001477845 anvs:MarkWhiteMember 2024-12-31 0001477845 anvs:MariaMaccecchiniMember 2024-12-31 0001477845 anvs:ClaudineBruckMember 2024-12-31 0001477845 anvs:MarkWhiteMember 2024-10-01 2024-12-31 0001477845 anvs:MariaMaccecchiniMember 2024-10-01 2024-12-31 0001477845 anvs:ClaudineBruckMember 2024-10-01 2024-12-31 0001477845 2024-10-01 2024-12-31 0001477845 2024-06-30 0001477845 2025-03-18 0001477845 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2024-12-31 0001477845 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2024-12-31 0001477845 anvs:WarrantsClassifiedAsLiabilitiesMember 2024-12-31 0001477845 us-gaap:FairValueInputsLevel3Member us-gaap:EstimateOfFairValueFairValueDisclosureMember 2023-12-31 0001477845 us-gaap:CarryingReportedAmountFairValueDisclosureMember 2023-12-31 0001477845 anvs:WarrantsClassifiedAsLiabilitiesMember 2023-12-31 0001477845 anvs:WarrantsClassifiedAsLiabilitiesMember 2023-10-31 2023-10-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-12-31 0001477845 us-gaap:CommonStockMember 2023-01-01 2023-12-31 0001477845 us-gaap:SubsequentEventMember 2025-02-03 2025-02-03 0001477845 us-gaap:ForeignCountryMember 2024-01-01 2024-12-31 0001477845 us-gaap:DomesticCountryMember 2024-01-01 2024-12-31 0001477845 anvs:WarrantsClassifiedAsEquityMember 2020-01-31 0001477845 us-gaap:SubsequentEventMember anvs:SecondaryOfferingMember 2025-02-03 0001477845 us-gaap:PrivatePlacementMember 2024-03-15 2024-03-21 0001477845 anvs:CommonStockPurchaseAgreementMember 2024-04-25 2024-04-25 0001477845 srt:ChiefExecutiveOfficerMember 2024-12-31 0001477845 us-gaap:SubsequentEventMember anvs:SecondaryOfferingMember 2025-02-03 2025-02-03 0001477845 anvs:December2024AtMarketEquityOfferingMember 2024-01-01 2024-12-31 0001477845 anvs:November2023PrivatePlacementMember 2023-11-27 2023-11-27 0001477845 anvs:April2023PrivatePlacementMember 2023-04-07 2023-04-07 0001477845 anvs:March2023AtMarketEquityOfferingMember 2023-03-31 2023-04-04 0001477845 anvs:SingleReportableSegmentMember 2024-01-01 2024-12-31 0001477845 anvs:SingleReportableSegmentMember 2023-01-01 2023-12-31 0001477845 anvs:CommonStockPurchaseAgreementMember 2024-10-01 2024-12-31 0001477845 anvs:CommonStockPurchaseAgreementMember 2024-07-01 2024-09-30 0001477845 anvs:CommonStockPurchaseAgreementMember 2024-04-26 2024-06-30 0001477845 us-gaap:CommonStockMember 2024-01-01 2024-12-31 0001477845 us-gaap:AdditionalPaidInCapitalMember 2024-01-01 2024-12-31 0001477845 anvs:WarrantsClassifiedAsLiabilitiesMember 2024-01-01 2024-12-31 0001477845 anvs:WarrantsClassifiedAsLiabilitiesMember 2023-11-01 2023-12-31 0001477845 anvs:CommonStockPurchaseAgreementCommitmentSharesMember 2024-12-31 0001477845 srt:MinimumMember anvs:CommonStockPurchaseAgreementFixedPurchaseMember 2024-04-25 0001477845 anvs:CommonStockPurchaseAgreementCommitmentSharesMember 2024-04-25 0001477845 anvs:CommonStockPurchaseAgreementMember 2024-04-25 0001477845 anvs:CommonStockPurchaseAgreementFixedPurchaseMember 2024-04-25 2024-04-25 0001477845 anvs:CommonStockPurchaseAgreementVolumeWeightedAveragePricePurchaseMember 2024-04-25 2024-04-25 0001477845 anvs:CommonStockPurchaseAgreementAdditionalVolumeWeightedAveragePricePurchaseMember 2024-04-25 2024-04-25 0001477845 anvs:WarrantsClassifiedAsEquityMember 2024-01-01 2024-12-31 0001477845 anvs:WarrantsClassifiedAsEquityMember 2023-01-01 2023-12-31 0001477845 2024-01-01 2024-12-31 0001477845 2023-01-01 2023-12-31 0001477845 anvs:WarrantsClassifiedAsLiabilitiesMember 2023-10-31 0001477845 anvs:December2024AtMarketEquityOfferingMember 2024-12-11 0001477845 anvs:March2023AtMarketEquityOfferingMember 2023-03-31 0001477845 2024-12-31 0001477845 2023-12-31 iso4217:USD shares iso4217:USD shares pure anvs:lease anvs:Vote anvs:D anvs:segment 0001477845 2024 FY false true 0 0 0 0 10519933 14141521 0 http://fasb.org/us-gaap/2024#MonteCarloModelMember http://fasb.org/us-gaap/2024#BlackScholesMertonModelMember 0.0001 P5Y 10-K true 2024-12-31 --12-31 false 001-39202 ANNOVIS BIO, INC. DE 26-2540421 101 Lindenwood Drive, Suite 225 Malvern PA 19355 484 875-3192 Common Stock, par value $0.0001 per share ANVS NYSE No No Yes Yes Non-accelerated Filer true true true false false false 51312050 19486231 <p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-indent:0pt;margin:0pt;">Certain portions, as expressly described in this report, of the registrant’s proxy statement for the 2025 Annual Meeting of the Stockholders are incorporated by reference into Part III of this Annual Report on Form 10-K.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">Risk Management and Strategy</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has adopted processes designed to identify, assess and manage material risks from cybersecurity threats, which are integrated into the Company’s overall risk management systems and processes. Those processes include response to and an assessment of internal and external threats to the security, confidentiality, integrity and availability of our data and information systems, along with other material risks to our operations. The Company references the National Institute of Standards and Technology Cybersecurity Framework to help identify, assess, and manage cybersecurity risks and has adopted and tested a formal cybersecurity incident response plan. As part of our risk management process, the Company engages a third-party provider to conduct periodic maturity assessments. The Company stores data in cloud environments, with security appropriate to the data involved and has adopted controls around, among other things, access and acceptable use, backup and recovery and vendor risk assessment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our cybersecurity program is managed by the Annovis Incident Management Committee (the “AIMC”). The AIMC serves as the core team responsible for managing the enterprise-wide cybersecurity policy, maintenance and compliance across all platforms. The AIMC is responsible for the detection and initial assessment of potential cybersecurity threats and incidents. The AIMC classifies detected cyber incidents to allow prioritization, response and escalation. Incidents (if any) are documented for internal reporting processes and regularly shared with senior management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our third-party IT service provider is a key part of our cybersecurity program. We partner with a cybersecurity company and leverage their technology and expertise to better protect the Company. From time to time, we engage this vendor to monitor our environment, which includes an outsourced security operations center. We may also from time to time engage partners for periodic penetration testing and vulnerability assessments. We intend to continue to work to formalize our cybersecurity program, including developing processes for third-party service provider cyber-risk oversight and management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of a potential cybersecurity incident, the AIMC will conduct an assessment to determine the nature and scope of the incident and manages the incident in accordance with our incident response plan until the incident is contained and resolved. The AIMC will document findings and make them available to the Disclosure Committee, which includes cross functional senior management representation from, legal, finance, investor relations and business segments. The Disclosure Committee, in conjunction with third-party experts, including outside legal counsel, is responsible for assessing the materiality of any cybersecurity incident and coordinating external communications and disclosures, including with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, we are not aware of any cybersecurity threats that have materially affected or are reasonably likely to materially affect the Company's business strategy, results of operations, or financial condition, although we may be materially affected in the future by such risks or future material incidents. See “Risk Factors—Risks Related to Our Business Operations—Disruption, failure or cyber security breaches affecting or targeting computers and infrastructure used by us or our business partners may adversely impact our business and operations” for additional information regarding cybersecurity risks.</p> The Company has adopted processes designed to identify, assess and manage material risks from cybersecurity threats, which are integrated into the Company’s overall risk management systems and processes. Those processes include response to and an assessment of internal and external threats to the security, confidentiality, integrity and availability of our data and information systems, along with other material risks to our operations. true true <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our cybersecurity program is managed by the Annovis Incident Management Committee (the “AIMC”). The AIMC serves as the core team responsible for managing the enterprise-wide cybersecurity policy, maintenance and compliance across all platforms. The AIMC is responsible for the detection and initial assessment of potential cybersecurity threats and incidents. The AIMC classifies detected cyber incidents to allow prioritization, response and escalation. Incidents (if any) are documented for internal reporting processes and regularly shared with senior management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of a potential cybersecurity incident, the AIMC will conduct an assessment to determine the nature and scope of the incident and manages the incident in accordance with our incident response plan until the incident is contained and resolved. The AIMC will document findings and make them available to the Disclosure Committee, which includes cross functional senior management representation from, legal, finance, investor relations and business segments. The Disclosure Committee, in conjunction with third-party experts, including outside legal counsel, is responsible for assessing the materiality of any cybersecurity incident and coordinating external communications and disclosures, including with the Securities and Exchange Commission.</p> true Annovis Incident Management Committee Our third-party IT service provider is a key part of our cybersecurity program. We partner with a cybersecurity company and leverage their technology and expertise to better protect the Company. true false <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">Governance</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Roles and Responsibilities</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cybersecurity is an important part of our risk management processes and an area of focus for the Annovis management and Board of Directors. We continue to invest in cybersecurity and enhance our internal controls and processes, which are designed to help protect our systems and the information they contain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our Board is actively involved in the assessment, oversight and management of the material risks that could affect the Company. The Board has delegated to the Audit Committee the responsibility to oversee the integrity of the Company’s information technology and cybersecurity risks and to assess the risks and incidents relating to cybersecurity threats. While our Board and Audit Committee oversee cybersecurity risk, management, through the AIMC, is responsible for the implementation and management of cybersecurity risk management systems and processes and for the communication of incidents to senior management and the Audit Committee.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The AIMC meets with the Audit Committee on a quarterly basis and meets with the BOD at least annually. Additionally, the Audit Committee regularly meets with members of the Company’s internal audit function to discuss risk management activities, compliance, best practices, and other related matters.</p> Board and Audit Committee the AIMC, is responsible for the implementation and management of cybersecurity risk management systems and processes and for the communication of incidents to senior management and the Audit Committee.The AIMC meets with the Audit Committee on a quarterly basis and meets with the BOD at least annually AIMC, is responsible for the implementation and management of cybersecurity risk management systems and processes and for the communication of incidents to senior management and the Audit Committee true <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;white-space:nowrap;width:22.14%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:14.36%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:11%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;width:19.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:22.14%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Name and Title</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.32%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Action</p></td><td style="vertical-align:middle;white-space:nowrap;width:14.36%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Date</p></td><td style="vertical-align:middle;white-space:nowrap;width:11%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Plan</p></td><td style="vertical-align:middle;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Aggregate Number of securities to be sold</p></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Plan Expiration Date</p></td></tr><tr><td style="vertical-align:middle;width:22.14%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Maria Maccecchini, CEO &amp; Director</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.32%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Adoption</p></td><td style="vertical-align:middle;white-space:nowrap;width:14.36%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17-Dec-24</p></td><td style="vertical-align:middle;white-space:nowrap;width:11%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Rule 10b5-1</p></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">270,000</p></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">16-Sep-26</p></td></tr><tr><td style="vertical-align:middle;width:22.14%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Claudine Bruck, Director</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.32%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Adoption</p></td><td style="vertical-align:middle;white-space:nowrap;width:14.36%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17-Dec-24</p></td><td style="vertical-align:middle;white-space:nowrap;width:11%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Rule 10b5-1</p></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">21,426</p></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">31-Dec-25</p></td></tr><tr><td style="vertical-align:middle;width:22.14%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Mark White, Director</p></td><td style="vertical-align:middle;white-space:nowrap;width:13.32%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Adoption</p></td><td style="vertical-align:middle;white-space:nowrap;width:14.36%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">17-Dec-24</p></td><td style="vertical-align:middle;white-space:nowrap;width:11%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">Rule 10b5-1</p></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">51,426</p></td><td style="vertical-align:middle;white-space:nowrap;width:19.58%;background:#ffffff;border-bottom:1.5pt solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">30-Sep-26</p></td></tr></table> Maria Maccecchini CEO & Director true 17-Dec-24 270000 16-Sep-26 Claudine Bruck Director true 17-Dec-24 21426 31-Dec-25 Mark White Director true 17-Dec-24 51426 30-Sep-26 42 Ernst & Young LLP Philadelphia, Pennsylvania 10551916 5754720 3373717 4453544 13925633 10208264 2305974 1292837 1575013 2986273 3880987 4279110 737000 13680000 4617987 17959110 0.0001 0.0001 2000000 2000000 0 0 0.0001 0.0001 70000000 70000000 14141521 10519933 1414 1052 144155694 102507189 -134849462 -110259087 9307646 -7750846 13925633 10208264 19995447 38790603 6699481 6244408 26694928 45035011 -26694928 -45035011 331849 667898 1853189 3625893 -11837200 2104553 -11169302 -24590375 -56204313 -2.02 -6.23 -2.31 -6.23 12182475 9023138 12235444 9023138 8163923 816 82377488 -54054774 28323530 59897 6 8379 8385 4628406 4628406 50000 5 1056196 1056201 2246113 225 14436720 14436945 -56204313 -56204313 10519933 1052 102507189 -110259087 -7750846 220339 22 -22 3836770 3836770 891667 89 17342022 17342111 26788 3 156766 156769 2051428 205 16438012 16438217 431366 43 3874957 3875000 -24590375 -24590375 14141521 1414 144155694 -134849462 9307646 -24590375 -56204313 3836770 4628406 -3625893 11837200 1803189 -1079827 -3190832 1013138 -2668417 -1411260 -751012 -21894604 -39967304 18666797 16885946 8025003 450000 8385 26691800 17344331 4797196 -22622973 5754720 28377693 10551916 5754720 9317108 606201 50000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(1) Nature of Business and Management’s Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Annovis Bio, Inc. (the “Company” or “Annovis”) was incorporated on April 29, 2008, under the laws of the State of Delaware. Annovis is a clinical-stage drug platform company addressing neurodegeneration such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). The toxic cascade in neurodegeneration begins with high levels of neurotoxic proteins which lead to impaired axonal transport, inflammation, death of nerve cells and loss of cognition and motor function. The Company’s lead product candidate, buntanetap, is a small molecule administered orally that is designed to attack neurodegeneration by entering the brain and inhibiting the translation of multiple neurotoxic proteins thereby impeding the toxic cascade.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Going Concern</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since its founding, the Company has been engaged in organizational activities, including raising capital, and research and development activities. The Company has not generated substantial revenues and has not yet achieved profitable operations, nor has it ever generated positive cash flows from operations. There is no assurance that profitable operations, if achieved, could be sustained on a continuing basis. The Company is subject to those risks associated with any clinical stage pharmaceutical company that has substantial expenditures for research and development. There can be no assurance that the Company’s research and development projects will be successful, that products developed will obtain necessary regulatory approval, or that any approved product will be commercially viable. In addition, the Company operates in an environment of rapid technological change and is largely dependent on the services of its employees and consultants. Further, the Company’s future operations are dependent on the success of the Company’s efforts to raise additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has a history of incurring net losses and anticipates incurring additional losses until such time, if ever, that it can generate significant revenue from its product candidates currently in development. The Company’s primary source of capital has been the issuance of common stock and warrants to purchase common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since the Company’s inception, the Company has incurred losses and negative cash flows from operations. At December 31, 2024, the Company had cash and cash equivalents of $10.6 million and an accumulated deficit of $134.8 million. The Company’s net loss was $24.6 million and $56.2 million for the years ended December 31, 2024 and 2023, respectively. In addition, the Company’s operating loss was $26.7 million and $45.0 million for the years ended December 31, 2024 and 2023, respectively. The Company follows the provisions of Financial Accounting Standards Board, or FASB, Accounting Standards Codification, or ASC, Topic 205-40, Presentation of Financial Statements-Going Concern, or ASC 205-40, which requires management to assess the Company’s ability to continue as a going concern for one year after the date the financial statements are issued. The Company expects that its existing balance of cash and cash equivalents as of December 31, 2024, combined with cash raised in the first quarter of 2025 in connection with its December 2024 ATM with OpCo and February 2025 stock offering with ThinkEquity, is not sufficient to fund operations for the period through one year after the date of this filing and therefore management has concluded that substantial doubt exists about the Company’s ability to continue as a going concern. Management’s plans to mitigate this risk include raising additional capital through equity financings, debt or other potential alternatives. Management’s plans may also include the deferral of certain operating expenses unless and until additional capital is received. However, there can be no assurance that the Company will be successful in raising additional capital or that such capital, if available, will be on terms that are acceptable to the Company, or that the Company will be successful in deferring certain operating expenses. As such, management concluded that such plans do not alleviate the substantial doubt. If the Company is unable to raise sufficient additional capital or defer sufficient operating expenses, the Company may be compelled to reduce the scope of its operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared on a going concern basis, which contemplates the realization of assets and satisfaction of liabilities in the normal course of business, and do not include any adjustments relating to recoverability and classification of recorded asset amounts or the amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern.<span style="white-space:pre-wrap;"> </span></p> 0 10600000 -134800000 -24600000 -56200000 -26700000 -45000000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(2) Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b) Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In preparing the financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the accounting for research and development contracts, including clinical trial accruals, common stock warrant liabilities, derivative liabilities and the accounting and fair value measurement of equity awards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c) Segment Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company viewed its operations and managed its business as one operating segment consistent with how the Company's chief operating decision-maker, the Company's Chief Executive Officer, makes decisions regarding resource allocation and assesses performance. As of December 31, 2024, substantially all of the Company's assets were located in the United States. Refer to Note 11 for additional information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d) Basic and Diluted Net Income per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options and warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion or exercise of securities that would have an anti-dilutive effect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(e) Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly-liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents may include bank demand deposits and money market funds that invest primarily in certificates of deposit, commercial paper, and U.S. government agency securities and treasuries. The Company records interest income received on cash and cash equivalents to other income (expense), net in the statements of operations. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse effect on the Company’s financial condition, results of operations, and cash flows.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(f) Issuance Costs Associated with Equity Issuances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Issuance costs incurred in connection with the Company’s equity issuances, which primarily consist of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. Issuance costs related to the Equity Line of Credit (“ELOC”) Purchase Agreement are expensed as incurred as prescribed by ASC 815. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(g) Derivative Liability</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separate accounting from the underlying agreement under ASC 815 – <i style="font-style:italic;">Derivatives and Hedging</i>. An embedded derivative </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">that requires separation is accounted for as a separate liability or asset from the host agreement. The separated embedded derivative is accounted for at fair market value, with changes in fair value recognized in the statements of operations within the other financing costs line item. The Company determined that certain features under the ELOC Purchase Agreement (See Note 7 — Stockholders’ Equity (Deficit)) collectively qualified as an embedded derivative. The derivative was accounted for separately from the underlying ELOC Purchase Agreement and is accounted for at fair value. As of December 31, 2024, the liability balance was </span><span style="-sec-ix-hidden:Hidden_cLJWlZQJJUG8Jg1dho1-lA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">zero</span></span> because the ELOC facility had been exhausted and all shares from the equity line had been sold. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(h) Common Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">On October 31, 2023, the Company completed an underwritten offering whereby the Company sold (i) </span><span style="font-style:normal;font-weight:normal;">1,250,000</span><span style="font-style:normal;font-weight:normal;"> shares of common stock and (ii) warrants to purchase an aggregate of </span><span style="font-style:normal;font-weight:normal;">1,250,000</span><span style="font-style:normal;font-weight:normal;"> shares of common stock at an exercise price of </span><span style="font-style:normal;font-weight:normal;">$9.00</span><span style="font-style:normal;font-weight:normal;"> per share (“Canaccord Warrants”). The warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company’s control or not deemed to be indexed to the Company’s stock. The warrant liabilities are recorded at fair value regardless of the timing of the redemption feature, the redemption price, or the likelihood of redemption. These warrants are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of change in fair value of warrant liability in the statements of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise, expiration, or other settlement of the warrants. The warrants are classified as Level 3 liabilities. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(i) Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are either expensed as incurred, or recorded separately as a prepaid asset where expense is recognized when the service is performed. These costs are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on the Company’s contracts with its vendors and are realized in the ordinary course of business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(j) Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(k) Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, <i style="font-style:italic;">Compensation—Stock Compensation</i> (“ASC 718”). The Company has issued stock-based compensation awards, including stock options. ASC 718 requires all stock-based payments, including grants of stock options, to be recognized in the financial statements based on their grant date fair values. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. The Company recognizes forfeitures as they occur. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Expense related to stock-based compensation awards granted with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock options have a contractual term of 10 years. Expense for stock-based compensation awards with performance-based vesting conditions is only recognized when the performance-based vesting condition is deemed probable to occur. Expense related to stock-based compensation awards are recorded in research and development expense or general and administrative expense based on the underlying function of the individual that was granted the stock-based compensation award. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Estimating the fair value of stock options requires the input of subjective assumptions, including the expected term of the stock option, stock price volatility, the risk-free interest rate, and expected dividends. The assumptions used in the Company’s Black-Scholes option-pricing model represent Management’s best estimates and involve a number of variables, uncertainties, assumptions, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and the application of Management’s judgment, as they are inherently subjective. If any assumptions change, the Company’s stock-based compensation expense could be materially different in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The assumptions used in the Company’s Black-Scholes option-pricing model for stock options are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Term. </i>As Annovis does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the expected term of employee stock options subject to service-based vesting conditions is determined using the “simplified” method, as prescribed in SEC’s Staff Accounting Bulletin No. 107, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Volatility.</i> The expected volatility is based on historical volatilities of Annovis and similar entities within the Company’s industry for periods commensurate with the assumed expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate.</i> The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Dividends.</i> The expected dividend yield is 0% because Annovis has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(l) Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2024 and 2023, the Company had a full valuation allowance against its deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the provisions of ASC 740, <i style="font-style:italic;">Income Taxes</i><span style="white-space:pre-wrap;">, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions as of December 31, 2024 or 2023. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(m) Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Effective January 1, 2024, the Company retrospectively adopted Accounting Standards Update (“ASU”) 2023-07, <i style="font-style:italic;">Segment Reporting</i> <i style="font-style:italic;">(Topic 280): Improvements to Reportable Segment Disclosures</i> (“ASU 2023-07”) on an annual basis, which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items. ASU 2023-07 also requires public entities with a single reportable segment to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in FASB ASC Topic 280, <i style="font-style:italic;">Segment Reporting</i><span style="white-space:pre-wrap;">. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. See Note 11 for additional disclosures made as a result of adopting ASU 2023-07.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(n) Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In December 2023, the FASB issued ASU No. 2023-09, <i style="font-style:italic;">Income Taxes</i> <i style="font-style:italic;">(Topic 740): Improvements to Income Tax Disclosures</i> (“ASU 2023-09”), which improves income tax disclosures by requiring: (1) consistent categories and greater disaggregation of information in the rate reconciliation, and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The ASU indicates that all entities will apply the guidance prospectively with an option for retroactive application to each period presented in the financial statements. The Company has not determined the impact ASU 2023-09 may have on the Company’s financial statement disclosures, but it does not anticipate material impacts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In November 2024, the FASB issued ASU 2024-03, <i style="font-style:italic;">Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (</i>“ASU 2024-03”<i style="font-style:italic;">)</i>, which requires public entities, at annual and interim reporting periods, to disclose in a tabular format additional information about specific expense categories in the notes to the financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. <span style="white-space:pre-wrap;">The Company is still evaluating the impacts of this ASU on its future financial statements and disclosures. </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:2pt;margin-bottom:12pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Basis of Presentation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The accompanying financial statements have been prepared in conformity with accounting principles generally accepted in the United States of America (“U.S. GAAP”). Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP as found in the Accounting Standards Codification (“ASC”) and Accounting Standards Update (“ASU”) of the Financial Accounting Standards Board (“FASB”).</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b) Use of Estimates</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In preparing the financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to the inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions include those used in the accounting for research and development contracts, including clinical trial accruals, common stock warrant liabilities, derivative liabilities and the accounting and fair value measurement of equity awards.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c) Segment Information</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company viewed its operations and managed its business as one operating segment consistent with how the Company's chief operating decision-maker, the Company's Chief Executive Officer, makes decisions regarding resource allocation and assesses performance. As of December 31, 2024, substantially all of the Company's assets were located in the United States. Refer to Note 11 for additional information</p> 1 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d) Basic and Diluted Net Income per Share</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic net loss per share is determined using the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as stock options and warrants, which would result in the issuance of incremental shares of common stock. The computation of diluted net loss per shares does not include the conversion or exercise of securities that would have an anti-dilutive effect.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(e) Cash and Cash Equivalents</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers all highly-liquid investments with original maturities of three months or less to be cash equivalents. Cash equivalents may include bank demand deposits and money market funds that invest primarily in certificates of deposit, commercial paper, and U.S. government agency securities and treasuries. The Company records interest income received on cash and cash equivalents to other income (expense), net in the statements of operations. The Company has significant cash balances at financial institutions which throughout the year regularly exceed the federally insured limit of $250,000. Any loss incurred or a lack of access to such funds could have a significant adverse effect on the Company’s financial condition, results of operations, and cash flows.</p> 250000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(f) Issuance Costs Associated with Equity Issuances</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;">Issuance costs incurred in connection with the Company’s equity issuances, which primarily consist of direct incremental legal, printing, listing and accounting fees, are offset against proceeds received in the issuances and charged to additional paid-in capital in the period the equity issuance is completed. Issuance costs related to the Equity Line of Credit (“ELOC”) Purchase Agreement are expensed as incurred as prescribed by ASC 815. </span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(g) Derivative Liability</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Company evaluates all features contained in financing agreements to determine if there are any embedded derivatives that require separate accounting from the underlying agreement under ASC 815 – <i style="font-style:italic;">Derivatives and Hedging</i>. An embedded derivative </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">that requires separation is accounted for as a separate liability or asset from the host agreement. The separated embedded derivative is accounted for at fair market value, with changes in fair value recognized in the statements of operations within the other financing costs line item. The Company determined that certain features under the ELOC Purchase Agreement (See Note 7 — Stockholders’ Equity (Deficit)) collectively qualified as an embedded derivative. The derivative was accounted for separately from the underlying ELOC Purchase Agreement and is accounted for at fair value. As of December 31, 2024, the liability balance was </span><span style="-sec-ix-hidden:Hidden_cLJWlZQJJUG8Jg1dho1-lA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">zero</span></span> because the ELOC facility had been exhausted and all shares from the equity line had been sold. </p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(h) Common Stock Warrants</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:normal;font-weight:normal;">On October 31, 2023, the Company completed an underwritten offering whereby the Company sold (i) </span><span style="font-style:normal;font-weight:normal;">1,250,000</span><span style="font-style:normal;font-weight:normal;"> shares of common stock and (ii) warrants to purchase an aggregate of </span><span style="font-style:normal;font-weight:normal;">1,250,000</span><span style="font-style:normal;font-weight:normal;"> shares of common stock at an exercise price of </span><span style="font-style:normal;font-weight:normal;">$9.00</span><span style="font-style:normal;font-weight:normal;"> per share (“Canaccord Warrants”). The warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company’s control or not deemed to be indexed to the Company’s stock. The warrant liabilities are recorded at fair value regardless of the timing of the redemption feature, the redemption price, or the likelihood of redemption. These warrants are subject to re-measurement at each balance sheet date and any change in fair value is recognized as a component of change in fair value of warrant liability in the statements of operations. The Company will continue to adjust the liability for changes in fair value until the earlier of the exercise, expiration, or other settlement of the warrants. The warrants are classified as Level 3 liabilities. </span></p> 1250000 1250000 9 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(i) Research and Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development costs are either expensed as incurred, or recorded separately as a prepaid asset where expense is recognized when the service is performed. These costs are primarily comprised of personnel-related expenses and external research and development expenses incurred under arrangements with third parties, such as contract research organizations and consultants. At the end of each reporting period, the Company compares the payments made to each service provider to the estimated progress towards completion of the related project. Factors that the Company considers in preparing these estimates include the number of patients enrolled in studies, milestones achieved, and other criteria related to the efforts of its vendors. These estimates will be subject to change as additional information becomes available. Depending on the timing of payments to vendors and estimated services provided, the Company will record net prepaid or accrued expenses related to these costs. Prepaid clinical expenses represent valid future economic benefits based on the Company’s contracts with its vendors and are realized in the ordinary course of business.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(j) Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="background:#ffffff;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses.</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(k) Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its stock-based compensation awards in accordance with FASB ASC Topic 718, <i style="font-style:italic;">Compensation—Stock Compensation</i> (“ASC 718”). The Company has issued stock-based compensation awards, including stock options. ASC 718 requires all stock-based payments, including grants of stock options, to be recognized in the financial statements based on their grant date fair values. The Company uses the Black-Scholes option-pricing model to determine the fair value of stock options granted. The Company recognizes forfeitures as they occur. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Expense related to stock-based compensation awards granted with service-based vesting conditions is recognized on a straight-line basis based on the grant date fair value over the associated service period of the award, which is generally the vesting term. Stock options have a contractual term of 10 years. Expense for stock-based compensation awards with performance-based vesting conditions is only recognized when the performance-based vesting condition is deemed probable to occur. Expense related to stock-based compensation awards are recorded in research and development expense or general and administrative expense based on the underlying function of the individual that was granted the stock-based compensation award. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Estimating the fair value of stock options requires the input of subjective assumptions, including the expected term of the stock option, stock price volatility, the risk-free interest rate, and expected dividends. The assumptions used in the Company’s Black-Scholes option-pricing model represent Management’s best estimates and involve a number of variables, uncertainties, assumptions, </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">and the application of Management’s judgment, as they are inherently subjective. If any assumptions change, the Company’s stock-based compensation expense could be materially different in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The assumptions used in the Company’s Black-Scholes option-pricing model for stock options are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Term. </i>As Annovis does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate expected term, the expected term of employee stock options subject to service-based vesting conditions is determined using the “simplified” method, as prescribed in SEC’s Staff Accounting Bulletin No. 107, whereby the expected term equals the arithmetic average of the vesting term and the original contractual term of the stock option.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Volatility.</i> The expected volatility is based on historical volatilities of Annovis and similar entities within the Company’s industry for periods commensurate with the assumed expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Risk-Free Interest Rate.</i> The risk-free interest rate is based on the interest rate payable on U.S. Treasury securities in effect at the time of grant for a period that is commensurate with the assumed expected term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Expected Dividends.</i> The expected dividend yield is 0% because Annovis has not historically paid, and does not expect for the foreseeable future to pay, a dividend on its common stock.</p> P10Y 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(l) Income Taxes</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company provides for income taxes using the asset and liability approach. Deferred tax assets and liabilities are recorded based on the differences between the financial statement and tax bases of assets and liabilities and the tax rates in effect when these differences are expected to reverse. Deferred tax assets are reduced by a valuation allowance if, based on the weight of available evidence, it is more likely than not that some or all of the deferred tax assets will not be realized. As of December 31, 2024 and 2023, the Company had a full valuation allowance against its deferred tax assets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject to the provisions of ASC 740, <i style="font-style:italic;">Income Taxes</i><span style="white-space:pre-wrap;">, which prescribes a more likely-than-not threshold for the financial statement recognition of uncertain tax positions. ASC 740 clarifies the accounting for income taxes by prescribing a minimum recognition threshold and measurement attribute for the financial statement recognition and measurement of a tax position taken or expected to be taken in a tax return. There are currently no open federal or state tax audits. The Company has not recorded any liability for uncertain tax positions as of December 31, 2024 or 2023. </span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(m) Recently Adopted Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Effective January 1, 2024, the Company retrospectively adopted Accounting Standards Update (“ASU”) 2023-07, <i style="font-style:italic;">Segment Reporting</i> <i style="font-style:italic;">(Topic 280): Improvements to Reportable Segment Disclosures</i> (“ASU 2023-07”) on an annual basis, which requires public entities to disclose information about their reportable segments’ significant expenses and other segment items. ASU 2023-07 also requires public entities with a single reportable segment to apply the disclosure requirements in ASU 2023-07, as well as all existing segment disclosures and reconciliation requirements in FASB ASC Topic 280, <i style="font-style:italic;">Segment Reporting</i><span style="white-space:pre-wrap;">. This guidance is effective for fiscal years beginning after December 15, 2023 and interim periods within fiscal years beginning after December 15, 2024. See Note 11 for additional disclosures made as a result of adopting ASU 2023-07.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(n) Recent Accounting Pronouncements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In December 2023, the FASB issued ASU No. 2023-09, <i style="font-style:italic;">Income Taxes</i> <i style="font-style:italic;">(Topic 740): Improvements to Income Tax Disclosures</i> (“ASU 2023-09”), which improves income tax disclosures by requiring: (1) consistent categories and greater disaggregation of information in the rate reconciliation, and (2) income taxes paid disaggregated by jurisdiction. It also includes certain other amendments to improve the effectiveness of income tax disclosures. ASU 2023-09 is effective for annual periods beginning after December 15, 2024. Early adoption is permitted. The ASU indicates that all entities will apply the guidance prospectively with an option for retroactive application to each period presented in the financial statements. The Company has not determined the impact ASU 2023-09 may have on the Company’s financial statement disclosures, but it does not anticipate material impacts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In November 2024, the FASB issued ASU 2024-03, <i style="font-style:italic;">Income Statement — Reporting Comprehensive Income — Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses (</i>“ASU 2024-03”<i style="font-style:italic;">)</i>, which requires public entities, at annual and interim reporting periods, to disclose in a tabular format additional information about specific expense categories in the notes to the financial statements. ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. <span style="white-space:pre-wrap;">The Company is still evaluating the impacts of this ASU on its future financial statements and disclosures. </span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(3) Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company measures certain assets and liabilities at fair value in accordance with ASC 820, <i style="font-style:italic;">Fair Value Measurements and Disclosures</i>. ASC 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability (the exit price) in an orderly transaction between market participants at the measurement date. The guidance in ASC 820 outlines a valuation framework and creates a fair value hierarchy that serves to increase the consistency and comparability of fair value measurements and the related disclosures. In determining fair value, the Company maximizes the use of quoted prices and observable inputs. Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from independent sources. The fair value hierarchy is broken down into three levels based on the source of inputs as follows: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 1—Valuations based on unadjusted quoted prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 2—Valuations based on observable inputs and quoted prices in active markets for similar assets and liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 36pt;">Level 3—Valuations based on unobservable inputs and models that are supported by little or no market activity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following tables provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of December 31, 2024 and 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurement at </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 491,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 491,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total assets measured and recorded at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 491,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 491,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 737,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 737,000</p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities measured and recorded at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 737,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 737,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Fair Value Measurement at </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,136,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,136,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets measured and recorded at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,136,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,136,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,680,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,680,000</p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities measured and recorded at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,680,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,680,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company did not transfer any financial instruments into or out of Level 3 classification, during the year ended December 31, 2024 or 2023. </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Canaccord Warrants</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The common stock warrants issued in connection with the Company’s equity financing in November 2023 (“Canaccord Warrants”) were classified as liabilities at the time of issuance due to certain cash settlement adjustment features that are outside of the Company’s control or not deemed to be indexed to the Company’s stock. The Canaccord Warrant liability is remeasured each reporting period with the change in fair value recorded to other income (expense), net in the statements of operations until the warrants are exercised, expired, reclassified, or otherwise settled. From their date of issuance until the period ended June 30, 2024, the fair value of the Canaccord Warrants was estimated using a <span style="-sec-ix-hidden:Hidden_IDmi6EBxm0ykocQlpvyy7w;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Monte Carlo</span></span> simulation model, given the performance conditions outlined further below. However, during the quarter ended September 30, 2024, the Company determined that certain performance conditions could not be met and that going forward, their use as inputs for determining fair value was no longer appropriate. As such, after the period ended June 30, 2024, the fair value of the Canaccord Warrants is estimated using a <span style="-sec-ix-hidden:Hidden_MYnYPWwqd0e83MnNL4wIWQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Black-Scholes</span></span> option-pricing model.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The estimated fair value of the Canaccord Warrants is determined using Level 3 inputs. Inherent in both a Monte Carlo simulation model and a Black-Scholes option-pricing model are assumptions related to expected stock-price volatility, expected life, risk-free interest rate and other inputs. The Company estimates the volatility of its warrants based on an implied asset volatility calculated and believed to be reasonable for the Company over the holding period remaining. The risk-free interest rate is based on the market yield of U.S. Treasuries over a term commensurate with the remaining term to expiration. Any changes in these assumptions can change the associated valuation significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables provide quantitative information regarding Level 3 fair value measurements inputs as of their respective measurement dates. The table for the year ending December 31, 2024 presents inputs used under a Black-Scholes option-pricing model. The table for the year ending December 31, 2023 presents inputs used under a Monte Carlo simulation model:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Closing stock price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Number of warrants outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 308,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Phase III data probability of success</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Term (time to expiration in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Redemption hurdle price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Canaccord Warrants were exercisable immediately at an exercise price of $9.00 per unit, and redeemable at the Company’s option, in whole or in part, at a redemption price equal to $0.001 per Warrant upon 30 days’ prior written notice, at any time after:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Company’s public announcement of Positive Topline Data (as defined in the Warrant Agreement) from its Phase 3 in patients with Parkinson’s Disease; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the date on which (a) the closing price of the Company’s common stock on the principal exchange or trading facility on which it is then traded has equaled or exceeded </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$14.25</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> and (b) the average daily trading value (“ADTV”) of the Company’s common stock is equal to or exceeds </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$2,000,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, for </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">two</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> consecutive Trading Days. </span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the year ended December 31, 2024, the Company released topline data from its Phase 3 study in patients with Parkinson’s Disease. It was determined that based on the data, both criteria required for redemption of the Canaccord Warrants were not met. As such, the probability of success and redemption hurdle price inputs were no longer used in the Black-Scholes option-pricing model outlined above for the year ending December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The Warrants were exercisable immediately and will expire on November 2, 2028, five years from the date of issuance. See Note 7 – Stockholders’ Equity (Deficit) for additional background.</p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following tables provides the carrying value and fair value of certain financial assets and liabilities of the Company measured at fair value on a recurring basis as of December 31, 2024 and 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Fair Value Measurement at </b></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:36.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.3%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 491,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 491,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total assets measured and recorded at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 491,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 491,006</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 737,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 737,000</p></td></tr><tr><td style="vertical-align:bottom;width:46.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Total liabilities measured and recorded at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.49%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 737,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.21%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 737,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">    </p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">Fair Value Measurement at </b></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="8" style="vertical-align:bottom;white-space:nowrap;width:37.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Carrying Value</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 1</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 2</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Level 3</b></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,136,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,136,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total assets measured and recorded at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,136,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,136,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Warrant liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,680,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,680,000</p></td></tr><tr><td style="vertical-align:bottom;width:45.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total liabilities measured and recorded at fair value</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,680,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.16%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,680,000</p></td></tr></table> 491006 491006 491006 491006 737000 737000 737000 737000 5136677 5136677 5136677 5136677 13680000 13680000 13680000 13680000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables provide quantitative information regarding Level 3 fair value measurements inputs as of their respective measurement dates. The table for the year ending December 31, 2024 presents inputs used under a Black-Scholes option-pricing model. The table for the year ending December 31, 2023 presents inputs used under a Monte Carlo simulation model:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:8pt;margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercise price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 9.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Closing stock price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.03</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 18.70</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Number of warrants outstanding</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 308,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Phase III data probability of success</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 60</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 55</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Term (time to expiration in years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.84</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Redemption hurdle price</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.25</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Risk-free rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3.9</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 9 9 5.03 18.7 308333 1200000 0.60 0.80 0.55 3.84 4.84 14.25 0.043 0.039 9 0.001 P30D 14.25 2000000 2 P5Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(4) Prepaid Expenses and Other Current Assets</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Prepaid expenses and other current assets consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid clinical expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,998,811</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,391,219</p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 346,313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23,455</p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21,098</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,074</p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,796</p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,373,717</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,453,544</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Prepaid expenses and other current assets consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid clinical expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 2,998,811</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,391,219</p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 346,313</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 23,455</p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prepaid insurance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21,098</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 18,074</p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Security deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 7,495</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 20,796</p></td></tr><tr><td style="vertical-align:bottom;width:72.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3,373,717</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.86%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.68%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,453,544</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 2998811 4391219 346313 23455 21098 18074 7495 20796 3373717 4453544 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(5) Accrued Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued clinical expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 948,695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,645,589</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 364,717</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 96,848</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional fees and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 261,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 243,836</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,575,013</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,986,273</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Accrued expenses consisted of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">As of December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued clinical expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 948,695</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,645,589</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Payroll and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 364,717</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 96,848</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Accrued professional fees and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 261,601</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 243,836</p></td></tr><tr><td style="vertical-align:bottom;width:72.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Total accrued expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,575,013</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.53%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,986,273</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 0pt 36pt;"><span style="font-size:1pt;margin-bottom:12pt;margin-left:0pt;visibility:hidden;">​</span></p> 948695 2645589 364717 96848 261601 243836 1575013 2986273 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(6) Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Research &amp; Development</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The Company has entered contracts with CROs and CMOs related the Company’s clinical trials. The contracts require upfront payments, milestone payments, and pass-through cost reimbursements, to be made. While the contracts are generally cancellable with (written) notice, the Company is obligated to make payments for services rendered through the termination date of the project with any applicable CRO/CMO.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b) Leases</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company maintains one short-term lease associated with occupying its corporate headquarters. Total rental expense was $0.1 million and $0.1 million for the years ended December 31, 2024 and 2023, respectively. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c) Employment Agreements</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has an agreement with its Chief Executive Officer that provides for severance payments upon termination of the agreement by the Company for any reason other than for cause, death or disability or by the employee for good reason. The maximum aggregate severance payments under the agreement was estimated to be $1.1 million at December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d) Litigation</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company is subject, from time to time, to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">For both the years ended December 31, 2024 and December 31, 2023 the Company did not have any pending legal actions deemed to be material.</p> 1 100000 100000 1100000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(7) Stockholders’ Equity (Deficit)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(a) Overview</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company’s Amended and Restated Certificate of Incorporation was adopted on January 31, 2020, in conjunction with the closing of the Company’s initial public offering (the “IPO”) and amended on June 15, 2023 to increase the authorized number of shares. Currently, there are two classes of stock authorized which are designated, respectively, common stock and preferred stock. The total number of shares which the Company is authorized to issue is 72,000,000, each with a par value of $0.0001 per share. Of these shares, 70,000,000 is designated as common stock and 2,000,000 is <span style="-sec-ix-hidden:Hidden_sH-lbMPWqkOGFnPa1im7Pg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preferred</span></span> stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(b) Common Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Dividends</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of Company stock outstanding having rights that are senior to or equivalent to holders of common stock, the holders of the common stock are entitled to receive dividends when and as declared by the Board of Directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Liquidation</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subject to the rights of holders of all classes of stock outstanding having rights that are senior to or equivalent to holders of common stock as to liquidation, upon the liquidation, dissolution or winding up of the Company, the assets of the Company will be distributed to the holders of common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:36pt;text-indent:-36pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;font-weight:normal;">Voting</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The holders of common stock are entitled to one vote for each share of common stock held. There is no cumulative voting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(c) Preferred Stock</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Preferred stock may be issued from time to time by the Board in one or more series. There was no preferred stock issued or outstanding as of December 31, 2024 or December 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;">(d) IPO Warrants</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In conjunction with the closing of the Company’s Initial Public Offering (“IPO”), the Company granted its underwriters 0.1 million warrants to purchase shares of Company common stock (“IPO Warrants”) at an exercise price of $7.50 per share, which was 125% of the IPO price. The IPO Warrants have a <span style="-sec-ix-hidden:Hidden_nIEprH3FlECzxDG_jmJGRg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five-year</span></span> term and were exercisable as of January 29, 2021 and have been classified by the Company as a component of stockholders’ equity. At both December 31, 2024 and December 31, 2023, 2,400 of the IPO Warrants were outstanding. No IPO Warrants were exercised during the years ended December 31, 2024 or 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(e) March 2023 ATM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 31, 2023, the Company, entered into an At the Market (“ATM”) Equity Offering Sales Agreement (the “Sales Agreement” or “March 2023 ATM”) with BofA Securities, Inc. (“BofA”) and ThinkEquity LLC (“ThinkEquity” and, together with BofA, the “Sales Agents”), as sales agents, pursuant to which the Company could offer and sell, from time to time through the Sales Agents, shares of the Company’s common stock, par value $0.0001 per share (the “Common Stock”), having an aggregate offering price of up to $50.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 4, 2023, the Company delivered written notice to BofA and ThinkEquity to terminate the Sales Agreement, effective April 9, 2023. The Company was not subject to any termination penalties related to the termination of the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Prior to termination of the Sales Agreement, the Company sold 0.7 million shares of Common Stock pursuant to the Sales Agreement at a price of $10.88 per share, for gross proceeds of $7.6 million before commissions. As a result of the termination of the Sales Agreement, the Company will not offer or sell any additional shares of Common Stock under the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(f) April 2023 Private Placement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 7, 2023, the Company sold 0.1 million shares of its common stock in a private placement to individual members of its Board of Directors and management at a price of $12.61 per share, for aggregate proceeds of $1.1 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(g) November 2023 Equity Offering and Warrant Issuance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 31, 2023, the Company entered into an underwritten offering with a Canaccord Genuity LLC whereby the Company sold (i) 1,250,000 shares of common stock and (ii) warrants (“Canaccord Warrants”) to purchase an aggregate of 1,250,000 shares of common stock at an exercise price of $9.00 per share. The offering closed on November, 2, 2023. The warrants were exercisable immediately on the date of issuance and will expire five years after the date of issuance. The Company received $6.8 million in net cash proceeds after deducting underwriter discount and fees, as well as other third-party costs. The Canaccord Warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company’s control or not deemed to be indexed to the Company’s stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a roll forward of the Common Stock Warrant Liability during the years ended December 31, 2023 and 2024, respectively:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of Canaccord Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,449,001</p></td></tr><tr><td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of 50,000 warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (606,201)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;">Change in fair value of warrant liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,837,200</p></td></tr><tr><td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,680,000</p></td></tr><tr><td style="vertical-align:middle;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,625,893)</p></td></tr><tr><td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of 891,667 warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,317,107)</p></td></tr><tr><td style="vertical-align:top;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 737,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(h) Warrant Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had the following common stock warrants outstanding:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercised or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">date</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">IPO warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_x2mt2vNGpkmX_I7rt27w1w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_hS9S4DOFWEOzsGyH4QCjfA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">January 29, 2026</p></td></tr><tr><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Canaccord warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_IEv4e_C0VEWG-Y-PNjt6jw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (891,667)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">November 2, 2028</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(i) November 2023 Private Placement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">On November 27, 2023, the Company sold 0.2 million shares of its common stock in a private placement to individual members of its Board of Directors and management at a price of $6.10 per share, for aggregate proceeds of $1.3 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">(j) March 2024 Registered Direct Offerings</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 15, 2024 and March 21, 2024, the Company entered into two separate securities purchase agreements with the same institutional investor. When aggregating the results of both purchase agreements, the Company issued 0.4 million shares for net proceeds of $3.9 million in registered direct offerings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">(k) April 2024 ELOC Purchase Agreement</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On April 25, 2024, the Company entered into an ELOC Purchase Agreement with an ELOC Purchaser, whereby we could offer and sell, from time to time at our sole discretion, and whereby the ELOC Purchaser committed to purchase, up to 2.0 million shares of shares of the Company’s common stock. The term of the agreement was until the expiration of the Company’s active S-3 Registration Statement, unless earlier terminated or exhausted. Due to certain pricing and settlement provisions, the ELOC Purchase Agreement qualified as a standby equity purchase agreement and included an embedded put option and embedded forward option. The Company therefore accounted for the ELOC Purchase Agreement as a derivative measured at fair value, with changes in the fair value recognized in the statements of operations within other financing costs. The Company initially recognized a derivative liability of $1.7 million related to the purchased put option at inception of the ELOC Purchase Agreement. The Company then expensed the difference between the discounted purchase price of the settled forward and the fair value of shares on the date of settlement as a noncash financing issuance cost. The Company recognized $1.3 million of noncash financing costs during the year ended December 31, 2024 related to the discounted purchase price of the settled forward and the underlying fair value of the shares issued.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon execution of the ELOC Purchase Agreement, the Company agreed to issue to the ELOC Purchaser 33,937 shares of Common Stock as commitment shares (the “Commitment Shares”). The fair value of the Commitment Shares was $0.5 million, which was expensed within other financing costs in the statements of operations during the year ended December 31, 2024. The Company also incurred issuance costs of $0.1 million, consisting of legal costs incurred in connection with the ELOC Purchase Agreement, which were expensed within other financing costs in the statements of operations during the year ended December 31, 2024. The ELOC Purchaser agreed that during the term of the Purchase Agreement, neither it nor any of its affiliates would engage in any short sales or hedging transactions involving the Company’s common stock. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the ELOC Purchase Agreement, on any business day (the “Purchase Date”), if the Company’s stock price is greater than or equal to $5.00 per share, the Company could direct the ELOC Purchaser to purchase common stock. The ELOC Purchaser’s committed obligation under any single Fixed Purchase could not exceed the lower of 25,000 shares of Common Stock or $250,000 (“Fixed Purchases”). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the Company could also direct the ELOC Purchaser, on any trading day in which the Company submitted a Fixed Purchase notice for the maximum amount allowed for such Fixed Purchase, to purchase an additional amount of the Company’s common stock (a “VWAP Purchase”). The ELOC Purchaser’s committed obligation under any single VWAP Purchase could not exceed a number of shares of Common Stock equal to the lesser of (i) 300% of the number of Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Fixed Purchase Notice and (ii) 30% of the trading volume in the Company’s Common Stock on the NYSE during the applicable VWAP Purchase Period on the applicable VWAP Purchase Date (“VWAP Purchase Maximum Amount”). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company could also direct the ELOC Purchaser, on any trading day for which a VWAP Purchase had been completed and all of the shares had been placed, to purchase an additional amount of the Company’s common stock (an “Additional VWAP Purchase”). The ELOC Purchaser’s committed obligation under any single Additional VWAP Purchase was the lesser of (i) 300% of the number of Shares directed by the Company to be purchased by the Investor pursuant to the corresponding Fixed Purchase Notice and (ii) a number of Shares equal to (A) the Additional VWAP Purchase Share Percentage multiplied by (B) the trading volume of shares of Common Stock traded during the applicable Additional VWAP Purchase Period on the applicable Additional VWAP Purchase Date for such Additional VWAP Purchase (“Additional VWAP Purchase Maximum Amount”). The applicable pricing structure for each purchase type is outlined below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The purchase price per share for Fixed Purchases (“Fixed Purchase Price”) equals 95% of the lesser of:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the daily volume weighted average price (“VWAP”) of the Company’s Common Stock on the NYSE for the five (5) Trading Days immediately preceding the applicable Fixed Purchase Date for such Fixed Purchase; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Closing Sale Price of a share of Common Stock on the applicable Fixed Purchase Date. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The purchase price per share for VWAP Purchases (“VWAP Purchase Price”) equals 95% of the lesser of:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the VWAP during the applicable VWAP Purchase Period during the applicable VWAP Purchase Date.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Closing Sale Price of the Common Stock on the applicable VWAP Purchase Date.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The purchase price per share for Additional VWAP Purchases (“Additional VWAP Purchase Price”) equals 95% of the lesser of:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the VWAP for the applicable Additional VWAP Purchase Period during the applicable Additional VWAP Purchase Date; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">●</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the Closing Sale Price of the Common Stock on such applicable Additional VWAP Purchase Date.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the commitment shares referenced above, a total of 2.0 million shares of the Company’s common stock were issued under the ELOC Purchase Agreement during the year ended December 31, 2024, for net proceeds of $14.6 million. The facility was fully exhausted during 2024 and no further shares are available to issue as of December 31, 2024. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following is a roll-forward of the ELOC derivative liability from date of execution to December 31, 2024: </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at April 25, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,697,500</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Settlements and changes in fair value of ELOC derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,192,500)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at June 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 505,000</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Settlements and changes in fair value of ELOC derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (62,500)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at September 30, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 442,500</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Settlements and changes in fair value of ELOC derivative liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (442,500)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Fair value at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;background:#ffff00;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="font-style:italic;font-weight:bold;">(l) December 2024 ATM</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 11, 2024, the Company entered into an Equity Distribution Agreement (“Distribution Agreement”) with Oppenheimer &amp; Co. Inc., (“OpCo”) relating to the sale of shares of the Company’s common stock. In accordance with the terms of the Distribution Agreement, The Company may offer and sell shares of its common stock having an aggregate offering price of up to $50.0 million from time to time through or to OpCo, acting as agent or principal.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">During the year-ended December 31, 2024, the Company sold 26,788 million shares of common stock pursuant to the Distribution Agreement for gross proceeds of $0.2 million before commissions.</p> 2 72000000 0.0001 70000000 2000000 1 0 0 100000 7.5 1.25 2400 2400 0 0 0.0001 50000000 700000 10.88 7600000 100000 12.61 1100000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On October 31, 2023, the Company entered into an underwritten offering with a Canaccord Genuity LLC whereby the Company sold (i) 1,250,000 shares of common stock and (ii) warrants (“Canaccord Warrants”) to purchase an aggregate of 1,250,000 shares of common stock at an exercise price of $9.00 per share. The offering closed on November, 2, 2023. The warrants were exercisable immediately on the date of issuance and will expire five years after the date of issuance. The Company received $6.8 million in net cash proceeds after deducting underwriter discount and fees, as well as other third-party costs. The Canaccord Warrants are liability classified as they contain certain cash settlement adjustment features that are outside of the Company’s control or not deemed to be indexed to the Company’s stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a roll forward of the Common Stock Warrant Liability during the years ended December 31, 2023 and 2024, respectively:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:middle;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of Canaccord Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,449,001</p></td></tr><tr><td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of 50,000 warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (606,201)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#212529;">Change in fair value of warrant liabilities</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,837,200</p></td></tr><tr><td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,680,000</p></td></tr><tr><td style="vertical-align:middle;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of warrant liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,625,893)</p></td></tr><tr><td style="vertical-align:middle;width:85.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Exercise of 891,667 warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (9,317,107)</p></td></tr><tr><td style="vertical-align:top;width:85.21%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrant liability at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.08%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 737,000</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 1250000 1250000 9 P5Y 6800000 2449001 50000 -606201 -11837200 13680000 3625893 891667 9317107 737000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had the following common stock warrants outstanding:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;width:11.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">    </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Outstanding </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercise </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exercised or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">price per</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expiration</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Classification</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Granted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Expired</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">date</b></p></td></tr><tr><td style="vertical-align:bottom;width:16.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">IPO warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_x2mt2vNGpkmX_I7rt27w1w;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_hS9S4DOFWEOzsGyH4QCjfA;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7.50</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">January 29, 2026</p></td></tr><tr><td style="vertical-align:bottom;width:16.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Canaccord warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Liability</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,200,000</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_IEv4e_C0VEWG-Y-PNjt6jw;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> —</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (891,667)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 308,333</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9.00</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 3pt 0pt 0pt;">November 2, 2028</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 2400 2400 7.5 1200000 891667 308333 9 200000 6.1 1300000 2 400000 3900000 2 1700000 1300000 33937 500000 100000 5 25000 250000 3 0.30 3 0.95 0.95 0.95 2000000 14600000 1697500 1192500 505000 62500 442500 442500 0 50000000 26788 200000 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(8) Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Effective upon the closing of the Company’s IPO on January 31, 2020, the Company’s 2019 Equity Incentive Plan (the “2019 Plan”) became effective, succeeding the Company’s previous equity incentive plan. No new options may be issued under the previous plan, although shares subject to grants which are cancelled or forfeited will again be available under the 2019 Plan. Effective June 12, 2024, the 2019 Plan was amended to increase the number of shares authorized from 2,000,000 to 3,000,000. As of December 31, 2024, the 2019 Plan contained 354,299 shares available for future grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The 2019 Plan provides for grants to employees, members of the Board, consultants and advisors to the Company, in the form of stock options, stock awards and other equity-based awards. The amount and terms of grants are determined by the Board, except when they are below previously approved thresholds allowing the Company’s CEO to grant awards on a discretionary basis. The Company’s stock options generally carry a maximum term of 10 years after date of grant and are exercisable in cash, or as otherwise determined by the Board. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense in the statements of operations, including the fair value of stock awards to consultants and advisors for services rendered, for the years ended December 31, 2024 and 2023 was as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,510,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,414,867</p></td></tr><tr><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,326,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,213,539</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,836,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,628,406</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the Company’s stock option activity:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In Thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,954,774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 17,863</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 870,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (300,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 570</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (189,248)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,336,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,298</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,824,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,298</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The weighted average grant date fair value of stock options granted during the years ended December 31, 2024 and 2023 was $5.16 and $7.39, respectively. During the year ended December 31, 2024 the Company received no cash proceeds from the exercises of stock options. For the year ended December 31, 2023, the Company received $8,385 cash proceeds from the exercises of stock options. As of December 31, 2024, there was unrecognized stock-based compensation expense related to unvested stock option awards, related to service-based options of $2.4 million, which will be recognized over a remaining weighted-average period of 1.0 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the years ended December 31, 2024 and 2023, the Company issued 870,494 and 367,329 options, respectively. Under the grant agreements for the 2024 stock option grants, 382,282 of the options vested immediately and 468,212 of the options vest in substantially equal quarterly installments over two years from the date of grant. There are also 20,000 stock option grants that vest as consulting services are performed and awards are earned. Under the grant agreements for the 2023 stock option grants, 94,624 of the options vested immediately, and 272,705 of the options vest in substantially equal quarterly installments over two years from the date of grant. All of the options have a 10-year term prior to expiration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The assumptions utilized in the fair value calculations for stock options granted during the years ended December 31, 2024 and 2023, respectively, were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average expected option term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-style:italic;font-weight:bold;">Related Party Transaction</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">During the year ended December 31, 2024, the Company issued 20,000 non-qualified stock options to a member of its Board of Directors in consideration for the member’s agreement to serve as a consultant to the Company. The options were issued in one tranche, at a grant price of $5.27 per share. 8,069 of the awards became vested during the year ended December 31, 2024. </p> 0 2000000 3000000 354299 P10Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock-based compensation expense in the statements of operations, including the fair value of stock awards to consultants and advisors for services rendered, for the years ended December 31, 2024 and 2023 was as follows:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.49%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';">    </span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.12%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">    </p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,510,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,414,867</p></td></tr><tr><td style="vertical-align:bottom;width:73.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,326,326</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,213,539</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.7%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3,836,770</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.67%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 4,628,406</p></td></tr></table> 2510444 2414867 1326326 2213539 3836770 4628406 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table summarizes the Company’s stock option activity:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Term</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.67%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(In Thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,954,774</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 13.41</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;">6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 17,863</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 870,494</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.01</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (300,000)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 3.13</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 570</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Forfeited</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (189,248)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 20.61</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 2,336,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 11.39</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 7.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,298</p></td></tr><tr><td style="vertical-align:bottom;width:58.87%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable at December 31, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,824,122</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.77%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 12.80</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 6.8</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0.05pt 0pt;"> 1,298</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p> 1954774 13.41 P6Y1M6D 17863000 870494 6.01 300000 3.13 570000 189248 20.61 2336020 11.39 P7Y3M18D 1298000 1824122 12.8 P6Y9M18D 1298000 5.16 7.39 0 8385 2400000 P1Y 870494 367329 382282 468212 P2Y 20000 94624 272705 P2Y P10Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average risk-free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.18</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4.17</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average expected option term (years)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted average expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 120</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:63.19%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr></table> 0.0418 0.0417 P5Y3M18D P5Y6M 1.23 1.20 0 0 20000 5.27 8069 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(9) Net Loss Per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has reported a net loss for the years ended December 31, 2024 and 2023, and the basic and diluted net loss per share attributable to common stockholders are the same for both years because all warrants and stock options have been excluded from the computation of diluted weighted-average shares outstanding because such securities would have an antidilutive impact.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets forth the computation of basic and diluted net loss per common share for the years ended December 31, 2024 and 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.12%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share – Basic:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,590,375)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56,204,313)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average common shares outstanding, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,182,475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,023,138</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basic net loss per common share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.02)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6.23)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share – Diluted:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,590,375)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56,204,313)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> Less: gain from change in fair value applicable to dilutive liability-classified warrants</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,625,893)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> Numerator for diluted net loss per share</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28,216,268)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56,204,313)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> Denominator for basic net loss per share</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,182,475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,023,138</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> Plus: incremental shares underlying “in the money” liability-classified warrants outstanding</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,969</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> Denominator for diluted net loss per share</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,235,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,023,138</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Diluted net loss per common share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.31)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6.23)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Potentially dilutive securities, whose effect would have been antidilutive, were excluded from the computation of diluted earnings per share for each of the years ended December 31, 2024 and 2023. Total antidilutive securities that were excluded from the computation of diluted weighted-average shares outstanding were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,336,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,954,774</p></td></tr><tr><td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,202,400</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The following table sets forth the computation of basic and diluted net loss per common share for the years ended December 31, 2024 and 2023:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.12%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.68%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share – Basic:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">  </p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,590,375)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56,204,313)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Weighted-average common shares outstanding, basic</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,182,475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,023,138</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Basic net loss per common share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.02)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6.23)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Net loss per share – Diluted:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Numerator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> Net loss</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (24,590,375)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56,204,313)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> Less: gain from change in fair value applicable to dilutive liability-classified warrants</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,625,893)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> Numerator for diluted net loss per share</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28,216,268)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (56,204,313)</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Denominator</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">​</span></p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> Denominator for basic net loss per share</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,182,475</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,023,138</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> Plus: incremental shares underlying “in the money” liability-classified warrants outstanding</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 52,969</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> —</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;"> Denominator for diluted net loss per share</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,235,444</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,023,138</p></td></tr><tr><td style="vertical-align:bottom;width:68.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">Diluted net loss per common share</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2.31)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.52%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (6.23)</p></td></tr></table> -24590375 -56204313 12182475 9023138 -2.02 -6.23 -24590375 -56204313 -3625893 -28216268 -56204313 12182475 9023138 52969 12235444 9023138 -2.31 -2.31 -6.23 -6.23 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Potentially dilutive securities, whose effect would have been antidilutive, were excluded from the computation of diluted earnings per share for each of the years ended December 31, 2024 and 2023. Total antidilutive securities that were excluded from the computation of diluted weighted-average shares outstanding were as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,336,020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,954,774</p></td></tr><tr><td style="vertical-align:bottom;width:72.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,400</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,202,400</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p> 2336020 1954774 2400 1202400 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(10) Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The federal and state provision (benefit) for income taxes was $0 for the years ended December 31, 2024 and 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements for the years ended December 31, 2024 and 2023 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal income tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax, change in rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of warrants </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company’s deferred tax assets are comprised of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,634,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,607,158</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,390,635</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,245,472</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,137,406</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,334,494</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Section 174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12,802,738</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,793,442</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">R&amp;D credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,198,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,132,475</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 76,757</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 14,553</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 37,240,555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30,127,594</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,240,555)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (30,127,594)</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had U.S. federal net operating loss (“NOL”) carryforwards of $54.1 million which may be available to offset future income tax liabilities. Federal NOL carryforwards generated in 2017 and prior of $2.8 million will expire beginning in 2032. The remaining federal NOL carryforwards generated in 2018 and later do not expire. As of December 31, 2024, the Company also had U.S. state NOL carryforwards of $56.6 million which may be available to offset future income tax liabilities and will expire beginning in 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has recorded a full valuation allowance against its net deferred tax assets as of December 31, 2024 and 2023 because the Company has determined that is it more likely than not that these assets will not be fully realized due to historic net operating losses incurred. The Company recorded a net change in valuation allowance of $7.1 million and $11.7 million in the years ended December 31, 2024 and 2023, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2024, the Company had federal research and development tax credit carryforwards of $5.2 million available to reduce future tax liabilities, which expire beginning in 2028.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Under the provisions of the Internal Revenue Code, the NOL and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of certain cumulative changes in the ownership interest of significant stockholders over a three-year period in excess of 50%, as defined under Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. This could limit the amount of tax attributes that can be utilized annually to offset future taxable income or tax liabilities. The amount of </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;">the annual limitation is determined based on the value of the Company immediately prior to the ownership change. Subsequent ownership changes may further affect the limitation in future years. The Company has completed financings since its inception which may have resulted in a change in control as defined by Sections 382 and 383 of the Internal Revenue Code, or could result in a change in control in the future. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company files tax returns as prescribed by the tax laws of the jurisdictions in which it operates. In the normal course of business, the Company is subject to examination by federal and state jurisdictions, where applicable. The Company’s tax years from 2021 to the present remain open for review. All open years may be examined to the extent that tax credits or NOL carryforwards are used in future periods. To the extent the Company utilizes any tax attributes from a tax period that may otherwise be closed due to statute expiration, the tax authorities may adjust the tax attributes upon their examination of the future period in which the attribute was utilized. The Company will recognize interest and penalties related to uncertain tax positions in income tax expense. As of December 31, 2024, the Company had no accrued interest or penalties related to uncertain tax positions and no amounts have been recognized in the Company’s statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Effective for tax years beginning after December 31, 2021, taxpayers are required to capitalize any expenses incurred that are considered incidental to research and experimentation (R&amp;E) activities under IRC Section 174. While taxpayers historically had the option of deducting these expenses under IRC Section 174, the December 2017 Tax Cuts and Jobs Act mandates capitalization and amortization of R&amp;E expenses for tax years beginning after December 31, 2021. Expenses incurred in connection with R&amp;E activities in the US must be amortized over a 5-year period if incurred, and R&amp;E expenses incurred outside the US must be amortized over a 15-year period. R&amp;E activities are broader in scope than qualified research activities considered under IRC Section 41 (relating to the research tax credit). For the year ended December 31, 2024, the Company performed an analysis based on available guidance and determined that it will continue to be in a loss position even after the required capitalization and amortization of its R&amp;E expenses. The Company will continue to monitor this issue for future developments, but it does not expect R&amp;E capitalization and amortization to require it to pay cash taxes now or in the near future.</p> 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">A reconciliation of income tax provision (benefit) computed at the statutory federal income tax rate to income taxes as reflected in the financial statements for the years ended December 31, 2024 and 2023 is as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31, </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Federal income tax benefit at statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 3.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State and local tax, change in rates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Permanent differences</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;">0.0 </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in fair value of warrants </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (4.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28.9)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (20.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Effective income tax rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.09%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%  </p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.46%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 0.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table> 0.21 0.21 0.04 0.031 0 -0.035 -0.019 -0.004 0.043 0.045 0 0.004 0.015 -0.044 -0.289 -0.207 0 0 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">Deferred taxes are recognized for temporary differences between the basis of assets and liabilities for financial statement and income tax purposes. The significant components of the Company’s deferred tax assets are comprised of the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">​</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;"> </b><span style="font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:29.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">As of December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.7%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 13,634,896</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 9,607,158</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Stock compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,390,635</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,245,472</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Capitalized R&amp;D</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,137,406</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 1,334,494</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Section 174</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 12,802,738</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 10,793,442</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">R&amp;D credit carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 5,198,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 4,132,475</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 76,757</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 14,553</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 37,240,555</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> 30,127,594</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Less valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37,240,555)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"> </p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (30,127,594)</p></td></tr><tr><td style="vertical-align:bottom;width:68.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred taxes</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.15%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:12.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.6pt 0pt 0pt;"> —</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">​</span></p> 13634896 9607158 4390635 4245472 1137406 1334494 12802738 10793442 5198123 4132475 76757 14553 37240555 30127594 37240555 30127594 0 0 54100000 2800000 56600000 7100000 11700000 5200000 0 0 P5Y P15Y <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;background:#ffffff;">(11) Segment Information</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;background:#ffffff;">The Company is a clinical-stage biopharmaceutical company and has not generated any revenue since commencing significant operations in 2008. The Company’s operations are organized and reported as a single reportable segment, which includes all activities related to the discovery, development, and commercialization of our lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. This presentation is consistent with how the Company’s chief operating decision maker (“CODM”), its Chief Executive Officer, assesses the performance of the Company and makes operating decisions. The accounting policies of the segment are the same as those described in the summary of significant accounting policies (see Note 2). The CODM assesses performance and decides how to allocate resources based on net loss as reported on the statements of operations. The CODM uses net loss to monitor actual operating results, assess cash runway, and benchmark against the Company’s competitors. The measure of segment assets is reported on the balance sheets as total assets. The Company’s assets are held in the United States.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;background:#ffffff;">When evaluating the Company’s financial performance, the CODM regularly reviews the following expense categories that comprise net loss. The table below sets forth the Company’s segment information as reviewed by the CODM:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Program expenses related to clinical-stage product candidates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,723,518)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (35,104,702)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Program expenses related to preclinical and discovery programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (568,214)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (583,154)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel-related expenses (including stock-based compensation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,525,586)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,444,920)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative professional and consultant fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,687,276)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,152,485)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other segment items¹</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,190,333)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (749,750)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 331,849</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 667,898</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other non-cash income (expense) items²</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,772,704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,837,199)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24,590,374)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (56,204,313)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;background:#ffffff;">¹ Other segment items included in net loss include insurance expense, information technology expenses, warrant commissions and other miscellaneous expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;background:#ffffff;">² Other non-cash income (expense) items includes financing costs from our ELOC and change in fair value of our liability classified warrants.</span><span style="font-weight:normal;background:#ffffff;"> </span></p> <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;background:#ffffff;">When evaluating the Company’s financial performance, the CODM regularly reviews the following expense categories that comprise net loss. The table below sets forth the Company’s segment information as reviewed by the CODM:</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">​</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:41.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended December 31, </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:18.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">    </b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:20.24%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Program expenses related to clinical-stage product candidates</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (16,723,518)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (35,104,702)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Program expenses related to preclinical and discovery programs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (568,214)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (583,154)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Personnel-related expenses (including stock-based compensation)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,525,586)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (6,444,920)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">General and administrative professional and consultant fees</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,687,276)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (2,152,485)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other segment items¹</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (1,190,333)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (749,750)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Interest income</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 331,849</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 667,898</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Other non-cash income (expense) items²</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,772,704</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (11,837,199)</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:58.67%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net Loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.75%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (24,590,374)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.74%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">​</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (56,204,313)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">​</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;background:#ffffff;">¹ Other segment items included in net loss include insurance expense, information technology expenses, warrant commissions and other miscellaneous expenses.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><span style="font-weight:normal;background:#ffffff;">² Other non-cash income (expense) items includes financing costs from our ELOC and change in fair value of our liability classified warrants.</span><span style="font-weight:normal;background:#ffffff;"> </span></p> 16723518 35104702 568214 583154 6525586 6444920 1687276 2152485 1190333 749750 331849 667898 1772704 -11837199 -24590374 -56204313 <p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 0pt;">(12) Subsequent Events</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Subsequent to December 31, 2024, the Company sold 0.1 million shares of its common stock under its ATM with OpCo, which the Company entered into in December 2024. The Company received net proceeds of $0.5 million after deducting commissions and fees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On February 3, 2025, the Company entered into an Underwriting Agreement with ThinkEquity LLC, acting as representative of the underwriters with respect to an underwritten public offering of 5.3 million units of the Company. Each unit sold consisted of one share of common stock and one warrant to purchase one share of common stock (the “ThinkEquity Warrants”), at a per unit price of $4.00 (the “Offering”). Aggregate gross proceeds from the Offering were $21.0 million before deducting underwriting discounts and other estimated offering expenses. The Warrants have an exercise price of $5.00 per share, are immediately exercisable and expire five years from the date of issuance. The shares of Common Stock and Warrants were issued separately. The Company has agreed to suspend sales of its Common Stock under the OpCo ATM Facility for a period of six months after the closing of the Offering.</p> 100000 500000 5300000 1 1 4 21000000 5 P5Y P6M

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